Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
4-(HETERO)ARYL SUBSTITUTED INDOLINONES
Document Type and Number:
WIPO Patent Application WO/2002/055517
Kind Code:
A2
Abstract:
The present invention relates to 4-arylindolinones of formula (I), as well as pharmaceutical compositions thereof, capable of modulating protein kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. The present invention relates to methods for treating protein kinase related disorders. Formula (I) wherein: R?1¿ is an optionally substituted aryl or heteroaryl substituent, R?2¿-R?5¿ are as in claim 1.

Inventors:
CUI JINGRONG (US)
ZHANG RUOFEI (US)
SHEN HONG (US)
CHU JI YU (US)
ZHANG FANG-JIE (US)
KOENIG MARCEL (US)
DO STEVEN HUY (US)
LI XIAOYUAN (US)
WEI CHUNG CHEN (US)
TANG PENG CHO (US)
Application Number:
PCT/US2001/048564
Publication Date:
July 18, 2002
Filing Date:
December 20, 2001
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
CUI JINGRONG (US)
ZHANG RUOFEI (US)
SHEN HONG (US)
CHU JI YU (US)
ZHANG FANG-JIE (US)
KOENIG MARCEL (US)
DO STEVEN HUY (US)
LI XIAOYUAN (US)
WEI CHUNG CHEN (US)
TANG PENG CHO (US)
International Classes:
A61K31/136; A61K31/337; A61K31/404; A61K31/416; A61K31/4192; A61K31/4439; A61K31/454; A61K31/496; A61K31/513; A61K31/5377; A61K31/541; A61K31/55; A61K45/00; A61P3/10; A61P9/00; A61P9/10; A61P11/16; A61P13/08; A61P13/12; A61P17/06; A61P19/02; A61P29/00; A61P31/10; A61P35/00; A61P37/02; A61P43/00; C07D209/34; C07D209/42; C07D401/14; C07D403/06; C07D403/14; C07D413/14; C07D417/14; C07D487/04; (IPC1-7): C07D403/06; A61P35/00; A61P29/00; A61K31/496; C07D403/14; C07D209/34; C07D401/14; C07D209/42; C07D487/04
Domestic Patent References:
WO2002002551A12002-01-10
WO2001094312A22001-12-13
WO2001049287A12001-07-12
WO2000035909A12000-06-22
WO1999061422A11999-12-02
WO2000008202A22000-02-17
WO1998050356A11998-11-12
WO2000035908A12000-06-22
Foreign References:
US5792783A1998-08-11
US6114371A2000-09-05
US6147106A2000-11-14
Attorney, Agent or Firm:
Burrous, Beth A. (N.W. Washington, DC, US)
Download PDF:
Claims:
What is claimed is:
1. A compound of the formula I: wherein: Rl is an aryl or heteroaryl substituent, optionally substituted by one or more substituent selected from the group consisting of halogen, OR6, COR6, COOR6, OCOR6, CONR6R',R6NCOR',NR6R,CN,N02,CX3,SR6, SOR6,SO2Rb,SO2OR6, SO2NR6R7, R6NSO2R7, perfluoroalkyl, lower alkyl, lower alkyl further substituted by one or more of R2, lower alkenyl, lower alkenyl further substituted by one or more of R2, lower alkynyl, lower alkynyl further substituted by one or more of R2, cycloalkyl, cycloalkyl further substituted by one or more of R2, a heterocyclic ring, a heterocyclic ring further substituted by one or more of R2, aryl and aryl further substituted by one or more of R2 ; R2 is selected from the group consisting of hydrogen, halogen,OR6,COR6, COOR6, OCOR6, CONR6R7, R6NCOR7, NR6R7, CN, NO2, CX3, SR6, SOR6, SO2R6, SO2OR6, SO2NR6R7, R6NSO2R7, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, a heterocyclic ring and aryl; R3 is selected from the group consisting of hydrogen, halogen,OR6,COR6, COOR6, OCOR6, CONR6R7, R6NCOR7, NR6R7, CN, NO2, CX3, SR6, SOR6, SO2R6, SO2OR6, SO2NR6R7, R6NSO2R7, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, a heterocyclic ring, a heterocyclic ring further substituted by one or more of R2 and aryl, wherein said lower alkyl is further substituted by CONR6R7, NR6R7, SO2R6, R6NSO2R, or S02WR7 ; R4 is selected from the group consisting of hydrogen, halogen,OR6,COR6, COOR6, OCOR6, CONR6R7, R6NCOR7, NR6R7, CN, NO2, CX3, SR6, SOR6, SO2R6, SO2OR6, SO2NR6R7, R6NSO2R7, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, a heterocyclic ring and aryl, wherein said lower alkyl is further substituted by CONR6R7, NR6R7, SO2R6, R6NSO2R, or SO2NR6R7 ; R5 is selected from the group consisting of hydrogen, halogen, OR6, COR6, COOR6, OCOR6, CONR6R7, R6NCOR7, NR6R7, CN, NO2, CX3, SR6, SOR6, SO2R6, S020R6,So2NR6R7,R6NSo2R7, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, a heterocyclic ring and aryl; provided that no more than one of R3, R4, or R5 is hydrogen; R3 and R4 or R4 and R5 may be linked together to form a 4, 5, 6or 7membered ring optionally containing one or more hetero atoms selected from the group consisting of 0, N, S, SO and SO2, which may contain 1 or 2 double bonds and may be further substituted by one or more of (CH2) nNR6R, (CH2)nCR6R7, (CH2)nC(O)(CH2)nNR6R7, (CH2)nSO2R6R7, (CH2)nNSO2R6R7 or (CH2)nC(O)R6 wherein n is 04; R6 and R7 are independently selected fromthe. group consisting of hydrogen,CX3, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, a heterocyclic ring and aryl; wherein lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, the heteocyclic ring or aryl may be further substituted by one or more of (i)NRI2RI3, (ii) hydroxy, (iii) halo, (iv) a heterocyclic ring, (v) lower alkyl, (vi)C (O)NR12R13, (vii) OR12, (viii) SO2R12R13, or (ix) COR6; wherein said heterocyclic ring (iv) may be further substituted by one or more of lower alkyl,COR12,NRi2CORl3, halogen,OR12, CX3, C(O)NR12R13, SO2R12R13, or SO2NR12R13, or R6 and R7 may be linked together to form a 4, 5 or 6 membered ring, optionally containing a hetero atom selected from the group consisting of N, O, S and SO2, which may be further substituted byCoNRI2RI3, lower alkyl, hydroxy, (CH2)nNR12R13, (CH2)nheterocycle, (CH2)nC(O)NR12R13, (CH2)nSO2R12R13, or (CH2)nNSO2R12R13, wherein said heterocycle may be further substituted by halo, lower alkyl,CORI2, hydroxy, C(O)NR12R13, OR12, SO2R12R13, or SO2NR12R13; X is fluorine, chlorine, bromine or iodine; *12 is selected from the group consisting of hydrogen,CX3, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl,(CH2) ncycloalkyl,(CH2) nheterocycle, and aryl; Rl3 is selected from the group consisting of hydrogen,CX3, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, (CH2)ncycloalkyl, (CH2)nheterocycle, and aryl; or Rl2 and R13 may be linked together to form a 4, 5or 6membered ring optionally containing one or more hetero atoms selected from the group consisting of 0, N, S, SO and SO2, which may contain 1 or 2 double bonds; or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1, wherein R3 and R4 or R4 and R may be linked together to form a ring.
3. The compound of claim 2, wherein the R3 and R4 or R4 and RS are linked together to form a ring, the ring together with pyrrole is selected from the group consisting of :.
4. The compound of claim 1, wherein said compound is selected from the group consisting of : 2methyl4 [3 (4methylpiperazin1ylpropyl]5 (2oxo4phenyl1, 2dihydro indol3ylidenemethyl)lHpyrrole3carboxylic acid ester, 3 [3, 5dimethyl4 (4methylpiperazinelcarbonyl)lHpyrrol2ylmethylene]4 phenyl1,3dihydroindol2one, 2,4dimethyl5(2oxo4phenyl1,2dihydroindol3ylidenemethyl)1Hpyrrole3 carboxylic acid (2diethylaminoethyl)amide, 3 [3, 5dimethyl4 (4methylpiperazine1carbonyl)1Hpyrrol2ylmethylene]4 (4 fluorophenyl)1,3dihydroindol2one, 5[4(4fluorophenyl)2oxo1,2dihydroindol3ylidenemethyl]2,4dimethyl1H pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5 [4 (4fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyl1H pyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 5 [4 (4fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyllH pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 4(4fluorophenyl)3[5methyl3(4methylpiperazine1carbonyl)1Hpyrrol2 ylmethylene]1, 3dihydroindol2one, 2 [4 (4fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]5methyllH pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 3 [3 (3dimethylaminopyrrolidine. 1carbonyl)5methyl1Hpyrrol2ylmethylene] 4 (4fluorophenyl)1, 3dihydroindol2one, 3[3((R)3dimethylaminopyrrolidine1carbonyl)5methyl1Hpyrrol2 ylmethylene]4 (4fluorophenyl)1, 3dihydroindol2one, 3 [3 ( (S)3dimethylaminopyrrolidine1carbonyl)5methyllHpyrrol2 ylmethylene]4(4fluorophenyl)1,3dihydroindol2one, 3 [3, 5dimethyl4 (4methylpiperazine1carbonyl)1Hpyrrol2ylmethylene]4 (3 fluorophenyl)1, 3dihydroindol2one, 5 [4 (3fluorophenyl)2oxo1,2dihydroindol3ylidenemethyl]2,4dimethyllH pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5 [4 (3fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyl1H pyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 5 [4 (3fluorophenyl)2oxo1,2dihydroindol3ylidenemethyl]2,4dimethyllH pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 3 [3 (3dimethylaminopyrrolidine1carbonyl)5methyllHpyrrol2ylmethylene] 4 (3fluorophenyl)1, 3dihydroindol2one, 3 [3 ( (R)3dimethylaminopyrrolidine1carbonyl)5methyllHpyrrol2 ylmethylene]4 (3fluorophenyl)1, 3dihydroindol2one, <BR> <BR> <BR> 3 [3 ( (S)3dimethylaminopyrrolidine1carbonyl)5methyllHpyrrol2<BR> <BR> <BR> <BR> <BR> ylmethylene]4 (3fluorophenyl)1, 3dihydroindol2one, 5[4 (3fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2methyl4 [3 (4 methylpiperazin1yl)propyl]1Hpyrrole3carboxylic acid ethyl ester, 3 [3 (cis3, 5dimethylpiperazine1carbonyl)5methyllHpyrrol2ylmethylene]4 (3fluorophenyl)1, 3dihydroindol2one, 3 [3 (traras3, 5dimethylpiperazine1carbonyl)5methyl1Hpyrrol2ylmethylene] 4 (3fluorophenyl)1, 3dihydroindol2one, 4 (4chlorophenyl)3 [3, 5dimethyl4 (4methylpiperazinelcarbonyl)lHpyrrol 2ylmethylene]1,3dihydroindol2one, 5 [4 (4chlorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2,4dimethyl1 H pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5 [4 (4chlorophenyl)2oxo1,2dihydroindol3ylidenemethyl]2,4dimethyl1H pyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 5[4 (4chlorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyl1 H pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 4 (4chlorophenyl)3 [3 (3dimethylaminopyrrolidine1carbonyl)5methyl1H pyrrol2ylmethylene]1, 3dihydroindol2one, 4 (4chlorophenyl)3 [3 (3dimethylaminopyrrolidine1carbonyl)5methyl1H pyrrol2ylmethylene]1, 3dihydroindol2one, 5 [4 (4chlorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2methyl4 [3 (4 methylpiperazin1yl)propyl]IHpyrrole3carboxylic acid ethyl ester, 4 (4chlorophenyl)3 [3 (cis3, 5dimethylpiperazinelcarbonyl)5methyllH pyrrol2ylmethylene]1, 3dihydroindol2one, 4(4chlorophenyl)3[3(trans3,5dimethylpiperazine1carbonyl)5methyl1H pyrrol2ylmethylene]1, 3dihydroindol2one, <BR> <BR> <BR> <BR> 4 (3chlorophenyl)3 [3, 5dimethyl4 (4methylpiperazinelcarbonyl)lHpyrrol<BR> <BR> <BR> <BR> <BR> <BR> 2ylmethylene]1, 3dihydroindol2one, 5 [4 (3chlorophenyl)2oxo1,2dihydroindol3ylidenemethyl]2,4dimethyllH pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5 [4 (3chlorophenyl)2oxo1,2dihydroindol3ylidenemethyl]2,4dimethyl1H pyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 5 [4 (3chlorophenyl)2oxo1,2dihydroindol3ylidenemethyl]2,4dimethyllH pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 4 (3chlorophenyl)3 [3 (3dimethylaminopyrrolidinelcarbonyl)5methyl1H pyrrol2ylmethylene]1,3dihydroindol2one, 4 (3chlorophenyl)3 [3 ( (R)3dimethylaminopyrrolidine1carbonyl)5methyl 1Hpyrrol2ylmethylene]1, 3dihydroindol2one, 4(3chlorophenyl)3[3((S)3dimethylaminopyrrolidine1carbonyl)5methyl 1Hpyrrol2ylmethylene]1, 3dihydroindol2one, 2 [4 (3chlorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]5methyllH pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 4 (3chlorophenyl)3 [3 (cis3, 5dimethylpiperazine1carbonyl)5methyl1H pyrrol2ylmethylene]1, 3dihydroindol2one, 4 (3chlorophenyl)3 [3 (trans3, 5dimethylpiperazine1carbonyl)5methyl1H pyrrol2ylmethylene]1, 3dihydroindol2one, 3 [3, 5dimethyl4 (4methylpiperazine1carbonyl)lHpyrrol2ylmethylene]4 (4 methoxyphenyl)1, 3dihydroindol2one, 5 [4 (4methoxyphenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyl 1Hpyrrole3carboxylic acid (2diethylaminoethyl)amide, 5 [4 (4methoxyphenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyl 1Hpyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 5 [4 (4methoxyphenyl)2oxo1, 2dihydroindol3ylidenemethyl]2,4dimethyl 1Hpyrrole3carboxylic acid (2[1, 2,3] triazol1ylethyl)amide, 3[4(cis3,5dimethylpiperazine1carbonyl)3,5dimethyl1Hpyrrol2 ylmethylene]4 (4methoxyphenyl)1, 3dihydroindol2one, 3[4(trans3,5dimethylpiperazine1carbonyl)3,5dimethyl1Hpyrrol2 <BR> <BR> <BR> <BR> ylmethylene]4 (4methoxyphenyl)1, 3dihydroindol2one,<BR> <BR> <BR> <BR> <BR> <BR> 2 [4 (4methoxyphenyl)2oxo1, 2dihydroindol3ylidenemethyl]5methyllH pyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 2 [4 (4methoxyphenyl)2oxo1, 2dihydroindol3ylidenemethyl]5methyllH pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 3 [3 (3dimethylaminopyrrolidine1carbonyl)5methyl1 Hpyrrol2ylmethylene] <BR> <BR> <BR> 4 (4methoxyphenyl)1, 3dihydroindol2one,<BR> <BR> <BR> <BR> <BR> <BR> 3 [3 ( (R)3dimethylaminopyrrolidine1carbonyl)5methyllHpyrrol2<BR> <BR> <BR> <BR> <BR> <BR> ylmethylene]4 (4methoxyphenyl)1, 3dihydroindol2one,.<BR> <BR> <BR> <BR> <BR> <BR> <BR> <P> 3 [3 ( (S)3dimethylaminopyrrolidine1carbonyl)5methyl1Hpyrrol2 ylmethylene]4 (4methoxyphenyl)1, 3dihydroindol2one, 3[3,5dimethyl4(4methylpiperazine1carbonyl)1Hpyrrol2ylmethylene]4(3 methoxyphenyl)1,3dihydroindol2one, 5 [4 (3methoxyphenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyl 1Hpyrrole3carboxylic acid (2diethylaminoethyl)amide, 5 [4 (3methoxyphenyl)2oxo1, 2dihydroindol3ylidenemethyl]2,4dimethyl 1Hpyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 5 [4 (3methoxyphenyl)2oxo1, 2dihydroindol3ylidenemethyl]2,4dimethyl 1Hpyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 3[4(cis3,5dimethylpiperazine1carbonyl)3,5dimethyl1Hpyrrol2 ylmethylene]4 (3methoxyphenyl)1, 3dihydroindol2one, 3 [4 (trans3, 5dimethylpiperazine1carbonyl)3, 5dimethyl1Hpyrrol2 ylmethylene]4 (3methoxyphenyl)1, 3dihydroindol2one, 2[4(3methoxyphenyl)2oxo1,2dihydroindol3ylidenemethyl]5methyl1H pyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 2 [4 (3methoxyphenyl)2oxo1, 2dihydrofindol3ylidenemethyl]5methyl1H pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 5 [4 (3methoxyphenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyl 1Hpyrrole3carboxylic acid (2diisopropylaminoethyl)amide, 4 (4bromophenyl)3 [3, 5dimethyl4 (4methylpiperazine1carbonyl)lHpyrrol 2ylmethylene]1, 3dihydroindol2one, 5 [4 (4bromophenyl)2oxo1, 2dihydroindo l3ylidenemethyl]2, 4dimethyl1 pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5 [4 (4bromophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyllH pyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 5 [4 (4bromophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2,4dimethyllH pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 4(4bromophenyl)3[4(cis3,5dimethylpiperazine1carbonyl)3,5dimethyl1H pyrrol2ylmethylene]1, 3dihydroindol2one, 4 (4bromophenyl)3 [4 (trans3, 5dimethylpiperazinelcarbonyl)3, 5dimethyl 1Hpyrrol2ylmethylene]1, 3dihydroindol2one, 2 [4 (4bromophenyl)2oxo1, 2dihydroindol3ylidenemethyl]5methyllH pyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 2 [4 (4bromophenyl)2oxo1, 2dihydroindol3ylidenemethyl]5methyl1H pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 5 [4 (4bromophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyllH pyrrole3carboxylic acid (2diisopropylaminoethyl)amide, 5 [4 (4bromophenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methyl1H pyrrole3carboxylic acid (2diethylaminoethyl)amide, 4 (3Bromophenyl)3 [3, 5dimethyl4 (4methylpiperazinelcarbonyl)lHpyrrol 2ylmethylene]1, 3dihydroindol2one, 5 [4 (3bromophenyl)2oxol, 2dihydrpindol3ylidenemethyl]2, 4dimethyl177 pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5 [4 (3bromophenyl)2oxo1,2dihydroindol3ylidenemethyl]2,4dimethyl1H pyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 5 [4 (3bromophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyllH pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 3 [4 (cis3, 5dimethylpiperazine1carbonyl)3, 5dimethyl1Hpyrrol2 ylmethylene]4 (3bromophenyl)1, 3dihydroindol2one, 3 [4 (trans3, 5dimethylpiperazine1carbonyl)3, 5dimethyl1Hpyrrol2 ylmethylene]4 (3bromophenyl)1, 3dihydroindol2one, 2 [4 (3bromophenyl)2oxo1, 2dihydroindol3ylidenemethyl]5methyl1H pyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 2 [4 (3bromophenyl)2oxo1, 2dihydroindol3ylidenemethyl]5methyl1H pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 5 [4 (3bromophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyllH pyrrole3carboxylic acid (2diisopropylaminoethyl)amide, 5 [4 (4fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methyl1H pyrrole2carboxylic acid (2diethylaminoethyl)amide, 5 [4 (3fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methyllH pyrrole2carboxylic acid (2diethylaminoethyl)amide, 5 [4 (4chlorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methyllH pyrrole2carboxylic acid (2diethylaminoethyl)amide, 5 [4 (3chlorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methyl1H pyrrole2carboxylic acid (2diethylaminoethyl)amide, 5 [4 (4bromophenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methyl1H pyrrole2carboxylic acid (2diethylaminoethyl)amide, 5 [4 (3bromophenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methyl IH pyrrole2carboxylic acid (2diethylaminoethyl)amide, 5 [4 (4methoxyphenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methyllH pyrrole2carboxylic acid (2diethylaminoethyl)amide, 5[4(3methoxyphenyl)2oxo1,2dihydroindol3ylidenemethyl]4methyl1H pyrrole2carboxylic acid (2diethylaminoethyl)amide, 3(3, 5dimethyllHpyrrol2ylmethylene)4(4fluorophenyl)1,3dihydroindol2 one, 3 (3, 5dimethyl1Hpyrrol2ylmethylene)4 (3fluorophenyl)1, 3dihydroindol2 one, 3(3,5dimethyl1Hpyrrol2ylmethylene)4(4chlorophenyl)1,3dihydroindol2 one, 3 (3, 5dimethyllHpyrrol2ylmethylene)4 (3chlorophenyl)1, 3dihydroindol2 one, 3(3, 5dimethyllHpyrrol2ylmethylene)4(4bromophenyl)1,3dihydroindol2 one, 3(3,5dimethyl1Hpyrrol2ylmethylene)4(3bromophenyl)1, 3dihydroindol2 one, 3 (3, 5dimethyllHpyrrol2ylmethylene)4 (4methoxyphenyl)1, 3dihydroindol 2one, 3(3, 5dimethyllHpyrrol2ylmethylene)4(3methoxyphenyl)1,3dihydroindol 2one, 5 [4 (4Fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methyl1H pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5 [4 (3Fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methyl1H pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5 [4 (4Chlorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methyl1H pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5 [4 (3Chlorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methyllH pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5[4 (3Bromophenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methyl1H pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5 [4 (4Methoxyphenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methyl1H pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5 [4 (3Methoxyphenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methyl1H pyrrole3carboxylic acid (2diethylaminoethyl)amide, 3[3,5Dimethyl4(4methyl[piperzine1carbonyl)1Hpyrrol2ylmethylene]4(2 fluorophenyl)1,3dihydroindol2one, 5 [4 (2Fluorophenyl)2oxo1,2dihydroindol3ylidenemethyl]2,4dimethyl1H pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5 [4 (2Fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyl1H pyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 5 [4 (2Fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyl1H pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 2 [4 (2Fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]5methyl1H pyrrole3carboxylic acid (2diethylaminoethyl)amide, 2 [4 (2Fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]5methyllH pyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 2 [4 (2Fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]5methyllH pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 3 [3 (cis3, 5dimethylpiperazinecarbonyl)5methyllHpyrrol2ylmethylene]4 (2fluorophenyl)1,3dihydroindol2one, 3 [3 (trans3, 5dimethylpiperazinecarbonyl)5methyl1 Hpyrrol2ylmethylene]4 (2fluorophenyl)1,3dihydroindol2one, 5 [4 (4Fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyl1 H pyrrole3carboxylic acid (3diethylaminopropyl)amide, 2 [4 (4Fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]5methyllH pyrrole3carboxylic acid (3pyrrolidin1ylpropyl)amide, 5 [4 (3Fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyl1H pyrrole3carboxylic acid (3diethylaminopropyl)amide, 3 [3, 5Dimethyl4 (4methylpiperazinelcarbonyl)lHpyrrol2ylmethylene]4 (3 trifluoromethylphenyl)1, 3dihydroindol2one, 2,4Dimethyl5 [2oxo4 (3trifluoromethylphenyl)1, 2dihydroindol3 ylidenemethyl]lHpyrrole3carboxylic acid (2diethylaminoethyl)amide, 2,4Dimethyl5 [2oxo4 (3trifluoromethylphenyl)1,2dihydroindol3 ylidenemethyl]1Hpyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 2,4Dimethyl5 [2oxo4 (3trifluoromethylphenyl)1, 2dihydroindol3 ylidenemethyl]lHpyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 5methyl2 [2oxo4 (3trifluoromethylphenyl)1, 2dihydroindol3ylidenemethyl] 1Hpyrrole3carboxylic acid (2diethylaminoethyl)amide, 5methyl2 [2oxo4 (3trifluoromethylphenyl)1, 2dihydroindol3ylidenemethyl] 1Hpyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 5methyl2 [2oxo4 (3trifluoromethylphenyl)1, 2dihydroindol3ylidenemethyl] 1Hpyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 3 {3[cis3, 5dimethylpiperazine1carbonyl]SmethyllHpyrrol2ylmethylene} 4 (2trifluoromethylphenyl)1, 3dihydroindol2one, 2,4Dimethyl5 [2oxo4 (3trifluoromethylphenyl)1, 2dihydroindol3 ylidenemethyl]lHpyrrole3carboxylic acid (3diethylaminopropyl)amide, 5methyl2 [2oxo4 (3trifluoromethylphenyl)1, 2dihydroindol3ylidenemethyl] 1Hpyrrole3carboxylic acid (3pyrrolidin1ylpropyl)amide, 3 [3methyl4 (4methylpiperazine1carbonyl)lHpyrrol2ylmethylene]4 (3 trifluoromethylphenyl)1, 3dihydroindol2one, 3 3Methyl4[cis3,5dimethylpiperazine1carbonyl]1Hpyrrol2ylmethylene} 4 (3trifluoromethylphenyl)1, 3dihydroindol2one, 4(3chloro4fluorophenyl)3[3,5dimethyl4(4methylpiperazine1carbonyl) 1 Hpyrrol2ylmethylene]1, 3dihydroindol2one, 5 [4 (3chloro4fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4 dimethyllHpyrrole3carboxylic acid (2diethylaminoethyl)amide, 5 [4 (3chloro4fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4 dimethyl1 Hpyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 2 [4 (3chloro4fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]5methyl 1Hpyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 2 [4 (3chloro4 fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]5 methyl1 Hpyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 2 [4 (3chloro4fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]5methyl lHpyrrole3carboxylic acid (3pyrrolidin1ylpropyl)amide, 4 (4chlorophenyl)3 {3, 5dimethyl4 [3 (4methylpiperazinlyl)3oxopropyl] 1Hpyrrol2ylmethylene}1, 3dihydroindol2one, 4 (2fluorophenyl)3 [3methyl4 (4methylpiperazine1carbonyl)1Hpyrrol2 ylmethylene]1, 3dihydroindol2one, 4(4fluorophenyl)3[3methyl4(4methylpiperazine1carbonyl)1Hpyrrol2 ylmethylene]1,3dihydroindol2one, 4(4chlorophenyl)3[3methyl4(4methylpiperazine1carbonyl)1Hpyrrol2 ylmethylene]1, 3dihydroindol2one, 4(4bromophenyl)3[3methyl4(4methylpiperazine1carbonyl)1Hpyrrol2 ylmethylene]1, 3dihydroindol2one, 4 (3bromophenyl)3 [3methyl4 (4methylpiperazine1carbonyl)lHpyrrol2 ylmethylene]1, 3dihydroindol2one, 4 (4methoxyphenyl)3 [3methyl4 (4methylpiperazinelcarbonyl)lHpyrrol2 ylmethylene]1,3dihydroindol2one, 4 (3methoxyphenyl)3 [3methyl4 (4methylpiperazinelcarbonyl)lHpyrrol2 ylmethylene]1, 3dihydroindol2one, 3 [3methyl4 (4methylpiperazine1carbonyl)1Hpyrrol2ylmethylene]4phenyl 1,3dihydroindol2one, 3 {4[cis3, 5dimethylpiperazine1carbonyl]3methyl1 Hpyrrol2ylmethylene} 4 (4fluorophenyl)1, 3dihydroindol2one, 4(4Chlorophenyl)3{4[cis3,5dimethylpiperazine1carbonyl]3methyl1H pyrrol2ylmethylene]1,3dihydroindol2one, 4 (4Bromophenyl)3 {4 [cis3, 5dimethylpiperazinelcarbonyl]3methyllH pyrrol2ylmethylene]1, 3dihydroindol2one, 3{4[cis3, 5dimethylpiperazine1carbonyl]3methyllHpyrrol2ylmethylene} 4 (4methoxyphenyl)1, 3dihydroindol2one, 3 {4 [cis3, 5dimethylpiperazine1carbonyl] 3methyl1Hpyrrol2ylmethylene} 4 (3methoxyphenyl)1, 3dihydroindol2one, 3{4[cis3, 5dimethylpiperazine1carbonyl]3methyllHpyrrol2ylmethylene} 4phenyl1,3dihydroindol2one, 4(4chlorophenyl)3{4{3[cis3,5dimethylpiperazin1yl]3oxopropyl}3, 5 dimethyllHpyrrol2ylmethylene}1, 3dihydroindol2one, 3 {4 {3 [cis3, 5Dimethylpiperazin1yl]3oxopropyl}3; 5dimethyllHpyrrol2 ylmethylene}4 (4fluorophenyl)1, 3dihydroindol2one, 3 [3, 5Dimethyl4 (4methylpiperazinelcarbonyl)lHpyrrol2ylmethylene]4 (4 trifluoromethoxyphenyl)1, 3dihydroindol2one, 2,4Dimethyl5 [2oxo4 (4trifluoromethoxyphenyl)1,2dihydroindol3 ylidenemethyl]lHpyrrole3carboxylic acid (2diethylaminoethyl)amide, 2,4Dimethyl5 [2oxo4 (4trifluoromethoxyphenyl)1, 2dihydroindol3 ylidenemethyl]1Hpyrrole3carboxylic acid (2[1, 2,3] triazol1ylethyl)amide, 5methyl2 [2oxo4 (4trifluoromethoxyphenyl)1, 2dihydroindol3 <BR> <BR> <BR> <BR> ylidenemethyl]IHpyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide,<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> 5methyl2 [2oxo4 (4trifluoromethoxyphenyl)1, 2dihydroindol3 ylidenemethyl]lHpyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 5methyl2 [2oxo4 (4trifluoromethoxyphenyl)1, 2dihydroindol3 ylidenemethyl]lHpyrrole3carboxylic acid (3pyrrolidin1ylpropyl)amide, <BR> <BR> <BR> <BR> <BR> 3 [3 (trans3, 5Dimethylpiperazine1carbonyl)5methyl1 Hpyrrol2ylmethylene]<BR> <BR> <BR> <BR> <BR> <BR> 4 (3fluorophenyl)1, 3dihydroindol2one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> 4 (4Chlorophenyl)3 [3 (trans3, 5dimethylpiperazine1carbonyl)5methyllH pyrrol2ylmethylene]1, 3dihydroindol2one, 4 (3Chlorophenyl)3 [3 (trans3, 5dimethylpiperazine1carbonyl)5methyl1 H pyrrol2ylmethylene]1,3dihydroindol2one, 3 [4 (trans3, 5Dimethylpiperazine1carbonyl)3, 5dimethyllHpyrrol2 ylmethylene]4 (4methoxyphenyl)l, 3dihydroindol2one, 3[4(trans3,5Dimethylpiperazine1carbonyl)3,5dimethyl1Hpyrrol2 ylmethylene]4 (3methoxyphenyl)1, 3dihydroindol2one, 4 (4Bromophenyl)3 [4 [trans3, 5dimethylpiperazinelcarbonyl)3, 5dimethyl 1Hpyrrol2ylmethylene] 1, 3dihydroindol2one, 3 [4 (trans3, 5Dimethylpiperazine1carbonyl)3, 5dimethyllHpyrrol2 ylmethylene]4 (3bromophenyl)1, 3dihydroindol2one, 3 3 [trans3, 5dimethylpiperazine1carbonyl]5methyllHpyrrol2ylmethylene} 4 (2fluorophenyl)1, 3dihydroindol2one, 3 {3[trans3, 5dimethylpiperazine1carbonyl]5methyllHpyrrol2ylmethylene} 4 (2trifluoromethylphenyl)1, 3dihydroindol2one, 3 {3Methyl4[trans3, 5dimethylpiperazine1carbonyl]lHpyrrol2 ylmethylene}4 (3trifluoromethylphenyl)1, 3dihydroindol2one, 3 {4[trans3, 5dimethylpiperazine1carbonyl]3methyl1 Hpyrrol2 ylmethylene}4 (4fluorophenyl)1, 3dihydroindol2one, 4 (4Chlorophenyl)3 {4 [trans3, 5dimethylpiperazine1carbonyl]3methyl1H pyrrol2ylmethylene]1, 3dihydroindol2one, 4 (4Bromophenyl)3 {4 [trans3, 5dimethylpiperazine1carbonyl]3methyl1H pyrrol2ylmethylene]1, 3dihydroindol2one, 3{4[trans3,5dimethylpiperazine1carbonyl] 3methyl1Hpyrrol2 ylmethylene}4 (4methoxyphenyl)1, 3dihydroindol2one, 3 {4 [trans3, 5dimethylpiperazine1carbonyl] 3methyllHpyrrol2 ylmethylene}4 (3methoxyphenyl)1, 3dihydroindol2one, 3{4[trans3, 5dimethylpiperazine1carbonyl]3methyllHpyrrol2 ylmethylene}4phenyl1, 3dihydroindol2one, 4(4chlorophenyl)3{4{3[trans3,5dimethylpiperazin1yl]3oxopropyl}3, 5 dimethyl1 Hpyrrol2ylmethylene}1, 3dihydroindol2one, 3{4{3[trans3,5Dimethylpiperazin1yl]3oxopropyl}3,5dimethyl1Hpyrrol 2ylmethylene}4 (4fluorophenyl)1, 3dihydroindol2one, 2Methyl4 [3 (4methylpiperazin1yl)propyl]5 (2oxo4phenyl1, 2dihydro indol3ylidenemethyl)lHpyrrole3carboxylic acid ethyl ester, 3 [3, 5Dimethyl4 (4methylpiperazine1carbonyl)IHpyrro 12ylmethylene]4 phenyl1,3dihydroindol2one, 2,4Dimethyl5(2oxo4phenyl1, 2dihydroindol3ylidenemethyl)lHpyrrole3 carboxylic acid (2diethylaminoethyl)amide, 3 [3, 5Dimethyl4 (4methylpiperazine1carbonyl)lHpyrrol2ylmethylene]4 (4 fluorophenyl)1, 3dihydroindol2one, 5 [4 (4Fluorophenyl)2oxo1,2dihydroindol3ylidenemethyl]2,4dimethyllH pyrrole3carboxylic acid (2dimethylaminoethyl)amide, 5 [4 (4Fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2,4dimethyl1 H pyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 5 [4 (4Fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyl1H pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 4(4Fluorophenyl)3[5methyl3(4methyl piperazine1carbonyl)1Hpyrrol2 ylmethylene]1, 3dihydroindol2one, 2 [4(4Fluorophenyl)2oxo1,2dihydroindol3ylidenemethyl]5methyl1H pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl) amide, 3 [3 ( (S)3Dimethylaminopyrrolidinelcarbonyl)5methyllHpyrrol2 yhnethylene]4 (4fluorophenyl)1, 3dihydro indol2one, 3 [3 ( (R)3Dimethylaminopyrrolidine1carbonyl)5methyllHpyrrol2 ylmethylene]4 (4fluorophenyl)1, 3dihydro indol2one, 3 [3, 5Dimethyl4 (4methyl. piperazine1carbonyl)lHpyrrol2ylmethylene]4 (3 fluorophenyl)1, 3dihydroindol2one, 5 [4 (3Fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyllH pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5 [4 (3Fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2,4dimethyllH pyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 5 [4 (3Fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyllH pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 3 [3 ( (S)3Dimethylaminopyrrolidinelcarbonyl)5methyllHpyrrol2 ylmethylene]4(3fluorophenyl)1, 3dihydro indol2one, 3 [3((R)3Dimethylaminopyrrolidine1carbonyl)5methyl1 Hpyrrol2 <BR> <BR> <BR> <BR> ylmethylene]4 (3fluorophenyl)1, 3dihydro indol2one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> 5 [4 (3Fluoropheny])2oxo1, 2dihydroindol3ylidenemethyl]2methyl4 [3 (4 methylpiperazinlyl)propyl]lHpyrrole3carboxylic acid ethyl ester, 3 [3 (cis3, 5Dimethylpiperazinelcarbonyl)5methyllHp yrrol2ylmethylene]4 (3fluorophenyl)1, 3dihydro indol2one, 4 (4Chlorophenyl)3 [3, 5dimethyl4 (4methylpiperazinelcarbonyl)lHpyrrol 2ylmethylene]1,3dihydroindol2one, 5 [4 (4Chlorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyllH pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5[4(4Chlorophenyl)2oxo1,2dihydroindol3ylidenemethyl]2,4dimethyl1H pyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 5 [4 (4Chlorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyllH pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 4 (4Chlorophenyl)3 [3 ( (S)3dimethylaminopyrrolidine1carbonyl)5methyl 1 Hpyrrol2ylmethylene]1, 3dihydroindol2one, 4 (4Chlorophenyl)3 [3 ( (R)3dimethylaminopyrrolidme1carbonyl)5methyl 1 Hpyrrol2ylmethylene]1, 3dihydroindol2one, 5 [4 (4Chlorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2methyl4 [3 (4 methylpiperazin1yl)propyl]lHpyrrole3carboxylic acid ethyl ester, 4 (4Chlorophenyl)3 [3 (cis3, 5dimethylpiperazine1carbonyl)5methyllH pyrrol2 ylmethylene]I, 3dihydroindol2one, 4(3Chlorophenyl)3[3,5dimethyl4(4methylpiperazine1carbonyl)1Hpyrrol 2ylmethylene]1, 3dihydroindol2one, 5 [4 (3Chlorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyllH pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5 [4 (3Chlorophenyl)2oxo1,2dihydroindol3ylidenemethyl]2,4dimethyl1H pyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 5 [4 (3Chlorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyl1H pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 4(3Chlorophenyl)3[3((S)3dimethylaminopyrrolidine1carbonyl)5methyl <BR> <BR> <BR> <BR> 1Hpyrrol2ylmethylene]1, 3dihydroindol2one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> 4 (3Chlorophenyl)3 [3 ( (R)3dimethylaminopyrrolidinelcarbonyl)5methyl 1Hpyrrol2ylmethylene]1, 3dihydroindol2one, 2 [4 (3Chlorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]5methyl1 H pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 4(3Chlorophenyl)3[3(cis3,5dimethylpiperazine1carbonyl)5methyl1H pyrrol2 ylmethylene]1, 3dihydroindol2one, 3[3,5Dimethyl4(4methylpiperazine1carbonyl)1Hpyrrol2ylmethylene]4(4 methoxyphenyl)1, 3dihydroindol2one, 5 [4 (4Methoxyphenyl)2oxo1, 2dihydroindol3ylidenemethy]2, 4dimethyllH pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5 [4 (4Methoxyphenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyl 1Hpyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 5 [4 (4Methoxyphenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyl 1Hpyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 3 [4 (cis3, 5Dimethylpiperazinelcarbonyl)3, 5dimethyl1 Hpyrrol2 ylmethylene]4 (4methoxyphenyl)1, 3dihydroindol2one, 2[4(4Methoxyphenyl)2oxo1,2dihydroindol3ylidenemethyl]5methyl1H pyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 2[4(4Methoxyphenyl)2oxo1,2dihydroindol3ylidenemethyl]5methyl1H pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 3[3((S)3Dimethylaminopyrrolidine1carbonyl)5methyl1Hpyrrol2 <BR> <BR> <BR> <BR> ylmethylene]4 (4methoxyphenyl)1, 3dihydroindol2one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> 3 [3 ( (R)3Dimethylaminopyrrolidine1carbonyl)5methyllHpyrrol2 ylmethylene]4 (4methoxyphenyl)1, 3dihydroindol2one, 3 [3, 5Dimethyl4 (4methylpiperazine1carbonyl)lHpyrrol2ylmethylene]4 (3 methoxyphenyl)1, 3dihydroindol2one, 5 [4 (3Methoxyphenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyl 1Hpyrrole3carboxylic acid (2diethylaminoethyl)amide, 5 [4 (3Methoxyphenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyl 1Hpyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 5 [4 (3Methoxyphenyl)2oxo1,2dihydroindol3ylidenemethyl]2,4dimethyl lHpyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 3 [4 (cis3, 5Dimethylpiperazine1carbonyl)3, 5dimethyllHpyrrol2 ylmethylene]4 (3methoxyphenyl)1, 3dihydroindol2one, 2[4(3Methoxyphenyl)2oxo1,2dihydroindol3ylidenemethyl]5methyl1H pyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 2[4(3Methoxyphenyl)2oxo1,2dihydroindol3ylidenemethyl]5methyl1H pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 5 [4 (3Methoxyphenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyl lHpyrrole3carboxylic acid (2diisopropylaminoethyl)amide, 4 (4Bromophenyl)3 [3, 5dimethyl4 (4methylpiperazinelcarbonyl)lHpyrrol 2ylmethylene]1, 3dihydroindo 12one, 5 [4 (4Bromophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyl1H pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5[4(4Bromophenyl)2oxo1,2dihydroindol3ylidenemethyl]2,4dimethyl1H pyrrole3carboxylic acid (2pyrrolidinIylethyl)amide, 5[4(4Bromophenyl)2oxo1,2dihydroindol3ylidenemethyl]2,4dimethyl1H pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, <BR> <BR> <BR> <BR> <BR> 4 (4Bromophenyl)3 [4 [cis3, 5dimethyl. piperazine1carbonyl)3, 5dimethyl<BR> <BR> <BR> <BR> <BR> <BR> 1 Hpyrrol2ylmethylene]1, 3dihydroindol2one, 2[4 (4Bromophenyl)2oxo1, 2dihydroindol3ylidenemethyl]5methyl1H pyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 2 [4 (4Bromophenyl)2oxo1, 2dihydroindol3ylidenemethyl]5methyl1H pyrrole3carboxylic acid (2El, 2,3] triazol1ylethyl)amide, 5[4(4Bromophenyl)2oxo1,2dihydroindol3ylidenemethyl]2,4dimethyl1H pyrrole3carboxylic acid (2diisopropylaminoethyl)amide, 5 [4 (4Bromophenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methyl1H pyrrole3carboxylic acid (2diethylaminoethyl)amide, 3 [3, 5Dimethyl4 (4methylpiperazine1carbonyl)lHpyrrol2ylmethylene]4 (3 bromophenyl)1,3dihydroindol2one, 5 [4 (3Bromophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyl1 H pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5[4(3Bromophenyl)2oxo1,2dihydroindol3ylidenemethyl]2,4dimethyl1H pyrrole3carboxylic acid (2pyrrolidinIylethyl)amide, 5 [4 (3Bromophenyl)2oxo1,2dihydroindol3ylidenemethyl]2,4dimethyl1 H pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 3 [4 (cis3, 5Dimethylpiperazine1carbonyl)3, 5dimethyl1 Hpyrrol2 ylmethylene]4 (3bromophenyl)1, 3dihydroindol2one, 2[4(3Bromophenyl)2oxo1,2dihydroindol3ylidenemethyl]5methyl1H pyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 2 [4 (3Bromophenyl)2oxo. 1, 2dihydroindol3ylidenemethyl]5methylIH pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 5[4(4Bromophenyl)2oxo1,2dihydroindol3ylidenemethyl]2,4dimethyl1H pyrrole3carboxylic acid (2diisopropylaminoethyl)amide, 5[4(4Fluorophenyl)2oxo1,2dihydroindol3ylidenemethyl]4methyl1H pyrrole2carboxylic acid (2diethylaminoethyl)amide, 5. [4 (3Fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methyl1 H pyrrole2carboxylic acid (2diethylaminoethyl)amide, 5 [4 (4Chlorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methyllH pyrrole2carboxylic acid (2diethylaminoethyl)amide, 5[4(3Chlorophenyl)2oxo1,2dihydroindol3ylidenemethyl]4methyl1H pyrrole2carboxylic acid (2diethylaminoethyl)amide, 5 [4 (4Bromophenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methyl1 H pyrrole2carboxylic acid (2diethylaminoethyl)amide, 5 [4 (3Bromophenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methyl1 H pyrrole2carboxylic acid (2diethylaminoethyl)amide, 5 [4 (4Methoxyphenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methyl1 H pyrrole2carboxylic acid (2diethylaminoethyl)amide, 5 [4 (3Methoxyphenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methyl1H pyrrole2carboxylic acid (2diethylaminoethyl)amide, 3(3,5Dimethyl1Hpyrrol2ylmethylene)4 (4fluorophenyl)1,3dihydroindol2 one, 3 (3, 5DimethyllHpyrrol2ylmethylene)4 (3fluorophenyl)1, 3dihydroindol2 one, 3 (3, 5DimethyllHpyrrol2ylmethylene)4 (4chiorophenyl)1, 3dihydroindol2 one, 3 (3, 5Dimethyl1Hpyrrol2y ! methylene)4 (3chlorophenyl)1, 3dihydroindol2 one, 3 (3, 5DimethyllHpyrrol2ylmethylene)4 (4bromophenyl)1,3dihydroindol2 one, 3(3, 5Dimethyl1 Hpyrrol2ylmethylene)4 (3bromophenyl)1, 3díhydroindol2 one, 3(3,5Dimethyl1Hpyrrol2ylmethylene)4 (4methoxyphenyl)I, 3dihydroindol 2one, 3 (3, 5Dimethyl1Hpyrrol2ylmethylene)4 (3methoxyphenyl)1, 3dihydroindol 2one, 5 [4 (4Fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methylIH pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5 [4 (3Fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methyl1H pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5 [4 (4Chlorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methylI H pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5 [4 (3Chlorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]4methylI H pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5[4(3bromophenyl)2oxo1,2dihydroindol3ylidenemethyl]4methyl1H pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5[4(4Methoxyphenyl)2oxo1,2dihydroindol3ylidenemethyl]4methyl1H pyrrole3carboxylic acid (2diethylaminoethyl)amide, 5 [4 (3Methoxyphenyl)2oxo1, 2dlhydro indol3ylidenemethyl]4methyllH pyrrole3carboxylic acid (2diethylaminoethyi)amide, <BR> <BR> <BR> <BR> <BR> 3 [3, 5Dirnethyl4 (4methylpiperazine1carbonyl)lHpyrrol2ylmethylene]4 (2<BR> <BR> <BR> <BR> <BR> <BR> fluorophenyl)1, 3dlhydroindol2one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> 5 [4 (2Fluorophenyl)2oxo1, 2dlhydroindol3ylidenemethyl]2, 4dimethyllH pyrrole3carboxylic acid (2diethylaminoethyl)anide, 5 [4 (2Fluorophenyl)2oxo1,2dlhydroindol3ylideneniethyl]2,4dimethyl1H pyrrole3carboxylic acid (2pyrrolidin1ylethyl)anTlide, 5 [4 (2Fluorophenyl)2oxo1, 2dlhydroindol3ylidenemethyl]2,4dimethyl1 H pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 2 [4 (2fluorophenyi)2oxo1, 2dihydroindol3ylidenemethyl]5methyl1H pyrrole3carboxylic acid (2diethylaminoethyl)amide, 2 [4 (2fluorophenyl)2oxo1, 2dlhydroindol3ylidenemethyl]5methyl1 H pyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 2 [4 (2fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]5methyl1 H pyrrole3carboxylic acid (2 [1, 2, 3] triazol1ylethyl) amide, 3 [3 (cis3, 5dimethylpiperazine1carbonyl)5methyllHpyrrol2ylmethylene]4 (2fluorophenyl)1, 3dihydro indol2one, 5 [4 (4Fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4dimethyl1H pyrrole3carboxylic acid (3diethylaminopropyl)amide, 2 [4 (4fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]5methyllH pyrrole3carboxylic acid (3pyrrolidin1ylpropyl)amide, 5[4(3Fluorophenyl)2oxo1,3dihydroindol3ylidenemethyl]2,4dimethyl1H pyrrole3carboxylic acid (3diethylaminopropyl)amide, 3[3,5Dimethyl4(4methylpiperazine1carbonyl)1Hpyrrol2ylmethylene]4(3 trifluoromethylphenyl)I, 3dihydroindol2one, 2,4Dimethyl5 [2oxo4 (3trifluoromethylphenyl)1,2dihydroindol3 ylidenemethyl]lHpynole3carboxylic acid (2diethylaminoethyl)amide, 2,4LMmethyl5 [2oxo4 (3trifluoromethylphenyl)1,2dihydroindol3 ylidenemethyl]lHpyrrole3carboxylic acid (2pyrrolidinIylethyl)aniide, 2,4Dimethyl5 [2oxo4 (3trifluoromethylphenyl)1,2dihydroindol3 ylidenemethyl]4Hpyrrole3carboxylic acid (2[1, 2,3] triazol1ylethyl)amide, 5methyl2[2oxo4(3trifluoromethylphenyl)1,2dihydroindol3ylidenemethyl] 1Hpyrrole3carboxylic acid (2diethylaminoethyl)amide, 5methyl2 [2oxo4 (3trifluoromethylphenyl)1, 2dihydroindol3ylidenemethyl] lHpyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 5methyl2 [2oxo4 (3trifluoromethylphenyl)1, 2dihydroindol3ylidenemethyl]I Hpyrrole3carboxylic acid (2 [1, 2,3] triazolIylethyl)amide, 3 [3 (cis3, 5dimethylpiperazine1carbonyl)5methyl1 Hpyrrol2ylmethylene]4 (2trifluoromethylphenyl)1, 3dihydroindol2one 2, 4Dimethyl~[2oxo4(3 trifluoromethylphenyl)1, 2dihydroindol3ylidenemethyl]1Hpyrrole3carboxylic acid (3diethylaminopropvl)amide, 2,4Dimethyl5 [2oxo4 (3trifluoromethylphenyl)1, 2dihydroindol3 ylidenemethyl]1Hpyrrole3carboxylic acid (3diethylaminopropyl)amide, 5methyl2 [2oxo4 (3trifluoromethylphenyl)l, 2dihydroindol3ylidenemethyl] lHpyrrole3carboxylic acid (3pyrrolidin1ylpropyl)amide, 3 [3methyl4 (4methylpiperazine1carbonyl)1Hpyrrol2ylmethylene]4 (3 trifluoromethylphenyl)I, 3dihydro indol2one, 3 [3Methyl4 (cis3, 5dimethylpiperazine1carbonyl)lHpyrrol2ylmethylene]4 (3trifluoromethylphenyl)1, 3dihydroindol2one, 4 (3chloro4fluorophenyl)3 [3, 5dimethyl4 (4methylpiperazine1carbonyl) 1Hpyrrol2ylmethylene]1,3dihydroindol2one, 5 [4 (3chloro4fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]2, 4 dimethyl1Hpyrrole3carboxylicacid (2diethylaminoethyl)amide, 5 [4 (3chloro4fluorophenyl)2oxo1,2dihydroindol3ylidenemethyl]2,4 dimethyl1Hpyrrole3carboxylicacid 2[1, 2,3] triazol1ylethyl)amide, 2 [4 (3chloro4fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]5methyl 1Hpyrrole3carboxylic acid (2pyrrolidin1ylethyl)amide, 2 [4 (3. chloro4 fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]5 methyli N pyrrole3carboxylic acid (2 [1, 2,3] triazol1ylethyl)amide, 2 [4 (3chloro4fluorophenyl)2oxo1, 2dihydroindol3ylidenemethyl]5methyl 1H pyrrole3carboxylic acid (3pyrrolidin1ylpropyl)amide, 4 (4chlorophenyl)3 [3, 5dimethyl4 [3 (4methylpiperazin1yl)3oxopropyl] 1Hpyrrol2ylmethylene]1, 3dihydroindol2one, 4 (2fluorophenyl)3 [3methyl4 (4methylpiperazine1carbonyl)1 Hpyrrol2 ylmethylene]1, 3dihydroindol2one, 4 (4fluorophenyl)3 [3methyl4 (4methylpiperazine1carbonyl)1Hpyrrol2 ylmethylene]1,3dihydroindol2one, 4 (4chlorophenyl)3 [3methyl4. (4methylpiperazine1carbonyl)lHpyrrol2 ylmethylene]1,3dihydroindol2one, <BR> <BR> <BR> <BR> <BR> 4 (4bromophenyl)3 [3methyl4 (4methylpiperazine1carbonyl)1 Hpyrrol2<BR> <BR> <BR> <BR> <BR> ylmethylene]1, 3dihydroindol2one,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 4 (3bromophenyl)3 [3methyl4 (4methylpiperazine1carbonyl)lHpyrrol2 ylmethylene]1,3dihydroindol2one, 4 (4methoxyphenyl)3 [3methyl4 (4methylpiperazine1carbonyl)lHpyrrol2 ylmethylene]1,3dihydroindol2one, 4 (3methoxyphenyl)3 [3methyl4 (4methylpiperazineIcarbonyl)1 Hpyrrol2 ylmethylene]1, 3dihydroindol2. one, 3[3methyl4(4methylpiperazine1carbonyl)1Hpyrrol2ylmethylene]4phenyl 1,3dihydroindol2one, 3 [4 (cis3, 5dimethylpiperazinelcarbonyl)3methyllHpyrrol2ylmethylene]4 (4fluorophenyl)1, 3dihydro indol2one, 4 (4Chlorophenyl)3 [4 [cis3, 5dimethylpiperazineIcarbonyl]3methyl1 H pyrrol2 ylmethylene]1,3dihydroindol2one, 4 (4Bromophenyl)3 [4 (cis3, 5dimethylpiperazine1carbonyl)3methyl1 H pyrrol2 ylmethylene]1, 3dihydroindol2one, 3 [4 (cis3, 5dimethylpiperazinelcarbonyl)3methyllHpyrrol2ylmethylene4 (4methoxyphenyl)1, 3dihydroindol2one, 3 [4 (cis3, 5dimethylpiperazinelcarbonyl)3methyllHpyrrol2ylmethylene]4 (3methoxyphenyl)1,3dihydroindol2one, 3 [4 (cis3, 5dimethylpiperazine1carbonyl)3methyl1 Hpyrrol2ylmethylene]4 phenyl1,3dihydroindol2one, 4(4chlorophenyl)3[4[3(cis3,5dimethylpiperazin1yl)3oxopropyl]3, 5 dimethyl1 Hpyrrol2ylmethylene]1, 3dihydroindol2one, 3[4[3(cis3,5Dimethylpiperazin1yl)3oxopropyl]3,5dimethyl1Hpyrrol2 ylmethylene]4 (4fluorophenyl)1, 3dihydroindol2one, 3[3,5Dimethyl4(4methylpiperazine1carbonyl)1Hpyrrol2ylmethylene]4(4 trifluoromethoxyphenyl)1, 3dihydroindol2one, 2,4Dimethyl5 [2oxo4 (4trifluoromethoxyphenyl)1,2dihydroindol3 ylidenemethyl]lHpyrrole3carboxylic acid (2diethylaminoethyl)amide, 2,4Dimethyl5 [2oxo4 (4trifluoromethoxy phenyl)1, 2dihydroindol3 ylidenemethyl]lHpyrrole3carboxylic acid (2 [1, 2,3] triazol 1ylethyl)amide, 5methyl2[2oxo4(4trifluoromethoxyphenyl)1, 2dihydroindol3 ylidenemethyl]lHpyrrole3carboxylic acid (2. pyrrolidin1ylethyl)amide, 5methyl2 [2oxo4 (4trifluoromethoxyphenyl)1, 2dihydroindol3 ylidenemethyl]lHpyrrole3carboxylic acid (2 [1, 2,3] triazol 1ylethyl)amide, 5methyl2 [2oxo4 (4trifluoromethoxyphenyl)1, 2dihydroindol3 ylidenemethyl]1 Hpyrrole3carboxylic acid (3pyrrolidin1yIpropyl)amide, 3[3(trans3,5Dimethylpiperazine1carbonyl)5methyl1Hpyrrol2ylmethylene] 4 (3fluorophenyl)1, 3dihydro indol2one, 4 (4Chlorophenyl)3 [3 (trans3, 5dimethyl piperazinelcarbonyl)5methyllH pyrrol2 ylmethylene]1,3dihydroindol2one, 4(3Chlorophenyl)3[3(trans3,5dimethyl piperazine1carbonyl)5methyl1H pyrrol2 ylmethylene]1, 3dihydroindol2one, 3 [4 (trans3, 5Dimethylpiperazinelcarbonyl)3, 5dimethyllHpyrrol2 ylmethylene]4 (4methoxyphenyl)1, 3dihydroindol2one, 3[4(trans3,5Dimethylpiperazine1carbonyl)3,5dimethyl1Hpyrrol2 ylmethylene]4 (3methoxyphenyl)1, 3dihydroindol2one, 4(4Bromophenyl)3[4[trans3,5dimethyl piperazine1carbonyl)3,5dimethyl 1Hpyrrol2ylmethylene]1,3dihydroindol2one, 3 [4 (trans3, 5Dimethylpiperazinelcarbonyl)3, 5dimethylIHpyrro12 ylmethylene]4 (3bromophenyl)1, 3dihydroindol2one, 3 [3 [trans3, 5dimethylpiperazineIcarbonyl]5methyllHpyrrol2ylmethylene] 4 (2fluorophenyl)1, 3dihydroindol2one, 3[3[trans3,5dimethylpiperazine1carbonyl]5methyl1Npyrrol2ylmethylene] 4 (2trifluoromethylphenyl)1, 3dihydroindol2one, 3 [3Methyl4 [trans3, 5dimethylpiperazine1carbonyl]lHpyrrol2ylmethylene] 4 (3trifluoromethylphenyl)1, 3dihydroindo 12one, 3[4[trans3,5dimethylpiperazine1carbonyl]3methyl1Npyrrol2ylmethylene] 4 (4fluorophenyl)1, 3dihydroindol2one, 4(4Chlorophenyl)3[4[trans3,5dimethylpiperazine1carbonyl]3methyl1H pyrrol2ylmethylene]1,3dihydroindol2one, 4 (4Bromophenyl)3 [4 [trans3, 5dimethylpiperazinelcarbonyl]3methyllH pyrrol2ylmethylene]1,3dihydroindol2one, 3 [4 [trans3, 5dimethylpiperazine1carbonyl]3methyllHpyrrol2ylmethylene] 4 (4methoxyphenyl)1, 3dihydroindol2one, 3 [4 [trans3, 5dimethylpiperazine1carbonyl]3methyl1 Hpyrrol2ylmethylene] 4 (3methoxyphenyl)1, 3dihydroindol2one, 3 {4 [trans3, 5dimethylpiperazine1carbonyl]3methyllHpyrrol2ylmethylene] 4phenyl1, 3dihydroindol2one, 4 (4chlorophenyl)3 (4 [3 [trans3, 5dimethylpiperazin1yl]3oxopropyl]3, 5 dimethyl1 Hpyrrol2ylmethylene]1, 3dihydroindol2one and 3 (4 [3 [trans3, 5Dimethylpiperazin1yl]3oxopropyl]3, 5dimethyllHpyrrol2 ylmethylene]4 (4fluorophenyl)l, 3dihydroindol2one.
5. A method of modulating the catalytic activity of a protein kinase comprising contacting said protein kinase with a compound of claim 1, or a pharmaceutically acceptable salt thereof.
6. The method of claim 5, wherein said protein kinase is selected from the group consisting of a receptor tyrosine kinase, a nonreceptor tyrosine kinase and a serinethreonine kinase.
7. The method of claim 6, wherein said receptor tyrosine kinase whose catalytic activity is modulated by a compound of this invention is selected from the group consisting of EGF, HER2, HER3, HER4, IR, IGF1R, IRR, PDGFRa, PDGFRß, CSFIR, CKit, Cfms, FlklR, Flk4, KDR/Flk1, Flt1, FGFR1R, FGFR2R, FGFR3R, FGFR4R, DDR1, DDR2 and Met.
8. The method of claim 6, wherein said cellular tyrosine kinase whose catalytic activity is modulated by a compound of this invention is selected from the group consisting of Src, Frk, Btk, Csk, Abl, ZAP70, Fes/Fps, Fak, Jak, Ack, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr, Aur 2 and Yrk.
9. The method of claim 6, wherein said serinethreonine protein kinase whose catalytic activity is modulated by a compound of this invention is selected from the group consisting of CDK2, Raf, NEK and BUB 1.
10. A method for treating a protein kinase related disorder comprising administering to an organism in need thereof a therapeutically effective amount of a compound of claim 1, or pharmaceutically acceptable salt thereof.
11. The method of claim 10, wherein said protein kinase related disorder is selected from the group consisting of a receptor tyrosine kinase related disorder, a non receptor tyrosine kinase disorder and a serinethreonine kinase related disorder.
12. The method of claim 10, wherein said protein kinase related disorder is selected from the group consisting of a MET kinase related disorder, FLK kinase related disorder, a FGFR kinase related disorder, SRC kinase related disorder, a DDR kinase related disorder, and a PDGFR kinase related disorder.
13. The method of claim 10, wherein said protein kinase related disorder is a cancer.
14. The method of claim 13, wherein said cancer is selected from the group consisting of squamous cell carcinoma, astrocytoma, Kaposi's sarcoma, glioblastoma, lung cancer, bladder cancer, head and neck cancer, melanoma, ovarian cancer, prostate cancer, breast cancer, smallcell lung cancer, glioma, colorectal cancer, genitourinary cancer and gastrointestinal cancer.
15. The method of claim 10, wherein said protein kinase related disorder is selected from the group consisting of diabetes, an autoimmune disorder, a hyperproliferation disorder, restenosis, fibrosis, psoriasis, von HeppelLindau disease, osteoarthritis, rheumatoid arthritis, angiogenesis, an inflammatory disorder, an immunological disorder and a cardiovascular disorder.
16. The method of claim 10, wherein said organism is a human.
17. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof.
18. The pharmaceutical composition of claim 17, which further comprises a physiologically acceptable carrier or excipient.
19. The pharmaceutical composition of claim 17, which further comprises other therapeutic agents.
20. The pharmaceutical composition of claim 19, wherein the other therapeutic agent is selected from the group consisting of an alkylating agent, an antimetabolic chemotherapeutic agent, a natural product based chemotherapeutic agent, mitoxantrone or paclitaxel.
21. A compound of formula II : wherein each Rs is independently halogen,OR6,COR6,COOR6, OCOR6, CONR6R,R6NCOR',NR6R,CN,NO2,CX3,SR6, SOR6,SO2R6,S020R6, SO2NR6R7, R6NSO2R7, perfluoroalkyl, lower alkyl, lower alkyl further substituted by one or more of R2, lower alkenyl, lower alkenyl further substituted by one or more of R2, lower alkynyl, lower alkynyl further substituted by one or more of R, cycloalkyl, cycloalkyl further substituted by one or more of R2, a heterocyclic ring, a heterocylic ring further substituted by one or more of R2, aryl and aryl further substituted by one or more of R2 ; R2 is selected from the group consisting of hydrogen, halogen, OR6, COR6, COOR6, OCOR6,CONR6R',R12NCOR3,NR6R',RGNC (O) R',CN,NO2, CX3,SR6, SOR6,SO2R6,SO20R6,SO2NR6R',R6NS02R, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, a heterocyclic ring and aryl; R6 and R7 are independently selected from the group consisting of hydrogen,CX3, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, a heterocyclic ring and aryl; wherein lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, the heteocyclic ring or aryl may be further substituted by one or more of (i)NR12R13, (ii) hydroxy, (iii) halo, (iv) a heterocyclic ring, (v) lower alkyl, (vi) C(O)NR12R13, (vii) OR12, (viii) SO2R12R13, or (ix)COR6 ; wherein said heterocyclic ring (iv) may be further substituted by one or more of lower alkyl, COR12, NR12COR13, halogen,OR, CX3, C(O)NR12R13, SO2R12R13, or SO2NR12R13, or R6 and R7 may be linked together to form a 4, 5 or 6 membered ring, optionally containing a hetero atom selected from the group consisting of N, O, S and SO2, which may be further substituted byCONRI2R3, lower alkyl, hydroxy, (CH2)nNR12R13, (CH2)nheterocycle, (CH2)nC(O)NR12R13, (CH2)nSO2R12R13, or (CH2)nNSO2R12R13, wherein said heterocycle may be further substituted by halo, lower alkyl, COR12, hydroxy, C(O)NR12R13, OR12,SO2R13R13, or SO2NR12R13; X is fluorine, chlorine, bromine or iodine; R12 is selected from the group consisting of hydrogen,CX3, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl,(CH2) ncycloalkyl,(CH2) nheterocycle, and aryl; Rl3 is selected from the group consisting of hydrogen,CX3, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, (CH2)ncycloalkyl, (CH2)nheterocycle, and aryl; or R 12 and R13 may be linked together to form a 4, 5or 6membered ring optionally containing one or more hetero atoms selected from the group consisting of 0, N, S, SO and SO2, which may contain 1 or 2 double bonds and may be further substituted by halogen, OR6,COR6,COOR6, OCOR6,CONR6R',R'ZNCOR'3,NRR',R6NC (O) R',CN, NO2, CX3, SR6, SOR6, SO2R6,SO2OR6, SO2NR6R7, R6NSO2R7, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, a heterocyclic ring and aryl; R9 is selected from the group consisting of halogen,CX3, lower alkyl, cycloalkyl, a heterocyclic ring and aryl, each of which may be further substituted by halogen, OR6, COOR6, OCOR6, CONR6R7, R6NCOR7, NR6R7, CX3, SR6, SOR6, SO2R6, SO2OR6, SO2NR6R7, or R6NSO2R7; and mis 1 or2, or a pharmaceutically acceptable salt thereof.
22. A compound of claim 21 wherein R8 is hydrogen, halogen, lower alkyl or lower alkyl substituted with R2 ; R2 is hydroxy or hydrogen; n is 02; R9 is lower alkyl ; m is 1 or 2 ; R6 and R7 independently are lower alkyl which may be substituted with hydrogen, hydroxy or NR 12R13 ; R6 and R7 can form a 5 or 6 membered ring with one or more hetero atoms selected from N, O which is further substituted with lower alkyl or (CH2)nNR12R13 ; RI2 and Rl3 independently are hydrogen, lower alkyl,C (O)lower alkyl, or (CH2) ncycloalkyl; or Rl2 and Rl3 can form a 5 or 6 membered ring having one or more hetero atoms selected from the group consisting of O and N and having 1 or 2 double bonds wherein the ring is further substituted with hydroxy,C (O)lower alkyl orNR6C (O)lower alkyl.
23. A compound of formula III: wherein each R8 is independently halogen,OR6,COR6,COOR6, OCOR6, CONR6R',R6NCOR7,NR6R',CN,NO2,CX3,SR6,SO2R6,SO2OR6,S02NR6R', R6NSO2R7, perfluoroalkyl, lower alkyl, lower alkyl further substituted by one or more of R2, lower alkenyl, lower alkenyl further substituted by. one or more of R2, lower alkynyl, lower alkynyl further substituted by one or more of R2, cycloalkyl, cycloalkyl further substituted by one or more of R2, a heterocyclic ring, a heterocyclic ring further substituted by one or more of R2, aryl and aryl further substituted by one or more of R2; is selected from the group consisting of hydrogen, halogen,OR6,COR6, COOR6, OCOR6, CONR6R7, R6NCOR7, NR6R7, CN, NO2, CX3, SO2R6, SO2OR6, SO2NR6R7, R6NSO2R7, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, a heterocyclic ring and aryl; R6 and R7 are independently selected from the group consisting of hydrogen,CX3, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, a heterocyclic ring and aryl; wherein lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, the heteocyclic ring or aryl may be further substituted by one or more ofNRI2Rl3, hydroxy, halo, a heterocyclic ring, lower alkyl,C (O)NRI2Ri3,OR12, orSOaR12R13 ; wherein said a heterocyclic ring may be further substituted by one or more of lower alkyl, COR12, NR12COR3, halogen, OR12, CX3, C(O)NR12R13, SO2R12R13, or SO2NR12R13, or R6 and R7 may be linked together to form 4 4, 5 or 6 membered ring, optionally containing a hetero atom selected from the group consisting of N, O, S, SO and SO2, which may be further substituted by CONRI2R13, lower alkyl, hydroxy, (CH2)nNR12R13, (CH2) n heterocycle, (CH2)nC(O)NR12R13, (CH2)nSO2R12R13, or (CH2)nNSO2R12R13, wherein said heterocycle may be further substituted by lower alkyl, COR12, hydroxy (O)NR12R13, OR12, SO2R12R13, or SO2NR12R13; X is fluorine, chlorine, bromine or iodine; Rl° is H, lower alkyl, lower alkyl substituted with one or more of R2,(CH2) nNR6R7, CONR6R7, SO2NR6R7, (CH2)nSR6, (CH2)nSOR6, (CH2)nSO2R6, (CH2)nSO2NR6R7, or (CH2) nOR6 ; R'1 is H, lower alkyl, lower alkyl substituted with one or more of R2,(CH2) nNR6R7, CONR6R7, SO2NR6R7, (CH2)nSR6, (CH2)nSOR6, (CH2)nSOR6, (CH2)nSO2NR6R7, or (CH2) nOR6 ; Rl2 is selected from the group consisting of hydrogen,CX3, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl,(CH2) nheterocycle, and aryl; Rl3 is selected from the group consisting of hydrogen,CX3, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, (CH2)nheterocycle, and aryl; or Rl2 and R13 may be linked together to form a 4, 5or 6membered ring optionally containing one or more hetero atoms selected from the group consisting of 0, N, S, SO and SO2, which may contain 1 or 2 double bonds; and wherein is a single or double bond; and n is 04, or a pharmaceutically acceptable salt thereof.
Description:
4-ARYL SUBSTITUTED INDOLINONES [0001] This application relates to provisional application serial no. 60/256,479, the entire contents of which are hereby incorporated by reference.

BACKGROUND OF THE INVENTION [0002] The following is offered as background information only and is not admitted to be prior art to the present invention.

[0003] Protein kinases ("PKs") are enzymes that catalyze the phosphorylation of hydroxy groups on tyrosine, serine and threonine residues of proteins. The consequences of this seemingly simple activity are staggering; cell growth, differentiation and proliferation, i. e., virtually all aspects of cell life in one way or another depend on PK activity. Furthermore, abnormal PK activity has been related to a host of disorders, ranging from relatively non-life threatening diseases such as psoriasis to extremely virulent diseases such as glioblastoma (brain cancer).

[0004] The PKs can be conveniently broken down into two classes, the protein tyrosine kinases (PTKs) and the serine-threonine kinases (STKs).

[0005] One of the prime aspects of PTK activity is their involvement with growth factor receptors. Growth factor receptors are cell-surface proteins. When bound by a growth factor ligand, growth factor receptors are converted to an active form which interacts with proteins on the inner surface of a cell membrane. This leads to phosphorylation on tyrosine residues of the receptor and other proteins and to the formation inside the cell of complexes with a variety of cytoplasmic signaling molecules that, in turn, effect numerous cellular responses such as cell division (proliferation), cell differentiation, cell growth, expression of metabolic effects to the extracellular microenvironment, etc. For a more complete discussion, see Schlessinger and Ullrich, Neuron 9 : 303-391 (1992), which is incorporated by reference, including any drawings, as if fully set forth herein.

[0006] Growth factor receptors with PTK activity are known as receptor tyrosine kinases ("RTKs"). They comprise a large family of transmembrane receptors with diverse biological activity. At present, at least nineteen (19) distinct subfamilies of RTKs have been identified. An example of these is the subfamily designated the "HER"RTKs, which include EGFR (epithelial growth factor receptor), HER2, HER3 and HER4. These RTKs consist of an extracellular glycosylated ligand binding domain, a transmembrane domain and an intracellular cytoplasmic catalytic domain that can phosphorylate tyrosine residues on proteins. l0007] Another RTK subfamily consists of insulin receptor (IR), insulin-like growth factor I receptor (IGF-1R) and insulin receptor related receptor (IRR). IR and IGF-1R interact with insulin, IGF-I and IGF-II to form a heterotetramer of two entirely extracellular glycosylated a subunits and two/3 subunits which cross the cell membrane and which contain the tyrosine kinase domain.

[0008] A third RTK subfamily is referred to as the platelet derived growth factor receptor ("PDGFR") group, which includes PDGFRa, PDGFRß, CSFIR, c-kit and c- fms. These receptors consist of glycosylated extracellular domains composed of variable numbers of immunoglobin-like loops and an intracellular domain wherein the tyrosine kinase domain is interrupted by unrelated amino acid sequences.

(0009] Another group which, because of its similarity to the PDGFR subfamily, is sometimes subsumed into the later group is the fetus liver kinase ("flk") receptor subfamily. This group is believed to be made of up of kinase insert domain-receptor fetal liver kinase-1 (KDR/FLK-1), flk-lR, flk-4 and fms-like tyrosine kinase 1 (flt-1).

[0010] A further member of the tyrosine kinase growth factor receptor family is the fibroblast growth factor ("FGF") receptor subgroup. This group consists of four receptors, FGFRl-4, and seven ligands, FGF1-7. While not yet well defined, it appears that the receptors consist of a glycosylated extracellular domain containing a variable number of immunoglobin-like loops and an intracellular domain in which the tyrosine kinase sequence is interrupted by regions of unrelated amino acid sequences.

[0011] Still another member of the tyrosine kinase growth factor receptor family is the vascular endothelial growth factor ("VEGF") receptor subgroup. VEGF is a dimeric glycoprotein similar to PDGF but has different biological functions and target cell specificity in vivo. In particular, VEGF is presently thought to play an essential role is vasculogenesis and angiogenesis.

[0012] Still another member of the tyrosine kinase growth factor receptor family is MET, often referred to as c-Met. c-Met is thought to play a role in priimary tumor growth and metastasis. l0013l A more complete listing of the known RTK subfamilies is described in Plowman et al., DN&P, 7 (6): 334-339 (1994), which is incorporated by reference, including any drawings, as if fully set forth herein.

[0014] In addition to the RTKs, there also exists a family of entirely intracellular PTKs called"non-receptor tyrosine kinases"or"cellular tyrosine kinases."This latter designation, abbreviated"CTK,"will be used herein. CTKs do not contain extracellular and transmembrane domains. At present, over 24 CTKs in 11 subfamilies (Src, Frk, Btk, Csk, Abl, Zap70, Fes, Fps, Fak, Jak and Ack) have been identified. The Src subfamily appear so far to be the largest group of CTKs and includes Src, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr and Yrk. For a more detailed discussion of CTKs, see Bolen, Oncogene, 8: 2025-2031 (1993), which is incorporated by reference, including any drawings, as if fully set forth herein.

[0015] The serine/threonine kinases, STKs, like the CTKs, are predominantly intracellular although there are a few receptor kinases of the STK type. STKs are the most common of the cytosolic kinases; i. e., kinases that perform their function in that part of the cytoplasm other than the cytoplasmic organelles and cytoskelton. The cytosol is the region within the cell where much of the cell's intermediary metabolic and biosynthetic activity occurs; e. g., it is in the cytosol that proteins are synthesized on ribosomes.

[00161 RTKs, CTKs and STKs have all been implicated in a host of pathogenic conditions including, significantly, cancer. Other pathogenic conditions which have been associated with PTKs include, without limitation, psoriasis, hepatic cirrhosis, diabetes, angiogenesis, restenosis, ocular diseases, rheumatoid arthritis and other inflammatory disorders, immunological disorders such as autoimmune disease, cardiovascular disease such as atherosclerosis and a variety of renal disorders.

[0017] With regard to cancer, two of the major hypotheses advanced to explain the excessive cellular proliferation that drives tumor development relate to functions known to be PK regulated. That is, it has been suggested that malignant cell growth results from a breakdown in the mechanisms that control cell division and/or differentiation. It has been shown that the protein products of a number of proto- oncogenes are involved in the signal transduction pathways that regulate cell growth and differentiation. These protein products of proto-oncogenes include the extracellular growth factors, transmembrane growth factor PTK receptors (RTKs), cytoplasmic PTKs (CTKs) and cytosolic STKs, discussed above.

[0018] In view of the apparent link between PK-related cellular activities and wide variety of human disorders, it is no surprise that a great deal of effort is being expended in an attempt to identify ways to modulate PK activity. Some of these have involved biomimetic approaches using large molecules patterned on those involved in the actual cellular processes (e. g., mutant ligands (U. S. Application Serial No.

4,966,849); soluble receptors and antibodies (Application No. WO 94/10202, Kendall and Thomas, Proc. Nat'1 Acad. Sci., 90: 10705-10709 (1994), Kim, et al., Nature, 362: 841-844 (1993)); RNA ligands (Jelinek, et al., Biochemistry, 33: 10450-56); Takano, et al., Mol. Bio. Cell, 4: 358A (1993); Kinsella, et al., Exp. Cell Res., 199: 56- 62 (1992); Wright, et al., J. Cellular Phys., 152: 448-57) and tyrosine kinase inhibitors (WO 94/03427 ; WO 92/21660; WO 91/15495; WO 94/14808 ; U. S. Patent No.

5,330,992; Mariani, et al., Proc. Am. Assoc. CancerRes., 35: 2268 (1994)).

[0019] In addition to the above, attempts have been made to identify small molecules which act as PK inhibitors. For example, bis-monocylic, bicyclic and heterocyclic aryl compounds (PCT WO 92/20642), vinylene-azaindole derivatives (PCT WO 94/14808) and 1-cyclopropyl-4-pyridylquinolones (U. S. Patent No.

5,330,992) have been described as tyrosine kinase inhibitors. Styryl compounds (U. S.

Patent No. 5,217,999), styryl-substituted pyridyl compounds (U. S. Patent No.

5,302,606), quinazoline derivatives (EP Application No. 0 566 266 A1), selenaindoles and selenides (PCT WO 94/03427), tricyclic polyhydroxylic compounds (PCT WO 92/21660) and benzylphosphonic acid compounds (PCT WO 91/15495) have all been described as PTK inhibitors useful in the treatment of cancer.

SUMMARY OF THE INVENTION [0020] A family of novel pyrrole-substituted 2-indolinone compounds have been discovered which exhibit PK modulating ability and have a salutary effect against disorders related to abnormal PK activity (U. S. Patent No. 5,792,783; U. S.

Application No. 09/322,297). It has been demonstrated that this family of compounds modulates the catalytic activity of receptor tyrosine kinases (RTKs), non- receptor protein tyrosine kinases (CTKs) and serine/threonine protein kinases (STKs).

[0021] For example, the catalytic activity of RTKs such as, without limitation, EGF, MET, HER2, HER3, HER4, IR, IGF-1R, IRR, PDGFRa, PDGFRß, CSFIR, C-Kit, C- fins, Flk-lR, Flk4, KDR/Flk-1, Flt-1, FGFR-1R, FGFR-2R, FGFR-3R and FGFR-4R may be modulated with pyrrole-substituted 2-indolinone compounds, in particular Met may be modulated. By affecting the catalytic activity of RTKs, CTKs and/or STKs, such compounds can interfere with the signals transduced by such proteins.

This application also encompasses affecting the catalytic activity of protein kinases disclosed in U. S. Application Nos. 09/233,857; 09/291,417; 60/149,005 and 60/136,503, and PCT Application No. PCT/US99/13533, the entire disclosures of which are hereby incorporated by reference.

1. CHEMISTRY [0022] In one aspect, the present invention relates to compounds haivng the following chemical structure (Formula I). wherein: [0023] Rl is an aryl or heteroaryl substituent, optionally substituted by one or more substituent selected from the group consisting of halogen,-OR6,-COR6,-COOR6, -OCOR6,-CONR6R7,-R6NCOR7,-NR6R7,-CN,-NO2,-CX3,-SR6,SOR6,-SO2 R6, -SO2OR6,-SO2NR6R7,-R6NSO2R7,perfluoroalkyl, lower alkyl, lower alkyl further substituted by one or more of R2, lower alkenyl, lower alkenyl further substituted by one or more of R2, lower alkynyl, lower alkynyl further substituted by one or more of R2, cycloalkyl, cycloalkyl further substituted by one or more of R2, a heterocyclic ring, a heterocyclic ring further substituted by one or more of R2, aryl and aryl further substituted by one or more of R2 ; [0024] R2 is selected from the group consisting of hydrogen, halogen,-OR6,-COR6, -COOR6,-OCOR6,-CONR6R7,-R6NCOR7,-NR6R7,-CN,-NO2,-CX3,-SR6,-S OR6, -SO2R6,-SO2OR6,-SO2NR6R7,-R6NSO2R7,perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, a heterocyclic ring and aryl; [0025] R3 is selected from the group consisting of hydrogen, halogen,-OR6,-COR6, - COOR6,-OCOR6,-CONR6R7,-R6NCOR7,-NR6R7,-CN,-NO2,-CX3,-SR6,-SO R6, -SO2R6,-SO2OR6,-SO2NR6R7,-R6NSo2R7, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, a heterocyclic ring, a heterocyclic ring further substituted by one or more of R2, and aryl, wherein said lower alkyl is further substituted by-CONR6R7, NR6R7,-SO2R6,-R6NSO2R, or -SO2NR6R7 ; [0026] R4 is selected from the group consisting of hydrogen, halogen,-OR6,-COR6, <BR> <BR> <BR> - COOR6,-OCOR6,-CONRR',-RNCOR',-NR6R7,-CN,-NO2,-CX3,-SR6, SOR6, -SO2R6,-SO2OR6,-SO2NR6R7,-R6NSO2R7, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, a heterocyclic ring and aryl, wherein said lower alkyl is further substituted by -CONR6R7, NR6R7, -SO2R6, -R6NSO2R, or S02NR ; [0027l R5 is selected from the group consisting of hydrogen, halogen,-OR6,-COR6, -COOR6,-OCOR6,-CONR6R7,-R6NCOR7,-NR6R7,-CN,-NO2,-CX3,-SR6,-S OR6, -SO2R6,-SO2OR6,-SO2NR6R7,-R6NSO2R7,perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, a heterocyclic ring and aryl; provided that no more than one of R3, R4, or Rs is hydrogen; [0028] R3 and R4 or R4 and R5 may be linked together to form a 4-, 5-, 6-or 7- membered ring optionally containing one or more hetero atoms selected from the group consisting of O, N, S, SO and SO2, which may contain 1 or 2 double bonds and may be further substituted by one or more of- (CH2)n-NR6R7,-(CH2)n-CR6R7, -(CH2)n-C(O)-(CH2)n-NR6R7,-(CH2)nSO2R6R7,-(CH2)nSO2R6R7 or -(CH2)n-C(O)-R6, wherein n is 0-4; [0029] R6 and R7 are independently selected from the group consisting of hydrogen, -CX3, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, a heterocyclic ring and aryl; wherein lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, the heteocyclic ring or aryl may be further substituted by one or more of (i)-NR12R13, (ii) hydroxy, (iii) halo, (iv) a heterocyclic ring, (v) lower alkyl, (vi)-C (O)-NR12R13, (vii)-OR12,(viii)-SO2R12R13, or (ix)-COR6 ; wherein said heterocyclic ring (iv) may be further substituted by one or more of lower alkyl,-COR12,-NRl2CoRl3, halogen, -OR12,CX3,-C(O)NR12R13,-SO2R12R12, or-SO2NR12R13, [0030] or R6 and R7 may be linked together to form a 4,5-or 6-membered ring, optionally containing a hetero atom selected from the group consisting of N, O, S and SO2, which may be further substituted by-CONRI2Ri3, lower alkyl, hydroxy, -(CH2)n=NR12R13,-(CH2)n-heterocycle,-(CH2)n-C(O)-NR12R13,-(C H2)nSO2R12R13, or -(CH2)nNSO2R12R13, wherein said heterocycle may be further substituted by halo, lower alkyl,-COR12, hydroxy,-C (O)-NR12R13,-OR12,-SO2R12R13, or-SO2NR12R13; [0031] X is fluorine, chlorine, bromine or iodine; [0032] Rl2 is selected from the group consisting of hydrogen,-CX3, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl,- n-cycloalkyl,-(CH2) n-heterocycle, and aryl ; [0033] R13 is selected from the group consisting of hydrogen,-CX3, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, -(CH2)n-cycloalkyl,-(CH2)n-heterocycle, and aryl; [0034] or R 12 and R13 may be linked together to form a 4-, 5-or 6-membered ring optionally containing one or more hetero atoms selected from the group consisting of O, N, S, SO and SO2, which may contain 1 or 2 double bonds; or a pharmaceutically acceptable salt thereof.

Compounds-Preferred Structural Features [0035] In a preferred aspect, R3 and R4 or R4 and Rs may be linked together to form a ring.

[0036] In a particularly preferred aspect, R3 and R4 or R4 and Rs are linked together to form a ring, the ring together with pyrrole is selected from the group consisting of : [0037] In another preferred aspect, R3 may be excluded when both R4 and R5 are hydrogen. In still a further preferred aspect, R'is aryl.

[0038] A preferred aspect of the invention relates to compounds of Formula II [0039] wherein each R8 is independently halogen,-OR6,-COR6,-COOR6, OCOR6, <BR> <BR> <BR> - CONR6R',-R6NCOR',-NR6R',-CN,-N02,-CX3,-SR6, SOR6,-S02R6,-S02OR6, -SO2NR6R7,-R6NSO2R7, perfluoroalkyl, lower alkyl, lower alkyl further substituted by one or more of R2, lower alkenyl, lower alkenyl further substituted by one or more of R, lower alkynyl, lower alkynyl further substituted by one or more of R, cycloalkyl, cycloalkyl further substituted by one or more of R2, a heterocyclic ring, a heterocylic ring further substituted by one or more of R2, aryl and aryl further substituted by one or more of R2 ; [0040] R2 is selected from the group consisting of hydrogen, halogen,-OR6,-COR6, -COOR6,OCOR6,-CONR6R7,-R12NCOR13,-NR6R7,-R6NC(O)R7,-CN, - N02,-CX3,-SR6,-SOR6,-SO2R6,-SO2OR6,-S02NR6R,-R6NS02R, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, a heterocyclic ring and aryl; [0041] R6 and R7 are independently selected from the group consisting of hydrogen, -CX3, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, a heterocyclic ring and aryl; wherein lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, the heteocyclic ring or aryl may be further substituted by one or more of (i)-NRizRl3, (ii) hydroxy, (iii) halo, (iv) a heterocyclic ring, (v) lower alkyl, (vi)-C(O)-NR12R13,(vii)-OR12,(viii)-SO2R12R13, or (ix)-COR6 ; wherein said heterocyclic ring (iv) may be further substituted by one or more of lower alkyl,-CORI2,-NRI2CoRl3, halogen, -OR12,CX3,-C(O)NR12R13,-SO2R12R13, or-SO2NR12R13, [0042] or R6 and R may be linked together to form a 4,5-or 6-membered ring, optionally containing a hetero atom selected from the group consisting of N, O, S and SO2, which may be further substituted by-CoNRl2RI3, lower alkyl, hydroxy, -(CH2)n-NR12R13,-(CH2)n-heterocycle,-(CH2)n-C(O)-NR12R13,-(C H2)nSO2R12R13, or - (CH2)nNSO2R12R13, wherein said heterocycle may be further substituted by halo, lower alkyl,-COR12,hydroxy,-C(O)-NR12R13,-OR12,-SO2R12R13,or -SO2NR12R13 ; [0043] X is fluorine, chlorine, bromine or iodine; [0044] Rl2 is selected from the group consisting of hydrogen,-CX3, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl,- (CH2)n-cycloalkyl,-(CH2)n-heterocycle, and aryl; [0045] R13 is selected from the group consisting of hydrogen,-CX3, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl,- n-cycloalkyl,-(CH2) n-heterocycle, and aryl; [0046] or RI2 and Rl3 may be linked together to form a 4-, 5-or 6-membered ring optionally containing one or more hetero atoms selected from the group consisting of O, N, S, SO and SO2, which may contain 1 or 2 double bonds and may be further substituted by halogen, -OR6,-COR6,-COOR6, OCOR6,-CONR6R7,-R12NCOR13, -NR6R7,-R6NC(O)R7,-CN,-NO2,-CX3,-SR6,SOR6,-SO2R6,-SO2OR6,-SO 2NR6R7, -R6NSO2R7,perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, a heterocyclic ring and aryl; [0047] R9 is selected from the group consisting of halogen,-CX3, lower alkyl, cycloalkyl, a heterocyclic ring and aryl, each of which may be further substituted by halogen,-OR6,-COOR6,-OCOR6,-CONR6R7,-R6NCOR,-NR6R7,-CX3,-SR6 , SOR6, SO2R6,-SO2OR6, S02NR6R7, or-R6NSO2R7 ; and m is 1 or 2, or a pharmaceutically acceptable salt thereof.

[0048] Another preferred aspect of the invention relates to compounds of Formula III, [0049] wherein each R8 is independently halogen,-OR6,-COR6,-COOR6, OCOR6, -CONR6R7,-R6NCOR7,-NR6R7,-CN,-NO2,-CX3,-SR6,-SO2R6,-SO2OR6, -SO2NR6R7,-R6NSO2R7,perfluoroalkyl, lower alkyl, lower alkyl further substituted by one or more of R2, lower alkenyl, lower alkenyl further substituted by one or more of R2, lower alkynyl, lower alkynyl further substituted by one or more of R2, cycloalkyl, cycloalkyl further substituted by one or more of R2, a heterocyclic ring, a heterocyclic ring further substituted by one or more of R2, aryl and aryl further substituted by one or more of R2 ; [0050] R2 is selected from the group consisting of hydrogen, halogen,-OR6,-COR6, - COOR6, OCOR6,-CONR6R',-R6NCOR',-NR6R',-CN,-NO2,-CX3,-S02R6, -SO2OR6,-SO2NR6R7,-R6NSO2R7, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, a heterocyclic ring and aryl; [0051] R6 and R are independently selected from the group consisting of hydrogen, -CX3, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, a heterocyclic ring and aryl; wherein lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, the heteocyclic ring or aryl may be further substituted by one or more of (i)-NR12R13, (ii) hydroxy, (iii) halo, (iv) a heterocyclic ring, (v) lower alkyl, (vi)-C(O)-NR12R13,(vii)-OR12,(viii)-SO2R12R13, or (ix)-COR6 ; wherein said heterocyclic ring (iv) may be further substituted by one or more of lower alkyl,-COR12,-NR12COR13, halogen, -OR12,CX3,-C(O)NR12R13,-SO2R12R13,or-SO2NR12R13, [0052] or R6 and R7 may be linked together to form a 4,5-or 6-membered ring, optionally containing a hetero atom selected from the group consisting of N, O, S and SO2, which may be further substituted by-CoNRI2Rl3, lower alkyl, hydroxy, - (CH20n-NR12R13,-(CH2)n-heterocycle,-(CH2)n-C(O)-NR12R13,-(CH 2)nSO2R12R13, or - (CH2)nNSO2R12R13, wherein said heterocycle may be further substituted by halo, lower alkyl,-CORI2, hydroxy,-C (O)-NR12R13,-OR12,-SO2R12R13,or-SO2NR12R13; [0053] X is fluorine, chlorine, bromine or iodine; [0054] Rl° is H, lower alkyl, lower alkyl substituted with one or more of R2, - (CH2) nNR6R7,-CONR6R7,-SO2NR6R7,-(CH2)n-SR6,-(CH2)n-SOR6,-(CH2)n-S O2R6, -(CH2) n-So2NR6R7 or-(CH2) n-OR6 ; [0055] R11 is H, lower alkyl, lower alkyl substituted with one or more of R2, - (CH2) nNR6R7,-CONR6R7,-SO2NR6R7,-(CH2)n-SR6,-(CH2)n-SOR6,-(CH2)n-S O2R6, - (CH2)n-SO2NR6R7,or-(CH2)n-OR6 ; [0056] R 12 is selected from the group consisting of hydrogen,-CX3, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl,- (CH2) n-cycloalkyl,- (CH2) n-heterocycle, and aryl; [0057] Rl3 is selected from the group consisting of hydrogen,-CX3, perfluoroalkyl, lower alkyl, lower alkenyl, lower alkynyl,-(CH2) n-cycloalkyl,-(CH2) n-heterocycle, and aryl; [0058] or Rl2 and Rl3 may be linked together to form a 4-, 5-or 6-membered ring optionally containing one or more hetero atoms selected from the group consisting of O, N, S, SO and SO2, which may contain 1 or 2 double bonds; and [0059] wherein--is a single or double bond ; and n is 0-4, or a pharmaceutically acceptable salt thereof.

[0060] The compounds presented herein are exemplary only and are not to be construed as limiting the scope of this invention in any manner.

[0061] The chemical formulae referred to herein may exhibit the phenomena of tautomerism and structural isomerism. For example, the compounds described herein may adopt an E or a Z configuration about the double bond connecting the 2- indolinone moiety to the pyrrole moiety or they may be a mixture of E and Z. This invention encompasses any tautomeric or structural isomeric form and mixtures thereof which possess the ability to modulate RTK, CTK and/or STK activity and is not limited to any one tautomeric or structural isomeric form.

[0062] In addition, the formulae referred to herein may also exhibit stereoisomerism, in which such compounds may adopt an R or S configuration at chiral centers. Thus, this invention also encompasses any stereoisomeric form, their corresponding enantiomers (d-and 1-or (+) and (-) isomers) and diastereomers thereof, and mixtures thereof, which possess the ability to modulate RTK, CTK and/or STK activity and is not limited to any one stereoisomeric form. [0063] Table 1 shows the chemical structures of the preferred compounds of the invention.

TABLE 1 Preferred 4-Aryl Substituted Indolinones Example Structure Name N 2-Methyl-4- [3- (4-methyl-piperazin-1- 1 So yl)-propyl]-5- (2-oxo-4-phenyl-1, 2- I' dihydro-indol-3-ylidenemethyl)-IH- 5, HN t pyrrole-3-carboxylic acid ethyl ester a H, C 3- [3,5-Dimethyl-4- (4-methyl- /\ 'piperazine-1-carbonyl)-lH-pyrrol-2- ylmethylene]-4-phenyl-1, 3-dihydro- indol-2-one CH, o (_CH, 2,4-Dimethyl-5-(2-oxo-4-phenyl-1,2- 3 4 dihydro-indol-3-ylidenemethyl)-lH- pyrrole-3-carboxylic acid (2- o diethylamino-ethyl)-amide H 3- [3, 5-Dimethyl-4- (4-methyl- 4 (J _<N<, N-cH, piperazine-1-carbonyl)-lH-pyrrol-2- 0h CH, ylmethylene]-4- (4-fluoro-phenyl)-1, 3- dihydro-indol-2-one CH, Nc 0 N-/5- [4- (4-Fluoro-phenyl)-2-oxo-1, 2- O N,. r 5 dihydro-indol-3-ylidenemethyl]-2, 4- CH, dimethyl-lH-pyrrole-3-carboxylic acid o (2-diethylamino-ethyl)-amide H ? 0no 5- [4- (4-Fluoro-phenyl)-2-oxo-1, 2- 6 0 m dihydro-indol-3-ylidenemethyl]-2, 4- dimethyl-lH-pyrrole-3-carboxylic acid N (2-pyrrolidin-1-yl-ethyl)-amide H H "5- [4- (4-Fluoro-phenyl)-2-oxo-1, 2- 7 N dihydro-indol-3-ylidenemethyl]-2, 4- dimethyl-lH-pyrrole-3-carboxylic acid j'N'CH o" (2- [1, 2,3] triazol-1-yl-ethyl)-amide H PU. CH, 4- (4-Fluoro-phenyl)-3- [5-methyl-3- (4- 8 $ out methyl piperazine-1-carbonyl)-1H- pyrrol-2-ylmethylene]-1, 3-dihydro- indol-2-one N H N.-N 2- [4- (4-Fluoro-phenyl)-2-oxo-1, 2- 9 1F NH dihydro-indol-3-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (2- , HN CH, [1,2,3] triazol-1-yl-ethyl) amide H H . Qt4 IN. CH, 3- [3- ( (S)-3-Dimethylamino-pyrrolidine- 10 o=< l-carbonyl)-5-methyI-lH-pyrrol-2- 8 CH, yhnethylene]-4-(4-fluoro-phenyl)-1,3- OH dihydro indol-2-one i N N N'CH, 3- [3- ( (R)-3-Dimethylamino-pyrrolidine- 11 o= l-carbonyl)-5-methyl-lH-pyrroI-2- ylmethylene]-4- (4-fluoro-phenyl)-1, 3- 0 dihydro indol-2-one 0 N 3- [3, 5-Dimethyl-4- (4-methyl- 12 u <, N-CH, piperazine-l-carbonyl)-lH-pyrrol-2- ylmethylene]-4- (3-fluoro-phenyl)-1, 3- dihydro-indol-2-one CH, o N vCH 5-[4-(3-Fluoro-phenyl)-2-oxo-1,2- 13 H dihydro-indol-3-ylidenemethyl]-2,4- dimethyl-lH-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide 0 H o INO 5- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- 14 F92 vH dihydro-indol-3-ylidenemethyl]-2, 4- dimethyl-lH-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide H H 5- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- F 0 N-N 15 F ", c, H dihydro-indol-3-ylidenemethyl]-2,4- 'Hc, , dimethyl-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide w CH, 9w8N 3- [3- ( (S)-3-Dimethylamino-pyrrolidine- 16 Fs 0< 1-carbonyl)-5-methyl-lH-pyrrol-2- Y-CH ylmethylene]-4-(3-fluoro-phenyl)-1,3- dihydro indol-2-one N H C, tt ('N' 3- [3- ( (R)-3-Dimethylamino-pyrrolidine- 17 F< o « l-carbonyl)-5-methyl-lH-pyrrol-2- J CH, ylmethylene]-4- (3-fluoro-phenyl)-1, 3- N =e dihydro indol-2-one H , CE N 5- [4- (3-Fluoro-phenyl])-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-2- methyl-4- [3- (4-methyl-piperazin-1-yl)- t §4oS propyl]-lH-pyrrole-3-carboxylicacid ethyl ester n H, C H 3- [3- (cis-3, 5-Dimethyl-piperazine-l- 19 F o<N carbonyl)-5-methyl-lH-pyrrol-2- ct% yhnethylene]-4- (3-fluoro-phenyl)-1, 3- o dihydro indol-2-one H H 0 4- (4-Chloro-phenyl)-3- [3, 5-dimethyl-4- 20 ( '''cH, (4-methyl-piperazine-l-caibonyl)-lH- pyrrol-2-ylmethylene]-1, 3-dihydro- indol-2-one H CH, P o '- 5- [4- (4-Chloro-phcnyl)-2-oxo-l, 2- H, C N dihydro-indol-3-ylidenemethyl]-2, 4- T rNkCH, dimethyl-lH-pyrrole-3-carboxylic acid o (2-diethylamino-ethyl)-amide H ci o 5- [4- (4-Chloro-phenyl)-2-oxo-l, 2- 22 N dihydro-indol-3-ylidenemethyl]-2,4- vHN CH, dimethyl-lH-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide H c, KY 5-[4-(4-Chloro-phenyl)-2-oxo-1, 2- 23 dihydro-indol-3-ylidenemethyl]-2,4- N H CHz dimethyl-lH-pyrrole-3-carboxylic acid 0 (2- [1, 2,3] triazol-1-yl-ethyl)-amide y'"vH, 4- (4-Chloro-phenyl)-3- [3- ( (S)-3- 24 0 dimethylamino-pyrrolidine-l-carbonyl)- 5-methyl-lH-pyrrol-2-ylmethylene]-1, 3- W^H ° dihydro-indol-2-one N H H H, 4- (4-ChIoro-phenyl)-3- [3- ( (R)-3- 25 o dimethylamino-pyrrolidine-l-carbonyl)- 5-methyl-lH-pyrrol-2-ylmethylene]-1, 3- i H o dihydro-indol-2-one VU N 5- [4- (4-Chloro-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-2- 26 ß o-- methyl-4- [3- (4-methyl-piperazin-1-yl)- Y OCH propyl]-lH-pyrrole-3-carboxylic acid ANSO ethyl ester h 4- (4-Chloro-phenyl)-3- [3- (cis-3, 5- 27 A, o='dimethyl-piperazme-l-carbonyl)-5- methyl-lH-pyrrol-2 ylmethylene]-1, 3- o dihydro-indol-2-one 0 H 4- (3-Chloro-phenyl)-3- [3, 5-dimethyl-4- 28''y,-. (4-methyl-piperazine-l-carbonyl)-lH- 0H pyrrol-2-ylmethylene]-1, 3-dihydro- N indol-2-one H <CHI 0 5- [4- (3-Chloro-phenyl)-2-oxo-1, 2- 29 G i ' H dihydro-indol-3-ylidenemethyl]-2,4- IfN-'cH, dimethyl-lH-pyrrole-3-carboxylic acid 0 (2-diethylamino-ethyl)-amide H 5- [4- (3-Chloro-phenyl)-2-oxo-1, 2- 30 °',""'J dihydro-indol-3-ylidenemethyl]-2,4- '\, o cH, dimethyl-lH-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide H 5- [4- (3-Chloro-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-2, 4- 3 1 G H C O HN N /HCH 'dimethyl-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide -"cH. 4- (3-Chloro-phenyl)-3- [3- ( (S)-3- 32 a i dimethylamino-pyrrolidine-l-carbonyl)- 5-methyl-lH-pyrrol-2-ylmethylene]-1, 3- dihydro-indol-2-one K Cl C) 4- (3-Chloro-phenyl)-3- [3- ( (R)-3- 33 oN dimethylamino-pyrrolidine-l-carbonyl)- 5-methyl-lH-pyrrol-2-ylmethylene]-1, 3- , i N o dihydro-indol-2-one H H 2- [4- (3-Chloro-phenyl)-2-oxo-1, 2- 34 °', ° dihydro-indol-3-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (2- N 0 NO [1, 2, 3] triazol-1-yl-ethyl)-amide "'cH, 4- (3-Chloro-phenyl)-3- [3- (cis-3, 5- 35 a o « N dimethyl-piperazine-l-carbonyl)-5- CH, methyl-lH-pyrrol-2 ylmethylene]-1, 3- dihydro-indol-2-one o-' 3- [3, 5-Dimethyl-4- (4-methyl- 36 b gNx N CH piperazine-l-carbonyl)-lH-pyrrol-2- NCH3 yhnethylene]-4- (4-methoxy-phenyl)-1, 3- 0 dihydro-indol-2-one R o'"'o 5- [4- (4-Methoxy-phenyl)-2-oxo-1, 2- 37 h H3CN H dihydro-indol-3-ylidenemethyl]-2, 4- dimethyl-lH-pyrrole-3-carboxylic acid ¢ » oH (2-diethylamino-ethyl)-amide H . CH, ( o CH, N-l 5- [4- (4-Methoxy-phenyl)-2-oxo-1, 2- 38 1 m dihydro-indol-3-ylidenemethyl]-2,4- < _HN CH3 dimethyl-lH-pyrrole-3-carboxylic acid uN) =O (2-pyrrolidin-l-yl-ethyl)-amide H 0'CH3 VO""N o NN 5- [4- (4-Methoxy-phenyl)-2-oxo-1, 2- 39 0 3 ZH dihydro-indol-3-ylidenemethyl]-2,4- N cH, dimethyl-lH-pyrrole-3-carboxylic acid o (2- [1, 2,3] triazol-1-yl-ethyl)-amide N H . CHj o H 3- [4- (is-3 ; 5-Dimethyl-piperazine-1- carbonyl)-3, 5-dimethyl-lH-pyrrol-2- 40 CH H, ylmethylene]-4- (4-methoxy-phenyl)-1, 3- o dihydro-indol-2-one H H o. cH, p-N 2- (4- (4-Methoxy-phenyl)-2-oxo-1, 2- 41 ( °" dihydro-mdol-3-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (2- pyrrolidin-1-yl-ethyl)-amide H -. FN. NN 2- [4- (4-Methoxy-phenyl)-2-oxo-1, 2- 42 dq ot dihydro-indol-3-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (2- [ [1, 2, 3] triazol-1-yl-ethyl)-amide H H . cH, 'en, 3- [3- ( (S)-3-Dimethylammo-pyrrolidme- 43 ß Ot l-carbonyl)-5-methyl-lH-pyrrol-2- HCH, ylmethylene]-4-(4-methoxy-phenyl)-1,3- dihydro-indol-2-one CHX O. CHI N. CH3 3- [3- ( (R)-3-Dimethylamino-pyrrolidine- 44 i. 0 1-carbonyl)-5-methyl-lH-pyrrol-2- X} _/CH ylmethylene]-4-(4-methoxy-phenyl)-1,3- dihydro-indol-2-one N H Hc-° HC N° 3- [3, 5-Dimethyl-4- (4-methyl- 45 V_, N-CH 3 piperazine-l-carbonyl)-IH-pyrrol-2- yl nethylene]-4- (3-methoxy-phenyl)-1, 3- dihydro-indol-2-one c O NeH'S- [4- (3-Methoxy-phenyl)-2-oxo-1, 2- 46 H dihydro-indol-3-ylidenemethyl]-2, 4- dimethyl-1H-pyrrole-3-carboxylic acid 0 (2-diethylamino-ethyl)-amide H _o o , 5- [4- (3-Methoxy-phenyl)-2-oxo-i, 2- 47 H dihydro-indol-3-ylidenemethyl]-2, 4- dimethyl-lH-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide H 5- [4- (3-Methoxy-phenyl)-2-oxo-1, 2- O N-N 48 HC N-N dihydro-indol-3-ylidenemethyl]-2,4- dimethyl-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide H 3_ (4- (cis-3, 5-Dimethyl-piperazine-1- 49''. " carbonyl)-3,5-dimethyl-lH-pyrrol-2- 1 en, cH, ylmethylene]-4- (3-methoxy-phenyl)- 1, 3-dihydro-indol-2-one H- 2- [4- (3-Methoxy-phenyl)-2-oxo-l, 2- 50 ° q °ffi_ dihydro-indol-3-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (2- o pyrrolidin-1-yl-ethyl)-amide H H JW N sN 2- [4- (3-Methoxy-phenyl)-2-oxo-1, 2- 51 '°T) ° dihydro-indol-3-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (2- o [1, 2,3] triazol-1-yl-ethyl)-amide H CC -H, 5- [4- (3-Methoxy-phenyl)-2-oxo-l, 2- 52 HC-0 HNc N dihydro-indol-3-ylidenemethyl]-2, 4- dimethyl-lH-pyrrole-3-carboxylic acid vHN-o (2-diisopropylamino-ethyl)-amide NV 4- (4-Bromo-phenyl)-3- [3, 5-dimethyl-4- 53 . . ' (4-methyl-piperazine-l-carbonyl)-lH- 6, H CH, pyrrol-2-ylmethylene]-1, 3-dihydro- indol-2-one , c ° r-c", 5- [4- (4-Bromo-phenyl)-2-oxo-1, 2- r \ JN* N 54''J "-cw, dihydro-indol-3-ylidenemethyl]-2,4- N CH3 dimethyl-lH-pyrrole-3-carboxylic acid N (2-diethylamino-ethyl)-amide H sr 0 5- [4- (4-Bromo-phenyl)-2-oxo-1, 2-. 55 h vH dihydro-indol-3-ylidenemethyl]-2, 4- N diinethyl-lH-pyrrole-3-carboxylic acid (2-pyrrolidin-I-yl-ethyl)-amide H N o "5- [4- (4-Bromo-phenyl)-2-oxo-1, 2- 56 h H3CQ-N~ dihydro-indol-3-ylidenemethyl]-2,4- 56 H oH CH dimethyl-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide NH Br O CH, 4- (4-Bromo-phenyl)-3- [4- [cis-3, 5- 57 dimethyl-piperazine-l-carbonyl)-3, 5- JU N CHs CH dimethyl-lH-pyrrol-2-ylmethylene]-1, 3- dihydro-indol-2-one H Br 0-i-Nc) 2- [4- (4-Bromo-phenyl)-2-oxo-1, 2- 58 h °> dihydro-indol-3-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (2- pyrrolidin-1-yl-ethyl)-amide pfNN 2- [4- (4-Bromo-phenyl)-2-oxo-1, 2- 59 ß °t, dihydro-indol-3-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (2- El, 2,3] triazol-1-yl-ethyl)-amide H H Bt 0 1, 6c--kN,, CN 5- [4- (4-Bromo-phenyl)-2-oxo-1, 2- 60 Hcf N~ dihydro-indol-3-ylidenemethyl]-2,4- T HHN+cc dimethyl-lH-pyrrole-3-carboxylic acid N ° (2-diisopropylamino-ethyl)-amide C sr (N CH, 5- [4- (4-Bromo-phenyl)-2-oxo-1, 2- 61] HCo ~ dihydro-indol-3-ylidenemethyl]-4- t HHN methyl-lH-pyrrole-3-carboxylic acid (2- G diethylamino-ethyl)-amide Br Ok 3- [3, 5-Dimethyl-4-(4-methyl- 62 V__/N-CH, piperazine-l-carbonyl)-lH-pyrrol-2- N CH3 ylmethylene]-4- (3-bromo-phenyl)-1, 3- GLN dihydro-indol-2-one (CH 5- [4- (3-Bromo-phenyl)-2-oxo-1, 2- 63 8 ce-. H3CSN~ dihydro-indol-3-ylidenemethyl]-2, 4- 4 ct% dimethyl-IH-pyrrole-3-carboxylic acid 9 (2-diethylamino-ethyl)-amide H o NO 5- [4- (3-Bromo-phenyl)-2-oxo-1, 2- 64 i"° p dihydro-indol-3-ylidenemethyl]-2,4- dimethyl-lH-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide "S- [4- (3-Bromo-phenyl)-2-oxo-1, 2- B O N-N 65 i"' dihydro-indol-3-ylidenemethyl]-2,4- dimethyl-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide 3- [4- (cis-3, 5-Dimethyl-piperazine-l- 66'')''"carbonyl)-3, 5-dmiethyl-lH-pyrrol-2- 0NHIH3 yhnethylene]-4- (3-bromo-phenyl)-1, 3- dihydro-indol-2-one 2- [4- (3-Bromo-phenyl)-2-oxo-1, 2- 67 dihydro-indol-3-ylidenemethyl]-5- r p methyl-I H-pyrrole-3-carboxylic acid (2- pyrrolidin-1-yl-ethyl)-amide 2- [4- (3-Bromo-phenyl)-2-oxo-. 1,2- 68 dihydro-indol-3-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide H CH o -"'5- [4- (3-Bromo-phenyl)-2-oxo-l, 2- 69 4 CH3 dihydro-indol-3-ylidenemethyl]-2, 4- , p, dimethyl-lH-pyrrole-3-carboxylic acid (2-diisopropylamino-ethyl)-amide F p HC 5- [4- (4-Fluoro-phenyl)-2-oxo-1, 2- 70 H dihydro-indol-3-ylidenemetliyl]-4- v NHa k methyl-lH-pyrrole-2-carboxylic acid (2- o 0 cl, diethylamino-ethyl)-amide HC C 5- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- 71 Y 4fNN^cH3 dihydro-indol-3-ylidenemethyl]-4- 09 0 6 methyl-lH-pyrrole-2-carboxylic acid (2- diethylamino-ethyl)-amide 5- [4- (4-Chloro-phenyl)-2-oxo-1, 2- 72 ¢ < N dihydro-indol-3-ylidenemethyl]-4- 0H L, CH, methyl-lH-pyrrole-2-carboxylic acid (2- N diethylamino-ethyl)-amide H Us H, 5- [4- (3-Chloro-phenyl)-2-oxo-1, 2- 73 N 10--'N'CH dihydro-indol-3-ylidenemethyl]-4- 0H 0 CH, methyl-lH-pyrrole-2-carboxylic acid (2- diethylamino-ethyl)-amide Br S- [4- (4-Bromo-phenyl)-2-oxo-1, 2- 74 W > N ^ dihydro-indol-3-ylidenemethyl]-4- N o o CH"'methyl-lH-pyrrole-2-carboxylic acid (2- 'diethylamino-ethyl)-amide Br H, C 5- [4- (3-Bromo-phenyl)-2-oxo-1, 2- 75 > < HNN^CH dihydro-indol-3-ylidenemethyl]-4- o" CH methyl-lH-pyrrole-2-carboxylic acid (2- 'diethylamino-ethyl)-amide CH 5- [4- (4-Methoxy-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-4- 76 0 CH, methyl-lH-pyrrole-2-carboxylic acid (2- 0 0 diethylamino-etllyl)-amide 5- [4- (3-Methoxy-phenyl)-2-oxo-1, 2- 77fNCH dihydro-indol-3-ylidenemethyl]-4- o H CHz methyl-lH-pyrrole-2-carboxylic acid (2- diethylamino-ethyl)-amide F S" 3- (3, 5-Dimethyl-lH-pyrrol-2- y inethylene)-4 (4-fluoro-phenyl)-1, 3- dihydro-indol-2-one H NU 3- (3, 5-Dimethyl-lH-pyrrol-2- HO ylmethylene)-4 (3-fluoro-phenyl)-1, 3- dihydro-indol-2-one H CRI "°° 3- (3, 5-Dimethyl-1H-pyrrol-2- 80 N CH ylmethylene)-4 (4-chloro-phenyl)-1, 3- dihydro-indol-2-one H 3_ (3, 5-Dimethyl-1H-pyrrol-2- 81 ylmethylene)-4 (3-chloro-phenyl)-1, 3- dihydro-indol-2-one H Br 82 3- (3, 5-Dimethyl-1H-pyrrol-2- ylmethylene)-4 (4-bromo-phenyl)-1, 3- ° dihydro-indol-2-one N N Br HC 3- (3, 5-Dimethyl-lH-pyrrol-2- go yhnethylene)-4 (3-bromo-phenyl)-1, 3- IN0 dihydro-indol-2-one N H o. CH 84 3- (3, 5-Dimethyl-lH-pyrrol-2- 84 ylmethylene)-4 (4-methoxy-phenyl)-I, 3- % =OH dihydro-indol-2-one N H 85 Q 3- (3, 5-DimethyI-lH-pyrrol-2- ylmethylene)-4 (3-methoxy-phenyl)-1, 3- o dihydro-indol-2-one N CH3 5- [4- (4-Fluoro-phenyl)-2-oxo-1, 2- 86 H dihydro-indol-3-ylidenemethyl]-4- methyl-1H-pyrrole-3-carboxylic acid (2- o diethylamino-ethyl)-amide CH3 CHj CH, 5- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- 87 N dihydro-indol-3-ylidenemethyl]-4- methyl-lH-pyrrole-3-carboxylic acid (2- Y-PY'Y oh diethylamino-ethyl)-amide H H l) o N-/5- [4- (4-Chloro-phenyl)-2-oxo-1, 2- 88 dihydro-indol-3-ylidenemethyll-4- methyl-I H-pyrrole-3-carboxylic acid (2- N o diethylamino-ethyl)-amide 0 CH, C'H3C 5_ 4- (3-Chloro-phenyl)-2-oxo-1, 2- 89 llCt vHN dihydro-indol-3-ylidenemethyl]-4- methyl-I H-pyrrole-3-carboxylic acid (2- o diethylamino-ethyl)-amide H CM, o 5- [4- (3-bromo-phenyl)-2-oxo-l, 2- 90 Ces, cßN~ dihydro-indol-3-ylidenemethyl]-4- X <HN methyl-lH-pyrrole-3-carboxylic acid (2- diethylamino-ethyl)-amide H CH, H, C0 5- [4- (4-Methoxy-phenyl)-2-oxo-1, 2- 91 h H3C2N dihydro-indol-3-ylidenemethyl]-4- methyl-IH-pyrroIe-3-carboxylic acid (2- o diethylamino-ethyl)-amide H CH ci% o 0 5- [4- (3-Methoxy-phenyl)-2-oxo-1, 2- 92 H dihydro indol-3-ylidenemethyl]-4- methyl-lH-pyrrole-3-carboxylic acid (2- diethylamino-ethyl)-amide H 3- [3, 5-Dimethyl-4- (4-methyl- 93 Fe 1Xs CH piperazine-l-carbonyl)-lH-pyrrol-2- = H 3 ylmethylene]-4-(2-fluoro-phenyl)-1,3- N dihydro-indol-2-one o rc*% 5- [4- (2-Fluoro-phenyl)-2-oxo-1, 2- Non 94 jC) L 'dihydro-indol-3-ylidenemethyl]-2, 4- /ON H CH ; dimethyl-lH-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide ~ND 5- [4-(2-Fluoro-phenyl)-2-oxo-1, 2- 95 G H3kN dihydro-indol-3-ylidenemethyl]-2,4- dimethyl-lH-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide w o 5- [4- (2-Fluoro-phenyl)-2-oxo-1, 2- 96 cN dihydro-indol-3-ylidenemethyl]-2, 4- dimethyl-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide N/-CH, "--CH, 2- [4- (2-fluoro-phenyl)-2-oxo-1, 2- 97, 3 o>> dihydro-indol-3-ylidenemethyl]-5- N CH, methyl-lH-pyrrole-3-carboxylic acid (2- nah diethylamino-ethyl)-amide N H 2- [4- (2-fluoro-phenyl)-2-oxo-1, 2- 98, 3 o% _ dihydro-indol-3-ylidenemethyl]-5- methyl-1H-pyrrole-3-carboxylic acid (2- N pyffolidin-1-yl-ethyl)-amide H HN'-l 2- [4- (2-fluoro-phenyl)-2-oxo-1, 2- 99 2 °t, dihydro-indol-3-ylidenemethyl]-5- cH, methyl-lH-pyrrole-3-carboxylic acid (2- o [1, 2,3] triazol-1-yl-ethyl) amide vHN CCtH H CH3 3- [3- (cis-3, 5-dimethyl-piperazine-l- 100 o= (carbonyl)-5-methyl-lH-pyrrol-2- yl ylmethylene]-4- (2-fluoro-phenyl)-1, 3- dihydro indol-2-one 0 H S- [4- (4-Fluoro-phenyl)-2-oxo-1, 2- 101 ! dihydro-indol-3-ylidenemethyl]-2, 4- , _¢ H CH3 dimethyl-lH-pyrrole-3-carboxylic acid Ws HNw (3-diethylamino-propyl)-amide H 0 2- [4- (4-fluoro-phenyl)-2-oxo-1, 2- 102, A, oq dihydro-indol-3-ylidenemethyl]-5- v methyl-lH-pyrrole-3-carboxylic acid (3- c H CH pyrrolidin-l-yl-propyl)-amide N N ozon S- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- 103 4 EH CHa dihydro-indol-3-ylidenemethyl]-2, 4- dimethyl-lH-pyrrole-3-carboxylic acid uH (3-diethylamino-propyl)-amide NU H 3- [3, 5-Dimethyl-4- (4-methyl- 104 N-piperazine-l-carbonyl)-lH-pyrrol-2- H "'ylmethylene]-4- (3-trifluoromethyl- phenyl)-1, 3-dihydro-indol-2-one 2, 4-Dimethyl-5- [2-oxo-4- (3- F c"Nl-, _Ct% trifluoromethyl-phenyl)-1, 2-dihydro- indol-3-ylidenemethyl]-lH-pyrrole-3- tCSoH z carboxylic acid (2-diethylamino-ethyl)- amide 2, 4-Dimethyl-5- [2-oxo-4- (3- FM H : C SN~NO trifluoromethyl-phenyl)-1, 2-dihydro- I 106 t AN% indol-3-ylidenemethyl]-lH-pyrrole-3- > carboxylic acid (2-pyrrolidin-1-yl- ethyl)-aniide 2, 4-Dimethyl-5- [2-oxo-4- (3- 107 0 trifluoromethyl-phenyl)-1, 2-dihydro- "indol-3-ylidenemethyl]-lH-pyrrole-3- carboxylic acid (2- [1, 2,3] triazol-1-yl- ethyl)-amide FF NJC bCHa 5-methyl-2-[2-oxo-4-(3-trifluoromethyl- 109 0 phenyl)-1, 2-dihydro-indol-3- ylidenemethyl]-lH-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide H Fp H- 5-methyl-2- [2-oxo-4- (3-tniluoromethyl- 109 phenyl)-1, 2-dihydro-indol-3- ylidenemethyl]-lH-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide H NiNNtSN 5-methyl-2-[2-oxo-4-(3-trifluoromethyl- 110 phenyl)-1, 2-dihydro-indol-3- ylidenemethyl]-I H-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide NU H 3- [3- (cis-3, 5-dimethyl-piperazine-l- G 4 carbonyl)-5-methyl-lH-pyrrol-2- t os ylmethylene]-4-(2-trifluoromethyl- phenyl)-1, 3-dihydro-indol-2-one 2, 4-Dimethyl-5- [2-oxo-4- (3- 112 trifluoromethyl-phenyl)-1, 2-dihydro- 112 1 indol-3-ylidenemethyl]-lH-pyrrole-3- carboxylic acid (3-diethylamino-propyl)- amide 0 F F HJ 5-methyl-2-[2-oxo-4-(3-trifluoromethyl- 113 0 phenyl)-1, 2-dihydro-indol-3- ylidenemethyl]-lH-pyrrole-3-carboxylic >,acid (3-pyrrolidin-1-yl-propyl)-amide N N H FF o 3- [3-methyl-4- (4-methyl-piperazine-1- 114 t N4Nt carbonyl)-lH-pyrrol-2-ylmethylene]-4 = N (3-trifluoromethyl-phenyl)-1, 3-dihydro i indol-2-one F F 0 3- [3-Methyl-4- (cis-3, 5-dimethyl- 115 W piperazine-l-carbonyl)-lH-pyrrol-2- N ylmethylene]-4- (3-trifluoromethyl- phenyl)-1, 3-dihydro-indol-2-one 4- (3-chloro-4-fluoro-phenyl)-3- [3, 5- 1 16 tJ KN<N_aw dimethyl-4-(4-methyl-piperazine-1- gHN CHz carbonyl)-1 H-pyrrol-2-ylmethylene]- 1, 3-dihydro-indol-2-one zut 5- [4- (3-chloro-4-fluoro-phenyl)-2-oxo- 117 17 t X 1, 2-dihydro-indol-3-ylidenemethyl]-2, 4- N {S 'dimethyl-lH-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide o 5- [4- (3-chloro-4-fluoro-phenyl)-2-oxo- 118 2 1S2-dihydro-indol-3-ylidenemethyl]-24- WHxa, dimethyl-l H-pyrrole-3-carboxylic acid N (2- [1, 2, 3] triazol-1-yl-ethyl)-amide H F 2- [4- (3-chloro-4-fluoro-phenyl)-2-oxo- 119 G i ° 1, 2-dihydro-indol-3-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (2- pyrrolidin-1-yl-ethyl)-amide F O N- NN 2- [4- (3-chloro-4--fluoro-phenyl)-2-oxo- 120 °T") °" l, 2-dihydro-indol-3-ylidenemethyl]-5- NCH, methyl-lh pyrrole-3-carboxylic acid (2- . W>HNHO [1, 2,3] triazol-1-yl-ethyl)-amide H Q 2- [4- (3-chloro-4-fluoro-phenyl)-2-oxo- 121 1, 2-dihydro-indol-3-ylidenemethyl]-5- 9 yrrole-3-carboxylic acid (3- pyrrolidin-1-yl-propyl)-amide N H C O N N 4- (4-chloro-phenyl)-3- [3, 5-dimethyl-4- 122 WJ < [3-(4-methyl-piperazin-1-yl)-3-oxo- KH= H CH3 propyl]-lH-pyrrol-2-ylmethylene]-1, 3- dihydro-indol-2-one H H O N N 4- (2-fluoro-phenyl)-3- [3-methyl-4- (4- 123 F 4 methyl-piperazine-l-carbonyl)-l H- pyrrol-2-ylmethylene]-1, 3-dihydro- indol-2-one H N N-CH 4- (4-fluoro-phenyl)-3- [3-methyl-4- (4- 124 !', 'methyl-piperazine-l-carbonyl)-lH- pyrrol-2-ylmethylene]-1, 3-dihydro- indol-2-one H ciN-CH 4- (4-chloro-phenyl)-3- [3-methyl-4- (4- 125 methyl-piperazine-l-carbonyl)-lH- pyrrol-2-ylmethylene]-1, 3-dihydro- 0 indol-2-one Br O H Br O N N-CH 4- (4-bromo-phenyl)-3- [3-methyl-4- (4- 126 W < methyl-piperazine-l-carbonyl)-lH- pyrrol-2-ylmethylene]-1, 3-dihydro- ° indol-2-one H 0-. er N N-cH, 4- (3-bromo-phenyl)-3- [3-methyl-4- (4- 127 »/methyl-piperazine-1-carbonyl)-1 H- pyrrol-2-ylmethylene]-1, 3-dihydro- 0 indol-2-one NU H 4- (4-methoxy-phenyl)-3- [3-methyl-4- (4- 128 0''-'''methyl-piperazine-l-carbonyl)-lH- pyrrol-2-ylmethylene]-1, 3-dihydro- indol-2-one 0 Nc Nl--\ N-Cit 4- (3-methoxy-phenyl)-3- [3-methyl-4- (4- 129 j methyl-piperazine-l-carbonyI)-lH- pyrrol-2-ylmethylene]-1, 3-dihydro- indol-2-one 0 "I c 130 -CH, 3- [3-methyl-4- (4-methyl-piperazine-1- 130 9 KH carbonyl)-lH-pyrrol-2-ylmethylene]-4- N phenyl-1, 3-dihydro-indol-2-one H F CH, 3- [4- (cis-3, 5-ditnethyl-piperazine-l- 131 i ', N ""carbonyl)-3-methyl-lH-pyrrol-2- H ylmethylene]-4- (4-fluoro-phenyl)-1, 3- ° dihydro indol-2-one NU m HC 0/- CN 4- (4-Chloro-phenyl)-3- [4- [cis-3, 5- 132 N NH dimethyl-piperazine-l-carbonyl]-3- methyl-lH-pyrrol-2 ylmethylene]-1, 3- dihydro-indol-2-one ar 0 Br O/_¢CHz 4-(4-Bromo-phenyl)-3-[4-(cis-3, 5- ""'dimethyl-piperaz ne) 1-carbonyl) 3- 133 gO methyl-lH-pyrrol-2 ylmethylene]-1, 3- dihydro-indol-2-one 0'CH3 CN 3- [4- (cis-3, 5-dimethyl-piperazine-l- 134 0"- ( carbonyl)-3-methyl-lH-pyn-ol-2- i a "'ylmethylene-4- (4-methoxy-phenyl)-1, 3- dihydro-indol-2-one 0-- CH 3- [4- (cis-3, 5-dimethyl-piperazine- 1- OHjC y-N MM'-'' 135 J 3-< carbonyl)-3-methyl-lH-pyn-ol-2- H ylmethylene]-4- (3-methoxy-phenyl)-1, 3- dihydro-indol-2-one 0 3- [4- (cis-3, 5-dimethyl-piperazine-1- 136 13 @N<NH carbonyl)-3-methyl-1H-pyrrol-2- c"'ylmethylene]-4-phenyl-1, 3-dihydro- H mdol-2-one N 4- (4-chloro-phenyl)-3- [4- [3- (cis-3, 5- 137 H, N NH dimethyl-piperazin-1-yl)-3-oxo-propyl]- JJ'c", '3, 5-dimethyl-lH-pyrrol-2-ylmethylene]- ° 1, 3-dihydro-indol-2-one 3- {4- [3- (cis-3, 5-Dimethyl-piperazin-1- 138 b Ha CNH yl)-3-oxo-propyl]-3, 5-dimethyl-lH- 0N CH, CN pyrrol-2-ylrnethylene}-4- (4-fluoro- N phenyl)-1, 3-dihydro-indol-2-one F o 3- [3, 5-Dimethyl-4- (4-methyl- 139 h HJCX C\ piperazine-l-carbonyl)-lH-pyrrol-2- 'ylmethylene]-4- (4-trifluoromethoxy- o phenyl)-1, 3-dihydro-indol-2-one H F-F 2, 4-Dimethyl-5- [2-oxo-4- (4- 140 _CH3 trifluoromethoxyphenyl)-1, 2-dihydro- (/_ H indol-3-ylidenemethyl]-lH-pyrrole-3- {CHX carboxylic acid (2-diethylamino-ethyl)- amide 2, 4-Dimethyl-5- [2-oxo-4- (4- 41 rk, N-N trifluoromethoxy phenyl)-1,2-dihydro- indol-3-ylidenemethyl]-lH-pyrrole-3- gg H CHj carboxylic acid (2- [1, 2,3] triazol 1-yl- ethyl)-amide FO-)-F ND 5-methyl-2- [2-oxo-4- (4- o trifluoromethoxy-phenyl)-1, 2-dihydro- 14 9 < indol-3-ylidenemethyl]-lH-pyrrole-3- = H carboxylic acid (2-pyrrolidin-1-yl- ethyl)-amide F-F 5-methyl-2- [2-oxo-4- (4- 143 oi trifluoromethoxy-phenyl)-1, 2-dihydro- indol-3-ylidenemethyl]-lH-pyrrole-3- H carboxylic acid (2- [1, 2,3] triazol 1-yl- ethyl)-amide 5-methyl-2- [2-oxo-4- (4- 144 ° o N trifluoromethoxy-phenyl)-1, 2-dihydro- i indol-3-ylidenemethyl]-lH-pyrrole-3- carboxylic acid (3-pyrrolidin-1-yl- propyl)-amide No H39AiH 3- [3- (trans-3, 5-Dimethyl-piperazine-l- 145 F carbonyl)-5-methyl-lH-pyrrol-2- ou H2 ylmethylene]-4- (3-fluoro-phenyl)-1, 3- H-'CH dihydro-indol-2-one N H N 4- (4-Chloro-phenyl)-3- [3- (trans-3, 5- 146 h os dimethylpiperazine-1-carbonyl)-5- methyl-lH-pyrrol-2 ylmethylene]-1, 3- H dihydro-indol-2-one H 3C (NH _ H 4- (3-Chloro-phenyl)-3- [3- (trans-3, 5- 147 cl °< dimethyl piperazine-1-carbonyl)-5- methyl-lH-pyrrol-2 ylmethylene]-1, 3- dihydro-indol-2-one N H zu OCF 3- [4- (trans-3, 5-Dimethylpiperazine-l- 148 0 carbonyl)-3,5-dimethyl-lH-pyrrol-2- ylmethylene]-4- (4-methoxy-phenyl)-1, 3- C dihydro-indol-2-one H "H 3- [4- (trans-3, 5-Dimethyl-piperazine-1- 149 ° carbonyl)-3,5-dimethyl-lH-pyrrol-2- ylmethylene]-4- (3-methoxy-phenyl)-1, 3- dihydro-indol-2-one H H3C=NH 4- (4-Bromo-phenyl)-3- [4- [trans-3, 5- 150 0 dimethyl piperazine-1-carbonyl)-3, 5- dimethyl-lH-pyrrol-2-ylmethylene]-1, 3- H dihydro-indol-2-one N H3C ZONE H3 H 3- [4- (trans-3, 5-Dimethyl-piperazine-l- 151 Brp Ot carbonyl)-3,5-dimethyl-lH-pyrrol-2- ylmethylene]-4- (3-bromo-phenyl)-1, 3- r\ dihydro-indol-2-one H H wN 3- [3- [trans-3, 5-dimethyl-piperazine-1- 152 o oi carbonyl]-5-methyl-lH-pyrrol-2- ylmethylene]-4- (2-fluoro-phenyl)-1, 3- dihydro-indol-2-one N W H F F > 3- {3-[trans-3, 5-dimethyl-piperazine-1- 153 F F o carbonyl]-5-methyl-lH-pyrrol-2- ylmethylene}-4- (2-trifluoromethyl- phenyl)-1, 3-dihydro-indol-2-one N H 3- [3-Methyl-4- [trans-3, 5-dimethyl- 154 F H"N piperazine-l-carbonyl]-lH-pyrrol-2- H ylmethylene]-4- (3-trifluoromethyl- N phenyl)-1, 3-dihydro-indol-2-one "H o, H, 3- {4- [trans-3, 5-dimethyl-piperazine-1- 155 X » N carbonyl]-3-methyl-lN-pyrrol-2- N iH3 ylmethylene}-4-(4-fluoro-phenyl)-1, 3- N dihydro-indol-2-one H 4- (4-Chloro-phenyl)-3- [4- [trans-3, 5- 156 dimethyl-piperazine-l-carbonyl]-3- H"H"CH methyl-lH-pyrrol-2-ylmethylene]-1, 3- dihydro-indol-2-one w o, H 4- (4-Bromo-phenyl)-3- [4- [trans-3, 5- H3C 157, gNXN dimethyl-piperazine-l-carbonyl]-3- irH. , methyl-lH-pyrrol-2-ylmethylene]-l, 3- dihydro-indol-2-one tri AH3 o ofCHß 3-{4-[trans-3, 5-dimethyl-piperazine-1- 158 U >\_, N carbonyl]-3-methyl-lH-pyrrol-2- ylmethylene)-4- (4-methoxy-phenyl)- 1, 3-dihydro-indol-2-one H CHO , ", 3_ {4- [trans-3, 5-dimethyl-piperazine-1- 159', ( 4"carbonyl]-3-methyl-1H-pyrrol-2- H H-H ylmethylene}-4- (3-methoxy-phenyl)- 1, 3-dihydro-indol-2-one 0 ,-"'3- {4- [trans-3, 5-dimethyl-piperazine-1- 160 Ç X \ carbonyl]-3-methyl-lH-pyrrol-2- SNCHt H, ylmethylenel-4-phenyl-1, 3-dihydro- H NH indol-2-one JS Hs SH 4-(4-chloro-phenyl)-3-{4-{3-[trans-3,5- 161 k__/N dimethyl-piperazin-1-yl]-3-oxo-propyl)- 3, 5-dimethyl-1H-pyrrol-2-ylmethylene}- 1, 3-dihydro-indol-2-one H 3- { 3- {3- [trans-3, 5-Dimethyl-piperazin- 162 1-yl]-3-oxo-propyl}-3, 5-dimethyl-lH- H pyrrol-2-yhnethylene}-4- (4-fluoro- N phenyl)-1, 3-dihydro-indol-2-one M N 4- (2-Fluoro-phenyl)-3- [l- [5- (2- 163 F pyrrolidin-I-yl-ethyl)-4, 5,6,7- r nN tetrahydro-lH-indol-2-yl]-meth-(Z)- o ylidene]-1, 3-dihydro-indol-2-one N H F N 4- (3-Fluoro-phenyl)-3- [l- [5- (2- 164 pyrrolidin-1-yl-ethyl)-4, 5,6,7- 1 NH tetrahydro-lH-indol-2-yl]-meth-(Z)- o ylidene]-1, 3-dihydro-indol-2-one N H c 0 N 4- (2-Fluoro-phenyl)-3- [l- [5- (2- 165 J21 < morpholin-4-yl-ethyl)-4, 5,6,7- tetrahydro-lH-indol-2-yl]-meth- (Z)- oH ylidene]-1, 3-dihydro-indol-2-one H H 0 4- (3-Fluoro-phenyl)-3- [1- [5- (2- 166 morpholin-4-yl-ethyl)-4, 5,6,7- N tetrahydro-lH-indol-2-yl]-meth- (Z)- o"ylidene]-1, 3-dihydro-indol-2-one N H H CL, 4- (2-Fluoro-phenyl)-3- [1- {5- [2- (4- methyl-piperazin-1-yl)-ethyl]-4, 5,6,7- tetrahydro-1H-indol-2-yl}-meth- (Z)- o ylidene]-1,3-dihydro-indol-2-one ZON CH, F C 4- (3-Fluoro-phenyl)-3- [l- {5- [2- (4- methyl-piperazin-1-yl)-ethyl]-4, 5,6,7- tetrahydro-lH-indol-2-yl}-meth- (Z)- o ylidene]-1, 3-dihydro-indol-2-one H H CHg F \ CHa F o 5- [4- (4-Fluoro-phenyl)-2-oxo-1, 2- 169 dihydro-indol- (3Z)-ylidenemethyl]-4- methyl-lH-pyrrole-3-carboxylic acid (2- o"diethylamino-ethyl)-amide N H CHg Cl O N-/5- [4- (3-Chloro-phenyl)-2-oxo-1, 2- 170 H dihydro-indol- (3Z)-ylidenemethyl]-4- J methyl-lH-pyrrole-3-carboxylic acid (2- i diethylamino-ethyl)-amide N H CH3 /oN 5- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- -N dihydro-indol- (3Z)-ylidenemethyl]-2, 4- Y/rN""CH dimethyl-lH-pyrrole-3-carboxylicacid methyl- (1-methyl-piperidin-4-yl)-amide 1-t4 H 0 H3c 5-Methoxy-3- [I- [3-methyl-4- 172 (morpholine-4-carbonyl)-lH-pyrrol-2- H C Oug NH yl]-meth-(Z)-ylidene]-4-phenyl-1,3- dihydro-indol-2-one H o -N°1 5- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- F [F1 H3C>HN/<H h=N dihydro-indol-(3Z)-ylidenemethyl]-2, 4- 173 T <NtCH3 dimethyl-lH-pyrrole-3-carboxylic acid NU (2-hydroxy-3- [1, 2, 3] triazol-1-yl- H propyl)-amide C"N 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-5- 174 ot methyl-lH-pyrrole-3-carboxylic acid (2- hydroxy-3- [1, 2,3] triazol-1-yl-propyl)- N CH3 H amide NU H NU H +/2-[4-(3-Fluoro-phenyl)-2-oxo-1,2- N dihydro-indol-(3Z)-ylidenemethyl]-5- 175 Fn 0t methyl-lH-pyrrole-3-carboxylic acid (2- N CH 3 hydroxy-3- [1, 2, 3] tfiazol-2-yl-propyl)- oh amide N H 0 H_'-'N 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-5- 176 F ° methyl-lH-pyrrole-3-carboxylic acid (2- hydroxy-3-morpholin-4-yl-propyl)- amide Nos 0 N \+HN N 4- (3-Fluoro-phenyl)-3- [1- {5-methyl-3- F [2- (4-methyl-piperazin-1-yl)-2-oxo- ethyl]-1H-pyrrol-2-yl}-meth- (Z)- N CF6 ylidene]-1, 3-dihydro-indol-2-one razz H N Fi3C-N 2- {2-[4-(3-Fluoro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-5- methyl-lH-pyrrol-3-yl}-N-methyl-N- (l- methyl-piperidin-4-yl)-acetamide H H CH3 N H3CN tA 3-[1-{3-[2-((3R, 5S)-3, Dimethyl- F piperazin-1-yl)-2-oxo-ethyl]-5-methyl- t l H-pyrrol-2-yl}-meth-(Z)-ylidene]-4-(3- N CH3 fluoro-phenyl)-1, 3-dihydro-indol-2-one I o N H 0 0 N N0 4- (3-Fluoro-phenyl)-3- [1- [5-methyl-3- (2-morpholin-4-yl-2-oxo-ethyl)-lH- pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one H 0 4- (3-Fluoro-phenyl)-3- [ 1- {5-methyl-3- 181 =o [2-oxo-2-(4-pyrrolidin-1-yl-piperidin-1- yl)-ethyl]-IH-pyrrol-2-yl}-meth- (Z)- ylidene]-1, 3-dihydro-indol-2-one I zozo N H chiera NEZ 4- (3-Fluoro-phenyl)-3- [1- {5-methyl-3- Wo [2-oxo-2-((S)-2-pyrrolidin-1-ylmethyl- 0 182 F pyrrolidin-1-yl)-ethyl]-lH-pyrrol-2-yl}- meth- (Z)-ylidene]-1, 3-dihydro-indol-2- /C (/HN CH3 one 11 L >0 one razz N H /-NU NON HN OH 2- {2- [4- (3-FluorO-phenyl)-2-oxo-1, 2- 183 F dihydro-indol- (3Z)-ylidenemethyl]-5- I methyl-lH-pyrrol-3-yl}-N- (2-hydroxy- N CH3 3- [1, 2,3] triazol-1-yl-propyl)-acetamide ° N H HN 2- {2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- 184 F t dihydro-indol-(3Z)-ylidenemethyl]-5- < h methyl-lH-pyrrol-3-yl}-N-(2-pyrrolidin- , <NXCH 1-yl-ethyl)-acetamide N H H HN 2- {2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- 18 =o dihydro-indol- (3Z)-ylidenemethyl]-5- methyl-lH-pyrrol-3-yl}-N- (3-pyrrolidin- CN 1-yl-propyl)-acetamide 11 1 » ° o !- ! o D M N- (2, 4-Dioxo-1,2,3,4-tetrahydro- F H pyrimidin-5-ylmethyl)-2- {2- [4- (3- 186 fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- f (3Z)-ylidenemethyl]-5-methyl-lH- CF pyrrol-3-yl}-acetamide H HC 0 \=o 4- (2-FIuoro-phenyl)-3- [l- {5-methyl-3- [2- (4-methyl-piperazin-1-yl)-2-oxo- ethyl]-1H-pyrrol-2-yl}-meth- (Z)- F c ylidene]-1, 3-dihydro-indol-2-one WN N H X H, c- N 2- {2- [4- (2-Fluoro-phenyl)-2-oxo-1, 2- 18 8 t dihydro-indol-(3Z)-ylidenemethyl]-5- methyl-IH-pyrrol-3-yl}-N-methyl-N- (I- methyl-piperidin-4-yl)-acetamide CCSo N H H ; H3 N N N 3- 3-[1- {3-[2-((3R, 5S)-3, 5-Dimethyl- 189 A t piperæin-1-yl)-2-oxo-ethyl]-5-methyl- 1H-pyrrol-2-yl}-meth- (Z)-ylidene]-4- (2- H cH3 fluoro-phenyl)-1, 3-dihydro-indol-2-one 11 1 » ° H H "M 0 0 4- (2-Fluoro-phenyl)-3- [ 1- [5-methyl-3- 190 n t (2-morpholin-4-yl-2-oxo-ethyl)-lH- FX, t/t pyrrol-2-yl]-meth-(Z)-ylidene]-1,3- dihydro-indol-2-one H H H Q t 4-(2-Fluoro-phenyl)-3-[1- {5-methyl-3- 191 =o [2-oxo-2- (4-pyrrolidin-1-yl-piperidin-1- m 9 yl)-ethyl]-lH-pyrrol-2-yl}-meth-(Z)- F ylidene]-1, 3-dihydro-indol-2-one w/OH,, CHa frT-\" H H 4- (4-Chloro-phenyl)-3- [1- {3, 5- dimethyl-4- [3- (4-methyl-piperazin-1- 192 T 89N k CH3 yl)-3-oxo-propyl]-1 H-pyrrol-2-yl}- meth- (Z)-ylidene]-1, 3-dihydro-indol-2- one H ci 0 CH, 4- (4-Chloro-phenyl)-3-fl- {4- [3- ( (3R, 5S)-3, 5-dimethyl-piperazin-1-yl)- 193 T/r-cH, CH, 3-oxo-propyl]-3,5-dimethyl-lH-pyrrol- 0H 2-yl}-meth- (Z)-ylidene]-1, 3-dihydro- N indol-2-one H F O H3C 3- [l- {3, 5-Dimethyl-4- [3- (4-methyl- 194 > < 3 piperazin-1-yl)-3-oxo-propyl]-lH- pyrrol-2-yl}-meth- (Z)-ylidene]-4- (4- N fluoro-phenyl)-1, 3-dihydro-indol-2-one H o S 5- [4- [3- (2-Hydroxy-ethyl)-phenyl]-2- L Y Y Y) P Y 3 N oxo-1, 2-dihydro-indol- (3Z)- 195 9 < ylidenemethyl]-2, 4-dimethyl-lH- I oH cH3 pyrrole-3-carboxylic acid (2-pyrrolidin- 1-yl-ethyl)-amide H OH 0 5- [4- [3- (2-Hydroxy-ethyl)-phenyl]-2- oxo-1, 2-dihydro-indol- (3Z)- 196 </kc \\ ylidenemethyl]-2, 4-dimethyl-lH- zu 14 N11 pyrrole-3-carboxylicacid (2- [1, 2, 3] triazol-1-yl-ethyl)-amide H HO I NN 2- [4- [3- (2-Hydroxy-ethyl)-phenyl]-2- ol oxo-1, 2-dihydro-indol- (3Z)- 197 ylidenemethyl]-5-methyl-lH-pyrrole-3- N CH3 carboxylic acid (2- [1, 2,3] triazol-1-yl- I. N 0 ethyl)-amide ZON H 9H, 0 0 H, C 3- [l- [3, 5-Dimethyl-4- (4-pyrrolidin-1-yl- W NC31 piperidine-1-carbonyl)-lH-pylrol-2-yl]- 198 N CH3 metll- (Z)-ylidene]-4- (3-methoxy- ° phenyl)-1, 3-dihydro-indol-2-one H H, C 0 4- (2-Chloro-phenyl)-3- [l- [3, 5-dimethyl- 4- (4-pyrrolidin-1-yl-piperidine-1- 0H carbonyl)-lH-pyrrol-2-yl]-meth- (Z)- N ylidene]-1, 3-dihydro-indol-2-one ci cl N 4- (4-Chloro-phenyl)-3- [1- [3, 5-dimethyl- 200-No 4- (4-pyrrolidin-1-yl-piperidine-l- lyH 3 carbonyl)-lH-pyrrol-2-yl]-meth- (Z)- W N) =O ylidene3-1, 3-dihydro-indol-2-one H ci H3C 0 4- (3-Chloro-phenyl)-3- [l- [3, 5-dimethyl- NANO 4- (4-pyrrolidin- 1-yl-piperidine-I- < H 3 carbonyl)-lH-pyrrol-2-yl]-meth-(Z)- ylidene]-1, 3-dihydro-indol-2-one F HaC N' 3- [1- [3,5-Dimethyl-4- (4-pyrrolidin-1-yl- piperidine-l-carbonyl)-lH-pyrrol-2-yl]- 0H meth- (Z)-ylidene]-4- (3-fluoro-phenyl)- 1, 3-dihydro-indol-2-one 0 3- [l- [5-Methyl-3- (4-pyrrolidin-1-yl- N piperidine-1-carbonyl)-lH-pyrrol-2-yl]- meth- (Z)-ylidene]-4-phenyl-1, 3- N CH3 dihydro-indol-2-one N H N 0 H (4-(4-Chloro-phenyl)-3-[5-methyl-3- 2 4 lt N (4-pyrrolidin-1-yl-piperidine-1- O i 1 < carbonyl)-lH-pyrrol-2-yl]-meth-(Z)- N c ylidene]-1, 3-dihydro-indol-2-one H 0 H H 4- (3-Fluoro-phenyl)-3- [I- [5-methyl-3- 205 F 0=' (4-pyrrolidin-1-yl-piperidine-1- carbonyl)-1H-pyrrol-2-yl]-meth- (Z)- CN ylidene]-1, 3-dihydro-indol-2-one I o 0 eHN c Q"3- [l- [5-Methyl-3- (moipholme-4- 0 carbonyl)-lH-pyrrol-2-yl]-meth- (Z)- 206 ylidenel-4-phenyl-1, 3-dihydro-indol-2- one N 0 H 0 Nc 4- (2-Chloro-phenyl)-3- [I- [5-methyl-3- 207) 2 t\ (morpholine-4-carbonyl)-lH-pyrrol-2- H''CH3 yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol- H Cl 2-one N H po a C 4_ 4- (4-Chloro-phenyl)-3- [l- [5-methyl-3- -.. jij -, (morpholme-4-carbonyl)-lH-pyn'ol-2- NCH3 yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol- ozone N H 0 4- (3-Fluoro-phenyl)-3- [l- [5-methyl-3- 209 < t (morpholine-4-carbonyl)-lH-pyrrol-2- NCH3 yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol- 0 2-once N 0 o H HO 2- [4- (3-Chloro-phenyl)-2-oxo-1, 2- Cl N dihydro-indol-(3Z)-ylidenemethyl]-5- 210 j °' methyl-lH-pyrrole-3-carboxylicacid (2, 6-dioxo-1, 2,3,6-tetrahydro-pyrimidin- 4-ylmethyl)-amide H HaC N 4- (3-Chloro-phenyl)-3- [1- [3-methyl-4- (4-pyrrolidin-1-yl-piperidine-1- Y H carbonyl)-lH-pyrrol-2-yl]-meth- (Z)- ylidene]-1, 3-dihydro-indol-2-one H 'D o 4- (3-Chloro-phenyl)-3- [ 1- [3-methyl-4- (2-pyrrolidin-1-ylmethyl-pyrrolidine-1- carbonyl)-lH-pyrrol-2-yl]-meth- (Z)- ylidene]-1, 3-dihydro-indol-2-one NON N H N 5- [4- (3-Chloro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-4- H methyl-lH-pyrrole-3-carboxylic acid (2- morpholin-4-yl-ethyl)-amide N cl H, CH 5- [4- (3-Chloro-phenyl)-2-oxo-1, 2- 214 N 1--Np dihydro-indol- (3Z)-ylidenemethyl]-4- oH H3C methyl-lH-pyrrole-3-carboxylic acid [3- (2-methyl-piperidin-1-yl)-propyl]-amide O b 5- [4- (3-Chloro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-4- H methyl-lH-pyrrole-3-carboxylic acid (2- piperidin-1-yl-ethyl)-amide H o N 5- [4- (3-Chloro-phenyl)-2-oxo-1, 2- 216 dihydro-indol- (3Z)-ylidenemethyl]-4- i methyl-lH-pyrrole-3-carboxylic acid (2- pyridin-4-yl-ethyl)-amide H H ci H3C HN\ 5- [4- (3-Chloro-phenyl)-2-oxo-1, 2- 217 N'N dihydro-indol- (3Z)-ylidenemethyl]-4- COH C methyl-lH-pyrrole-3-carboxylic acid (2- N pyrrolidin-1-yl-ethyl)-amide H au 5- [4- (3-Chloro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-4- < HN methyl-lH-pyrrole-3-carboxylic acid [3- (2-oxo-pyrrolidin-1-yl)-propyl]-amide o S- [4- (3-Chloro-phenyl)-2-oxo-1, 2- Cl o¢ H3CXHN OH dihydro-indol-(3Z)-ylidenemethyl]-4- 219 \-i methyl-IH-pyrrole-3-carboxylic acid (2- o hydroxy-3-morpholin-4-yl-propyl)- N amide Cl 5- [4- (3-Chloro-phenyl)-2-oxo-1, 2- < y-'P"dihydro-mdol- (3Z)-ylidenemethyt]-4- 220 X rHN NNoN methyl-lH-pyrrole-3-carboxylic acid (2- N oH hydroxy-3- [1, 2,3] triazol-1-yl-propyl)- amide NO 3- [1- {3, 5-DimethyI-4- [2-oxo-2- (4- 221 3c pyaolidin-1-yl-piperidin-1-yl)-ethyl]- 221 0 1H-pyrrol-2-yl}-meth- (Z)-ylidene]-4- (2- N H CH3 fluoro-phenyl)-1, 3-dihydro-indol-2-one o N H t 3- [1-{3,5-Dimethyl-4-[2-oxo-2-((S)-2- x pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- 222) H3C ethyl]-lH-pyrrol-2-yl}-meth-(Z)- ylidene]-4- (2-fluoro-phenyl)-1, 3- cH'dihydro-indol-2-one N H H H3c N 2- {5- [4- (2-Fluoro-phenyl)-2-oxo-1, 2- F 0 N 0 dihydro-indol- (3Z)-ylidenemethyl]-2, 4- o °"'dimethyl-lH-pyrrol-3-yl}-N- (2- morpholin-4-yl-ethyl)-acetamide H, CH t 3- {4-[2-((3R, 5S)-3, 5-Dimethyl- H3C N-/CH'piperazin-1-yl)-2-oxo-ethyl]-3, 5- 224 FX H0 dimethyl-lH-pyrrol-2-yl}-meth-(Z)- ) % N CH3 ylidene]-4-(2-fluoro-phenyl)-1,3- o dihydro-indol-2-one H H H3C N ~ N\X) 2- {5- [4-(2-Fluoro-phenyl)-2-oxo-1, 2- 225 F 0 dihyclro-indol- (3Z)-ylidenemediyl]-2, 4- dimethyl-lH-pyrrol-3-yl}-N- (2- ° piperidin-1-yl-ethyl)-acetamide Nu 2-f 5- [4- (2-Fluoro-phenyl)-2-oxo-1, 2- 226 F 0 dihydro-indol- (3Z)-ylidenemethyl]-2, 4- dimethyl-lH-pyrrol-3-yl}-N- (2-pyridin- N 4-yl-ethyl)-acetamide H H C N'N 2- {5- [4- (2-Fluoro-phenyl)-2-oxo-1, 2- 227 F 0 dihydro-indol- (3Z)-ylidenemethyl]-2, 4- A (K" dimethyl-lH-pyrrol-3-yl}-N- (2- ° pyrrolidin-1-yl-ethyl)-acetamide H CH3 INCH3 3- [1- {3, 5-Dimethyl-4- [2- (4-methyl- 22 e H3C\S piperazin-l-yl)-2-oxo-ethyl]-lH-pyrrol- F N CH3 2-yl}-meth- (Z)-ylidene]-4- (2-fluoro- o phenyl)-1, 3-dihydro-indol-2-one N H C9 H3C N-) 3- [l- [3, 5-Dimethyl-4- (2-morpholin-4- I 1 o yl-2-oxo-ethyl)-lH-pyrrol-2-yl]-meth- 1 H CH3 (Z)-ylidene]-4-(2-fluoro-phenyl)-1, 3- dihydro-indol-2-one VH H, c"^ N- (2-Diethylamino-ethyl)-2- f 5- [4- (2- 230 F XO NL CH3 fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- = H CH3 (3Z)-ylidenemethyl]-2,4-dimethyl-lH- H pyrrol-3-yl}-acetamide H 4- (2-Chloro-phenyl)-3- [l- [3, 5-dimethyl- cl H3C \_N-CH, 4- (4-methyl-piperazine-l-carbonyl)-lH- 0H pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one H H ND 2- [4- (2-Chloro-phenyl)-2-oxo-1, 2- JJ y- dihydro-indol- (3Z)-ylidenemethyl]-5- H''CH3 methyl-lH-pyrrole-3-carboxylic acid (2- 0H pyrrolidin-1-yl-ethyl)-amide N H N 2- [4- (2-Chloro-phenyl)-2-oxo-1, 2- 233 0 dihydro-indol- (3Z)-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (3- pyrrolidin-1-yl-propyl)-amide 11 1 F° 0 C 4- (2-Chloro-phenyl)-3- [1- [3-methyl-4- °"Y/-- (4-methyl-piperazme-l-carbonyl)-lH- 0H pyffol-2-yl]-metli- (Z)-ylidene]-1, 3- dihydro-indol-2-one H H H3c, 0 H3c 4- (3-Methoxy-phenyl)-3- [I- [3-methyl- 4- (morpholine-4-carbonyl)-lH-pyrrol-2- 235 yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol- 2-one H F O c ! A. H, c 4- (3-CMoro-4-Huoro-phenyl)-3- [l- [3- 236 methyl-4- (morpholine-4-carbonyl)-IH- pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one N H 0 3- [l- {3, 5-Dimethyl-4- [2-oxo-2- (4- 237 FFC N--/pyrrolidin-1-yl-piperidin-1-yl)-ethyl]- W 0 1H-pyrrol-2-yl}-meth- (Z)-ylidene)-4- (3- \/H' fluoro-phenyl)-1, 3-dihydro-indol-2-one H 0 H HO N N 2_fs_ (4- (3-Fluoro-phenyl)-2-oxo-1, 2- FH3 N+/dihydro-indol-(3Z)-ylidenemethyl]-2, 4- 238 W wo dimethyl-lH-pyrrol-3-yl}-N-(2- N CH3 hydroxy-3- [1, 2,3] triazol-2-yl-propyl)- acetamide H 0 FH3C N-) 3- [I- [3, 5-Dimethyl-4- (2-morpholin-4- 239 C o yl-2-oxo-ethyl)-lH-pyrrol-2-yl]-meth- (, (Z)-ylidene]-4- (3-fluoro-phenyl)-1, 3- 0H dihydro-indol-2-one N H OH 4- (3-Fluoro-phenyl)-3- [l- {4- [2- (4- 240 3 0 hydroxy-piperidin-1-yl)-2-oxo-ethyl]- T vNtCH3 3,5-dimethyl-lH-pyrrol-2-yl}-meth- (Z)- o'ylidene]-1, 3-dihydro-indol-2-one N NU 2- {5- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- 241 W KGo dihydro-indol-(3Z)-ylidenemethyl]-2, 4- dimethyl-lH-pyrrol-3-yl}-N- (2- morpholin-4-yl-ethyl)-acetamide H H NCH FH3C H CH3 N-(2-Diethylamino-ethyl)-2- {5-[4-(3- 242 0 fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- M (3Z)-ylidenemethyI]-2, 4-dimethyMH- N pyrrol-3-yl}-acetamide H H-N FH3C 2- [5- [4- (3-Fluoro-phenyl)-2-oxo- 1, 2- 243 W o dihydro-indol-(3Z)-ylidenemethyl]-2,4- dimethyl-lH-pyrrol-3-yl}-N- (2- pyrrolidin-1-yl-ethyl)-acetamide H H HH c_m 3- {4-[2-((3R, 5S)-3, 5-Dimethyl- + H3C ~ H3 piperazin-1-yl)-2-oxo-ethyl]-3, 5- 244 Lj J (o dimethyl-lH-pyrrol-2-yl}-meth- (Z)- N CF ylidene]-4- (3-fluoro-phenyl)-1, 3- so dihydro-indol-2-one H H FFC N fN 2-15- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- 245 0 dihydro-indol- (3Z)-ylidenemethyl]-2, 4- dimethyl-lH-pyrrol-3-yl}-N- (2-pyridin- ! 4-yl-ethyl)-acetamide H N 2-Fluoro-5- {3- [l- [5-methyl-3- (4- N F NS pyrrolidin-l-yl-piperidine-l-carbonyl)- 246 I w o 1H-pyrrol-2-yl]-meth- (Z)-ylidene]-2- W 43 oxo-2, 3-dihydro-lH-indol-4-yl}- KA H CH3 benzonitrile I o 0 H N HO N-N 2- [4- (3-Cyano-4-fluoro-phenyl)-2-oxo- 1, 2-dihydro-indol- (3Z)-ylidenemethyl]- 247 Xq °A 5-methyl-lH-pyrrole-3-carboxylic acid NCH3 (2-hydroxy-3- [1, 2, 3] triazol-2-yl- o propyl)-amide N H t-LC Lj H S-f 3- [1- [3- ( (3R, SS)-3, 5-Dimethyl- piperazine-l-carbonyl)-5-methyl-lH- 248 pyrrol-2-yl]-meth- (Z)-ylidene]-2-oxo- 2, 3-dihydro-lH-indol-4-yl}-2-fluoro- zozo benzonitrile HN HIC N-CH3 F 3- [I- [3- (3-Dimethylamino-propyl)- 249 ß 4,5,6,7-tetrahydro-lH-indol-2-yl]-meth- (Z)-ylidene]-4- (4-fluoro-phenyl)-1, 3- dihydro-indol-2-one N N t-t) C N-CHUG 3- [I- [3- (3-Dimethylainino-propyl)- 250 4,5,6,7-tetrahydro-lH-indol-2-yl]-meth- FV 4 (Z)-ylidene]-4-(2-fluoro-phenyl)-1, 3- dihydro-indol-2-one 0 H3C N-CH3 cl 4- (4-Chloro-phenyl)-3- [l- [3- (3- 251 dimethylamino-propyl)-4, 5,6,7- tetrahydro-lH-indol-2-yl]-meth- (Z)- ylidene]-1, 3-dihydro-indol-2-one ; o N H HsC N-CHg 4- (3-Chloro-phenyl)-3- [1- [3- (3- dimethylamino-propyl)-4, 5,6,7- tetrahydro-lH-indol-2-yl]-meth- (Z)- ylidene]-1, 3-dihydro-indol-2-one I o N H H N-CHO 4- (2-Chloro-phenyl)-3- [1- [3- (3- dimethylamino-propyl)-4, 5,6,7- C) r.-A tetrahydro-lH-mdol-2-yl]-meth- (Z)- H ylidene]-1, 3-dihydro-indol-2-one N H 0 4-Biphenyl-3-yl-3- [l- [3, 5-dimethyl-4- J J''0 (4-pyrrolidm-l-yl-pipendme-l- gv HN CH3 carbonyl)-lH-pyrrol-2-yl]-meth-(Z)- ylidene]-1, 3-dihydro-indol-2-one H , l 5- [4-Biphenyl-3-yl-2-oxo-1, 2-dihydro- F6C indol- (3Z)-ylidenemethyl]-2, 4-dimethyl- 255 t ßHN CH3 lH-pyrrole-3-carboxylic acid (2- hydroxy-3- [1, 2, 3] triazol-1-yl-propyl)- amide chu, W p CH, 4-Biphenyl-3-yl-3- [1- [4- ( (3R, 5S)-3, 5- N NH2 dimethyl-piperazine-l-carbonyl)-3, 5- . dimethyl-lH-pyn-ol-2-yI]-meth- (Z)- ylidene]-1, 3-dihydro-indol-2-one H 0 AF 4- (3-Fluoro-phenyl)-3- [1- [4- (4-hydroxy- /-oH piperidine-l-carbonyl)-3, 5-dimethyl-lH- H pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- t dihydro-indol-2-one H F H3C0 3- [I- [3, 5-Dimethyl-4- (4-pyridin-2-yl- V--/piperazine-l-carbonyl)-lH-pyrrol-2-yl]- 0H meth- (Z)-ylidene]-4- (3-fluoro-phenyl)- 1, 3-dihydro-indol-2-one p o N- 5- [4- (3-Fluoro-phenyl)-2-oxo-l, 2- 259 H dihydro-indol- (3Z)-ylidenemethyl]-2, 4- Y, fNcH- dimethyl-lH-pyrrole-3-carboxylicacid (2-piperidin-1-yl-ethyl)-amide NU fCH3 o N-" 5- [4-BiphenyI-2-yl-2-oxo-l, 2-dihydro- N indol- (3Z)-ylidenemethyl]-2, 4-dimethyl- 260 1H-pyrrole-3-carboxylic acid (2- i N o diethylamino-ethyl)-amide N I i H N 2- [4-Biphenyl-2-yl-2-oxo-1, 2-dihydro- 261 o=, (indol-(3Z)-ylidenemethyl]-5-methyl-lH- pyrrole-3-carboxylic acid (3-pyrrolidin- N CH3 1-yl-propyl)-amide N H H 0 ci N 2- [4- (4-Chloro-phenyl)-2-oxo-1, 2- 262 (of dihydro-indol-(3Z)-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (3- 1S CHg pyrrolidm-l-yl-propyl)-amide I o 0 H N 0 2- [4- (3-Chloro-phenyl)-2-oxo-1, 2- 263 ci 0 dihydro-indol- (3Z)-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (3- pyrrolidin-1-yl-propyl)-amide I o N H 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- F 0 dihydro-indol- (3Z)-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (3- pyrrolidin-1-yl-propyl)-amide I o \+HN H 0 Br H 2- [4- (4-Bromo-phenyl)-2-oxo-1, 2- 265 o==<"dihydro-indol- (3Z)-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (3- N HN CH3 pyrrolidin-l-yl-propyl)-amide I o H H 0 5-Methyl-2- [2-oxo-4-phenyl-1, 2- 266 °-dihydro-indol- (3Z)-ylidenemethyl]-lH- pyrrole-3-carboxylic acid (3-pyrrolidin- 1-yl-propyl)-amide 11 1 » ° N H o F FH3 r--i 5- [4- (3, 5-Difluoro-phenyl)-2-oxo-1, 2- w H3C r_, 267 H dihydro-indol- (3Z)-ylidenemethyll-2, 4- dimethyl-lH-pyrrole-3-carboxylic acid > (2-pyrrolidin-1-yl-ethyl)-amide s N H H N 2- [4- (3, 5-Difluoro-phenyl)-2-oxo-1, 2- 268 FbN dihydro-indol- (3Z)-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (3- pyrrolidin-1-yl-propyl)-amide H H 0 FH3c N' 4- (3, 5-Difluoro-phenyl)-3- [1- [3, 5- /- dimethyl-4- (4-methyl-piperazine-l- 269 \ i oH carbonyl)-lH-pyrrol-2-yl]-meth- (Z)- N ylidene]-1, 3-dihydro-indol-2-one H 0 4- (3, 5-Difluoro-phenyl)-3- [l- [5-methyl- 270 F Fo N 3- (4-pyrrolidin-1-yl-piperidine-l- carbonyl)-lH-pyrrol-2-yl]-meth- (Z)- N CH3 ylidene]-1, 3-dihy (Iro-indol-2-one N ZON H H HO 0 3- [1- {3,5-Dimethyl-4- [3- (4-methyl- piperazin-1-yl)-3-oxo-propyl]-1H- 271 rcH, pyrrol-2-yl}-meth- (Z)-yHdene]-4- [3- (2- o"hydroxy-ethyl)-phenyl]-1, 3-dihydro- H indol-2-one HO o CH3 3- [l- {4- [3- ( (3R, 5S)-3, 5-Dimethyl- H, C N NH piperazin-l-yl)-3-oxo-propyl]-3, 5- 272 N CH, CH, dimethyl-lH-pyrrol-2-yl)-meth- (Z)- (>o ylidene]-4- [3-(2-hydroxy-ethyl)- phenyl]-1, 3-dihydro-indol-2-one HO H, C 0 4- [3- (2-Hydroxy-ethyl)-phenyl]-3- [l- [3- methyl-4- (4-methyl-piperazine-1- j'j carbonyl)-lH-pyrroI-2-yl]-meth- (Z)- ylidene]-1, 3-dihydro-indol-2-one H H "°") o cH, 3- [l- [4- ( (3R, 5S)-3, 5-Dimethyl- H, C N NH piperazine-l-carbonyl)-3-methyl-lH- 274 pyrrol-2-yl]-meth- (Z)-ylidene]-4- [3- (2- I o'hydroxy-ethyl)-phenyl]-1, 3-dihydro- N indol-2-one HO H N 2- [4- [3- (2-Hydroxy-ethyl)-phenyl]-2- oxo-1, 2-dihydro-indol- (3Z)- 275 ° ylidenemethyl]-5-methyl-lH-pyrrole-3- carboxylic acid (3-pyrrolidin-1-yl- H propyl)-amide N H CM Ho (-cH, 3- [l- [3- ( (3R, 5S)-3, 5-Dimethyl- piperazine-l-carbonyl)-5-methyl-1H- 276 11 pyrrol-2-yl]-metli- (Z)-ylidene]-4- [3- (2- NCH3 hydroxy-ethyl)-phenyl]-1, 3-dihydro- o indol-2-one N H HO O c (3- {3- [1- [3-Methyl-4- (morpholine-4- -N/ 277 \-O carbonyl)-lH-pyrrol-2-yl]-meth- (Z)- N ylidene]-2-oxo-2, 3-dihydro-lH-indol-4- 1 o yl}-phenyl)-acetic acid H CH3 HN 4-13- [2- ( (3R, 5S)-3, 5-Dimethyl- ° o piperazin-1-yl)-2-oxo-ethyl]-phenyl}-3- tHt, C N/ [1- [3-methyl-4- (morpholine-4- carbonyl)-lH-pyrrol-2-yl]-meth- (Z)- ylidene]-1, 3-dihydro-indol-2-one H H3C. N. CH3 N- (2-Dimethylamino-ethyl)-2- (3- f 3- [1- HN O O [3-methyl-4- (morpholine-4-carbonyl)- 279 Nc 1H-pyrrol-2-yl]-meth- (Z)-ylidene]-2- w HNß oxo-2, 3-dihydro-lH-indol-4-yl}- phenyl)-acetamide I o N H CH3 N 0 5- [4- (2-Fluoro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-4- phenyl-lH-pyrrole-3-carboxylic acid o"methyl- (1-methyl-piperidin-4-yl)-amide N H mo 0 5- [4- (2-Fluoro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-4- 281 F N phenyl-lH-pyrrole-3-carboxylic acid (2- W\H CH3CH3 diethylamino-ethyl)-amide 0 0 5- [4- (2-Fluoro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-4- 282 phenyl-lH-pyrrole-3-carboxylic acid (2- uH) = pyrrolidin-l-yl-ethyl)-amide 0 H H o N, N-Dimethyl-2- (3- {3- [l- [3-methyl-4- ( (4-methyl-piperazine-1-carbonyl)-lH- 283 pyrrol-2-yl]-meth- (Z)-ylidene]-2-oxo- 2, 3-dihydro-lH-indol-4-yl}-phenyl)- acetamide H . N o 2- (3- {3- [1- [3, 5-Dimethyl-4- (4- I HC ° 9 pyrrolidin-l-yl-piperidine-l-carbonyl)- 284 9 vN>3 lH-pyrrol-2-yl]-meth-(Z)-ylidene]-2- = H CHs oxo-2,3-dihydro-lH-indol-4-yl}- phenyl)-N, N-dimethyl-acetamide CH3 N', o 5- [4- (3-Dimethylcarbamoylmethyl- phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- 285 9 Ac <N ylidenemethyl]-2,4-dimethyl-lH- % = H H3CJ) pyrrole-3-carboxylic acid (2- diethylamino-ethyl)-amide OH 3- [1- [3, 5-Dimethyl-4- (4-pyrrolidin-1-yl- 286 No piperidine-l-carbonyl)-lH-pMol-2-yl]- N CH3 meth- (Z)-ylidene]-4- [3- (2-hydroxy- \ I o ethyl)-phenyl]-1,3-dihydro-indol-2-one N H CH, H3 N, CH 30 4- [3- (2-Dimethylamino-ethyl)-phenyl]- o 3- [l- [3-methyl-4- (morpholine-4- carbonyl)-lH-pyrrol-2-yl]-meth- (Z)- ylidene]-1, 3-dihydro-indol-2-one H CH3 N, clo 4- [3- (2-Dimethylamino-ethyl)-phenyll- H3C N 3- [1- [4- (4-hydroxy-piperidine-1- 288 > t \ OH carbonyl)-3, 5-dimethyl-lH-pyrrol-2-yl]- meth- (Z)-ylidene]-1, 3-dihydro-indol-2- ! one N H N 3- {3- [l- [3-Metliyl-4- (morpholine-4- HN o carbonyl)-lH-pyrrol-2-yl]-meth- (Z)- 289 0 Fc N/--\ ylidene]-2-oxo-2,3-dihydro-lH-indol-4- N yl}-N- (2-pyrrolidin-1-yl-ethyl)- benzamid N H 0 3- {3- [l- [3-Methyl-4- (morpholine-4- HN carbonyl)-1 H-pyrrol-2-yl]-meth-(Z)- 290 ov H3C XN\ ylidene]-2-oxo-2, 3-dihydro-lH-indol-4- W 4 o yl}-N-(3-pyrrolidin-1-yl-propyl)- benzamid H wu N H CH3 sNCH3 HN 0 N- (2-Dimethylamino-ethyl)-3- {3- [I- [3- 291 0 H3C methyl-4- (morpholine-4-carbonyl)-IH- pyrrol-2-yl]-meth- (Z)-ylidene]-2-oxo- 2, 3-dihydro-lH-indol-4-yl}-benzamide 11 1 F° EH H H H. CR, N- (3-Dimethylamino-propyl)-3- {3- [1- HN O [3-methyl-4-(morpholine-4-carbonyl)- 292 0 HC 1H-pyrrol-2-yl]-meth- (Z)-ylidene]-2- /1 oxo-2, 3-dihydro-lH-indol-4-yl}- benzamid o N H N. CH3 N-Methyl-3-f 3- [l- [3-methyl-4- o u H3C kN (morpholine-4-carbonyl)-lH-pyrrol-2- 293 W 4 yl]-meth-(Z)-ylidene]-2-oxo-2,3- dihydro-lH-indol-4-yl}-N- (l-methyl- o piperidin-4-yl)-benzamide /N H HN 2- {2- [4- (2-Fluoro-phenyl)-2-oxo-1, 2- 294 t dihydro-indol-(3Z)-ylidenemethyl]-5- methyl-lH-pyrrol-3-yl}-N- (2-pyrrolidin- F N CN 1-yl-ethyl)-acetamide N H H 0 SN N- (2, 4-Dioxo-1,2,3,4-tetrahydro- pyrimidin-5-yhnethyl)-2- {2- [4- (2- 295 fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)-ylidenemethyl]-5-methyl-1H- f ' M pyrrol-3-yl}-acetamide H CH, o 5- [4- (3-Ammo-lH-indazol-5-yl)-2-oxo- 296 N F6c N 1, 2-dihydro-indol- (3Z)-ylidenemethyl]- 2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide H H N-N O ~ND 5-[4-(3-Amino-lH-indazol-5-yl)-2-oxo- 297 f", 1, 2-dihydro-indol- (3Z)-ylidenemethyl]- I RN CH3 2,4-dimethyl-lH-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide H c HO 3 3-13- [l- [3-Methyl-4- (morpholine-4- 298 9 8/carbonyl)-lH-pyrrol-2-yl]-meth-(Z)- ylidene]-2-oxo-2, 3-dihydro-lH-indol-4- 11 yl}-benzoic acid N H FHC 0 5- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- 3 N OH dihydro-indol- (3Z)-ylidenemethyll-2, 4- 299 N < dimethyl-IH-pyrrole-3-carboxylic acid I oH (2-hydroxy-3-pyrrolidin-1-yl-propyl)- amide H rich3 FH3c No-N'--CH3 3- [I- [4- (3-Diethylainino-pyrrolidine-l- carbonyl)-3, 5-dimethyl-lH-pyrrol-2-yl]- NCH3 meth- (Z)-ylidene]-4- (3-fluoro-phenyl)- I N0 1, 3-dihydro-indol-2-one H Ck CH3 N 3- [I- [3- (3-Diethylamino-pyrrolidine-l- 301 F o= (carbonyl)-5-methyl-lH-pyrrol-2-yl]- meth- (Z)-ylidenel-4- (3-fluoro-phenyl)- 'N cr 1, 3-dihydro-indol-2-one 11 1 0 H oh o N lui CN CN N) 3- [1- {4- [2- (3-Diethylamino-pyrrolidin- 1-yl)-2-oxo-ethyl]-3, 5-dimethyl-1H- H C o pyrrol-2-yl}-meth- (Z)-ylidene]-4- (3- X HN CH3 fluoro-phenyl)-1, 3-dihydro-indol-2-one I o N H CH3 CH3 N 3- [1- {3- [2- (3-Diethylamino-pyrrolidin- 303 F o 1-yl)-2-oxo-ethyl]-5-methyl-lH-pyrrol- 2-yl}-meth- (Z)-ylidene]-4- (3-fluoro- N CN phenyl)-1, 3-dihydro-indol-2-one c H o F "-' 5- [4- (2, 4-Difluoro-phenyl)-2-oxo-1, 2- H dihydro-indol- (3Z)-ylidenemethyl]-2, 4- F T VNKCH dimethyl-lH-pyrrole-3-carboxylic acid o"3 (2-pyrrolidin-1-yl-ethyl)-amide N H t4o F 2- [4- (2, 4-Difluoro-phenyl)-2-oxo-1, 2- 0 dihydro-indol- (3Z)-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (3- CH3 pyrrolidin-1-yl-propyl)-amide I o 0 F w H3c N 4- (2, 4-Difluoro-phenyl)-3- [1- [3, 5- 306 F4J A N-CH3 dimethyl-4-(4-methyl-piperazine-1- F AyHC carbony !)-lH-pyrroI-2-yl]-meth- (Z)- ylidene]-1, 3-dihydro-indol-2-one H N 4- (2, 4-Difluoro-phenyl)-3- [1- [3-methyl- 4- (morpholine-4-carbonyl)-lH-pyrrol-2- 307 j °-/1 yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol- d H i; y N CH fT\ 2-one I o 0 ch) ra ch3 oH q, _ (3_Chloro-phenyl)-3- [1- [4- ( (R)-3- 308 N hydroxy-pyrrolidine-l-carbonyl)-3- H methyl-lH-pyrrol-2-yl]-meth- (Z)- W ylidene]-1, 3-dihydro-indol-2-one H OH cam n 4- (3-Chloro-phenyl)-3- [l- [3- ( (R)-3- hydroxy-pyrrolidine-1-carbonyl)-5- r-L methyl-lH-pyrrol-2-yl]-meth- (Z)- ylidene]-1, 3-dihydro-indol-2-one 0 N p crom HC 0 NO"'OH 4- (2-Fluoro-phenyl)-3- [l- [4- ( (R)-3- 310 F N hydroxy-pyrrolidine-l-carbonyl)-3- methyl-lH-pyrrol-2-yl]-meth- (Z)- ylidene]-1, 3-dihydro-indol-2-one cnra < 89 N, 3 4-(3-Fluoro-phenyl)-3- [1-[4-((R)-3- 311 N CH3 hydroxy-pyrrolidine-l-carbonyl)-3, 5- g91s H CFi3 dimethyl-lH-pyrrol-2-yl]-meth-(Z)- ylidene]-1, 3-dihydro-indol-2-one H OHChiral 4- (3-Fluoro-phenyl)-3- (1- {4- [2- ( (R)-3- 312 1 0 hydroxy-pyrrolidin-1-yl)-2-oxo-ethyl]- N CH, 3,5-dimethyl-lH-pyrrol-2-yl}-meth- (Z)- ylidene]-1, 3-dihydro-indol-2-one N H 0 N-CH3 4- (2, 6-Difluoro-phenyl)-3- [1- [3-methyl- 313 F F/N 4- (4-methyl-piperazine-l-carbonyl)-lH- H pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one H 0 4- (2, 6-Difluoro-phenyl)-3- [1- [3, 5- 314 F+FA/SCH 3 dimethyl-4-(4-methyl-piperazine-1- H carbonyl)-lH-pyrrol-2-yl]-meth- (Z)- ylidene]-1, 3-dihydro-indol-2-one H , QH3 N 4- (3-Chloro-phenyl)-3- [1- [5-methyl-3- (4-methyl-piperazine-1-carbonyl)-1 H- pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one I o N H N N 4- (3-Fluoro-phenyl)-3- [1- [5-methyl-3- 316 F 1 0 (4-methyl-piperazine-1-carbonyl)-1H- pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one c rio N H o O 5- [4- (2, 6-Difluoro-phenyl)-2-oxo-1, 2- 317 1< VH dihydro-indol-(3Z)-ylidenemethyl]-2, 4- N CH3 dimethyl-IH-pyrTole-3-carboxylic acid 0H (2-pyrrolidin-1-yl-ethyl)-amide N H 2- [4- (2, 6-Difluoro-phenyl)-2-oxo-1, 2- 0 dihydro-indol- (3Z)-ylidenemethyl]-5- 318 F F methyl-lH-pyrrole-3-carboxylic acid (3- NCH3 pyrrolidin-1-yl-propyl)-amide 11 1 F° N H 0 4- (2, 6-Difluoro-phenyl)-3- [1- [3, 5- F FNo-,, o dimethyl-4- (4-pyrrolidin-1-yl- 319 NCH3 piperidine-l-carbonyl)-IH-pyrrol-2-yl]- onc 0H meth- (Z)-ylidene]-1, 3-dihydro-indol-2- one H one , r-N N- AN 4° 2- [4- (2-Fluoro-phenyl)-2-oxo-1, 2- 320 dihydro-indol- (3Z)-ylidenemethyl]-5- F HGH3 methyl-lH-pyrrole-3-carboxylic acid [2- X (4-acetyl-piperazin-1-yl)-ethyl]-amide I'N 0 H 0 . j/-N N- F 0N CH3 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- zozo 321 dihydro-indol- (3Z)-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid [2- ° (4-acetyl-piperazin-1-yl)-ethyl]-amide N H H XCH3 5- [4- (2-Fluoro-phenyl)-2-oxo-1, 2- 322 C0N dihyclro-indol- (3Z)-ylidenemethyl]-4- F<J < H methyl-lH-pyrrole-3-carboxylic acid [2- ( (4-acetyl-piperazin-1-yl)-ethyl]-amide N H 0 5- [4- (2-Fluoro-phenyl)-2-oxo-1, 2- fuzzF N dihydro-indol- (3Z)-ylidenemethyl]-4- 323 J methyl-lH-pyrrole-3-carboxylic acid (2- piperidin-1-yl-ethyl)-amide NU H _j-No 2- [4- (3-Chloro-phenyl)-2-oxo-1, 2- 0 dihydro-indol- (3Z)-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (2- o piperidin-1-yl-ethyl)-amide s N H CRI 5- 4- (3-Chloro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-4- 325 0N N methyl-lH-pyrrole-3-carboxylic acid (2- X o \ piperidin-l-yl-ethyl)-amide N HO No 2-[4-(3-Chloro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-5- 326 Tj °" methyl-lH-pyrrole-3-carboxylicacid (2- N bANkCHa hydroxy-3-pyrrolidin-1-yl-propyl)- oH amide N H H Y 2-[4-(3-Fluoro-phenyl)-2-oxo-1,2- N'dihydro-indol-(3Z)-ylidenemethyl]-5- 327) ° methyl-lH-pyrrole-3-carboxylic acid (2- ' hydroxy-3-pyrrolidin-I-yl-propyl)- H amide 0 N H HC 0 OH 5- [4- (3-Chloro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-4- 328 N methyl-lH-pyrrole-3-carboxylic acid (2- o hydroxy-3-pyrrolidin-1-yl-propyl)- amide S- [4- (2-Fluoro-phenyl)-2-oxo-1, 2- Hc I dihydro-indol- (3Z)-ylidenemethyl]-4- 329 FAC ÇN methyl-lH-pyrrole-3-carboxylic acid (2- o hydroxy-3-pyrrolidin-1-yl-propyl)- amide 9c N 5- [4- (3-Chloro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-2, 4- 330 N dimethyl-lH-pytrole-3-carboxylic acid N (2-hydroxy-3-pyrrolidin-1-yl-propyl)- amide H o Chiral 4- (3-Chloro-phenyl)-3- [I- [4- ( (S)-3- 331 N CH3 hydroxy-pyrrolidine-I-carbonyl)-3, 5- S/H 3 dimethyl-lH-pyrrol-2-yl]-meth-(Z)- N ylidene]-1, 3-dihydro-indol-2-one H CiC 0..--,., oOH Chiral 4- (3-Chloro-phenyl)-3- [l- [4- ( (S)-3- hydroxy-pyrrolidine-1-carbonyl)-3- eo methyl-1 H-pyrrol-2-yl]-meth-(Z)- ylidene]-1, 3-dihydro-indol-2-one H OH Chiral 4- (3-Chloro-phenyl)-3- [l- [3- ( (S)-3- hydroxy-pyrrolidine-l-carbonyl)-5- methyl-lH-pyrrol-2-yl]-meth- (Z)- < H CH3 ylidene]-1, 3-dihydro-indol-2-one N H 0 Chiral N OH 4- (2-Fluoro-phenyl)-3- [l- [4- ( (S)-3- 334 F N hydroxy-pyrrolidine-I-carbonyl)-3- methyl-lH-pyrrol-2-yl]-meth- (Z)- N ylidene]-1, 3-dihydro-indol-2-one N p Chiral FC NsOH 4- (3-Fluoro-phenyl)-3- [1- [4- ( (S)-3- 335 N CH, hydroxy-pWolidine-l-carbonyl)-3, 5- << HN ciH3 dimethyl-lH-pyrrol-2-yl]-meth-(Z)- v N ylidene]-1, 3-dihydro-indol-2-one H OHChira 4- (3-Fluoro-phenyl)-3-jl- {4- [2- ( (S)-3- 336 1 0 hydroxy-pyrrolidin-1-yl)-2-oxo-ethyl]- Y o 3, 5-dimethyl-lH-pyrrol-2-yl}-meth (Z)- X ii H ylidene]-1, 3-dihydro-indol-2-one NH 4-3-Fluoro-hen 1-3-1-4-4 h drox- Y) -Y Y 337 N CH3 piperidin-1-yhnethyl)-3, 5-dimethyl-lH- 0H pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- N dihydro-indol-2-one H P 3- [l- (3, 5-Dimethyl-4-morpholin-4- K T rcH yhnethyl-lH-pyrrol-2-yl)-meth- (Z)- {< HN 3 ylidene]-4-(3-fluoro-phenyl)-1X3- dihydro-indol-2-one OH OH F 0 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]- , Ju/HN 4,5,6,7-tetrahydro-lH-indole-3- carboxylic acid H N 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]- 340 F 0 4, 5,6,7-tetrahydro-lH-indole-3- carboxylic acid (3-pyrrolidin-1-yl- propyl)-amide N N H OH Chira v 4- (3-Fluoro-phenyl)-3- [1- [3- (3-hydroxy- pyrrolidine-l-carbonyl)-4, 5,6,7- T eNS tetrahydro-lH-indol-2-yl]-meth-(Z)- ylidene]-1, 3-dihydro-indol-2-one 0 H HO Chiral C 4- (2-Fluoro-phenyl)-3- [1- {3- [ (S)-2- (4- hydroxy-piperidin-1-ylmethyl)- 342 o N pyrrolidine-1-carbonyl]-5-methyl-lH- pyrrol-2-yl}-meth- (Z)-ylidene]-1, 3- F S CH3 dihydro-indol-2-one N H H Chiral 4- (2-Fluoro-phenyl)-3- [1-13- [ (S)-2- ( (R)- N J 3-hydroxy-pyrrolidin-1-ylinethyl)- 343 of pyrrolidine-1-carbonyl]-5-methyl-lH- F n pyrrol-2-yl}-meth-(Z)-ylidene]-1, 3- dihydro-indol-2-one N 0 OHChiral 4- (3-Fluoro-phenyl)-3- [1- {4- [ (S)-2- ( (R)- o 3-hydroxy-pyrrolidin-1-ylmethyl)- 344 "3 N pyrrolidine-1-carbonyl)-3, 5-dimethyl- N CH, 1H-pyrrol-2-yl)-meth- (Z)-ylidene]-1, 3- o dihydro-indol-2-one N H HO, Chira N ,,. 4- (3-Fluoro-phenyl)-3- [1- f 3- [ (S)-2- ( (R)- 3-hydroxy-pyrrolidin-1-ylmethyl)- 345 0 pyrrolidine-l-carbonyll-5-methyl-IH- pyrrol-2-yl)-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one 0 --\ o N 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- o Ho dihydro-indol- (3Z)-ylidenemethyl]-5- 346 methyl-lH-pyrrole-3-carboxylic acid {2- CH [4- (2-hydroxy-acetyl)-piperazin-1-yl]- N » ° ethyl}-amide H H 0 4- (2, 6-Difluoro-phenyl)-3- [1- [4- (3- 0 piperidin-1-yl-propionyl)-1, 4,5,6,7,8- 347 n NT hexahydro-pyrrolo [3, 2-b] azepin-2-yl]- Nz meth-(Z)-ylidene] 1, 3-dihydro-indol-2- one N H H3C O As 0 5- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-4- (3- nu methanesulfonyl-propyl)-2-methyl-lH- N H pyrrole-3-carboxylicacid H H H 0 H 0 5- [4- (4-Chloro-phenyl)-2-oxo-1, 2- 349 OH dihydro-indol- (3Z)-ylidenemethyl]-4- (3- methanesulfonyl-propyl)-2-methyl-lH- CN pyrrole-3-carboxylic acid H H3C cmm 4- (3-Fluoro-phenyl)-3- [1- [4- ( (R)-3- F) o OH hydroxy-pyrrolidine-l-carbonyl)-3-(3- 350 < XN, 3 methanesulfonyl-propyl)-5-methyl-lH- I NH CH3 pyrrol-2-yl]-meth-(Z)-ylidene]-1,3- o dihydro-indol-2-one H H3C O S'O 4- (3-Fluoro-phenyl)-3- [l- [3- (3- F methanesulfonyl-propyl)-5-methyl-4- (4- 351 \_N-CH3 methyl-piperazine-l-carbonyl)-IH- N CH3 pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- o dihydro-indol-2-one N H Fq o S'O ci 4- (4-Chloro-phenyl)-3- [1- [3- (3- ° methanesulfonyl-propyl)-5-methyl-4- (4- 352 1 V__ZN-CF6 methyl-piperazine-l-carbonyl)-IH- T CH3 pyrrol-2-yl]-meth-(Z)-ylidene]-1,3- o dihydro-indol-2-one HAN H, C u OH'\-H (cH3 3- [1- [3- ( (3R, SS)-3, 5-Dimethyl- o o 4 piperazine-1-carbonyl)-5-methyl-1 H- 353 I 1 pyrrol-2-yl]-meth- (Z)-ylidene]-4- [3- (2- hydroxy-ethoxy)-phenyl]-1, 3-dihydro- o indol-2-one N H OH 0 3- [l- [3, 5-Dimethyl-4- (4-methyl- piperazine-l-carbonyl)-lH-pyrrol-2-yl]- 354 1 3 NON-CH3 meth- (Z)-ylidene]-4- [3- (2-hy (iroxy- ethoxy)-phenyl]-1, 3-dihydro-indol-2- N one Nue H OH 0 4- [3- (2-Hydroxy-ethoxy)-phenyl]-3- [l- 3-meth 1-4-4-meth 1-i erazine-1- 355 cl3 carbonyl)-IH-pyrrol-2-yll-meth- (Z)- o ylidene]-1, 3-dihydro-indol-2-one N 0 H OH oS 5- [4- [3- (2-Hydroxy-ethoxy)-phenyl]-2- 0 H3C oxo-1, 2-dihydro-indol- (3Z)- 356 W ts \) ylidenemethyl]-2,4-dimethyl-lH- . X HN CH3 N pyrrole-3-carboxylic acid (2-pyrrolidin- WSHF l-yl-ethyl)-amide N H OH 3- [l- [3, 5-Dimethyl-4- (4-pyrrolidin-1-yl- piperidine-1-carbonyl)-lH-pyrrol-2-yl]- 357 J'O meth- (Z)-y ! idene]-4- [3- (2-hydroxy- LH c"3 ethoxy)-phenyl]-l, 3-dihydro-indol-2- one H N 4- [3- (2-Hydroxy-ethoxy)-phenyl]-3- [l- ) NS [5-methyl-3-(4-pyrrolidin-1-yl- 358 0 1 0 piperidine-l-carbonyl)-lH-pyrrol-2-yl]- meth- (Z)-ylidene]-1, 3-dihydro-indol-2- N o N H OH Chira 4- [3- (2-Hydroxy-ethoxy)-phenyl]-3- [I- [4- ( (R)-3-hydroxy-pyrrolidine-1- 359 9 Xc carbonyl)-3,5-dimethyl-lH-pyrrol-2-yl]- JH meth- (Z)-ylidene]-l, 3-dihydro-mdol-2- H one H cri 0 oH 5_ [4- (4-Chloro-phenyl)-2-oxo-1, 2- 360 T vNkCH3 dihydro-indol-(3Z)-ylidenemethyl]-2,4- o dimethyl-lH-pyrrole-3-carboxylic acid w cl OH 2- [4- (4-Chloro-phenyl)-2-oxo-1, 2- 361 y/N CH, dihydro-indol- (3Z)-yIidenemethyl]-5- CWo methyl-lH-pyrrole-3-carboxylic acid VNH 0 F HC N 3- [I- [3, 5-Dimethyl-4- (4-morpholin-4- 362 rq c N) yl-piperidine-l-carbonyl)-lH-pyrrol-2- yl]-meth- (Z)-ylidene]-4- (3-fluoro- phenyl)-1, 3-dihydro-indol-2-one H o, CH3 @mMN 4- (3, 4-Dimethoxy-phenyl)-3- [1- [3- 363 W U N-CH methyl-4-(4-methyl-piperazine-1- N carbonyl)-lH-pyrrol-2-yl]-meth- (Z)- 0 H ylidene]-1, 3-dihydro-tindol-2-one H H3C H H C 3 sN CH3o /CH, 4- (3, 4-Dimethoxy-phenyl)-3- [l- [3- o oW ((3R, SS)-3, 5-dimethyl-piperazine-1- 364 t aJ > carbonyl)-5-methyl-lH-pyrrol-2-yl]- meth- (Z)-ylidene]-1, 3-dihydro-indol-2- o once N H . C H , _, '" V 5- [4- (3, 4-Dimethoxy-phenyl)-2-oxo-1, 2- (j) rY dihydro-mdol- (3Z)-yIidenemethyl]-2, 4- dimethyl-lH-pyrrole-3-carboxylic acid ¢> (2-pyrrolidin-1-yl-ethyl)-amide H N IK-0 2- [4- (3, 4-Dimethoxy-phenyl)-2-oxo-1, 2- 0 0 dihydro-indol- (3Z)-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (3- pyrrolidin-1-yl-propyl)-amide H H 0 4- (3, 4-Dimethoxy-phenyl)-3- [l- [5- 367 0 0 methyl-3- (4-pyrrolidin-1-yl-piperidine- a g) 1-carbonyl)-lH-pyrrol-2-yl]-meth-(Z)- N CH3 ylidene]-1, 3-dihydro-indol-2-one N 0 N H Chiral H Chir31 o'I H3 °,, oH 4- (3, 4-Dimethoxy-phenyl)-3- [ 1- [4- ( (R)- 368 3-hydroxy-pyrrolidine-I-carbonyl)-3, 5- 1 ,, N CH3 dimethyl-lH-pyrrol-2-yl]-meth-(Z)- ylidene]-1, 3-dihydro-indol-2-one H H, 2,4-Dimethyl-5- [4- (3-methylcarbamoyl- H H phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- i X H 3 ylidenemethyl]-lH-pyrrole-3-carboxylic N0 acid (2-pyrrolidin-1-yl-ethyl)-amide H 0 1, cl so 5- [4- (4-Chloro-phenyl)-2-oxo-1, 2- H C N dihydro-indol- (3Z)-ylidenemethyl]-2, 4- 370 H dimethyl-lH-pyrrole-3-carboxylic acid NCH3 [2- (l, 1-dioxo-10-fliiomorpholin-4-yl)- o ethyl]-amide H 0 11 5- [4- (2-Fluoro-phenyl)-2-oxo-1, 2- HSN dihydro-indol-(3Z)-ylidenemethyl]-4- 371 Fj3 3 XH methyl-lH-pyrrole-3-carboxylic acid [2- (1, 1-dioxo-1 -thiomorpholin-4-yl)- o ethyl]-amide NU H 0 5- [4- (2, 6-Difluoro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-4- 372 F4F 4 HN methyl-lH-pyrrole-3-carboxylic acid [2- (l, 1-dioxo-10-thiomorpholin-4-yl)- oH ethyl]-amide N H 0 5- [4- (2, 6-Difluoro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-2, 4- 373 < X dimethyl-lH-pyrrole-3-carboxylic acid NCH3 [2- (1, 1-dioxo-10-tWomorpholin-4-yl)- o ethyl]-amide ZON H H \---/S'6 2- [4- (2, 6-Difluoro-phenyl)-2-oxo-1, 2- o dihydro-indol- (3Z)-ylidenemethyl]-5- 374 F F methyl-lH-pyrrole-3-carboxylic acid [2- CF (1, 1-dioxo-10-tWomorpholin-4-yl)- N o ethyl]-amide N H o I 1 °H, 5- [4- (2, 6-Difluoro-phenyl)-2-oxo-1, 2- 375 F X FNH CH3 dihydro-indol-(3Z)-ylidenemethyl]-2,4- o dimethyl-lH-pyrrole-3-carboxylic acid OH OH 0 2- [4- (2, 6-Difluoro-phenyl)-2-oxo-1, 2- 376 N CH3 dihydro-indol- (3Z)-ylidenemethyl]-5- o methyl-lH-pyrrole-3-carboxylic acid HN 0 0 5_ [4- (2, 6-Difluoro-phenyl)-2-oxo-1, 2- 377 t n N dihydro-indol-(3Z)-ylidenemethyl]-4- o methyl-lH-pyrrole-3-carboxylic acid N H F 3- [1- (4- { (S)-2- [ (Cyclopropylmethyl- amino)-methyl]-pyrrolidine-l- 378 < rHN (N carbonyl}-3, 5-dimethyl-lH-pyrrol-2-yl)- /N Y Y PY'Y) - OH H meth- (Z)-ylidene]-4- (3-fluoro-phenyl)- HN 1, 3-dihydro-indol-2-one chiera 3- [1- (3- f (S)-2- [ (Cyclopropylinethyl- wFoR amino)-methyl]-pyrrolidine-1- 379 N < carbonyl}-5-methyl-lH-pyrrol-2-yl)- H meth- (Z)-ylidene]-4- (3-fluoro-phenyl)- N 0 1, 3-dihydro-indol-2-one H Chiral H 4- (2, 6-Difluoro-phenyl)-3- [l- [4- ( (S)- N pyrrolidine-2-carbonyl)-1, 4, 5, 6, 7, 8- 380 F F hexallydro-pyrrolo [3,2-b] azepin-2-yl]- meth- (Z)-ylidene]-1, 3-dihydro-indol-2- 0 one N H Ho NJ 2- [4- (3, 5-Difluoro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-5- 381 1 °t, methyl-lH-pyrrole-3-carboxylic acid (2- hydroxy-3-pyrrolidin-1-yl-propyl)- N amide N H Ho NJ 2_ (4- (2, 4-Difluoro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-5- 382 t 1 t methyl-lH-pyrrole-3-carboxylic acid (2- hydroxy-3-pyrrolidin-1-yl-propyl)- N amide I o N H HeN 2-[4-(3-Chloro-4-fluoro-phenyl)-2-oxo- 1, 2-dihydro-indol- (3Z)-ylidenemethyl]- 383 fj °Y-i 5-methyl-lH-pyn'ole-3-carboxylicacid N CH3 (2-hydroxy-3-pyrrolidin-1-yl-propyl)- amide N H Ho, o "° 2- [4- (4-Chloro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-5- 384 methyl-lH-pyrrole-3-carboxylic acid (2- > k C H 3 am i d e hydroxy-3-pyrrolidin-1-yl-propyl)- ) M N CHg amide N H 0 N -y 2- [4- (2, 3-Difluoro-phenyl)-2-oxo-l, 2- N dihydro-indol-(3Z)-ylidenemethyl]-5- 385 Fs 0S methyl-lH-pyrrole-3-carboxylic acid (2- F hydroxy-3-pyrrolidin-1-yl-propyl)- N methyl-amide rT\ WSN<O 4- (3-Fluoro-phenyl)-3- [1- [4- ( (R)-3- hydroxy-pyrrolidin-1-ylmethyl)-3, 5- mo dimethyl-1 H-pyrrol-2-yl]-meth-(Z)- N ylidene]-1, 3-dihydro-indol-2-one NQ 4- (2-Fluoro-phenyl)-3- [l- [4- (3-hydroxy- 387 FX gNk OH piperidin-l-ylmethyl)-3, 5-dimethyl-lH- 'N ¢>° pyrrol-2-yl]-meth-(Z)-ylidene]-1, 3- dihydro-indol-2-one H F 0 N 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- 388 dihydro-indol- (3Z)-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (2- c piperidin-1-yl-ethyl)-amide NU H H 0 N, N J--N, H3 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-5- 389 ttJ y- methyl-lH-pyrrole-3-carboxylic acid [2- . gH (3-acetylamino-pyrrolidin-1-yl)-ethyl]- won amide N H H oN 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- 390 F 0N dihydro-indol- (3Z)-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (1- methyl-piperidin-4-ylmethyl)-amide 11 1 » ° N H O _/ HAN r-NOH 2_4- (3-Fluoro-phenyl)-2-oxo-1, 2- "0 ° dmydro-mdol- (3Z)-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid [2- o" (4-hydroxy-piperidin-1-yl)-ethyl]-amide "0 HO N9=0 0 HHo'-jN 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-5- 392 0 methyl-lH-pyrrole-3-carboxylic acid [3- (1, 1-dioxo-10-thiomorpholin-4-yl)-2- hydroxy-propyl]-amide I w oH N H cl °"5- [4- (4-Chloro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-2, 4- 393//N^CH dimethyl-1H-pyrrole-3-carboxylic acid 0H [3- (l, 1-dioxo-10-thiomorpholin-4-yl)- H 2-hydroxy-propyl]-amide o OH 5- [4- (2, 6-Difluoro-phenyl)-2-oxo-1, 2- JE) N\-/S=o dihydro-indol- (3Z)-ylidenemethyl]-4- 394 F F methyl-IH-pyrrole-3-carboxylic acid [3- o (1, 1-dioxo-10-thiomorpholin-4-yl)-2- hydroxy-propyl]-amide O N 4- (2, 6-Difluoro-phenyl)-3- [1- [3-methyl- H, C No 4- ( (S)-3-pyrrolidin-1-ylmethyl- 395'"IT" ? pipendine-l-carbonyl)-lH-pyn-ol-2-yl]- o"meth- (Z)-ylidene]-1, 3-dihydro-indol-2- H one Cl o 4- (4-Chloro-phenyl)-3- [l- [3, 5-dimethyl- No 4- ( (S)-3-pyrrolidin-1-ylmethyl- 396 y "NcH pipendme-l-carbonyl)-lH-pyrrol-2-yl]- ¢noH meth-(Z)-ylidene]-1, 3-dihydro-indol-2- one - nez 4- (3-Fluoro-phenyl)-3- [I- [5-methyl-3- 397 F 0< (4-pyrrolidin-1-ylmethyl-piperidine-1- carbonyl)-lH-pyrrol-2-yl]-meth- (Z)- HN CH3 ylidene]-1, 3-dihydro-indol-2-one 11 1 F° N N H N F 3- [l- [3, 5-Dimethyl-4- (l-methyl-1, 2,3,6- 398 W S tetrahydro-pyridin-4-yl)-lH-pyrrol-2- N yl]-meth- (Z)-ylidene]-4- (3-fluoro- o phenyl)-1,3-dihydro-indol-2-one N H F H-N3F 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- F N-H dihydro-indol- (3Z)-ylidenemethyl]-5- 399 W °t- methyl-lH-pyrrole-3-carboxylic acid [2- (2, 2,2-trifluoro-ethylamino)-ethyl]- í,!- ! H amide N O H 0 -cit , N 3- [l- [4- (I-Acetyl-piperidine-4- carbonyl)-1, 4,5,6,7,8-hexahydro- 400 N pyrrolo [3,2-b] azepin-2-yl]-meth- (Z)- ylidene]-4- (3-fluoro-phenyl)-1, 3- dihydro-indol-2-one H N H oS o N /\ (R)-l- {2- [4- (3-Fluoro-pheny !)-2-oxo- 1, 2-dihydro-indol- (3Z)-ylidenemethyl]- 401 F> 0Y 5-methyl-lH-pyrrole-3-carbonyl}- piperidine-3-carboxylic acid cyclopropylamide o 0 0 CH3 N 4- (3-Fluoro-phenyl)-3- [1- [4-methyl-3- cH3 (4-methyl-piperazine-1-carbonyl)-lH- pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one t! JI° N H 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- 403 F ° cH3 dihydro-indol- (3Z)-ylidenemethyl]-4- methyl-lH-pyrrole-3-carboxylic acid (3- pyrrolidin-1-yl-propyl)-amide N H NCH, N 3- [l- [3, 5-Dimethyl-4- (l-methyl- J')-T (pipendin-4-yl)-lH-pyrrol-2-yl]-meth- H CH3 (Z)-ylidene]-4- (3-fluoro-phenyl)-1, 3- uNW dihydro-indol-2-one N H INCH3 F N H, C 3- [l- [3, 5-Dimethyl-4- (I-methyl- 405 piperidin-4-yl)-lH-pyrrol-2-yl]-meth- N (Z)-ylidene]-4- (4-fluoro-phenyl)-1, 3- dihydro-indol-2-one NCH3 N CHg FH3C 4- (2, 3-Difluoro-phenyl)-3- [I- [3, 5- 406 F dimethyl-4- (l-methyl-piperidin-4-yl)- 1 lCH CH3 lH-pyrrol-2-yl]-meth-(Z)-ylidene]-1,3- dihydro-indol-2-one N g H N 4- (3, 5-Difluoro-phenyl)-3- [1- [3, 5- 407 dimethyl-4- (l-methyl-piperidin-4-yl)- N CN 1H-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- o dihydro-indol-2-one H CH3 N H c 4- (2, 6-Difluoro-phenyl)-3- [1- [3, 5- dimethyl-4- (1-methyl-piperidin-4-yl)- F F J N CH3 1H-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one N H ce . CHH N OH 3c 4- (3, 4-Dimethoxy-phenyl)-3- [I- [3, 5- 409 C dimethyl-4-(1-methyl-piperidin-4-yl)- HCH3 1H-pyrrol-2-yl)-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one N H OH F 0 2- [4- (2, 3-Difluoro-phenyl)-2-oxo-1, 2- 410 X XHNXCH3 dihydro-indol-(3Z)-ylidenemethyl]-5- o methyl-lH-pyrrole-3-carboxylic acid zon H 0 F Hic Ij y 5- [4- (2, 3-Difluoro-phenyl)-2-oxo-l, 2- 411 1 CH3 dihydro-indol- (3Z)-ylidenemethyl]-2, 4- o dimethyl-lH-pyrrole-3-carboxylic acid N H CL3 H c 4- (2, 4-Difluoro-phenyl)-3- [1- [3, 5- 412 s ~, dimethyl-4-(1-methyl-pipendin-4-yl)- CH3 1H-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one N H EH F H3c 4- (2, 3-Difluoro-phenyl)-3- [l- [3, 5- ..,. Ff dimethyi-4- (4-methyl-piperazine-l- carbonyl)-1H-pyrrol-2-yl]-meth- (Z)- ylidene]-1, 3-dihydro-indol-2-one H 4- (2, 3-Difluoro-phenyl)-3- [l- [3, 5- F No dimethyl-4- (4-pyrrolidin-1-yl- 414 N H CH3 piperidine-1-carbonyl)-lH-pyrrol-2-yl]- 1 0H meth- (Z)-ylidene]-1, 3-dihydro-indol-2- one chiera 4- (2, 3-Difluoro-phenyl)-3- [1- [3, 5- F °k dimethyl-4-((S)-2-pyrrolidin-1- 415 SF to ylmethyl-pyrrolidine-l-carbonyl)-lH- N pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- o dihydro-indol-2-one N H OH (-CH, 4- (2, 3-Difluoro-phenyl)-3- [l- [3- o 0= ( ((3R, SS)-3, 5-dimethyl-piperazine-1- 416 F/W/carbonyl)-5-methyl-lH-pyrrol-2-yl]- meth- (Z)-ylidene]-1, 3-dihydro-indol-2- one N H H 2- [4- (2, 3-Difluoro-phenyl)-2-oxo-1, 2- 417 F 0 dihydro-indol- (3Z)-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (3- pyrrolidin-1-yl-propyl)-amide H oh 0 No H 0 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- F 0 CF6 dihydro-indol- (3Z)-ylidenemethyl]-5- iodo-4-methyl-lH-pyrrole-3-carboxylic acid (3-pyrrolidin-1-yl-propyl)-amide 11 1 » 0 N CH Cht ° HO N 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-5- 419 F o methyl-lH-pyrrole-3-carboxylic acid [ (S)-2-hydroxy-3- (3-methyl-2, 5-dioxo- CN imidazolidin-1-yl)-propyl]-ainide 0 YH3 o H N of N) HO N- 2- [4- (3-Fluoro-phenyl)-2-oxo-l, 2- N dihydro-indol- (3Z)-ylidenemethyl]-5- 420 F o methyl-lH-pyrrole-3-carboxylic acid [ (R)-2-hydroxy-3- (3-methyl-2, 5-dioxo- NCH3 imidazolidin-1-yl)-propyl]-amide I N 0 po Nez d 4- (3-Fluoro-phenyl)-3- [l- [5-methyl-3- 421 F 0= (3-morpholin-4-yl-azetidine-1- carbonyl)-lH-pyrrol-2-yl]-meth- (Z)- ylidene]-1, 3-dihydro-indol-2-one H O N H cam 0 ()-CH, N 3- [1-13- [3- ( (2R,6S)-2,6-Dimethyl- morpholin-4-yl)-azetidme-1-carbonyl]- 422 F N 422 F 0 5-methyl-IH-pyrrol-2-yll-meth- (Z)- ylidene]-4- (3-fluoro-phenyl)-1, 3- N CH3 dihydro-indol-2-one h\ N H H Chira 4- (3-Fluoro-phenyl)-3- [1- {3- [ (S)-2- ( (S)- Fe3-fluoro-pyrrolidin-1-ylmethyl)- PY'Y Y) 423 eJ/CH3 pyrrolidine-1-carbonyl]-5-methyl-lH- 'pyrrol-2-yl}-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one H Chira 4- (3-Fluoro-phenyl)-3- [1- {3- [ (R)-2- ( (S)- F oR'-Nj 3-fluoro-pyrrolidin-1-ylmethyl)- s 424 N CH3 pyrrolidine-l-carbonyl]-5-methyl-lH- pyrrol-2-yl}-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one H H N N 3- [I- [3- (4-Cyclopropylamino- 425 F 0 piperidine-l-carbonyl)-5-methyl-lH- N CH3 pyrrol-2-yl]-meth- (Z)-ylidene]-4- (3- fluoro-phenyl)-1, 3-dihydro-indol-2-one "I H N/ 0 "oral NH 3- [I- [3- ( (2R, 4R)-2- Cyclopropylaminomethyl-4-hydroxy- 426 Fe1 of pyrrolidine-l-carbonyl)-5-methyl-lH- pyrrol-2-yl]-meth- (Z)-ylidene]-4- (3- rX HN CH3 fluoro-phenyl)-1, 3-dihydro-indol-2-one N H HO Nu 2- [4- (2, 3-Difluoro-phenyl)-2-oxo-1, 2- F 0 dihydro-indol- (3Z)-ylidenemethyl]-5- 427 F methyl-lH-pyrrole-3-carboxylic acid (3- N CH, cyclopropylamino-2-hydroxy-propyl)- h') =o amide --- HO X S 2- [4- (2, 3-Difluoro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-5- 428 methyl-IH-pyaole-3-carboxylic acid (2- FAH CH3 Y Y PY d Y P PY) vN ° H amide N 0 HO Chin N 4- (2, 3-Difluoro-phenyl)-3- [l- {3- [ (S)-2- N J ((R)-3-hydroxy-pyrrolidin-1-ylmethyl)- 429 F> o= (_ pyrrolidine-l-carbonyl]-5-methyl-lH- F pyrrol-2-yl)-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one I o 0 H F mudra N 4- (2, 3-Difluoro-phenyl)-3- [1- {3- [ (S)-2- N ((S)-3-fluoro-pyrrolidin-1-ylmethyl)- 430 Fn o= (ss pyrrolidine-l-carbonyl]-5-methyl-lH- F pyrrol-2-yl)-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one H 0 H H Chiral nu 3- [1- [3- ( (S)-3- Cyclopropylaminomethyl-piperidine-1- 431 0 carbonyl)-5-methyl-IH-pyrrol-2-ylj- w A/k meth-(Z)-ylidene]-4-(3-fluoro-phenyl)- 1, 3-dihydro-indol-2-one o lah H H Chira wu ci 4- (4-Chloro-phenyl)-3- [I- [3- ( (S)-3- Cl NJ cyclopropylaminomethyl-piperidine-l- 432 A on carbonyl)-5-methyl-lH-pyrrol-2-yl]- 1 meth- (Z)-ylidene]-1, 3-dihydro-indol-2- 9 H one o 0 N H :, q N 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl)-5- 433 Fa q 0Y, methyl-lH-pyrrole-3-carboxylic acid (2- hydroxy-3-pyrrolidin-1-yl-propyl)- methyl-amide N H HO N H 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2- dihydro-indol- (3Z)-ylidenemethyl]-5- 434 tJ/r methyl-lH-pyrrole-3-carboxylic acid (3- 1/ N CHg cyclopropylamino-2-hydroxy-propyl)- o amide N H N 4- (3-Fluoro-phenyl)-3- [1- [4- (2- 435 W £) pyrrolidin-1-yl-ethyl)-4, 5,6,7- /N tetrahydro-lH-indol-2-yl]-meth-(Z)- I o ylidene]-1,3-dihydro-indol-2-one N H [0064] In a second aspect, this inventions is directed to a pharmaceutical composition comprising one or more compounds of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

Biochemistry [0065J Another aspect of this invention relates to a method for the modulation of the catalytic activity of a PK by contacting a PK with a compound of this invention or a physiologically acceptable salt thereof.

[0066] A further aspect of this invention is that the modulation of the catalytic activity of PKs using a compound of this invention may be carried out in vitro or in vivo.

[0067] A still further aspect of this invention is that the protein kinase whose catalytic activity is being modulated by a compound of this invention is selected from the group consisting of receptor protein tyrosine kinases, cellular tyrosine kinases and serine-threonine kinases.

[0068] It is an aspect of this invention that the receptor tyrosine protein kinase whose catalytic activity is modulated by a compound of this invention is selected from the group consisting of EGF, HER2, HER3, HER4, IR, IGF-1R, IRR, PDGFRa, PDGFR, CSFIR, C-Kit, C-fins, Flk-lR, Flk4, KDR/Flk-1, Flt-l, FGFR-1R, FGFR- 2R, FGFR-3R, FGFR-4R, MET, DDR-1 and DDR-2.

[0069] In addition, it is an aspect of this invention that the cellular tyrosine kinase whose catalytic activity is modulated by a compound of this invention is selected from the group consisting of Src, Frk, Btk, Csk, Abl, ZAP70, Fes/Fps, Fak, Jak, Ack, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr and Yrk.

[0070] Another aspect of this invention is that the serine-threonine protein kinase whose catalytic activity is modulated by a compound of this invention is selected from the group consisting of CDK2, Raf, NEK and BUB 1.

[0071] Another aspect of this inventions relates to a method for treating or preventing a protein kinase related disorder in an organism comprising administering a therapeutically effective amount of a compound or a salt thereof Formula 1 to an organism.

[0072] It is an aspect of this invention that the above-referenced protein kinase related disorder is selected from the group consisting of a receptor protein tyrosine kinase related disorder, a cellular tyrosine kinase disorder and a serine-threonine kinase related disorder.

[0073] In yet another aspect of this invention, the above referenced protein kinase related disorder is selected from the group consisting of a Met related disorder, a PDGFR related disorder, an IGFR related disorder and a flk related disorder.

[0074) The above referenced protein kinase related disorders include by way of example and not limitation, cancers such as lung cancer, NSCLC (non small cell ling cancer), bone cancer, pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, gynecologic tumors (e. g., uterine sarcomas, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina or carcinoma of the vulva), Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system (e. g., cancer of the thyroid, parathyroid or adrenal glands), sarcomas of soft tissues, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, solid tumors of childhood, lynphocytic lymphomas, cancer of the bladder, cancer of the kidney or uerter (e. g., renal cell carcinoma, carcinoma of the renal pelvis), pediatric malignancy, neoplasms of the cnetral nervous system (e. g., primary CNS lymphom, spinal axis tumors, brain stem glioma or pituitary adenomas), Barrett's esophagus (pre-malignant syndrome), neoplastic cutaneous disease, psoriasis, mycoses fungoides and benign prostatic hypertrophy, diabetes related diseases such as diabetic retinopathy, retinal ischemia and retinal neovascularization, hepatic cirrhosis, cardiovascular disease such as atherosclerosis, immunological disease such as autoimmune disease and renal disease.

Preferably, the disease is cancer such as acute myeloid leukemia and colorectal cancer.

[0075] The above referenced protein kinase related disorder also includes disorders selected from the group consisting of diabetes, a hyper-proliferation disorder, hyperproliferative disorders of the kidney, von Hippel-Lindau disease, restenosis, fibrosis, psoriasis, osteoarthritis, rheumatoid arthritis, an inflammatory disorder and angiogenesis in yet another aspect of this invention.

[0076] Additional disorders which may be treated or prevented using the compounds of this invention are immunological disorders such as autoimmune diseases (e. g., AIDS, lupus, etc.) and cardiovascular disorders such as atherosclerosis.

[0077] It is an aspect of this invention that the protein kinase related disorder being treated or prevented by administration of a compound of this invention is a CDK2 related disorder.

[0078] The organism in which the protein kinase related disorder is being treated or prevented is a human being in yet another aspect of this invention.

[0079] It is as aspect of this invention that a chemical compound that modulates the catalytic activity of a protein kinase may be identified by contacting cells expressing said protein kinase with a compound or a salt thereof of Formula 1 and then monitoring said cells for an effect.

[0080] The above-referenced effect is selected from a change or an absence of change in a cell phenotype, a change or absence of change in the catalytic activity of said protein kinase or a change or absence of change in the interaction of said protein kinase with a natural binding partner in a final aspect of this invention.

[00811 It is also an aspect of this invention that a compound described herein, or its salt, might be combined with other chemotherapeutic agents for the treatment of the diseases and disorders discussed above. For instance, a compound or salt of this invention might be combined with alkylating agents such as fluorouracil (5-FU) alone or in further combination with leukovorin ; or other alkylating agents such as, without limitation, other pyrimidine analogs such as LOFT, capecitabine, gemcitabine and cytarabine, the alkyl sulfonates, e. g., busulfan (used in the treatment of chronic granulocytic leukemia), improsulfan and piposulfan; aziridines, e. g., benzodepa, carboquone, meturedepa and uredepa; ethyleneimines and methylmelamines, e. g., altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimethylolmelamine ; and the nitrogen mustards, e. g., chlorambucil (used in the treatment of chronic lymphocytic leukemia, primary macroglobulinemia and non-Hodgkin's lymphom), cyclophosphamide (used in the treatment of Hodgkin's disease, multiple myeloma, neuroblastoma, breast cancer, ovarian cancer, lung cancer, Wilm's tumor and rhabdomyosarcoma), estramustine, ifosfamide, novembrichin, prednimustine and uracil mustard (used in the treatment of primary thrombocytosis, non-Hodgkin's lymphoma, Hodgkin's disease and ovarian cancer); and triazines, e. g., dacarbazine (used in the treatment of soft tissue sarcoma).

[0082] Likewise a compound or salt of this invention might be expected to have a beneficial effect in combination with other antimetabolite chemotherapeutic agents such as, without limitation, folic acid analogs, e. g. methotrexate (used in the treatment of acute lymphocytic leukemia, choriocarcinoma, mycosis fungiodes breast cancer, head and neck cancer and osteogenic sarcoma) and pteropterin; and the purine analogs such as mercaptopurine and thioguanine which find use in the treatment of acute granulocytic, acute lymphocytic and chronic granulocytic leukemias.

[0083] A compound or salt of this invention might also be expected to prove efficacious in combination with natural product based chemotherapeutic agents such as, without limitation, the vinca alkaloids, e. g., vinblastin (used in the treatment of breast and testicular cancer), vincristine and vindesine; the epipodophylotoxins, e. g., etoposide and teniposide, both of which are useful in the treatment of testicular cancer and Kaposi's sarcoma; the antibiotic chemotherapeutic agents, e. g, daunorubicin, doxorubicin, epirubicin, mitomycin (used to treat stomach, cervix, colon, breast, bladder and pancreatic cancer), dactinomycin, temozolomide, plicamycin, bleomycin (used in the treatment of skin, esophagus and genitourinary tract cancer); and the enzymatic chemotherapeutic agents such as L-asparaginase.

[0084] In addition to the above, a compound or salt of this invention might be expected to have a beneficial effect used in combination with the platinum coordination complexes (cisplatin, etc.) ; substituted ureas such as hydroxyurea; methylhydrazine derivatives, e. g., procarbazine ; adrenocortical suppressants, e. g., mitotane, aminoglutethimide ; and hormone and hormone antagonists such as the adrenocorticosteriods (e. g., prednisone), progestins (e. g., hydroxyprogesterone caproate); estrogens (e. g., diethylstilbesterol); antiestrogens such as tamoxifen; androgens, e. g, testosterone propionate; and aromatase inhibitors (such as anastrozole.

[0085] Finally, the combination of a compound of this invention might be expected to be particularly effective in combination with mitoxantrone or paclitaxel for the treatment of solid tumor cancers or leukemias such as, without limitation, acute myelogenous (non-lymphocytic) leukemia.

[0086] The above method can be carried out in combination with a chemotherapeutic agent selected from the gorup consisting of mitotic inhibitors, alkylating agetns, antimetabolites, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, antiangiogenic agents such as MMP-2, MMP-9 and COX-2 inhibitors, and anti-androgens.

[0087] Examples of useful COX-II inhibitors include VioxxTM, CELEBREXTM (alecoxib), valdecoxib, paracoxib, rofecoxib, and Cox 189. Examples of useful matrix metalloproteinase inhibitors are described in WO 96/33172 (published Oct. 24,1996), WO 96/27583 (published Mar. 7,1996), European Patent Application No.

97304971. 1 (filed Jul. 8, 1997), European Patent Application No. 99308617. 2 (filed Oct. 29,1999), WO 98/07697 (published Feb. 26,1998), WO 98/03516 (published Jan. 29,1998), WO 98/34918 (published Aug. 13,1998), WO 98/34915 (published Aug. 13,1998), WO 98/33768 (published Aug. 6,1998), WO 98/30566 (published Jul. 16,1998), European Patent Publication 606,046 (published Jul. 13,1994), European Patent Publication 931,788 (published Jul. 28,1999), WO 90/05719 (published May 31,1990), WO 99/52910 (published Oct. 21,1999), WO 99/52889 (published Oct. 21,1999), WO 99/29667 (published Jun. 17,1999), PCT International Application No. PCT/IB98/01113 (filed Jul. 21,1998), European Patent Application No. 99302232.1 (filed Mar. 25,1999), Great Britain patent application number 9912961.1 (filed Jun. 3,1999), U. S. Provisional Application No. 60/148,464 (filed Aug. 12,1999), U. S. Pat. No. 5,863,949 (issued Jan. 26,1999), U. S. Pat. No.

5,861,510 (issued Jan. 19,1999), and European Patent Publication 780,386 (published Jun. 25,1997), all of which are incorporated herein in their entireties by reference.

Preferred MMP-2 and MMP-9 inhibitors are those that have little or no activity inhibiting MMP-1. More preferred, are those that selectively inhibit MMP-2 and/or MMP-9 relative to the other matrix-metalloproteinases (i. e. MMP-1, MMP-3, MMP- 4, MMP-5, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, MMP-12, and MMP-13).

10088] Some specific examples of MMP inhibitors useful in the present invention are AG-3340, RO 32-3555, RS 13-0830, and the compounds recited in the following list: 100891 3- [ [4- (4-fluoro-phenoxy)-benzenesulfonyl]- (1-hydroxycarbamoyl- cyclopentyl)-amino]-propionic acid; 3-exo-3- [4- (4-fluoro-phenoxy)- benzenesulfonylamino]-8-oxa-bicyclo [3.2. l] octane-3-carboxylic acid hydroxyamide; (2R, 3R) 1- [4- (2-chloro-4-fluoro-benzyloxy)-benzenesulfonyl]-3-hydroxy-3-m ethyl- pip eridine-2-carboxylic acid hydroxyamide; 4- [4- (4-fluoro-phenoxy)- benzenesulfonylamino]-tetrahydro-pyran-4-carboxylic acid hydroxyamide ; 3- [ [4- (4- fluoro-phenoxy)-benzenesulfbnyl]- (1-hydroxycarbamoyl-cyclobutyl)-a mino]- propionic acid ; 4- [4- (4-chloro-phenoxy)-benzenesulfonylamino]-tetrahydro-pyran-4- carboxylic acid hydroxyamide; (R) 3- [4- (4-chloro-phenoxy)-benzenesulfonylamino]- tetrahydro-pyran-3-carboxyli c acid hydroxyamide; (2R, 3R) 1- [4- (4-fluoro-2-methyl- benzyloxy)-benzenesulfonyl]-3-hydroxy-3-methyl-pip eridine-2-carboxylic acid hydroxyamide; 3-[[(4-(4-fluoro-phenoxy)-benzenesulfonyl]-(1-hydroxycarbamo yl-1- methyl-ethyl)-amino]-propinonic acid; 3-[[4-(4-fluoro-phenoxy)-benzenesulfonyl]-(4- hydroxycarbamoyl-tetrahydro-py ran-4-yl)-amino]-propionic acid; 3-exo-3- [4- (4- chloro-phenoxy)-benzenesulfonylamino]-8-oxa-bicyclo [3.2.1] octane-3-carboxylic acid hydroxyamide ; 3-endo-3- [4- (4-fluoro-phenoxy)-benzenesulfo : ylamino]-8-oxa- bicyclo [3.2. l] octane-3-carboxylic acid hydroxyamide; and (R) 3- [4- (4-fluoro- phenoxy)-benzenesulfonylamino]-tetrahydro-furan-3-carboxyli c acid hydroxyamide; and pharmaceutically acceptable salts and solvates of said compounds.

[0090] Other anti-angiogenesis agents, including other COX-II inhibitors and other MMP inhibitors, can also be used in the present invention.

[0091] A compound of Formula (I) can also be used with signal transduction inhibitors, such as agents that can inhibit EGFR (epidermal growth factor receptor) responses, such as EGFR antibodies, EGF antibodies, and molecules that are EGFR inhibitors; VEGF (vascular endothelial growth factor) inhibitors; and erbB2 receptor inhibitors, such as organic molecules or antibodies that bind to the erbB2 receptor, for example, HERCEPTIN. TM. (Genentech, Inc. of South San Francisco, Calif., USA).

EGFR inhibitors are described in, for example in WO 95/19970 (published Jul. 27, 1995), WO 98/14451 (published Apr. 9,1998), WO 98/02434 (published Jan. 22, 1998), and U. S. Pat. No. 5,747,498 (issued May 5,1998), and such substances can be used in the present invention as described herein.

[0092] EGFR-inhibiting agents include, but are not limited to, the monoclonal antibodies C225 and anti-EGFR 22Mab (ImClone Systems Incorporated of New York, N. Y., USA), the compounds ZD-1839 (AstraZeneca), BIBX-1382 (Boehringer Ingelheim), MDX-447 (Medarex Inc. of Annandale, N. J., USA), and OLX-103 (Merck & Co. of Whitehouse Station, N. J., USA), VRCTC-310 (Ventech Research) and EGF fusion toxin (Seragen Inc. of Hopkinton, Mass.).

[0093] These and other EGFR-inhibiting agents can be used in the present invention.

[0094] VEGF inhibitors, for example SU-5416, SU 11248, SU-6668 (Sugen Inc. of South San Francisco, Calif., USA), can also be combined with a compound of Formula (1). VEGF inhibitors are described in, for example in WO 99/24440 (published May 20,1999), PCT International Application PCT/IB99/00797 (filed May 3,1999), in WO 95/21613 (published Aug. 17,1995), WO 99/61422 (published Dec. 2,1999), U. S. Pat. No. 5,834,504 (issued Nov. 10,1998), WO 01/60814, WO 98/50356 (published Nov. 12,1998), U. S. Pat. No. 5,883,113 (issued Mar. 16,1999), U. S. Pat. No. 5,886,020 (issued Mar. 23,1999), U. S. Pat. No. 5,792,783 (issued Aug.

11, 1998), WO 99/10349 (published Mar. 4,1999), WO 97/32856 (published Sep. 12, 1997), WO 97/22596 (published Jun. 26,1997), WO 98/54093 (published Dec. 3, 1998), WO 98/02438 (published Jan. 22,1998), WO 99/16755 (published Apr. 8, 1999), and WO 98/02437 (published Jan. 22,1998), all of which are incorporated herein in their entireties by reference. Other examples of some specific VEGF inhibitors useful in the present invention are IM862 (Cytran Inc. of Kirkland, Wash., USA); anti-VEGF monoclonal antibody of Genentech, Inc. of South San Francisco, Calif. ; and angiozyme, a synthetic ribozyme from Ribozyme (Boulder, Colo.) and Chiron (Emeryville, Calif.). These and other VEGF inhibitors can be used in the present invention as described herein.

[0095] ErbB2 receptor inhibitors, such as GW-282974 (Glaxo Wellcome plc), and the monoclonal antibodies AR-209 (Aronex Pharmaceuticals Inc. of TheWoodlands, Tex., USA) and 2B-1 (Chiron), can furthermore be combined with a compound of Formula (1) for example those indicated in WO 98/02434 (published Jan. 22,1998), WO 99/35146 (published Jul. 15,1999), WO 99/35132 (published Jul. 15,1999), WO 98/02437 (published Jan. 22,1998), WO 97/13760 (published Apr. 17,1997), WO 95/19970 (published Jul. 27,1995), U. S. Pat. No. 5,587,458 (issued Dec. 24,1996), and U. S. Pat. No. 5,877,305 (issued Mar. 2,1999), which are all hereby incorporated herein in their entireties by reference. ErbB2 receptor inhibitors useful in the present invention are also described in U. S. Provisional Application No. 60/117,341, filed Jan. 27,1999, and in U. S. Provisional Application No. 60/117, 346, filed Jan. 27,1999, both of which are incorporated in their entireties herein by reference. The erbB2 receptor inhibitor compounds and substance described in the aforementioned PCT applications, U. S. patents, and U. S. provisional applications, as well as other compounds and substances that inhibit the erbB2 receptor, can be used with a compound of Formula (I), in accordance with the present invention.

[0096] A compound of Formula (I) can also be used with other agents useful in treating cancer, including, but not limited to, agents capable of enhancing antitumor immune responses, such as CTLA4 (cytotoxic lymphocite antigen 4) antibodies, and other agents capable of blocking CTLA4; and anti-proliferative agents such as other farnesyl protein transferase inhibitors, for example the farnesyl protein transferase inhibitors described in the references cited in the"Background"section, of US Patent No, 6,258,824 Bl. Specific CTLA4 antibodies that can be used in the present invention include those described in U. S. Provisional Application 60/113,647 (filed Dec. 23,1998) which is incorporated by reference in its entirety, however other CTLA4 antibodies can be used in the present invention.

[0097] The above method can be also be carried out in combination with radiation therapy, wherein the amount of a compound of Formula (I) in combination with the radiation therapy effective in treating the above diseases.

[0098] Techniques for administering radiation therapy are known in the art, and these techniques can be used in the combination therapy described herein. The administration of the compound of the invention in this combination therapy can be determined as described herein.

[0099] Another aspect of the invention is directed ot the use of a compound of Formula (I) in the preparation of a medicament, which is useful in the treatment of a disease mediated by abnormal Met kinase activity.

DETAILED DESCRIPTION OF THE INVENTION I. Definitions 101001 The terms"indolinone","2-indolinone"and"indolin-2-one"are used interchangeably herein to refer to a molecule having the chemical structure: [0101]"Pyrrole"refers to a molecule having the chemical structure: [0102]"Pyrrole-substituted 2-indolinone"and"3-pyrrolidinyl-2-indolinone"are used interchangeably herein to refer to a chemical compound having the general structure shown in Formula I.

[0103]"Pharmaceutically acceptable salt"or"pharmaceutically acceptable salt thereof'refer to those salts which retain the biological effectiveness and properties of the free bases and which are obtained by reaction with inorganic or organic acids, such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, acetic acid, benzenesulfonic acid (besylate), benzoic acid, camphorsulfonic acid, citric acid, fumaric acid, gluconic acid, glutamic acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, mucic acid, pamoic acid, pantothenic acid, succinic acid, tartaric acid, and the like.

[0104] A'pharmaceutical composition"refers to a mixture of one or more of the compounds described herein, or physiologically acceptable salts thereof, with other chemical components, such as physiologically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.

[0105] As used herein, a"physiologically acceptable carrier"refers to a carrier or diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.

[0106] An"excipient"refers to an inert substance added to a pharmaceutical composition to further facilitate administration of a compound. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives (including microcrystalline cellulose), gelatin, vegetable oils, polyethylene glycols, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like.

[0107]"Alkyl"refers to a saturated aliphatic hydrocarbon including straight chain, branched chain or cyclic groups. Preferably, the alkyl group has 1 to 20 carbon atoms (whenever a numerical range; e. g.,"1-20", is stated herein, it means that the group, in this case the alkyl group, may contain 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc. up to and including 20 carbon atoms). More preferably, it is a medium size alkyl having 1 to 10 carbon atoms. Most preferably, it is a lower alkyl having 1 to 4 carbon atoms. The alkyl group may be substituted or unsubstituted. When substituted, the substituent group (s) is preferably one or more individually selected from halogen,- <BR> <BR> <BR> OR6,-COR6,-COOR6, OCOR6,-CONR6R',-R6NCOR',-NR6R',-CN,-NO2,-CX3,-<BR> <BR> <BR> <BR> <BR> SR6,-SOR6,-SO2R,-SO2OR6,-S02NR6R7, thiocarbonyl,-R6NSo2R7, perfluoroalkyl, 0-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, silyl, ammonium, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, heterocycle, heteroaryl and aryl.

[0108]"Alkenyl"refers to an aliphatic hydrocarbon having at least one carbon- carbon double bond, including straight chain, branched chain or cyclic groups having at least one carbon-carbon double bond. Preferably, the alkenyl group has 2 to 20 carbon atoms (whenever a numerical range; e. g.,"2-20", is stated herein, it means that the group, in this case the alkenyl group, may contain 2 carbon atoms, 3 carbon atoms, etc. up to and including 20 carbon atoms). More preferably, it is a medium size alkenyl having 2 to 10 carbon atoms. Most preferably, it is a lower alkenyl having 2 to 6 carbon atoms. The alkenyl group may be substituted or unsubstituted.

When substituted, the substituent group (s) is preferably one or more individually selected from halogen, -OR6,-COR6,-COOR6, OCOR6,-CONR6R7,-R6NCOR7,- NR6R7,-CN,-NO2,-CX3,-SR6,-SOR6,-SO2R6,-SO2OR6,-So2NR6R7, thiocarbonyl, -R6NSo2R7, perfluoroalkyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N- thiocarbamyl, silyl, ammonium, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, heterocycle, heteroaryl and aryl.

[0109]"Alkynyl"refers to an aliphatic hydrocarbon having at least one carbon- carbon triple bond, including straight chain, branched chain or cyclic groups having at least one carbon-carbon triple bond. Preferably, the alkenyl group has 2 to 20 carbon atoms (whenever a numerical range; e. g.,"2-20", is stated herein, it means that the group, in this case the alkynyl group, may contain 2 carbon atoms, 3 carbon atoms, etc. up to and including 20 carbon atoms). More preferably, it is a medium size alkynyl having 2 to 10 carbon atoms. Most preferably, it is a lower alkynyl having 2 to 6 carbon atoms. The alkynyl group may be substituted or unsubstituted. When substituted, the substituent group (s) is preferably one or more individually selected from halogen, -OR6,-COR6,-COOR6, OCOR6,-CoNR6R7,-R6NCoR7,-NR6R7,-CN <BR> <BR> <BR> -NO2,-CX3,-SR6,-SOR6,-SO2R6,-SO2OR6,-So2NR6R7, thiocarbonyl,-R6NSo2R7, perfluoroalkyl, 0-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, silyl, ammonium, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, heterocycle, heteroaryl and aryl.

[0110] A"cycloalkyl"group refers to an all-carbon monocyclic or fused ring (i.e., rings which share an adjacent pair of carbon atoms) group wherein one of more of the rings does not have a completely conjugated pi-electron system. Examples, without limitation, of cycloalkyl groups are cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, adamantane, cyclohexadiene, cycloheptane and, cycloheptatriene. A cycloalkyl group may be substituted or unsubstituted. When substituted, the substituent group (s) is preferably one or more individually selected from halogen,-OR",-COR",-COOR", OCOR6,-CoNR6R7,-R6NCoR7,-NR6R7,-CN, <BR> <BR> <BR> -NO2,-CX3,-SR6,-SOR6,-SO2R6,-SO2OR6,-So2NR6R7, thiocarbonyl,-R6NSo2R7, perfluoroalkyl, 0-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, silyl, ammonium, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, heterocycle, heteroaryl and aryl.

[0111] An"aryl"group refers to an all-carbon monocyclic or fused-ring polycyclic (i. e., rings which share adjacent pairs of carbon atoms) groups having a completely conjugated, pi-electron system. Examples, without limitation, of aryl groups are phenyl, naphthalenyl and anthracenyl. The aryl group may be substituted or unsubstituted. When substituted, the substituted group (s) is preferably one or more selected halogen,-OR6,-COR6,-COOR6, OCOR6,-CoNR6R7,-R6NCoR7,-NR6R7,- CN,-NO2,-CX3,-SR6,-SOR6,-SO2R6,-SO2OR6,-S02NR6R, thiocarbonyl,- R6NS02R, perfluoroalkyl, O-carbamyl, N-carbamyl, O-thiocarbamyl, N- thiocarbamyl, silyl, ammonium, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, heterocycle, heteroaryl and aryl.

[0112] As used herein, a"heteroaryl"group refers to a monocyclic or fused ring (i. e., rings which share an adjacent pair of atoms) group having in the ring (s) one or more atoms selected from the group consisting of nitrogen, oxygen and sulfur and, in addition, having a completely conjugated pi-electron system. Examples, without limitation, of heteroaryl groups are pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrimidine, quinoline, isoquinoline, purine and carbazole. The heteroaryl group may be substituted or unsubstituted. When substituted, the substituted group (s) is preferably one or more selected from halogen,- <BR> <BR> <BR> OR6,-COR6,-COOR6, OCOR6,-CONR6R',-R6NCOR,-NR6R7,-CN,-NO2,-CX3,-<BR> <BR> <BR> <BR> <BR> SR6,-SOR6,-SO2R6,-SO2OR6,-SO2NR6R, thiocarbonyl,-R6NS02R, perfluoroalkyl, 0-carbamyl, N-carbamyl, O-thocarbamyl, N-thiocarbamyl, silyl, ammonium, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, heterocycle, heteroaryl and aryl, where X is halogen.

[0113] A"heterocyclic ring"or"heterocycle"group refers to a monocyclic or fused ring group having in the ring (s) one or more atoms selected from the group consisting of nitrogen, oxygen and sulfur. The rings may also have one or more double bonds.

However, the rings may or may not have a completely conjugated pi-electron system.

The heterocyclic ring may be substituted or unsubstituted. The heterocyci ring may contain one or more oxo groups. When substituted, the substituted group (s) is preferably one or more selected halogen,-OR6,-COR6,-COOR6, OCOR6,-CONRbR, <BR> <BR> <BR> -R6NcoR7,-NR6R7,-CN,-NO2,-CX3,-SR6,-SOR6,-S02R6,-SO20R6,-So2 NR6R7, thiocarbonyl,-R6NSo2R7, perfluoroalkyl, 0-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, silyl, ammonium, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, heterocycle, heteroaryl and aryl.

10114] X refers to a halogen group selected from the group consisting of fluorine, chlorine, bromine and iodine.

[0115] The definitions of Rl-Rl3 are defined in the present specification.

[0116] Compounds that have the saine molecular formula but difer in the nature or sequence of bonding of their atoms or arrangements of their atoms in space are termed "isomers."Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers". Stereoisomers that are not mirror images of one another are termed "diastereomers"and those that are non-superimposable mirror images of each other are termed"enantiomers". When a compound has an asymmetric center, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R-and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i. e., as (+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a"racemic mixture".

[0117] The compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)-or (S)- stereoisomers or as mixtures thereof. For example, if the R6 substituent in a compound of formula (I) is 2-hydroxyethyl, then the carbon to which the hydroxy group is attached is an asymmetric center and therefore the compound of Formula (I) can exist as an (R)-or (S)-stereoisomer. Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see discussion in Chapter 4 of"Advanced Organic Chemistry", 4th edition J. March, John Wiley and Sons, New York, 1992).

[0118] The compounds of Formula (I) may exhibit the phenomena oftautomerism and structural isomerism. For example, the compounds described herein may adopt an E or a Z configuration about the double bond connecting the 2-indolinone moiety to the pyrrole moiety or they may be a mixture of E and Z. This invention encompasses any tautomeric or structural isomeric form and mixtures thereof which possess the ability to modulate RTK, CTK and/or STK activity and is not limited to any one tautomeric or structural isomeric form.

[0119] It is contemplated that a compound of Formula (I) would be metabolized by enzymes in the body of the organism such as human being to generate a metabolite that can modulate the activity of the protein kinases. Such metabolites are within the scope of the present invention.

[0120] As used herein,"PK"refers to receptor protein tyrosine kinase (RTKs), non- receptor or"cellular"tyrosine kinase (CTKs) and serine-threonine kinases (STKs).

[0121] The term"method"refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by, practitioners of the chemical, pharmaceutical, biological, biochemical and medical arts.

10122] As used herein, the term"modulation"or"modulating"refers to the alteration of the catalytic activity of RTKs, CTKs and STKs. In particular, modulating refers to the activation of the catalytic activity of RTKs, CTKs and STKs, preferably the activation or inhibition of the catalytic activity of RTKs, CTKs and STKs, depending on the concentration of the compound or salt to which the RTK, CTK or STK is exposed or, more preferably, the inhibition of the catalytic activity of RTKs, CTKs and STKs.

[0123] The term"catalytic activity"as used herein refers to the rate of phosphorylation of tyrosine under the influence, direct or indirect, of RTKs and/or CTKs or the phosphorylation of serine and threonine under the influence, direct or indirect, of STKs.

[0124] The term"contacting"as used herein refers to bringing a compound of this invention and a target PK together in such a manner that the compound can affect the catalytic activity of the PK, either directly, i. e., by interacting with the kinase itself, or indirectly, i. e., by interacting with another molecule on which the catalytic activity of the kinase is dependent. Such"contacting"can be accomplished in vitro, i. e., in a test tube, a petri dish or the like. In a test tube, contacting may involve only a compound and a PK of interest or it may involve whole cells. Cells may also be maintained or grown in cell culture dishes and contacted with a compound in that environment. In this context, the ability of a particular compound to affect a PK related disorder, i. e., the IC50 of the compound, defined below, can be determined before use of the compounds in vivo with more complex living organisms is attempted. For cells outside the organism, multiple methods exist, and are well-known to those skilled in the art, to get the PKs in contact with the compounds including, but not limited to, direct cell microinjection and numerous transmembrane carrier techniques.

[0125]"In vitro"refers to procedures performed in an artificial environment such as, e. g., without limitation, in a test tube or culture medium. The skilled artisan will understand that, for example, an isolated PK may be contacted with a modulator in an in vitro environment. Alternatively, an isolated cell may be contacted with a' modulator in an in vitro environment.

[0126] As used herein,"in vivo"refers to procedures performed within a living organism such as, without limitation, a mouse, rat, rabbit, ungulate, bovine, equine, porcine, canine, feline, primate, or human.

[0127] As used herein,"PK related disorder,""PK driven disorder,"and"abnormal PK activity"all refer to a condition characterized by inappropriate ; i. e., under or, more commonly, over, PK catalytic activity, where the particular PK can be an RTK, a CTK or an STK. Inappropriate catalytic activity can arise as the result of either: (1) PK expression in cells which normally do not express PKs, (2) increased PK expression leading to unwanted cell proliferation, differentiation and/or growth, or, (3) decreased PK expression leading to unwanted reductions in cell proliferation, differentiation and/or growth. Over-activity of a PK refers to either amplification of the gene encoding a particular PK or production of a level of PK activity which can correlate with a cell proliferation, differentiation and/or growth disorder (that is, as the level of the PK increases, the severity of one or more of the symptoms of the cellular disorder increases). Under-activity is, of course, the converse, wherein the severity of one or more symptoms of a cellular disorder increase as the level of the PK activity decreases.

[0128] As used herein, the terms"prevent","preventing"and"prevention"refer to a method for barring an organism from acquiring a PK related disorder in the first place.

[0129] As used herein, the terms"treat","treating"and"treatment"refer to a method of alleviating or abrogating a PK mediated cellular disorder and/or its attendant symptoms. With regard particularly to cancer, these terms simply mean that the life expectancy of an individual affected with a cancer will be increased or that one or more of the symptoms of the disease will be reduced.

[0130] The term"organism"refers to any living entity comprised of at least one cell. A living organism can be as simple as, for example, a single eukaryotic cell or as complex as a mammal. In a preferred aspect, the organism is a mammal. In a particularly preferred aspect, the mammal is a human being.

10131] The term"therapeutically effective amount"as used herein refers to that amount of the compound being administered which will relieve to some extent one or more of the symptoms of the disorder being treated. In reference to the treatment of cancer, a therapeutically effective amount refers to that amount which has the effect of (1) reducing the size of the tumor, (2) inhibiting (that is, slowing to some extent, preferably stopping) tumor metastasis, (3) inhibiting to some extent (that is, slowing to some extent, preferably stopping) tumor growth, and/or, (4) relieving to some extent (or, preferably, eliminating) one or more symptoms associated with the cancer.

[0132] By"monitoring"is meant observing or detecting the effect of contacting a compound with a cell expressing a particular PK. The observed or detected effect can be a change in cell phenotype, in the catalytic activity of a PK or a change in the interaction of a PK with a natural binding partner. Techniques for observing or detecting such effects are well-known in the art. For example, the catalytic activity of a PK may be observed by determining the rate or amount of phosphorylation of a target molecule.

[0133]"Cell phenotype"refers to the outward appearance of a cell or tissue or the biological function of the cell or tissue. Examples, without limitation, of a cell phenotype are cell size, cell growth, cell proliferation, cell differentiation, cell survival, apoptosis, and nutrient uptake and use. Such phenotypic characteristics are measurable by techniques well-known in the art.

[0134] A"natural binding partner"refers to a polypeptide that binds to a particular PK in a cell. Natural binding partners can play a role in propagating a signal in a PK- mediated signal transduction process. A change in the interaction of the natural binding partner with the PK can manifest itself as an increased or decreased concentration of the PK/natural binding partner complex and, as a result, in an observable change in the ability of the PK to mediate signal transduction.

[0135] As used herein,"administer"or"administration"refers to the delivery of a compound or salt of the present invention or of a pharmaceutical composition containing a compound or salt of this invention to an organism for the purpose of prevention or treatment of a PK-related disorder.

[0136] A"pharmaceutical composition"refers to a mixture of one or more of the compounds described herein, or pharmaceutically acceptable salts or prodrugs thereof, with other chemical components, such as pharmaceutically acceptable excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.

[0137]"Pharmaceutically acceptable excipient"refers to an inert substance added to a pharmaceutical composition to further facilitate administration of a compound.

Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols.

[0138]"Pharmaceutically acceptable salt"refers to those salts, which retain the biological effectiveness and properties of the parent compound. Such salts include: [0139] (1) acid addition salt which is obtained by reaction of the free base of the parent compound with inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, phosphoric acid, sulfuric acid, and perhcloric acid and the like, or with organic acids such as acetic acid, oxalic acid, (D) or (L) malic acid, maleic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, tartaric acid, citric acid, succinic acid or malonic acid and the like, preferably hydrochloric acid or (L)-malic acid; or [0140] (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e. g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like.

[0141] The compound of Formula (I) may also act as a prodrug. A"prodrug"refers to an agent, which is converted into the parent drug in vivo. Prodrugs are often useful because, in some situations, they may be easier to administer than the parent drug.

They may, for instance, be bioavailable by oral administration whereas the parent drug is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. An example, without limitation, of a prodrug would be a compound of the present invention, which is, administered as an ester (the "prodrug"), carbamate or urea.

Indications [0142] The PKs whose catalytic activity is modulated by the compounds of this invention include protein tyrosine kinases of which there are two types, receptor tyrosine kinases (RTKs) and cellular tyrosine kinases (CTKs), and serine-threonine kinases (STKs). RTK mediated signal transduction, is initiated by extracellular interaction with a specific growth factor (ligand), followed by receptor dimerization, transient stimulation of the intrinsic protein tyrosine kinase activity and phosphorylation. Binding sites are thereby created for intracellular signal transduction molecules and lead to the formation of complexes with a spectrum of cytoplasmic signaling molecules that facilitate the appropriate cellular response (e. g., cell division, metabolic effects on the extracellular microenvironment, etc.). See, Schlessinger and Ullrich, Neuron, 9: 303-391 (1992).

[0143] It has been shown that tyrosine phosphorylation sites on growth factor receptors function as high-affinity binding sites for SH2 (src homology) domains of signaling molecules. Fantl et al., Cell, 69: 413-423 (1992), Songyang et al., Mol. Cell.

Biol., 14: 2777-2785 (1994), Songyang et al., Cell, 72: 767-778 (1993), and Koch et al., Science, 252: 668-678 (1991). Several intracellular substrate proteins that associate with RTKs have been identified. They may be divided into two principal groups: (1) substrates that have a catalytic domain, and (2) substrates which lack such domain but which serve as adapters and associate with catalytically active molecules.

Songyang et al., Cell, 72: 767-778 (1993). The specificity of the interactions between receptors and SH2 domains of their substrates is determined by the amino acid residues immediately surrounding the phosphorylated tyrosine residue. Differences in the binding affinities between SH2 domains and the amino acid sequences surrounding the phosphotyrosine residues on particular receptors are consistent with the observed differences in their substrate phosphorylation profiles. Songyang et al., Cell, 72: 767-778 (1993). These observations suggest that the function of each RTK is determined not only by its pattern of expression and ligand availability but also by the array of downstream signal transduction pathways that are activated by a particular receptor. Thus, phosphorylation provides an important regulatory step which determines the selectivity of signaling pathways recruited by specific growth factor receptors, as well as differentiation factor receptors. l0144] STKs, being primarily cytosolic, affect the internal biochemistry of the cell, often as a down-line response to a PTK event. STKs have been implicated in the signaling process which initiates DNA synthesis and subsequent mitosis leading to cell proliferation.

[0145] Thus, PK signal transduction results in, among other responses, cell proliferation, differentiation, growth and metabolism. Abnormal cell proliferation may result in a wide array of disorders and diseases, including the development of neoplasia such as carcinoma, sarcoma, glioblastoma and hemangioma, disorders such as leukemia, psoriasis, arteriosclerosis, arthritis and diabetic retinopathy and other disorders related to uncontrolled angiogenesis and/or vasculogenesis.

101461 A precise understanding of the mechanism by which the compounds of the invention, in particular, the compounds generated in vivo from the compounds of the invention, inhibit PKs is not required in order to practice the present invention.

However, while not hereby being bound to any particular mechanism or theory, it is believed that the compounds interact with the amino acids in the catalytic region of PKs. PKs typically possess a bi-lobate structure wherein ATP appears to bind in the cleft between the two lobes in a region where the amino acids are conserved among PKs. Inhibitors of PKs are believed to bind by non-covalent interactions such as hydrogen bonding, van der Waals forces and ionic interactions in the same general region where the aforesaid ATP binds to the PKs. More specifically, it is thought that the 2-indolinone component of the compounds of this invention binds in the general space normally occupied by the adenine ring of ATP. Specificity of a particular molecule for a particular PK may then arise as the result of additional interactions between the various substituents on the 2-indolinone core and the amino acid domains specific to particular PKs. Thus, different indolinone substituents may contribute to preferential binding to particular PKs. The ability to select compounds active at different ATP (or other nucleotide) binding sites makes the compounds of this invention useful for targeting any protein with such a site. The compounds disclosed herein may thus have utility as in vitro assays for such proteins as well as exhibiting in vivo therapeutic effects through interaction with such proteins.

[0147] In another aspect, the protein kinase, the catalytic activity of which is modulated by contact with a compound of this invention, is a protein tyrosine kinase, more particularly, a receptor protein tyrosine kinase. Among the receptor protein tyrosine kinases whose catalytic activity can be modulated with a compound of this invention, or salt thereof, are, without limitation, selected from the group consisting of Met, Flk, FGFR, PDGFR, HER, IR, IGF, IRR, CSFIR, C-Kit, C-fms, flt. In a preferred aspect, the receptor protein tyrosine kinases whose catalytic activity can be modulated with a compound of this invention, or salt thereof, are, without limitation, Met, Flk-lR, Flk4, KDR/Flk-1, FGFR-1R, FGFR-2R, FGFR-3R, FGFR-4R, PDGFRa, PDGFRß, HER2, HER3, HER4, IRR, CSFIR, C-Kit and C-fins, preferably Met.

[0148] The protein tyrosine kinase whose catalytic activity is modulated by contact with a compound of this invention, or a salt thereof, can also be a non-receptor or cellular protein tyrosine kinase (CTK). Thus, the catalytic activity of CTKs such as, without limitation, Src, Frk, Btk, Csk, Abl, ZAP70, Fes, Fps, Fak, Jak, Ack, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr, Aur2 and Yrk may be modulated by contact with a compound or salt of this invention.

[0149] Still another group of PKs which may have their catalytic activity modulated by contact with a compound of this invention are the serine-threonine protein kinases such as, without limitation, CDK2, Raf, NEK (including NEK 4a, NEK 4b, NEK 5 and NEK 6) and BUB 1.

[0150] In another aspect, this invention relates to a method for treating or preventing a PK related disorder by administering a therapeutically effective amount of a compound of this invention, or a salt thereof, to an organism.

[0151] It is also an aspect of this invention that a pharmaceutical composition containing a compound of this invention, or a salt thereof, is administered to an organism for the purpose of preventing or treating a PK related disorder.

[0152] This invention is therefore directed to compounds that modulate PK signal transduction by affecting the enzymatic activity of RTKs, CTKs and/or STKs, thereby interfering with the signals transduced by such proteins. More particularly, the present invention is directed to compounds which modulate RTK, CTK and/or STK mediated signal transduction pathways as a therapeutic approach to cure many kinds of solid tumors, including but not limited to carcinomas, sarcomas including Kaposi's sarcoma, erythroblastoma, glioblastoma, meningioma, astrocytoma, melanoma and myoblastoma. Treatment or prevention of non-solid tumor cancers such as leukemia are also contemplated by this invention. Indications may include, but are not limited to brain cancers, bladder cancers, ovarian cancers, gastric cancers, pancreas cancers, colon cancers, blood cancers, lung cancers and bone cancers.

[0153] Further examples, without limitation, of the types of disorders related to inappropriate PK activity that the compounds described herein may be useful in preventing, treating and studying, are cell proliferative disorders, fibrotic disorders, metabolic disorders and infectious diseases.

[0154] Cell proliferative disorders, which may be prevented, treated or further studied by the present invention include cancer, blood vessel proliferative disorders and mesangial cell proliferative disorders.

[0155] Blood vessel proliferative disorders refer to disorders related to abnormal vasculogenesis (blood vessel formation) and angiogenesis (spreading of blood vessels). While vasculogenesis and angiogenesis play important roles in a variety of normal physiological processes such as embryonic development, corpus luteum formation, wound healing and organ regeneration, they also play a pivotal role in cancer development where they result in the formation of new capillaries needed to keep a tumor alive. Other examples of blood vessel proliferation disorders include arthritis, where new capillary blood vessels invade the joint and destroy cartilage, and ocular diseases, like diabetic retinopathy, where new capillaries in the retina invade the vitreous, bleed and cause blindness.

[0156] Two structurally related RTKs have been identified to bind VEGF with high affinity: the fins-like tyrosine 1 (fit-1) receptor (Shibuya et al., Oncogene, 5: 519-524 (1990); De Vries et al., Science, 255: 989-991 (1992) and the KDR/FLK-1 receptor, also known as VEGF-R2. Vascular endothelial growth factor (VEGF) has been reported to be an endothelial cell specific mitogen with in vitro endothelial cell growth promoting activity. Ferrara & Henzel, Biochem. Biophys. Res. Comm., 161: 851-858 (1989); Vaisman et al., J. Biol. Chem., 265: 19461-19566 (1990).

Information set forth in U. S. Application Serial Nos. 08/193,829,08/038,596 and 07/975,750, strongly suggest that VEGF is not only responsible for endothelial cell proliferation, but also is the prime regulator of normal and pathological angiogenesis.

See generally, Klagsburn & Soker, Current Biology, 3 (10): 699-702 (1993); Houck, et al., J. Biol. Chem., 267: 26031-26037 (1992).

[0157] Normal vasculogenesis and angiogenesis play important roles in a variety of physiological processes such as embryonic development, wound healing, organ regeneration and female reproductive processes such as follicle development in the corpus luteum during ovulation and placental growth after pregnancy. Folkman & Shing, J. Biological Chem., 267 (16): 10931-10934 (1992). Uncontrolled vasculogenesis and/or angiogenesis has been associated with diseases such as diabetes as well as with malignant solid tumors that rely on vascularization for growth.

Klagsburn & Soker, Current Biology, 3 (10): 699-702 (1993); Folkham, J. Natl.

CancerInst., 82: 4-6 (1991) ; Weidner, et al., NewEngl. J. Med., 324: 1-5 (1991).

[01581 As presently understood, the role of VEGF in endothelial cell proliferation and migration during angiogenesis and vasculogenesis indicates an important role for the KDR/FLK-1 receptor in these processes. Diseases such as diabetes mellitus (Folkman, 198, in XIth Congress of Thrombosis and Haemostasis (Verstraeta, et al., eds.), pp. 583-596, Leuven University Press, Leuven) and arthritis, as well as malignant tumor growth may result from uncontrolled angiogenesis. See e. g., Folkman, N. Engl. J. Med., 285: 1182-1186 (1971). The receptors to which VEGF specifically binds are an important and powerful therapeutic target for the regulation and modulation of vasculogenesis and/or angiogenesis and a variety of severe diseases which involve abnormal cellular growth caused by such processes. Plowman, et al., DN&P, 7 (6): 334-339 (1994). More particularly, the KDR/FLK-1 receptor's highly specific role in neovascularization make it a choice target for therapeutic approaches to the treatment of cancer and other diseases which involve the uncontrolled formation of blood vessels.

[0159] Thus, one aspect of the present invention relates to compounds capable of regulating and/or modulating tyrosine kinase signal transduction including KDR/FLK-1 receptor signal transduction in order to inhibit or promote angiogenesis and/or vasculogenesis, that is, compounds that inhibit, prevent, or interfere with the signal transduced by KDR/FLK-1 when activated by ligands such as VEGF. Although it is believed that the compounds of the present invention act on a receptor or other component along the tyrosine kinase signal transduction pathway, they may also act directly on the tumor cells that result from uncontrolled angiogenesis.

[01601 Although the nomenclature of the human and murine counterparts of the generic"flk-I"receptor differ, they are, in many respects, interchangeable. The murine receptor, Flk-1, and its human counterpart, KDR, share a sequence homology of 93.4% within the intracellular domain. Likewise, murine FLK-I binds human VEGF with the same affinity as mouse VEGF, and accordingly, is activated by the ligand derived from either species. Millauer et al., Cell, 72: 835-846 (1993); Quinn et al., Proc. Natl. Acad. Sci. USA, 90: 7533-7537 (1993). FLK-1 also associates with and subsequently tyrosine phosphorylates human RTK substrates (e. g., PLC-y or p85) when co-expressed in 293 cells (human embryonal kidney fibroblasts).

[0161] Models which rely upon the FLK-1 receptor therefore are directly applicable to understanding the KDR receptor. For example, use of the murine FLK-1 receptor in methods which identify compounds that regulate the murine signal transduction pathway are directly applicable to the identification of compounds which may be used to regulate the human signal transduction pathway, that is, which regulate activity related to the KDR receptor. Thus, chemical compounds identified as inhibitors of.

KDR/FLK-1 in vitro, can be confirmed in, suitable in vivo models. Both in vivo mouse and rat animal models have been demonstrated to be of excellent value for the examination of the clinical potential of agents acting on the KDR/FLK-1 induced signal transduction pathway.

[0162] Thus, in one aspect, this invention is directed to compounds that regulate, modulate and/or inhibit vasculogenesis and/or angiogenesis by affecting the enzymatic activity of the KDR/FLK-1 receptor and interfering with the signal transduced by KDR/FLK-1. In another aspect, the present invention is directed to compounds which regulate, modulate and/or inhibit the KDR/FLK-1 mediated signal transduction pathway as a therapeutic approach to the treatment of many kinds of solid tumors including, but not limited to, glioblastoma, melanoma and Kaposi's sarcoma, and ovarian, lung, mammary, prostate, pancreatic, colon and epidermoid carcinoma. In addition, data suggest the administration of compounds which inhibit the KDR/Flk-1 mediated signal transduction pathway may also be used in the treatment of hemangioma, restenois and diabetic retinopathy.

[0163] A further aspect of this invention relates to the inhibition of vasculogenesis and angiogenesis by other receptor-mediated pathways, including the pathway comprising the flt-1 receptor.

[0164] Receptor tyrosine kinase mediated signal transduction is initiated by extracellular interaction with a specific growth factor (ligand), followed by receptor dimerization, transient stimulation of the intrinsic protein tyrosine kinase activity and autophosphorylation. Binding sites are thereby created for intracellular signal transduction molecules which leads to the formation of complexes with a spectrum of cytoplasmic signaling molecules that facilitate the appropriate cellular response, e. g, cell division and metabolic effects to the extracellular microenvironment. See, Schlessinger and Ullrich, Neuron, 9: 1-20 (1992).

[01651 The close homology of the intracellular regions of KDR/FLK-1 with that of the PDGF-P receptor (50.3% homology) and/or the related flt-1 receptor indicates the induction of overlapping signal transduction pathways. For example, for the PDGF-P receptor, members of the src family (Twamley et al., Proc. Natl. Acad. Sci. USA, 90: 7696-7700 (1993)), phosphatidylinositol-3'-kinase (Hu et al., Mol. Cell. Biol., 12: 981-990 (1992), phospholipase cy (Kashishian & Cooper, Mol. Cell. Biol., 4: 49-51 (1993)), ras-GTPase-activating protein, (Kashishian et al., EMBO J., 11 : 1373-1382 (1992), PTP-ID/syp (Kazlauskas et al., Proc. Natl. Acad. Sci. USA, 90: 6939-6943 (1993)), Grb2 (Arvidsson et al., Mol. Cell. Biol., 14: 6715-6726 (1994)), and the adapter molecules Shc and Nck (Nishimura et al., Mol. Cell. Biol., 13: 6889-6896 (1993)), have been shown to bind to regions involving different autophosphorylation sites. See generally, Claesson-Welsh, Prog. Growth FactorRes., 5: 37-54 (1994).

Thus, it is likely that signal transduction pathways activated by KDR/FLK-1 include the ras pathway (Rozakis et al., Nature, 360: 689-692 (1992)), the PI-3'-kinase, the src-mediated and the plcy-mediated pathways. Each of these pathways may play a critical role in the angiogenic and/or vasculogenic effect of KDR/FLK-1 in endothelial cells. Consequently, a still further aspect of this invention relates to the use of the organic compounds described herein to modulate angiogenesis and vasculogenesis as such processes are controlled by these pathways.

[0166] Conversely, disorders related to the shrinkage, contraction or closing of blood vessels, such as restenosis, are also implicated and may be treated or prevented by the methods of this invention.

[01671 Fibrotic disorders refer to the abnormal formation of extracellular matrices.

Examples of fibrotic disorders include hepatic cirrhosis and mesangial cell proliferative disorders. Hepatic cirrhosis is characterized by the increase in extracellular matrix constituents resulting in the formation of a hepatic scar. An increased extracellular matrix resulting in a hepatic scar can also be caused by a viral infection such as hepatitis. Lipocytes appear to play a major role in hepatic cirrhosis.

Other fibrotic disorders implicated include atherosclerosis.

[0168] Mesangial cell proliferative disorders refer to disorders brought about by abnormal proliferation of mesangial cells. Mesangial proliferative disorders include various human renal diseases such as glomerulonephritis, diabetic nephropathy and malignant nephrosclerosis as well as such disorders as thrombotic microangiopathy syndromes, transplant rejection, and glomerulopathies. The RTK PDGFR has been implicated in the maintenance of mesangial cell proliferation. Floege et al., Kidney International, 43: 47S-54S (1993).

[0169] Many cancers are cell proliferative disorders and, as noted previously, PKs have been associated with cell proliferative disorders. Thus, it is not surprising that PKs such as, for example, members of the RTK family have been associated with the development of cancer. Some of these receptors, like EGFR (Tuzi et al., Br. J.

Cancer, 63: 227-233 (1991), Torp et al., APMIS, 100: 713-719 (1992)) HER2/neu (Slamon et aL, Science, 244: 707-712 (1989)) and PDGF-R (Kumabe et al., Oncogene, 7 : 627-633 (1992)) are over-expressed in many tumors and/or persistently activated by autocrine loops. In fact, in the most common and severe cancers these receptor over- expressions (Akbasak and Suner-Akbasak et al., J : Neurol. Sci., 111: 119-133 (1992), Dickson et al., Cancer Treatment Res., 61: 249-273 (1992), Korc et al., J. Clin.

Invest., 90: 1352-1360 (1992)) and autocrine loops (Lee and Donoghue, J. Cell. Biol., 118: 1057-1070 (1992), Korc et al., supra, Akbasak and Suner-Akbasak et al., supra) have been demonstrated. For example, EGFR has been associated with squamous cell carcinoma, astrocytoma, glioblastoma, head and neck cancer, lung cancer and bladder cancer. HER2 has been associated with breast, ovarian, gastric, lung, pancreas and bladder cancer. PDGFR has been associated with glioblastoma and melanoma as well as lung, ovarian and prostate cancer. The RTK c-met has also been associated with malignant tumor formation. For example, c-met has been associated with, among other cancers, colorectal, thyroid, pancreatic, gastric and hepatocellular carcinomas and lymphomas. Additionally c-met has been linked to leukemia. Over-expression of the c-met gene has also been detected in patients with Hodgkins disease and Burkitts disease.

[0170] IGF-IR, in addition to being implicated in nutritional support and in type-II diabetes, has also been associated with several types of cancers. For example, IGF-I has been implicated as an autocrine growth stimulator for several tumor types, e. g. human breast cancer carcinoma cells (Arteaga et al. J. Clin. Invest., 84: 1418-1423 (1989)) and small lung tumor cells (Macauley et al., Cancer Res., 50: 2511-2517 (1990)). In addition, IGF-I, while integrally involved in the normal growth and differentiation of the nervous system, also appears to be an autocrine stimulator of human gliomas. Sandberg-Nordqvist et al., Cancer Res., 53: 2475-2478 (1993). The importance of IGF-IR and its ligands in cell proliferation is further supported by the fact that many cell types in culture (fibroblasts, epithelial cells, smooth muscle cells, T-lymphocytes, myeloid cells, chondrocytes and osteoblasts (the stem cells of the bone marrow)) are stimulated to grow by IGF-I. Goldring and Goldring, Eukaryotic Gene Expression, 1: 301-326 (1991). In a series of recent publications, Baserga suggests that IGF-IR plays a central role in the mechanism of transformation and, as such, could be a preferred target for therapeutic interventions for a broad spectrum of human malignancies. Baserga, Cancer Res., 55: 249-252 (1995), Baserga, Cell, 79: 927-930 (1994), Coppola et al., Mol. Cell. Biol., 14: 4588-4595 (1994).

[01711 STKs have been implicated in many types of cancer including, notably, breast cancer (Cance, et al., Int. J. Cancer, 54: 571-77 (1993)).

10172] The association between abnormal PK activity and disease is not restricted to cancer. For example, RTKs have been associated with diseases such as psoriasis, diabetes mellitus, endometriosis, angiogenesis, atheromatous plaque development, Alzheimer's disease, von Hippel-Lindau disease, epidermal hyperproliferation, neurodegenerative diseases, age-related macular degeneration and hemangiomas. For example, EGFR has been indicated in corneal and dermal wound healing. Defects in Insulin-R and IGF-1R are indicated in type-II diabetes mellitus. A more complete correlation between specific RTKs and their therapeutic indications is set forth in Plowman et al., DN&P, 7: 334-339 (1994).

[0173] As noted previously, not only RTKs but CTKs including, but not limited to, src, abl, fps, yes, fyn, lyn, lck, blk, hck, fgr and yrk (reviewed by Bolen et al., FASEB J., 6: 3403-3409 (1992)) are involved in the proliferative and metabolic signal transduction pathway and thus could be expected, and have been shown, to be involved in many PTK-mediated disorders to which the present invention is directed.

For example, mutated src (v-src) has been shown to be an oncoprotein (pop60'-") in chicken. Moreover, its cellular homolog, the proto-oncogene pp6oc-"transmits oncogenic signals of many receptors. Over-expression of EGFR or HER2/neu in tumors leads to the constitutive activation of pp60C srC, which is characteristic of malignant cells but absent in normal cells. On the other hand, mice deficient in the expression of c-src exhibit an osteopetrotic phenotype, indicating a key participation of c-src in osteoclast function and a possible involvement in related disorders.

[0174] Similarly, Zap70 has been implicated in T-cell signaling which may relate to autoimmune disorders.

[0175] STKs have been associated with inflammation, autoimmune disease, immunoresponses, and hyperproliferation disorders such as restenosis, fibrosis, psoriasis, osteoarthritis and rheumatoid arthritis.

[0176] PKs have also been implicated in embryo implantation. Thus, the compounds of this invention may provide an effective method of preventing such embryo implantation and thereby be useful as birth control agents.

[0177] In yet another aspect, the compounds of the instant invention can also be used as anti-infective agents. For example, indolinone compounds are known to exhibit antibacterial and antifungal activities. See, e. g., Singh and Jha,"Indolinone derivatives as potential antimicrobial agents,"Zentralbl. Mikrobiol,. 144 (2): 105-109 (1989). In addition, indolinone compounds have been reported to exhibit significant antiviral activity. See, e. g., Maass et al.,"Viral resistance to the thiazolo-iso- indolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase,"Antimicrob. Agents Chemother., 37 (12): 2612-2617 (1993).

[0178] Finally, both RTKs and CTKs are currently suspected as being involved in hyperimmune disorders.

101791 A method for identifying a chemical compound that modulates the catalytic activity of one or more of the above discussed protein kinases is another aspect of this invention. The method involves contacting cells expressing the desired protein kinase with a compound of this invention (or its salt) and monitoring the cells for any effect that the compound has on them. The effect may be any observable, either to the naked eye or through the use of instrumentation, change or absence of change in a cell phenotype. The change or absence of change in the cell phenotype monitored may be, for example, without limitation, a change or absence of change in the catalytic activity of the protein kinase in the cells or a change or absence of change in the interaction of the protein kinase with a natural binding partner.

Pharmaceutical Compositions and Use [0180] A compound of the present invention or a physiologically acceptable salt thereof, can be administered as such to a human patient or can be administered in pharmaceutical compositions in which the foregoing materials are mixed with suitable carriers or excipient (s). Techniques for formulation and administration of drugs may be found in"Remington's Pharmacological Sciences,"Mack Publishing Co., Easton, PA, latest edition.

Routes of Administration [0181] Suitable routes of administration may include, without limitation, oral, intraoral, rectal, transmucosal or intestinal administration or intramuscular, epicutaneous, parenteral, subcutaneous, transdermal, intramedullary, intrathecal, direct intraventricular, intravenous, intravitreal, intraperitoneal, intranasal, intramuscular, intradural, intrarespiratory, nasal inhalation or intraocular injections.

The preferred routes of administration are oral and parenteral.

[0182] Alternatively, one may administer the compound in a local rather than systemic manner, for example, via injection of the compound directly into a solid tumor, often in a depot or sustained release formulation.

[0183] Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with tumor-specific antibody. The liposomes will be targeted to and taken up selectively by the tumor.

Composition/Formulation [0184] Pharmaceutical compositions of the present invention may be manufactured by processes well known in the art, e. g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, lyophilizing processes or spray drying.

[0185] Pharmaceutical compositions for use in the methods of the present invention may be'prepared by any methods of pharmacy, but all methods include the step of bringing in association the active ingredient with the carrier which constitutes one or more necessary ingredients. In particular, pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

[0186] Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, patches, syrups, elixirs, gels, powders, magmas, lozenges, ointments, creams, pastes, plasters, lotions, discs, suppositories, nasal or oral sprays, aerosols and the like.

[0187] For injection, the compounds of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such buffers with or without a low concentration of surfactant or cosolvent, or physiological saline buffer.

For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

[0188] For oral administration, the compounds can be formulated by combining the active compounds with pharmaceutically acceptable carriers well known in the art.

Such carriers enable the compounds of the invention to be formulated as tablets, pills, lozenges, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient. Pharmaceutical preparations for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding other suitable auxiliaries if desired, to obtain tablets or dragee cores. Useful excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol, cellulose preparations such as, for example, maize starch, wheat starch, rice starch and potato starch and other materials such as gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinyl-pyrrolidone (PVP). If desired, disintegrating agents may be added, such as cross-linked polyvinyl pyrrolidone, agar, or alginic acid. A salt such as sodium alginate may also be used.

[0189] Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.

Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

[0190] Pharmaceutical compositions which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with a filler such as lactose, a binder such as starch, and/or a lubricant such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, liquid polyethylene glycols, cremophor, capmul, medium or long chain mono-di-or triglycerides. Stabilizers may be added in these formulations, also.

[0191] For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray using a pressurized pack or a nebulizer and a suitable propellant, e. g., without limitation, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetra-fluoroethane or carbon dioxide. In the case of a pressurized aerosol, the dosage unit may be controlled by providing a valve to deliver a metered amount. Capsules and cartridges of, for example, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

[0192] The compounds may also be formulated for parenteral administration, e. g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e. g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating materials such as suspending, stabilizing and/or dispersing agents.

[0193] Pharmaceutical compositions for parenteral administration include aqueous solutions of a water soluble form, such as, without limitation, a salt, of the active compound. Additionally, suspensions of the active compounds may be prepared in a lipophilic vehicle. Suitable lipophilic vehicles include fatty oils such as sesame oil, synthetic fatty acid esters such as ethyl oleate and triglycerides, or materials such as liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers and/or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

[0194] Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e. g., sterile, pyrogen-free water, before use.

[0195] The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, using, e. g., conventional suppository bases such as cocoa butter or other glycerides.

[0196] In addition to the formulations described previously, the compounds may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection. A compound of this invention may be formulated for this route of administration with suitable polymeric or hydrophobic materials (for instance, in an emulsion with a pharmacologically acceptable oil), with ion exchange resins, or as a sparingly soluble derivative such as, without limitation, a sparingly soluble salt.

[0197] A non-limiting example of a pharmaceutical carrier for the hydrophobic compounds of the invention is a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer and an aqueous phase such as the VPD co-solvent system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant Polysorbate 80TM, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol. The VPD co-solvent system (VPD: D5W) consists of VPD diluted 1: 1 with a 5% dextrose in water solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration. Naturally, the proportions of such a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics.

Furthermore, the identity of the co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of Polysorbate 80TM, the fraction size of polyethylene glycol may be varied, other biocompatible polymers may replace polyethylene glycol, e. g., polyvinyl pyrrolidone, and other sugars or polysaccharides may substitute for dextrose.

[0198] Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs. In addition, certain organic solvents such as dimethylsulfoxide also may be employed, although often at the cost of greater toxicity.

[0199] Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days.

Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.

[0200] The pharmaceutical compositions herein also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include, but are not limited to, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

[0201] Many of the PK modulating compounds of the invention may be provided as physiologically acceptable salts wherein the claimed compound may form the negatively or the positively charged species. Examples of salts in which the compound forms the positively charged moiety include, without limitation, quaternary ammonium (defined elsewhere herein), salts such as the hydrochloride, sulfate, carbonate, lactate, tartrate, maleate, succinate wherein the nitrogen atom of the quaternary ammonium group is a nitrogen of the selected compound of this invention which has reacted with the appropriate acid. Salts in which a compound of this invention forms the negatively charged species include, without limitation, the sodium, potassium, calcium and magnesium salts formed by the reaction of a carboxylic acid group in the compound with an appropriate base (eg. sodium hydroxide (NaOH), potassium hydroxide (KOH), Calcium hydroxide (Ca (OH) 2), etc.).

Dosage [0202] Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an amount sufficient to achieve the intended purpose, ie., the modulation of PK activity or the treatment or prevention of a PK-related disorder.

[0203] More specifically, a therapeutically effective amount means an amount of compound effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated.

[0204] Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

[0205] For any compound used in the methods of the invention, the therapeutically effective amount or dose can be estimated initially from cell culture assays. Then, the dosage can be formulated for use in animal models so as to achieve a circulating concentration range that includes the IC50 as determined in cell culture (i. e., the concentration of the test compound which achieves a half-maximal inhibition of the PK activity). Such information can then be used to more accurately determine useful doses in humans.

[0206] Toxicity and therapeutic efficacy of the compounds described herein can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e. g., by determining the ICso and the LDso (both of which are discussed elsewhere herein) for a subject compound. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition.

(See e. g, Fingl, et al., 1975, in"The Pharmacological Basis of Therapeutics", Ch. 1 p. l).

[0207] Dosage amount and interval may be adjusted individually to provide plasma levels of the active species which are sufficient to maintain the kinase modulating effects. These plasma levels are referred to as minimal effective concentrations (MECs). The MEC will vary for each compound but can be estimated from in vitro data, e. g., the concentration necessary to achieve 50-90% inhibition of a kinase may be ascertained using the assays described herein. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. HPLC assays or bioassays can be used to determine plasma concentrations.

[0208] Dosage intervals can also be determined using MEC value. Compounds should be administered using a regimen that maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50- 90%. At present, the therapeutically effective amounts of compounds of Formula (I) may range from approximately 25 mg/m2 to 150 mg/m2 perday. Even more preferably 25 mg/m2 to 1000 mg/m2.

[02091 In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration and other procedures known in the art may be employed to determine the correct dosage amount and interval.

[0210] The amount of a composition administered will, of course, be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, etc.

Packaging [0211] The compositions may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accompanied by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or of human or veterinary administration. Such notice, for example, may be of the labeling approved by the U. S. Food and Drug Administration for prescription drugs or of an approved product insert. Compositions comprising a compound of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition. Suitable conditions indicated on the label may include treatment of a tumor, inhibition of angiogenesis, treatment of fibrosis, diabetes, and the like.

EXAMPLES Compound Synthesis [0212] The compounds of this invention, as well as the precursor indolinones, may be readily synthesized using techniques well known in the chemical arts. It will be appreciated by those skilled in the art that other synthetic pathways for forming the compounds of the invention are available and that the following is offered by way of example and not limitation.

[0213] The following syntheses of representative compounds of this invention are shown by way of example only and are not to be construed as limiting the scope of this invention as to synthetic approach or as to the compounds whose syntheses are exemplified.

[0214] It will be clear to those skilled in the art, based both on known general principles of organic synthesis and on the disclosures herein appropriate changes and modifications to the following syntheses that may be effected without departing from the scope or spirit of the invention as defined in the appended claims.

[0215] HPLC data was obtained with a Zorbax SB C18 column (4.6 mm ID x 7.5 cm), a Perkin Elmer series 200 pump programmed to run from 10% acetonitrile/water 0.1% TFA (solvent A) to 90% acetonitrile/water (solvent B) with a flow rate of 1.5 mL/min. After 0.1 min on solvent A, a 5 min linear program to solvent B was run, followed by 3 min on solvent B, before recycling to solvent A (2 min). Detection was with a Perkin Elmer diode array detector recording at 215 and 280 nM). NMR spectra were recorded on a Bruker instrument at 300 MHz.

A. General synthetic procedure.

[0216] The following general methodology may be employed to prepare the compounds of this invention: [0217] The appropriately substituted 2-oxindole (1 equiv.), the appropriately substituted aldehyde (1.2 equiv.) and a base (0.1 equiv.) are mixed in a solvent (1-2 ml/mmol 2-oxindole) and the mixture is then heated for from about 2 to about 12 hours. After cooling, the precipitate that forms is filtered, washed with cold ethanol or ether and vacuum dried to give the solid product. If no precipitate forms, the reaction mixture is concentrated and the residue is triturated with dichloromethane/ether, the resulting solid is collected by filtration and then dried.

The product may optionally be further purified by chromatography.

[0218] The base may be an organic or an inorganic base. If an organic base is used, preferably it is a nitrogen base. Examples of organic nitrogen bases include, but are not limited to, diisopropylamine, trimethylamine, triethylamine, aniline, pyridine, 1,8- diazabicyclo [5.4.1] undec-7-ene, pyrrolidine and piperidine.

[0219] Examples of inorganic bases are, without limitation, ammonia, alkali metal or alkaline earth hydroxides, phosphates, carbonates, bicarbonates, bisulfates and amides. The alkali metals include, lithium, sodium and potassium while the alkaline earths include calcium, magnesium and barium.

[0220] In a presently preferred aspect of this invention, when the solvent is a protic solvent, such as water or alcohol, the base is an alkali metal or an alkaline earth inorganic base, preferably, a alkali metal or an alkaline earth hydroxide.

[0221] It will be clear to those skilled in the art, based both on known general principles of organic synthesis and on the disclosures herein which base would be most appropriate for the reaction contemplated.

[0222] The solvent in which the reaction is carried out may be a protic or an aprotic solvent, preferably it is a protic solvent. A"protic solvent"is a solvent which has hydrogen atom (s) covalently bonded to oxygen or nitrogen atoms which renders the hydrogen atoms appreciably acidic and thus capable of being"shared"with a solute through hydrogen bonding. Examples of protic solvents include, without limitation, water and alcohols.

[0223] An"aprotic solvent"may be polar or non-polar but, in either case, does not contain acidic hydrogens and therefore is not capable of hydrogen bonding with solutes. Examples, without limitation, of non-polar aprotic solvents, are pentane, hexane, benzene, toluene, methylene chloride and carbon tetrachloride. Examples of polar aprotic solvents are chloroform, tetrahydro-furan, dimethylsulfoxide and dimethylformamide.

[0224] In a presently preferred aspect of this invention, the solvent is a protic solvent, preferably water or an alcohol such as ethanol.

[0225] The reaction is carried out at temperatures greater than room temperature.

The temperature is generally from about 30° C to about 150° C, preferably about 80°C to about 100° C, most preferable about 75° C to about 85° C, which is about the boiling point of ethanol. By"about"is meant that the temperature range is preferably within 10 degrees Celsius of the indicated temperature, more preferably within 5 degrees Celsius of the indicated temperature and, most preferably, within 2 degrees Celsius of the indicated temperature. Thus, for example, by"about 75° C"is meant 75° C i 10° C, preferably 75° C 5° C and most preferably, 75° C + 2° C. B. General Procedures for the Syntheses of 4-Aryl-lH-indole.

Procedure A: Preparation of 4- (4, 4,5,5-tetramethyl- 1,3,2] dioxaborolan-2-yl)-lH-indole.

[0226] To a mixture of 4-bromoindole (1, 9.80g, 50 mmol), pinacole diborate (2, 13.97g, 55 mmol), and KOAc (14.72g, 150 mmol) in DMSO (200 mL) was added Palladium catalyst PdCl2 (dppyCH2Cl2 (1.22g, 1.5 mmol). The system was degassed, and then charged with nitrogen for three times. The mixture was stirred at 80 °C oil bath under nitrogen for 22 hours. TLC2 showed the complete disappearance of the starting material 4-bromoindole (1). The mixture was cooled to room temperature, and then poured to water (1 L). The product was extracted with ethyl acetate for three times. The combined extracts were washed by brine for five times to remove DMSO solvent, and then dried over Na2S04. During the washing step, the catalyst may precipitate out, which was removed by filtration. The ethyl acetate solution was filtered and condensed. The residue was purified on a silica gel column eluting with EtOAc-hexane (9: 1). The first fraction provided the side product indole (1.25g, 21% yield), Rf0. 55 (EtOAc-Hexane 5: 1). The second fraction provided the product 4- (4,4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl)-lH-indole as a white solid (3,8. 01g, 66%), Rf0. 46 (EtOAc-Hexane 5: 1).

[0227]'H NMR (300 MHz, DMSO-d6) 8 11.03 (bs, 1H, N-H)), 7.49 (d, J 7.7 Hz, 1H, H-5), 7.38 (dd, J0. 9 Hz, J7. 0 Hz, 1H, H-7), 7.38 (t, J2.6Hz, 1H, H-2), 7.06 (dd, J 7. 7 Hz, J 7. 0 Hz, 1H, H-6), 6.73 (bd, J2.2 Hz, 1H, H-3), 1.32 (s, 12H, 4CH3).

[02281 MS m/z 244 [M++1].

Preparation of 4-Aryl-lH-Indole.

[0229] To a mixture of 4- (4, 4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl)-lH-indole (3,1 molar equivalent), and aryl bromide (4,1.01 molar equivalent) in THF (0.3 M)) were added Palladium catalyst Pd (PPh3) 4 (0.03 molar equivalent) and the freshly prepared sodium hydroxide solution (2.76N, 3 equivalent). The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times.

The mixture was stirred under nitrogen at 70°C oil bath for 6-24 hours. TLC showed the completion of the coupling reaction. The mixture was cooled to room temperature, diluted with ethyl acetate, and separated from water layer. The ethyl acetate solution was washed by brine, and dried over Na2SO4. After filtration, the solvents were evaporated, and the crude product was purified by a silica gel column.

Procedure B: Preparation of 4-Aryl-lH-Indole.

[02301 To a mixture of 4-bromoindole (1 molar equivalent), and aryl boronic acid (1 molar equivalent) in THF (0.3 M)) were added Palladium catalyst Pd (PPh3) 4 (0.03 molar equivalent) and the freshly prepared sodium hydroxide solution (2.76N, 3 equivalent). The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times. The mixture was stirred under nitrogen at 70°C oil bath for 6-24 hours. TLC showed the completion of the coupling reaction.

The mixture was cooled to room temperature, diluted with ethyl acetate, and separated from water layer. The ethyl acetate solution was washed by brine, and dried over Na2SO4. After filtration, the solvents were evaporated, and the crude product was purified by a silica gel column Example A-1. 4-Phenyl-1H-indole 102311 To a mixture of 4- (4, 4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl)-lH-indole (pinacle 4-indoleboronate (2 g, 8.2 mmol) and 3-bromobenzene (0.87 mL, 8.3 mmol) in THF (28 mL) were added Palladium catalyst Pd (PPh3) 4 (284 mg, 0.25 mmol) and the freshly prepared sodium hydroxide solution (984 mg in 9 mL of water). The system was degassed and then charged with nitrogen for three times. The mixture was stirred under nitrogen at 70 °C oil bath for 6 hours. The reaction solution was cooled to room temperature, diluted with ethyl acetate and separated from water layer.

The ethyl acetate solution was washed by brine, dried over Na2S04 and concentrated.

The residue was purified on a silica gel column eluting with hexanes : EtOAc 9: 1 to give 1.38 g (78%) of 4-phenyl-lH-indole as a colorless liquid.

[0232]'H NMR (360 MHz, DMSO-d6) 8 11.26 (br s, 1H, NH), 7.66 (d, J= 7.9 Hz, 2H), 7.50 (t, J= 7.5 Hz, 2H), 7.35-7.43 (m, 3H), 7.18 (t, J= 7.5 Hz, 1H), 7.08 (d, J= 7.1 Hz, 1E :), 6.41 (brs, 1H).

[0233] MS m/z 194 [M++1].

Example A-2.4- (4-Fluoro-phenyl)-lH-indole [0234] To a mixture of 4- (4, 4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl)-lH-indole (3,4.0 g, 16.4 mmol), and 4-bromofluorobenzene (3.45 g, 19.7 mmol) in THF (80 mL)) were added Palladium catalyst Pd (PPh3) 4 (0.57 g, 0.49 mmol) and the freshly prepared sodium hydroxide solution (2.0 g, 49.3 mmol in 25 mL water). The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times. The mixture was stirred under nitrogen at 70°C oil bath for 15 hours.

TLC showed the completion of the coupling reaction. The mixture was cooled to room temperature, diluted with ethyl acetate, and separated from water layer. The ethyl acetate solution was washed by brine, dried over Na2S04, and concentrated.

The crude product was purified by a silica gel column eluting with hexanes-EtOAc (9: 1) to provide 2.75 g (80%) of the product 4-(4-fluoro-phenyl)-lH-indole as a white solid.

102351'H-NMR (400 MHz, DMSO-d6) 6 11.26 (br s, 1H, NH), 7.68 (m, 2H, aromatic), 7.41 (m, 2H, aromatic), 7.32 (m, 2H aromatic), 7.17 (m, 1H, aromatic), 7.05 (m, 1H, aromatic), 6.51 (m, 1H, aromatic).

[0236] MS m/z 212 [M++1].

Example A-3.4- (3-Fluoro-phenyl)-lH-indole [02371 To a mixture of 4-(4, 4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl)-lH-indole (3,2.43 g, 10 mmol), and 3-bromofluorobenzene (1.09 mL, 10 mmol) in THF (34 mL)) were added Palladium catalyst Pd (PPh3) 4 (347 mg, 0. 3 mmol) and the freshly prepared sodium hydroxide solution (1.20 g, 30 mmol in 14 mL water). The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times. The mixture was stirred under nitrogen at 70°C oil bath for 15 hours.

TLC showed the completion of the coupling reaction. The mixture was cooled to room temperature, diluted with ethyl acetate, and separated from water layer. The ethyl acetate solution was washed by brine, dried over Na2S04, and concentrated.

The crude product was purified by a silica gel column eluting with hexanes-EtOAc (9: 1) to provide 1.88 g (88%) of the product 4- (3-fluoro-phenyl)- 1H-indole as a colorless syrup.

[0238] 'H-NMR (400 MHz, DMSO-d6) 8 11.30 (br s, 1H, NH), 7.52 (m, 2H, aromatic), 7.45 (m, 3H, aromatic), 7.20 (m, 2H, aromatic), 7.12 (m, 1H, aromatic), 6.55 (m, 1H, aromatic).

[0239] MS m/z 212 [M++1].

Example A-4. 4- (4-Chloro-phenyl)-lH-indole [0240] To a mixture of 4- (4, 4,5,5-tetramethyl- (1,3,2] dioxaborolan-2-yl)-lH-indole (3,2.43 g, 10 mmol), and 4-bromochlorobenzene (2.87 g, 15 mmol) in THF (34 mL)) were added Palladium catalyst Pd (PPh3) 4 (347 mg, 0.3 mmol) and the freshly prepared sodium hydroxide solution (1.20 g, 30 mmol in 14 mL water). The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times. The mixture was stirred under nitrogen at 70°C oil bath for 15 hours.

TLC showed the completion of the coupling reaction. The mixture was cooled to room temperature, diluted with ethyl acetate, and separated from water layer. The ethyl acetate solution was washed by brine, dried over Na2S04, and concentrated.

The crude product was purified by a silica gel column eluting with hexanes-EtOAc (9: 1) to provide 2.02 g (89%) of the product 4-(4-chloro-phenyl)-lH-indole as a white solid.

[0241] 'H-NMR (400 MHz, DMSO-d6) 8 11.29 (br s, 1H, NH), 7.70 (m, 2H, aromatic), 7.55 (m, 2H, aromatic), 7.43 (m, 2H, aromatic), 7.19 (t, 1H, aromatic), 7.08 (m, 1H aromatic), 6.53 (m, 1H, aromatic).

Example A-5.4- (3-Chloro-phenyl)-lH-indole [0242] To a mixture of 4-(4, 4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl)-1H-indole (3,2.43 g, 10 mmol), and 3-bromochlorobenzene (1.76 mL, 15 mmol) in THF (34 mL)) were added Palladium catalyst Pd (PPh3) 4 (347 mg, 0.3 mmol) and the freshly prepared sodium hydroxide solution (1.20 g, 30 mmol in 14 mL water). The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times. The mixture was stirred under nitrogen at 70°C oil bath for 15 hours.

TLC showed the completion of the coupling reaction. The mixture was cooled to room temperature, diluted with ethyl acetate, and separated from water layer. The ethyl acetate solution was washed by brine, dried over Na2SO4, and concentrated.

The crude product was purified by a silica gel column eluting with hexanes-EtOAc (9: 1) to provide 2.06 g (91%) of the product 4-(3-chloro-phenyl)-1H-indole as a white solid.

102431'H-NMR (400 MHz, DMSO-d6) 8 11. 32 (br s, 1H, NH), 7.66 (m, 2H, aromatic), 7.53 (t, 1H, aromatic), 7.45 (m, 3H, aromatic), 7.20 (t, 1H, aromatic), 7.1 l (d, 1H, aromatic), 6.53 (d, 1H, aromatic).

Example A-6.4- (4-Bromo-phenyl)-lH-indole [0244] To a mixture of 4-(4, 4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl)-lH-indole (3,2.43 g, 10 mmol), and 1,4-dibromobenzene (11.8 g, 50 mmol) in THF (34 mL)) were added Palladium catalyst Pd (PPh3) 4 (347 mg, 0.3 mmol) and the freshly prepared sodium hydroxide solution (1.20 g, 30 mmol in 14 mL water). The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times. The mixture was stirred under nitrogen at 70°C oil bath for 15 hours.

TLC showed the completion of the coupling reaction. The mixture was cooled to room temperature, diluted with ethyl acetate, and separated from water layer. The ethyl acetate solution was washed by brine, dried over Na2SO4, and concentrated.

The crude product was purified by a silica gel column eluting with hexanes-EtOAc (9: 1) to provide 1.50 g (55%) of the product 4- (4-bromo-phenyl)-lH-indole as a white solid.

[0245] 'H-NMR (400 MHz, DMSO-d6) 8 11.29 (br s, 1H, NH), 7.65 (m, 4H, aromatic), 7.41 (m, 2H, aromatic), 7.17 (t, 1H, aromatic), 7.08 (m, 1H, aromatic), 6.51 (m, 1H, aromatic).

Example A-7.4- (3-Bromo-phenyl)-lH-indole [0246] To a mixture of 4- (4, 4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl)-lH-indole (3,2.43 g, 10 mmol), and 1,4-dibromobenzene (11.8 g, 50 mmol) in THF (34 mL)) were added Palladium catalyst Pd (PPh3) 4 (347 mg, 0.3 mmol) and the freshly prepared sodium hydroxide solution (1.20 g, 30 mmol in 14 mL water). The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times. The mixture was stirred under nitrogen at 70°C oil bath for 15 hours.

TLC showed the completion of the coupling reaction. The mixture was cooled to room temperature, diluted with ethyl acetate, and separated from water layer. The ethyl acetate. solution was washed by brine, dried over Na2S04, and concentrated.

The crude product was purified by a silica gel column eluting with hexanes-EtOAc (9: 1) to provide 2.02 g (74%) of the product 4- (3-bromo-phenyl)-lH-indole as a white solid.

[0247] IH-NMR (400 MHz, DMSO-d6) 8 11.33 (br s, 1H, NH), 7.80 (m, 1H, aromatic), 7.68 (d, 1H, aromatic), 7.57 (m, 1H, aromatic), 7.45 (m, 3H, aromatic), 7.19 (t, 1H, aromatic), 7.10 (d, 1H, aromatic), 6.52 (m, 1H, aromatic).

[0248] MS m/z 271, 273 [M++1].

Example A-8. 4-(4-Methoxy-phenyl)-1H-indole [0249] To a mixture of 4-bromoindole (1.96 g, 10 mmol), and 4- methoxyphenylboronic acid (1.52 g, 10 mmol) in THF (34 mL)) were added Palladium catalyst Pd (PPh3) 4 (347 mg, 0.3 mmol) and the freshly prepared sodium hydroxide solution (1.20 g, 30 mmol in 14 mL water). The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times. The mixture was stirred under nitrogen at 70°C oil bath for 16 hours. TLC showed the completion of the coupling reaction. The mixture was cooled to room temperature, diluted with ethyl acetate, and separated from water layer. The ethyl acetate solution was washed by brine, dried over Na2S04, and concentrated. The crude product was purified by a silica gel column eluting with hexanes-EtOAc (9: 1) to provide 1.85 g (83%) of the product 4-(4-Methoxy-phenyl)-1H-indole as a white solid.

10250] 'H-NMR (400 MHz, DMSO-d6) 8 11.21 (br s, 1H, NH), 7.61 (m, 2H, aromatic), 7.38 (m, 2H, aromatic), 7.15 (t, 1H, aromatic), 7.05 (m, 3H, aromatic), 6.52 (m, 1H, aromatic), 3.30 (s, 3H, CH3).

[02511 MS m/z 224 [M++ll.

Example A-9.4- (3-Methoxy-phenyl)-lH-indole [0252] To a mixture of 4-bromoindole (1.96 g, 10 mmol), and 3- methoxyphenylboronic acid (1.52 g, 10 mmol) in THF (34 mL)) were added Palladium catalyst Pd (PPh3) 4 (347 mg, 0.3 mmol) and the freshly prepared sodium hydroxide solution (1.20 g, 30 mmol in 14 mL water). The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times. The mixture was stirred under nitrogen at. 70°C oil bath for 16 hours. TLC showed the completion of the coupling reaction. The mixture was cooled to room temperature, diluted with ethyl acetate, and separated from water layer. The ethyl acetate solution was washed by brine, dried over Na2S04, and concentrated. The crude product was purified by a silica gel column eluting with hexanes-EtOAc (9: 1) to provide 1.83 g (82%) of the product 4-(3-methoxy-phenyl)-lH-indole as colorless syrup.

[0253] 1H-NMR (400 MHz, DMSO-d6) 8 11.26 (br s, 1H, NH), 7.41 (m, 3H, aromatic), 7.25 (d, 1H, aromatic), 7.18 (m, 2H, aromatic), 7.11 (d, 1H, aromatic), 6.95 (m, 1H, aromatic), 6.57 (m, 1H, aromatic), 3.82 (s, 3H, CH3).

10254] MS m/z 224 [M++1].

Example A-10.4- (2-Fluoro-phenyl)-lH-indole (0255] To a mixture of 4-(4, 4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl)-1H-indole (3,2.431 g, 10.0 mmol), and 2-bromofluorobenzene (1.75 g, 10.1 mmol) in THF (34 mL)) were added Palladium catalyst Pd (PPh3) 4 (0.347 g, 0.30 mmol) and the freshly prepared sodium hydroxide solution (1.20 g, 30.0 mmol in 14 mL water). The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times. The mixture was stirred under nitrogen at 75°C oil bath for 15 hours.

TLC showed the completion of the coupling reaction. The mixture was cooled to room temperature, diluted with ethyl acetate, and separated from water layer. The ethyl acetate solution was washed by brine, dried over Na2S04, and concentrated.

The crude product was purified by a silica gel column eluting with hexanes-EtOAc (9: 1) to provide 1.35 g (64%) of the product 4- (2-fluoro-phenyl)-lH-indole as a white solid.

10256] IH-NMR (400 MHz, DMSO-d6) 8 11.25 (br s, 1H, NH), 7.55 (m, 1H, aromatic), 7.38 (m, 5H, aromatic), 7.18 (t, 1H, aromatic), 7.03 (d, 1H, aromatic), 6.27 (m, 1H, aromatic)..

[0257] MS m/z 212 [M++1].

Example A-11. 4- (3-Trifluoromethyl-phenyl)-lH-indole [0258] To a mixture of, 4-bromoindole (3.00 g, 15.3 mmol), and 3- trifluoromethylphenylboronic acid (2.91 g, 15.3 mmol) in THF (52 mL)) were added Palladium catalyst Pd (PPh3) 4 (530 mg, 0.46 mmol) and the freshly prepared sodium hydroxide solution (1.84 g, 45.9 mmol in 21 mL water). The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times.

The mixture was stirred under nitrogen at 75°C oil bath for 16 hours. TLC showed the completion of the coupling reaction. The mixture was cooled to room temperature, diluted with ethyl acetate, and separated from water layer. The ethyl acetate solution was washed by brine, dried over Na2S04, and concentrated. The. crude product was purified by a silica gel column eluting with hexanes-EtOAc (9: 1) to provide 3.55 g (89%) of the product 4- (3-trifluoromethyl-phenyl)-lH-indole.

10259] IH-NMR (400 MHz, DMSO-d6) 5 11.40 (br s, 1H, NH), 7.98 (t, 1H, aromatic), 7.95 (s, 1H, aromatic), 7.73 (m, 2H, aromatic), 7.50 (d, 1H, aromatic), 7.47 (t, 1H, aromatic), 7.22 (t, 1H, aromatic), 7.16 (d, 1H, aromatic), 6.54 (s, 1H, aromatic).

[02601 MS m/z 262 [M++1].

Example A-12.4- (3-Chloro-4-fluoro-phenyl)-IH-indole [0261] To a mixture of 4-(4, 4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl)-1H-indole (3,3.00 g, 12. 34 mmol), and 4-bromo-2-chloro-fluorobenzene (2.58 g, 12.34 mmol) in THF (42 mL)) were added Palladium catalyst Pd (PPh3) 4 (0.428 g, 0.37 mmol) and the freshly prepared sodium hydroxide solution (1.50 g, 37.02 mmol in 17 mL water).

The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times. The mixture was stirred under nitrogen at 75°C oil bath for 15 hours. TLC showed the completion of the coupling reaction. The mixture was cooled to room temperature, diluted with ethyl acetate, and separated from water layer. The ethyl acetate solution was washed by brine, dried over Na2S04, and concentrated. The crude product was purified by a silica gel column eluting with hexanes-EtOAc (9: 1) to provide 2.11 g (70%) of the product 4- (3-chloro-4-fluoro- phenyl)-1H-indole as a white solid.

[0262]'H-NMR (400 MHz, DMSO-d6) 5 11.34 (br s, 1H, NH), 7.79 (dd, 1H, aromatic), 7.67 (m, 1H, aromatic), 7.53 (t, 1H, aromatic), 7.44 (m, 2H, aromatic), 7.19 (t, 1H, aromatic), 7.10 (d, 1H, aromatic), 6.52 (m, 1H, aromatic).

[0263] MS m/z 244 [M--1].

ExampleA-13.4- (3-Trifluoromethoxy-phenyl)-lH-indole 102641 To a mixture of 4-bromoindole (4.50 g, 22.95 mmol), and 4- trifluoromethoxyphenylboronic acid (4.73 g, 22.95 mmol) in THF (78 mL)) were added Palladium catalyst Pd (PPh3) 4 (795.6 mg, 0.69 mmol) and the freshly prepared sodium hydroxide solution (2.75 g, 68.9 mmol in 32 mL water). The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times. The mixture was stirred under nitrogen at 75°C oil bath for 16 hours. TLC showed the completion of the coupling reaction. The mixture was cooled to room temperature, diluted with ethyl acetate, and separated from water layer. The ethyl acetate solution was washed by brine, dried over Na2S04, and concentrated. The crude product was purified by a silica gel column eluting with hexanes-EtOAc (9: 1) to provide 5.56 g (78%) of the product 4- (4-trifluoromethoxy-phenyl)-lH-indole.

[0265]'H-NMR (400 MHz, DMSO-d6) 5 11.32 (br s, 1H, NH), 7. 78 (d, 2H, aromatic), 7.45 (m, 4H, aromatic), 7.20 (t, 1H, aromatic), 7. 10 (d, 1H, aromatic), 6.55 (m, 1H, aromatic).

[02661 MS m/z 278 [M++1].

Example A-14.2-Fluoro-5 (lH-indol-4-yl)-benzonitrile [0267] To a mixture of 4- (4, 4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl)-lH-indole (4 g, 16.4 mmol), and 5-bromo-2-fluorobenzonitrile (3.28 g, 16.4 mmol) in THF (564 mL) were added Palladium catalyst Pd (PPh3) 4 (0.6 g, 0.5 mmol) and the freshly prepared sodium carbonate solution (5.22 g in 23 mL of water). The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times. The mixture was stirred under nitrogen at 83 °C oil bath for overnight. TLC showed the completion of the coupling reaction. The mixture was cooled to room temperature, diluted with ethyl acetate, and separated from water layer. The ethyl acetate solution was washed with brine, and dried over Na2S04. After filtration, the solvents were evaporated, and the crude product was purified by a silica gel column to give 2.18 g (56%) of2-fluoro-5- (177-indol-4-yl)-benzonitrile.

Example A-15.4-Biphenyl-3-yl-lH-indole [0268] To a mixture of 4-bromoindole (2. 1 g, 10 mmol), and 3-biphenylboronic acid (2.2 g, 10 mmol) in THF (34.5 mL) were added Palladium catalyst Pd (PPh3) 4 (0.35 g, i 0.3 mmol) and the freshly prepared sodium hydroxide solution (1.21 g, 30 mmol in 14 mL of water). The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times. The mixture was stirred under nitrogen at 75°C oil bath for overnight. TLC showed the completion of the coupling reaction.

The mixture was cooled to room temperature, diluted with ethyl acetate, and separated from water layer. The ethyl acetate solution was washed with brine, and dried over Na2S04. After filtration, the solvents were evaporated, and the crude product was purified on a silica gel column to give 4-biphenyl-3-yl-lH-indole.

Example A-16. 4-Biphenyl-2-yl-lH-indole [0269] To a mixture of 4-bromoindole (1 g, 5 mmol), and 2-biphenylboronic acid (1 g, 5 mmol) in THF (17 mL) were added Palladium catalyst Pd (PPh3) 4 (0.2 g, 0.17 mmol) and the freshly prepared sodium hydroxide solution (0.6 g, 15 mmol in 7 mL of water). The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times. The mixture was stirred under nitrogen at 75°C oil bath for overnight. TLC showed the completion of the coupling reaction.

The mixture was cooled to room temperature, diluted with ethyl acetate, and separated from water layer. The ethyl acetate solution was washed with brine, and dried over Na2S04. After filtration, the solvents were evaporated, and the crude product was purified on a silica gel column to give 1.26 g (93%) of 4-biphenyl-2-yl-1H-indole.

Example A-17.4- (3, 5-Difluoro-phenyl)-lH-indole [0270] To a mixture of 4-bromoindole (12.42 g, 63.3 mmol), and 3,5- difluorophenylboronic acid (10.0 g, 63. 3 mmol) in THF (108 mL) were added Palladium catalyst Pd (PPh3) 4 (2. 2 g, 1.9 mmol) and the freshly prepared sodium hydroxide solution (7.6 g, 190 mmol in 89 mL water). The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times. The mixture was stirred under nitrogen at 85°C oil bath for overnight. TLC showed the completion of the coupling reaction. The mixture was cooled to room temperature, filtered through celite, diluted with ethyl acetate, and separated from water layer. The ethyl acetate solution was washed with brine, dried over Na2S04, and concentrated.

The crude product was purified by a silica gel column to provide 4- (3, 5-difluoro- phenyl)-lH-indole.

Example A-18. [3- (lH-Indol-4-yl)-phenyl]-acetic acid [0271] To a mixture of4- (4, 4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl)-1H-indole (15.52 g, 63.72 mmol), and 3-bromo-phenylacetic acid (13.78 g, 63.72 mmol) in THF (192 mL) were added Palladium catalyst Pd (PPh3) 4 (2.21 g, 1.9 mmol) and the freshly prepared sodium hydroxide solution (7.65 g in 90 mL of water). The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times. The mixture was stirred under nitrogen in a 70 °C oil bath for over the weekend. TLC showed the completion of the coupling reaction. The mixture was cooled to room temperature, diluted with ethyl acetate, and separated from water layer. The water layer was acidified with dil. HCI solution to pH 4-5 and extracted with ethyl acetate. The ethyl acetate solution was washed with water, brine, and dried over Na2S04. After filtration, the solvents were evaporated, and the crude product was purified on a silica gel column to give 13.5 g (84%) of [3-(lH-indol-4-yl)- phenyl]-acetic acid.

Example A-19. 2- [3- (lH-Indbl-4-yl)-phenyl]-N, lV-dimethyl-acetamide [0272] Dimethylamine (2M in THF, 5 mL) was added to a mixture of [3- (lH-indol- 4-yl)-phenyl]-acetic acid (1.26 g, 5 mmol), EDC (1.19 g, 1.25 eq.) and HOBt (675 mg, 1 eq.) in THF (10 mL) was stirred at rt for 5 hours. The reaction was concentrated, diluted with ethyl acetate, washed with 10% Na2C03 (3x), brine, dried and concentrated. The residue was purified on a silica gel column to give 658 mg of 2- [3- (1H-iIndol-4-yl)-phenyl]-N, N-dimethyl-acetamide as a solid.

Example A-20. {2- [3- (lH-Indol-4-yl)-phenyl]-ethyl}-dimethyl-amine [0273] To a suspension of LAH (276 mg, 7.2 mmol) in THF (20 mL) under nitrogen at rt was added dropwise a solution of 2- [3- (1H-iIndol-4-yl)-phenyl]-N, N-dimethyl- acetamide (500 mg, 1.8 mmol) in THF (10 mL). After stirring at rt for 6 hours, the reaction was quenched with water (0.6 mL) dropwise. The precipitate was filtered off, washed with ethyl acetate (3x), the filtrate was concentrated t give 640 mg of {2- [3- (lH-indol-4-yl)-phenyl]-ethyl}-dimethyl-amine.

Example A-21. 5-(1H-Indol-4-yl)-1H-indazol-3-ylamine [02741 Hydrazine hydrate (0.4 mL, 12.7 mmol) was added to a solution of 2-fluoro- 5- (lH-indol-4-yl)-benzonitrile (1.2 g, 5.08 mmol) in n-butanol (25 mL). The mixture was heated to reflux under nitrogen for 3 days. The reaction was cooled to room temperature and the solvent was removed. The residue was purified on a silica gel column eluting with DCM: MeOH (95: 5) to give 1.05 g (83%) of 5-(1H-indol-4-yl)- lH-indazol-3-ylamine as a white foam.

[0275] 1H-NMR (400 MHz, DMSO-d6) S 11.40 (s, 1H, NH), 11.18 (s, 1H, NH), 7.96 (s, 1H), 7.54 (dd, 1H), 7.29-7.38 (m, 3H), 7.14 (t, 1H), 7.05 (d, 1H), 6.58 (s, 1H), 5.4 (br s, 2H, NH2).

[0276] MS m/z 249 [M++1].

Example A-22. 4-(2,6-Difluoro-phenyl)-1H-indole 102771 To a mixture of 4-(4, 4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl)-1H-indole (11.34 g, 46.6 mmol), and 1-bromo-2, 6-difluorobenzene (9 g, 46.6 mmol) in 1, 2- dimethoxyethane (204 mL) were added Palladium catalyst Pd (PPh3) 4 (1.62 g, 1.4 mmol) and the freshly prepared sodium carbonate solution (15.19 g in 66 mL of water). The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times. The mixture was stirred under nitrogen at 110°C oil bath for overnight. TLC showed the completion of the coupling reaction.

The mixture was cooled to room temperature, diluted with ethyl acetate, and separated from water layer. The ethyl acetate solution was washed with brine, and dried over Na2S04. After filtration, the solvents were evaporated, and the crude product was purified by a silica gel column to give 9.77 g (91 %) of 4-(2, 6-difluoro-phenyl)-lH- indole.

Example A-23.3-(lH-iIndol-4-yl)-benzoic acid [0278] To a mixture of 4-bromoindole (11.81 g, 60.26 mmol), and 3- carboxyphenylboronic acid (10.0 g, 60.6 mmol) in acetonitrile (100 mL) and DMF (100 mL) were added Palladium catalyst Pd (PPh3) 4 (2.09 g, 1.81 mmol) and the freshly prepared sodium hydroxide solution (9.64 g, 241 mmol in 80 mL water). The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times. The mixture was stirred under argon at 110°C oil bath for 4 hours. TLC showed the completion of the coupling reaction. The mixture was cooled to room temperature, filtered through celite, diluted with ethyl acetate, and separated from water layer. The ethyl acetate solution was washed with brine, dried over MgS04, and concentrated. The crude product was purified by a silica gel column eluting with DCM: Hexanes: acetic acid (100: 1: 1) to provide 10.2 g (71%) of 3- (1H indol-4-yl)-benzoic acid as a gray yellow solid.

[0279]'H-NMR (400 MHz, DMSO-d6) 8 13.02 (s, 1H, NH), 11.31 (s, 1H), 8. 21-8. 26 (m, 1H), 7.87-7.97 (m, 2H), 7.58-7.65 (m, 1H), 7.41-7.45 (m, 2H), 7.08-7.22 (m, 2H), 6.51 (br s, 1H).

[0280] MS m/z 238 [M++1].

Example A-24. 4- (3, 4-Dimethoxy-phenyl)-lH-indole [0281] To a mixture of 4- (4, 4,5,5-tetramethyl- [1,3,2] indole (10 g, 41. 1 mmol), and 4-bromoveratrole (8. 93 g, 41. 1 mmol) in THF (140 mL) were added Palladium catalyst Pd (PPh3) 4 (1.43 g, 1.23 mmol) and the freshly prepared sodium hydroxide solution (5.08 g in 58 mL of water). The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times. The mixture was stirred under nitrogen at 80°C oil bath for overnight. TLC showed the completion of the coupling reaction. The mixture was cooled to room temperature, diluted with ethyl acetate, and separated from water layer. The ethyl acetate solution was washed with brine, and dried over Na2SO4. After filtration, the solvents were evaporated, and the crude product was purified by a silica gel column to give 7.47 g (72%) of 4- (3, 4-dimethoxy-phenyl)-lH-indole.

Example A-25.2- [3- (lH-Indol-4-yl)-phenoxy]-ethanol [0282] A mixture of 3-bromo-phenol (10 g, 56.64 mmol), 2-bromoethanol (4.65 mL) and cesium carbonate (18.64 g, 1 eq.) in DMF (25 mL) was stirred at rt for overnight. The mixture was then heated in a 70 °C oil bath for about 3 hours. More 2- bromoethanol (3 mL) was added and heating was increased to 80 °C and stirred for overnight. The reaction was allowed to cool to rt and the insolubles were filtered off.

The filtrate was poured into water and extracted with ethyl acetate (2x 200 mL), washed with 10% Na2C03 (3x), brine (2x), dried and concentrated. The residue was purified on a silica gel column to give 2- (3-bromo-phenoxy)-ethanol.

[0283] To a mixture of 4-(4, 4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl)-lH-indole (5.49 g, 22.5 mmol) and 2- (3-bromo-phenoxy)-ethanol (4.9 g, 22.5 mmol) in THF (68 mL) was added Palladium catalyst Pd (PPh3) 4 (473 mg, 0.03 eq.) and the freshly prepared sodium hydroxide solution (2.7 g in 31.5 mL of water). The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times. The mixture was stirred under nitrogen at 70 °C oil bath for overnight. TLC showed the completion of the coupling reaction. The mixture was cooled to room temperature, diluted with ethyl acetate, and separated from water layer. The ethyl acetate solution was washed with brine (4x), and dried over Na2S04 and concentrated.

The residue was purified on a silica gel column to give 5.4 g (95%) of 2- [3- (1H indol-4-yl)-phenoxy]-ethanol.

[0284]'H-NMR (400 MHz, CDCI3) 8 8.35 (br s, 1H, NH), 7.39 (m, 2H), 7.32 (m, 1H), 7.28 (m, 2H), 7.24 (m, 1H), 7.19 (dd, 1H), 6.93 (m, 1H), 6.73 (m, 1H), 4.15 (m, 3H), 4.0 (m, 2H).

[0285] MS m/z 254 [M++l].

Example A-26.4- (2, 3-Difluoro-phenyl)-lH-indole [0286] To a mixture of 4-(4, 4,5,5-tetramethyl- [1,3,2] dioxaborolan-2-yl)-lH-indole (3. 78 g, 15.5 mmol), and 1-brom-2, 3-difluorobenzene (3 g, 15.5 mmol) in THF (55 mL) were added Palladium catalyst Pd (PPh3) 4 (0.54 g, 0.47 mmol) and the freshly prepared sodium hydroxide solution (1.865 g, 47 mmol in 22 mL of water). The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times. The mixture was stirred under nitrogen at 75°C oil bath for overnight. TLC showed the completion of the coupling reaction. The mixture was cooled to room temperature, diluted with ethyl acetate, and separated from water layer. The ethyl acetate solution was washed with brine, and dried over Na2S04.

After filtration, the solvents were evaporated, and the crude product was purified by a silica gel column to give 2.92 g (82%) of 4-(2, 3-difluoro-phenyl)-lH-indole.

Example A-27.4- (2, 4-Difluoro-phenyl)-lH-indole 102871 To a mixture of 4-bromoindole (6.2 g, 31.7 mmol), and 2,4- difluorophenylboronic acid (5 g, 31.7 mmol) in THF (108 mL) were added Palladium catalyst Pd (PPh3) 4 (0. 67 g, 0.95 mmol) and the freshly prepared sodium hydroxide solution (3.8 g, 95 mmol in 45 mL of water). The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times. The mixture was stirred under nitrogen at 80°C oil bath for over the weekend. TLC showed the completion of the coupling reaction. The mixture was cooled to room temperature, diluted with ethyl acetate, and separated from water layer. The ethyl acetate solution was washed with brine, and dried over Na2S04. After filtration, the solvents were evaporated, and the crude product was purified by a silica gel column to give 6.55 g (90%) of 4-(2, 4-difluoro-phenyl)-lH-indole.

ExampleA-28.4-(2-Chloro-phenyl)-lH-indole [0288] To a mixture of 4-bromoindole (5. 5 g, 28 mmol), and 2-chlorophenylboronic acid (4.4 g, 28 mmol) in THF (96 mL) were added Palladium catalyst Pd (PPh3) 4 (0. 975 g, 0.8 mmol) and the freshly prepared sodium hydroxide solution (3.4 g, 84 mmol in 40 mL of water). The system was degassed and then charged with nitrogen.

The degas procedure was repeated for three times. The mixture was stirred under nitrogen at 75°C oil bath for overnight. TLC showed the completion of the coupling reaction. The mixture was cooled to room temperature, diluted with ethyl acetate, and separated from water layer. The ethyl acetate solution was washed with brine, and dried over Na2S04. After filtration, the solvents were evaporated, and the crude product was purified by a silica gel column to give 2.41 g (38%) of 4- (2-chloro- phenyl)-1H-indole.

Example A-29.13-(lH-Indol-4-yl)-phenyl]-acetic acid methyl ester [0289] A mixture of [3-(lH-indol-4-yl)-phenyl]-acetic acid (4 g, 15.9 mmol), 4N HCI (20 drops) in methanol (30 mL) and dioxane was stirred at rt for 4 hours. The reaction was concentrated, diluted in ethyl acetate, washed with NaHCO3 (2x), brine (2x), dried and concentrated to give 3.72 g (88%) of [3-(lH-Indol-4-yl)-phenyl]-acetic acid methyl ester. General Procedure for the Syntheses of the Precursor, 4-Aryl-1, 3-dihydro-indol- 2-one R R 1. Pyridium Tribromide I'I, t-BuOH/AcOH/EtOH 2. Zn O N H/N. H [0290] To the suspension of 4-aryl-lH-indole (1 molar equivalent) in 2-methyl-2- propanol-ethanol-acetic acid (3: 2: 1) (11 mL) (0.1 M) was added pyridinium tribromide (90% purity from Aldrich, 3 molar equivalent) portionwise. The mixture was stirred at 27°C for 3 hours, and then to the mixture was added acetic acid. Zinc dust (10 molar equivalent) was added to the reaction mixture portionwise, and the reaction mixture was stirred at room temperature for one hour. The unreacted zinc dust was filtered off and washed with ethanol. The filtrate was concentrated and the syrupy residue was suspended in water for 1 hour. The solid product was precipitated out, filtered, and washed repeatedly with water to remove the zinc salt and pyridine salt. After high vacuum dry, a pure product was obtained. If the product couldn't precipitate out, ethyl acetate was used to extract the product from water. The combined extracts were washed with water, 0.5% HCl water solution, sat. Na2C03, and brine, dried over Na2S04. After filtration, condensation, the crude product was triturated with diethyl ether to provide pure product.

Example A-30.4-Phenyl-1,3-dihydro-indol-2-one [0291] To the suspension of 4-phenyl-lH-indole (1.1 g, 5.7 mmol) in 2-methyl-2- propanol (33 mL), ethanol (22 mL) and acetic acid (11 mL) was added pyridinium tribromide (90% purity from Aldrich, 6.1 g, 17.1 mmol) portionwise over 10 minutes.

The mixture was stirred at room temperature for 2 hours, and then to the mixture was added acetic acid (50 mL). After stirring atoom temperature for one homrfwater (0.5 mL) and zinc (3.7 g, 57 mmol) were added to the reaction mixture and stirring was continued for another hour. The unreacted zinc dust was filtered off and washed with methanol. The filtrate was concentrated and the syrupy residue was suspended in water (100 mL) for overnight. The solid product was filtered, washed repeatedly with water to remove the zinc salt and pyridine salt. After high vacuum dry, 800 mg (67%) of 4-phenyl-1, 3-dihydro-indol-2-one as a light yellow solid was obtained.

[0292]'H NMR (360 MHz, DMSO-d6) 10.46 (br s, 1H, NH), 7.56 (d, J= 7.1 Hz, 1H), 7.45 (t, J= 7.6 Hz, 1H), 7. 37 (m, 1H), 7.27 (t, J= 7.7 Hz, 1H), 7.01 (d, J= 7.7 Hz, 1H), 6.82 (d, J= 7.7 Hz, 1H), 3.59 (s, 2H, CH2).

[0293] MS m/z 210 [M++1].

Example A-31.4- (4-Fluoro-phenyl)-1, 3-dihydro-indol-2-one [0294] To the suspension of 4- (4-fluoro-phenyl)-lH-indole (2.28 g, 10.79 mmol) in t-BuOH-ethanol-acetic acid (3: 2: 1) (147 mL) was added pyridinium tribromide (90% purity from Aldrich, 11.51 g, 32.38 mmol)) portionwise. The mixture was stirred at 27°C for 3 hours, and then to the mixture was added acetic acid (108 mL).

Zinc dust (10.52 g, 162 mmol) was added to the reaction mixture portionwise, and the reaction mixture was stirred at room temperature for one hour. The unreacted zinc dust was filtered off and washed with ethanol. The filtrate was concentrated and the syrupy residue was suspended in water for 4 hour. The solid product was precipitated out, filtered, and washed repeatedly with water to remove the zinc salt and pyridine salt. After high vacuum dry, a pure product (2.40 g, 98%) was obtained.

10295] IH NMR (360 MHz, DMSO-d6) 10.47 (br s, 1H, NH), 7.61 (m, 2H, aromatic), 7.27 (m, 3H, aromatic), 7.12 (d, 1H, aromatic), 6.90 (d, 1H, aromatic), 3.59 (s, 2H).

Example A-32.4- (3-Fluoro-phenyl)-1,3-dihydro-indol-2-one [0296] To the suspension of 4- (3-fluoro-phenyl)-lH-indole (1.40 g, 6.63 mmol) in t- BuOH-ethanol-acetic acid (3: 2: 1) (81 mL) was added pyridinium tribromide (90% purity from Aldrich, 7.07 g, 19.88 mmol)) portionwise. The mixture was stirred at 27°C for 3 hours, and then to the mixture was added acetic acid (30 mL). Zinc dust was added to the reaction mixture portionwise until the color changed from deep red to light yellow, and the reaction mixture was stirred at room temperature for one hour.

The unreacted zinc dust was filtered off and washed with ethanol. The filtrate was concentrated, and the syrupy residue was dissolved in ethyl acetate, which was washed with water, 0.5 N HCI, sat. NaHC03 and brine, and dried over Na2S04. After filtration and evaporation, the crude product was triturated with diethyl ether to provide product 4- (3-fluoro-phenyl)-1, 3-dihydro-indol-2-one (1.34 g, 89%) as a tan solid.

[02977 'H-NMR (400 MHz, DMSO-d6) 8 10.50 (br s, 1H, NH), 7.51 (m, 1H, aromatic), 7.47 (m, 2H, aromatic), 7.43 (t, 1H, aromatic), 7.30 (m, 1H, aromatic), 7.22 (d 1H, aromatic), 6.85 (d, 1H, aromatic), 3.64 (s, 2H, CH2)- Example A-33.4- (4-Chtoro-phenyl)-1, 3-dihydro-indol-2-one [0298] To the suspension of 4- (4-chloro-phenyl)-lH-indole (1.52 g, 6.68 mmol) in t-BuOH-ethanol-acetic acid (3: 2: 1) (81 mL) was added pyridinium tlibromide (90% purity from Aldrich, 7.12 g, 20.0 mmol)) portionwise. The mixture was stirred at 27°C for 3 hours, and then to the mixture was added acetic acid (30 mL). Zinc dust was added to the reaction mixture portionwise until the color changed from deep red to light yellow, and the reaction mixture was stirred at room temperature for one hour.

The unreacted zinc dust was filtered off and washed with ethanol. The filtrate was concentrated, and the syrupy residue was suspended in water (500 mL) for 0.5 hour.

The solid product was precipitated out, filtered, and washed repeatedly with water to remove the zinc salt and pyridine salt. After high vacuum dry, a pure product (1.54 g, 94%) was obtained.

[02991'H-NMR (400 MHz, DMSO-d6) 8 11.29 (br s, 1H, NH), 7.70 (m, 2H, aromatic), 7. 55 (m, 2H, aromatic), 7.43 (m, 2H, aromatic), 7.19 (t, 1H, aromatic), 7.08 (m, 1H aromatic), 6.53 (m, 1H, aromatic).

Example A-34.4- (3-Chloro-phenyl)-1, 3-dihydro-indol-2-one [0300] To the suspension of 4-(3-chloro-phenyl)-lH-indole (1. 52 g, 6.68 mmol) in t-BuOH-ethanol-acetic acid (3: 2: 1) (81 mL) was added pyridinium tribromide (90% purity from Aldrich, 7.12 g, 20.0 mmol)) portionwise. The mixture was stirred at 27°C for 3 hours, and then to the mixture was added acetic acid (30 mL). Zinc dust was added to the reaction mixture portionwise until the color changed from deep red to light yellow, and the reaction mixture was stirred at room temperature for one hour.

The unreacted zinc dust was filtered off and washed with ethanol. The filtrate was concentrated, and the syrupy residue was dissolved in ethyl acetate, which was washed with water, 0.5 N HCI, sat. NaHCO3 and brine, and dried over Na2SO4. After filtration and evaporation, the crude product was triturated with diethyl ether to provide product 4- (3-chloro-phenyl)-1, 3-dihydro-indol-2-one (1.55 g, 95%) as a tan solid.

[0301] IH-NMR (400 MHz, DMSO-d6) 8 10.50 (br s, 1H, NH), 7.62 (m, 1H, aromatic), 7.56 (m, 1H, aromatic), 7.52 (m, 2H, aromatic), 7.29 (t, 1H, aromatic), 7.03 (d, 1H, aromatic), 6.85 (m, 1H, aromatic),, 3.63 (s, 2H, CH2)- Example A-35.4- (4-Bromo-phenyl)-1,3-dihydro-indol-2-one [0302] To the suspension of 4- (4-bromo-phenyl)-1H indole (1.20 g, 4.41 mmol) in t-BuOH-ethanol-acetic acid (3: 2: 1) (54 mL) was added pyridinium tribromide (4.23 g, 13.23 mmol)) portionwise. The mixture was stirred at 27°C for 3 hours, and then to the mixture was added acetic acid (30 mL). Zinc dust was added to the reaction mixture portionwise until the color changed from deep red to light yellow, and the reaction mixture was stirred at room temperature for one hour. The unreacted zinc dust was filtered off and washed with ethanol. The filtrate was concentrated, and the syrupy residue was suspended in water (300 mL) for 0.5 hour. The solid product was precipitated out, filtered, and washed repeatedly with water to remove the zinc salt and pyridine salt. After high vacuum dry, a pure product (1.12 g, 88%) was obtained.

[0303 'H-NMR (400 MHz, DMSO-d6) 6 10.50 (br s, 1H, NH), 7.64 (d, 2H, aromatic), 7.54 (d, 2H, aromatic), 7.28 (t, 1H, aromatic), 7.01 (d, 1H, aromatic), 6.84 (d, 1H, aromatic), 3.60 (s, 2H, CH2).

ExampleA-36.4- (3-Bromo-phenyl)- 1, 3-dihydro-indol-2-one [0304] To the suspension of 4- (3-bromo-phenyl)-lH-indole (1.48 g, 5.44 mmol) in t-BuOH-ethanol-acetic acid (3: 2: 1) (66 mL) was added pyridinium tribromide (90% purity from Aldrich, 5.80 g, 16.3 mmol)) portionwise. The mixture was stirred at 27°C for 3 hours, and then to the mixture was added acetic acid (26 mL). Zinc dust was added to the reaction mixture portionwise until the color changed from deep red to light yellow, and the reaction mixture was stirred at room temperature for one hour.

The unreacted zinc dust was filtered off and washed with ethanol. The filtrate was concentrated, and the syrupy residue was dissolved in ethyl acetate, which was washed with water, 0.5 N HC1, sat. NaHCO3 and brine, and dried over Na2S04. After filtration and evaporation, the crude product was triturated with diethyl ether to provide product 4- (3-bromo-phenyl)-1, 3-dihydro-indol-2-one (1.02 g, 65%) as a tan solid.

[03051'H-NMR (400 MHz, DMSO-d6) 8 10.50 (br s, 1H, NH), 7.74 (m, 1H, aromatic), 7.58 (m, 2H, aromatic), 7.41 (t, 1H, aromatic), 7.28 (t, 1H, aromatic), 7.02 (d, 1H, aromatic), 6.85 (d, 1H, aromatic), 3.62 (s, 2H, CH2).

Example A-37.4- (4-Methoxy-phenyl)-1, 3-dihydro-indol-2-one [0306] To the suspension of 4- (4-methoxy-phenyl)-IH-indole (1.84 g, 8. 24 mmol) in t-BuOH-ethanol-acetic acid (3: 2: 1) (99 mL) was added pyridinium tribromide (90% purity from Aldrich, 8.78g, 24. 72 mmol)) portionwise. The mixture was stirred at 27°C for 3 hours, and then to the mixture was added acetic acid (40 mL). Zinc dust was added to the reaction mixture portionwise until the color changed from deep red to light yellow, and the reaction mixture was stirred at room temperature for one hour.

The unreacted zinc dust was filtered off and washed with ethanol. The filtrate was concentrated, and the syrupy residue was dissolved in ethyl acetate, which was washed with water, 0.5 N HC1, sat. NaHCO3 and brine, and dried over Na2S04. After filtration and evaporation, the crude product was triturated with diethyl'ether to provide product 4- (4-methoxy-phenyl)-1, 3-dihydro-indol-2-one (1.66 g, 84%) as a tan solid.

[0307] IH-NMR (400 MHz, DMSO-d6) 8 10.44 (br s, 1H, NH), 7.50 (m, 2H, aromatic), 7.24 (m, 1H, aromatic), 6.97 (m, 3H, aromatic), 6.78 (m, 1H, aromatic), 3.79 (s, 3H, CH3), 3.58 (s, 2H, CH2).' Example A-38.4- (3-Methoxy-phenyl)-1, 3-dihydro-indol-2-one [0308] To the suspension of 4- (4-methoxy-phenyl)-lH-indole (1.73 g, 7.75 mmol) in t-BuOH-ethanol-acetic acid (3: 2: 1) (93 mL) was added pyridinium tribromide (90% purity from Aldrich, 8.26g, 23.24 mmol)) portionwise. The mixture was stirred at 27°C for 3 hours, and then to the mixture was added acetic acid (38 mL). Zinc dust was added to the reaction mixture portionwise until the color changed from deep red to light yellow, and the reaction mixture was stirred at room temperature for one hour.

The unreacted zinc dust was filtered off and washed with ethanol. The filtrate was concentrated, and the syrupy residue was dissolved in ethyl acetate, which was washed with water, 0.5 N HCI, sat. NaHC03 and brine, and dried over Na2SO4. After filtration and evaporation, the crude product was triturated with diethyl ether to provide product 4- (3-methoxy-phenyl)-1, 3-dihydro-indol-2-one (0.97 g, 52%) as a tan solid.

[03091 IH-NMR (400 MHz, DMSO-d6) 8 10.45 (br s, 1H, NH), 7.34 (t, 1H, aromatic), 7.25 (t, 1H, aromatic), 7.12 (d, 1H, aromatic), 7.08 (m, 1H, aromatic), 7.02 (d, 1H, aromatic), 6.93 (m, 1H, aromatic), 6.82 (d, 1H, aromatic), 3.80 (s, 3H, CH3).

Example A-39.4- (2-Fluoro-phenyl)-1, 3-dihydro-indol-2-one [03101 To the suspension of 4- (2-fluoro-phenyl)-lH-indole (1.30 g, 6.15 mmol) in t- BuOH-ethanol-acetic acid (3: 2: 1) (74 mL) was added pyridinium tribromide (5.90 g, 18. 46 mmol)) portionwise. The mixture was stirred at 27°C for 3 hours, and then to the mixture was added acetic acid (30 mL). Zinc dust was added to the reaction mixture portionwise until the color changed from deep red to light yellow, and the reaction mixture was stirred at room temperature for one hour. The unreacted zinc dust was filtered off and washed with ethanol. The filtrate was concentrated, and the syrupy residue was dissolved in ethyl acetate, which was washed with water, 0.5 N HCI, sat. NaHC03 and brine, and dried over Na2SO4. After filtration and evaporation, the crude product was triturated with diethyl ether to provide product 4- (2-fluoro- phenyl)-1, 3-dihydro-indol-2-one (0.59 g, 42%) as a tan solid.

10311] IH-NMR (400 MHz, DMSO-d6) 8 10.51 (br s, 1H, NH), 7.50 (m, 1H, aromatic), 7.48 (m, 1H, aromatic), 7.29 (m, 3H, aromatic), 6.95 (d, 1H, aromatic), 6.87 (d, 1H, aromatic), 3.39 (s, 2H, CH2).

Example A-40.4- (3-Trifluoromethyl-phenyl)-1, 3-dihydro-indol-2-one 10312] To the suspension of 4-(3-trifluoromethyl-phenyl)-lH-indole (3.37 g, 12.90 mmol) in t-BuOH-ethanol-acetic acid (3: 2: 1) (155 mL) was added pyridinium tribromide (12.38 g, 38. 70 mmol)) portionwise. The mixture was stirred at 27°C for 3 hours, and then to the mixture was added acetic acid (63 mL). Zinc dust was added to the reaction mixture portionwise until the color changed from deep red to light yellow, and the reaction mixture was stirred at room temperature for one hour. The unreacted zinc dust was filtered off and washed with ethanol. The filtrate was concentrated, and the syrupy residue was dissolved in ethyl acetate, which was washed with water, 0.5 N HCI, sat. NaHCO3 and brine, and dried over Na2SO4. After filtration and evaporation, the crude product was triturated with diethyl ether to provide product 4- (3-trifluoromethyl-phenyl)-1, 3-dihydro-indol-2-one (2.07 g, 58%) as a tan solid.

103131'H-NMR (400 MHz, DMSO-d6) 8 10.52 (br s, 1H, NH), 7.90 (d, 1H, aromatic), 7.87 (s, 1H, aromatic), 7.74 (d, 1H, aromatic), 7.69 (t, 1H, aromatic), 7.31 (t, 1H, aromatic), 7.07 (d, 1H, aromatic), 6.88 (d, 1H, aromatic), 3.64 (s, 2H, CH2).

Example A-41.4- (3-chloro4-fluoro-phenyl)-1, 3-dihydro-indol-2-one (0314] To the suspension of 4-(3-chloro-4-fluoro-phenyl)-lH-indole (2.03g, 8.26 mmol) in t-BuOH-ethanol-acetic acid (3: 2: 1) (99 mL) was added pyridinium tribromide (7.93 g, 24.79 mmol)) portionwise. The mixture was stirred at 27°C for 3 hours, and then to the mixture was added acetic acid (40 mL). Zinc dust was added to the reaction mixture portionwise until the color changed from deep red to light yellow, and the reaction mixture was stirred at room temperature for one hour. The unreacted zinc dust was filtered off and washed with ethanol. The filtrate was concentrated, and the syrupy residue was dissolved in ethyl acetate, which was washed with water, 0.5 N HCI, sat. NaHC03 and brine, and dried over Na2S04. After filtration and evaporation, the crude product was triturated with diethyl ether to provide product 4-(3-chloro-4-fluoro-phenyl)-1,3-dihydro-indol-2-one (1.39 g, 64%) as a tan solid.

10315] IH-NMR (400 MHz, DMSO-d6) 8 10.52 (br s, 1H, NH), 7.79 (dd, 1H, aromatic), 7.59 (m, 1H, aromatic), 7.49 (t, 1H, aromatic), 7.28 (t, 1H, aromatic), 7.02 (d, 1H, aromatic), 6.85 (d, 1H, aromatic), 3. 63 (s, 2H, CH2).

Example A-42.4- (4-Trifluoromethoxy-phenyl)-1, 3-dihydro-indol-2-one [0316] To the suspension of 4- (4-trifluoromethoxy-phenyl)-1H indole (4.93 g, 17.78 mmol) in t-BuOH-ethanol-acetic acid (3: 2: 1) (261 mL) was added pyridinium tribromide (17.06 g, 53.34 mmol)) portionwise. The mixture was stirred at 27°C for 3 hours, and then to the mixture was added acetic acid (105 mL). Zinc dust was added to the reaction mixture portionwise until the color changed from deep red to light yellow, and the reaction mixture was stirred at room temperature for one hour.

The unreacted zinc dust was filtered off and washed with ethanol. The filtrate was concentrated, and the syrupy residue was dissolved in ethyl acetate, which was washed with water, 0.5 N HCI, sat. NaHC03 and brine, and dried over Na2S04. After filtration and evaporation, the crude product was triturated with diethyl ether to provide product 4- (4-trifluoromethoxy-phenyl)-1, 3-dihydro-indol-2-one (2.05 g, 39%) as a tan solid.

[03171'H-NMR (400 MHz, DMSO-d6) 8 10.50 (br s, 1H, NH), 7.71 (d, 2H, aromatic), 7.43 (d, 2H, aromatic), 7.29 (t, 1H, aromatic), 7.03 (d, 1H, aromatic), 6.85 (d, 1H, aromatic), 3.62 (s, 2H, CH2).

ExampleA-43.4-13-(2-Hydroxy-ethyl)-phenyl]-1, 3-dihydro-indol-2-one [0318] To a suspension of NaBH4 (600 mg, 16 mmol) in 15% H20/MeOH (6 mL) under nitrogen at rt was added dropwise a solution of [3-(2-oxo-2,3-dihydro-1H- indol-4-yl)-phenyl]-acetic acid methyl ester (450 mg, 1.6 mmol) in THF (3 mL). After stirring at rt for overnight, to the reaction was added CaC12 (300 mg) and stirring was continued for another 5 hours. The reaction was quenched with acetic acid (2 mL), concentrated, diluted with ethyl acetate, washed with 0.5 N HCl (3x 15 mL), 10% NaHC03 (3x 15 mL), brine (lx), dried and concentrated. The oily residue was purified to give 384 mg (95%) of 4- [3- (2-hydroxy-ethyl)-phenyl]-1, 3-dihydro-indol- 2-one.

[03191'H-NMR (400 MHz, DMSO-d6) 5 10.49 (s, 1H, NH), 7. 35-7. 43 (m, 3H), 7.28 (t, 1H), 7.23 (d, 1H), 7.03 (d, 1H), 6.83 (d, 1H), 4.68 (t, 1H, OH), 3.67 (m, 2H), 3.62 (s, 2H), 2.80 (t, 2H).

[0320] MS m/z 254.1 [M++1].

Example A-44.2-Fluoro-5- (2-oxo-2, 3-dihydro-lH-indol-4-yl)-benzonitrile 10321] To the suspension of 2-fluoro-5-(lH-indol-4-yl)-benzonitrile (2.68 g, 11.34 mmol) in t-BuOH : ethanol: acetic acid (72 mL: 43 mL: 23 mL) was added pyridinium tribromide (10.91 g, 34.1 mmol) portionwise. The mixture was stirred at room temperature for 3 hours, and then to the mixture was added acetic acid (55 mL). Zinc dust (4 g, 61.2 mmol) was added to the reaction mixture portionwise. After stirring for one hour, any unreacted zinc was filtered off and most of the solvent was removed under reduced pressure. The residue was diluted with ethyl acetate, washed with water (3x), sat. NaHC03, brine, dried over Na2SO4, concentrated and triturated with ether to give 1.93 g (68%) of 2-fluoro-5-(2-oxo-2, 3-dihydro-lH-indol-4-yl)-benzonitrile.

(0322] 'H-NMR (400 MHz, DMSO-d6) o 10. 52 (s, 1H, NH), 8.13 (dd, IH), 7.96 (m, 1H), 7.59 (t, 1H), 7.28 (t, 1H), 7.03 (d, 1H), 6.85 (d, 1H), 3.64 (s, 2H).

[0323] MS mlz 251. 4 [M-1].

Example A-45.4-Biphenyl-3-yl-1, 3-dihydro-indol-2-one [0324] To the suspension of 4-bipheny-3-yl-lH-indole (3.5 g, 13 mmol) in t-BuOH : ethanol: acetic acid (82 mL : 49 mL: 269 mL) was added pyridinium tribromide (12.7 g, 40 mmol) portionwise. The mixture was stirred at room temperature for 3 hours, and then to the mixture was added acetic acid (63 mL). Zinc dust (4.39 g, 67 mmol) was added to the reaction mixture portionwise. After stirring for one hour, any unreacted zinc was filtered off and most of the solvent was removed under reduced pressure. The residue was diluted with ethyl acetate, washed with water (3x), sat.

NaHCO3, brine, dried over Na2S04, concentrated and triturated with ether to give 2.67 g (72%) of 4-biphenyl-3-yl-1, 3-dihydro-indol-2-one.

[03251 IH-NMR (400 MHz, DMSO-d6) 8 10.49 (s, 1H, NH), 7.78 (m, 1H), 7.71 (m, 2H), 7.65 (m, 1H), 7.53 (m, 2H), 7.47 (m, 2H), 7.37 (m, 1H), 7.28 (t, 1H), 7.10 (d, 1H), 6.83 (d, 1H), 3.66 (s, 2H).

[03261 MS m/z 286 [M++1].

ExampleA-46.4-Biphenyl-2-yl-1,3-dihydro-indol-2-one [0327] To the suspension of 4-bipheny-2-yl-lH-indole (1.18 g, 4.4 mmol) in t- BuOH : ethanol: acetic acid (28 mL: 17 mL: 9 mL) was added pyridinium tribromide (4.39 g, 13.7 mmol) portionwise. The mixture was stirred at room temperature for 3 hours, and then to the mixture was added acetic acid (22 mL). Zinc dust (1.63 g, 25 mmol) was added to the reaction mixture portionwise. After stirring for one hour, any unreacted zinc was filtered off and most of the solvent was removed under reduced pressure. The residue was diluted with ethyl acetate, washed with water (3x), sat.

NaHC03, brine, dried over Na2SO4, concentrated and triturated with ether to give 0.93 g (74%) of 4-biphenyl-2-yl-1, 3-dihydro-indol-2-one.

[0328] 'H-NMR (400 MHz, DMSO-d6) 8 10.30 (s, 1H, NH), 7.35-7.45 (m, 4H), 7.2 (m, 4H), 7.12 (m, 1H), 7.08 (t, 1H), 6.67 (m, 2H), 2.86 (s, 2H).

Example A-47.4- (3, 5-Difluoro-phenyl)-1, 3-dihydro-indol-2-one [0329] To the suspension of 4- (3, 5-difluoro-phenyl)-1H-indole (13.52 g, 59 mmol) in t-BuOH : ethanol: acetic acid (375 mL: 225 mL: 115 mL) was added pyridinium tribromide (57 g, 177 mmol) portionwise. The mixture was stirred at room temperature for 3 hours, and then to the mixture was added with acetic acid (286 mL).

Zinc dust (19.25 g, 295 mmol) was added to the reaction mixture portionwise. After stirring for one hour, any unreacted zinc was filtered off and most of the solvent was removed under reduced pressure. The residue was diluted with ethyl acetate, washed with water (5x), neutralized with IN HC1, washed with sat. NaHCO3, brine, dried over Na2SO4, concentrated and triturated with ether to give 9.88 g (68%) of 4-(3, 5- difluoro-phenyl)-1, 3-dihydro-indol-2-one.

[03301 IH-NMR (400 MHz, DMSO-d6) 5 10.51 (s, 1H, NH), 7.2-7.35 (m, SH), 7.04 (dd, 1H), 6.86 (d, 1H), 3.66 (s, 2H).

[0331] MS m/z 244 [M-1].

Example A-48. [3-(2-Oxo-2, 3-dihydro-lH-indol-4-yl)-phenyll-acetic acid [0332] To the suspension of [3-(1H-indol-4-yl)-phenyl]-acetic acid (3.52 g, 14 mmol) in t-BuOH : ethanol : acetic acid (93 mL: 56 mL: 67 mL) was added pyridinium tribromide (14.14 g, 42 mmol) portionwise. The mixture was stirred at room temperature for 3 hours, and then to the mixture was added acetic acid (60 mL).

Water (2 mL) and zinc dust (14 g, excess) were added to the reaction mixture portionwise. After stirring for one hour, any unreacted zinc was filtered off and most of the solvent was removed under reduced pressure. The residue was diluted with ethyl acetate, washed with water (3x), sat. NaHC03, brine, dried over Na2SO4 and concentrated to give 2.59 g (70%) of [3- (2-oxo-2, 3-dihydro-lH-indol-4-yl)-phenyl]- acetic acid.

[0333]'H-NMR (400 MHz, DMSO-d6) 8 12.32 (br s, 1H, OH), 10.46 (s, 1H, NH), 7.43 (m, 2H), 7.37 (t, 1H), 7.25 (m, 2H), 6.98 (dd, 1H), 6.80 (d, 1H), 3.63 (s, 2H), 3.58 (s, 2H).

[0334] MS m/z 266 [M-1].

Example A-49. N, N-Dimethyl-2-13-(2-oxo-2, 3-dihydro-lH-indol-4-yl)- phenyll-acetamide [0335] To the suspension of 2-[3-(1H-iIndol-4-yl)-phenyl]-N,N-dimethyl-acetamide (1.6 g, 5 mmol) in t-BuOH : ethanol: acetic acid (332 mL: 20 mL: 24 mL) was added pyridinium tribromide (5 g, 15 mmol) portionwise. The mixture was stirred at room temperature for 3 hours, and then to the mixture was added acetic acid (22 mL).

Water (0. 7 mL) and zinc dust (5 g) were added to the reaction mixture portionwise.

After stirring for one hour, any unreacted zinc was filtered off and most of the solvent was removed under reduced pressure. The residue was diluted with ethyl acetate, washed with 0.5 N HCI (2x), 10% Na2C03 (2x), brine (2x), water, dried over Na2SO4, concentrated and triturated with ether to give NN-dimethyl-2- [3- (2-oxo-2, 3-dihydro- <BR> <BR> <BR> 1 H-indol-4-yl)-phenyl]-acetamide.<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>[03361 MS m/z 293 [M-1].

Example A-50.4- [3- (2-Dimethylamino-ethyl)-phenyl]-1, 3-dihydro-indol-2- one [0337] To the suspension of {2- [3- (1H-indol-4-yl)-phenyl]-ethyl}-dimethyl-amine (600 mg, 2. 2 mmol) in t-BuOH : ethanol: acetic acid (14.5 mL: 8. 8 mL: 10.5 mL) was added pyridinium tribromide (2.3 g, 6.6 mmol) portionwise. The mixture was stirred at room temperature for 3 hours, and then to the mixture was added acetic acid (9.24 mL). Water (0.32 mL) and zinc dust (2.2 g, 61.2 mmol) was added to the reaction mixture portionwise. After stirring for one hour, any unreacted zinc was filtered off and most of the solvent was removed under reduced pressure. The residue was diluted with ethyl acetate, washed with water (3x), sat. NaHC03, brine, dried over Na2S04 and concentrated. The residue was dissolved in methanol (10 mL) and hydrogenated using 10% Pd-C for overnight. The reaction was filtered through celite and the filtrate was concentrated. The residue was purified on a silica gel column to give 4- [3- (2-dimethylamino-ethyl)-phenyl]-1, 3-dihydro-indol-2-one [03381'H-NMR (400 MHz, DMSO-d6) 8 10.49 (s, 1H, NH), 7. 37-7.46 (m, 3H), 7.26 (t, 2H), 6.81 (d, 1H), 3.60 (s, 2H), 3.08 (m, 2H), 2.93 (m, 2H), 2.62 (s, 6H, 2xCH3).

[0339] MS PI/Z 281.1 [M++1].

Example A-51.4- H-indazol-5-yl)-1, 3-dihydro-indol-2-one [0340] To the suspension of 5-(1H-indol-4-yl)-1H-indazol-3-ylamine (0.82 g, 3.33 mmol) in t-BuOH : ethanol: acetic acid (20.5 mL: 12 mL: 6 mL) was added pyridinium tribromide (3.17 g, 9.9 mmol) portionwise. The mixture was stirred at room temperature for 3 hours, it immediately became a dark pink color. Zinc dust (excess) was added to the reaction mixture portionwise. After stirring for one hour, the unreacted zinc was filtered off and the solvent was removed under reduced pressure. The residue was washed with ample of water. The solid was triturated with DCM to give 0.563 g (77%) of 4 (3-amino-lH-indazol-5-yl)-1, 3-dihydro-indol-2-one.

Example A-52.4- (2, 6-Difluoro-phenyl)-1, 3-dihydro-indol-2-one 103411 To the suspension of 4-(2, 6-difluoro-phenyl)-lH-indole (9.5 g, 41.4 mmol) in t-BuOH : ethanol: acetic acid (262 mL: 155 mL : 81 mL) was added pyridinium tribromide (40.28 g, 126 mmol) portionwise. The mixture was stirred at room temperature for 3 hours, and then to the mixture was added more acetic acid (200 mL). Zinc dust (14.2 g, 217 mmol) was added to the reaction mixture portionwise.

After stirring for one hour, the unreacted zinc was filtered off and most of the solvent was removed under reduced pressure. The residue was diluted with ethyl acetate, washed with water (5x), sat. NaHC03 (2x), brine (3x), dried over Na2SO4, concentrated, triturated with ether to give 7.1 g (70%) of 4- (2, 6-difluoro-phenyl)-1, 3- dihydro-indol-2-one as a white solid.

[0342] 'H-NMR (400 MHz, DMSO-d6) 8 10.53 (s, 1H, NH), 7.50 (m, 1H), 7.25 (m, 3H), 6.90 (m, 2H), 3.25 (s, 2H).

Example A-53.3- (2-oxo-2, 3-dihydro-lH-indol-4-yl)-benzoic acid [0343] To the suspension of 3-(lH-iIndol-4-yl)-benzoic acid (7.58 g, 33 mmol) in t- BuOH : ethanol: acetic acid (150mL : I OOML : 50 mL) was added pyridinium tribromide (31.66 g, 99 mmol) portionwise. The mixture was stirred at room temperature for 2 hours, and then to the mixture was added with acetic acid (150 mL).

Water (4 mL) and Zinc dust (13.07 g, 200 mmol) was added to the reaction mixture portionwise and stirring was continued at room temperature for 2 hours. The solvent was removed under reduced pressure. The oily residue was suspended in IN HCl (400 mL) and stirred at room temperature overnight. The precipitate solid was collected by filtration, purified by recrystallization from ethyl acetate to give (6.4 g, 77%) of 3- (2- oxo-2,3-dihydro-lH-indol-4-yl)-benzoic acid as a pinkish white solid.

[0344] 1H-NMR (400 MHz, DMSO-d6) 8 10.50 (br s, 1H, NH), 8.01-8.05 (m, 1H), 7.90-7.95 (m, 1H), 7.82-7.87 (m, 1H), 7.54-7.60 (m, 1H), 7.26-7.32 (m, 1H), 7.04 (d, J= 7.1 Hz, 1H), 6.84 (d, J= 7.4 Hz, 1H), 3.58 (s, 2H).

Example A-54. N-Methyl-3- (2-oxo-2, 3-dihydro-lH-indol-4-yl)-benzamide [0345] A mixture of 3-(2-oxo-2, 3-dihydro-lH-indol-4-yl)-benzoic acid (1.27 g, 5.0 mmol), HOBt (0.68 g, 5. 0 mmol) and EDC (1.44 g, 7.5 mmol) in DMF (10 mL) was stirred at room temperature for 30 minutes. To the mixture was added methylamine (2M in THF, 3.75 mL, 7.5 mmol), it was then stirred at room temperature for overnight. Most of the solvent was removed under reduced pressure and the residue was diluted with sat. NaHCO3 (20 mL). The precipitate was collected by filtration, washed with water and dried. The crude product was recrystallized from DCM- hexane to give 1.14 g (86%) of N-methyl-3-(2-oxo-2, 3-dihydro-lH-indol-4-yl)- benzamid as a light yellow solid.

[0346]'H-NMR (400 MHz, DMSO-d6) 8 8.46-8.53 (m, 1H), 7.94 (m, 1H), 7.80-7.85 (m, 1H), 7.68-7.74 (m, 1H), 7.52 (t, J= 7.8 Hz, 1H), 7.28 (t, J= 7.8 Hz, 1H), 7.05 (dd, J= 0.8,7.8 Hz, 1H), 6.83 (d, J= 7.4 Hz, 1H), 3.63 (s, 2H), 2.79 (d, J = 4.6 Hz, 3H).

10347] MS m/z 267 [M++1].

Example A-55.4- (3, 4-Dimethoxy-phenyl)-1, 3-dihydro-indol-2-one [0348] To the suspension of 4- (3, 4-dimQthoxy-phenyl)-IH-indole (14.7 g, 58 mmol) in t-BuOH : ethanol: acetic acid (367 mL: 217 mL: 113 mL) was added pyridinium tribromide (55.68 g, 174 mmol) portionwise. The mixture was stirred at room temperature for 3 hours, and then to the mixture was added more acetic acid (287 mL). Zinc dust (18.95 g, 290 mmol) was added to the reaction mixture portionwise.

After stirring for one hour, water was added to the reaction. The unreacted zinc was filtered off and most of the solvent was removed under reduced pressure. The residue was diluted with ethyl acetate, washed with water (6x), sat. NaHC03 (2x), brine (3x), dried over Na2S04, concentrated and triturated with ether to give 10.14 g (65%) of 4- (3,4-dimethoxy-phenyl)-1,3-dihydro-indol-2-one as an earth colored solid.

103491 IH-NMR (400 MHz, DMSO-d6) 8 10.44 (s, 1H, NH), 7.22 (t, 1H), 7.18 (m, 2H), 7.0 (m, 2H), 6.77 (d, 1H), 3.79 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 3.6 (s, 2H).

Example A-56.4-13-(2-Hydroxy-ethoxy)-phenyll-1, 3-dihydro-indol-2-one [0350] To the suspension of2- [3- (17-f-indol-4-yl)-phenoxy]-ethanol (5.4 g, 21 mmol) in t-BuOH : ethanol: acetic acid (139.5 mL: 84 mL: 100.5 mL) was added pyridinium tribromide (21.21 g, 63 mmol) portionwise. The mixture was stirred at room temperature for 3 hours, and then to the mixture was added more acetic acid (90 mL) and water (3 mL). Zinc dust (21 g) was added to the reaction mixture portionwise. After stirring for one hour, the unreacted zinc was filtered off and most of the solvent was removed under reduced pressure. The residue was diluted with ethyl acetate, washed with IN HCl (3x), water (1x), brine (2x), dried over Na2SO4, concentrated. The residue was recrystallized to give 1.82 g (32%) of 4- [3- (2-hydroxy- ethoxy)-phenyl]-1, 3-dihydro-indol-2-one.

[0351] 1H-NMR (400 MHz, DMSO-d6) 8 10.46 (s, 1H, NH), 7.33 (t, 1H), 7.25 (t, 1H), 7.09 (d, 1H), 7.06 (m, 1H), 7.0 (dd, 1H), 6.92 (dd, 1H), 6.80 (d, 1H), 4.86 (t, 1H), 4.02 (t, 2H), 3.71 (q, 2H), 3.58 (s, 2H).

[0352] MS m/z 270 [M++1].

Example A-57.4- (2, 3-Difluoro-phenyl)-1, 3-dihydro-indol-2-one [03531 To the suspension of 4-(2,3-difluoro-phenyl)-1H-indole (2.85 g, 12.4 mmol) in t-BuOH : ethanol: acetic acid (78. 5 mL: 46.5 mL: 24. 13 mL) was added pyridinium tribromide (11.93 g, 37.3 mmol) portionwise. The mixture was stirred at room temperature for 3 hours, and then to the mixture was added with acetic acid (60 mL).

Zinc dust (4.1 g, 62.2 mmol) was added to the reaction mixture portionwise. After stirring for one hour, any unreacted zinc was filtered off and most of the solvent was removed under reduced pressure. The residue was diluted with ethyl acetate, washed with water (5x), sat NaHCO3, brine, dried over Na2SO4, concentrated and triturated with ether to give 2.32 g (76%) of 4- (2, 3-difluoro-phenyl)-1, 3-dihydro-indol-2-one as an earth colored solid.

[03541 IH-NMR (400 MHz, DMSO-d6) 8 10.53 (br s, 1H, NH), 7.45 (m, 1H), 7.29 (m, 3H), 6.96 (d, J= 7.8 Hz, 1H), 6.88 (d, J= 7.8 Hz, 1H), 3.41 (s, 2H).

[03551 MS m/z 246.2 [M++1].

Example A-58.4-Bromo-5-methoxy-1,3-dihydro-indol-2-one [0356] To the suspension of 5-methoxyindole (5.0 g, 34 mmol) in t-BuOH : ethanol: acetic acid (215 mL: 127 mL: 66 mL) was added pyridinium tribromide (32.6 g, 102 mmol) portionwise. The mixture was stirred at room temperature for 3 hours, and then to the mixture was added with more acetic acid (165 mL). Zinc dust (11.1 g, 170 mmol) was added to the reaction mixture portionwise. After stirring for one hour, the unreacted zinc was filtered off, and the solvent was removed under reduced pressure.

The residue was diluted with water, extracted with ethyl acetate. The combined extracts were washed with water (5x), sat. NaHC03 (2x), brine (3x), dried over Na2S04, concentrated, triturated with ether to give 2.12 g (26%) of 4-bromo-5- methoxy-1, 3-dihydro-indol-2-one.

[0357] 1H-NMR (400 MHz, DMSO-d6) 8 10.41 (s, 1H, NH), 6.90 (d, J= 8Hz, 1H), 6.74 (d, J= 8 Hz, 1H), 3.77 (s, 3H, OCH3), 3.42 (s, 2H).

Example A-59.4- (2, 4-Difluoro-phenyl)-1, 3-dihydro-indol-2-one 103581 To the suspension of 4- (2, 4-difluoro-phenyl)-lH-indole (6.42 g, 28 mmol) in t-BuOH : ethanol: acetic acid (177 mL: 105 mL: 55 mL) was added pyridinium tribromide (27 g, 84 mmol) portionwise. The mixture was stirred at room temperature for 3 hours, and then to the mixture was added with acetic acid (136 mL). Zinc dust (9.8 g, 150 mmol) was added to the reaction mixture portionwise. After stirring for one hour, any unreacted zinc was filtered off and most of the solvent was removed under reduced pressure. The residue was diluted with ethyl acetate, washed with water (5x), neutralized with IN HC1, washed with sat. NaHC03, brine, dried over Na2S04, concentrated and triturated with ether to give 5.16 g (75%) of 4- (2, 4-difluoro-phenyl)- 1, 3-dihydro-indol-2-one.

[0359] 1H-NMR (400 MHz, DMSO-d6) 8 10.50 (s, 1H, NH), 7.54 (m, 1H), 7.35 (m, 1H), 7.25 (t, 1H), 7.16 (m, 1H), 6.91 (d, IH), 6.85 (d, 1H), 3.37 (s, 2H).

Example A-60.4- (2-Chloro-phenyl)-1, 3-dihydro-indol-2-one [0360] To the suspension of 4-(2-chloro-phenyl)-lH-indole (2.4 g, 10.6 mmol) in t- BuOH : ethanol: acetic acid (67 mL: 40 mL: 21 mL) was added pyridinium tribromide (10.5 g, 32 mmol) portionwise. The mixture was stirred at room temperature for 3 hours, and then to the mixture was added acetic acid (52 mL). Zinc dust (3.5 g, 53 mmol) was added to the reaction mixture portionwise. After stirring for one hour, any unreacted zinc was filtered off and most of the solvent was removed under reduced pressure. The residue was diluted with ethyl acetate, washed with water (3x), sat.

NaHCO3, brine, dried over Na2S04, concentrated and triturated with ether to give 1.96 g (76%) of 4- (2-chloro-phenyl)-1, 3-dihydro-indol-2-one.

[0361] 'H-NMR (400 MHz, DMSO-d6) 8 10. 53 (s, 1H, NH), 7.56 (m, 1H), 7.41 (m, 3H), 7.26 (t, 1H), 6.86 (m, 2H), 3.26 (s, 2H).

[0362] MS m/Z 244. 2 [M++1].

Example A-61. [3- (2-Oxo-2, 3-dihydro-lH-indol-4-yl)-phenyl]-acetic acid ethyl ester [03631 To the suspension of [3- (lH-indol-4-yl)-phenyl]-acetic acid methyl ester (3.72 g, 14 mmol) in t-BuOH : ethanol: acetic acid (93 mL: 56 mL: 67.2 mL) was added pyridinium tribromide (14.14 g, 44 mmol) portionwise. The mixture was stirred at room temperature for 3 hours, and then to the mixture was added acetic acid (60 mL). Water (2 mL) and zinc dust (14 g, excess) was added to the reaction mixture portionwise. After stirring at rt for one hour, any unreacted zinc was filtered off and most of the solvent was removed under reduced pressure. The residue was diluted with diluted with water (380 mL), extracted with ethyl acetate, washed with 0.5 N HCI (2x), 10% Na2C03, (2x), brine (2x), water (1x), dried overNa2SO4, concentrated and triturated with ether to give [3-(2-oxo-2,3-dihydro-1H-indol-4-yl)-phenyl]-acetic acid methyl ester.

[0364] MS m/z 282 [M++1].

Syntheses of the Precursor, Pyrrole Aldehydes: 5-Formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (Pyrrole Aldehyde-1) 0 0 0 sodium nitrite 1-Y 0 ethyl-3-oxobutyrate 0-0 acetic acid N zinc dust, acetic acid '//''-'f U 0 0 1 0 H Ho Step 1 FW 267.33 Stepi 0 o triethyl orthoformate H trifluoroacetic acid N N 0 H step 2 0 H FW 267.33 FW 195.22 O O H O O potassium hydroxide H H H N N FW 195.22 FW 167.17 Step 1 : 10365] t-Butyl-3-oxobutyrate (158 g, 1 mol) was dissolved in 200 mL of acetic acid in a 500 mL 3-neck round bottom flask equipped with a thermometer, addition funnel and mechanical stirring. The mixture was cooled in an ice bath to about 10 °C.

Sodium nitrite (69 g, 1 mol) was added over 75 minutes keeping the temperature under 15 °C. The cold bath was removed and the mixture stirred for 30 minutes and then allowed to stand for 3.5 hours to give t-butyl-2-hydroximino-3-oxobutyrate.

[0366] Ethyl-3-oxobutyrate (130 g, 1 mol) was dissolved in 400 mL of acetic acid in a 2 L 3-neck round bottom flask equipped with a thermometer, an addition funnel, mechanical stirring and placed in an oil bath. Zinc dust (50 g, 0.76 mol) was added and the mixture heated to 60 °C with stirring. The crude t-butyl-2-hydroximino-3- oxobutyrate solution prepared above was cautiously added keeping the temperature at about 65 °C by slowing the addition and cooling the flask. More zinc dust (4 x 50 g, 3.06 mol) was added in portions during the addition with the last portion added after all the t-butyl ester had been added. The temperature of the mixture reached a maximum of 80 °C. At the end of the additions the temperature was 64 °C. The temperature was increased by heating to 70-75 °C for one hour and then poured into 5 L of water. The gray floating precipitate was collected by vacuum filtration and washed with 2 L of water to give 354 g of wet crude product. The crude product was dissolved in 1 L of hot methanol and hot filtered to remove zinc. The filtrate was cooled to give a precipitate that was collected by vacuum filtration to give 118 g of product. The filtrate was put in the refrigerator overnight to give a total of 173.2 g of 3,5-dimethyl-lH-pyrrole-2,4-dicarboxylic acid 2-tert-butyl ester 4-ethyl ester.

Step 2: [0367] 3,5-Dimethyl-lH-pyrrole-2,4-dicarboxylic acid 2-tert-butyl ester 4-ethyl ester (80. 1 g, 0.3 mol) and 400 mL of trifluoroacetic acid were stirred for 5 minutes in a 2 L 3-neck round bottom flask equipped with mechanical stirring and warmed to 40 °C in an oil bath. The mixture was then cooled to-5 °C and triethyl orthoformate (67.0 g, 0.45 mol) was added all at once. The temperature increased to 15 °C. The mixture was stirred for about 1 minute, removed from the cold bath and then stirred for 1 hour. The trifluoroacetic acid was removed by rotary evaporation and the residue put in the refrigerator where it solidified. The solid was dissolved by warming and poured into 500 g of ice. The mixture was extracted with 800 mL of dichloromethane to give a red solution and a brown precipitate, both of which were saved. The precipitate was isolated and washed with 150 mL of saturated sodium bicarbonate solution. The dichloromethane phase was washed with 150 mL of sodium bicarbonate and both bicarbonate solutions discarded. The dichloromethane solution was washed with 3 times with 100 mL of water each time. The dichloromethane solution was evaporated to dryness and the dark residue recrystallized twice from hot ethyl acetate after decolorizing with Darco to give golden yellow needles. The brown precipitate was recrystallized from 350 mL of hot ethyl acetate after decolorizing with Darco to give a yellow-red solid. All the recrystallized solids were combined and recrystallized from 500 mL of hot ethanol to give 37.4 g (63.9 %) of 5-formyl-2, 4.-dimethyl-lH-pyrrole-3-carboxylic acid ethyl ester as yellow needles (mp 165.6-166.3 °C, lit. 163-164 °C). The evaporated residues from the ethyl acetate and ethanol mother liquors were recrystallized from 500 mL of ethanol to give 10.1 g (17.1 %) of a second crop of dirty yellow needles.

Step 3: [0368] 5-Formyl-2,4-dimethyl-lH-pyrrole-3-carboxylic acid ethyl ester (2 g, 10 mmol) was added to a solution of potassium hydroxide (3 g, 53 mmol) dissolved in methanol (3 mL) and water (10 mL). The mixture was refluxed for 3 hours, cooled to room temperature and acidified with 6 N hydrochloric acid to pH3. The solid was collected by filtration, washed with water and dried in a vacuum oven overnight to give 1.6 g (93%) of 5-formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid.

03691 1H NMR (300 MHz, DMSO-d6) 8 12.09 (s, br, 2H, NH & COOH), 9.59 (s, 1H, CHO), 2.44 (s, 3H, CH3), 2.40 (s, 3H, CH3).

[0370] MS m/z 167 (M+).

II. General amidation procedure: [0371] The 5-formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid is dissolved in DMF (0.3M) with stirring. To the solution is added l-ethyl-3- (3-dimethylamino- propylcarbodiimide hydrochloride (EDC, 1.2 equiv.), 1-hydroxybenzotriazole (HOBt, 1.2 eq) followed by the appropriate amine (1.2 eq). The reaction solution is stirred for 12h, and then DMF solvent was removed. The residue was purified on a silica gel column eluting with 1-5% methanol in dichloromethane to provide the product. Example B-1.3,5-Dimethyl-4-(4-methyl-piperazine-1-carbonyl)-lH-pyrro le-2- carbaldehyde [0372] 5-Formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (5 g, 29.9 mmol) reacted with N-methylpiperazine (4.0 mL) to give 5.3g (72%) of 3, 5-imethyl-4- (4- methyl-piperazine-1-carbonyl)-1H-pyrrole-2-carbaldehyde.

[0373] 1H NMR (360 MHz, DMSO-d6) # 11.82 (s, 1H, NH), 9.50 (s, 1H, CHO), 3.14 (br m, 4H, 2xCH2), 2.29 (br m, 4H, 2xCH2), 2.19 (s, 3H, CH3), 2.17 (s, 3H, CH3), 2.14 (s, 3H, CH3).

[0374] MS m/z 249 [M] +.

Example B-2.5-Formyl-2,4-dimethyl-lH-pyrrole-3-carboxylic acid (2- diethylamino-ethyl)-amide 10375] 5-Formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (5 g, 2.99 mmol) reacted with N,N-diethylethylenediamine (4.62 mL) to give 6.19g (78%) of 5-formyl- 2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide.

[0376] 1H NMR (360 MHz, DMSO-d6) 8 11.7 (br s, 1H, NH), 9.52 (s, 1H, CHO), 7.27 (m, 1H, CONH), 3.2 (m, 2H, NCH2), 2.5 (m, 6H, 3xNCH2), 2.35 (s, 3H, CH3), 2.30 (s, 3H, CH3), 0.95 (t, J= 6.7Hz, 6H, 2xNCH2CH3).

[0377] MS m/z 266 (M++1) Example B-3. 5-Formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2-pyrrolidin- 1-yl-ethyl)-amide [0378] 5-Formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (5 g, 29.9 mmol) reacted with 1- (2-aminoethyl) pyrrolidine (4.1 g, 35.9 mmol) to give 5.7g (73%) of 5- formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide.

[0379] 1H NMR (360 MHz, DMSO-d6) 5 11.79 (br s, 1H, NH), 9.53 (s, 1H, CHO), 7.41 (m, 1H, CONH), 3.28-3.34 (m, 2H, NCH2), 2.53-2.60 (m, 6H, NCH2 and 2xNCH2CH2), 2.35 (s, 3H, CH3), 2.3 (s, 3H, CH3), 1.68 (m, 4H, 2xCH2).

103801 MS m/z 264. 1 (M+) Example B-4.5-Formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide [03811 5-Formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2 g, 11.96 mmol) reacted with 2- [1, 2,3] triazol-1-yl-ethylamine (2.66 g, 14.36 mmol) to give 3.05g (98%) of 5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl- ethyl)-amide.

[0382]'H NMR (360 MHz, DMSO-d6) 8 11.83 (br s, 1H, NH), 9.52 (s, 1H, CHO), 8.12 (d, 1H, J=1. 3 Hz, triazole hydrogen), 7.72 (d, 1H, J= 1.27 Hz, triazole hydrogen), 7.63 (t, 1H, J= 5.6 Hz, CONH), 4.55 (m, 2H, NCH2), 3.66 (m, 2H, CH2), 2.26 (s, 3H, CH3), 2.21 (s, 3H, CH3).

[0383] MS m/z 262 (M++1).

Example B-5.3, 5-Dimethyl-4-[(cis)-3,5-dimethyl-piperazine-1-carbonyl]-1H- pyrrole-2-carbaldehyde [0384] 5-Formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2 g, 11.96 mmol) reacted with cis-2, 6-dimethylpiperazine (2.66 g, 14. 36 mmol) to give 2.27g (72%) of 3,5-dimethyl-4-[(cis)-3,5-dimethyl-piperazine-1-carbonyl]-1H -pyrrole-2- carbaldehyde.

[0385] 1H NMR (360 MHz, DMSO-d6) 8 11.84 (br s, 1H, NH), 9.51 (s, 1H, CHO), 4.30 (br s 1H, NH), 2.50 (m, 4H, 2xCH2), 2.28 (m, 8H, 2XCH3 and 2XCH), 0.96 (m, 6H, 2XCH3).

[0386] MS m/z 264 (M++1). Example B-6.5-Formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (3- diethylamino-propyl)-amide [0387] 5-Formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (3.0g, 17.9mmol) reacted with diethylamino propylamine (2.57 g, 19.7 mmol) to give 3.19g (64%) of 5- formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-diethylamino-propyl)-amide.

[0388] 1H NMR (360 MHz, DMSO-d6) 8 11.78 (br s, 1H, NH), 9.52 (s, 1H, CHO), 7.5 (m, 1H, CONH), 3.21 (q, J= 6.4Hz, 2H, NCH2CH3), 2.5 (m, 6H, NCH2CH3 and 2xNCH23), 2. 35 (s, 3H, CH3), 2.29 (s, 3H, CH3), 1.63 (m, 2H, CH2), 0.96 (t,J= 6.8Hz, 6H, NCH2CH3).

[0389] MS m/z 280 (M++1).

Example B-7.5-Formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2- diisopropylamino-ethyl)-amide [0390] 5-Formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (3.0g, 17.9mmol) reacted with diisopropylamino ethylamine (3.56 mL, 19.7 mmol) to give 4.93g (94%) of 5-formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (3-diisopropylamino-ethyl)- amide.

[03911 1H NMR (360 MHz, DMSO-d6) 5 11. 78 (br s, 1H, NH), 9.54 (s, 1H, CHO), 7.29 (m, 1H, CONH), 3.15 (m, 2H, CH2), 2.51 (m, 4H, CH2 and 2XCH), 2.38 (s, 3H, CH3), 2.32 (s, 3H, CH3), 0.97 (d, 12H, 4XCH3).

[0392] MS m/z 294 (M++1).

Example B-8.5-Formyl-4-methyl-lH-pyrrole-3-carboxylic acid NaH oo o DMF, Et20 s NC OOC-rt, 1 hr 0 step 1 stop1 step 1 POCI3, DMF 0 KOH, EtOH OH OoC-rt, 2hr f 100°C, 2.5 hr 46% aN) b 0d 9 46% 87% step 2 step 3 Stepl : Preparation of 4-Methyl-lH-pyrrole-3-carboxylic acid ethyl ester [0393] To a suspension of sodium hydride (4 g of 60% dispersion, 2eq, washed with diethyl ether) in diethyl ether (200 mL), cooled in an ice bath with stirring was added slowly a solution of ethyl crotonate (6.2 mL, 50 mmol) and p-tosylmethyl isocyanide (9.7 g, 50 mmol) in 80 mL of DMSO and 160 mL diethyl ether. Upon complete addition of the solution, the reaction mixture was stirred at room temperature for 1 hr.

The reaction was quenched with 400 mL water and extracted into diethyl ether (2x100 mL), dried (MgS04) and concentrated to afford 6g (78%) of 4-methyl-lH-pyrrole-3- carboxylic acid ethyl ester as a brown oil which solidified upon standing.

[0394] 1H NMR (300 MHz, DMSO-d6) # 11. 1 (br s, 1H,NH), 9.78 (t, J= 2. 7Hz, 1H), 6.56 (s, 1H), 4.12 (q, J=7. 2Hz, 2H, OCH2CH3), 2.15 (s, 3H, CH3), 1.22 (t, J= 7.2Hz, 3H, OCH2CH3).

[0395] MS m/z 153 [M+].

[0396] (Lit. ref. : Cheng et al., J. Heterocyclic Chem., 1976,13,1145-1147).

[0397] Step 2: Preparation of 5-Formyl-4-methyl-1H-pyrrole-3-carboxylic acid ethyl ester [0398] POC13 (4 mL, 1.1 eq) added to 9 mL (3 eq) of DMF cooled in an ice bath.

After 15 mins, a solution of the 4-methyl-1H-pyrrole-3-carboxylic acid ethyl ester (6g, 39.2mmol) in DMF (2M, 20 mL) was added to the reaction and stirring continued at rt. After 2 hr, the reaction mixture was diluted with water (100 mL) and basified to pH=11 with IN NaOH. The aqueous layer was extracted into DCM (2x250 mL), washing the combined organic layers with water (2x400 mL), dried (MgS04), filtered through a plug of silica and concentrated to afford a pinkish solid. Trituration with hexanes afforded 3.3g (46%) of 5-formyl-4-methyl-1H-pyrrole-3-carboxylic acid ethyl ester as a tan solid [0399] IH NMR (300 MHz, DMSO-d6) 8 12.4 (br s, 1H, NH), 9.69 (s, 1H, CHO), 7.59 (s, 1H), 4.16 (q, J= 6. 8 Hz, 2H, OCH2CH3), 2.48 (s, 3H, CH3), 1.24 (t, J= 6. 8 Hz, 3H, OCH2CH3).

[0400] MS m/z 181 [M+].

[0401] (Lit. ref. : Bonnett, Raymond; Hamzetash, Dariush; Valles, Maria Asuncion; J. Chem. Soc. Perkin Trans 1 ; 1987; 1387-1388).

[0402] Step 3: Preparation of 5-formyl-4-methyl-lH-pyrrole-3-carboxylic acid [0403] KOH (5 g, 2 eq) was added to a suspension of 5-formyl-4-methyl-lH- pyrrole-3-carboxylic acid ethyl ester (8.13 g, 44.8 mmol) in water (100 mL) and EtOH (50 mL) with stirring. The mixture was heated to reflux for 2.5 hr, cooled to rt, concentrated to about 2/3 volume, diluted with water (300 mL) and acidified to pH=3 using 1N HCl. The white solid was collected by filtration and dried to afford 6 g (87%) of 5-formyl-4-methyl-lH-pyrrole-3-carboxylic acid as a tan solid.

[0404] IH NMR (300 MHz, DMSO-d6) 6 12.28 (br s, 1H, Cl2$, 12.13 (br s, 1H, NH), 9.68 (s, 1H, CHO), 7.55 (d, J= 3.6 Hz, 1H), 3.32 (s, 3H, CH3).

[0405] MS m/z 153 [M+].

A. General amidation procedure: [0406] To the solution of 5-formyl-4-methyl-1H-pyrrole-3-carboxylic acid in DMF (0.3M) was added 1-ethyl-3-(3-dimethylamino-propylcarbodiimide hydrochloride (EDC, 1.2 equiv.), 1-hydroxybenzotriazole (HOBt, 1.2 eq) followed by the appropriate amine (1.2 eq). The reaction solution was stirred for 12h, and then DMF solvent was removed. The residue was purified on a silica gel column eluting with 1- 5% methanol in dichloromethane to provide the product.

Example B-9. 3-Methyl-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrole-2- carbaldehyde [0407] 5-Formyl-4-methyl-lH-pyrrole-3-carboxylic acid (500 mg, 3.27mmol) reacted with 1-methylpiperazine (0.43 mL, 3.92 mmol) to give 3-methyl-4- (4-methyl- piperazine-1-carbonyl)-lH-pyrrole-2-carbaldehyde.

[04081'HNMR (300 MHz, DMSO-d6) 5 12.25 (br s, IH, NH), 9.66 (s, 1H, CHO), 7.35 (s, 1H), 3.7 (m, 4H, 2XCH2), 3.16 (m, 4H, 2XCH2), 2.73 (s, 3H, CH3), 2.32 (s, 3H, CH3).

[0409] MS 236 [M++1]. ExampleB-10.4- [ (cis)-3, 5-dimethyl-piperazine-l-carbonyl]-3-methyl-lH pyrrole-2-carbaldehyde [0410] 5-Formyl-4-methyl-1H-pyrrole-3-carboxylic acid (1.00 g, 6.54 mmol) reacted with cis-2, 6-dimethylpiperazine (822 mg, 7.19 mmol) to give 4- [ (cis)-3, 5- dimethyl-piperazine-1-carbonyl]-3-methyl-1H-pyrrole-2-carbal dehyde (1. 43 g, 88%).

[0411 'HNMR (300 MHz, DMSO-d6) 8 12. 08 (br s, 1H, NH), 9.65 (s, 1H, CHO), 7.23 (s, 1H), 4.09 (br s, 2H, CH2), 2.62 (m, 2H, CH2), 2.40 (br s, 2H, 2XCH), 2.29 (s, 3H, CH3), 0.93 (br d, 6H, J= 4.6 Hz, 2XCH3).

[0412] MS mlz 248 [M--1].

Example B-11. 5-Formyl-4-methyl-lH-pyrrole-2-carboxylic acid DMF, POCI3 1. KOHaq 0 r. t., 3. 5 h0 0 2. HClaq 0 0 Step 1 H N Step H N OH Step 1: Preparation of 5-Formyl-4-methyl-1H-pyrrole-2-carboxylic acid ethyl ester [0413] To the ice-cold 3 mL (39.2 mmol) of dimethylformamide (DMF) was added phosphorus oxychloride (0.67 mL, 7.18 mmol) drop wise and the resultant mixture was stirred for 30 minutes. A solution of 1 g (6.53 mmol) of 4-methyl-lH-pyrrole-2- carboxylic acid ethyl ester in 3 mL of DMF was added to the reaction. After 1 h, the reaction was warmed to room temperature for another 2.5 h. The reaction mixture was diluted with water (100 mL) and basified to pH = 11 with IN sodium hydroxide solution. The precipitate was removed by filtration, rinsing with water and dried to afford 0.8 g (68%) of 5-formyl-4-methyl-lH-pyrrole-2-carboxylic acid ethyl ester as a white solid.

[0414] 1H NMR (360 MHz, DMSO-d6) 8 12.6 (br s, 1H, NH-1), 9.78 (s, 1H, CHO- 5), 6.68 (s, 1H, H-3), 4.26 (q, J= 7.0 Hz, 2H, OCH2CH3), 2.28 (s, 3H, CH3-4), 1.28 (t, J= 7.0 Hz, 3H, OCH2CH3).

[0415] MS m/z 181 (M+).

Step 2: Preparation of 5-Formyl-4-methyl-1H-pyrrole-2-carboxylic acid [0416] To a solution of 0.8 g (4.4 mmol) of 5-formyl-4-methyl-lH-pyrrole-2- carboxylic acid ethyl ester in 35 mL of water and 15 mL of ethanol was added 0.5 gram (8.9 mmol) of potassium hydroxide. The reaction mixture was heated to 100 °C for 1 h, cooled to room temperature, and evaporated ethanol. The water layer was acidified to pH = 3 using 2N hydrogen chloride solution. The precipitate was filtered and washed with water to afford 0.67 g (68%) of 5-formyl-4-methyl-1H-pyrrole-2- carboxylic acid as a tan solid.

[04171 IH NMR (360 MHz, DMSO-d6) 8 12.92 (br s, 1H, CO2H-5), 12.48 (br s, 1H, NH-1), 9.76 (s, 1H, CHO-5), 6.63 (s, 1H, H-3), 2.28 (s, 3H, CH3-4).

[0418] MS m/z 152 [M--1].

Example B-12.5-Formyl-4-methyl-lH-pyrrole-2-carboxylic acid (2- diethylamino-ethyl)-amide [0419] To a solution of 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid (2.50 g, 16. 32 mmol) in DMF (54 mL) was added 1-ethyl-3- (3-dimethylamino- propylcarbodiimide hydrochloride (EDC, 3.76 g, 19.59 mmol), 1- hydroxybenzotriazole (HOBt, 2.65 g, 19.59 mmol) followed by diethylaminoethyl amine (2. 75 mL, 19.59 mmol). The reaction solution was stirred for 12h, and then DMF solvent was removed. The residue was purified on a silica gel column eluting with 1-5% methanol in dichloromethane to provide 3.2 g (78%) of 5-formyl-4- methyl-lH-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)-amide.

[0420] IH NMR (360 MHz, DMSO-d6) 8 12.22 (br s, 1H, NH), 9.73 (s, 1H, CHO), 8.29 (t, 1H, J= 5. 5 Hz, CONH), 6.66 (s, 1H, H-3), 3.28 (m, 2H, CH2), 2.50 (m, 6H, 3XCH2), 2.30 (s, 3H, CH3), 0.94 (t, 6H, J= 7.2 Hz, 2XCH3).

[0421] MS m/z 252 [M++1].

B. General amidation procedure: 0422] To the solution of 2-formyl-5-methyl-lH-pyrrole-3-carboxylic acid in DMF (0. 3M) was added l-ethyl-3- (3-dimethylamino-propylcarbodiimide hydrochloride (EDC, 1.2 equiv.), 1-hydroxybenzotriazole (HOBt, 1.2 eq) followed by the. appropriate amine (1.2 eq). The reaction solution was stirred for 12h, and then DMF solvent was removed. The residue was purified on a silica gel column eluting with 1- 5% methanol in dichloromethane to provide the product.

Example B-13.2-Formyl-5-methyl-lH-pyrrole-3-carboxylic acid (2- diethylamino-ethyl)-amide [0423] 2-Formyl-5-methyl-1H-pyrrole-3-carboxylic acid (3.0 g, 19.6mmol) reacted with N,N-diethylethylenediamine (3.03 mL, 21.5 mmol) to give 2-formyl-5-methyl- lH-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide (4.65 g, 94%).

[0424] 1HNMR (400 MHz, DMSO-d6) 812. 16 (br s, 1H, NH), 9.96 (s, 1H, CHO), 8.28 (m, 1H, CONH), 6.40 (s, 1H, H-4), 3.27 (m, 2H, CH2), 2.49 (m, 6H, 3XCH2), 2.22 (s, 3H, CH3), 0.95 (t, 6H, J= 7.1 Hz, 2XCH3) [0425] MS m/z 252 [M++1].

Example B-14.2-Formyl-5-methyl-lH-pyrrole-3-carboxylic acid (2- pyrrolidin-1-yi-ethyl)-amide [0426] 2-Fomryl-5-methyl-1H-pyrrole-3-carboxylic acid (3.0 g, 19.6mmol) reacted with 1- (2-aminoethyl) pyrrolidine (2.73 mL, 21.5 mmol) to give 2-formyl-5-methyl- 1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide (3.71 g, 76%).

[0427] 1HNMR (400 MHz, DMSO-d6) 8 12.16 (br s, 1H, NH), 9.96 (s, 1H, CHO), 8.32 (m, 1H, CONH), 6.42 (s, 1H, H-4), 3. 31 (m, 2H, CH2), 2.54 (m, 6H, 3XCH2), 2.23 (s, 3H, CH3), 1.66 (m, 4H, 2XCH2) [0428] MS m/z 250 [M++1]. Example B-15. 2-Formyl-5-methyl-1H-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide [0429] 2-Formyl-5-methyl-1H-pyrrole-3-carboxylic acid (2.0 g, 13.06 mmol) reacted with 2- [1, 2,3] triazol-1-yl-ethylamine (1.76 g, 15.67 mmol) to give 2-formyl- 5-methyl-1H-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide (2.55 g, 79%).

[0430] 1HNMR (400 MHz, DMSO-d6) 8 12.17 (br s, 1H, NH), 9.90 (s, 1H, CHO), 8.32 (t, 1H, J= 5.6 Hz, CONH), 8.10 (d, 1H, J= 0.85 Hz, triazole CH), 7.70 (d, 1H, J = 0.85 Hz, triazole CH), 6.37 (s, 1H, H-4), 4.56 (m, 2H, CH2), 3.65 (m, 2H, CH2), 2.22 (s, 3H, CH3).

[0431] MS m/z 248 [M++1].

Example B-16. 3- [ (3R)-3-Dimethylamino-pyrrolidine-l-carbonyl]-5- methyl-lH-pyrrole-2-carbaldehyde [0432] 2-Formyl-5-methyl-lH-pyrrole-3-carboxylic acid (536 mg, 3.50 mmol) reacted with (3R)- (+)-3-dimethylamino-pyrrolidine (480 mg, 4.20 mmol) to give 3- [(3R)-3-dimethylamino-pyrrolidine-1-carbonyl]-5-methyl-1H-py rrole-2-carbaldehyde (600 mg, 69%).

[0433] 1HNMR (400 MHz, DMSO-d6) 8 12.23 (br s, 1H, NH), 9.63 (s, 1H, CHO), 6.28 (s, 1H, H-4), 3.89 (m, 2H, CH2), 3.70 (m, 2H, CH2), 2.76 (m, 7H, 2XCH3 and CH), 2.29 (m, 1H, CH2), 2.24 (s, 3H, CH3), 2.15 (m, 1H, CH2).

[0434] MS m/z 250 [M++1]. <BR> <BR> <BR> <BR> <BR> <P>Example B-17. 3-[(3S)-3-Dimethylamino-pyrrolidine-l-carbonyl]-5-methyl- 1H-pyrrole-2-carbaldehyde [0435] 2-Formyl-5-methyl-lH-pyrrole-3-carboxylic acid (548 mg, 3.58 mmol) reacted with (3S)-(-)-3-dimethylamino-pyrrolidine (490 mg, 4.29 mmol) to give 3- [(3S)-3-dimethylamino-pyrrolidine-1-carbonyl]-5-methyl-1H-py rrole-2-carbaldehyde (460 mg, 52%).

[0436] 1HNMR (400 MHz, DMSO-d6) 5 12.22 (br s, 1H, NH), 9.63 (s, 1H, CHO), 6.28 (s, 1H, H-4), 3.90 (m, 2H, CH2), 3.73 (m, 2H, CH2), 2.73 (m, 7H, 2XCH3 and CH), 2.28 (m, 1H, CH2), 2.24 (s, 3H, CH3), 2.21 (m, 1H, CH2).

[0437] MS m/z 250 [M++1].

Example B-18. 3-[(cis)-3,5-Dimethyl-piperazine-1-carbonyl]-5-methyl-1H- pyrrole-2-carbaldehyde [0438] 2-Formyl-5-methyl-1H-pyrrole-3-carboxylic acid (1.00 g, 6.53 mmol) reacted with cis-2, 6-dimethylpiperazine (900 mg, 7.84 mmol) to give 3- [ (cis)-3, 5- dimethyl-piperazine-1-carbonyl]-5-methyl-1H-pyrrole-2-carbal dehyde (1.20 g, 74%).

[0439] 1HNMR (400 MHz, DMSO-d6) 8 12.12 (br s, 1H, NH), 9.40 (s, 1H, CHO), 6.05 (s, 1H, H-4), 4.15 (m, 1H, CH2), 3.65 (m, 1H, CH2), 2.59 (m, 2H, CH2), 2.30 (m, 2H, 2XCH), 2.24 (s, 3H, CH3), 0.94 (m, 7H, 2XCH3 and NH).

[0440] MS m/z 250 [M++1].

Example B-19. 3,5-Dimethyl-4-[3-(4-methyl-piperazin-1-yl)-3-oxo-propyl]- 1H-pyrrole-2-carbaldehyde [0441] 3- (5-Formyl-2, 4-dimethyl-lH-pyrrol-3-yl)-propionic acid (1.37 g, 6.50 mmol) reacted with 1-methylpiperazine (719.6 mg, 7.15 mmol) to give 3,5-dimethyl- 4- [3- (4-methyl-piperazin-1-yl)-3-oxo-propyl]-lH-pyrrole-2-carbald ehyde (1.30 g, 72%).

[0442] 1HNMR (400 MHz, DMSO-d6) 8 11.40 (br s, 1H, NH), 9.42 (s, 1H, CHO), 3.41 (m, 2H, CH2), 3.31 (m, 2H, CH2), 2.54 (m, 2H, CH2), 2.37 (m, 2H, CH2), 2.19 (s, 3H, CH3), 2.18 (m, 2H, CH2), 2.15 (s, 3H, CH3), 2.12 (s, 3H, CH3).

[0443] MS m/z 278 [M++1]. Example B-20. 3,5-Dimethyl-4-[3-[(cis)-3,5-dimethyl-piperazin-1-yl)]-3- oxo-propyl]-lH-pyrrole-2-carbaldehyde [0444] 3- (5-Formyl-2, 4-dimethyl-1H pyrrol-3-yl)-propionic acid (1.37 g, 6.50 mmol) reacted with cis-2, 6-dimethylpiperazine (822 mg, 7.15 mmol) to give 3,5- dimethyl-4-[3-[(cis)-3,5-dimethyl-piperazin-1-yl)-3-oxo-prop yl]-1H-pyrrole-2- carbaldehyde (1.42 g, 75%).

[0445]'HNMR (400 MHz, DMSO-d6). 8 11.39 (br s, 1H, NH), 9.42 (s, 1H, CHO), 4.25 (m, 1H, CH2), 3.54 (m, 1H, CH2), 2.54 (m, 2H, CH2), 2.45 (m, 2H, 2XCH), 2.36 (ni, 4H, 2XCH2), 2.20 (s, 3H, CH3), m2.14 (s, 3H, CH3), 1.94 (t, 1H, J= 11. 5 Hz, NH), 0.93 (d, 3H, J= 5.9 Hz, CH3), 0. 88 (d, 3H, J= 5.6 Hz, CH3).

[0446] MS m/z 292 [M++1].

Example B-21.4- (3-Piperidin-1-yl-propionyl)-1,4,5,6, 7,8-hexahydro- pyrrolo [3,2-b] azepine-2-carbaldehyde [0447] To a stirred solution of 1, 5,6,7-tetrahydro-indol-4-one (5.4 g) in pyridine (40 mL) was added hydroxyammonium chloride (2 eq.) at rt. After 2 hours, the solvent was removed and the residue was diluted with water and extracted with ethyl acetate.

The combined extracts were washed with brine, dried and concentrated to give 5.5 g of 1, 5,6,7-tetrahydro-indol-4-one oxime as a pale yellow solid.

[0448] 1H NMR (400 MHz, DMSO-d6) 6 10.85 (br s, 1H, NH), 9.85 (s, 1H, N-OH), 6.66 (m, 1H), 6.58 (m, 1H), 2.62 (m, 2H), 2.28 (m, 2H), 1.82 (m, 2H).

[0449] MS m/z 151.01 [M++1].

[0450] To a stirred solution of 1,5, 6,7-tetrahydro-indol-4-one oxime (1.2 g, 7.7 mmol) in DCM (anhydrous, 250 mL) was added DIBAL-H (1M solution in DCM, 35 mL) at 0 °C under nitrogen. After 2 hours, NaF (7g) was added followed by water (2.24 g). After 20 mins, the reaction was filtered through celite and the solvent was removed to give 350 mg of 1, 4,5,6,7,8-hexahydro-pyrrolo [3,2-b] azepine as a brown oil.

[0451] 1H NMR (400 MHz, DMSO-d6) S 9.74 (s, 1H, NH), 6.14 (m, 1H), 5.47 (m, 1H), 4.2 (br s, 1H, NH), 2.78 (m, 2H), 2.47 (m, 2H), 1.60 (m, 2H), 1.46 (m, 2H).

[0452] To a solution of 3-piperidin-1-yl-propionic acid (472 mg, 3 mmol) in DCM (15 mL) at 0 °C was added oxalyl chloride (4.5 mmol) followed by one drop of DMF.

After stirring for 2 hours at rt, the solvent was removed to give 3-piperidin-1-yl- propionyl chloride as a white solid. To a solution of 1,4,5,6,7,8-hexahydro- pyrrolo [3,2-b] azepine (347 mg, 2.55 mmol) in DCM (10 mL) was added TEA (1 eq.) and 1-piperidinepropionic acid chloride. The mixture was stirred at rt for overnight.

The reaction was diluted with DCM, washed with NaHCO3, brine, dried and concentrated. The residue was purified on a silica gel column to give 230 mg of 3- piperidin-1-yl-l- (5, 6,7,8-tetrahydro-1H-pyrrolo [3,2-b] azepin-4-yl)-propan-1-one as a light brown gel.

104531'H NMR (400 MHz, DMSO-d6) 8 10. 59 (s, 1H, NH), 6.42 (m, 1H), 5.91 (m, 1H), 3.45 (m, 2H), 2.56 (m, 2H), 2.41 (m, 4H), 2.19 (m, 4H), 1.66 (m, 2H), 1.51 (m, 2H), 1.40 (m, 4H), 1.29 (m, 2H).

[0454] MS m/z 276.4 [M++1].

[0455] 3-Piperidin-1-yl-1- (5, 6,7,8-tetrahydro-1H-pyrrolo [3,2-b] azepin-4-yl)- propan-1-one (225 mg, 0.8 mmol) was formylated with POC13 (91 µL, 1.2 eq.) and DMF (1 mL) using standard Vilsmierer condition to give 96 mg of 4- (3-piperidin-1-yl- propionyl)-1, 4,5,6,7,8-hexahydro-pyrrolo [3,2-b] azepine-2-carbaldehyde as a light yellow solid.

[0456] 1H NMR (400 MHz, DMSO-d6) S 12.09 (br s, 1H, NH), 9.30 (s, 1H, NH), 6.96 (s, 1H), 3.48 (m, 2H), 2.67 (m, 2H), 2.43 (m, 4H), 2.17 (m, 4H), 1.69 (m, 2H), 1.56 (m, 2H), 1.40 (m, 4H), 1.31 (m, 2H).

[0457] MS m/z 304.4 [M++1].

Example B-22. 4-((S)-Pyrrolidine-2-carbonyl)-1, 4,5,6,7,8-hexahydro- pyrrolo [3,2-b] azepine-2-carbaldehyde [0458] To a solution of (S)-pyrrolidine-1, 2-dicarboxylic acid 1-tert-butyl ester (664 mg) in DCM (10 mL) at 0 °C was added oxalyl chloride (4.7 mmol), followed by one drop of DMF. After stirring at rt for 2 hours, the solvent was concentrated to give S)- 2-chlorocarbonyl-pyrrolidine-1-carboxylic acid ter-butyl ester. To a solution of 1, 4,5,6,7,8-hexahydro-pyrrolo [3,2-b] azepine (350 mg, 2.6 mmol) was added TEA (362 µL) and (S)-2-chlorocarbonyl-pyrrolidine-1-carboxylic acid tert-butyl ester (dissolved in 10 mL of DCM). After stirring at rt for overnight, the reaction was diluted with DCM, washed with NaHC03, brine, dried and concentrated. The residue was purified on a silica gel column to give 410 mg of (S)-2- (5, 6,7, 8-tetrahydro-1H- pyrrolo [3,2-b] azepine-4-carbonyl)-pyrrolidine-1-carboxylic acid tert-butyl ester as a light brown liquid.

[0459] MS m/z 232.5 [M+-Boc].

[0460] (S)-2-(5,6,7,8-Tetrahydro-1H-pyrrolo [3,2-b] azepine-4-carbonyl)- pyrrolidine-1-carboxylic acid tert-butyl ester (400 mg, 1.2 mmol) was formylated with POC13 (134 µL, 1.2 eq.) using standard Vilsmierer condition to give 225 mg of 4-((S)-pyrrolidine-2-carbonyl)-1, 4,5,6,7,8-hexahydro-pyrrolo [3,2-b] azepine-2- carbaldehyde as a light yellow solid.

[0461] MS m/z 260. 4 [M-1].

Example B-23.4- (1-Acetyl-piperidine-4-carbonyl)-1,4,5,6,7,8-hexahydro- pyrrolo[3,2-b]azepine-2-carbaldehyde [0462] To a mixture of l-acetyl-piperidine-4-carboxylic acid (822 mg, 4.8 mmol, 1.2 eq.), EDC (920 mg, 1.2 eq.), HOBt (648 mg, 1.2 eq.) in DCM (15 mL) was added TEA (1.3 mL, 2 eq.) and 1, 4, 5,6,7,8-hexahydro-pyrrolo [3,2-b] azepine (550 mg, 4 mmol). The mixture was stirred at rt for 2 days. The reaction was diluted with DCM, washed with water, sat. NaHC03, brine, dried and concentrated. The residue was purified on a silica gel column to give 1.1 g of 1-[4-(5, 6,7,8-tetrahydro-1H- pyrrolo [3,2-b] azepine-4-carbonyl)-piperidin-1-yl]-ethanone as a white solid.

[0463] MS m/z 290. 2 [M++1].

[0464] 1-[4-(5, 6,7,8-Tetrahydro-lH-pyrrolo [3,2-b] azepine-4-carbonyl)-piperidin-1- yl]-ethanone (1.1 g) was formylated with POC13 (186 pL, 1.2 eq.) and DMF using standard Vilsmierer condition to give 240 mg of 4- (l-acetyl-piperidine-4-carbonyl)- 1, 4,5,6,7,8-hexahydro-pyrrolo [3, 2-b] azepine-2-carbaldehyde as a gold colored solid.

[0465] MS m/z 318.2 [M++1].

Example B-24.4- (2-Pyrrolidin-1-yl-ethyl)-4, 5,6, 7-tetrahydro-1H-indole-2- carbaldehyde [0466] To a mixture of 1, 5,6,7-tetrahydro-4H-indol-4-one (2.7 g, 20 mmol) and tosyl chloride (3.8 g, 20 mmol) in THF (30 mL) was added DIPEA (5.3 mL, 30 mmol). After heating at 70 °C for 18 hours, the solvent was removed and the residue dissolved in ethyl acetate, washed (3x) with NaHCO3 (sat.). The solid was recrystallized to give 4.35 g of 1-(p-tosyl)-1, 5,6,7-tetrahydro-indol-4-one as a brown solid.

[0467] 1H NMR (400 MHz, DMSO-d6) 8 7.90 (d, 2H), 7.48 (d, 2H), 7.41 (d, 1H), 6.51 (d, 1H), 2.95 (t, 2H), 2.39 (s, 3H, CH3), 2.33 (t, 2H), 1.99 (m, 2H).

[0468] MS m/z 290 [M++1].

[0469] Triethyl phosphonoacetate (9.5 mL, 48 mmol) was added to sodium hydride (60%) suspended in THF (80 mL) at 0 °C, followed by 1-(p-tosyl)-1, 5,6,7-tetrahydro- indol-4-one (11.56 g, 40 mmol). The mixture was heated to reflux for 18 hours. The reaction was quenched with NH4C1 (sat.) and extracted with ethyl acetate. After washing with NaHC03 (sat.) and brine, the solvent was removed and the residue was recrystallized to give 8.2 g of as [1-(p-tosyl)-1, 5,6,7-tetrahydro-indol- (4E)-ylidene]- acetic acid ethyl ester a brown solid.

[0470] 1H NMR (400 MHz, DMSO-d6) 8 7.81 (d, 2H), 7.45 (d, 2H), 7.33 (d, 1H), 6.74 (d, 1H), 5.98 (br s, 1H), 4.04 (q, 2H), 2.88 (m, 2H), 2.78 (t, 2H), 2.37 (s, 3H.

CH3), 1.73 (m, 2H), 1.17 (t, 3H).

[0471] MS mlz 360 [M++1].

[0472] [1-(p-Tosyl)-1, 5,6,7-tetrahydro-indol- (4E)-ylidene]-acetic acid ethyl ester (6.2 g) was hydrogenated using 1% Pd-C (0.6 g) in methanol (280 mL) to give 6.5 g of [1- (p-tosyl)-4, 5,6,7-tetrahydro-lH-indol-4-yl]-acetic acid ethyl ester.

[0473] 1H NMR (400 MHz, DMSO-d6) 8 7.72 (d, 2H), 7.42 (d,. 2H), 7.21 (br d, 1H), 6.18 (br d, 1H), 4.04 (m, 2H), 2.86 (m, 1H), 2.58 (m, 3H), 2.36 (s, 3H, CH3), 2.23 (dd, 1H), 1.74 (m, 2H), 1.54 (m, 1H), 1.24 (m, 1H), 1.14 (t, 3H).

[0474] MS mlz 362 [M++1].

[0475] [1-(p-Tosyl)-4, 5,6, 7-tetrahydro-1H-indol-4-yl]-acetic acid ethyl ester (3 g) was hydrolyzed using NaOH (4N, 10 mL) in MeOH (10 mL) and THF (10 mL) at rt for 1 hour. The reaction was adjusted to pH 3 and extracted with ethyl acetate, dried and concentrated to give 2 g of [1- (p-tosyl)-4, 5,6,7-tetrahydro-lH-indol-4-yl]-acetic acid as a white solid.

[0476] 1H NMR (400 MHz, DMSO-d6) 8 7.71 (d, 2H), 7.42 (d, 2H), 7.18 (d, 1H), 6.21 (d, 1H), 2.83 (m, 1H), 2.56 (m, 2H), 2.45 (m, 1H), 2.36 (s, 3H, CH3), 2.07 (dd, 1H) 1.73 (m, 2H), 1.52 (m, 1H), 1.2 (m, 1H).

[0477] MS m/z 334 [M++1].

[0478] To a mixture of [1-(p-Tosyl)-4, 5,6,7-tetrahydro-1H-indol-4-yl]-acetic acid (1 g, 3 mmol), HOBt (486 mg, 1.2 eq.), EDC (690 mg, 1.2 eq.) in DMF (5 mL) was added TEA (1 mL, 2.5 eq.) and pyrrolidine (0.3 mL, 1.2 eq.). The mixture was stirred at rt for overnight. The reaction was diluted with DCM, washed with NaHC03, citric acid (3% aq.), water, brine, dried and concentrated. The residue was purified on a silica gel column to give 913 mg ofl-pyrrolidin-l-yl-2- [l- (toluene-4-sulibnyl)- 4,5,6, 7-tetrahydro-1H-indol-4-yl]-ethanone as a white semi-solid.

[0479]'H NMR (400 MHz, DMSO-d6) 8 7.73 (d, 2H), 7.43 (d, 2H), 7.19 (d, 1H), 6.17 (d, 1H), 3.3 (m, 4H), 2.92 (m, 1H), 2.58 (m, 2H), 2.44 (d, 1H), 3.77 (s, 3H, CH3), 2.18 (dd, 1H), 1.74 (m, 6H), 1.55 (m, 1H), 1.24 (m, 1H).

[0480] Pyrrolidin-1-yl-2- [1-(toluene-4-sulfonyl)-4, 5,6,7-tetrahydro-1H-indol-4-yl]- ethanone (840 mg) was reduced using lithium aluminum hydride (4 eq.) in THF (80 mL) at reflux for 5 hours to give 480 mg of mainly 4-(2-pyrrolidin-1-yl-ethyl)- 4,5,6, 7-tetrahydro-1H-indole as an oil.

[0481] MS m/z 373 [M++l].

[0482] 4- (2-Pyrrolidin-1-yl-ethyl)-4, 5,6, 7-tetrahydro-1H-indole (475 mg, 2.2 mmol) was formylated with POC13 (0.25 mL, 1.2 eq.) and DMF (2 ml) using standard Vilsmierer condition to give 250 mg of 4-(2-pyrrolidin-1-yl-ethyl)-4, 5,6,7-tetrahydro- lH-indole-2-carbaldehyde as alight yellow solid.

[0483] 1H NMR (400 MHz, DMSO-d6) 8 13.63 (br s, 1H, NH), 9.26 (s, 1H, CHO), 6.77 (s, 1H), 4.2 (br s, 1H), 3.15 (s, 2H), 2.5 (m, 6H), 1.83 (m, 3H), 1.68 (m, 4H), 1.57 (m, 1H), 1.50 (m, 1H), 1.27 (m, 1H).

[04841 MS m/z [M++1].

General procedure for 3,5-dimethyl-4-methylaminopyrrole aldehydes [0485] A mixture of 3, 5-dimethyl-lH-pyrrole-2-carbaldehyde (20 mmol) in THF (40 mL), water (20 mL), acetic acid (3 mL), formaldehyde (37% wt. % solution in water, 5 mL) and the appropriate amine (30 mL) was heated to reflux (oil bath 90-100 °C) for 6 hours. The reaction was concentrated to a volume of 30 mL, basified with 2N NaOH and extracted with ethyl acetate (2x150 mL) and DCM (4x 100 mL). The combined organic layers were concentrated and the residue was purified on a silica gel column to give the desired product.

Example B-25.4-(4-hydroxy-piperidin-1-ylmethyl)-3, 5-dimethyl-lH- pyrrole-2-carbaldehyde [0486] A mixture of 3, 5-dimethyl-1H-pyrrole-2-carbaldehyde (2.5 g, 20 mmol) in THF (40 mL), water (20 mL), acetic acid (3 mL), formaldehyde (37% wt. % solution in water, 5 mL) and the appropriate amine (30 mL) was heated to reflux (oil bath 90- 100 °C) for 6 hours and then stirred at rt for overnight. The reaction was concentrated to a volume of 30 mL, basified with 2N NaOH and extracted with ethyl acetate (2x150 mL) and DCM (4x100 mL). The combined organic layers were concentrated and the residue was purified on a silica gel column to give 2.3 g (49%) of 4- (4- hydroxy-piperidin-l-ylmethyl)-3, 5-dimethyl-1H-pyrrole-2-carbaldehyde as a solid.

10487]'H NMR (400 MHz, DMSO-d6) 8 11.50 (br s, 1H, NH), 9.43 (s, 1H, CHO), 4.50 (br s, 1H), 3.41 (v br s, 1H, OH), 3.15 (s, 2H), 2.60 (m, 2H), 2.22 (s, 3H, CH3), 2.16 (s, 3H, CH3), 1.94 (m, 2H), 1.66 (m, 2H), 1.27 (m, 2H). Example B-26. 3,5-Dimethyl-4-morpholin-4-ylmethyl-lH-pyrrole-2-' carbaldehyde [0488] A mixture of 3,5-dimethyl-1H-pyrrole-2-carbaldehyde (1.85 g, 15 mmol), di- morpholine-methane (5 mL, 27 mL) in THF (40 mL), water (15 mL) and acetic acid (4 mL) was heated to reflux (oil bath 90-95 °C) for 6 hours. The reaction was concentrated to a volume of 20 mL, basified with Na2C03 and extracted with ethyl acetate (3x75 mL). The combined extracts were dried, concentrated and the residue was purified on a silica gel column to give 2 g (36%) of 3, 5-dimethyl-4-morpholin-4- ylmethyl-lH-pyrrole-2-carbaldehyde as a solid.

[0489] 1H NMR (400 MHz, DMSO-d6) 8 11.51 (br s, 1H, NH), 9.44 (s, 1H, CHO), 3.51 (m, 4H), 3.19 (s, 2H), 2.28 (m, 4H), 2.23 (s, 3H, CH3), 2.17 (s, 3H, CH3).

Example B-27.3,5-Dimethyl-4- (1-methyl-1,2,3,6-tetrahydro-pyridin-4-yl)- 1H-pyrrole-2-carbaldehyde [0490] To a solution of 3, 5-dimethyl-lH-pyrrole-2-carboxylic acid ethyl ester (836 mg, 5 mmol) in acetic acid (10 mL) and TFA (5 mL) under nitrogen was added 1- methyl-piperidin-4-one (0.8 mL, 6.67 mmol). The mixture was then heated in a 95 °C oil bath for overnight. The reaction was concentrated, dissolved in ethyl acetate, washed with NaHCO3, brine, dried and concentrated. The residue was purified on a silica gel column to give 1.12 g (85%) of 3,5-dimethyl-4-(1-methyl-1, 2,3,6- tetrahydro-pyridin-4-yl)-lH-pyrrole-2-carboxylic acid ethyl ester.

[04911'H NMR (400 MHz, CDC13) 8 8.56 (s, 1H, NH), 5.49 (m, 1H), 4.29 (q, 2H), 3.09 (m, 2H), 2.63 (t, 2H), 2.41 (s, 3H, CH3), 2.34 (m, 2H), 2.26 (s, 3H, CH3), 2.21 (s, 3H, CH3), 1.34 (t, 3H).

[0492] MS m/z 263 [M++1].

[0493] A mixture of 3,5-dimethyl-4-(1-methyl-1, 2,3,6-tetrahydro-pyridin-4-yl)-lH- pyrrole-2-carboxylic acid ethyl ester (1.02 g, 3.9 mmol), KOH (0.287 g, 5.1 mmol) in water (5 mL) and methanol (10 mL) was heated to reflux under nitrogen for 3 days.

The cooled reaction was extracted with ethyl acetate (3x), dried and concentrated to give 380 mg of 4-(2, 4-dimethyl-lH-pyrrol-3-yl)-1-methyl-1, 2,3,6-tetrahydro- pyridine. The aqueous layer was adjusted to pH 7, the resulted precipitate was collected by filtration, washed with water to give 380mg of 4-(2, 4-dimethyl-lH- pyrrol-3-yl)-1-methyl-1, 2,3,6-tetrahydro-pyridine and 480 mg of 3, 5-dimethyl-4- (1- methyl-l, 2,3,6-tetrahydro-pyridin-4-yl)-1H-pyrrole-2-carboxylic acid.

10494] IH NMR (400 MHz, DMSO-d6) 8 10.05 (br s, 1H, NH), 6.25 (s, 1H), 5.30 (m, 1H), 2.92 (m, 2H), 2.48 (m, 2H), 2.24 (m, 2H), 2.23 (s, 3H, CH3), 2.06 (s, 3H, CH3), 1.88 (d, 3H, CH3).

[0495] Triethyl orthoformate (6 mL) was added to a solution of 4- (2, 4-dimethyl-lH- pyrrol-3-yl)-1-methyl-1, 2,3,6-tetrahydro-pyridine (360 mg) in TFA (6 mL) at 0 °C.

The mixture was stirred at 0 °C for 10 mins and then at rt for 40 mins. The solvent was removed and to the residue was added NaHC03, extracted with ethyl acetate, dried and concentrated to give 356 mg of 3,5-dimethyl-4-(1-methyl-1, 2,3,6- tetrahydro-pyridin-4-yl)-lH-pyrrole-2-carbaldehyde. [0496] 1H NMR (400 MHz, CDCl3) # 9. 49 (s, 1H, CHO), 9.10 (br s, 1H, NH), 5.52 (m, 1H), 3.12 (m, 2H), 2.66 (t, 2H), 2.43 (s, 3H), 2.35 (m, 2H), 2.26 (s, 3H), 2.24 (s, 3H).

Example B-28.3,5-Dimethyl-4- (1-methyl-piperidin-4-yl)-lH-pyrrole-2- carbaldehyde [0497] 3,5-Dimethyl-lH-pyrrole-2-carboxylic acid ethyl ester (7.97 g) in methanol (200 mL) and acetic acid (5 mL) was hydrogenated using 10% Pd-C at rt overnight to give 10.25 g of 3, 5-dimethyl-4- (l-methyl-piperidin-4-yl)-lH-pyrrole-2-carboxylic acid ethyl ester as acetic acid salt.

[0498] IH NMR (400 MHz, DMSO-d6) 8 10.97 (br s, 1H, NH), 4.15 (q, 2H), 2.84 (m, 2H), 2.35 (m, 1H), 2.20 (s, 3H, CH3), 2.18 (s, 3H, CH3), 2.15 (s, 3H, CH3), 1.95 (m, 2H), 1.82 (m, 2H), 1.47 (m, 2H), 1.23 (t, 3H).

[0499] MS m/z 265 {M++1].

[0500] A solution of 3,5-dimethyl-4- (1-methyl-piperidin-4-yl)-lH-pyrrole-2- carboxylic acid ethyl ester, di-acetic acid salt (4.87 g, 12.67 mmol), LiOH (1.8 g, 75 mmol) in methanol (20 mL) and water (10 mL) was heated in a 90 °C oil bath for 6 hours. The cooled reaction was adjusted to pH 7 with 6N HC1 and concentrated to give 3,5-dimethyl-4- (l-methyl-piperidin-4-yl)-lH-pyrrole-2-carboxylic acid, LiCl salt. This was used in the next step without further purification.

[0501] A solution of 3v5-dimethyl-4-(l-methyl-piperidin-4-yl)-lH-pyrrole-2- carboxylic acid (12.67 mmol) in TFA (75 mL) was stirred at 0 °C for 30 mins. To the mixture was added triethyl orthoformate (20 mL), it was then allowed to warm up slowly to rt for 2 hours. The solvent was removed and to the residue was added NaHCO3, extracted with ethyl acetate, dried and concentrated to give 2.56 g of 3,5- dimethyl-4- (1-methyl-piperidin-4-yl)-lH-pyrrole-2-carbaldehyde as a light yellow solid.

[0502] IH NMR (400 MHz, DMSO-d6) 8 11.43 (br s, 1H, NH), 9.41 (s, 1H, CHO), 2.82 (m, 2H), 2.65 (m, 5H), 2.24 (s, 3H, CH3), 2.19 (s, 3H, CH3), 1.95 (m, 3H), 1.64 (m, 2H).

Example B-29. (2-Formyl-5-methyl-1H-pyrrol-3-yl)-acetic acid [0503] A solution of 3-ethoxycarbonylmethyl-5-methyl-lH-pyrrole-2-carboxylic- acid ethyl ester (7 g, 29.26 mmol), LiOH (7 g, 10 eq.) in methanol (90 mL) and water (30 mL) was heated in a 70 °C oil bath for 3 hours. The cooled reaction was adjusted to pH 3 with 3N HCl, the resulted precipitate was collected by filtration, washed with water and dried to give 4.67 g (87%) of 3-carboxymethyl-5-methyl-lH-pyrrole-2- carboxylic acid.

[0504] IH NMR (400 MHz, DMSO-d6) 8 11.88 (s, 2H, 2x COOH), 11.2 (s, 1H, NH), 5.68 (s, 1H), 3.6 (s, 2H), 2.14 (s, 3H, CH3).

[0505] MS m/z 182 [M-1].

[0506] A suspension of 3-carboxymethyl-5-methyl-lH-pyrrole-2-carboxylic acid (1.5,8.2 mmol) in TFA (6 mL) was heated under nitrogen in a 55 °C oil bath until all of the solid had dissolved and no more C02 gas given off. The reaction was cooled to 0 °C and used in the next step.

[0507] To a solution of (5-methyl-lH-pyrrol-3-yl)-acetic acid (8.2 mmol) in TFA (6 mL) at 0 °C was added triethyl orthoformate (6 mL), it was then at 0 °C for 10 mins and at rt for 0.5 hours. The reaction was poured into water, extracted with ethyl acetate, dried and concentrated. The residue was purified on a silica gel column to give 1.15 g (84%) of (2-formyl-5-methyl-lH-pyrrol-3-yl)-acetic acid.

10508] 'H NMR (400 MHz, DMSO-d6) 812. 26 (br s, 1H, COOH), 11.67 (s, 1H, NH), 9.41 (s, 1H, CHO), 5.90 (d, 1H), 3.64 (s, 2H), 2.18 (s, 3H, CH3).

Example B-30.5-Formyl-4- (3-methanesulfonyl-propyl)-2-methyl-lH- pyrrole-3-carboxylic acid [0509] Oxone (614 mg, 1 mmol) dissolved in water (2 mL) was added portionwise to a solution of 5-formyl-2-methyl-4- (3-methylsulfanyl-propyl)-1H pyrrole-3- carboxylic acid ethyl ester (269 mg, 1 mmol) in methanol (4 mL) cooled in an ice bath. The mixture was stirred for 3 hours, keeping the temp between 0 °C and rt. The reaction was diluted with 10 mL of water, the resulted precipitate was collected by vacuum filtration, washed with water and dried to give 95 mg of the desired product.

The water filtrate was extracted with ethyl acetate, dried and concentrated to give another 74 mg of the product. Total of 169 mg (56%) of 5-formyl-4- (3- methanesulfonyl-propyl)-2-methyl-lH-pyrrole-3-carboxylic acid ethyl ester was obtained.

[0510] IH NMR (400 MHz, DMSO-d6) 5 12.26 (br s, 1H, NH), 9.61 (s, 1H, CHO), 4.19 (q, 2H), 3.06 (m, 4H), 2.93 (s, 3H, CH3), 2.42 (s, 3H, CH3), 1.93 (m, 2H, 1. 27 (t, 3H).

[0511] Lithium hydroxide (179.6 mg, 7.5 mmol) was added to a suspension of 5- formyl-4- (3-methanesulfonyl-propyl)-2-methyl-lH-pyrrole-3-carboxylic acid ethyl ester (450 mg, 1.5 mmol) in methanol (6 mL) and water (6 mL). The mixture was heated under nitrogen in a 65 °C oil bath for 20 hours. The cooled reaction was adjusted to pH 2 using IN HCI, the resulted precipitate was collected by vacuum filtration, washed with water and dried to give 356 mg (87%) of 5-formyl-4- (3- methanesulfonyl-propyl)-2-methyl-lH-pyrrole-3-carboxylic acid.

[0512]'H NMR (400 MHz, DMSO-d6) 5 12.20 (br s, 2H, OH, NH), 9.59 (s, 1H, CHO), 3.07 (m, 4H), 2.92 (s, 3H, CH3), 2.41 (s, 3H, CH3), 1.96 (m, 2H).

General Procedure for the Synthesis of 3-Substituted 4-Aryl-1, 3-dihydro-indol-2- one R erz g Ni EFaYI XR + 10 N Ethanol \ H'' /N/N H H 10513] To a solution of 4-aryl-1, 3-dihydro-indol-2-one (1 molar equivalent) and pyrrole aldehyde (1 molar equivalent in ethanol (0.125 M) was added catalytic amount of piperidine. The reaction mixture was stirred at room temperature for three days, and a yellow solid product was precipitated out, or a yellow solution was observed. If it was precipitated out, the yellow solid product was filtered, washed by ethanol, and dried under high vacuum. If it was not precipitated, the product was purified on a silica gel column eluting with MeOH-CH2CI2. Example 1.2-Methyl-4- [3- (4-methyl-piperazin-1-yl)-propyl]-5- (2-oxo-4- phenyl-1,2-dihydro-indol-3-ylidenemethyl)-lH-pyrrole-3- carboxylic acid ethyl ester [0514] To a solution of 4-phenyl-1, 3-dihydro-indol-2-one (41.9 mg, 0.20 mmol) and 5-formyl-2-methyl-4-[3-(4-methyl-piperazin-1-yl)-propyl]-1H- pyrrole-3-carboxylic acid ethyl ester (64.2 mg, 0.20 mmol) in ethanol (1 mL) was added piperidine (0.1 mL). The reaction mixture was stirred at 70 °C for over-night. The solvent was evaporated and the residue was purified on a silica gel column eluting with MeOH- CH2CL2 1: 9 to provide 2-methyl-4- [3- (4-methyl-piperazin-1-yl)-propyl]-5- (2-oxo-4- phenyl-1, 2-dihydro-indol-3-ylidenemethyl)-1H-pyrrole-3-carboxylic acid ethyl ester as a yellow solid (30 mg, 29%).

[0515] 1H-NMR (400 MHz, DMSO-d6) # 13.85 (br s, 1H, pyrrole NH), 11.12 (br s, 1H, CONH), 7.53 (m, 3H, aromatic), 7.44 (m, 2H, aromatic), 7.21 (t, 1H, aromatic), 6.94 (d, 1H, aromatic), 6.89 (s, 1H, aromatic), 6.78 (d, 1H, aromatic), 4.24 (q, 2H, OCH2), 2.50 (m, 11H, 3xCH2+CH3), 2.33 (s, 3H, CH3), 2.10 (m, 4H, 2xCH2), 1.26 (m, 5H, CH2+CH3).

[0516] MS m/z 511 [M--1].

Example 2. 3-[3,5-Dimethyl-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrol -2- ylmethylenel-4-phenyl-1, 3-dihydro-indol-2-one [0517] To a solution of 4-phenyl-1, 3-dihydro-indol-2-one (41.9 mg, 0.20 mmol) and 3,5-dimethyl-4- (4-methyl-piperazine-1-carbonyl)-1H-pyrrole-2-carbaldehyde (49.9 mg, 0.20 mmol) in ethanol (1 mL) was added piperidine (0.1 mL). The reaction mixture was stirred at 70 °C for over-night. The solvent was evaporated and the residue was crystallized from EtOAc-hexanes to provide 3- [3, 5-dimethyl-4- (4- methyl-piperazine-1-carbonyl)-lH-pyrrol-2-ylmethylene]-4-phe nyl-1, 3-dihydro- indol-2-one as a yellow solid (50 mg, 57%).

10518] 1H-NMR (400 MHz, CD30D) 8 7.53 (m, 2H, aromatic), 7.47 (m, 1H, aromatic), 7.40 (m, 2H, aromatic), 7.18 (t, 1H, aromatic), 6.93 (d, 1H, aromatic), 6.87 (s, 1H, aromatic), 6.81 (d, 1H, aromatic), 3.71 (br s, 2H, CH2), 3.45 (br s, 2H, CH2), 2.42 (br s, 4H, 2xCH2), 2.30 (s, 3H, CH3), 2.28 (s, 3H, CH3), 1.60 (s, 3H, CH3).

[0519] MS m/z 441 [M++1].

Example 3. 2,4-Dimethyl-5- (2-oxo-4-phenyl-1, 2-dihydro-indol-3- ylidenemethyl)-lH-pyrrole-3-carboxylic acid (2-diethylamino- ethyl)-amide [0520] To a solution of 4-phenyl-1, 3-dihydro-indol-2-one (41.9 mg, 0.20 mmol) and 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylamino-ethyl0-amide (53. 1 mg, 0.20 mmol) in ethanol (1 mL) was added piperidine (0.1 mL). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide 2,4-dimethyl-5- (2-oxo-4-phenyl-1,2-dihydro-indol-3- ylidenemethyl)-lH-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide (51 mg, 56%) [0521] 1H-NMR (400 MHz, DMSO-d6) 8 13. 48 (br s, 1H, pyrrole NH), 11.03 (br s, 1H, CONH), 7.43 (m, 6H, aromatic), 7.18 (t, 1H, CONH), 7.18 (t, 1H, aromatic), 6.93 (m, 1H, aromatic), 6.77 (m, 2H, aromatic), 3.21 (m, 2H, CH2), 2.48 (m, 6H, 3xCH2), 2.38 (s, 3H, CH3), 1.66 (s, 3H, CH3), 0.87 (t, 6H, 2xCH3).

[0522] MS m/z 455 [M--1].

Example 4.3- [3, 5-Dimethyl-4- (4-methyl-piperazine-1-carbonyl)-lH-pyrrol-2- ylmethylene]-4- (4-fluoro-phenyl)-1, 3-dihydro-indol-2-one [0523] To a solution of 4- (4-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 3,5-dimethyl-4- (4-methyl-piperazine-1-carbonyl)-1H pyrrole-2- carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide 3- [3, 5-Dimethyl-4- (4-methyl-piperazine-1-carbonyl)- 1H-pyrrol-2-ylmethylene]-4- (4-fluoro-phenyl)-1, 3-dihydro-indol-2-one as a yellow solid (63.9 mg, 56%) [0524] 'H-NMR (400 MHz, DMSO-d6) 8 13.45 (br s, 1H, pyrrole NH), 11.04 (br s, 1H, CONH), 7.47 (m, 2H, aromatic), 7.39 (m, 2H, aromatic), 7.19 (t, 1H, aromatic), 6.92 (m, 1H, aromatic), 6.79 (m, 1H, aromatic), 6.71 (s, 1H, aromatic), 3.31 (s, 4H, 2xCH2), 2.38 (m, 7H, 2xCH2+CH3), 2.17 (s, 3H, CH3), 1.60 (s, 3H, CH3).

[0525] MS m/z 457 [M--1].

Example 5.5- [4- (4-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide [0526] To a solution of 4- (4-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino- ethyl)-amide (69.0 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide 5-[4-(4-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide as a yellow solid (82.9 mg, 70%) [0527] 'H-NMR (400 MHz, DMSO-d6) 8 13.47 (br s, 1H, pyrrole), 11.04 (br s, 1H, CONH), 7.46 (m, 2H, aromatic), 7.38 (m, 2H, aromatic), 7.32 (t, 1H, CONH), 7.18 (t, 1H, aromatic), 6.93 (m, 1H, aromatic), 6.79 (m, 1H, aromatic), 6.71 (s, 1H, aromatic), 3.20 (m, 2H, CH2), 2.49 (m, 6H, 3xCH2), 2.39 (s, 3H, CH3), 1.74 (s, 3H, CH3), 0.95 (t, 6H, 2xCH3).

[0528] MS m/z 473 [M--1].

Example 6.5- [4- (4-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyll- 2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl- ethyl)-amide [0529] To a solution of 4- (4-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl- ethyl)-amide (68. 5 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (4-fluoro-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-car boxylic acid (2- pyrrolidin-l-yl-ethyl)-amide as a yellow solid (90.0 mg, 76%).

[0530]'H-NMR (400 MHz, DMSO-d6) 8 13.46 (br s, 1H, pyrrole NH), 11.04 (br s, 1H, CONH), 7. 42 (m, 5H, aromatic+CONH), 7.18 (t, 1H, aromatic), 6.92 (m, 1H, aromatic), 6.79 (m, 1H, aromatic), 6.71 (s, 1H, aromatic), 3.32 (m, 2H, CH2), 2.49 (m, 2H, CH2), 2.45 (m, 4H, 2xCH2), 2.38 (s, 3H, CH3), 1.73 (s, 3H, CH3), 1.67 (m, 4H 2xCH2).

10531] MSm/z471 [r-1].

Example 7.5- [4- (4-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 2,4-dimethyl-lH-pyrrole-3-carboxylic acid (2- [1,2,3] triazol-1-yl- ethyl)-amide [0532] To a solution of 4- (4-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2-[1,2, 3] triazol-1- yl-ethyl)-amide (67.9 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (4-Fluoro-phenyl)-2-oxo- 1, 2-dihydro-indol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-c arboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide as a yellow solid (42.8 mg, 36%).

[0533] 'H-NMR (400 MHz, DMSO-d6) 8 13.47 (br s, 1H, pyrrole NH), 11.04 (br s, 1H, CONH), 8. 10 (m, 1H, aromatic), 7.71 (m, 1H, aromatic), 7.61 (m, 1H, CONH), 7.60 (m, 2H, aromatic), 7.38 (m, 2H, aromatic), 7.20 (m, 1H, aromatic), 6.93 (m, 1H, aromatic), 6.78 (m, 1H, aromatic), 6.70 (s, 1H, aromatic), 4.53 (m, 2H, CH2), 3.63 (m, 2H, CH2), 2.30 (s, 3H, CH3), 1.65 (s, 3H, CH3). MS mlz 469 [M :-1].

Example 8.4- (4-Fluoro-phenyl)-3- 5-methyl-3- (4-methyl-piperazine-1- carbonyl)-lH-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one [0534] To a solution of 4- (4-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 5-methyl-3-(4-methyl-piperazine-1-carbonyl)-1H-pyrrole-2-car baldehyde (61.2 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 4- (4-fluoro-phenyl)-3- [5-methyl-3- (4-methyl- piperazine-l-carbonyl)-1H-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one as a yellow solid (44.1 mg, 40%).

[05335 'H-NMR (400 MHz, DMSO-d6) 8 13.63 (br s, 1H, pyrrole NH), 11.10 (br s, 1H, CONH), 7.40 (m, 2H, aromatic), 7.24 (m, 3H, aromatic), 6.97 (s, 1H, vinyl), 6.91 (m, 1H, aromatic), 6.75 (m, 1H, aromatic), 6.07 (s, 1H, aromatic), 3.44,3.30 (2xm, 4H, 2xCH2), 2.32 (s, 3H, CH3), 2.18 (m, 7H, 2xCH2+CH3).

[05361 MS m/z 443 [M--1].

Example 9. 2- [4- (4-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 5-methyl-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)- amide [0537] To a solution of 4- (4-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl- ethyl)-amide (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product as a yellow solid 2- [4- (4-fluoro-phenyl)- 2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]-5-methyl-1H-pyrrole-3-carbo xylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide (74.3 mg, 65%).

[0538] 1H-NMR (400 MHz, DMSO-d6) 5 13.84 (br s, 1H, pyrrole NH), 11.12 (br s, 1H, CONH), 7.98 (m, 2H, aromatic), 7.93 (s, 1H, aromatic), 7.73 (m, 1H, aromatic), 7.38 (m, 2H, aromatic), 7.23 (m, 3H, aromatic+CONH), 6.92 (m, 1H, aromatic), 6.77 (m, 1H, aromatic), 6.32 (m, 1H, aromatic), 4.53 (m, 2H, CH2), 3.63 (m, 2H, CH2), 2.30 (s, 3H, CH3), 1.65 (s, 3H, CH3).

[05391 MS m/z 455 [M Example 10.3- [3- ( (S)-3-Dimethylamino-pyrrolidine-1-carbonyl)-5-methyl-lH- pyrrol-2-ylmethylene]-4- (4-fluoro-phenyl)-1, 3-dihydro-indol-2-one [0540] To a solution of 4- (4-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 3- [3- ( S)-dimethylamino-pyrrolidine-l-carbonyl]-5-methyl-1H-pyrrole -2- carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3- [3- [3- (3S)-dimethylamino-pyrrolidine- 1-carbonyl]-5-methyl-lH-pyrrol-2-ylmethylene]-4- (4-fluoro-phenyl)-1, 3-dihydro- indol-2-one as a yellow solid (64.4 mg, 56%).

[05411 'H-NMR (400 MHz, DMSO-d6) 13.69 (br d, 1H, pyrrole NH), 11. 10 (br s, 1H, CONH), 7.40 (m, 2H, aromatic), 7.20 (m, 4H, aromatic), 6.92 (m, 1H, aromatic), 6.75 (m, 1H, aromatic), 6.20 (m, 1H, aromatic), 3.30 (m, 4H, 4XCH), 3.00 (m, 1H, CH), 2.60 (m, 1H, CH), 2.33 (s, 3H, CH3), 2.21 (s, 3H, CH3), 2.08 (s, 3H, CH3), 1.64 (m, 1H, CH).

10542] MS m/z 457 [M--1].

Example 11.3- [3- ( (R)-3-Dimethylamino-pyrrolidine-l-carbonyl)-5-methyl-lH- pyrrol-2-ylmethylene]-4- (4-fluoro-phenyl)-1, 3-dihydro-indol-2-one [0543] To a solution of 4- (4-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 3- [3- (3R)-dimethylamino-pyrrolidine-l-ca : bonyl]-5-methyl-1H-pyrrole-2- carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3- [3- [3- (3R)-dimethylamino-pyrrolidine- 1-carbonyl]-5-methyl-1H pyrrol-2-ylmethylene]-4- (4-fluoro-phenyl)-1, 3-dihydro- indol-2-one as a yellow solid (63.9,56%).

[05444 'H-NMR (400 MHz, DMSO-d6) 8 13.69 (br d, 1H, pyrrole NH), 11. 10 (br s, 1H, CONH), 7.40 (m, 2H, aromatic), 7.20 (m, 4H, aromatic), 6.92 (m, 1H, aromatic), 6.75 (m, 1H, aromatic), 6.20 (m, 1H, aromatic), 3.33 (m, 4H, 4XCH), 3.00 (m, 1H, CH), 2.60 (m, 1H, CH), 2.33 (s, 3H, CH3), 2.21 (s, 3H, CH3), 2.08 (s, 3H, CH3), 1.64 (m, 1H, CH).

[0545] MS m/z 457 [M--1].

Example 12.3- [3, 5-Dimethyl-4- (4-methyl-piperazine-1-carbonyl)-lH-pyrrol-2- ylmethylene]-4- (3-fluoro-phenyl)-1, 3-dihydro-indol-2-one [0546] To a solution of 4- (3-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 3,5-dimethyl-4-(4-methyl-piperazine-1-carbonyl)-lH-pyrrole-2 - carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide 3- [3, 5-dimethyl-4- (4-methyl-piperazine-1-carbonyl)- <BR> <BR> <BR> <BR> lH-pyrrol-2-ylmethylene]-4-(3-fluoro-phenyl)-1,3-dihydro-ind ol-2-one as a yellow solid (65 mg, 57%) [0547] 1H-NMR (400 MHz, DMSO-d6) 8 13. 45 (br s, 1H, pyrrole NH), 11.06 (br s, 1H, CONH), 7.59 (m, 1H, aromatic), 7.33 (m, 3H, aromatic), 7.20 (t, 1H, aromatic), 6.94 (d, 1H, aromatic), 6.80 (d, 1H, aromatic), 6.77 (s, 1H, aromatic), 3.38 (m, 4H, 2xCH2), 2.24 (m, 7H, 2xCH2+CH3), 2.16 (s, 3H, CH3), 1.59 (s, 3H, CH3).

[0548] MS m/z 459 [M++1].

Example 13.5- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diemthylamino-ethyl0- amide [0549] To a solution of 4- (3-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2-diethylamino- ethyl)-amide (69.0 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide 5- [4- (3-fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-2,4-dimethyl-lH-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide as a yellow solid (70 mg, 59%) [0550] 1H-NMR (400 MHz, DMSO-d6) 8 13.48 (br s, 1H, pyrrole NH), 11.07 (br s, 1H, CONH), 7.59 (m, 1H, aromatic), 7.32 (m, 4H, aromatic), 7.20 (t, 1H, CONH), 6.95 (d, 1H, aromatic), 6.80 (m, 2H, aromatic), 3.22 (m, 2H, CH2), 2.49 (m, 6H, 3xCH2), 2.39 (s, 3H, CH3), 1.73 (s, 3H, CH3), 0.95 (t, 6H, 2xCH3).

105511 MS m/z 475 [M++1]. Example 14.5-14-(3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyll- 2,4-dimethyl-lH-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl- ethyl)-amide [0552] To a solution of 4- (3-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl- ethyl)-amide (68.5 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (3-fluoro-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2- pyrrolidin-l-yl-ethyl)-amide as a yellow solid (56.4 mg, 48%).

[0553] 1H-NMR (400 MHz, DMSO-d6) 8 13.47 (br s, 1H, pyrrole NH), 11.06 (br s, 1H, CONH), 7.59 (m, 1H, aromatic), 7.46 (t, 1H, CONH), 7.34 (m, 3H, aromatic), 7.20 (t, 1H, aromatic), 6.95 (d, 1H, aromatic), 6.80 (m, 2H, aromatic), 3.27 (m, 2H, CH2), 2.50 (m, 2H, CH2), 2.45 (m, 4H, 2xCH2), 2.38 (s, 3H, CH3), 1.72 (s, 3H, CH3), 1.67 (m, 4H 2xCH2).

[0554] MS m/z 473 [M++1].

Example 15.5- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-[1, 2,3] triazol-1-yl- ethyl)-amide [0555] To a solution of 4- (3-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1- yl-ethyl)-amide (67.9 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (3-fluoro-phenyl)-2-oxo- 1,2-dihydro-indol-3-ylidenemethyl]-2,4-dimethyl-lH-pyrrole-3 -carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide as a yellow solid (49.9 mg, 42%).

0556] IH-NMR (400 MHz, DMSO-d6) 6 13. 47 (br s, 1H, pyrrole NH), 11.06 (br s, 1H, CONH), 8.10 (s, 1H, aromatic), 7.72 (m, 1H, aromatic), 7.63 (m, 2H, CONH+aromatic), 7.33 (m, 3H, aromatic), 7.20 (t, 1H, aromatic), 6.95 (d, 1H, aromatic), 6.80 (m, 2H, aromatic), 4.53 (m, 2H, CH2), 3.63 (m, 2H, CH2), 2.29 (s, 3H, CH3), 1.64 (s, 3H, CH3).

[0557] MS m/z 471 [M++1].

Example 16.3-13-((S)-3-Dimethylamino-pyrrolidine-1-carbonyl)-5-methy l-lH- pyrrol-2-ylmethylenel-4- (3-fluoro-phenyl)-1, 3-dihydro-indol-2-one [0558] To a solution of 4- (3-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0. 25 <BR> <BR> <BR> mmol) and 3-[(3S)-3-dimethylamino-pyrrolidine-1-carbonyl]-5-methyl-lH- pyrrole-2- carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3- [3- [ (3S)-3-dimethylamino-pyrrolidine- 1-carbonyl]-5-methyl-lH-pyrrol-2-ylmethylene]-4- (3-fluoro-phenyl)-1, 3-dihydro- indol-2-one as a yellow solid (60.9 mg, 53%).

05591 IH-NMR (400 MHz, DMSO-d6) 8 13.63 (br d, 1H, pyrrole NH), 11.12 (br s, 1H, CONH), 7.47 (m, 1H, aromatic), 7.21 (m, 5H, aromatic), 6.94 (d, 1H, aromatic), 6.77 (d, 1H, aromatic), 6.19 (m, 1H, aromatic), 3.30 (m, 4H, 4XCH), 3.00 (m, 1H, CH), 2.60 (m, 1H, CH), 2. 33 (s, 3H, CH3), 2.21 (s, 3H, CH3), 2.07 (s, 3H, CH3), 1.61 (m, 1H, CH).

[0560] MS m/z 459 [M++1].

Example 17.3-13-((R)-3-DimethyEamino-pyrrolidine-l-carbonyl)-5-methy l-lN- pyrrol-2-ylmethylene]-4-(3-fluoro-phenyl)-1,3-dihydro-indol- 2-one [0561] To a solution of 4-(3-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 3-[(3R)-3-dimethylamino-pyrrolidine-1-carbonyl]-5-methyl-1H- pyrrole-2- carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3- [3- [ (3R)-3-dimethylamino-pyrrolidine- 1-carbonyl]-5-methyl-lH-pyrrol-2-ylmethylene]-4-(3-fluoro-ph enyl)-1,3-dihydro- indol-2-one as a yellow solid (63.5,55%).

05621 IH-NMR (400 MHz, DMSO. d6) 6 13. 64 (br d, 1H, pyrrole NH), 11.12 (br s, 1H, CONH), 7.47 (m, 1H, aromatic), 7.22 (m, 5H, aromatic), 6.94 (d, 1H, aromatic), 6.78 (d, 1H, aromatic), 6.19 (m, 1H, aromatic), 3.31 (m, 4H, 4XCH), 3.00 (m, 1H, CH), 2.60 (m, 1H, CH), 2.33 (s, 3H, CH3), 2.21 (s, 3H, CH3), 2.07 (s, 3H, CH3), 1.61 (m, 1H, CH).

[0563] MS m/z 459 [M++1].

Example 18.5- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 2-methyl-4- [3- (4-methyl-piperazin-1-yl)-propyl]-lH-pyrrole-3- carboxylic acid ethyl ester [0564] To a solution of 4- (3-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 5-formyl-2-methyl-4- [3- (4-methyl-piperazin-1-yl)-propyl]-lH-pyrrole-3- carboxylic acid ethyl ester (80.3 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5-[4-(3-fluoro- phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]-2-methyl-4- [3- (4-methyl- piperazin-1-yl)-propyl]-1H-pyrrole-3-carboxylic acid ethyl ester as a yellow solid (60.9 mg, 53%).

[0565] 1H-NMR (400 MHz, DMSO-d6) 5 13.85 (br s, 1H, pyrrole NH), 11.33 (br s, 1H, CONH), 7.58 (m, 1H, aromatic), 7.32 (m, 3H, aromatic), 7.22 (t, 1H, aromatic), 6.95 (d, 1H, aromatic), 6.90 (m, 1H, aromatic), 6.80 (d, 1H, aromatic), 4.17 (q, 2H, OCH2), 3.30 (s, 1H, CH3), 2.26 (m, IOH, 5xCH2), 2.11 (s, 3H, CH3), 2.00 (m, 2H, CH2), 1.26 (m, 5H, CH2+CH3).

[05661 MS m/z 531 [M++1].

Example19.3- [3- (cis)-3, 5-Dimethyl-piperazine-l-carbonyl)-5-methyl-lH- pyrrol-2-ylmethylene]-4- (3-fluoro-phenyl)-1, 3-dihydro-indol-2-one [0567] To a solution of 4- (3-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 3-[(cis)-3,5-dimethyl-piperazine-1-carbonyl]-5-methyl-1H-pyr role-2- carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. The reaction solution was evaporated, and purified on a silica gel column eluting with MeOH- CH2C12 95: 5 to provide pure product 3- [3- [ (cis)-3, 5-Dimethyl-piperazine-1- carbonyl)]-5-methyl-1 H-pyrrol-2-ylmethylene]-4- (3-fluoro-phenyl)-1, 3-dihydro- indol-2-one as a yellow solid (74.5 mg, 65%).

[0568 'H-NMR (400 MHz, DMSO-d6) 6 13.60 (br s, 1H, pyrrole NH), 11.11 (brs, 1H, CONH), 7.48 (m, 1H, aromatic), 7.20 (m, 4H, aromatic), 6.94 (m, 2H, aromatic), 6.77 (d, 1H, aromatic), 6.06 (d, 1H, aromatic), 4.13 (m, 1H, CH), 3.41 (m, 1H, CH), 2.37 (m, 6H, CH+CH2+CH3), 2.05 (m, 1H, CH), 1.04 (m, 3H, CH3), 0.80 (m, 3H, CH3).

[05691 MS m/z 459 [M++1].

Example 20. 4-(4-Chloro-phenyl)-3-[3,5-dimethyl-4-(4-methyl-piperazine-1 - carbonyl)-lH-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one [0570] To a solution of 4-(4-chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 3,5-dimethyl-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrole-2 - carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide 4- (4-Chloro-phenyl)-3- [3, 5-dimethyl-4- (4-methyl- piperazine-1-carbonyl)-lH-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one as a yellow solid (54 mg, 45%) [0571]'H-NMR (400 MHz, DMSO-d6) 8 13.42 (br s, 1H, pyrrole NH), 11.05 (br s, 1H, CONH), 7.62 (d, 2H, aromatic), 7.45 (d, 2H, aromatic), 7.19 (t, 1H, aromatic), 6.95 (d, 1H, aromatic), 6.79 (d, 1H, aromatic), 6.66 (s, 1H, aromatic), 3.31 (m, 4H, 2xCH2), 2. 38 (m, 7H, 2xCH2+CH3), 2.17 (s, 3H, CH3), 1.60 (s, 3H, CH3).

[0572] MS m/z 475 [M++1].

Example 21.5- [4- (4-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyll- 2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-dimethylamino-ethyl)- amide [0573] To a solution of 4-(4-chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino- ethyl)-amide (69.0 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide 5- [4- (4-chloro-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide as a yellow solid (59.4 mg, 48%).

[05741 IH-NMR (400 MHz, DMSO-d6) 5 13.44 (br s, 1H, pyrrole NH), 11.05 (br s, 1H, CONH), 7.61 (m, 2H, aromatic), 7.44 (m, 2H, aromatic), 7.33 (t, 1H, CONH), 7. 19 (t, 1H, aromatic), 6.95 (m, 1H, aromatic), 6.80 (m, 1H, aromatic), 6.71 (s, 1H, aromatic), 3.20 (m, 2H, CH2), 2.49 (m, 6H, 3xCH2), 2.39 (s, 3H, CH3), 1.74 (s, 3H, CH3), 0.95 (t, 6H, 2xCH3).

[05751 MS m/Z 491 [M++1].

Example 22.5- [4- (4-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyll- 2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl- ethyl)-amide [0576] To a solution of 4- (4-chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl- ethyl)-amide (68.5 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (4-chloro-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- pyrrolidin-l-yl-ethyl)-amide as a yellow solid (54.9 mg, 45%).

(05777 'H-NMR (400 MHz, DMSO-d6) 8 13.43 (br s, 1H, pyrrole NH), 11.05 (br s, 1H, CONH), 7.61 (m, 2H, aromatic), 7.44 (m, 3H, aromatic), 7.19 (t, 1H, aromatic), 6.93 (m, 1H, aromatic), 6.79 (m, 1H, aromatic), 6.66 (s, 1H, aromatic), 3.30 (m, 2H, CH2), 2.50 (m, 2H, CH2), 2.47 (m, 4H, 2xCH2), 2. 38 (s, 3H, CH3), 1.73 (s, 3H, CH3), 1.67 (m, 4H 2xCH2).

[0578] MS m/z 489 [M++1]. Example 23.5- [4- (4-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyll- 2,4-dimethyl-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl- ethyl)-amide [0579] To a solution of 4-(4-chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1- yl-ethyl)-amide (67.9 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (4-chloro-phenyl)-2-oxo- 1, 2-dihydro-indol-3-ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide as a yellow solid (43.4 mg, 36%).

(0580] 1H-NMR (400 MHz, DMSO-d6) 8 13.44 (br s, 1H, pyrrole NH), 11.05 (br s, 1H, CONH), 8. 10 (m, 1H, aromatic), 7.71 (m, 1H, aromatic), 7.62 (m, 3H, aromatic), 7.46 (m, 2H, aromatic), 7.20 (m, 1H, aromatic), 6.93 (m, 1H, aromatic), 6.78 (m, 1H, aromatic), 6.65 (s, 1H, aromatic), 4.53 (m, 2H, CH2), 3.64 (m, 2H, CH2), 2.30 (s, 3H, CH3), 1.64 (s, 3H, CH3).

[0581] MS ntlz 487 [M++1].

Example 24. 4-(4-Chloro-phenyl)-3-[3-((S)-3-dimethylamino-pyrrolidine-1- carbonyl)-5-methyl-lH-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2- one [0582] To a solution of 4- (4-chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 3- [ (3S-3-dimethylamino-pyrrolidine-1-carbonyl]-5-methyl-1H-pyrr ole-2- carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 4-(4-Chloro-phenyl)-3-[3-(3S)-3- dimethylamino-pyrrolidine-l-carbonyl]-5-methyl-1H-pyrrol-2-y lmethylene]-1, 3- dihydro-indol-2-one as a yellow solid (60.1 mg, 51%).

0583] 1H-NMR (400 MHz, DMSO-d6) 8 13.71 (br d, 1H, pyrrole NH), 11.13 (br s, 1H, CONH), 7.47 (m, 2H, aromatic), 7.40 (m, 2H, aromatic), 7.27 (d, 1H, aromatic), 7.20 (t, 1H, aromatic), 6.93 (d, 1H, aromatic), 6.74 (m, 1H, aromatic), 6.20 (m, 1H, aromatic), 3.30 (m, 4H, 4XCH), 3.00 (m, 1H, CH), 2.60 (m, 1H, CH), 2.33 (s, 3H, CH3), 2.21 (s, 3H, CH3), 2.08 (s, 3H, CH3), 1.64 (m, 1H, CH).

[0584] MS m/z 475 [M++1].

Example25.4- (4-Chloro-phenyl)-3- [3- ( (R)-3-dimethylamino-pyrrolidine-1- carbonyl)-5-methyl-1H-pyrrol-2-ylmethylene]-1, 3-dihydro indol-2- one [0585] To a solution of 4- (4-chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 3- [ (3R)-3-dimethylamino-pyrrolidine-l-carbonyl]-5-methyl-lH-pyr role-2- carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 4- (4-chloro-phenyl)-3- [3- [ (3R)-3- dimethylamino-pyrrolidine-1-carbonyl)-5-methyl-1 H-pyrrol-2-ylmethylene]-1, 3- dihydro-indol-2-one as a yellow solid (44.8,38%).

[0586] 'H-NMR (400 MHz, DMSO-d6) 8 13.72 (br d, 1H, pyrrole NH), 11. 13 (br s, 1H, CONH), 7.47 (m, 2H, aromatic), 7.40 (m, 2H, aromatic), 7.26 (d, 1H, aromatic), 7.20 (t, 1H, aromatic), 6.92 (m, 1H, aromatic), 6.73 (m, 1H, aromatic), 6.22 (m, 1H, aromatic), 3.33 (m, 4H, 4XCH), 3.00 (m, 1H, CH), 2.60 (m, 1H, CH), 2.33 (s, 3H, CH3), 2.21 (s, 3H, CH3), 2.08 (s, 3H, CH3), 1.64 (m, 1H, CH).

[0587] MS m/z 475 [M++1]. Example 26.5- [4- (4-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 2-methyl-4- [3- (4-methyl-piperazin-1-yl)-propyl]-IH-pyrrole-3- carboxylic acid ethyl ester 10588] To a solution of 4- (4-chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 5-formyl-2-methyl-4- [3- (4-methyl-piperazin-1-yl)-propyl]-lH-pyrrole-3- carboxylic acid ethyl ester (80.3 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (4-chloro- phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]-2-methyl-4- [3- (4-methyl- piperazin-l-yl)-propyl]-lH-pyrrole-3-carboxylic acid ethyl ester as a yellow solid (38. 8 mg, 28%).

105891'H-NMR (400 MHz, DMSO-d6) 8 13.88 (br s, 1H, pyrrole NH), 11.17 (br s, 1H, CONH), 7.60 (m, 2H, aromatic), 7.50 (m, 2H, aromatic), 7.22 (t, 1H, aromatic), 6.94 (m, 2H, aromatic), 6.77 (d, 1H, aromatic), 4.17 (q, 2H, OCH2), 3.30 (s, 1H, CH3), 2.25 (m, IOH, 5xCH2), 2.11 (s, 3H, CH3), 2.06 (m, 2H, CH2), 1.26 (m, 5H, CH2+CH3).

10590] MS m/z 547 [M++1].

Example27.4- (4-Chloro-phenyl)-3- [3- (cis)-3, 5-dimethyl-piperazine-l- carbonyl)-5-methyl-lH-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2- one [0591] To a solution of 4- (4-chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 3-[(cis)-3, 5-dimethyl-piperazine-1-carbonyl]-5-methyl-lH-pyrrole-2- carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3- [3- [ (cis)-3, 5-dimethyl-piperazine-1- carbonyl)]-5-methyl-1H-pyrrol-2-ylmethylene]-4-(4-chloro-phe nyl)-1, 3-dihydro- indol-2-one as a yellow solid (22.1 mg, 19%).

[0592] 1H-NMR (400 MHz, DMSO-d6) 8 13.7 0 (br s, 1H, pyrrole NH), 11.13 (br s, 1H, CONH), 7.47 (m, 2H, aromatic), 7.40 (m, 2H, aromatic), 7.20 (t, 1H, aromatic), 7.08 (s, 1H, aromatic), 6.93 (m, 1H, aromatic), 6.73 (d, 1H, aromatic), 6.07 (m, 1H, aromatic), 4.20 (m, 1H, CH), 3.43 (m, 2H, CH2), 2.33 (m, 5H, CH2+CH3), 2.05 (m, 1H, CH), 1.04 (m, 3H, CH3), 0.80 (m, 3H, CH3).

[0593] MS m/z 475 [M++1].

Example 28. 4- (3-Chloro-phenyl)-3- [3, 5-dimethyl-4- (4-methyl-piperazine-l- carbonyl)-lH-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one [0594] To a solution of 4- (3-chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 3, 5-dimethyl-4-(i-methyl-piperazine-1-carbonyl)-lH-pyrrole-2- carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide 3- [3, 5-dimethyl-4- (4-methyl-piperazine-1-carbonyl)- 1H pyrrol-2-ylmethylene]-4- (3-chloro-phenyl)-1, 3-dihydro-indol-2-one as a yellow solid (61 mg, 51%) [0595] IH-NMR (400 MHz, DMSO-d6) 6 13.45 (br s, 1H, pyrrole NH), 11.06 (br s, 1H, CONH), 7.57 (m, 2H, aromatic), 7.53 (m, 1H, aromatic), 7.20 (t, 1H, aromatic), 6.95 (d, 1H, aromatic), 6.80 (d, 1H, aromatic), 6.77 (s, 1H, aromatic), 3.30 (m, 4H, 2xCH2), 2.24 (m, 7H, 2xCH2+CH3), 2.17 (s, 3H, CH3), 1.61 (s, 3H, CH3).

[0596] MS m/z 475 [M++1]. <BR> <BR> <BR> <BR> <BR> <BR> <P>Exmanle 29. 5- [4- (3-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide [0597] To a solution of 4- (3-chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2-diethylamino- ethyl)-amide (69.0 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. The reaction solution was evaporated, and purified on a silica gel column eluting with MeOH- CH2CI2 5: 95 to provide pure product 5- [4- (3-chloro-phenyl)-2-oxo-1, 2-dihydro-indol- 3-ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide as a yellow solid (73 mg, 59%) 10598] 1H-NMR (400 MHz, DMSO-d6) 5 13.51 (br s, 1H, pyrrole NH), 11.09 (br s, 1H, CONH), 7.69 (m, 1H, aromatic), 7.57 (m, 2H, ar@matic), 7.53 (m, 1H, aromatic), 7.41 (m, 1H, aromatic), 7.21 (t, 1H, aromatic), 6.96 (d, 1H, aromatic), 6.80 (m, 2H, aromatic), 3.22 (m, 2H, CH2), 2.49 (m, 6H, 3xCH2), 2.42 (s, 3H, CH3), 1.76 (s, 3H, CH3), 0. 80 (t, 6H, 2xCH3).

[0599] MS tnlz 491 [M++1].

Example 30.5- [4- (3-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyll- 2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl- ethyl)-amide [0600] To a solution of 4- (3-chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl- ethyl)-amide (68. 5 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. The reaction solution was evaporated, and purified on a silica gel column eluting with MeOH- CH2CI2 5: 95 to provide pure product 5- [4- (3-chloro-phenyl)-2-oxo-1, 2-dihydro-indol- 3-ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl- ethyl)-amide as a yellow solid (75 mg, 61%).

[0601]'H-NMR (400 MHz, DMSO-d6) 8 13.48 (br s, 1H, pyrrole NH), 11.06 (br s, 1H, CONH), 7.66 (m, 1H, aromatic), 7.58 (m, 2H, aromatic), 7.52 (s, 1H, aromatic), 7.47 (t, 1H, CONH), 7.04 (m, 2H, aromatic), 7.20 (t, 1H, aromatic), 6.95 (d, 1H, aromatic), 6.80 (d, 1H, aromatic), 6.78 (s, 1H, aromatic), 3.30 (m, 2H, CH2), 2.50 (m, 2H, CH2), 2.45 (m, 4H, 2xCH2), 2. 38 (s, 3H, CH3), 1.74 (s, 3H, CH3), 1.67 (m, 4H 2xCH2).

[0602] MS m/z 489 [M++1].

Exmaple 31. 5-[4-(3-Chloro-phenyl)-2-oxo-1,2-dihydro-indol-3-ylidenemeth yl]- 2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-[1, 2,3] triazol-1-yl- ethyl)-amide [0603] To a solution of 4- (3-chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1- yl-ethyl)-amide (67.9 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (3-chloro-phenyl)-2-oxo- 1,2-dihydro-indol-3-ylidenemethyl]-2,4-dimethyl-lH-pyrrole-3 -carboxylic acid (2- [1,2,3] triazol-1-yl-ethyl)-amide as a yellow solid (54 mg, 44%).

[0604] 1H-NMR (400 MHz, DMSO-d6) 8 13.48 (br s, 1H, pyrrole NH), 11.07 (br s, 1H, CONH), 8.10 (m, 1H, aromatic), 7.72 (s, 1H, aromatic), 7.64 (t, 1H, CONH), 7.58 (m, 2H, aromatic), 7.52 (m, 1H, aromatic), 7.41 (m, 1H, aromatic), 7.20 (t, 1H, aromatic), 6.94 (d, 1H, aromatic), 6.80 (d, 1H, aromatic), 6.77 (s, 1H, aromatic), 4.53 (m, 2H, CH2), 3.64 (m, 2H, CH2), 2.29 (s, 3H, CH3), 1.66 (s, 3H, CH3).

[0605] MS m/z 487 [M++1].

Example32.4- (3-Chloro-phenyl)-3- [3- ( (S)-3-dimethylamino-pyrrolidine-l- carbonyl)-5-methyl-1H-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2- one [0606] To a solution of 4- (3-chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 3- [ (3S)-3-dimethylamino-pyrrolidine-1-carbonyl]-5-methyl-lH-pyr role-2- carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 4- (3-Chloro-phenyl)-3- [3- [ (3S)-3- dimethylamino-pyrrolidine-l-carbonyl)-5-methyl-1H-pyrrol-2-y lmethylene]-1, 3- dihydro-indol-2-one as a yellow solid (70 mg, 59%).

[0607] 1H-NMR (400 MHz, DMSO-d6) # 13.64 (br d, 1H, pyrrole NH), 11.12 (brs, 1H, CONH), 7.50 (m, 2H, aromatic), 7.41 (s, 1H, aromatic), 7.36 (m, 1H, aromatic), 7.21 (m, 2H, aromatic), 6.94 (d, 1H, aromatic), 6.78 (d, 1H, aromatic), 6.21 (m, 1H, aromatic), 3.54,3.26 (2xm, 1H, CH), 3.39 (m, 2H, CH2), 3.04 (m, 1H, CH), 2.60 (m, 1H, CH), 2.33 (s, 3H, CH3), 2.23 (s, 3H, CH3), 2.08 (s, 3H, CH3), 1.96 (m, 1H, CH), 1.63 (m, 1 H, CH).

[0608] MS m/z 475 [M++1].

Example33.4- (3-Chloro-phenyl)-3- [3- ( (R)-3-dimethylamino-pyrrolidine-1- carbonyl)-5-methyl-lH-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2- one [0609] To a solution of 4- (3-chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 3-[(3R)-3-dimethylamino-pyrrolidine-1-carbonyl]-5-methyl-1H- pyrrole-2- carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 4- (3-chloro-phenyl)-3- [3- [ (3R)-3- dimethylamino-pyrrolidine-1-carbonyl)-5-methyl-1H-pyrrol-2-y lmethylene]-1, 3- dihydro-indol-2-one as a yellow solid (71 mg, 60%).

[0610]'H-NMR (400 MHz, DMSO-d6) 8 13.63 (br m, 1H, pyrrole NH), 11.12 (br s, 1H, CONH), 7.45 (m, 2H, aromatic), 7.41 (s, 1H, aromatic), 7.36 (m, 1H, aromatic), 7.21 (m, 2H, aromatic), 6.94 (d, 1H, aromatic), 6.78 (d, 1H, aromatic), 6.21 (m, 1H, aromatic), 3.54,3.26 (2xm, 1H, CH), 3.39 (m, 2H, CH2), 3.04 (m, 1H, CH), 2.60 (m, 1H, CH), 2.33 (s, 3H, CH3), 2.23 (s, 3H, CH3), 2.08 (s, 3H, CH3), 1.96 (m, 1H, CH), 1.63 (m, 1H, CH).

[0611] MS m/z 475 [M++1].

Example 34.2- [4- (3-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 5-methyl-1H-pyrrole-3-carboxylic acid (2-[1, 2,3] triazol-1-yl-ethyl)- amide [0612] To a solution of 4-(3-chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl- ethyl)-amide (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 2- [4- (3-chloro-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxy lic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide as a yellow solid (64 mg, 54%).

[0613] 'H-NMR (400 MHz, DMSO-d6) 8 13.82 (br s, 1H, pyrrole NH), 11.14 (br s, 1H, CONH), 8.02 (m, 3H, aromatic), 7.74 (s, 1H, aromatic), 7.46 (m, 2H, aromatic), 7.40 (m, 1H, aromatic), 7.33 (m, 1H, aromatic), 7.22 (t, 1H, aromatic), 6.94 (d, 1H, aromatic), 6.78 (d, 1H, aromatic), 6.34 (m, 1H, aromatic), 4.51 (m, 2H, CH2), 3.50 (m, 2H, CH2), 2.31 (s, 3H, CH3).

[0614] MS m/z 473 [M++1].

Example35.4- (3-Chloro-phenyl)-3- [3- ( (cis)-3, 5-dimethyl-piperazine-1- carbonyl)-5-methyl-lH-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2- one [0615] To a solution of 4- (3-chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 3-[(cis)-3,5-dimethyl-piperazine-1-carbonyl]-5-methyl-1H-pyr role-2- carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. The reaction solution was evaporated, and purified on a silica gel column eluting with MeOH- CH2CI2 5: 95to provide pure product 3-[3-[(cis-3,5-dimethyl-piperazine-1-carbonyl)]- <BR> <BR> <BR> 5-methyl-lH-pyrrol-2-ylmethylene]-4-(3-chloro-phenyl)-1,3-di hydro-indol-2-one as a yellow solid (67 mg, 56%).

[0616]'H-NMR (400MHz, DMSO-) 8 13.60 (br s, 1H, pyrrole NH), 11.12 (br s, 1H, CONH), 7.45 (m, 2H, aromatic), 7.40 (s, 1H, aromatic), 7.33 (m, 1H, aromatic), 7.20 (t, 1H, aromatic), 6.94 (m, 2H, aromatic), 6.77 (d, 1H, aromatic), 6.06 (m, 1H, aromatic), 4.13 (m, 1H, CH), 3.32 (m, 1H, CH), 2.39 (m, 6H, CH+CH2+CH3), 2.05 (m, 1H, CH), 1.04 (m, 3H, CH3), 0.80 (m, 3H, CH3). MS m/z 475 [M++1].

Example 36. 3-[3,5-Dimethyl-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrol -2- ylmethylenel4-(4-methoxy-phenyl)-1, 3-dihydro-indol-2-one [0617] To a solution of 4- (4-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 3,5-dimethyl-4-(4-methyl-piperazine-1-carbonyl)-lH-pyrrole-2 - carbaldehyde (64.8 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide 3- [3, 5-dimethyl-4- (4-methyl-piperazine-1-carbonyl)- 1H-pyrrol-2-ylmethylene]-4- (4-methoxy-phenyl)-1, 3-dihydro-indol-2-one as a yellow solid (85 mg, 72%) [0618] 'H-NMR (400 MHz, DMSO-d6) 8 13.42 (br s, 1H, pyrrole NH), 10.98 (br s, 1H, CONH), 7.30 (m, 2H, aromatic), 7.15 (t, 1H, aromatic), 7.10 (m, 2H, aromatic), 6.89 (d, 1H, aromatic), 6.76 (m, 2H, aromatic), 3.80 (s, 3H, OCH3), 3.31 (m, 4H, 2xCH2), 2.22 (m, 7H, 2xCH2+CH3), 2.15 (s, 3H, CH3), 1.60 (s, 3H, CH3).

[0619] MS m/z 471 [M++1].

Example 37. 5- [4- (4-Methoxy-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyll-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- diethylamino-ethyl)-amide [0620] To a solution of 4- (4-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- diethylamino-ethyl)-amide (69.0 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide 5- [4- (4-methoxy-phenyl)-2-oxo- 1, 2-dihydro-indol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-c arboxylic acid (2- diethylamino-ethyl)-amide as a yellow solid (87 mg, 72%).

[0621] 1H-NMR (400 MHz, DMSO-d6) 8 13.44 (br s, 1H, pyrrole NH), 10.98 (br s, 1H, CONH), 7.31 (m, 3H, aromatic), 7.16 (t, 1H, aromatic), 7.11 (m, 2H, aromatic), 6.90 (m, 1H, aromatic), 6.78 (m, 2H, aromatic), 3.82 (s, 3H, OCH3), 3.22 (m, 2H, CH2), 2.49 (m, 6H, 3xCH2), 2.39 (s, 3H, CH3), 1.73 (s, 3H, CH3), 0.95 (t, 6H, 2xCH3).

[0622] MS m/Z 487 [M++1].

Example 38.5- [4- (4-Methoxy-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- pyrrolidin-1-yl-ethyl)-amide [0623] To a solution of 4- (4-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1- yl-ethyl)-amide (68.5 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (4-Methoxy-phenyl)-2- oxo-1, 2-dihydro-indol-3-ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide as a yellow solid (86 mg, 71%).

[0624] 'H-NMR (400 MHz, DMSO-d6) 8 13.46 (br s, 1H, pyrrole NH), 10.99 (br s, 1H, CONH), 7.41 (m, 1H, CONH), 7.32 (m, 2H, aromatic), 7.16 (t, 1H, aromatic), 7. 11 (m, 2H, aromatic), 6.90 (m, 1H, aromatic), 6.78 (m, 2H, aromatic), 3.82 (s, 3H, OCH3), 3.28 (m, 2H, CH2), 2.50 (m, 2H, CH2), 2.46 (m, 4H, 2xCH2), 2.37 (s, 3H, CH3), 1.73 (s, 3H, CH3), 1.67 (m, 4H 2xCH2).

[0625] MS m/z 485 [M++1].

Example 39. 5- [4- (4-Methoxy-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide [0626] To a solution of 4- (4-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide (67.9 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (4-methoxy- phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3- carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide as a yellow solid (54 mg, 45%).

[0627] 1H-NMR (400 MHz, DMSO-d6) 8 13.47 (br s, 1H, pyrrole NH), 11.00 (br s, 1H, CONH), 8.10 (m, 1H, aromatic), 7.71 (m, 1H, aromatic), 7.60 (m, 1H, CONH), 7.31 (m, 2H, aromatic), 7.16 (t, 1H, aromatic), 7.10 (m, 2H, aromatic), 6.89 (m, 1H, aromatic), 6.78 (m, 2H, aromatic), 4.53 (m, 2H, CHa), 3.82 (s, 3H, OCH3), 3.63 (m, 2H, CH2), 2.29 (s, 3H, CH3), 1.61 (s, 3H, CH3).

[0628] MS m/z 483 [M++1].

Example 40.3- [4- ( (cis)-3, 5-Dimethyl-piperazine-l-carbonyl)-3, 5-dimethyl-lH- pyrrol-2-ylmethylene]-4-(4-methoxy-phenyl)-1, 3-dihydro-indol-2- one [0629] To a solution of 4- (4-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 4-[(cis)-3, 5-dimethyl-piperazine-1-carbonyl)-3, 5-dimethyl-lH- pyrrole-2-carbaldehyde (68.5 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3-[4-[(cis)-3,5-Dimethyl- piperazine-1-carbonyl)-3, 5-dimethyl-1H-pyrrol-2-ylmethylene]-4-(4-methoxy- phenyl)-1, 3-dihydro-indol-2-one as a yellow solid (88 mg, 73%).

[06301'H-NMR (400 MHz, DMSO-d6) 8 13.40 (br s, 1H, pyrrole NH), 10.99 (br s, 1H, CONH), 7.33 (m, 2H, aromatic), 7.16 (t, 1H, aromatic), 7.10 (m, 2H, aromatic), 6.90 (m, 1H, aromatic), 6.77 (m, 2H, aromatic), 3.80 (s, 3H, OCH3), 3.43 (m, 1H, CH), 2.52 (m, 1H, CH), 2.23 (m, 4H, 2xCH2), 1.57 (m, 3H, CH3), 1.04 (m, 3H, CH3), 0.90 (m, 6H, 2xCH3).

[0631] MS m/z 485 [M++1].

Example 41.2- [4- (4-Methoxy-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (2- pyrrolidin-1-yl-ethyl)-amide [06321 To a solution of 4-(4-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 2-Formyl-5-methyl-lH-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl- ethyl)-amide (64.8 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 2- [4- (4-Methoxy-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-5-methyl-1H-pyrrole-3-carboxy lic acid (2-pyrrolidin- 1-yl-ethyl)-amide as a yellow solid (90 mg, 77%).

[0633] 1H-NMR (400 MHz, DMSO-d6) 6 13.73 (br s, 1H, pyrrole NH), 11.05 (br s, 1H, CONH), 7.99 (s, 1H, aromatic), 7.67 (t, 1H, CONH), 7.26 (m, 2H, aromatic), 7.17 (t, 1H, aromatic), 6.98 (m, 2H, aromatic), 6.87 (m, 1H, aromatic), 6.74 (m, 1H, aromatic), 6.35 (m, 1H, aromatic), 3.81 (s, 3H, OCH3), 3.13 (m, 2H, CH2), 2.46 (m, 6H, 3xCH2), 2.31 (s, 3H, CH3), 1.68 (m, 4H 2xCH2).

[0634] MS m/z 471 [M'*+l].

Example 42. 2- [4- (4-Methoxy-phenyl)-2-oxo-1, 2-dihydro.-indol-3- ylidenemEthyl]-5-methyl-1H-pyrrole-3-carboxylic acid (2- [1,2,3] triazol-1-yl-ethyl)-amide [0635] To a solution of 4- (4-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 2-Formyl-5-methyl-1H-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1- yl-ethyl)-amide (64.8 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 2- [4- (4-Methoxy-phenyl)-2- oxo-1, 2-dihydro-indol-3-ylidenemethyl]-5-methyl-1H-pyrrole-3-carbo xylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide as a yellow solid (61 mg, 52%).

[0636] 1H-NMR (400 MHz, DMSO-d6) 8 13.84 (br s, 1H, pyrrole NH), 11.12 (br s, 1H, CONH), 7.98 (m, 3H, aromatic), 7.73 (s, 1H, aromatic), 7.27 (m, 2H, aromatic), 7.18 (t, 1H, aromatic), 6.99 (m, 2H, aromatic), 6.88 (m, 1H, aromatic), 6.75 (m, 1H, aromatic), 6.30 (m, 1H, aromatic), 4.47 (t, 2H, CH2), 3.75 (m, 3H, OCH3), 3.45 (m, 2H, CH2), 2.30 (s, 3H, CH3).

[0637] MS m/z 469 [M++1]. Example 43.3- [3- ( (35-3-Dimethylamino-pyrrolidine-l-carbonyl)-5-methyl-lH- pyrrol-2-ylmethylene]-4- (4-methoxy-phenyl)-1, 3-dihydro-indol-2- one [0638] To a solution of 4- (4-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 3-[(3s)-3-Dimethylamino-pyrrolidine-l-carbonyl]-5-methyl-lH- pyrrole-2-carbaldehyde (64.8 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3- [3- [ (3S)-3-dimethylamino- <BR> <BR> <BR> pyrrolidine-1-carbonyl)-5-methyl-1H-pyrrol-2-ylmethylene]-4- (4-methoxy-phenyl)- 1, 3-dihydro-indol-2-one as a yellow solid (94 mg, 80%).

[0639] 1H-NMR (400 MHz, DMSO-d6) 8 13.69 (br m, 1H, pyrrole NH), 11.10 (br s, 1H, CONH), 7.29 (m, 2H, aromatic), 7.18 (m, 2H, aromatic), 6.98 (m, 2H, aromatic), 6.88 (d, 1H, aromatic), 6.73 (d, 1H, aromatic), 6.15 (s, 1H, aromatic), 3.84 (m, 3H, OCH3), 3.32 (m, 1H, CH), 3.00 (4xm, 2H, 2xCH), 2.60 (m, 1H, CH), 2.55,2.00 (4xm, 2H, 2XCH), 2.33 (m, 3H, CH3), 2.19 (s, 3H, CH3), 2.05 (s, 3H, CH3), 1.64 (m, 1H, CH).

[0640] MS m/z 471 [M++1]. Example 44. 3-13-((R)-3-Dimethylamino-pyrrolidine-l-carbonyl)-5-methyl-l H-<BR> <BR> pyrrol-2-ylmethylene]-4- (4-methoxy-phenyl)-1, 3-dihydro-indol-2- one [0641] To a solution of 4- (4-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 3- [ (3R)-3-Dimethylamino-pyrrolidine-l-carbonyl]-5-methyl-1H- pyrrole-2-carbaldehyde (64.8 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3- [3- ( (R)-3-dimethylamino- <BR> <BR> <BR> pyrrolidine-1-carbonyl)-5-methyl-1H-pyrrol-2-ylmethylene]-4- (4-methoxy-phenyl)- 1, 3-dihydro-indol-2-one as a yellow solid (95 mg, 81%).

[0642] 1H-NMR (400 MHz, DMSO-d6) 8 13.69 (br d, 1H, pyrrole NH), 11.10 (br s, 1H, CONH), 7.29 (m, 2H, aromatic), 7.18 (m, 2H, aromatic), 6.98 (m, 2H, aromatic), 6.88 (d, 1H, aromatic), 6.73 (d, 1H, aromatic), 6.15 (s, 1H, aromatic), 3.84 (m, 3H, OCH3), 3.32 (m, 1H, CH), 3.00 (4xm, 2H, 2xCH), 2.52 (m, 1H, CH), 2.55 (m, 1H, CH), 2.00,1.90 (2xm, 1H, CH), 2.32 (m, 3H, CH3), 2.20 (s, 3H, CH3), 2.05 (s, 3H, CH3), 1.64 (m, 1 H, CH).

[0643] MS m/z 471 [M++1]. Example 45. 3-[3,5-Dimethyl-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrol -2- ylmethylene]-4- (3-methoxy-phenyl)-1, 3-dihydro-indol-2-one [0644] To a solution of 4-(3-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 3, 5-dimethyl-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrol-2- carbaldehyde (64.8 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. The reaction solution was evaporated, and purified on a silica gel column eluting with MeOH- CH2C12 5: 95 to provide 3-[3,5-dimethyl-4-(4-methyl-piperazine-1-carbonyl)-1H- pyrrol-2-ylmethylene]-4- (3-methoxy-phenyl)-1, 3-dihydro-indol-2-one as a yellow solid (62 mg, 53%) 106451'H-NMR (400 MHz, DMSO-d6) 8 13.45 (br s, 1H, pyrrole NH), 11.02 (br s, 1H, CONH), 7.46 (t, 1H, aromatic), 7.18 (t, 1H, aromatic), 7.04 (m, 1H, aromatic), 6.97 (m, 2H, aromatic), 6.92 (d, 1H, aromatic), 6.83 (s, 1H, aromatic), 6.80 (d, 1H, aromatic), 3.77 (s, 3H, OCH3), 3.30 (m, 4H, 2xCH2), 2.24 (m, 7H, 2xCH2+CH3), 2.17 (s, 3H, CH3), 1.58 (s, 3H, CH3).

10646] MS m/z 471 [M++1].

Example 46.5- [4- (3-Methoxy-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- diethylamino-ethyl)-amide [0647] To a solution of 4- (3-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- diethylamino-ethyl)-amide (69.0 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. The reaction solution was evaporated, and purified on a silica gel column eluting with MeOH-CH2CI2 5: 95 to provide 5- [4- (3-methoxy-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-car boxylic acid (2- diethylamino-ethyl)-amide as a yellow solid (94 mg, 78%).

[0648] 'H-NMR (400 MHz, DMSO-d6) 8 13.48 (br s, 1H, pyrrole NH), 11.02 (br s, 1H, CONH), 7.47 (t, 1H, aromatic), 7.35 (t, 1H, CONH), 7.19 (t, 1H, aromatic), 7.06 (m, 1H, aromatic), 6.98 (m, 2H, aromatic), 6.92 (d, 1H, aromatic), 6.88 (s, 1H, aromatic), 6.80 (d, 1H, aromatic), 3.77 (s, 1H, CH3), 3.25 (m, 2H, CH2), 2.38 (s, 3H, CH3), 2.50 (m, 6H, 3xCH2), 1.73 (s, 3H, CH3), 0.95 (t, 6H, 2xCH3).

[0649] MS m/z 487 [M++1].

Example 47.5- [4- (3-Methoxy-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- pyrrolidin-1-yl-ethyl)-amide [0650] To a solution of 4- (3-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1- yl-ethyl)-amide (68. 5 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. The reaction solution was evaporated, and purified on a silica gel column eluting with MeOH-CH2CI2 5: 95 to provide pure product 5- [4- (3-Methoxy-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2- pyrrolidin-l-yl-ethyl)-amide as a yellow solid (97 mg, 80%).

[0651] IH-NMR (400 MHz, DMSO-d6) 8 13.48 (br s, 1H, pyrrole NH), 11.01 (br s, 1H, CONH), 7.50 (m, 2H, aromatic), 7.17 (t, 1H, aromatic), 7.11 (m, 1H, aromatic), 6.97 (m, 2H, aromatic), 6.92 (d, 1H, aromatic), 6.87 (s, 1H, aromatic), 6.80 (d, 1H, aromatic), 3.78 (s, 3H, OCH3), 3.30 (m, 2H, CH2), 2.50 (m, 6H, 3xCH2), 2.37 (s, 3H, CH3), 1.70 (s, 3H, CH3), 1.68 (m, 4H 2xCH2).

10652] MS m/z 485 [M++1].

Example 48.5- [4- (3-Methoxy-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide [0653] To a solution of 4- (3-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide (67.9 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (3-methoxy- phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3- carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide as a yellow solid (18 mg, 15%).

106541'H-NMR (400 MHz, DMSO-d6) 8 13.47 (br s, 1H, pyrrole NH), 11.02 (br s, 1H, CONH), 8.10 (s, 1H, aromatic), 7.71 (s, 1H, aromatic), 7.62 (t, 1H, CONH), 7.46 (t, 1H, aromatic), 7.16 (t, 1H, aromatic), 7.07 (m, 1H, aromatic), 6.97 (m, 2H, aromatic), 6.95 (d, 1H, aromatic), 6.84 (s, 1H, aromatic), 6.80 (d, 1H, aromatic), 4.53 (m, 2H, CH2), 3.78 (s, 3H, OCH3), 3.63 (m, 2H, CH2), 2.29 (s, 3H, CH3), 1.61 (s, 3H, CH3).

[0655] MS tnlz 483 [M++1].

Example 49. 3- [4- ( (cis)-3, 5-Dimethyl-piperazine-l-carbonyl)-3, 5-dimethyl-lH- pyrrol-2-ylmethylene]-4- (3-methoxy-phenyl)-1, 3-dihydro-indol-2- one [0656] To a solution of 4- (3-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 4-[(cis)-3, 5-dimethyl-piperæine-1-carbonyl)-3, 5-dimethyl-lH- pyrrole-2-carbaldehyde (68.5 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. The reaction solution was evaporated, and purified on a silica gel column eluting with MeOH-CH2C12 5: 95 to provide pure product 3-[4-((cis)-3,5-Dimethyl-piperazine-1- carbonyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-4- (3-methoxy-phenyl)-1,3- dihydro-indol-2-one as a yellow solid (95 mg, 79%).

[0657] 1H-NMR (400 MHz, DMSO-d6) 8 13.40 (br s, 1H, pyrrole NH), 11.00 (br s, 1H, CONH), 7.46 (t, 1H, aromatic), 7.17 (t, 1H, aromatic), 7.05 (m, 1H, aromatic), 6.98 (m, 2H, aromatic), 6.92 (d, 1H, aromatic), 6.85 (s, 1H, aromatic), 6.80 (d, 1H, aromatic), 3.80 (s, 3H, OCH3), 3.43 (m, 1H, CH), 2.52 (m, 1H, CH), 2.23 (m, 4H, 2xCH2), 1.57 (m, 3H, CH3), 1.04 (m, 3H, CH3), 0.90 (m, 6H, 2xCH3).

[06581 MS m/z 485 [M++1].

Example 50.2- [4- (3-Methoxy-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-5-methyl-1H-pyrrole-3-carboxylic acid (2- pyrrolidin-1-yl-ethyl)-amide [0659] To a solution of 4- (3-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 2-Formyl-5-methyl-lH-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl- ethyl)-amide (64.8 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 2- [4- (3-Methoxy-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-5-methyl-1H-pyrrole-3-carboxy lic acid (2-pyrrolidin- l-yl-ethyl)-amide as a yellow solid (40 mg, 34%).

[0660]'H-NMR (400 MHz, DMSO-d6) S 13.80 (br s, 1H, pyrrole NH), 11.09 (br s, 1H, CONH), 8. 03 (s, 1H, aromatic), 7.71 (t, 1H, CONH), 7.32 (m, 1H, aromatic), 7.28 (t, 1H, aromatic), 6.90 (m, 4H, aromatic), 6.78 (d, 1H, aromatic), 6.35 (m, 1H, aromatic), 3.74 (s, 3H, OCH3), 3.14 (m, 2H, CH2), 2.50 (m, 6H, 3xCH2), 2.32 (s, 3H, CH3), 1.69 (m, 4H 2xCH2).

[0661] MS m/z 471 [M++1].

Example 51.2- [4- (3-Methoxy-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide [0662] To a solution of 4- (3-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 2-Formyl-5-methyl-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-l- yl-ethyl)-amide (64.8 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 2- [4- (3-Methoxy-phenyl)-2- oxo-1,2-dihydro-indol-3-ylidenemethyl]-5-methyl-lH-pyrrole-3 -carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide as a yellow solid (51 mg, 43%).

[0663] 1H-NMR (400 MHz, DMSO-d6) # 13.86 (br s, 1H, pyrrole NH), 11.02 (br s, 1H, CONH), 8.00 (m, 3H, aromatic), 7.72 (s, 1H, aromatic), 7.65 (t, 1H, aromatic), 7.39 (t, 1H, aromatic), 6.92 (m, 4H, aromatic), 6.79 (d, 1H, aromatic), 6.30 (m, 1H, aromatic), 4.49 (t, 2H, CH2), 3.76 (s, 3H, OCH3), 3.47 (m, 2H, CH2), 2.29 (s, 3H, CH3).

[0664] MS m/z 469 [M++1].

Example 52.5- [4- (3-Methoxy-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyll-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- diisopropylamino-ethyl)-amide [0665] To a solution of 4- (3-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2- diisopropylamino-ethyl)-amide (73 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. The reaction solution was evaporated, and purified on a silica gel column eluting with MeOH-CH2CI2 5: 95 to provide pure product 5- [4- (3-methoxy-phenyl)- 2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-c arboxylic acid (2-diisopropylamino-ethyl)-amide as a yellow solid (95 mg, 79%).

[06661'H-NMR (400 MHz, DMSO-d6) 8 13.49 (br s, 1H, pyrrole NH), 11.03 (brs, 1H, CONH), 7.47 (m, 1H, aromatic), 7.33 (m, 1H, aromatic), 7.17 (t, 1H, aromatic), 7.06 (m, 1H, aromatic), 6.98 (m, 2H, aromatic), 6.92 (d, 1H, aromatic), 6.88 (s, 1H, aromatic), 6.80 (d, 1H, aromatic), 3.77 (s, 1H, CH3), 3.31 (m, 2H, CH2), 3.29 (m, 2H, CH2), 2.39 (s, 3H, CH3), 1.73 (m, 3H, CH3), 0. 99 (m, 12H, 4xCH3).

[0667] MS m/z 515 [M++1].

Example 53.4- (4-Bromo-phenyl)-3-13, 5-dimethyl-4- (4-methyl-piperazine-l- carbonyl)-lH-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one [0668] To a solution of 4- (4-bromo-phenyl)-1, 3-dihydro-indol-2-one (72 mg, 0.25 mmol) and 3,5-dimethylv4-(4-methyl-piperazine-1-carbonyl)-lH-pyrrole-2 - carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide 4- (4-bromo-phenyl)-3- [3, 5-dimethyl-4- (4-methyl- piperazine-l-carbonyl)-lH-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one as a yellow solid (38 mg, 29%) [0669]'H-NMR (400 MHz, DMSO-d6) 8 13.41 (br s, 1H, pyrrole NH), 11.04 (br s, 1H, CONH), 7.75 (d, 2H, aromatic), 7.395 (d, 2H, aromatic), 7.19 (t, 1H, aromatic), 6.93 (d, 1H, aromatic), 6.79 (d, 1H, aromatic), 6.64 (s, 1H, aromatic), 3.31 (m, 4H, 2xCH2), 2.25 (m, 7H, 2xCH2+CH3), 2.17 (s, 3H, CH3), 1.61 (s, 3H, CH3).

[0670] MS m/z 519 [M++1].

Example 54.5-14-(4-Bromo-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyll- 2,4-dimethyl-lH-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide [0671] To a solution of 4- (4-bromo-phenyl)-1, 3-dihydro-indol-2-one (72 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2-diethylamino- ethyl)-amide (69.0 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide 5- [4- (4-bromo-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide as a yellow solid (59 mg, 44%) 0672] 1H-NMR (400 MHz, DMSO-d6) 8 13.44 (br s, 1H, pyrrole NH), 11.04 (br s, 1H, CONH), 7.74 (d, 2H, aromatic), 7.37 (d, 2H, aromatic), 7.33 (t, 1H, CONH), 7.19 (t, 1H, aromatic), 6.93 (d, 1H, aromatic), 6.80 (m, 1H, aromatic), 6.66 (s, 1H, aromatic), 3.24 (m, 2H, CH2), 2.49 (m, 6H, 3xCH2), 2.39 (s, 3H, CH3), 1.75 (s, 3H, CH3), 0.96 (t, 6H, 2xCH3).

[0673] M/S 535 [M++1].

Example 55.5- [4- (4-Bromo-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 2,4-dimethyl-lH-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl- ethyl)-amide [0674] To a solution of 4- (4-bromo-phenyl)-1, 3-dihydro-indol-2-one (72 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl- ethyl)-amide (68.5 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (4-bromo-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-2,4-dimethyl-lH-pyrrole-3-car boxylic acid (2- pyrrolidin-l-yl-ethyl)-amide as a yellow solid (63 mg, 47%).

0675] IH-NMR (400 MHz, DMSO-d6) 8 13.43 (br s, 1H, pyrrole NH), 11.04 (br s, 1H, CONH), 7.74 (m, 2H, aromatic), 7.42 (t, 1H, CONH), 7.36 (d, 2H, aromatic), 7.19 (t, 1H, aromatic), 6.95 (d, 1H, aromatic), 6.79 (m, 1H, aromatic), 6.65 (s, 1H, aromatic), 3.30 (m, 2H, CHa), 2.50 (m, 2H, CH2), 2.46 (m, 4H, 2xCH2), 2.37 (s, 3H, CH3), 1.73 (s, 3H, CH3), 1.67 (m, 4H 2xCH2).

[06761 MS m/z 533 [M++1]. Example 56.5- [4- (4-Bromo-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 2,4-dimethyl-lH-pyrrole-3-carboxylic acid (2- [1,2,3] triazol-1-yl- ethyl)-amide [0677] To a solution of 4- (4-bromo-phenyl)-1, 3-dihydro-indol-2-one (72 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1- yl-ethyl)-amide (67. 9 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (4-bromo-phenyl)-2-oxo- 1,2-dihydro-indol-3-ylidenemethyl]-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide as a yellow solid (50 mg, 38%).

0678] 1H-NMR (400 MHz, DMSO-d6) 8 13.43 (br s, 1H, pyrrole NH), 11.05 (br s, 1H, CONH), 8.10 (s, 1H, aromatic), 7.72 (m, 3H, aromatic), 7.62 (t, 1H, CONH), 7.47 (d, 2H, aromatic), 7.19 (t, 1H, aromatic), 6.93 (d, 1H, aromatic), 6.78 (d, 1H, aromatic), 6.63 (s, 1H, aromatic), 4.53 (m, 2H, CH2), 3.64 (m, 2H, CH2), 2.30 (s, 3H, CH3), 1.64 (s, 3H, CH3).

[0679] MS m/z 531 [M++1].

Example 57.4- (4-Bromo-phenyl)-3- [4- [ (cis)-3, 5-dimethyl-piperazine-1- carbonyl)-3, 5-dimethyl-lH-pyrrol-2-ylmethylene]-1, 3-dihydro- indol-2-one 10680] To a solution of 4- (4-bromo-phenyl)-1, 3-dihydro-indol-2-one (72 mg, 0.25 mmol) and 4-[(cis)-3, 5-dimethyl-piperazine-1-carbonyl)-3, 5-dimethyl-lH-pyrrole-2- carbaldehyde (68.5 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 4- (4-bromo-phenyl)-3- [4- [ (cis)-3, 5- dimethyl-piperazine-l-carbonyl)-3, 5-dimethyl-1H-pyrrol-2-ylmethylene]- 1,3- dihydro-indol-2-one as a yellow solid (38 mg, 28%).

0681] IH-NMR (400 MHz, DMSO-d6) 8 13.40 (br m, 1H, pyrrole NH), 11.03 (br s, 1H, CONH), 7.74 (d, 2H, aromatic), 7.39 (d, 2H, aromatic), 7.19 (t, 1H, aromatic), 6.93 (d, 1H, aromatic), 6.79 (d, 1H, aromatic), 6.62 (s, 1H, aromatic), 4.20 (m, 1H, NH), 3.43 (m, 4H, 2xCH2), 2.52 (m, 2H, 2xCH), 2.23 (m, 3H, CH3), 1.59 (m, 3H, CH3), 0.90 (m, 6H, 2xCH3).

[0682] MS m/z 533 [M++1]. Example 58.2- [4- (4-Bromo-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 5-methyl-lH-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)- amide [0683] To a solution of 4- (4-bromo-phenyl)-1, 3-dihydro-indol-2-one (72 mg, 0.25 mmol) and 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)- amide (64.8 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 2- [4- (4-bromo-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxy lic acid (2-pyrrolidin- 1-yl-ethyl)-amide as a yellow solid (78 mg, 60%).

[0684] 1H-NMR (400 MHz, DMSO-d6) 8 13.73 (br s, 1H, pyrrole NH), 11.05 (br s, 1H, CONH), 8. 05 (s, 1H, aromatic), 7.72 (t, 1H, CONH), 7.58 (d, 2H, aromatic), 7.30 (d, 2H, aromatic), 7.19 (t, 1H, aromatic), 6.93 (d, 1H, aromatic), 6.75 (d, 1H, aromatic), 6.41 (s, 1H, aromatic), 3. 30 (m, 2H, CH2), 2.50 (m, 6H, 3xCH2), 2.31 (s, 3H, CH3), 1.67 (m, 4H 2xCH2).

[0685] MS m/z 519 [M++1].

Example 59.2- [4- (4-Bromo-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 5-methyl-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)- amide [0686] To a solution of 4- (4-bromo-phenyl)-1, 3-dihydro-indol-2-one (72 mg, 0.25 mmol) and 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (2- [1, 2,3] triåzol-1-yl- ethyl)-amide (64.8 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 2- [4- (4-bromo-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxy lic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide as a yellow solid (88 mg, 68%).

[0687]'H-NMR (400 MHz, DMSO-d6) 5 13. 84 (br s, 1H, pyrrole NH), 11.13 (brs, 1H, CONH), 8. 00 (m, 3H, aromatic), 7.73 (s, 1H, aromatic), 7.63 (m, 2H, aromatic), 7. 32 (d, 2H, aromatic), 7.21 (t, 1H, aromatic), 6.93 (d, 1H, aromatic), 6.76 (d, 1H, aromatic), 6.33 (m, 1H, aromatic), 4.53 (m, 2H, CH2), 3.54 (m, 2H, CHa), 2.29 (s, 3H, CH3).

[0688] MS m/s 517 [M++1]. Example 60.5- [4- (4-Bromo-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 2,4-dimethyl-lH-pyrrole-3-carboxylic acid (2-diisopropylamino- ethyl)-amide [0689] To a solution of 4- (4-bromo-phenyl)-1, 3-dihydro-indol-2-one (72 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2-diisopropylamino- ethyl)-amide (73 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (4-bromo-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-2,4-dimethyl-lH-pyrrole-3-car boxylic acid (2- diisopropylamino-ethyl)-amide as a yellow solid (40 mg, 28%).

0690] IH-NMR (400 MHz, DMSO-d6) 8 13. 44 (br s, 1H, pyrrole NH), 11. 04 (br s, 1H, CONH), 7.74 (d, 2H, aromatic), 7.38 (d, 2H, aromatic), 7.29 (t, 1H, CONH), 7.19 (t, 1H, aromatic), 6.93 (d, 1H, aromatic), 6.80 (d, 1H, aromatic), 6.72 (s, 1H, aromatic), 3.31 (m, 2H, CH2), 3.29 2.50 (m, 2H, 2xCH), (m, 2H, CH2), 2.39 (s, 3H, CH3), 1.73 (m, 3H, CH3), 0. 99 (m, 12H, 4xCH3).

10691] MS m/z 563 [M++1]. Example 61. 5-14- (4-Bromo-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 4-methyl-lH-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide 106921 To a solution of 4-(4-bromo-phenyl)-1, 3-dihydro-indol-2-one (72 mg, 0.25 mmol) and 5-formyl-4-methyl-lH-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide (62.8 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (4-bromo-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-4-methyl-1H-pyrrole-3-carboxy lic acid (2- diethylamino-ethyl)-amide (82 mg, 63%).

[0693] 1H-NMR (400 MHz, DMSO-d6) 5 13.41 (br s, 1H, pyrrole NH), 11.10 (br s, 1H, CONH), 7.75 (d, 2H, aromatic), 7.66 (m, 2H, aromatic), 7.39 (d, 2H, aromatic), 7.21 (t, 1H, aromatic), 6.93 (d, 1H, aromatic), 6.81 (m, 1H, aromatic), 6.73 (s, 1H, aromatic), 3.20 (m, 2H, CH2), 2.49 (m, 6H, 3xCH2), 1.74 (s, 3H, CH3), 0.95 (t, 6H, 2xCH3).

10694] MS m/z 521 [M++1].

Example 62.4- (3-Bromo-phenyl)-3- [3, 5-dimethyl-4- (4-methyl-piperazine-1- carbonyl)-lH-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one [0695] To a solution of 4- (3-bromo-phenyl)-1, 3-dihydro-indol-2-one (72 mg, 0.25 mmol) and 3, 5-dimethyl-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrole-2- carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide 4- (3-bromo-phenyl)-3- [3, 5-dimethyl-4- (4-methyl- piperazine-l-carbonyl)-lH-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one as a yellow solid (48 mg, 37%) [0696]'H-NMR (400 MHz, DMSO-d6) 5 13.45 (br s, 1H, pyrrole NH), 11.06 (br s, 1H, CONH), 7.69 (d, 1H, aromatic), 7.65 (s, 1H, aromatic), 7.52 (t, 1H, aromatic), 7.45 (d, 1H, aromatic), 7.20 (t, 1H, aromatic), 6.94 (d, 1H, aromatic), 6.81 (d, 1H, aromatic), 6.76 (s, 1H, aromatic), 3.33 (m, 4H, 2xCH2), 2.24 (m, 7H, 2xCH2+CH3), 2.17 (s, 3H, CH3), 1.62 (s, 3H, CH3).

[0697] MS m/z 519 [M++1].

Example 63.5- [4- (3-Bromo-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 2,4-dimethyl-lH-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide [0698] To a solution of 4- (3-bromo-phenyl)-1, 3-dihydro-indol-2-one (72 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2-diethylamino- ethyl)-amide (69.0 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide 5- [4- (3-bromo-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-2,4-dimethyl-lH-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide as a yellow solid (89. 7 mg, 67%) 10699] IH-NMR (400 MHz, DMSO-d6) 8 13.48 (br s, 1H, pyrrole NH), 11.06 (br s, 1H, CONH), 7.71 (d, 1H, aromatic), 7.65 (s, 1H, aromatic), 7.53 (t, 1H, aromatic), 7.44 (d, 1H, aromatic), 7.37 (t, 1H, CONH), 7.20 (t, 1H, aromatic), 6.94 (d, 1H, aromatic), 6.80 (d, 1H, aromatic), 6.78 (s, 1H, aromatic), 3.23 (m, 2H, CH2), 2.49 (m, 6H, 3xCH2), 2.39 (s, 3H, CH3), 1.76 (s, 3H, CH3), 0.95 (t, 6H, 2xCH3).

[0700] MS m/z 535 [M++1].

Example 64.5- [4- (3-Bromo-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 2,4-dimethyl-lH-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl- ethyl)-amide [0701] To a solution of 4- (3-bromo-phenyl)-1, 3-dihydro-indol-2-one (72 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl- ethyl)-amide (68. 5 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. The reaction solution was evaporated, and purified on a silica gel column eluting with MeOH- CH2C12 5: 95 to provide pure product 5- [4- (3-bromo-phenyl)-2-oxo-1, 2-dihydro-indol- 3-ylidenemethyl]-2,4-dimethyl-lH-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl- ethyl)-amide as a yellow solid (84 mg, 63%).

(0702] 'H-NMR (400 MHz, DMSO-d6) 8 13.48 (br s, 1H, pyrrole NH), 11.06 (br s, 1H, CONH), 7.71 (d, 1H, aromatic), 7.65 (s, 1H, aromatic), 7.52 (t, 1H, aromatic), 7.45 (m, 2H, CONH and aromatic), 7.20 (t, 1H, aromatic), 6.95 (d, 1H, aromatic), 6.80 (d, 1H, aromatic), 6.78 (s, 1H, aromatic), 3.30 (m, 2H, CH2), 2.52 (m, 6H, 3xCH2), 2.37 (s, 3H, CH3), 1.74 (s, 3H, CH3), 1.68 (m, 4H 2xCH2).

[0703] MS m/z 531 [M--1].

Example 65.5-14-(3-Bromo-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-[1, 2,3] triazol-1-yl- ethyl)-amide [0704] To a solution of 4- (3-bromo-phenyl)-1, 3-dihydro-indol-2-one (72 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2- [1, 2, 3]triazol-1- yl-ethyl)-amide (67.9 mg, 0. 26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (3-bromo-phenyl)-2-oxo- 1,2-dihydro-indol-3-ylidenemethyl]-2,4-dimethyl-lH-pyrrole-3 -carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide as a yellow solid (46.6 mg, 35%).

[0705] 1H-NMR (400 MHz, DMSO-d6) 8 13. 48 (br s, 1H, pyrrole NH), 11.07 (br s, 1H, CONH), 8.10 (s, 1H, aromatic), 7.72 (m, 2H, aromatic), 7.65 (m, 2H, aromatic), 7.52 (t, 1H, CONH), 7.42 (d, 1H, aromatic), 7.20 (t, 1H, aromatic), 6.94 (d, 1H, aromatic), 6.80 (d, 1H, aromatic), 6.76 (s, 1H, aromatic), 4.53 (m, 2H, CH2), 3.64 (m, 2H, CH2), 2.26 (s, 3H, CH3), 1.67 (s, 3H, CH3).

[0706] MS m/z 531 [M++1].

Example 66. 4- (3-Bromo-phenyl)-3- [4- (cis)-3, 5-dimethyl-piperazine-1-<BR> <BR> carbonyl)-3, 5-dimethyl-lH-pyrrol-2-ylmethylene]-1, 3-dihydro- indol-2-one [0707] To a solution of 4- (3-bromo-phenyl)-1, 3-dihydro-indol-2-one (72 mg, 0.25 mmol) and 4-[(cis)-3, 5-dimethyl-piperazine-1-carbonyl)-3, 5-dimethyl-lH-pyrrole-2- carbaldehyde (68.5 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. The reaction solution was evaporated, and purified on a silica gel column eluting with MeOH- CH2CI2 5: 95 to provide pure product 4- (3-bromo-phenyl)-3- [4- [ (cis)-3, 5-dimethyl- piperazine-1-carbonyl)-3, 5-dimethyl-1H-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2- one as a yellow solid (95 mg, 70%).

0708] IH-NMR (400 MHz, DMSO-d6) 8 13.43 (br m, 1H, pyrrole NH), 11.06 (br s, 1H, CONH), 7.70 (d, 1H, aromatic), 7.65 (s, 1H, aromatic), 7.52 (t, 1H, aromatic), 7.45 (d, 1H, aromatic), 7.20 (t, 1H, aromatic), 6.94 (d, 1H, aromatic), 6.80 (d, 1H, aromatic), 6.76 (s, 1H, aromatic), 3.30 (m, 4H, 2xCH2), 2.54 (m, 2H, 2xCH), 2.30 (brs, 1H, NH), 2.23 (s, 3H, CH3), 1.61 (s, 3H, CH3), 0.93 (m, 6H, 2xCH3).

[0709] MS m/z 531 [M--1]. Example 67.2- [4- (3-Bromo-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 5-methyl-lH-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)- amide [0710] To a solution of 4- (3-bromo-phenyl)-1, 3-dihydro-indol-2-one (72 mg, 0.25 mmol) and 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)- amide (64.8 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 2- [4- (3-bromo-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxy lic acid (2-pyrrolidin- 1-yl-ethyl)-amide as a yellow solid (93 mg, 72%).

107111'H-NMR (400 MHz, DMSO-d6) 8 13.80 (br s, 1H, pyrrole NH), 11.12 (br s, 1H, CONH), 8.02 (s, 1H, aromatic), 7.77 (t, 1H, CONH), 7.52 (m, 2H, aromatic), 7.38 (m, 2H, aromatic), 7.21 (t, 1H, aromatic), 6.93 (d, 1H, aromatic), 6.77 (d, 1H, aromatic), 6.39 (s, 1H, aromatic), 3.18 (dd, 2H, CH2), 2.48 (m, 6H, 3xCH2), 2.32 (s, 3H, CH3), 1.70 (m, 4H, 2xCH2).

[0712] MS m/z 519 [M++1].

Example 68.2- [4- (3-Bromo-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 5-methyl-1H-pyrrole-3-carboxylic acid (2-[1, 2,3] triazol-1-yl-ethyl)- amide [0713] To a solution of 4- (3-bromo-phenyl)-1, 3-dihydro-indol-2-one (72 mg, 0.25 mmol) and 2-formyl-5-methyl-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl- ethyl)-amide (64.8 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 2- [4- (3-bromo-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxy lic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide as a yellow solid (96 mg, 74%).

[0714] IH-NMR (400 MHz, DMSO-d6) 8 13.82 (br s, 1H, pyrrole NH), 11.14 (br s, 1H, CONH), 8.03 (t, 1H, CONH), 8.00 (s, 2H, aromatic), 7.74 (s, 1H, aromatic), 7.61 (m, 1H, aromatic), 7.53 (m, 1H, aromatic), 7.41 (t, 1H, aromatic), 7.35 (m, 1H, aromatic), 7.21 (t, 1H, aromatic), 6.94 (d, 1H, aromatic), 6.78 (d, 1H, aromatic), 6.34 (d, 1H, aromatic), 4.52 (m, 2H, CH2), 3.51 (m, 2H, CH2), 2.31 (s, 3H, CH3).

[0715] MS m/z 517 [M++1]. Example 69.5- [4- (3-Bromo-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 2,4-dimethyl-lH-pyrrole-3-carboxylic acid (2-diisopropylamino- ethyl)-amide [0716] To a solution of 4- (3-bromo-phenyl)-1, 3-dihydro-indol-2-one (72 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2-diisopropylamino- ethyl)-amide (73 mg, 0.25 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (3-bromo-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-2,4-dimethyl-lH-pyrrole-3-car boxylic acid (2- diisopropylamino-ethyl)-amide as a yellow solid (43 mg, 30%).

[0717] 1H-NMR (400 MHz, DMSO-d6) 8 13.50 (br s, 1H, pyrrole NH), 11.06 (br s, 1H, CONH), 7.71 (d, 1H, aromatic), 7.66 (s, 1H, aromatic), 7.52 (t, 1H, aromatic), 7.44 (d, 1H, aromatic), 7.34 (t, 1H, CONH), 7.20 (t, 1H, aromatic), 6.94 (d, 1H, aromatic), 6.80 (d, 1H, aromatic), 6.78 (s, 1H, aromatic), 3.13 (m, 2H, CH2), 2.97 (m, 2H, 2xCH), 2.50 (m, 2H, CH2), 2.40 (s, 3H, CH3), 1.76 (s, 3H, CH3), 0.97 (d, 12H, <BR> <BR> <BR> 4xCH3).<BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>[07181 MS m/z 563 [M++1]. Example 70.5- [4- (4-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 4-methyl-lH-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)- amide [0719] To a solution of 4- (4-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 5-formyl-4-methyl-lH-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)- amide (65.3 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. The reaction solution was evaporated, and purified on a silica gel column eluting with MeOH-CH2Cl2 5: 95 to provide pure product 5- [4- (4-fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-4-methyl-1H-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)-amide as a yellow solid (52 mg, 45%).

[0720] 1H-NMR (400 MHz, DMSO-d6) # 13.51 (brs, IH, pyrroleNH), 11. 10 (brs, 1H, CONH), 8. 26 (t, 1H, CONH), 7.48 (m, 2H, aromatic), 7.39 (m, 2H, aromatic), 7.23 (t, 1H, aromatic), 6.94 (d, 1H, aromatic), 6.80 (d, 1H, aromatic), 6.73 (s, 1H, aromatic), 6.68 (d, 1H, aromatic), 3.30 (m, 2H, CH2), 2.50 (m, 6H, 3xCH2), 1.69 (s, 3H, CH3), 0.96 (t, 6H, 2xCH3).

[0721] MS m/z 461 [M++1].

Example 71.5- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 4-methyl-lH-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)- amide [0722] To a solution of 4- (3-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 5-formyl-4-methyl-lH-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)- amide (65.3 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. The reaction solution was evaporated, and purified on a silica gel column eluting with MeOH-CHZCIZ 5: 95 to provide pure product 5- [4- (3-fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-4-methyl-lH-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)-amide as a yellow solid (26 mg, 23%).

[0723 'H-NMR (400 MHz, DMSO-d6) 8 13. 55 (br s, 1H, pyrrole NH), 11.12 (br s, 1H, CONH), 8.30 (t, 1H, CONH), 7.60 (dd, 1H, aromatic), 7.33 (m, 3H, aromatic), 7.25 (t, 1H, aromatic), 6.95 (d, 1H, aromatic), 6.83 (d, 1H, aromatic), 6.81 (s, 1H, aromatic), 6.69 (d, 1H, aromatic), 3.30 (m, 2H, CH2), 2.50 (m, 6H, 3xCH2), 1.69 (s, 3H, CH3), 0.96 (t, 6H, 2xCH3).

[0724] MS m/z 461 [M++1].

Example 72.5- [4- (4-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyll- 4-methyl-lH-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)- amide [0725] To a solution of 4- (4-Chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)- amide (65.3 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. The reaction solution was evaporated, and purified on a silica gel column eluting with MeOH-CH2CI2 5: 95 to provide pure product 5- [4- (4-chloro-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-4-methyl-lH-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)-amide as a yellow solid (80 mg, 67%).

[07261'H-NMR (400 MHz, DMSO-d6) 8 13.50 (br s, 1H, pyrrole NH), 11.10 (br s, 1H, CONH), 8.29 (brs, 1H, CONH), 7.63 (d, 2H, aromatic), 7.47 (d, 2H, aromatic), 7.24 (t, 1H, aromatic), 6.94 (d, 1H, aromatic), 6.82 (d, 1H, aromatic), 6.70 (m, 2H, aromatic), 3.30 (m, 2H, CH2), 2.57 (m, 6H, 3xCH2), 1.69 (s, 3H, CH3), 0. 98 (t, 6H, <BR> <BR> <BR> <BR> 2xCH3).<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>[07271 MS m/z 477 [M++1].

Example 73.5- [4- (3-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 4-methyl-lH-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)- amide [0728] To a solution of 4- (3-Chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)- amide (65.3 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. The reaction solution was evaporated, and purified on a silica gel column eluting with MeOH-CH2CI2 5: 95 to provide pure product 5- [4- (3-chloro-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-4-methyl-lH-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)-amide as a yellow solid (65 mg, 54%).

[0729] 1H-NMR (400 MHz, DMSO-d6) 8 13.53 (br s, 1H, pyrrole NH), 11.12 (br s, 1H, CONH), 8.31 (brs, 1H, CONH), 7.58 (m, 3H, aromatic), 7.42 (m, 1H, aromatic), 7.25 (t, 1H, aromatic), 6.92 (d, 1H, aromatic), 6.82 (d, 1H, aromatic), 6.80 (s, 1H, aromatic), 6.69 (d, 1H, aromatic), 3.30 (m, 2H, CH2), 2.57 (m, 6H, 3xCH2), 1.70 (s, 3H, CH3), 0.98 (t, 6H, 2xCH3).

[07301 MS m/z 475 [M'-1].

Example 74.5- [4- (4-Bromo-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 4-methyl-lH-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)- amide [0731] To a solution of 4- (4-bromo-phenyl)-1, 3-dihydro-indol-2-one (72.0 mg, 0.25 mmol) and 5-formyl-4-methyl-lH-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)- amide (65.3 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (4-bromo-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-4-methyl-lH-pyrrole-2-carboxy lic acid (2- diethylamino-ethyl)-amide as a yellow solid (26 mg, 20%).

[0732]'H-NMR (400 MHz, DMSO-d6) 8 13.48 (br s, 1H, pyrrole NH), 11.10 (br s, 1H, CONH), 8.24 (t, 1H, CONH), 7.76 (d, 2H, aromatic), 7.38 (d, 2H, aromatic), 7.24 (t, 1H, aromatic), 6.94 (d, 1H, aromatic), 6.81 (d, 1H, aromatic), 6.69 (m, 2H, aromatic), 3.26 (m, 2H, CH2), 2.50 (m, 6H, 3xCH2), 1.70 (s, 3H, CH3), 0.95 (t, 6H, 2xCH3).

[0733] MS m/z 521 [M++1].

Example 75.5- (4- (3-Bromo-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 4-methyl-lH-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)- amide [0734] To a solution of4- (3-bromo-phenyl)-1, 3-dihydro-indol-2-one (72 mg, 0.25 mmol) and 5-formyl-4-methyl-1H-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)- amide (65.3 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. The reaction solution was evaporated, and purified on a silica gel column eluting with MeOH-CH2C12 5: 95 to provide pure product 5- [4- (3-bromo-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-4-methyl-lH-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)-amide as a yellow solid (45 mg, 35%).

[0735] 'H-NMR (400 MHz, DMSO-d6) 8 13.52 (br s, 1H, pyrrole NH), 11.12 (br s, 1H, CONH), 8. 27 (t, 1H, CONH), 7.72 (d, 1H, aromatic), 7.68 (s, 1H, aromatic), 7.53 (t, 1H, aromatic), 7.46 (d, 1H, aromatic), 7.25 (t, 1H, aromatic), 6.95 (d, 1H, aromatic), 6.82 (d, 1H, aromatic), 6.79 (s, 1H, aromatic), 6.69 (s, 1H, aromatic), 3.29 (m, 2H, CH2), 2.50 (m, 6H, 3xCH2), 1.71 (s, 3H, CH3), 0.96 (t, 6H, 2xCH3).

[0736] MS m/z 519 [M--1].

Example 76.5- [4- (4-Methoxy-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-4-methyl-lH-pyrrole-2-carboxylic acid (2- diethylamino-ethyl)-amide [0737] To a solution of 4- (4-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 5-formyl-4-methyl-lH-pyrrole-2-carboxylic acid (2-diethylamino- ethyl)-amide (65.3 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (4-methoxy-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-4-methyl-lH-pyrrole-2-carboxy lic acid (2- diethylamino-ethyl)-amide as a yellow solid (65 mg, 55%).

[0738] 1H-NMR (400 MHz, DMSO-d6) 8 13.85 (br s, 1H, pyrrole NH), 8.18 (m, 1H, CONH), 7.33 (d, 2H, aromatic), 7.16 (t, 1H, aromatic), 7.10 (d, 2H, aromatic), 6.86 (d, 1H, aromatic), 6.76 (s, 1H, aromatic), 6.73 (d, 1H, aromatic), 6.65 (s, 1H, aromatic), 3.82 (s, 3H, OCH3), 3.25 (m, 2H, CH2), 2.47 (m, 6H, 3xCH2), 1.67 (s, 3H, CH3), 0.95 (t, 6H, 2xCH3). <BR> <BR> <BR> <BR> <BR> <BR> <P>[0739] MS m/z 473 [M++1].<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>Example 7. 5- [4- (3-Methoxy-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-4-methyl-lH-pyrrole-2-carboxylic acid (2- diethylamino-ethyl)-amide [07401 To a solution of 4- (3-methoxy-phenyl)-1, 3-dihydro-indol-2-one (72 mg, 0.25 mmol) and 5-formyl-4-methyl-lH-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)- amide (65.3 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. The reaction solution was evaporated, and purified on a silica gel column eluting with MeOH-CH2CI2 5: 95 to provide pure product 5- [4- (3-methoxy-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-4-methyl-lH-pyrrole-2-carboxylic acid (2-diethylamino-ethyl)-amide as a yellow solid (40 mg, 34%).

[0741] 1H-NMR (400 MHz, DMSO-d6) 8 13.52 (br s, 1H, pyrrole NH), 11.07 (br s, IH, CONH), 8. 26 (m, 1H, CONH), 7.48 (t, 1H, aromatic), 7.22 (t, 1H, aromatic), 7.06 (dd, 1H, aromatic), 7.00 (m, 2H, aromatic), 6.92 (d, 1H, aromatic), 6.89 (s, 1H, aromatic), 6.82 (d, 1H, aromatic), 6.67 (m, 1H, aromatic), 3.78 (s, 3H, CH3), 3.29 (m, 2H, CH2), 2.55 (m, 6H, 3xCH2), 1.67 (s, 3H, CH3), 0.97 (t, 6H, 2xCH3).

10742] MS m/z 471 [M--1].

Example 78.3- (3, 5-Dimethyl-lH-pyrrol-2-ylmethylene)-4- (4-fluoro-phenyl)-1,3- dihydro-indol-2-one [0743] To a solution of 4- (4-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 3,5-dimethyl-lH-pyrrole-2-carbaldehyde (32 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3- (3, 5-Dimethyl-1H pyrrol-2-ylmethylene)-4- (4-fluoro-phenyl)-1, 3-dihydro- indol-2-one as a yellow solid (35 mg, 45%).

0744] IH-NMR (400 MHz, DMSO-d6) 8 13.23 (br s, 1H, pyrrole NH), 10.93 (br s, 1H, CONH), 7.47 (dd, 2H, aromatic), 7.37 (t, 2H, aromatic), 7.14 (t, 1H, aromatic), 6.91 (d, 1H, aromatic), 6.76 (d, 1H, aromatic), 6.68 (s, 1H, aromatic), 5.91 (d, 1H, aromatic), 2.27 (s, 3H, CH3), 1.67 (s, 3H, CH3).

[0745] MS m/z 333 [M++1]. Example 79. 3- (3, 5-Dimethy)-IH-pyrrol-2-ylmethylene)-4- (3-fluoro-phenyl)-1, 3- dihydro-indol-2-one [0746] To a solution of 4- (3-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 3,5-dimethyl-lH-pyrrole-2-carbaldehyde (32 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3- (3, 5-Dimethyl-1H pyrrol-2-ylmethylene)-4- (3-fluoro-phenyl)-1, 3-dihydro- indol-2-one as a yellow solid (37 mg, 46%).

0747] IH-NMR (400 MHz, DMSO-d6) 8 13.24 (br s, 1H, pyrrole NH), 10.95 (br s, 1H, CONH), 7.59 (dd, 1H, aromatic), 7.31 (m, 3H, aromatic), 7.16 (t, 1H, aromatic), 6.93 (d, 1H, aromatic), 6.78 (d, 1H, aromatic), 6.76 (s, 1H, aromatic), 5.91 (d, 1H, aromatic), 2.27 (s, 3H, CH3), 1.65 (s, 3H, CH3).

[0748] MS m/z 333 [M++1].

Example 80. 3-(3,5-Dimethyl-1H-pyrrol-2-ylmethylene)-4-(4-chloro-phenyl) -1, 3- dihydro-indol-2-one [0749] To a solution of 4- (4-chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 3,5-dimethyl-lH-pyrrole-2-carbaldehyde (32 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3-(3,5-Dimethyl-1H-pyrrol-2-ylmethyl)-4-(4-chloro-phenyl)-1, 3-dihydro- indol-2-one as a yellow solid (36 mg, 41%).

[0750] IH-NMR (400 MHz, DMSO-d6) 8 13.21 (br s, 1H, pyrrole NH), 10.94 (br s, 1H, CONH), 7.60 (d, 2H, aromatic), 7.44 (d, 2H, aromatic), 7.15 (t, 1H, aromatic), 6.92 (d, 1H, aromatic), 6.77 (d, 1H, aromatic), 6.65 (s, 1H, aromatic), 5.91 (d, 1H, aromatic), 2.27 (s, 3H, Chu), 1.66 (s, 3H, CH3).

[0751] MS m/z 349 [M++1].

Example 81.3- (3, 5-Dimethyl-lH-pyrrol-2-ylmethylene)-4- (3-chloro-phenyl)-1,3- dihydro-indol-2-one [0752] To a solution of 4- (3-chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 3,5-dimethyl-lH-pyrrole-2-carbaldehyde (32 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3- (3, 5-Dimethyl-lH-pyrrol-2-ylmethylene)-4- (3-chloro-phenyl)-1, 3-dihydro- indol-2-one as a yellow solid (60 mg, 68%).

107531'H-NMR (400 MHz, DMSO-d6) 8 13.24 (br s, 1H, pyrrole NH), 10.96 (br s, 1H, CONH), 7.56 (m, 2H, aromatic), 7.50 (s, 1H, aromatic), 7.39 (m, 1H, aromatic), 7.16 (t, 1H, aromatic), 6.93 (d, 1H, aromatic), 6.78 (d, 1H, aromatic), 6.75 (s, 1H, aromatic), 5.92 (d, 1H, aromatic), 2.28 (s, 3H, CH3), 1.66 (s, 3H, CH3).

[0754] MS m/z 349 [M++1]. Example 82. 3-(3,5-Dimethyl-1H-pyrrol-2-ylmethylene)-4-(4-bromo-phenyl)- 1,3-dihydro-indol-2-one [0755] To a solution of 4- (4-bromo-phenyl)-1, 3-dihydro-indol-2-one (72 mg, 0.25 mmol) and 3,5-dimethyl-lH-pyrrole-2-carbaldehyde (32 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3-(3, 5-Dimethyl-lH-pyrrol-2-ylmethylene)-4-(4-bromo-phenyl)-1, 3-dihydro- indol-2-one as a yellow solid (50 mg, 51%).

[0756] 1H-NMR (400 MHz, DMSO-d6) 8 13.21 (br s, 1H, pyrrole NH), 10.94 (br s, 1H, CONH), 7.73 (d, 2H, aromatic), 7.38 (d, 2H, aromatic), 7.15 (t, 1H, aromatic), 6.92 (d, 1H, aromatic), 6.77 (d, 1H, aromatic), 6.63 (s, 1H, aromatic), 5.91 (d, 1H, aromatic), 2.27 (s, 3H, CH3), 1.66 (s, 3H, CH3).

[0757] MS m/z 393 [M++1].

Example 83.3- (3, 5-Dimethyl-lH-pyrrol-2-ylmethylene)-4- (3-bromo-phenyl)- 1,3-dihydro-indol-2-one [0758] To a solution of 4- (3-bromo-phenyl)-1, 3-dihydro-indol-2-one (72 mg, 0.25 i mmol) and 3,5-dimethyl-lH-pyrrole-2-carbaldehyde (32 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3- (3, 5-Dimethyl-lH-pyrrol-2-ylmethylene)-4- (3-bromo-phenyl)-1, 3-dihydro- indol-2-one as a yellow solid (71 mg, 71%).

[07591'H-NMR (400 MHz, DMSO-d6) 8 13.24 (br s, 1H, pyrrole NH), 10.95 (br s, 1H, CONH), 7.70 (m, 1H, aromatic), 7.64 (s, 1H, aromatic), 7.51 (t, 1H, aromatic), 7.44 (d, 1H, aromatic), 7.16 (t, 1H, aromatic), 6.93 (d, 1H, aromatic), 6.78 (d, 1H, aromatic), 6.74 (s, 1H, aromatic), 5.92 (d, 1H, aromatic), 2.28 (s, 3H, CH3), 1.67 (s, 3H, CH3).

[0760] MS m/z 393 [M++1].

Example 84. 3-(3, 5-Dimethyl-lH-pyrrol-2-ylmethylene)-4-(4-methoxy-phenyl)- 1,3-dihydro-indol-2-one [0761] To a solution of 4- (4-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 3,5-dimethyl-lH-pyrrole-2-carbaldehyde (32 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3-(3,5-Dimethyl-1H-pyrrol-2-ylmethylene)-4-(4-methoxy-phenyl )-1, 3- dihydro-indol-2-one as a yellow solid (57 mg, 66%).

[07621'H-NMR (400 MHz, DMSO-d6) 8 13.22 (br s, 1H, pyrrole NH), 10.89 (br s, 1H, CONH), 7.32 (d, 2H, aromatic), 7.11 (m, 3H, aromatic), 6.87 (d, 1H, aromatic), 6.75 (m, 2H, aromatic), 5.89 (d, 1H, aromatic), 3.82 (s, 3H, CH3), 2.27 (s, 3H, CH3), 1.64 (s, 3H, CH3).

[0763] MS m/z 345 [M++1].

Example 85. 3-(3,5-Dimethyl-1H-pyrrol-2-ylmethylene)-4-(3-methoxy-phenyl )- 1,3-dihydro-indol-2-one [0764] To a solution of 4-(3-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 3, 5-dimethyl-1H-pyrrol-2-carbaldehyde (32 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine- (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3-(3,5-Dimethyl-1H-pyrrol-2-ylmethylene)-4-(3-methoxy-phenyl )-1, 3- dihydro-indol-2-one as a yellow solid (60 mg, 69%).

[0765] 'H-NMR (400 MHz, DMSO-d6) 8 13.23 (br s, 1H, pyrrole NH), 10.91 (br s, 1H, CONH), 7.45 (t, 1H, aromatic), 7.14 (t, 1H, aromatic), 7.04 (m, 1H, aromatic), 6.97 (m, 2H, aromatic), 6.90 (d, 1H, aromatic), 6.85 (s, 1H, aromatic), 6.78 (d, 1H, aromatic), 5.90 (d, 1H, aromatic), 3.77 (s, 3H, OCH3), 2.27 (s, 3H, CH3), 1.64 (s, 3H, CH3).

[0766] MS m/z 345 [M++1].

Example 86.5- [4- (4-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyll- 4-methyl-lH-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide [0767] To a solution of 4- (4-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 5-formyl-4-methyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide (65.3 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (4-fluoro-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-4-methyl-lH-pyrrole-3-carboxy lic acid (2- diethylamino-ethyl)-amide (98.6 mg, 86%).

[0768] 'H-NMR (400 MHz, DMSO-d6) 8 13.45 (br s, 1H, pyrrole NH), 11. 11 (br s, 1H, CONH), 7.68 (m, 2H, CONH and aromatic), 7. 42 (m, 4H, aromatic), 7.21 (t, 1H, aromatic), 6.93 (d, 1H, aromatic), 6.79 (m, 3H, aromatic), 3.21 (m, 2H, CH2), 2.49 (m, 6H, 3xCH2), 1. 1. 84 (s, 3H, CH3), 0.95 (t, 6H, 2xCH3).

[0769] MS m/z 461 [M++1].

Example 87.5- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 4-methyl-lH-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide [0770] To a solution of 4- (3-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 5-formyl-4-methyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide (65.3 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (3-fluoro-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-4-methyl-1H-pyrrole-3-carboxy lic acid (2- diethylamino-ethyl)-amide (71.0 mg, 62%).

[0771] IH-NMR (400 MHz, DMSO-d6) 5 13.48 (br s, 1H, pyrrole NH), 11.12 (br s, 1H, CONH), 7.72 (t, 1H, CONH), 7.67 (d, 1H, aromatic), 7.60 (dd, 1H, aromatic), 7.33 (m, 3H, aromatic), 7.22 (t, 1H, aromatic), 6.94 (d, 1H, aromatic), 6.87 (s, 1H, aromatic), 6.82 (d, 2H, aromatic), 3.20 (m, 2H, CH2), 2.46 (m, 6H, 3xCH2), 1.84 (s, 3H, CH3), 0.95 (t, 6H, 2xCH3).

[0772] MS m/z 461 [M++1].

Example 88.5- [4- (4-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 4-methyl-lH-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide [0773] To a solution of 4- (4-chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 5-formyl-4-methyl-lH-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide (65.3 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room. temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (4-chloro-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-4-methyl-1H-pyrrole-3-carboxy lic acid (2- diethylamino-ethyl)-amide (76.6 mg, 64%).

[0774] 1H-NMR (400 MHz, DMSO-d6) 8 13.45 (br s, 1H, pyrrole NH), 11.11 (br s, 1H, CONH), 7.70 (t, 1H, CONH), 7.67 (d, 1H, aromatic), 7.62 (d, 2H, aromatic), 7.46 (d, 2H, aromatic), 7.22 (t, 1H, aromatic), 6.93 (d, 1H, aromatic), 6.81 (d, 1H, aromatic), 6.74 (s, 1H, aromatic), 3.20 (m, 2H, CH2), 2.49 (m, 6H, 3xCH2), 1.84 (s, 3H, CH3), 0.95 (t, 6H, 2xCH3).

[0775] MS m/z 477 [M++1].

Example 89.5- [4- (3-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 4-methyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide [0776] To a solution of 4- (3-chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 5-formyl4-methyl-lH-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide (65.3 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (3-chloro-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-4-methyl-1H-pyrrole-3-carboxy lic acid (2- diethylamino-ethyl)-amide (86.2 mg, 72%).

[0777] 'H-NMR (400 MHz, DMSO-d6) 8 13.47 (br s, 1H, pyrrole NH), 11.13 (br s, 1H, CONH), 7. 73 (t, 1H, CONH), 7.68 (d, 1H, aromatic), 7.58 (m, 2H, aromatic), 7.53 (s, 1H, aromatic), 7.41 (m, 1H, aromatic), 7.22 (t, 1H, aromatic), 6.94 (d, 1H, aromatic), 6.87 (s, 1H, aromatic), 6.82 (d, 1H, aromatic), 3.20 (m, 2H, CH2), 2.47 (m, 6H, 3xCH2), 1.85 (s, 3H, CH3), 0.95 (t, 6H, 2xCH3).

[0778] MS m/z 477 [M++1]. Example 90.5- [4- (3-Bromo-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 4-methyl-lH-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide [0779] To a solution of 4- (3-bromo-phenyl)-1, 3-dihydro-indol-2-one (72.0 mg, 0.25 mmol) and 5-formyl-4-methyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide (65.3 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (3-bromo-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-4-methyl-1H-pyrrole-3-carboxy lic acid (2- diethylamino-ethyl)-amide (93.5 mg, 72%).

[0780]'H-NMR (400 MHz, DMSO-d6) 8 13.47 (br s, 1H, pyrrole NH), 11.13 (br s, 1H, CONH), 7.72 (m, 2H, CONHand aromatic), 7.67 (m, 2H, aromatic), 7.53 (t, 1H, aromatic), 7.45 (d, 1H, aromatic), 7.22 (t, 1H, aromatic), 6.94 (d, 1H, aromatic), 6.86 (s, 1H, aromatic), 6.82 (d, 1H, aromatic), 3.20 (m, 2H, CH2), 2.47 (m, 6H, 3xCH2), 1.86 (s, 3H, CH3), 0.95 (t, 6H, 2xCH3).

[0781] MS m/z 521 [M++1].

Example91.5- [4- (4-Methoxy-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-4-methyl-lH-pyrrole-3-carboxylic acid (2- diethylamino-ethyl)-amide [0782] To a solution of 4-(4-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 5-formyl-4-methyl-1H-pyrrole-3-carboxylic acid (2-diethylamino- ethyl)-amide (65.3 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (4-methoxy-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-4-methyl-1 H-pyrrole-3-carboxylic acid (2- diethylamino-ethyl)-amide (90.4 mg, 76.5%).

[0783] 1H-NMR (400 MHz, DMSO-d6) 5 13.46 (br s, 1H, pyrrole NH), 11. 06 (br s, 1H, CONH), 7.69 (t, 1H, CONH), 7.65 (d, 1H, aromatic), 7.33 (d, 2H, aromatic), 7.19 (t, 1H, aromatic), 7.11 (d, 2H, aromatic), 6.89 (d, 1H, aromatic), 6.86 (s, 1H, aromatic), 6.79 (d, 1H, aromatic), 3.83 (S, 3H, OCH3), 3.20 (m, 2H, CH2), 2.47 (m, 6H, 3xCH2), 1.83 (s, 3H, CH3), 0.95 (t, 6H, 2xCH3).

[0784] MS m/z 473 [M++1].

Example 92.5- [4- (3-Methoxy-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-4-methyl-lH-pyrrole-3-carboxylic acid (2- diethylamino-ethyl)-amide [0785] To a solution of 4-(3-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 5-formyl-4-methyl-lH-pyrrole-3-carboxylic acid (2-diethylamino- ethyl)-amide (65. 3 mg, 0.26 mmol) in. ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. The solvent was evaporated and the solid was washed by ether for three times to provide pure product 5-[4-(3-methoxy-phenyl)-2-oxo-1,2-dihydro-indol-3-ylidenemet hyl]-4-methyl-1H- pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide (67.5 mg, 57%).

0786] IH-NMR (400 MHz, DMSO-d6) 8 13.48 (br s, 1H, pyrrole NH), 11.06 (br s, 1H, CONH), 7.70 (t, 1H, CONH), 7.66 (d, 1H, aromatic), 7.47 (t, 1H, aromatic), 7.20 (t, 1H, aromatic), 7.07 (dd, 1H, aromatic), 6.98 (m, 2H, aromatic), 6.86 (s, 1H, aromatic), 6.91 (d, 1H, aromatic), 6.81 (d, 1H, aromatic), 3.78 (s, 3H, OCH3), 3.20 (m, 2H, CH2), 2.48 (m, 6H, 3xCH2), 1.82 (s, 3H, CH3), 0.95 (t, 6H, 2xCH3).

[0787] MS m/z 473 [M++13.

Example 93.3-13, 5-Dimethyl-4-(4-methyl-piperazine-1-carbonyl)-lH-pyrrol-2- ylmethylene]-4-(2-fluoro-phenyl)-1, 3-dihydro-indol-2-one [0788] To a solution of 4- (2-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 3, 5-dìmethyl-4-(4-methyl-piperazine-1-carbonyl)-lH-pyrrole-2- carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. The solvent was evaporated and the solid was washed by ether for three times to provide pure product 3-[3,5-dimethyl-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrol -2-ylmethylene]-4-(2- fluoro-phenyl)-1, 3-dihydro-indol-2-one (59.5 mg, 52%) 10789] 1H-NMR (400 MHz, DMSO-d6) 8 13.47 (br s, 1H, pyrrole NH), 11.07 (br s, 1H, CONH), 7.56 (m, 1H, aromatic), 7.43 (m, 3H, aromatic), 7.21 (t, 1H, aromatic), 6.97 (d, 1H, aromatic), 6.83 (d, 1H, aromatic), 6.62 (s, 1H, aromatic), 3.37 (m, 4H, 2xCH2), 2.24 (m, 7H, 2xCH2+CH3), 2.16 (s, 3H, CH3), 1.55 (s, 3H, CH3).

[0790] MS m/z 457 [M--1].

Example 94. 5- [4- (2-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide [0791] To a solution of 4- (2-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino- ethyl)-amide (69.0 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide 5- [4- (2-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide as a yellow solid (98 mg, 83%).

[0792] 1H-NMR (400 MHz, DMSO-d6) 5 13.49 (br s, 1H, pyrrole NH), 11.08 (br s, 1H, CONH), 7.57 (m, 1H, aromatic), 7.42 (m, 4H, aromatic and CONH), 7.22 (t, 1H, aromatic), 6.97 (d, 1H, aromatic), 6.83 (d, 1H, aromatic), 6.65 (s, 1H, aromatic), 3.22 (dd, 2H, CH2), 2.49 (m, 6H, 3xCH2), 2.39 (s, 3H, CH3), 1.69 (s, 3H, CH3), 0.95 (t, 6H, 2xCH3).

[0793] MSmlz473 [M--I].

Example 95.5- [4- (2-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 2,4-dimethyl-lH-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl- ethyl)-amide [0794] To a solution of 4-(2-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-IH-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl- ethyl)-amide (68. 5 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (2-fluoro-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2- pyrrolidin-l-yl-ethyl)-amide as a yellow solid (62.5 mg, 53%).

[07951'H-NMR (400 MHz, DMSO-d6) 8 13.49 (br s, 1H, pyrrole NH), 11.08 (br s, 1H, CONH), 7.57 (m, 1H, aromatic), 7.45 (m, 4H, aromatic and CONH), 7.22 (t, 1H, aromatic), 6.97 (d, 1H, aromatic), 6.83 (d, 1H, aromatic), 6.65 (s, 1H, aromatic), 3.28 (dd, 2H, CH2), 2.52 (m, 6H, 3xCH2), 2.37 (s, 3H, CH3), 1.68 (m, 7H, CH3 and 2xCH2).

[0796] MS m/z 471 [M--1]. Example % 5- [4- (2-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyll- 2,4-dimethyl-lH-pyrrole-3-carboxylic acid (2-11, 2,3] triazol-1-yl- ethyl)-amide [0797] To a solution of 4- (2-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1- yl-ethyl)-amide (67.9 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (2-fluoro-phenyl)-2-oxo- 1,2-dihydro-indol-3-ylidenemethyl]-2,4-dimethyl-lH-pyrrole-3 -carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide as a yellow solid (52.8 mg, 45%).

[0798] 'H-NMR (400 MHz, DMSO-d6) 8 13.49 (br s, 1H, pyrrole NH), 11.07 (br s, 1H, CONH), 8.10 (s, 1H, aromatic), 7.71 (s, 1H, aromatic), 7.59 (m, 2H, aromatic) 7.44 (m, 3H, aromatic and CONH), 7.21 (t, 1H, CONH), 6.96 (d, 1H, aromatic), 6.83 (d, 1H, aromatic), 6.63 (d, 1H, aromatic), 4.53 (t, 2H, CH2), 3.63 (q, 2H, CH2), 2.29 (s, 3H, CH3), 1.59 (s, 3H, CH3).

[0799] MS m/z 469 [M--1]. Example 97.2-14-(2-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 5-methyl-lH-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide [0800] To a solution of 4- (2-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56. 8 mg, 0.25 mmol) and 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide (65.3 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 2- [4- (2-fluoro-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxy lic acid (2- diethylamino-ethyl)-amide as a yellow solid (57.5 mg, 50%).

[0801] 'H-NMR (400 MHz, DMSO-d6) 8 13. 90 (br s, 1H, pyrrole NH), 11. 16 (brs, 1H, CONH), 7.90 (s, 1H, aromatic), 7.50 (t, 1H, CONH), 7.40 (m, 2H, aromatic), 7.29 (d, 1H, aromatic), 7.25 (m, 2H, aromatic), 6.96 (d, 1H, aromatic), 6.78 (d, 1H, aromatic), 6.38 (s, 1H, aromatic), 3.20 (dd, 2H, CH2), 2.50 (m, 6H, 3xCH2), 2.32 (s, 3H, CH3), 1.24 (m, 6H, 2xCH3).

[0802] MS mlz 461 [M++1]. Example 98. 2- [4- (2-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 5-methyl-lH-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)- amide [0803] To a solution of 4- (2-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)- amide (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 2- [4- (2-fluoro-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-5-methyl-1H-pyrrole-3-carboxy lic acid (2-pyrrolidin- 1-yl-ethyl)-amideas a yellow solid (58.4 mg, 51%).

[08041'H-NMR (400 MHz, DMSO-d6) 8 13.85 (br s, 1H, pyrrole NH), 11.36 (brs, 1H, CONH), 7.86 (d, IH, aromatic), 7.75 (t, IH, CONH), 7.42 (m, 2H, aromatic), 7.30 (m, 2H, aromatic), 7.23 (t, 1H, aromatic), 6 : 95 (d, 1H, aromatic), 6.78 (d, 1H, aromatic), 6.37 (d, 1H, aromatic), 3.14 (dd, 2H, CH2), 2.48 (m, 6H, 3xCH2), 2.31 (s, 3H, CH3), 1.70 (m, 4H, 2xCH2).

[0805] MS m/z 457 [M--1].

Example 99.2- [4- (2-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- S-methyl-lH-pyrrole-3-carboxylic acid (2-11, 2, 3] triazol-1-yl-ethyl)- amide [0806] To a solution of 4- (2-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 2-formyl-5-methyl-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl- ethyl)-amide (61.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 2- [4- (2-fluoro-phenyl)-2-oxo-1, 2- dihydro-indol-3-ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxy lic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide as a yellow solid (74.1 mg, 65%).

[0807] 'H-NMR (400 MHz, DMSO-d6) 8 13.86 (br s, 1H, pyrrole NH), 11.15 (br s, 1H, CONH), 8. 01 (t, 1H, CONH), 7.84 (d, 1H, aromatic), 7.74 (d, 1H, aromatic), 7.47 (m, 1H, aromatic), 7.40 (m, 1H, aromatic), 7.32 (t, 1H, aromatic), 7.35 (m, 2H, aromatic), 7.23 (t, 1H, aromatic), 6.97 (d, 1H, aromatic), 6.80 (d, 1H, aromatic), 6.32 (d, 1H, aromatic), 4.50 (t, 2H, CH2), 3.50 (m, 2H, CH2), 2.32 (s, 3H, CH3). <BR> <BR> <P>[0808] MS m/z 455 [M--1].<BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>Example 100. 3- [3- ( (cis)-3, 5-Dimethyl-piperazine-l-carbonyl]-5-methyl-lH-<BR> <BR> <BR> pyrrol-2-ylmethylene]-4-(2-fluoro-phenyl)-1, 3-dihydro-indol-2-one [0809] To a solution of 4- (2-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 3-[(cis)-3, 5-dimethyl-piperazine-1-carbonyl]-5-methyl-lH-pyrrole-2- carbaldehyde (62.3 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3- {3- ( (cis)-3, 5-dimethyl-piperazine-1- carbonyl]-5-methyl-lH-pyrrol-2-ylmethylene}-4-(2-fluoro-phen yl)-1,3-dihydro- indol-2-one as a yellow solid (103.5 mg, 90%).

[0810]'H-NMR (400 MHz, DMSO-d6) 8 13. 66 (br s, 1H, pyrrole NH), 11.13 (br s, 1H, CONH), 7.46 (m, 1H, aromatic), 7.24 (m, 4H, aromatic), 6.96 (d, 1H, aromatic), 6.82 (s, 1H aromatic), 6.78 (d, 2H, aromatic), 6.04 (s, 1H, aromatic), 4.12 (m, 1H, CH), 3.41 (m, 1H, CH), 2.44 (m, 6H, CH+CH2+CH3), 2.05 (m, 1H, CH), 1.04 (m, 3H, CH3), 0.81 (m, 3H, CH3).

[08111 MS m/z457 [M--1].

Example 101.5- [4- (4-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 2,4-dimethyl-lH-pyrrole-3-carboxylic acid (3-diethylamino- propyl)-amide [0812] To a solution of 4- (4-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (3-diethylamino- propyl)-amide (69.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (4-fluoro-phenyl)-2-oxo- 1,2-dihydro-indol-3-ylidenemethyl]-2,4-dimethyl-lH-pyrrole-3 -carboxylic acid (3- diethylamino-propyl)-amide as a yellow solid (74.4 mg, 61%).

[0813] 1H-NMR (400 MHz, DMSO-d6) 8 13.47 (br s, 1H, pyrrole NH), 11.04 (br s, 1H, CONH), 7.55 (t, 1H, aromatic), 7.45 (m, 2H, aromatic), 7.37 (t, 1H aromatic), 7.

18 (t, 1H, CONH), 6.92 (d, 1H, aromatic), 6.78 (d, 1H, aromatic), 6.71 (s, 1H, aromatic), 3.18 (m, 2H, CH2), 2.44 (m, 6H, 3xCH2), 2.37 (s, 3H, CH3), 1.73 (s, 3H, CH3), 1.57 (m, 2H, CH2), 0.96 (t, 6H, 2xCH3).

[0814] MS m/z 487 [M--1].

Example 102. 2- [4- (4-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 5-methyl-lH-pyrrole-3-carboxylic acid (3-pyrrolidin-1-yl-propyl)- amide [0815] To a solution of 4- (4-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (3-pyrrolidin-1-yl- propyl)-amide (68. 5 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 2- [4- (4-fluoro-phenyl)-2-oxo- 1, 2-dihydro-indol-3-ylidenemethyl]-5-methyl-1H-pyrrole-3-carbo xylic acid (3- pyrrolidin-l-yl-propyl)-amide as a yellow solid (93.2 mg, 79%).

[0816] 'H-NMR (400 MHz, DMSO-d6) 8 13.88 (br s, 1H, pyrrole NH), 11.04 (br s, 1H, CONH), 7.93 (s, 1H, aromatic), 7.86 (t, 1H, CONH), 7.36 (m, 2H, aromatic), 7.20 (m, 3H, aromatic), 6.90 (d, 1H, aromatic), 6.74 (d, 1H, aromatic), 6.34 (s, 1H, aromatic), 3.10 (m, 2H, CH2), 2.40 (m, 6H, 3xCH2), 2.29 (s, 3H, CH3), 1.68 (m, 4H, 2xCH2), 1.59 (m, 2H, CH20.

10817] MS m/Z 471 [M--1]. ExamPle 103. 5- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]- 2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (3-diethylamino- propyl)-amide [0818] To a solution of 4-(3-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (3-diethylamino- propyl)-amide (69.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (3-fluoro-phenyl)-2-oxo- 1,2-dihydro-indol-3-ylidenemethyl]-2,4-dimethyl-lH-pyrrole-3 -carboxylic acid (3- diethylamino-propyl)-amide as a yellow solid (57.3 mg, 47%).

[0819] IH-NMR (400 MHz, DMSO-d6) 8 13.49 (br s, 1H, pyrrole NH), 11.07 (br s, 1H, CONH), 7.59 (m, 2H, aromatic), 7.32 (m, 3H, aromatic), 7.20 (t, 1H, CONH), 6.94 (d, 1H, aromatic), 6. 73 (m, 2H, aromatic), 3.18 (m, 2H, CH2), 2.45 (m, 6H, 3xCH2), 2.37 (s, 3H, CH3), 1.72 (s, 3H, CH3), 1.57 (m, 2H, CH2), 0.93 (t, 6H, <BR> <BR> <BR> 2xCH3).<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>[08201 MS mlz 487 [M--1 Example 104.3- 3, 5-Dimethyl-4- (4-methyl-piperazine-1-carbonyl)-lH-pyrrol-2- ylmethylene]-4- (3-trifluoromethyl-phenyl)-1, 3-dihydro-indol-2-one [0821] To a solution of 4- (3-trifluoromethyl-phenyl)-1, 3-dihydro-indol-2-one (69.3 mg, 0.25 mmol) and 3,5-dimethyl-4- (4-methyl-piperazine-l-carbonyl)-lH-pyrrole-2- carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. The solvent was evaporated and the solid was washed by ether for three times to provide pure product <BR> <BR> 3- [3, 5-dimethyl-4- (4-methyl-piperazine-l-carbonyl)-lH-pyrrol-2-ylmethylene]-4- (3- trifluoromethyl-phenyl)-1, 3-dihydro-indol-2-one (96.5 mg, 76%).

[0822] 1H-NMR (400 MHz, DMSO-d6) 8 13.44 (br s, 1H, pyrrole NH), 11.10 (br s, 1H, CONH), 7.76 (m, 4H, aromatic), 7.22 (t, 1H, aromatic), 6.95 (d, 1H, aromatic), 6.83 (d, 1H, aromatic), 6.58 (s, 1H, aromatic), 3.38 (m, 4H, 2xCH2), 2.29 (m, 7H, 2xCH2+CH3), 2.17 (s, 3H, CH3), 1.54 (s, 3H, CH3).

[0823] MS m/z 507 [M--1].

Example 105. 2,4-Dimethyl-5-12-oxo4- (3-trifluoromethyl-phenyl)-1, 2-dihydro- indol-3-ylidenemethyl]-lH-pyrrole-3-carboxylic acid (2- diethylamino-ethyl)-amide 10824] To a solution of 4- (3-trifluoromethyl-phenyl)-1, 3-dihydro-indol-2-one (69.3 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- diethylamino-ethyl)-amide (69.0 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide 2,4-dimethyl-5- [2-oxo-4- (3- <BR> <BR> trifluoromethyl-phenyl)-1, 2-dihydro-indol-3-ylidenemethyl]-lH-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide as a yellow solid (68 mg, 52%).

10825] IH-NMR (400 MHz, DMSO-d6) 8 13.49 (br s, 1H, pyrrole NH), 11. 10 (br s, 1H, CONH), 7.80 (m, ~1H, aromatic), 7.7 (m, 3H, aromatic), 7.31 (s, 1H, CONH), 7.21 (m, 1H, aromatic), 6.97 (d, 1H, aromatic), 6.83 (d, 1H, aromatic), 6.61 (s, 1H, aromatic), 3.22 (m, 2H, CH2), 2.40 (m, 6H, 3xCH2), 2.34 (s, 3H, CH3), 1.68 (s, 3H, CH3), 0.94 (m, 6H, 2xCH3).

[0826] MS m/z 523 [M--I].

Example 106.2,4-Dimethyl-5- [2-oxo-4- (3-trifluoromethyl-phenyl)-1,2-dihydro- indol-3-ylidenemethyl]-lH-pyrrole-3-carboxylic acid (2-pyrrolidin- 1-yl-ethyl)-amide [0827] To a solution of 4- (3-trifluoromethyl-phenyl)-1, 3-dihydro-indol-2-one (69.3 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2- pyrrolidin-l-yl-ethyl)-amide (68.5 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 2,4-dimethyl-5- [2- <BR> <BR> <BR> oxo-4- (3-trifluoromethyl-phenyl)-1, 2-dihydro-indol-3-ylidenemethyl]-lH-pyrrole-3- carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide as a yellow solid (69.2 mg, 53%).

[0828] 1H-NMR (400 MHz, DMSO-d6) # 13.47 (br s, 1H, pyrrole NH), 11. 10 (br s, 1H, CONH), 7.82 (m, 4H, aromatic), 7.44 (t, 1H, CONH), 7.22 (t, 1H, aromatic), 6.97 (dd, 1H, aromatic), 6.43 (dd, 1H, aromatic), 6.61 (s, 2H, aromatic), 3.28 (m, 2H, CH2), 2.51 (m, 2H, CH2), 2.44 (m, 4H, 2xCH2), 2.37 (s, 3H, CH3), 1.66 (s, 3H, CH3), 1.62 (m, 4H 2xCH2)..

[0829] MS m/z 523 [M++1]. Example 107. 2,4-Dimethyl-5- [2-oxo-4- (3-trifluoromethyl-phenyl)-1,2-dihydro- indol-3-ylidenemethyl]-lH-pyrrole-3-carboxylic acid (2- [1, 2, 3] triazol-1-yl-ethyl)-amide [0830] To a solution of 4-(3-trifluoromethyl-phenyl)-1, 3-dihydro-indol-2-one (69.3 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide (67.9 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 2,4-dimethyl-5- [2- <BR> <BR> <BR> oxo-4- (3-trifluoromethyl-phenyl)-1, 2-dihydro-indol-3-ylidenemethyl]-lH-pyrrole-3- carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide as a yellow solid (53 mg, 41%).

[0831]'H-NMR (400 MHz, DMSO-d6) 8 13.48 (br s, 1H, pyrrole NH), 11.06 (br s, 1H, CONH), 8.10 (s, 1H, aromatic), 7.81 (m, 4H, aromatic), 7.71 (d, 1H, aromatic), 7.63 (s, 1H, CONH+aromatic), 7.22 (t, 1H, aromatic), 6.66 (dd, 1H, aromatic), 6.83 (dd, 1H, aromatic), 6.59 (s, 1H, aromatic), 4.52 (t, 2H, CH2), 3.64 (m, 2H, CH2), 2.28 (s, 3H, CH3), 1.54 (s, 3H, CH3).

[0832] MS m/z 519 [M--1]. Example 108.5-Methyl-2- [2-oxo-4- (3-trifluoromethyl-phenyl)-1, 2-dihydro-indol- 3-ylidenemethyl]-lH-pyrrole-3-carboxylic acid (2-diethylamino- ethyl)-amide [08331 To a solution of 4- (3-trifluoromethyl-phenyl)-1, 3-dihydro-indol-2-one (69.3 mg, 0.25 mmol) and 2-formyl-5-methyl-lH-pyrrole-3-carboxylic acid (2- diethylamino-ethyl)-amide (65.3 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5-methyl-2-[2-oxo- 4- (3-trifluoromethyl-phenyl)-1, 2-dihydro-indol-3-ylidenemethyl]-lH-pyrrole-3- carboxylic acid (2-diethylamino-ethyl)-amide as a yellow solid (28 mg, 22%).

[0834] 1H-NMR (400 MHz, DMSO-d6) 8 13.81 (br s, 1H, pyrrole NH), 11.15 (br s, 1H, CONH), 8.01 (s, 1H, aromatic), 7.66 (m, SH, CONH+aromatic), 7.23 (t, 1H, aromatic), 6.95 (d, 1H, aromatic), 6.80 (dd, 1H, aromatic), 6.36 (d, 1H, aromatic), 3.33 (m, 2H, CH2), 2.50 (m, 6H, 3xCH2), 2.31 (s, 3H, CH3), 0.98 (t, 6H, 2xCH3).

10835] MS mlz 509 [M--1]. Example 109. 5-Methyl-2- [2-oxo-4- (3-trifluoromethyl-phenyl)-1, 2-dihydro-indol- 3-ylidenemethyl]-lH-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl- ethyl)-amide [0836] To a solution of 4- (3-trifluoromethyl-phenyl)-1, 3-dihydro-indol-2-one (69.3 mg, 0.25 mmol) and 2-formyl-5-methyl-lH-pyrrole-3-carboxylic acid (2-pyrrolidin-1- yl-ethyl)-amide (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5-methyl-2- [2-oxo-4- (3- <BR> <BR> <BR> trifluoromethyl-phenyl)-1, 2-dihydro-indol-3-ylidenemethyl]-1 H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide as a yellow solid (95 mg, 75%).

[0837] 1H-NMR (400 MHz, DMSO-d6) 8 13.79 (br s, 1H, pyrrole NH), 11.15 (br s, 1H, CONH), 7.99 (s, 1H, aromatic), 7.70 (m, 5H, CONH+aromatic), 7.23 (t, 1H, aromatic), 6.95 (dd, 1H, aromatic), 6.82 (dd, 1H, aromatic), 6.39 (m, 1H, aromatic), 3.13 (m, 2H, CH2), 2.47 (m, 6H, 3xCH2), 2.31 (s, 3H, CH3), 1.69 (m, 4H 2xCH2).

[0838] MS m/z 509 [M++1]. Example 110.5-Methyl-2- [2-oxo-4- (3-trifluoromethyl-phenyl)-1, 2-dihydro-indol- 3-ylidenemethyll-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1- yl-ethyl)-amide [0839] To a solution of 4- (3-trifluoromethyl-phenyl)-1, 3-dihydro-indol-2-one (69.3 mg, 0.25 mmol) and 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide (61.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5-methyl-2- [2-oxo- 4- (3-trifluoromethyl-phenyl)-1, 2-dihydro-indol-3-ylidenemethyl]-1H-pyrrole-3- carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide as a yellow solid (93.6 mg, 74%).

[0840]'H-NMR (400 MHz, DMSO-d6) S 13.80 (br s, 1H, pyrrole NH), 11.17 (br s,.

1H, CONH), 8.01 (m, 1H, aromatic), 7.96 (dd, 2H, aromatic), 7.77 (m, 1H, aromatic), 7.73 (d, 1H, aromatic), 7.68 (m, 3H, aromatic), 7.72 (t, 1H, aromatic), 6.96 (dd, 1H, aromatic), 6.83 (dd, 1H, aromatic), 6.34 (d, 1H aromatic), 4.45 (t, 2H, CH2), 3.44 (m, 2H, CH2), 2.30 (s, 3H, CH3).

[0841] MS m/z 505 [M--1].

Example111.3-13-((cis)-3, 5-Dimethyl-piperazine-l-carbonyl]-5-methyl-lH- <BR> <BR> pyrrol-2-ylmethylene]-4-(2-trifluoromethyl-phenyl)-1,3-dihyd ro-<BR> <BR> indol-2-one [0842} To a solution of 4- (3-trifluoromethyl-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 3-[(cis)-3, 5-dimethyl-piperæine-1-carbonyl]-5-methyl-lH- pyrrole-2-carbaldehyde (62.3 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3- [3- ( (cis)-3, 5-dimethyl- piperazine-l-carbonyl]-5-methyl-lH-pyrrol-2-ylmethylene]-4-( 2-trifluoromethyl- phenyl)-1, 3-dihydro-indol-2-one as a yellow solid (92.7 mg, 73%).

[08433 'H-NMR (400 MHz, DMSO-d6) 8 13.61 (br s, 1H, pyrrole NH), 11.15 (brs, 1H, CONH), 7.70 (m, 4H, aromatic), 7.22 (t, 1H, aromatic), 6,95 (dd, 1H, aromatic), 6.90 (s, 1H, aromatic), 6.69 (d, 1H, aromatic), 6.00 (d, 1H, aromatic), 4.01 (m, 1H, CH), 3,47 (m, 1H, CH), 2. 32 (m, 4H, 2xCH2), 2.32 (m, 3H, CH3), 0.96 (m, 6H, 2xCH3).

[0844J MS m/z 507 [M--1]. Example 112. 2,4-Dimethyl-5- [2-oxo-4- (3-trifluoromethyl-phenyl)-1,2-dihydro- indol-3-ylidenemethyl]-lH pyrrole-3-carboxylic acid (3- diethylamino-propyl)-amide 10845] To a solution of 4- (3-trifluoromethyl-phenyl)-1, 3-dihydro-indol-2-one (69.3 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (3- diethylamino-propyl)-amide (69.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 2,4-dimethyl-5- [2- <BR> <BR> <BR> oxo-4- (3-trifluoromethyl-phenyl)-1, 2-dihydro-indol-3-ylidenemethyl]-11-pyrrole-3- carboxylic acid (3-diethylamino-propyl)-amide as a yellow solid (72.6 mg, 54%).

[0846] 1H-NMR (400 MHz, DMSO-d6) 8 13.48 (br s, 1H, pyrrole NH), 11. 00 (br s, 1H, CONH), 7.88 (m, 1H, aromatic), 7.78 (m, 3H, aromatic), 7.60 (m, 1H, aromatic), 7.22 (t, 1H, aromatic), 6.97 (d, 1H, aromatic), 6.83 (d, 1H, aromatic), 6.61 (s, 1H, aromatic), 3.32 (m, 2H, CH2), 3. 20 (m, 2H, CH2), 2.49 (m, 6H, 3xCH2), 2.37 (s, 3H, CH3), 1.61 (s, 3H, CH3), 0.96 (s, 6H, 2xCH3).

10847] MS m/z 537 [M--1]. Example 113. 5-Methyl-2- [2-oxo-4- (3-trifluoromethyl-phenyl)-1, 2-dihydro-indol- 3-ylidenemethyl]-lH-pyrrole-3-carboxylic acid (3-pyrrolidin-1-yl- propyl)-amide [0848] To a solution of 4- (3-trifluoromethyl-phenyl)-1, 3-dihydro-indol-2-one (69.3 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (3- pyrrolidin-1-yl-propyl)-amide (69.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5-methyl-2-[2-oxo- 4- (3-trifluoromethyl-phenyl)-1, 2-dihydro-indol-3-ylidenemethyl]-1 H-pyrrole-3- carboxylic acid (3-pyrrolidin-1-yl-propyl)-amide as a yellow solid (52.2 mg, 40%).

[0849] 1H-NMR (400 MHz, DMSO-d6) 8 13.85 (br s, 1H, pyrrole NH), 11.05 (br s, 1H, CONH), 7.95 (s, 1H, aromatic), 7.85 (t, 1H, CONH), 7.67 (m, 4H, aromatic), 7.22 (t, 1H, aromatic), 6.96 (d, 1H, aromatic), 6.80 (dd, 1H, aromatic), 6.35 (d, 1H, aromatic), 3.42 (s, 2H, CH2), 3.10 (q, 2H, CH2), 2.49 (m, 6H, 3xCH2), 2.30 (s, 3H, CH3), 1.69 (m, 4H 2xCH2).

[0850] MS Hz 521 [M--1].

Example 114.3- 3-Methyl-4- (4-methyl-piperazine-1-carbonyl)-lH-pyrrol-2- ylmethylene]-4- (3-trifluoromethyl-phenyl)-1, 3-dihydro-indol-2-one [0851] To a solution of 4- (3-trifluoromethyl-phenyl)-1, 3-dihydro-indol-2-one (693 mg, 0.25 mmol) and 3-methyl-4-(4-methyl-piperazine-1-carbonyl)-lH-pyrrole-2- carbaldehyde (61.2 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3- [3-methyl-4- (4-methyl-piperazine-1- carbonyl)-1H-pyrrol-2-ylmethylene]-4- (3-trifluoromethyl-phenyl)-1, 3-dihydro-indol- 2-one as a yellow solid (46.9 mg, 38%).

[0852]'H-NMR (400 MHz, DMSO-d6) 8 13.45 (br s, 1H, pyrrole NH), 11.16 (br s, 1H, CONH), 7.98 (m, 1H, aromatic), 7.80 (m, 3H, aromatic), 7.39 (d, 1H, aromatic), 7.25 (t, 1H, aromatic), 6.96 (dd, 1H, aromatic), 6.85 (d, 1H, aromatic), 6.66 (s, 1H, aromatic), 3.38 (m, 4H, 2xCH2), 2.25 (m, 4H, 2xCH2), 2.17 (s, 3H, CH3), 1.56 (s, 3H, CH3).

[0853] MS m/z 493 [M-1].

Example 115.3- [4- ( (cis)-3, 5-dimethyl-piperazine-1-carbonyl]- 3-Methyl-lH- pyrrol-2-ylmethylene]-4- (3-trifluoromethyl-phenyl)-1, 3-dihydro- indol-2-one [0854} To a solution of 4- (3-trifluoromethyl-phenyl)-1, 3-dihydro-indol-2-one (69.3 mg, 0.25 mmol) and 4-[(cis)-3, 5-dimethyl-piperazine-1-carbonyl]-3-methyl-lH- pyrrole-2-carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3- {4-((cis)-3, 5-dimethyl- piperazine-l-carbonyl]-3-methyl-lH-pyrrol-2-ylmethylene}-4- (3-trifluoromethyl- phenyl)-1, 3-dihydro-indol-2-one as a yellow solid (34.3 mg, 27%).

[08551'H-NMR (400 MHz, DMSO-d6) 8 13.47 (br s, 1H, pyrrole NH), 11.16 (br s, 1H, CONH), 7.88 (m, 1H, aromatic), 7.81 (m, 3H, aromatic), 7.6 (dd, 1H, aromatic), 7.25 (t, 1H, aromatic), 6.96 (d, 1H, aromatic), 6.85 (d, 1H, aromatic), 6.66 (s, 1H, aromatic), 3.32 (m, 1H, CH), 2.46 (m, IH, CH), 2.50 (m, 4H, 2xCH2), 1. 54 (s, 3H, CH3), 0.92 (m, 6H, 2xCH3).

[0856] MS m/z 507 [M--1].

Example 116.4- (3-Chloro-4-fluoro)-3- [3, 5-dimethyl-4- (4-methyl-piperazine-l- carbonyl)-lH-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one [0857] To a solution of 4- (3-chloro-4-fluoro-phenyl)-1, 3-dihydro-indol-2-one (65.4 mg, 0.25 mmol) and 3, 5-dimethyl4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrole-2- carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. The solvent was evaporated and the solid was washed by ether for three times to provide pure product 4- (3-chloro-4-fluoro)-3- [3, 5-Dimethyl-4- (4-methyl-piperazine-1-carbonyl)-lH- pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one (59 mg, 48%).

Example 117. 5- 4- (3-Chloro-4-fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- diethylamino-ethyl)-amide [0858] To a solution a solution of 4- (3-Chloro-4-fluoro-phenyl)-2-oxo-1, 2-dihydro- indol-2-one (65.4 mg, 0.25 mmol) and 5-formyl-2, 4- dimethyl-lH-pyrrole-3- carboxylic acid (2-diethylamino-ethyl)-amide (69.0 mg, 0.26 mmol) in ethanol (2 ml) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide 5- [4- (3-Chloro-4- fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3-ylidenemethyl]-2,4-dimethyl-lH-pyrrole-3- carboxylic acid (2-diethylamino-ethyl)-amide (72 mg, 57%).

[0859] IH-NMR (400MHz), DMSO-d6) 8 13. 47 (br s, 1H, pyrrole NH), 11.07 (br s, 1H, CONH), 7.70 (d, 1H aromatic), 7.61 (t, 1H, CONH), 7.46 (m, 1H aromatic), 7.35 (m, 1H, aromatic), 7.20 (t, 1H, aromatic), 6.95 (d, 1H, aromatic), 6.82 (d, 1H, aromatic), 6.73 (d, 1H, aromatic), 3,24 (m, 2H, CH2), 2.50 (m, 6H, 3xCH2), 2. 38 (s, 3H, CH3), 1.78 (s, 3H, CH3), 0.95 (t, 6H, 2xCH3).

[0860] MS m/z 507 [M--1].

Example 118. 5- [4- (3-Chloro-4-fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide [0861] To a solution of 4- (3-chloro-4-fluoro-phenyl)-1, 3-dihydro-indol-2-one (65.4 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide (67.9 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5- [4- (3-chloro-4- fluoro-phenyl)-2-oxo-1,2-dihydro-indol-3-ylidenemethyl]-2,4- dimethyl-lH-pyrrole-3- carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide as a yellow solid (53 mg, 45%).

[0862] 'H-NMR (400 MHz, DMSO-d6) 8 13.47 (br s, 1H, pyrrole NH), 11.07 (br s, 1H, CONH), 8. 10 (s, 1H, aromatic), 7.70 (m, 2H, aromatic), 7.63 (t, 2H, CONH+aromatic), 7.46 (m, 1H, aromatic), 7.19 (t, 1H, aromatic), 6.93 (d, 1H, aromatic), 6.80 (d, 1H, aromatic), 6.71 (s, 1H, aromatic), 4.53 (m, 2H, CH2), 3.64 (m, 2H, CH2), 2.30 (s, 3H, CH3), 1.69 (s, 3H, CH3).

[0863] MS m/z 503 [M--1].

Example 119.2- [4- (3-Chloro-4-fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (2- pyrrolidin-1-yl-ethyl)-amide [0864] To a solution of 4- (3-chloro-4-fluoro-phenyl)-1, 3-dihydro-indol-2-one (65.4mg, 0.25 mmol) and 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (2- pyrrolidin-1-yl-ethyl)-amide (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 2- [4- (3-chloro-4- fluoro-phenyl)-2-oxo-1,2-dihydro-indol-3-ylidenemethyl]-5-me thyl-lH-pyrrole-3- carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide as a yellow solid (89 mg, 72%).

[0865] 'H-NMR (400 MHz, DMSO-d6) 8 13. 79 (br s, 1H, pyrrole NH), 11.13 (br s, 1H, CONH), 8.03 (s, 1H, aromatic), 7.80 (t, 1H, CONH), 7.50 (d, 1H, aromatic), 7.42 (t, 1H, aromatic), 7.32 (m, 1H, aromatic), 7.21 (t, 1H, aromatic), 6.93 (d, 1H, aromatic), 6.78 (d, 1H, aromatic), 6.43 (s, 1H, aromatic), 3.21 (m, 2H, CH2), 2.50 (m, 6H, 3xCH2), 2.31 (s, 3H, CH3), 1.67 (m, 4H 2xCH2).

[0866] MS m/z 491 [M--1]. Example 120. 2- [4- (3-Chloro-4--fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-5-methyl-1H-pyrrole-3-carboxylic acid (2- [1,2,3jtriazol-1-yl-ethyl)-amide [0867] To a solution of 4- (3-chloro-4-fluoro-phenyl)-1, 3-dihydro-indol-2-one (65.4 mg, 0.25 mmol) and 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide (61. 8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 2- [4- (3-chloro-4-- fluoro-phenyl)-2-oxo-1,2-dihydro-indol-3-ylidenemethyl]-5-me thyl-lH-pyrrole-3- carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide as a yellow solid (85 mg, 69%).

[0868] 1H-NMR (400 MHz, DMSO-d6) 8 13.81 (br s, 1H, pyrrole NH), 11.15 (br s, 1H, CONH), 8.07 (m, 1H, aromatic), 7.98 (d, 2H, aromatic), 7.74 (s, 1H, aromatic), 7.52 (d, 1H, aromatic), 7.47 (t, 1H, aromatic), 7.32 (m, 1H, aromatic), 7.22 (t, 1H, aromatic), 6.94 (d, 1H, aromatic), 6.78 (d, 1H, aromatic), 6.36 (s, 1H, aromatic), 4.53 (m, 2H, CH2), 3.53 (m, 2H, CH2), 2. 30 (s, 3H, CH3).

[0869] MS m/z 489 [M--1]. Example 121. 2- [4- (3-Chloro-4-fluoro-phenyl)-2-oxo-1, 2-dihydro-indol-3- ylidenemethyl]-5-m, pyrrole-3-carboxylic acid (3- pyrrolidin-1-yl-propyl)-amide [0870] To a solution of 4- (3-chloro-4-fluoro-phenyl)-1, 3-dihydro-indol-2-one (65.4 mg, 0.25 mmol) and 2-formyl-5-methyl-lH-pyrrole-3-carboxylic acid (3-pyrrolidin-1- yl-propyl)-amide (68.5 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 2- [4- (3-chloro-4-fluoro- phenyl)-2-oxo-1,2-dihydro-indol-3-ylidenemethyl]-5-methyl-1H -pyrrole-3-carboxylic acid (3-pyrrolidin-1-yl-propyl)-amide as a yellow solid (103 mg, 81%).

108711'H-NMR (400 MHz, DMSO-d6) 8 13.86 (br s, 1H, pyrrole NH), 11.05 (br s, 1H, CONH), 8.01 (s, 1H, aromatic), 7.91 (t, 1H, CONH), 7.50 (d, 1H, aromatic), 7.41 (t, 1H, aromatic), 7.31 (m, 1H, aromatic), 7.20 (t, 1H, aromatic), 6.93 (d, 1H, aromatic), 6.77 (d, 1H, aromatic), 6.40 (s, 1H, aromatic), 3.32 (m, 2H, CH2), 3.14 (m, 2H, CH2), 2.41 (m, 6H, 3xCH2), 2.31 (s, 3H, CH3), 1.67 (m, 4H 2xCH2), [0872] MS m/z 506 [M--1].

Example 122.4- (4-Chloro-phenyl)-3- {3, 5-dimethyl-4- [3- (4-methyl-piperazin-l- yl)-3-oxo-propyl]-lH-pyrrol-2-ylmethylene}-1, 3-dihydro-indol-2- one [0873] To a solution of 4- (4-chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 3,5-dimethyl-4- [3- (4-methyl-piperazin-1-yl)-3-oxo-propyl]-lH-pyrrole-2- carbaldehyde (72.1 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 4- (4-chloro-phenyl)-3- {3, 5-dimethyl-4- [3- (4-methyl-piperazin-1-yl)-3-oxo-propyl]-lH-pyrrol-2-ylmethyl ene}-1, 3-dihydro- indol-2-one as a yellow solid (47.4 mg, 38%).

[0874] 'H-NMR (400 MHz, DMSO-d6) 6 13. 27 (br s, 1H, pyrrole NH), 11.40 (br s, 1H, CONH), 7.60 (d, 2H, aromatic), 7.42 (dd, 2H, aromatic), 7.10 (t, 1H, aromatic), 6.91 (d, 1H, aromatic), 6.75 (d, 1H, aromatic), 6.66 (s, 1H, aromatic), 3.40 (m, 4H, 2xCH2), 2.52 (m, 4H, 2xCH2), 2.36 (m, 4H, 2xCH2) 2.24 (s, 3H, CH3), 2.19 (s, 3H, CH3), 1.59 (s, 3H, CH3).

[0875] MS m/z 503 [M++1].

Example 123. 4-(2-Fluoro-phenyl)-3-[3-methyl-4-(4-methyl-piperazine-1- carbonyl)-lB-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one [0876] To a solution of 4-(2-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 3-methyl-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrole-2-car baldehyde (61.2 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 4- (2-fluoro-phenyl)-3- [3-methyl-4- (4-methyl- piperazine-1-carbonyl)-1H-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one as a yellow solid (40 mg, 36%).

[0877] 'H-NMR (400 MHz, DMSO-d6) 8 13.51 (br s, 1H, pyrrole NH), 11.15 (brs, 1H, CONH), 7.57 (m, 1H, aromatic), 7.42 (m, 4H, aromatic), 7.25 (t, 1H, aromatic), 6.97 (d, 1H, aromatic), 6.85 (d, 1H, aromatic), 6.69 (s, 1H, aromatic), 3.40 (m, 4H, 2xCH2), 2.25 (m, 4H, 2xCH2), 2.17 (s, 3H, CH3), 1.62 (s, 3H, CH3).

[0878] MS m/z 445 [M++1].

Example 124.4-(4-Fluoro-phenyl)-3-13-methyl-4-(4-methyl-piperazine-1 - carbonyl)-lH-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one 10879] To a solution of 4- (4-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 3-methyl-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrole-2-car baldehyde (61.2 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 4- (4-fluoro-phenyl)-3- [3-methyl-4- (4-methyl- piperazine-1-carbonyl)-1H-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one as a yellow solid (39 mg, 36%).

[0880]'H-NMR (400 MHz, DMSO-d6) 8 13. 50 (br s, 1H, pyrrole NH), 11.12 (br s, 1H, CONH), 7.48 (m, 2H, aromatic), 7.39 (m, 3H, aromatic), 7.22 (t, 1H, aromatic), 6.93 (d, 1H, aromatic), 6.80 (t, 2H, aromatic), 3.45 (m, 4H, 2xCH2), 2.26 (m, 4H, 2xCH2), 2.17 (s, 3H, CH3), 1.67 (s, 3H, CH3).

[0881] MS m/z 445 [M++1].

Example 125.4- (4-Chloro-phenyl)-3- [3-methyl-4- (4-methyl-piperazine-l- carbonyl)-lH-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one [0882] To a solution of 4- (4-chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 3-methyl-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrole-2-car baldehyde (61.2 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 4- (4-chloro-phenyl)-3- [3-methyl-4- (4-methyl- piperazine-1-carbonyl)-1H-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one as a yellow solid (47 mg, 35%).

0883] IH-NMR (400 MHz, DMSO-d6) 8 13.46 (br s, 1H, pyrrole NH), 11.12 (br s, 1H, CONH), 7.60 (dd, 2H, aromatic), 7.42 (d, 2H, aromatic), 7.30 (d, 1H, aromatic), 7.20 (t, 1H, aromatic), 6.90 (d, 1H, aromatic), 6.80 (d, 1H, aromatic), 6.72 (s, 1H, aromatic), 3.44 (m, 4H, 2xCH2), 2.26 (m, 4H, 2xCH2), 2.17 (s, 3H, CH3), 1.67 (s, 3H, CH3).

[0884] MS m/z461 [M++1].

Example 126.4- (4-Bromo-phenyl)-3- [3-methyl-4- (4-methyl-piperazine-1- carbonyl)-lH-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one [0885] To a solution of 4- (4-bromo-phenyl)-1, 3-dihydro-indol-2-one (72.0 mg, 0.25 mmol) and 3-methyl-4-(4-methyl-pìperazine-1-carbonyl)-lH-pyrrole-2-ca rbaldehyde (61.2 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 4- (4-bromo-phenyl)-3- [3-methyl-4- (4-methyl- piperazine-1-carbonyl)-1H-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one as a yellow solid (42.8 mg, 34%).

[0886] 1H-NMR (400 MHz, DMSO-d6) 8 13.46 (br s, 1H, pyrrole NH), 11.12 (br s, 1H, CONH), 7.75 (d, 2H, aromatic), 7.40 (d, 3H, aromatic), 7.23 (t, 1H, aromatic), 6.93 (d, 1H, aromatic), 6.81 (d, 1H, aromatic), 6.71 (s, 1H, aromatic), 3.46 (m, 4H, 2xCH2), 2.26 (m, 4H, 2xCH2), 2. 17 (s, 3H, CH3), 1.67 (s, 3H, CH3).

[0887] MS m/z 507 [M++1].

Example 127. 4-(3-Bromo-phenyl)-3-[3-methyl-4-(4-methyl-piperazine-1- carbonyl)-lH-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one [0888] To a solution of 4- (3-bromo-phenyl)-1, 3-dihydro-indol-2-one (72.0 mg, 0.25 mmol) and 3-methyl-4-(4-methyl-piperazine-1-carbonyl)-lH-pyrrole-2-car baldehyde (61.2 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 4- (3-bromo-phenyl)-3- [3-methyl-4- (4-methyl- piperazine-1-carbonyl)-lH-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one as a yellow solid (61.4 mg, 49%).

[0889] 'H-NMR (400 MHz, DMSO-d6) 8 13.50 (br s, 1H, pyrrole NH), 11.14 (br s, 1H, CONH), 7.72 (dd, 1H, aromatic), 7.67 (d, 1H, aromatic), 7.53 (t, 1H, aromatic), 7.45 (d, 1H, aromatic), 7.40 (d, 1H, aromatic), 7.23 (d, 1H, aromatic), 6.94 (s, 1H, aromatic), 6.82 (d, 2H, aromatic), 3.46 (m, 4H, 2xCH2), 2.26 (m, 4H, 2xCH2), 2.17 (s, 3H, CH3), 1.67 (s, 3H, CH3).

[0890] MS m/z 504 [M++1].

Example 128.4- (4-Methoxy-phenyl)-3- 3-methyl-4- (4-methyl-piperazine-1- carbonyl)-lH-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one [0891] To a solution of 4- (4-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 3-methyl-4- (4-methyl-piperazine-1-carbonyl)-lH-pyrrole-2- carbaldehyde (61.2 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 4- (4-methoxy-phenyl)-3- [3-methyl-4- (4- <BR> <BR> <BR> <BR> methyl-piperazine-l-carbonyl)-1H-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one as a yellow solid (94 mg, 82%).

[0892]'H-NMR (400 MHz, DMSO-d6) 8 13.49 (br s, 1H, pyrrole NH), 11.08 (br s, 1H, CONH), 7.74 (d, 1H, aromatic), 7.35 (d, 1H, aromatic), 7.33 (s, 1H, aromatic), 7.20 (t, 1H, aromatic), 7.11 (m, 2H, aromatic), 6.89 (d, 1H, aromatic), 6.84 (s, 1H, aromatic), 6.79 (d, 1H, aromatic), 3.82 (s, 3H, OCH3), 3.45 (m, 4H, 2xCH2), 2.25 (m, 4H, 2xCH2), 2.17 (s, 3H, CH3), 1.66 (s, 3H, CH3).

[0893] MS m/z 457 [M++1].

Example 129.4- (3-Methoxy-phenyl)-3- [3-methyl-4- (4-methyl-piperazine-1- carbonyl)-lH-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one [0894] To a solution of 4-(3-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 3-methyl-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrole-2- carbaldehyde (61.2 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 4- (3-methoxy-phenyl)-3- [3-methyl-4- (4- methyl-piperazine-l-carbonyl)-IH-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one as a yellow solid (46.4 mg, 41%).

[0895] 'H-NMR (400 MHz, DMSO-d6) 6 13.50 (br s, 1H, pyrrole NH), 11. 10 (br s, 1H, CONH), 7.47 (t, 1H, aromatic), 7.38 (d, 1H, aromatic), 7.20 (t, 1H, aromatic), 7.06 (dd, 1H, aromatic), 6.99 (dd, 2H, aromatic), 6.91 (d, 2H, aromatic), 6.81 (d, 1H, aromatic), 3.78 (s, 3H, OCH3), 3.45 (m, 4H, 2xCH2), 2.26 (m, 4H, 2xCH2), 2.17 (s, 3H, CH3), 1.65 (s, 3H, CH3).

[08961 MS m/z 457 [M++1]. Example 130.3- 3-Methyl-4- (4-methyl-piperazine-l-carbonyl)-lH-pyrrol-2- ylmethylene]-4-phenyl-1, 3-dihydro-indol-2-one [0897] To a solution of 4-phenyl-1, 3-dihydro-indol-2-one (52.3 mg, 0.25 mmol) and 3-methyl-4- (4-methyl-piperazine-1-carbonyl)-1H-pyrrole-2-carbaldehyde (61.2 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3- [3-methyl-4- (4-methyl-piperazine-1.-carbonyl)-lH- pyrrol-2-ylmethylene]-4-phenyl-1, 3-dihydro-indol-2-one as a yellow solid (40.6 mg, 38%).

[0898] IH-NMR (400 MHz, DMSO-d6) 8 13.50 (br s, 1H, pyrrole NH), 11.11 (br s, 1H, CONH), 7.57 (m, 3H, aromatic), 7.44 (dd, 2H, aromatic), 7.36 (d, 1H, aromatic), 7.21 (t, 1H, aromatic), 6.92 (dd, 1H, aromatic), 6.80 (d, 2H, aromatic), 3.44 (s, 3H, OCH3), 3.41 (m, 4H, 2xCH2), 2.25 (m, 4H, 2xCH2), 2.17 (s, 3H, CH3), 1.59 (s, 3H, <BR> <BR> <BR> CH3).<BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>[0899] MS m/z 427 [M++1].

Example 131. 3- [4- ( (cis)-3, 5-Dimethyl-piperazine-l-carbonyl]- 3-methyl-lH- pyrrol-2-ylmethylene]-4- (4-fluoro-phenyl)-1, 3-dihydro-indol-2-one [0900] To a solution of 4- (4-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 4- [ (cis)-3, 5-dimethyl-piperazine-1-carbonyl]-3-methyl-lH-pyrrole-2- carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3- {4-((cis)-3, 5-dimethyl-piperazine-1- carbonyl]-3-methyl-1H-pyrrol-2-ylmethylene}-4-(4-fluoro-phen yl)-1, 3-dihydro- indol-2-one as a yellow solid (57.8 mg, 50%).

[0901] 'H-NMR (400 MHz, DMSO-d6) 8 13.49 (br s, 1H, pyrrole NH), 11.12 (brs, 1H, CONH), 7.49 (m, 2H, aromatic), 7.39 (m, 3H, aromatic), 7.21 (t, 1H, aromatic), 6.92 (d, 1H, aromatic), 6.80 (t, 2H, aromatic), 4.09 (br, 1H, CH), 3.67 (br, 1H, CH), 2.57 (m, 2H, CH2), 2.26 (m, 2H, 2xCH), 1.66 (s, 3H, CH3), 0.92 (s, 6H, 2xCH3). <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>[0902] MS m/z 458 [M--1].<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>Example 132. 4- (4-Chloro-phenyl)-3- [4- [ (cis)-3, 5-dimethyl-piperazine-1-<BR> <BR> <BR> <BR> <BR> <BR> carbonyl]-3-methyl-lH-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2- one [0903] To a solution of 4- (4-chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and 4- [ (cis)-3, 5-dimethyl-piperazine-1-carbonyl]-3-methyl-lH-pyrrole-2- carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 4- (4-chloro-phenyl)-3- {4- [ (cis)-3, 5- dimethyl-piperazine-l-carbonyl]-3-methyl-1H-pyrrol-2-ylmethy lene]-1, 3-dihydro- indol-2-one as a yellow solid (29 mg, 25%).

[0904] IH-NMR (400MHz, DMSO-d6) 6 13.44 (br s, 1H, pyrrole NH), 11.12 (brs, 1H, CONH), 7.61 (m, 2H, aromatic), 7.46 (dd, 2H, aromatic), 7.37 (d, 1H, aromatic), 7.22 (t, 1H, aromatic), 6.93 (t, 1H, aromatic), 6.82 (d, 1H, aromatic), 6.72 (s, 1H, aromatic), 4.21 (br, 1H, CH), 3.61 (br, 1H, CH), 2.57 (m, 2H, CHa), 2.28 (m, 2H, 2xCH), 1.61 (s, 3H,, CH3), 0.92 (m, 6H, 2xCH3). <BR> <BR> <P>[0905] MS m/z 473 [M--1].<BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>Example 133. 4- (4-Bromo-phenyl)-3- 4- (3, 5-dimethyl-piperazine-1-carbonyl)-3-<BR> <BR> <BR> methyl-lH-pyrrol-2-ylmethylene]-1, 3-dihydro-indol-2-one [0906] To a solution of 4- (4-bromo-phenyl)-1, 3-dihydro-indol-2-one (72. 0 mg, 0.25 mmol) and 4-[(cis)-3,5-dimethyl-piperazine-1-carbonyl]-3-methyl-1H-pyr role-2- carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 4- (4-bromo-phenyl)-3- [4- [ (cis)-3, 5- dimethyl-piperazine-1-carbonyl]-3-methyl-1H-pyrrol-2-ylmethy lene]-1, 3-dihydro- indol-2-one as a yellow solid (79 mg, 61%).

[0907] 'H-NMR (400 MHz, DMSO-d6) 8 13.43 (br s, 1H, pyrrole NH), 11.12 (br s, 1H, CONH), 7.76 (dd, 2H, aromatic), 7.39 (m, 3H, aromatic), 7.22 (t, 1H, aromatic), 6.93 (d, 1H, aromatic), 6.81 (d, 1H, aromatic), 6.70 (s, 1H, aromatic), 4.20 (br, 1H, CH), 3.60 (br, 1H, CH), 2.58 (m, 2H, CH2), 2.27 (m, 2H, CH), 1.63 (s, 3H, CH3), 0.92 (s, 6H, 2xCH3).

109081 MS m/z 519 [M++1].

Example 134.3- [4- ( (cis)-3, 5-dimethyl-piperazine-1-carbonyl]- 3-methyl-lH- pyrrol-2-ylmethylenel-4- (4-methoxy-phenyl)-1, 3-dihydro-indol-2- one [0909] To a solution of 4-(4-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 4- [ (cis)-3, 5-dimethyl-piperazine-1-carbonyl]-3-methyl-1H-pyrrole-2- carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3-{4-((cis)-3, 5-dimethyl-piperazine-1- carbonyl]-3-methyl-1H-pyrrol-2-ylmethylene}-4- (4-methoxy-phenyl)-1, 3-dihydro- indol-2-one as a yellow solid (74 mg, 63%).

[0910]'H-NMR (400 MHz, DMSO-d6) 8 13.47 (br s, 1H, pyrrole NH), 11.08 (br s, 1H, CONH), 7.34 (m, 3H, aromatic), 7.19 (t, 1H, aromatic), 7.11 (dd, 2H, aromatic), 6.89 (d, 1H, aromatic), 6.84 (s, 1H, aromatic), 6.78 (s, 1H, aromatic), 3.82 (s, 3H, OCH3), 4.45 (br, 1H, CH), 4.0 (br, 1H, CH), 2.58 (m, 2H, CH2), 2.29 (m, 2H, CH), 1.65 (s, 3H, CH3), 0.92 (s, 6H, 2xCH3).

[0911] MS m/z 471 [M++1].

Example 135.3- [4- ( (cis)-3, 5-dimethyl-piperazine-1-carbonylJ- 3-methyl-lH- pyrrol-2-ylmethylene]-4- (3-methoxy-phenyl)-1, 3-dihydro-indol-2- one [0912] To a solution of 4- (3-methoxy-phenyl)-1, 3-dihydro-indol-2-one (59.8 mg, 0.25 mmol) and 4- [(cis)-3, 5-dimethyl-piperazine-1-carbonyl]-3-methyl-1H-pyrrole-2- carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops).

The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3- [4- ( (cis)-3, 5-dimethyl-piperazine-l- carbonyl]-3-methyl-lH-pyrrol-2-ylmethylene]-4- (3-methoxy-phenyl)-1, 3-dihydro- indol-2-one as a yellow solid (42 mg, 36%).

[0913] 'H-NMR (400 MHz, DMSO-d6) 8 13.43 (br s, 1H, pyrrole NH), 11.10 (br s, 1H, CONH), 7.46 (q, 1H, aromatic), 7.36 (d, 1H, aromatic), 7.21 (t, 1H, aromatic), 7.06 (dd, 1H, aromatic), 6.99 (dd, 2H ; aromatic), 6.91 (d, 2H, aromatic), 6.81 (d, 1H, aromatic), 3.78 (s, 3H, OCH3), 4.30 (br"1H, CH), 4.00 (br, 1H, CH), 2.58 (m, 2H, CH2), 2.29 (m, 2H, CH), 1.64 (s, 3H, CH3), 0.92 (s, 6H, 2xCH3).

[0914] MS mlz 469 [M--1].

Example 136.3- [4- ( (cis)-3, 5-Dimethyl-piperazine-l-carbonyl]- 3-methyl-lH- pyrrol-2-ylmethylene]-4-phenyl-1, 3-dihydro-indol-2-one [0915] To a solution of 4-phenyl-1, 3-dihydro-indol-2-one (52.3 mg, 0.25 mmol) and 4- [ (cis)-3, 5-dimethyl-piperazine-1-carbonyl]-3-methyl-1H-pyrrole-2-carb aldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3- [4- ( (cis)-3, 5-dimethyl-piperazine-l-carbonyl]- 3- methyl-lH-pyrrol-2-ylmethylene]-4-phenyl-1, 3-dihydro-indol-2-one as a yellow solid (21.5 mg, 20%).

[0916] 1H-NMR (400 MHz, DMSO-d6) # 13.49 (br s, 1H, pyrrole NH), 11.10 (br s, 1H, CONH), 7.56 (m, 3H, aromatic), 7.44 (d, 2H, aromatic), 7.35 (d, 1H, aromatic), 7.22 (d, 1H, aromatic), 6.92 (d, 1H, aromatic), 6.81 (m, 2H, aromatic), 4.35 (br, 1H, CH), 3.70 (br, 1H, CH), 2.58 (m, 2H, CH2), 2.29 (m, 2H, CH), 1.58 (s, 3H, CH3), 0.92 (s, 6H, 2xCH3).

[0917] MS m/z 469 [M--1]. <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>Example 137. 4- (4-Chloro-phenyl)-3- [4- [3- ( (cis)-3, 5-dimethyl-piperazin-1-yl]-3- oxo-propyl]-3, 5-dimethyl-1H-pyrrol-2-ylmethylene]-1,3-dihydro- indol-2-one [0918] To a solution of 4- (4-chloro-phenyl)-1, 3-dihydro-indol-2-one (60.9 mg, 0.25 mmol) and3- [ (cis)-3, 5-dimethyl-piperazin-l-yl]-3-oxo-propyl]-3, 5-dimethyl-177- pyrrole-2-carbaldehyde (75.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 4- (4-chloro-phenyl)-3- [4- [3- ((cis)-3, 5-dimethyl-piperazin-1-yl]-3-oxo-propyl]-3, 5-dimethyl-lH-pyrrol-2- ylmethylene}-1, 3-dihydro-indol-2-one as a yellow solid (76.7 mg, 60%).

[0919] 'H-NMR (400 MHz, DMSO-d6) 5 13.25 (br s, 1H, pyrrole), 10.90 (br s, 1H, CONH), 7.61 (d, 2H, aromatic), 7.42 (d, 2H, aromatic), 7.17 (t, 1H, aromatic), 6.91 (d, 1H, aromatic), 6.75 (d, 1H, aromatic), 6.64 (s, 1H, aromatic), 4.24 (d, 1H, CH), 3.49 (d, 1H, CH), 3.40 (m, 4H, 2xCH2), 2.35 (m, 4H, 2xCH2), 2.23 (s, 3H, CH3), 1.59 (s, 3H, CH3), 0.92 (d, 3H, CH3), 0.84 (d, 3H, CH3).

[0920] MS m/z 517 [M++1]. Exami) le 138. 3- [4- [3- ( (cis)-3, 5-Dimethyl-piperazin-1-yl)-3-oxo-propyll-3, 5- dimethyl-lH-pyrrol-2-ylmethylene]-4- (4-fluoro-phenyl)-1, 3- dihydro-indol-2-one [0921] To a solution of 4- (4-fluoro-phenyl)-1, 3-dihydro-indol-2-one (56.8 mg, 0.25 mmol) and 3-[(cis)-3,5-dimethyl-piperazin-1-yl]-3-oxo-propyl]-3,5-dime thyl-1H- pyrrole-2-carbaldehyde (75.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 3- [4- [3- ( (cis)-3, 5-dimethyl- <BR> <BR> <BR> piperazin-1-yl]-3-oxo-propyl]-3, 5-dimethyl-1H pyrrol-2-ylmethylene}-4- (4-fluoro- phenyl)-1, 3-dihydro-indol-2-one as a yellow solid (60.7 mg, 49%).

[0922] 1H-NMR (400 MHz, DMSO-d6) 8 13.27 (br s, 1H, pyrrole NH), 10.89 (br s, 1H, CONH), 7.45 (m, 2H, aromatic), 7.36 (t, 2H, aromatic), 7.12 (t, 1H, aromatic), 6.90 (d, 1H, aromatic), 6.75 (d, 1H, aromatic), 6.66 (s, 1H, aromatic), 4.23 (d, 1H, CH), 3.46 (d, 1H, CH), 3.40 (m, 4H, 2xCH2), 2. 37 (m, 4H, 2xCH2), 2.23 (s, 3H, CH3), 1.60 (s, 3H, CH3), 0.92 (d, 3H, CH3), 0.84 (d, 3H, CH3).

[0923] MS mk 501 [M++1].

Example 139. 3-[3,5-Dimethyl-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrol -2- ylmethylenel-4- (4-trifluoromethoxy-phenyl)-1, 3-dihydro-indol-2- one [0924] To a solution of 4- (4-trifluoromethoxy-phenyl)-1, 3-dihydro-indol-2-one (73.3 mg, 0.25 mmol) and 3S5-dimethyl-4-(4-methyl-piperazine-l-carbonyl)-lH- pyrrole-2-carbaldehyde (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. The solvent was evaporated and the solid was washed by ether for three times to provide pure product 3-[3,5-dimethyl-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrol -2- ylmethylene]-4- (4-trifluoromethoxy-phenyl)-1, 3-dihydro-indol-2-one (79.9 mg, 61%).

[0925] 'H-NMR (400 MHz, DMSO-d6) 8 13.43 (br s, 1H, pyrrole NH), 11.06 (br s, 1H, CONH), 7.57 (m, 4H, aromatic), 7.20 (t, 1H, aromatic), 6.38 (d, 1H, aromatic), 6.80 (d, 1H, aromatic), 6.73 (s, 1H, aromatic), 3.32 (m, 4H, 2xCH2), 2.24 (m, 7H, 2xCH2+CH3), 2.16 (s, 3H, CH3), 1.56 (s, 3H, CH3).

[0926] MS m/z 523 [M--1].

Example 140.2,4-Dimethyl-5- [2-oxo-4- (4-trifluoromethoxy-phenyl)-1,2-dihydro- indol-3-ylidenemethyl]-lH-pyrrole-3-carboxylic acid (2- diethylamino-ethyl)-amide [0927] To a solution of 4- (4-trifluoromethoxy-phenyl)-1, 3-dihydro-indol-2-one (73.3 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- diethylamino-ethyl)-amide (69.0 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide 2,4-dimethyl-5- [2-oxo-4- (4- trifluoromethoxy-phenyl)-1, 2-dihydro-indol-3-ylidenemethyl]-lH-pyrrole-3- carboxylic acid (2-diethylamino-ethyl)-amide as a yellow solid (75.6 mg, 56%).

[0928] IH-NMR (400 MHz, DMSO-d6) 8 13.49 (br s, 1H, pyrrole NH), 11.07 (br s, 1H, CONH), 7.57 (m, 3H, aromatic), 7.29 (t, 1H, aromatic), 7.20 (t, 1H, aromatic), 6.94 (d, 1H, aromatic), 6.80 (d, 1H, aromatic), 6.74 (s, 1H, aromatic), 3.23 (q, 2H, CH2), 2.49 (m, 6H, 3xCH2), 2.39 (s, 3H, CH3), 1.70 (s, 3H, CH3), 0.95 (t, 6H, 2xCH3).

[0929] MS m/z 539 [M--1].

Example 141.2,4-Dimethyl-5- [2-oxo-4- (4-trifluoromethoxy-phenyl)-1,2-dihydro- indol-3-ylidenemethyl]-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide [0930] To a solution of 4- (4-trifluoromethoxy-phenyl)-1, 3-dihydro-indol-2-one (73.3 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2- [1, 2, 3]triazol-yl-ethyl)-amide (67.9 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 2,4-dimethyl-5- [2- <BR> <BR> <BR> oxo-4- (4-trifluoromethoxy-phenyl)-1, 2-dihydro-indol-3-ylidenemethyl]-lH-pyrrole- 3-carboxylic acid (2- [1, 2,3] triazol-I-yl-ethyl)-amide as a yellow solid (49.6 mg, 37%).

[0931] 1H-NMR (400 MHz, DMSO-d6) 8 13.47 (br s, IH, pyrrole NH), 11.07 (br s, 1H, CONH), 8. 10 (s, 1H, aromatic), 7.67 (m, 1H, aromatic), 7.57 (m, SH, aromatic+CONH), 7.20 (t, 1H, aromatic), 6.93 (d, 1H, aromatic), 6.78 (d, 1H, aromatic), 6.73 (s, 1H, aromatic), 4.53 (t, 2H, CH2), 3.64 (q, 2H, CH2), 2.29 (s, 3H, CH3), 1.59 (s, 3H, CH3).

[0932] MS m/z 535 [M--1].

Example142.5-Methyl-2- [2-oxo-4- (4-trifluoromethoxy-phenyl)-1, 2-dihydro- indol-3-ylidenemethyl]-lH-pyrrole-3-carboxylic acid (2-pyrrolidin- 1-yl-ethyl)-amide [0933] To a solution of 4- (4-trifluoromethoxy-phenyl)-1, 3-dihydro-indol-2-one (73.3 mg, 0.25 mmol) and 2-formyl-5-methyl-lH-pyrrole-3-carboxylic acid (2- pyrrolidin-l-yl-ethyl)-amide (64.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5-methyl-2- [2-oxo- 4-(4-trifluoromethoxy-phenyl)-1, 2-dihydro-indol-3-ylidenemethyl]-1 H-pyrrole-3- carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide as a yellow solid (93 mg, 71%).

[0934] 'H-NMR (400 MHz, DMSO-d6) 8 13.87 (br s, 1H, pyrrole NH), 11.13 (br s, 1H, CONH), 8.07 (s, 1H, aromatic), 7.74 (t, 1H, CONH), 7.47 (d, 2H, aromatic), 7.37 (d, 2H, aromatic), 7.21 (t, 1H, aromatic), 6.93 (d, 1H, aromatic), 6.77 (d, 1H, aromatic), 6.41 (d, 1H, aromatic), 3.17 (q, 2H, CH2), 2.49 (m, 6H, 3xCH2), 2.31 (s, 3H, CH3), 1.68 (m, 4H, 2xCH2).

[0935] MS m/z 523 [M--1]. Example 143. 5-Methyl-2- [2-oxo-4- (4-trifluoromethoxy-phenyl)-1, 2-dihydro- indol-3-ylidenemethyl]-lH-pyrrole-3-carboxylic acid (2- [1,2,3]triazol-1-yl-ethyl)-amide [0936] To a solution of 4- (4-trifluoromethoxy-phenyl)-1, 3-dihydro-indol-2-one (73.3 mg, 0.25 mmol) and 2-formyl-5-methyl-IH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide (61.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5-methyl-2- [2-oxo- 4- (4-trifluoromethoxy-phenyl)-1, 2-dihydro-indol-3-ylidenemethyl]-1 H-pyrrole-3- carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide as a yellow solid (96.6 mg, 74%).

[0937] 1H-NMR (400 MHz, DMSO-d6) 5 13.87 (br s, 1H, pyrrole NH), 11.15 (br s, 1H, CONH), 8.00 (m, 3H, aromatic), 7.72 (s, 1H, CONH), 7.49 (m, 2H, aromatic), 7.41 (d, 2H, aromatic), 7.21 (t, 1H, aromatic), 6.94 (d, 1H, aromatic), 6.78 (d, 1H, aromatic), 6. 34 (d, 1H, aromatic), 4.52 (t, 2H, CH2), 3.48 (m, 2H, CH2), 2.29 (s, 3H, CH3).

[0938] MS m/z 521 [M--1].

Example 144.5-Methyl-2- [2-oxo-4- (4-trifluoromethoxy-phenyl)-1,2-dihydro- indol-3-ylidenemethyl]-lH-pyrrole-3-carboxylic acid (3-pyrrolidin- 1-yl-propyl)-amide [0939] To a solution of 4- (4-trifluoromethoxy-phenyl)-1, 3-dihydro-indol-2-one (69.3 mg, 0.25 mmol) and 5-formyl-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (3- pyrrolidin-l-yl-propyl)-amide (69.8 mg, 0.26 mmol) in ethanol (2 mL) was added piperidine (3 drops). The reaction mixture was stirred at room temperature for three days. A yellow solid product was precipitated out, filtered, washed by ethanol for three times, and dried under high vacuum to provide pure product 5-methyl-2- [2-oxo- 4- (4-trifluoromethoxy-phenyl)-1, 2-dihydro-indol-3-ylidenemethyl]-1 H-pyrrole-3- carboxylic acid (3-pyrrolidin-1-yl-propyl)-amide as a yellow solid (96.8 mg, 72%).

[0940]'H-NMR (400 MHz, DMSO-d6) 8 13.93 (br s, 1H, pyrrole NH), 11.05 (br s, 1H, CONH), 8.04 (s, 1H, aromatic), 7.85 (t, 1H, CONH), 7.47 (m, 2H, aromatic), 7.35 (d, 1H, aromatic), 7.19 (t, 1H, aromatic), 6.92 (d, 1H, aromatic), 6.75 (d, 1H, aromatic), 6.40 (d, 1H, aromatic), 3.32 (m, 2H, CH2), 3.08 (q, 2H, CH2), 2.40 (m, 6H, 3xCH2), 2.30 (s, 3H, CH3), 1.67 (m, 4H 2xCH2), [0941] MS m/z 537 [M--1].

Example 145 4-(2-Fluoro-phenyl)-3-[1-[5-(2-pyrrolidin-1-yl-ethyl)-4, 5,6,7- tetrahydro-lH-indol-2-yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol-2- one 109421'H NMR (400 MHz, DMSO-d6) 8 13.09 (s, NH, 1H), 10.97 (s, NH, 1H), 7.56 (m, 1H), 7.36 (m, 3H), 7.16 (t, J= 7.8Hz, 1H), 6.93 (d, J= 7.8Hz, 1H), 6.79 (d, J = 7.8Hz, 1H), 6.40 (s, 1H), 5.86 (s, 1H), 2.66 (m, 2H), 2.56 (m, 2H), 2.43 (m, 6H), 2.03 (m ? 1H), 1.85 (m, 1H), 1.64 (m, 4H), 1.44 (m, 3H).

[0943] MS n/z 456.2 [M++1]- [0944] Example 146 4-(3-Fluoro-phenyl)-3-[1-[5-(2-pyrrolidin-1-yl-ethyl)-4, 5,6,7- tetrahydro-lH-indol-2-yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol-2- one [0945] 1H NMR (400 MHz, DMSO-d6) 8 13.12 (s, NH, 1H), 10.99 (s, NH, 1H), 7.55 (m, 1H), 7.32 (m, 1H), 7.26 (m, 2H), 7.18 (m, 1H), 6.90 (d, J= 7.8Hz, 1H), 6.76 (d, J= 7.4Hz, 1H), 6.50 (s, 1H), 5.93 (s, 1H), 3.06 (m, 6H), 2.68 (m, 2H), 2.51 (m, 2H), 2.06 (m, 1H), 1.84 (m, 4H), 1. 62 (m, 3H), 1.42 (m, 1H).

[0946] MS m/z 454 [M-1].

Example 147 4- (2-Fluoro-phenyl)-3- [l- [5- (2-morpholin-4-yl-ethyl)-4, 5,6,7- tetrahydro-lH-indol-2-yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol-2- one [0947] IH NMR (400 MHz, DMSO-d6) 8 13.11 (s, NH, 1H), 10.99 (s, NH, 1H), 7.58 (m, 1H), 7.41 (m, 3H), 7.18 (m, 1H), 6.94 (d, J= 7.4Hz, 1H), 6.80 (d, J= 8. 2 Hz, 1H), 6.42 (s, 1H), 5.88 (s, 1H), 3.54 (m, 4H), 2.69 (m, 2H), 2.56 (m, 1H), 2.32 (m, 6H), 2.04 (m, 1H), 1. 85 (m, 1H), 1.66 (m, 1H), 1.44 (m, 3H).

[0948] MS m/z 470 [M-1].

Example 148 4- (3-Fluoro-phenyl)-3- 1- [5- (2-morpholin-4-yl-ethyl)-4, 5,6,7- tetrahydro-lH-indol-2-yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol-2- one [0949] IH NMR (400 MHz, DMSO-d6) S 13.10 (s, NH, 1H), 10.96 (s, NH, 1H), 7.55 (m, 1H), 7.25 (m, 3H), 7.15 (t, J= 7.8Hz, 1H), 6.90 (d, J= 7.4Hz, 1H), 6.76 (d, J = 7.4 Hz, 1H), 6.55 (s, 1H), 5.92 (s, 1H), 3.53 (m, 4H), 2.68 (m, 2H), 2.56 (m, 1H), 2.31 (m, 6H), 2.04 (m, 1H), 1.85 (m, lH), 1.64 (m, 1H), 1.45 (m, 3H).

[0950] MS m/z 470 [M-1].

Example 149 4-(2-Fluoro-phenyl)-3-[1-{5-[2-(4-methyl-piperazin-1-yl)-eth yl]- 4,5,6,7-tetrahydro-1H-indol-2-yl}-meth-(Z)-ylidene]-1,3-dihy dro- indol-2-one [0951] MS m/z 483 [M-1].

Example 150 4-(3-Fluoro-phenyl)-3-[1-{5-[2-(4-methyl-piperazin-1-yl)-eth yl]- 4,5,6,7-tetrahydro-1 H-indol-2-yl}-meth- (Z)-ylidene]-1,3-dihydro- indol-2-one [0952] MS m/z 483 [M-1].

Example 151 5-[4-(4-Fluoro-phenyl)-2-oxo-1,2-dihydro-indol-(3Z)- ylidenemethyl]-4-methyl-lH-pyrrole-3-carboxylic acid (2- diethylamino-ethyl)-amide [0953] 1H NMR (400 MHz, DMSO-d6) 8 13.48 (s, NH, 1H), 11. 11 (s, NH, 1H), 7.68 (m, 2H), 7.43 (m, 4H), 7.21 (t, J = 7.7 Hz, 1H), 6.93 (dd, J = 0. 9Hz, J = 7.6Hz, 1H), 6.79 (m, 2H), 3.21 (m, 2H), 2.45 (m, 6H), 1.84 (s, 3H), 0.94 (t, J = 7.4Hz, 6H) [0954] MS m/z 461 [M++1].

Example 152 5- [4- (3-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-4-methyl-lH-pyrrole-3-carboxylic acid (2- diethylamido-ethyl)-amide [0955J'H NMR (400 MHz, DMSO-d6) 8 13.47 (s, NH, 1H), 11. 13 (s, NH, 1H), 7.72 (m, 1H), 7.67 (d, J= 3.5Hz, 1H), 7.58 (m, 2H), 7.53 (m, 1H), 7.41 (m, 1H), 7.2 (t, J= 7.7Hz, 1H), 6.94 (dd, J= 0.7Hz, J= 7.8Hz, 1H), 6.86 (s, 1H), 6.82 (dd, J= 0.8Hz, J= 7.7Hz, 1H), 3.19 (m, 2H), 2.44 (m, 6H), 1.85 (s, 3H), 0.95 (t, J= 7.3Hz, 6H).

[0956] MS m/z 477 [M++1].

Example 153 5- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid methyl- (1-methyl-piperidin-4-yl)-amide [0957] 1H NMR (400 MHz, DMSO-d6) # 13.40 (s, NH, 1H), 11.05 (s, NH, 1H), 7.56 (m, 1H), 7.28 (m, 3H), 7.17 (t, J = 7. 8Hz, 1H), 6.92 (d, J= 7.4Hz, 1H), 6.78 (d, I = 7.6Hz, 1H), 6.74 (s, 1H), 3.30 (m, 4H), 2.72 (m, 4H), 2.19 (s, 3H), 2.12 (br s, 3H), 1.92 (m, 1H), 1.74 (m, 2H), 1.54 (s, 3H), 1.40 (m, 1H).

[0958] MS m/z 485 [M-1].

Example 154 5-Methoxy-3- [1- [3-methyl-4- (morpholine-4-carbonyl)-lH-pyrrol-2- yl]-meth- (Z)-ylidene]-4-phenyl-1, 3-dihydro-indol-2-one [0959] To a mixture of 4-bromo-5-methoxy-3- [1- [3-methyl-4- (morpholine-4- carbonyl)-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol-2-one (223 mg, 0.5 mmol) and phenylboronic acid (73 mg, 0.6 mmol) in DME/water (5 mL) were added Palladium catalyst Pd (PPh3) 2Cl2 (10.5 mg) and sodium carbonate (106 mg, 1 mmol).

The system was degassed and then charged with nitrogen. The degas procedure was repeated for three times. The mixture was stirred under nitrogen at 85°C oil bath for overnight. TLC showed some de-bromination of the starting material. The degass procedure was repeated for three more times and the heating was continued for 3 more days. The mixture was cooled to room temperature, the unreacted starting material was filtered off and the mother liquor was concentrated. The residue was purified on a silica gel column to give 21 mg of5-methoxy-3- [l- [3-methyl-4- (morpholine-4-carbonyl)-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-4-phenyl-1, 3-dihydro- indol-2-one.

[0960] 1H NMR (400 MHz, DMSO-d6) 8 13.60 (s, NH, 1H), 10.91 (s, NH, 1H), 7.55 (m, 2H), 7.46 (m, 1H), 7.36 (d, J= 3.5Hz, 1H), 7.29 (m, 2H), 6.93 (m, 1H), 6.86 (m, 1H), 6.43 (s, IH), 3.62 (s, 3H), 3.53 (m, 4H), 3.44 (m, 4H), 1.54 (s, 3H).

[0961] MS m/z 444 [M+ +1].

Example 155 5- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- hydroxy-3- 1, 2,3] triazol-1-yl-propyl)-amide [0962]'H NMR (400 MHz, DMSO-d6) 8 13.51 (s, NH, 1H), 11. 09 (s, NH, 1H), 8.06 (d, J= 0.8Hz, 1H), 7.71 (d, J= 0.8Hz, lH), 7.61 (m, 2H), 7.32 (m, 3H), 7.19 (t, J = 7.8Hz, 1H), 6.94 (dd, J= 0. 8Hz, J= 7.8Hz, 1H), 6.81 (m, 2H), 5.36 (d, J= 5.9Hz, 1H), 4.47 (m, 1H), 4.26 (m, 1H), 3.96 (m, 1H), 3.24 (m, 2H), 2.41 (s, 3H), 1.76 (s, 3H).

[0963] MS m/z 499 [M-1].

Example 156 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (2-hydroxy- 3- [1, 2,3] triazol-1-yl-propyl)-amide [0964] 1H NMR (400 MHz, DMSO-d6) 8 13.90 (s, NH, 1H), 11. 16 (s, NH, 1H), 8. 11 (s, 1H), 8.04 (s, 1H), 8.01 (m, 1H), 7.75 (s, 1H), 7.39 (m, 1H), 7.18 (m, 3H), 7.12 (m, 1H), 6.93 (dd, J= 1. 2Hz, J= 7.8Hz, 1H), 6.77 (d, J= 7.8Hz, 1H), 6.48 (m, 1H), 5.33 (d, J= 5. 5Hz, 1H), 4.43 (m, 1H), 4.22 (m, 1H), 3.90 (m, 1H), 3.19 (m, 1H), 3.08 (m, 1H), 2.32 (s, 3H).

[0965] MS m/z 485 [M-1].

Example 157 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-1H-pyrrole-3-carboxylic acid (2-hydroxy- 3- [1, 2,3] triazol-2-yl-propyl)-amide [0966] 1H NMR (400 MHz, DMSO-d6) # 13.88 (s, NH, 1H), 11. 15 (s, NH, 1H), 8.02 (s, 1H), 7.97 (s, 1H), 7.82 (s, 2H), 7.40 (m, 1H), 7.17 (m, 4H), 6.93 (d, J= 7.8Hz, 1H), 6.77 (d, J= 7.8HZ, 1H), 6.47 (m, 1H), 5.17 (d, J= 5.9Hz, 1H), 4.35 (m, 2H), 4.19 (m, 1H), 3.51 (m, 2H), 3.24 (m, 1H), 3.10 (m, 1H), 2.32 (s, 3H).

[0967] MS m/z 485 [M-1].

Example 158 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (2-hydroxy- 3-morpholin-4-yl-propyl)-amide [0968]'H NMR (400 MHz, DMSO-d6) 8 13.88 (s, NH, 1H), 11.15 (s, NH, 1H), 8.02 (s, 1H), 7.82 (m, 1H), 7.46 (m, 1H), 7.18 (m, 4H), 6.93 (d, J= 7. 0Hz, 1H), 6.77 (d, J= 7.4HZ, 1H), 6.45 (m, 1H), 4.69 (m, 1H), 3.72 (m, 1H), 3.60 (m, 4H), 3.24 (m, 1H), 2.95 (m, 1H), 2.50 (m, 2H), 2.45 (m, 3H), 2.32 (s, 3H), 2.28 (m, 1H) [0969] MS m/z 503 [M-1].

Example 159 4- (3-Fluoro-phenyl)-3- 1- {5-methyl-3- [2- (4-methyl-piperazin-1-yl)- 2-oxo-ethyl]-lH-pyrrol-2-yl}-meth-(Z)-ylidene]-1, 3-dihydro-indol- 2-one [0970]'H NMR (400 MHz, DMSO-d6) 8 13.39 (s, NH, 1H), l 1. 02 (s, NH, 1H), 7.54 (m, 1H), 7.29 (m, 3H), 7.17 (t, J= 7.8Hz, 1H), 6.93 (dd, J= 0.8Hz, J= 7.4Hz, 1H), 6.77 (m, 2H), 5.90 (m, 1H), 3.39 (m, 2H), 3.25 (m, 2H), 2.99 (s, 2H), 2.94 (s, 3H), 2.22 (m, 4H), 2.17 (s, 3H).

[0971] MS m/z 457 [M-1].

Example 160 2-{2-[4-(3-Fluoro-phenyl)-2-oxo-1,2-dihydro-indol-(3Z)- ylidenemethyl]-5-methyl-lH-pyrrol-3-yl}-N-methyl-N-(l-methyl - piperidin-4-yl)-acetamide [0972] MS m/z 485 [M-1].

Example 161 3-[1-{3-[2-((cis)-3,5-Dimethyl-piperazin-1-yl)-2-oxo-ethyl]- 5- methyl-lH-pyrrol-2-yl}-meth- (Z)-ylidene]-4- (3-fluoro-phenyl)-1, 3- dihydro-indol-2-one 10973] lH NMR (400 MHz, DMSO-d6) 8 13.39 (s, NH, 1H), 11.07 (s, NH, 1H), 7.54 (m, 1H), 7.29 (m, 3H), 7.17 (t, J= 7.8Hz, 1H), 6.93 (d, J= 7. 0Hz, 1H), 6.77 (m, 2H), 5.89 (d, J=2. 3Hz, 1H), 4.14 (m, 1H), 3.36 (m, 1H), 2.98 (m, 2H), 2.42 (m, 4H), 2.00 (t, J=10. 9Hz, 1H), 2.29 (s, 3H), 0.92 (d, J= 6.3Hz, 3H), 0.88 (d, J=5.1Hz, 3H).

[0974] MS m/z 471 [M-1].

Example 162 4- (3-Fluoro-phenyl)-3- [l- [5-methyl-3- (2-morpholin-4-yl-2-oxo- ethyl)-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol-2-one [0975] 1H NMR (400 MHz, DMSO-d6) 6 13.41 (s, NH, 1H), 11. 05 (s, NH, 1H), 7.54 (m, 1H), 7.34 (m, 1H), 7.27 (m, 2H), 7.17 (t, J= 7.8Hz, 1H), 6.93 (d, J=7.8Hz, 1H), 6.77 (dd, J= 0. 8Hz, J= 7.8Hz, 1H), 6.75 (s, 1H), 5.92 (d, J= 2.3Hz, 1H), 3.53 (m, 4H), 3.39 (m, 2H), 3.34 (m, 4H), 3.01 (s, 2H), 2.29 (s, 3H).

[0976] MS m/z 444 [M-1].

Example 163 4- (3-Fluoro-phenyl)-3- [1- {5-methyl-3- [2-oxo-2- (4-pyrrolidin-1-yl- piperidin-1-yl)-ethyl]-1H-pyrrol-2-yl}-meth-(Z)-ylidene]-1, 3- dihydro-indol-2-one [09771 1H NMR (400 MHz, DMSO-d6) 5 13.38 (s, NH, 1H), 11. 00 (s, NH, 1H), 7.52 (m, 1H), 7.32 (m, 1H), 7.26 (m, 2H), 7.15 (t, J= 7.8Hz, 1H), 6.91 (dd, J=1. 2 Hz, J= 7.8Hz, 1H), 6.76 (m, 2H), 5.88 (d, J= 2.3Hz, 1H), 4.07 (m, 1H), 3.49 (m, 1H), 2.97 (m, 3H), 2.70 (m, 1H), 2.42 (m, 4H), 2.27 (s, 3H), 2.14 (m, 1H), 1.75 (m, 2H), 1.64 (m, 4H), 1.18 (m, 2H).

[0978] MS m/z 511 [M-1].

Example 164 4-(3-Fluoro-phenyl)-3-[1-{5-methyl-3-[2-oxo-2-((S)-2-pyrroli din-1- ylmethyl-pyrrolidin-1-yl)-ethyl]-1H-pyrrol-2-yl}-methyl-(Z)- ylidene]-1, 3-dihydro-indol-2-one [0979] 1H NMR (400 MHz, DMSO-d6) 8 13.38 (s, NH, 1H), 11. 00 (s, NH, 1H), 7.52 (m, 1H), 7.24 (m, 3H), 7.14 (t, J= 7.8Hz, 1H), 6.91 (d, J= 7.0 Hz, lH), 6.76 (m, 2H), 5.88 (d, J= 2.3Hz, lH), 3.99 (m, 1H), 3.21 (m, 2H), 2.90 (m, 2H), 2.55 (m, 2H), 2.40 (m, 4H), 2.31 (s, 3H), 1.86 (m, 4H), 1.62 (m, 4H).

[0980] MS m/z 511 [M-1].

Example 165 2- {2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrol-3-yl}-N-(2-hydroxy-3- [1, 2, 3]triazol-1-yl-propyl)-acetamide [0981] 1H NMR (400 MHz, DMSO-d6) # 13.35 (s, NH, 1H), 11. 00 (s, NH, 1H), 8.03 (d, J= 0. 8Hz, 1H), 7.82 (m, 1H), 7.71 (d, J= 0. 8Hz, 1H), 7.50 (m, 1H), 7.26 (m, 3H), 7.17 (t, J= 7.8Hz, 1H), 6.93 (dd, J=1. 2Hz, J= 7.8Hz, 1H), 6.78 (m, 2H), 5.96 (d, J=2. 3Hz, 1H), 5.34 (d, J= 5.4Hz, 1H), 4.40 (m, 1H), 4.21 (m, 1H), 3.86 (m, 1H), 3.08 (m, 2H), 2.82 (s, 2H), 2.29 (s, 3H).

[0982] MS m/z 499 [M-1].

Example 166 -{2-[4-(3-Fluoro-phenyl)-2-oxo-1,2-dihydro-indol-(3Z)- <BR> <BR> <BR> ylidenemethyl]-5-methyl-lH-pyrrol-3-yl}-N (2-pyrrolidin-1-yl-<BR> <BR> <BR> <BR> ethyl)-acetamide [0983] IH NMR (400 MHz, DMSO-d6) 8 13. 34 (s, NH, 1H), l 1. 00 (s, NH, 1H), 7.53 (m, 2H), 7.25 (m, 3H), 7.17 (t, J= 7.4Hz, 1H), 6.94 (dd, J= 0. 8Hz, J= 7.8 Hz, lH), 6.79 (m, 2H), 5.93 (d, J= 2.3Hz, lH), 3.11 (m, 2H), 2.76 (s, 2H), 2.42 (m, 6H), 2.28 (s, 3H), 1.66 (m, 4H).

[0984] MS m/z 471 [M-1].

Example 167 2- {2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyll-5-methyl-lH-pyrrol-3-yl}-N-(3-pyrrolidin-1-yl - propyl)-acetamide [0985] 1H NMR (400 MHz, DMSO-d6) # 13.34 (s, NH, 1H), 11. 01 (s, NH, 1H), 7.58 (m, 1H), 7.51 (m, 1H), 7.25 (m, 3H), 7.17 (t, J= 7.8Hz, 1H), 6.93 (d, J= 7.8 Hz, lH), 6.79 (m, 2H), 5.91 (d, J= 2.3Hz, lH), 3.20 (m, 2H), 2.74 (s, 2H), 2.37 (m, 5H), 2.28 (s, 3H), 1.64 (m, 3H) 1.53 (m, 2H).

[0986] MS m/z 485 [M-1]. Example 168 N-(2,4-Dioxo-1, 2,3,4-tetrahydro-pyrimidin-5-ylmethyl)-2- {2- [4- (3- <BR> <BR> fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)-ylidenemethyll-5-<BR> <BR> methyl-lH-pyrrol-3-yl}-acetamide [0987] 1H NMR (400 MHz, DMSO-d6) # 13.38 (s, NH, 1H),11. 02 (s, NH, 1H), 10.93 (s, 2H), 8.07 (m, 1H), 7.48 (m, 1H), 7.24 (m, 3H), 7.17 (t, J= 7.4Hz, 1H), 6.94 (dd, J= 0. 8Hz, J= 7.8Hz, 1H), 6.78 (m, 2H), 5.96 (d, J= 2.3Hz, 1H), 5.18 (s, 1H), 3.89 (d, J = 5. 5Hz, 2H), 2.86 (s, 2H), 2.29 (s, 3H).

[09881 MS m/z 498 [M-1].

Example 169 4-(2-Fluoro-phenyl)-3-[1-{5-methyl-3-[2-(4-methyl-piperazin- 1-yl)- 2-oxo-ethyl]-1H-pyrrol-2-yl}-methyl-(Z)-ylidene]-1,3-dihydro -indol- 2-one [0989] 1H NMR (400 MHz, DMSO-d6) 8 13.42 (s, NH, 1H), 11. 02 (s, NH, 1H), 7.56 (m, 1H), 7.45 (m, 1H), 7.36 (m, 2H), 7.19 (t, J= 7.4Hz, 1H), 6.95 (d, J= 7.8Hz, 1H), 6.80 (d, J= 7.4Hz, 1H), 6.59 (d, J = 1. 2Hz, 1H), 5.89 (d, J= 2.3Hz, 1H), 3.39 (m, 2H), 3.24 (m, 2H), 2.94 (m, 2H), 2.29 (s, 3H), 2.22 (m, 4H), 2.18 (s, 3H).

[0990] MS m/z 457 [M-1].

Example 170 2-{2-[4-(2-Fluoro-phenyl)-2-oxo-1,2-dihydro-indol-(3Z)- ylidenemethyl]-5-methyl-1H-pyrrol-3-yl}-N-methyl-N-(1-methyl - piperidin-4-yl)-acetamide [0991] MS m/z 485 [M-1].

Example 171 3-[1-{3-[2-((cis)-3,5-Dimethyl-piperazin-1-yl)-2-oxo-ethyl]- 5- methyl-1H-pyrrol-2-yl}-meth-(Z)-ylidene]-4-(2-fluoro-phenyl) -1, 3- dihydro-indol-2-one [0992] 1H NMR (400 MHz, DMSO-d6) 8 13.41 (s, NH, 1H), 11. 04 (s, NH, 1H), 7.54 (m, 1H), 7.44 (m, 1H), 7.36 (m, 2H), 7.19 (t, J= 7.4Hz, 1H), 6.96 (dd, J= 0. 8Hz, J= 7.8 Hz, 1H), 6.81 (d, J=7. 4Hz, 1H), 6.62 (s, 1H), 5.88 (d, J= 2. 0 Hz, 1H), 4.16 (m, 1H), 3.38 (m, 1H), 2.95 (m, 2H), 2.45 (m, 1H), 2.29 (s, 3H), 2.00 (t, J=10.7Hz, lH), 0.95 (d, J= 6.3Hz, 3H), 0.88 (d, J= 6. 3Hz, 3H).

[0993] MS m/z 471 [M-1].

Example 172 4- (2-Fluoro-phenyl)-3-11- [5-methyl-3- (2-morpholin-4-yl-2-oxo- ethyl)-lH-pyrrol-2-yl]-meth-(Z)-ylidene]-1, 3-dihydro-indol-2-one [0994] 1H NMR (400 MHz, DMSO-d6) 8 13.42 (s, NH, 1H), 11. 03 (s, NH, 1H), 7.56 (m, 1H), 7.44 (m, 1H), 7.36 (m, 2H), 7.19 (t, J= 7.8Hz, 1H), 6.96 (dd, J= 0. 8Hz, J= 7.8Hz, 1H), 6.81 (d, J= 7.4Hz, 1H), 6.59 (s, 1H), 5.92 (d, J= 2.3Hz, 1H), 3.53 (m, 4H), 3.39 (m, 2H), 3.27 (m, 2H), 2.95 (m, 2H), 2.29 (s, 3H).

[0995] MS m/z 444 [M-1]. Example 173 4-(2-Fluoro-phenyl)-3-[1-{5-methyl-3-[2-oxo-2-(4-pyrrolidin- 1-yl- piperidin-l-yl)-ethyl]-lH-pyrrol-2-yl}-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one [0996]'H NMR (400 MHz, DMSO-d6) 6 13.41 (s, NH, 1H), 11. 05 (s, NH, 1H), 7.56 (m, 1H), 7.46 (m, 1H), 7.35 (m, 2H), 7.19 (t, J= 7.8Hz, 1H), 6.96 (dd, J= 6.6Hz, 1H), 6.80 (dd, J= 0. 8Hz, J= 7.8Hz, 1H), 6.60 (s, 1H), 5.89 (d, J= 2.0 Hz, 1H), 4.11 (m, 1H), 3.48 (m, 1H), 3.34 (m, 4H), 2.42 (m, 3H), 2.71 (m, 1H), 2.29 (s, 3H), 2.42 (m, 1H), 1.78 (m, 2H), 1.67 (m, 4H), 1.21 (m, 2H).

[0997] MS m/z 511 [M-1].

Example 174 4- (4-Chloro-phenyl)-3- [1- {3, 5-dimethyl-4- [3- (4-methyl-piperazin- 1-yl)-3-oxo-propyl]-1H-pyrrol-2-yl}-meth-(Z)-ylidene]-1, 3- dihydro-indol-2-one [0998]'H NMR (400 MHz, DMSO-d6) 8 13.26 (s, NH, 1H), 10.89 (s, NH, 1H), 7.60 (d, J= 8.9Hz, 2H), 7.42 (d, J= 7.9 Hz, 2H), 7.13 (t, J= 7.6 Hz, lH), 6.91 (d, J= 7.4 Hz, 1H), 6.75 (d, J=7. 5 Hz, 1H), 6.64 (s, 1H), 3.39 (m, 4H), 2.54 (m, 4H), 2.36 (m, 4H), 2.24 (s, 3H), 2.19 (s, 3H), 1.59 (s, 3H).

[0999] MS m/z 503 [M-1].

Example 175 4-(4-Chloro-phenyl)-3-[1-{4-[3-((cis)-3,5-dimethyl-piperazin -1-yl)- 3-oxo-propyl]-3, 5-dimethyl-1H-pyrrol-2-yl}-methyl-(Z)-ylidene]-1, 3- dihydro-indol-2-one [1000]'H NMR (400 MHz, DMSO-d6) 8 13.25 (s, NH, 1H), 10.89 (s, NH, 1H), 7.59 (d, J=8.8 Hz, 2H), 7.42 (d, J=7.8 Hz, 2H), 7.13 (t, J=7.8 Hz, 1H), 6.91 (d, J= 8.0 Hz, 1H), 6.75 (d, J= 7.4 Hz, 1H), 6.64 (s, 1H), 4.22 (d, J= 12.0 Hz, lH), 3.49 (d, J= 10.4Hz, 1H), 2.53 (m, 2H), 2.32 (m, SH), 2.23 (s, 3H), 2.15 (m, lH), 1.92 (t, J= 1. 6Hz, 1H), 1.60 (s, 3H), 0.93 (d, J= 6.3Hz, 3H), 0.85 (d, J= 5.6Hz, 3H).

[1001] MS m/z 517 [M-1].

Example 176 3- [1- {3, 5-Dimethyl-4- [3- (4-methyl-piperazin-1-yl)-3-oxo-propyl]- 1H-pyrrol-2-yl}-meth-(Z)-ylidene]-4-(4-fluoro-phenyl)-1, 3- dihydro-indol-2-one [10021 IH NMR (400 MHz, DMSO-d6) 6 13.28 (s, NH, 1H), 10.89 (s, NH, 1H), 7.44 (m, 2H), @. 37 (m, H), 7.13 (t, J= 7.5 Hz, 1H), 6.90 (d, J= 7.4 Hz, 1H), 6.75 (d, I = 8.0 Hz, lH), 6.68 (s, 1H), 3.38 (m, 2H), 3.28 (m, 2H), 2.53 (m, 2H), 2.33 (t, J= 7.4Hz, 2H), 2.24 (s, 3H), 2.17 (m, 2H), 2.10 (m, 5H), 1.60 (s, 3H).

[1003] MS m/z 487 [M++1].

Example 177 5-[4-[3-(2-Hydroxy-ethyl)-phenyl]-2-oxo-1,2-dihydro-indol-(3 Z)- ylidenemethyl]-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- pyrrolidin-1-yl-ethyl)-amide [1004] 1H NMR (400 MHz, DMSO-d6) 8 13.42 (s, 1H, NH), 11. 03 (s, 1H, NH), 7.45 (m, 2H), 7.35 (d, 1H), 7.26 (s, 1H), 7.20 (d, 1H), 7.15 (t, 1H), 6.89 (d, 1H), 6.75 (d, 1H), 6.74 (s, 1H), 4.66 (t, 1H), 3.61 (m, 2H), 3.28 (m, 2H), 2.79 (m, 2H), 2.54 (m, 6H), 2.36 (s, 3H), 1.68 (m, 4H), 1.64 (s, 3H).

[1005] MS m/z 497 [M-1]. Example 178 5- [4- [3- (2-Hydroxy-ethyl)-phenyl]-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenmethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide [1006]'H NMR (400 MHz, DMSO-d6) 6 13.45 (s, NH, 1H), 11. 01 (s, NH, 1H), 8. 08 (s, 1H), 7.69 (s, 1H), 7.59 (t, J= 5.9 Hz, 1H), 7.42 (t, J= 7.6Hz, 1H), 7.31 (d, J= 7.8Hz, 1H), 7.24 (s, 1H), 7.19 (d, J= 7.4Hz, 1H), 7.15 (t, J= 7.8Hz, 1H), 6.88 (d, J= 7.8 Hz, 1H), 6.75 (d, J= 7.4 Hz, 1H), 6.72 (s, 1H), 4.66 (t, J= 5.1 Hz, 1H), 4.50 (t, J= 5. 8Hz, 2H), 3.60 (m, 4H), 2.76 (t, J= 7. 0Hz, 2H), 2.25 (s, 3H), 1.54 (s, 3H).

[1007] MS m/z 495 [M-1].

Example 179 2- [4- [3- (2-Hydroxy-ethyl)-phenyll-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (2- [1, 2,3] triazol-1-yl-ethyl)-amide 11008] IH NMR (400 MHz, DMSO-d6) 8 13.79 (s, 1H, NH), 11.10 (s, 1H, NH), 8.05 (t, 1H), 7.98 (s, 1H), 7.85 (s, 1H), 7.72 (s, 1H), 7.29 (t, 1H), 7.23 (d, 1H), 7.21 (s, 1H), 7.17 (t, 1H), 7.12 (d, 1H), 6.88 (d, 1H), 6.73 (d, 1H), 6.29 (s, 1H), 4.51 (t, 1H), 4.44 (t, 2H), 3.63 (dd, 2H), 3.42 (m, 2H), 2.74 (t, 2H), 2.26 (s, 3H).

{1009] MS mlz 481 [M-1].

Example 180 3-[1-[3,5-Dimethyl-4-(4-pyrrolidin-1-yl-piperidine-1-carbony l)-1H- pyrrol-2-yl]-meth-(Z)-ylidene]-4-(3-methoxy-phenyl)-1,3-dihy dro- indol-2-one [1010]'H NMR (400 MHz, DMSO-d6) 5 13.41 (s, NH, 1H), 11. 00 (s, NH, 1H), 7.43 (t, 1H), 7.15 (t, 1H), 7.02 (d, 1H), 6.96 (m, 2H), 6.89 (d, 1H), 6.82 (s, 1H), 6.77 (d, 1H), 4.20 (m, 1H), 3.74 (s, 3H), 3.60 (m, 1H), 2.92 (m, 2H), 2.43 (m, 4H), 2.21 (s, 3H), 1.78 (m, 2H), 1.63 (m, 4H), 1.55 (s, 3H), 1.22 (m, 3H).

[1011] MS m/z 523 [M-1].

Example 181 4-(2-Chloro-phenyl)-3-[1-[3,5-dimethyl-4-(4-pyrrolidin-1-yl- piperidine-l-carbonyl)-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one [1012]'H NMR (400 MHz, DMSO-d6) 8 13. 40 (s, NH, 1H), 10.50 (br s, NH, 1H), 7.66 (m, 1H), 7.51 (m, 2H), 7.43 (m, 1H), 7.19 (t, 1H), 6.94 (d, 1H), 6.74 (d, 1H), 6.38 (s, 1H), 4.20 (m, 1H), 3.60 (m, 1H), 2.92 (m, 2H), 2.43 (m, 4H), 2.21 (s, 3H), 1.78 (m, 2H), 1.63 (m, 4H), 1.55 (s, 3H), 1.22 (m, 3H).

[1013] MS m/z 528 [M-1].

Example 182 4- (4-Chloro-phenyl)-3- [1- [3, 5-dimethyl-4- (4-pyrrolidin-1-yl- piperidine-l-carbonyl)-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one [10141 1H NMR (400 MHz, DMSO-d6) 8 13.38 (s, NH, 1H), 11.02 (s, NH, 1H), 7.59 (d, 2H), 7.43 (d, 2H), 7.17 (t, 1H), 6.91 (d, 1H), 6.77 (d, 1H), 6.63 (s, 1H), 4.20 (m, 1H), 3.40 (m, 1H), 2.92 (m, 2H), 2.44 (m, 4H), 2.21 (s, 3H), 2.85 (m, 1H), 1.77 (m, 2H), 1.64 (m, 5H), 1.53 (s, 3H), 1.22 (m, 1H).

[1015] MS m/z 528 [M-1].

Example 183 4- (3-Chloro-phenyl)-3- [1- [3, 5-dimethyl-4- (4-pyrrolidin-1-yl- piperidine-l-carbonyl)-lH-pyrrol-2-yl]-meth-(Z)-ylidene]-1,3 - dihydro-indol-2-one [1016]'H NMR (400 MHz, DMSO-d6) S 13. 38 (s, NH, 1H), 10.50 (br s, NH, 1H), 7.52 (m, 2H), 7.39 (m, 1H), 7.17 (t, J= 7.8Hz, 1H), 7.04 (t, J= 8.2Hz, 1H), 6.92 (m, 1H), 6.78 (d, J= 7.4Hz, 1H), 6.74 (s, 1H), 4.20 (m, lH), 3.40 (m, 1H), 2.92 (m, 2H), 2.44 (m, 4H), 2.21 (s, 3H), 2.85 (m, 1H), 1.77 (m, 2H), 1.64 (m, SH), 1.53 (s, 3H), 1.22 (m, 1H).

[1017] MS m/z 528 [M-1].

Example 184 3-[1-[3,5-Dimethyl-4-(4-pyrrolidin-1-yl-piperidine-1-carbony l)-1H- (Z)-ylidene]-4- (3-fluoro-phenyl)-1, 3-dihydro- indol-2-one [1018] 1H NMR (400 MHz, DMSO-d6) 8 13.41 (s, NH, 1H), 11. 05 (s, NH, 1H), 7.57 (m, 1H), 7.28 (m, 3H), 7.17 (t, 1H), 6.92 (d, 1H), 6.78 (d, 1H), 6.74 (s, 1H), 4.15 (m, 1H), 3.49 (m, 1H), 2.93 (m, 2H), 2.43 (m, 4H), 2.21 (s, 3H), 2.14 (m, lH), 1.77 (m, 2H), 1.63 (m, 5H), 1.56 (s, 3H), 1.22 (m, 1H).

[1019] MS m/z 511 [M-1].

Example 185 3-[1-[5-Methyl-3-(4-pyrrolidin-1-yl-piperidine-1-carbonyl)-1 H- pyrrol-2-yl]-meth- (Z)-ylidene]-4-phenyl-1, 3-dihydro-indol-2-one [1020] 1H NMR (400 MHz, DMSO-d6) 8 13.65 (s, NH, 1H), 11.12 (s, NH, 1H), 7.43 (m, 3H), 7.37 (m, 2H), 7.20 (t, J= 7.8Hz, lH), 6.95 (s, lH), 6.92 (d, J= 7.8Hz, 1H), 6.76 (d, J= 7.4Hz, lH), 6.06 (d, J = 2.3Hz, 1H), 4.05 (m, 1H), 3.45 (m, 1H), 2.87 (m, 2H), 2.45 (m, 4H), 2.35 (s, 3H), 2.20 (m, 1H), 1.85 (m, 1H), 1.65 (m, 5H), 1.30 (m, 1H), 1.15 (m, 1H).

[1021] MS m/z 479 [M-1].

Example 186 4- (4-Chloro-phenyl)-3- [1- [5-methyl-3- (4-pyrrolidin-1-yl- piperidine-l-carbonyl)-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one [1022] 1H NMR (400 MHz, DMSO-d6) S 13.67 (s, NH, 1H), 11. 15 (s, NH, 1H), 7.49 (d, 2H), 7.40 (d, 2H), 7.21 (t, 1H), 7.06 (s, lH), 6.94 (d, 1H), 6.74 (d, 1H), 6.10 (s, 1H), 4.11 (m, 1H), 3.55 (m, 1H), 2.87 (m, 2H), 2.47 (m, 4H), 2.34 (s, 3H), 2.21 (m, 1H), 1.82 (m, 1H), 1.69 (m, 5H), 1.30 (m, IH) 1.20 (m, 1H).

[1023] MS m/z 514 [M-1]. Example 187 4- (3-Fluoro-phenyl)-3- [1- [5-methyl-3- (4-pyrrolidin-1-yl-piperidine- l-carbony 2-yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol- 2-one [1024] 1H NMR (400 MHz, DMSO-d6) 8 13.60 (s, NH, 1H), 11. 12 (s, NH, 1H), 7.48 (m, 1H), 7.23 (m, 4H), 6.95 (d, 1H), 6.94 (s, 1H), 6.78 (d, 1H), 6.09 (d, 1H), 4.08 (m, 1H), 3.52 (m, 1H), 2.81 (m, 2H), 2.47 (m, 4H), 2.32 (s, 3H), 2.18 (m, 1H), 1.82 (m, 1H), 1.67 (m, 5H), 1.21 (m, 2H).

[1025] MS m/z 497 [M-1].

Example 188 3-11-15-Methyl-3-(morpholine-4-carbonyl)-lH-pyrrol-2-yll-met h- (Z)-ylidene]-4-phenyl-1, 3-dihydro-indol-2-one [1026] 1H NMR (400 MHZ, DMSO-d6) # 13.63 (s, NH, 1H), 11.10 (s, NH, 1H), 7.39 (m, 5H), 7.18 (t, J = 7. 6Hz, 1H), 6.96 (s, 1H), 6.89 (d, J= 6. 6,1H), 6.73 (dd, J= 0. 8Hz, J= 7.8Hz, 1H), 6.06 (d, J= 2.3Hz, 1H), 3.52 (m, 2H), 3.35 (m, 4H), 3.18 (m, 2H), 2.26 (s, 3H).

[1027] MS m/z 412 [M-1].

Example 189 4- (2-Chloro-phenyl)-3- [l- [5-methyl-3- (morpholine-4-carbonyl)- 1H-pyrrol-2-yl]-meth-(Z)-ylidene]-1,3-dihydro-indol-2-one [1028 'H NMR (400 MHz, DMSO-d6) 8 13.65 (s, NH, lH), 11. 15 (s, NH, 1H), 7.54 (dd, J= 1. 6Hz, J= 8. 2Hz, 1H), 7.44 (m, 2H), 3.33 (dd, J= 2. 0Hz, J= 7. 0Hz, 1H), 7.20 (t, J= 7. 6Hz, 1H), 6.95 (dd, J = 0. 8Hz, J= 7. 8Hz, 1H), 6.69 (d, J= 7. 8Hz, 1H), 6.57 (s, 1H), 6.07 (d, J= 2.7Hz, 1H), 3.58 (m, 2H), 3.44 (m, 4H), 3.22 (m, 2H), 2.31 (s, 3H).

[1029] MS m/z 446 [M-1].

Example 190 4-(4-Chloro-phenyl)-3-[1-[5-methyl-3-(morpholine-4-carbonyl) - 1H-pyrrol-2-yl]-meth-(Z)-ylidene]-1,3-dihydro-indol-2-one [1030] 1H NMR (400 MHz, DMSO-d6) 8 13.67 (s, NH, 1H), 11. 14 (s, NH, 1H), 7.48 (dd, J = 2.0Hz, J=6. 6Hz, 2H), 7.38 (dd, J= 2. 0Hz, J=6. 6Hz, 2H), 7.19 (t, J= 7. 6Hz, 1H), 7.07 (s, 1H), 6.91 (dd, J = 0.8Hz, J = 7.8Hz, 1H), 6.73 (d, J = 7.4Hz, 1H), 6.10 (d, J = 2.3Hz, 1H), 3.54 (m, 2H), 3.42 (m, 4H), 3.27 (m, 2H), 2.31 (s, 3H).

[1031] MS m/z 446 [M-1].

Example 191 4-(3-Fluoro-phenyl)-3-[1-[5-methyl-3-(morpholine-4-carbonyl) -1H- pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol-2-one [1032] 1H NMR (400 MHz, DMSO-d6) 6 13.62 (s, NH, 1H), 11. 12 (s, NH, 1H), 7.48 (m, 1H), 7.21 (m, 2H), 7.18 (dd, J=1. 6Hz, J=7.0Hz, 2H), 6.96 (s, 1H), 6.92 (dd, J= 1. 2Hz, J=7.8Hz, 1H), 6.76 (dd, J=0.8Hz, J = 7. 4Hz, 1H), 6.09 (d, J= 2. 3Hz, 1H), 3.54 (m, 2H), 3.40 (m, 4H), 3.28 (m, 2H), 2.30 (s, 3H).

[1033] MS m/z 430 [M-1].

Example 192 2- [4- (3-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (2,6-dioxo- 1,2,3,6-tetrahydro-pyrimidin-4-ylmethyl)-amide [1034] IH NMR (400 MHz, DMSO-d6) 8 13.82 (s, NH, 1H), 11. 15 (s, NH, 1H), 10.99 (s, 1H), 10.85 (s, 1H), 8.31 (br t, 1H), 7.92 (s, 1H), 7.34 (m, 3H), 7.27 (m, 1H), 7.19 (t, J= 7.8Hz, 1H), 6.91 (d, J = 7.4Hz, 1H), 6.76 (d, J = 7.4Hz, 1H), 6.45 (s, 1H), 5.20 (s, 1H), 3.94 (br d, 2H), 2.31 (s, 3H).

[1035] MS m/z 500 [M-1].

Example 193 4-(3-Chloro-phenyl)-3-[1-[3-methyl-4-(4-pyrrolidin-1-yl- piperidine-1-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-1, 3- dihydro-indol-2-one [1036]'H NMR (400 MHz, DMSO-d6) 8 13.48 (s, NH, 1H), l 1. 18 (s, NH, 1H), 7.56 (m, 2H), 7.52 (m, 1H), 7.40 (m, 1H), 7.37 (d, J=3. 1Hz, 1H), 7.21 (t, J= 7.8Hz, 1H), 6.93 (dd, J= 0.8Hz, J= 7.4Hz, 1H), 6.81 (s, 1H), 6.80 (d, J= 7.4Hz, 1H), 3.90 (br m, 2H), 2.94 (m, 2H), 2.44 (m, 4H), 2.16 (m, 1H), 1.78 (m, 2H), 1.65 (s, 3H), 1.64 (m, 4H), 1.26 (m, 2H).

[1037] MS m/z 513 [M-1].

Example 194 4- (3-Chloro-phenyl)-3- [l- [3-methyl-4- (2-pyrrolidin-1-ylmethyl- pyrrolidine-1-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-1, 3- dihydro-indol-2-one [1038]'H NMR (400 MHz, DMSO-d6) 8 13.45 (s, NH, 1H), 11. 13 (s, NH, 1H), 7.57 (d, J= 2.3Hz, 1H), 7.56 (d, J= 1. 2Hz, 1H), 7.52 (m, 2H), 7.40 (m, 1H), 7.21 (t, J = 7.6Hz, 1H), 6.93 (dd, J= 0. 8Hz, J= 7. 0Hz, 1H), 6.83 (s, 1H), 6.80 (d, J= 7.4Hz, 1H), 4.19 (m, 1H), 3.41 (m, 2H), 2.55 (m, 2H), 2.43 (m, 4H), 1.86 (m, 4H), 1.70 (s, 3H), 1.63 (m, 4H).

[1039] MS m/z 514 [M-1].

Example 195 5-[4-(3-Chloro-phenyl)-2-oxo-1,2-dihydro-indol-(3Z)- ylidenemethyl]-4-methyl-lH-pyrrole-3-carboxylic acid (2- morpholin-4-yl-ethyl)-amide [1040]'H NMR (400 MHz, DMSO-d6) 8 13.46 (s, NH, 1H), 11. 12 (s, NH, 1H), 7.56 (t, J= 5. 6Hz, 1H), 7.67 (d, J=3.1Hz, 1H), 7.58 (d, J= 3. 1Hz, 1H), 7.57 (d, J= 0.8Hz, 1H), 7.52 (s, 1H), 7.40 (m, 1H), 7.21 (t, J= 7.6Hz, 1H), 6.93 (d, J= 7.8Hz, 1H), 6.85 (s, 1H), 6.80 (d, J= 7.8Hz, 1H), 3.54 (m, 4H), 3.26 (m, 4H), 2.37 (m, 4H), 1.84 (s, 3H).

[1041] MS m/z 489 [M-1].

Example 196 5- [4- (3-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-4-methyl-1H-pyrrole-3-carboxylic acid [3- (2- methyl-piperidin-1-yl)-propyl]-amide [1042]'H NMR (400 MHz, DMSO-d6) 8 13.45 (s, NH, 1H), 11. 13 (s, NH, 1H), 7.56 (m, 1H), 7.67 (d, J=3.1Hz, 1H), 7.58 (d, J= 2.3Hz, 1H), 7.57 (d, J=0.8Hz, 1H), 7.52 (s, 1H), 7.40 (m, 1H), 7.21 (t, J= 7.8Hz, 1H), 6.93 (d, J= 7.8Hz, 1H), 6.85 (s, 1H), 6.80 (d, J= 7.4Hz, 1H), 3.32 (m, 2H), 3.12 (m, 2H), 2.71 (m, 2H), 2.26 (m, 2H), 1.83 (s, 3H), 1.56 (m, 4H), 1.41 (m, 1H), 1.20 (m, 2H), 0.96 (d, J= 5.9Hz, 3H).

[1043] MS m/z 516 [M-1].

Example 197 5- [4- (3-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-4-methyl-lH-pyrrole-3-carboxylic acid (2- piperidin-1-yl-ethyl)-amide [1044] 1H NMR (400 MHz, DMSO-d6) # 13.51 (s, NH, 1H),11.15 (s, NH, 1H), 8. 27 (m, 1H), 7.82 (d, J=3.1Hz, 1H), 7.58 (d, J= 3. 1 Hz, 1H), 7.57 (d, J= L2Hz, IH), 7.52 (s, 1H), 7.40 (m, 1H), 7.22 (t, J= 7. 8Hz, 1H), 6.93 (d, J= 7.8Hz, 1H), 6.85 (s, 1H), 6.81 (d, J= 7.8Hz, 1H), 3.51 (m, 4H), 3.12 (m, 2H), 2.87 (m, 2H), 1.86 (s, 3H), 1.72 (m, 5H), 1.36 (m, 1H).

[1045] MS m/z 488 [M-1].

Example 198 5- [4- (3-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-4-methyl-lH-pyrrole-3-carboxylic acid (2-pyridin- 4-yl-ethyl)-amide [1046] 1H NMR (400 MHz, DMSO-d6) 8 13.45 (s, NH, 1H), 11.11 (s, NH, 1H), 8.43 (m, 2H), 7.96 (t, J= 5. 5Hz, 1H), 7.64 (d, J= 3.5Hz, 1H), 7.57 (dd, J= 1. 7Hz, J= 4.3Hz, 2H), 7.52 (s, 1H), 7.40 (m, 1H), 7.21 (m, 3H), 6.93 (d, J= 7.8Hz, 1H), 6.84 (s, 1H), 6.80 (d, J= 7.8Hz, 1H), 3.40 (m, 2H), 2.78 (t, J= 7.2Hz, 2H), 1.81 (s, 3H).

[1047] MS m/z 481 [M-1].

Example 199 5- [4- (3-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-4-methyl-1H-pyrrole-3-carboxylic acid (2- pyrrolidin-1-yl-ethyl)-amide [1048] 1H NMR (400 MHz, DMSO-d6) 8 13.46 (s, NH, 1H), 11. 12 (s, NH, 1H), 7.83 (t, J= 5. 9Hz, 1H), 7.69 (d, J= 3.5Hz, 1H), 7.58 (d, J= 2. 0Hz, 1H), 7.57 (d, J= 1.2Hz, 1H), 7.52 (d, J= 1.2Hz, 1H), 7.40 (m, 1H), 7.21 (t, J= 7.8Hz, 1H), 6.93 (dd, J = 0.8Hz, J= 7.8Hz, 1H), 6.85 (s, 1H),-6. 80 (dd, J= 0.8Hz, J= 7.4Hz, 1H), 3.26 (m, 2H), 2.50 (m, 6H), 1.84 (s, 3H), 1.67 (m, 4H).

[1049] MS m/z 473 [M-1].

Example 200 5- [4- (3-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-4-methyl-1H-pyrrole-3-carboxylic acid [3- (2-oxo- pyrrolidin-1-yl)-propyl]-amide [1050] 1H NMR (400 MHz, DMSO-d6) 8 13.44 (s, NH, 1H), 11. 12 (s, NH, 1H), 7.82 (br t, 1H), 7.67 (d, J= 3.5Hz, 1H), 7.58 (m, 2H), 7.52 (d, J= 1. 2Hz, 1H), 7.40 (m, 1H), 7.21 (t, J= 7.8Hz, 1H), 6.93 (dd, J= 0.8Hz, J= 7.8Hz, 1H), 6.85 (s, 1H), 6.80 (d, J= 7.4Hz, 1H), 3.31 (m, 2H), 3.17 (t, J= 7.2Hz, 2H), 3.10 (m, 2H), 2.19 (t, J= 8. 0Hz, 2H), 1.89 (m, 2H), 1.84 (s, 3H), 1.62 (m, 2H).

[1051] MS m/z 501 [M-1].

Example 201 5- [4- (3-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-4-methyl-1H-pyrrole-3-carboxylic acid (2-hydroxy- 3-morpholin-4-yl-propyl)-amide [1052] IH NMR (400 MHz, DMSO-d6) 8 13.47 (s, NH, 1H), 11. 13 (s, NH, 1H), 7. 80 (d, J=5. 5Hz, 1H), 7.72 (m, 1H), 7.57 (m, 2H), 7.53 (m, 1H), 7.40 (m, 1H), 7.21 (m, 1H), 6.94 (t, J= 6.4Hz, 1H), 6.85 (d, J= 5. lHz, 1H), 6.81 (t, J= 6.3Hz, 1H), 4.73 (m, 1H), 3.73 (m, 1H), 3.32 (d, J=5.1Hz, 2H), 3.28 (m, 1H), 3.04 (m, lH), 2.58 (m, 2H), 2.38 (m, 4H), 2.25 (m, 2H), 1.84 (m, 3H).

[1053] MS m/z 519 [M-1].

Example 202 5-[4-(3-Chloro-phenyl)-2-oxo-1,2-dihydro-indol-(3Z)- ylidenemethyl]-4-methyl-1H-pyrrole-3-carboxylic acid (2-hydroxy- 3- [1, 2,3] triazol-1-yl-propyl)-amide [1054] 1H NMR (400 MHz, DMSO-d6) 8 13.46 (s, NH, 1H), 11. 12 (s, NH, 1H), 8.05 (s, 1H), 7.97 (t, J= 5. 7Hz, 1H), 7.75 (d, J=3.1Hz, 1H), 7.68 (s, 1H), 7.58 (m, 2H), 7.52 (m, 1H), 7.40 (m, 1H), 7.21 (t, J= 7.8Hz, lH), 6.93 (d, J= 7.8Hz, 1H), 6.86 (s, 1H), 6.80 (d, J= 7. 4Hz, lH), 3.36 (d, J= 5. 5Hz, 1H), 4.45 (dd, J= 3.5Hz, J= 14.5Hz, 1H), 4.23 (dd, J= 7. 2Hz, J= 14.1 Hz, lH), 3.95 (m, 1H), 3.24 (t, J= 6. 0Hz, 1H), 3.20 (t, J=6. 0Hz, 1H), 1.86 (s, 3H).

[1055] MS m/z 501 [M-1].

Example 203 3-[1-{3,5-Dimethyl-4-[2-oxo-2-(4-pyrrolidin-1-yl-piperidin-1 -yl)- ethyl]-1H-pyrrol-2-yl}-meth-(Z)-ylidene]-4-(2-fluoro-phenyl) -1, 3- dihydro-indol-2-one 11056]'H NMR (400 MHz, DMSO-d6) 6 13.29 (s, NH, 1H), 10.93 (s, NH, 1H), 7.52 (m, lH), 7. 40 (m, 3H), 7.13 (t, J= 7.8 Hz, lH), 6.92 (dd, J= 0.78 Hz, J= 7.8 Hz, 1H), 6.77 (dd, J= 1.2 Hz, J= 7.8 Hz, 1H), 6.58 (s, 1H), 4.10 (d,J= 14.1 Hz, 1H), 3.79 (d, J=12. 9 Hz, 1H), 3.36 (m, 2H), 3.01 (t, J= 11.8 Hz, 1H), 2.67 (t, J= 11.1Hz, 1H), 2.42 (m, 4H), 2.17 (s, 3H), 2.12 (m, lH), 1.75 (d, J= 1.7Hz, 2H), 1.62 (m, 4H), 1.45 (s, 3H), 1.16 (m, 2H).

[1057] MS m/z 525 [M-1].

Example 204 3- 1- {3, 5-Dimethyl-4- 2-oxo-2- ( (S)-2-pyrrolidin-1-ylmethyl- pyrrolidin-l-yl)-ethyl]-lH-pyrrol-2-yl}-meth-(Z)-ylidene]-4- (2- fluoro-phenyl)-1, 3-dihydro-indol-2-one [1058] 1H NMR (400 MHz, DMSO-d6) 8 13.29 (s, NH, 1H), 10.93 (s, NH, 1H), 7.52 (m, lH), 7.40 (m, 3H), 7.13 (t, J= 7.8 Hz, lH), 6.92 (dd, J= 0.78 Hz, J= 7.8 Hz, 1H), 6.77 (dd, J= 0.8 Hz, J= 7.4 Hz, 1H), 6. 58 (s, 1H), 4.05 (m, 1H), 3.42 (m, 2H), 3.27 (m, 2H), 2.44 (m, 2H), 2.37 (m, 4H), 2.17 (s, 3H), 1.84 (m, 4H), 1.62 (m, 4H), 1.46 (s, 3H).

[1059] MS mlz 525 [M-1].

Example 205 2- {5- [4- (2-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-2, 4-dimethyl-lH-pyrrol-3-yl}-N (2-morpholin-4-yl- ethyl)-acetamide [1060]'H NMR (400 MHz, DMSO-d6) 8 13.31 (s, NH, 1H), 10.93 (s, NH, 1H), 7.51 (m, 2H), 7.40 (m, 3H), 7.14 (t, J= 7.6 Hz, lH), 6.92 (d, J= 7.8 Hz, 1H), 6.77 (d, J= 7.4 Hz, 1H), 6.59 (s, 1H), 3.47 (m, 4H), 3.11 (s, 2H), 3.07 (m, 2H), 2.27 (m, 6H), 2.22 (s, 3H), 1.52 (s, 3H).

[1061] MS m/z 501 [M-1].

Example 206 3- 1- {4- [2- ( (cis)-3, 5-Dimethyl-piperazin-1-yl)-2-oxo-ethyl]-3, 5- <BR> <BR> <BR> dimethyl-lH-pyrrol-2-yl}-meth- (Z)-ylidene]-4- (2-fluoro-phenyl)-<BR> <BR> <BR> <BR> <BR> 1,3-dihydro-indol-2-one [1062] 1H NMR (400 MHz, DMSO-d6) 8 13.29 (s, NH, 1H), 10.96 (s, NH, 1H), 7.51 (m, lH), 7.40 (m, 3H), 7.14 (t, J= 7.8 Hz, lH), 6.92 (d, J= 0.8Hz, J= 7.8 Hz, 1H), 6.77 (d, J= 0.8 Hz, J= 8.6 Hz, 1H), 6.58 (s, 1H), 4.15 (d, J=12. 1 Hz, IH), 3.71 (t, J = 8.2Hz, 1H), 3.28 (m, 2H), 2.43 (m, 4H), 2.17 (s, 3H), 1.96 (t, J= 1.5 Hz, 1H), 1.45 (s, 3H), 0.89 (d, J= 6.6 Hz, 6H).

Example 207 2- {5- [4- (2-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-2, 4-dimethyl-lH-pyrrol-3-yT}-N (2-piperidin-1-yl- ethyl)-acetamide [1063] IH NMR (400 MHz, DMSO-d6) 8 13.32 (s, NH, 1H), 10.94 (s, NH, 1H), 7.52 (m, lH), 7.39 (m, 4H), 7.14 (t, J= 7.6 Hz, 1H), 6.92 (d, J= 7. 0Hz, 1H), 6.77 (d, J= 7.4 Hz, 1H), 6.60 (s, 1H), 3.11 (s, 2H), 3.06 (m, 2H), 2.24 (m, 6H), 2.21 (s, 3H), 1.51 (s, 3H), 1.38 (m, 4H), 1.30 (m, 2H).

[1064] MS m/z 499 [M-1].

Example 208 2-{5-[4-(2-Fluoro-phenyl)-2-oxo-1,2-dihydro-indol-(3Z)- <BR> ylidenemethyl]-2, 4-dimethyl-lH-pyrrol-3-yl}-N (2-pyridin-4-yl-<BR> <BR> ethyl)-acetamide [1065] 1H NMR (400 MHz, DMSO-d6) 8 13.29 (s, NH, 1H), 10.93 (s, NH, 1H), 8. 40 (m, 2H), 7.72 (t, J = 5. 5Hz, 1H), 7.55 (m, lH), 7.40 (m, 3H), 7.14 (m, 3H), 6.92 (dd, J= 0.8Hz, J= 7.8Hz, 1H), 6.77 (dd, J= 0.8Hz, J= 8. 6Hz, 6.58 (s, 1H), 3.25 (m, 2H), 3.08 (s, 2H), 2.68 (m, 2H), 2.16 (s, 3H), 1.43 (s, 3H).

[1066] MS m/z 493 [M-1].

Example 209 2- {5- [4- (2-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl}-N-(2-pyrrolidin- 1-yl- ethyl)-acetamide [1067] 1H NMR (400 MHz, DMSO-d6) 8 13.30 (s, NH, lH), 10.93 (s, NH, 1H), 7.60 (t, J= 5. 5Hz, 1H), 7.53 (m, 1H), 7.42 (t, J= 7.4Hz, 1H), 7.37 (d, J=7. 4Hz, 1H), 7. 34 (d, J= 1. 5Hz, 1H), 7.14 (t, J= 7.8Hz, 1H), 6.92 (dd, J= 0. 8Hz, J=7.8Hz, 1H), 6.77 (d, J= 7.8Hz, 1H), 6.60 (s, 1H), 3.11 (s, 2H), 3.07 (m, 2H), 2.37 (m, 6H), 2.21 (s, 3H), 1.61 (m, 4H), 1.50 (s, 3H).

[1068] MS m/z 485 [M-1]. <BR> <BR> <BR> <BR> <BR> <BR> <P>Example 210 3- [1- {3, 5-Dimethyl-4-12- (4-methyl-piperazin-1-yl)-2-oxo-ethyl]-lH- pyrrol-2-yl}-meth-(Z)-ylidene]-4-(2-fluoro-[phenyl)-1, 3-dihydro- indol-2-one [1069] 1H NMR (400 MHz, DMSO-d6) 8 13.29 (s, NH, 1H), 10.94 (s, NH, 1H), 7.52 (m, 1H), 7.42 (m, 3H), 7.14 (t, J= 7.8Hz, 1H), 6.92 (dd, J=1.0Hz, J= 7.4Hz, 1H), 6.77 (dd, J= 0. 8Hz, J= 7.8Hz, 1H), 6.58 (s, 1H), 3.40 (m, 4H), 3.31 (s, 2H), 1.20 (m, 4H), 2.16 (s, 3H), 2.13 (s, 3H), 1.45 (s, 3H).

[1070] MS m/z 471 [M-1].

Example 211 3- [l- [3, 5-Dimethyl-4- (2-morpholin-4-yl-2-oxo-ethyl)-lH-pyrrol-2- yl]-meth- (Z)-ylidene]-4- (2-fluoro-phenyl)-1, 3-dihydro-indol-2-one [1071] IH NMR (400 MHz, DMSO-d6) 8 13.30 (s, NH, 1H), 10.95 (s, NH, 1H), 7.51 (m, lH), 7.40 (m, 3H), 7.14 (t, J= 7.8Hz, 1H), 6.92 (dd, J= 0. 8Hz, J= 7.8Hz, 1H), 6.77 (dd, J= 1. OHz, J= 7.4Hz, 1H), 6.59 (s, 1H), 3.50 (m, 4H), 3.46 (m, 2H), 3.31 (m, 4H), 2.17 (s, 3H), 1.45 (s, 3H).

[1072] MS m/z 458 [M-1].

Example 212 N-(2-Diethylamino-ethyl)-2-{5-[4-(2-fluoro-phenyl)-2-oxo-1, 2- dihydro-indol-(3Z)-ylidenemethyl]-2, 4-dimethyl-lH-pyrrol-3-yl}- acetamide 110731'H NMR (400 MHz, DMSO-d6) 8 13.31 (s, NH, 1H), 10.93 (s, NH, 1H), 7.53 (m, lH), 7.40 (m, 4H), 7.14 (t, J= 7.8Hz, 1H), 6.92 (d, J= 7.8Hz, 1H), 6.77 (d, J= 7.4Hz, 1H), 6.59 (s, 1H), 3.11 (s, 2H), 3.03 (m, 2H), 2.40 (m, 6H), 2.21 (s, 3H), 1.50 (s, 3H), 0.87 (t, J= 7. 0Hz, 6H).

[1074] MS m/z 487 [M-1].

Example 213 4-(2-Chloro-phenyl)-3-[1-[3,5-dimethyl-4-(4-ethyl-piperazine -1- carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-1,3-dihydro-indo l-2- one [1075] IH NMR (400 MHz, DMSO-d6) 813. 41 (s, lH, NH), 11.04 (s, lH, NH), 7.64 (m, 1 H), 7.5 (m, 2H), 7.41 (m, lH), 7.18 (t, J=8.7Hz, 1H), 6.93 (dd, J=0.9HzJ =9. 1Hz,1H), 6.73 (dd, J=1.1Hz, J=9. 1 Hz, lH), 6.37 (s, 1H). 3.28 (m, 4H), 2.22 (m, 4H), 2.19 (s, 3H), 2.13 (s, 3H), 1.48 (s, 3H) [1076] MS m/z 473 [M-1].

Example 214 2- [4- (2-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (2- pyrrolidin-1-yl-ethyl)-amide [1077] 1H NMR (400 MHz, DMSO-d6) 813. 80 (s, 1H, NH), 11.18 (br s, 1H, NH), 7.72 (t, 1 H), 7.62 (s, 1H), 7.47 (m, 1H), 7.37 (m, 2H), 7.30 (m, 1H), 7.18 (t, 1H), 6.92 (dd, lH), 6.67 (dd, 1H), 6.32 (d, 1H), 3.1 (m, 2H), 2.42 (m, 6H), 2.27 (s, 3H), 1. 67 (m, 4H).

[1078] MS m/z 473 [M-1].

Example 215 2- [4- (2-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-mehyl-lH-pyrrole-3-carboxylic acid (3- pyrrolidin-1-yl-propyl)-amide [1079] 1H NMR (400 MHz, DMSO-d6) 813. 81 (s, 1H, NH), 7.82 (t, l H), 7.59 (s, 1H), 7.46 (m, lH), 7.37 (m, 2H), 7.29 (m, 1 H), 7.17 (t, 1 H), 6.91 (dd, 1H), 6.66 (dd, 1H), 6.29 (t, 1H), 3.05 (m, 2H), 2.40 (m, 6H), 2.22 (s, 3H), 1.7 (m, 4H), 1.49 (m 2H).

[1080] MS m/z 488 [M-1].

Example 216 4- (2-Chloro-phenyl)-3- [1- [3-methyl-4- (4-methyl-piperazine-l- carbonyl)-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol-2- one [10811'H NMR (400 MHz, DMSO-d6) 813. 45 (s, 1H, NH), 11.12 (s, 1H, NH), 7.66 (m, 2 H), 7.52 (m, 2H), 7.43 (m, lH), 7.35 (d,J=3. 1 Hz, 1H), 7.21 (t, J= 7.8 Hz, 2 H), 6.93 (dd, J=0.8Hz4=7. 8Hz, lH), 6.76 (dd, J=0. 8Hz,J=7. 4Hz, 1H), 6.45 (s, l H), 3.42 (m, 4H), 2.22 (m, 4H), 2.18 (s, 3H), 1.60 (s, 3H) [1082] MS m/z 459 [M-1]. Example 217 4- (3-Methoxy-phenyl)-3- 1- [3-methyl-4- (morpholine-4-carbonyl)- 1H-pyrrol-2-yl]-meth-(Z)-ylidene]-1,3-dihydro-indol-2-one [1083] IH NMR (400 MHz, DMSO-d6) 813. 49 (s, 1H, NH), 11.08 (s, 1H, NH), 7.44 (t, J= 8.2 Hz, 1 H), 7.38 (d, J=3.1Hz, 1H), 7.17 (t, J=7.6Hz,1H), 7.09 (m, 1H), 6.95 (m, 2 H), 6.89 (s, 1H), 6.87 (d, J=0.8Hz, 1H), 6.78 (dd, J= 0.8HzJ= 7.4Hz, l H), 3.75 (s, 3H), 3.51 (m, 4H), 3.43 (m, 4H), 1.63 (s, 3H).

[1084] MS m/z 442 [M-1].

Example 218 4-(3-Chloro-4-fluoro-phenyl)-3-[1-[3-methyl-4-(morpholine-4- carbonyl)-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol-2- one [1085] 1H NMR (400 MHz, DMSO-d6) 813. 41 (s, 1H, NH), 11.13 (s, 1H, NH), 7.70 (dd, J= 2.2Hz, J= 7.4 Hz, 1 H), 7.59 (t, J= 9.0 Hz, 1H), 7.46 (m, 1H), 7.40 (d, J =3.1 Hz, 1H), 7.19 (t, J= 7.6 Hz, 1H), 7.19 (t, J= 7.6 Hz, l H), 6.92 (dd, J= 0.8 Hz, J = 7.4Hz, 1H), 6.80 (dd, J= 0.8 Hz, J= 7.4Hz, 1H), 6.76 (s, 1H), 3.52 (m, 4H), 3.38 (m, 4H), 1.69 (s, 3H).

[1086] MS m/z 464 [M-1].

Example 219 3- [1- {3, 5-Dimethyl-4- [2-oxo-2- (4-pyrrolidin-1-yl-piperidin-1-yl)- ethyl]-lH-pyrrol-2-yl}-meth- (Z)-ylidene]-4- (3-fluoro-phenyl)-1, 3- dihydro-indol-2-one [1087] 'H NMR (400 MHz, DMSO-d6) 8 13. 28 (s, 1H, NH), 10.93 (s, 1H, NH), 7.56 (m, 1H), 7.28 (m, 3H), 7.13 (t, 1H), 6.90 (dd, 1H), 6.75 (dd, 1H), 6.74 (s, 1H), 4.13 (m, 1H), 3.58 (m, 1H), 3.39 (s, 2H), 3.05 (m, 1H), 2.71 (m, 1H), 2.47 (m, 4H), 2.19 (m, 5H), 1.79 (m, 2H), 1.65 (m, 4H), 1.52 (s, 3H), 1.2 (m, 1H).

[1088] MS m/z 525 [M-1J.

Example 220 2- {5- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-2, 4-dimethyl-lH-pyrrol-3-yl}-N-(2-hydroxy-3- [1, 2,3] triazol-2-yl-propyl)-acetamide [1089] 1H NMR (400 MHz, DMSO-d6) 8 13.30 (s, 1H, NH), 10.93 (s, 1H, NH), 7.87 (t, 1H), 7.74 (s, 2H), 7.55 (m, H), 7.26 (m, 3H), 7.13 (t, 1H), 6.90 (d, H), 6.75 (m, H), 5.22 (m, 1H), 4.29 (m, 2H), 4.02 (m, 1H), 3.17 (s, 2H), 3.06 (m, 2H), 2.23 (s, 3H), 1.56 (s, 3H).

[1090] MS m/z 513 [M-1].

Example 221 3-[1-[3,5-Dimethyl-4-(2-morpholin-4-yl-2-oxo-ethyl)-1H-pyrro l-2- yl]-meth- (Z)-ylidene]-4- (3-fluoro-phenyl)-1, 3-dihydro-indol-2-one [1091] 1H NMR (400 MHz, DMSO-d6) 8 13.29 (s, 1H, NH), 10.92 (s, 1H, NH), 7.56 (m, lH), 7.28 (m, 3H), 7.13 (t, J= 7.8 Hz, lH), 6.90 (dd, J= 0.8 Hz, J=7.8 Hz, 1H), 6.75 (dd, J= 1.0 Hz, J= 7.4 Hz, lH), 6.75 (s, 1H), 3.49 (m, 6H), 3. 39 (m, 4H), 2.19 (s, 3H), 1.51 (s, 3H).

[1092] MS m/z 458 [M-1].

Example 222 4- (3-Fluoro-phenyl)-3- 1- {4- [2- (4-hydroxy-piperidin-1-yl)-2-oxo- ethyl]-3,5-dimethyl-1H-pyrrol-2-yl}-meth-(Z)-ylidene]-1, 3- dihydro-indol-2-one [1093] 1H NMR (400 MHz, DMSO-d6) 8 13.29 (s, 1H, NH), 10.92 (s, 1H, NH), 7.56 (m, 1H), 7.28 (m, 3H), 7.13 (t, J= 7.8 Hz, 1H), 6.90 (d, J= 7.4 Hz, 1H), 6.75 (dd, J= 0.78 Hz, J= 7.8 Hz, lH), 6.74 (s, lH), 4.72 (d, J= 3.9 Hz, 1H), 3.89 (m, 1H), 3.68 (m, 2H), 3.39 (m, 2H), 3.15 (m, 1H), 2.95 (m, 1H), 2.19 (s, 3H), 1.67 (m, 2H), 1.52 (s, 3H), 1.19 (m, 2H).

[1094] MS m/z 472 [M-1].

Example 223 2- {5- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl}-N-(2-morpholin-4 -yl- ethyl)-acetamide [1095] IH NMR (400 MHz, DMSO-d6) 8 13.31 (s, 1H, NH), 10.94 (s, 1H, NH), 7.56 (m, 2H), 7.28 (m, 3H), 7.13 (t, J= 7.6Hz, lH), 6.90 (dd, J= 0.8 Hz, J=7.8 Hz, 1H), 6.76 (d, J= 0.8 Hz, 1H), 6.74 (s, 1H), 3.54 (m, 2H), 3.50 (m, H), 3.15 (s, 2H), 3.19 (m, 2H), 2.29 (m, 6H), 2.25 (s, 3H), 1.60 (s, 3H).

[10961 MS m/z 501 [M-1].

Example 224 N (2-Diethylamino-ethyl)-2- {5- 4- (3-fluoro-phenyl)-2-oxo-1, 2- dihydro-indol-(3Z)-ylidenemethyl]-2, 4-dimethyl-lH-pyrrol-3-yl}- acetamide [1097] 1H NMR (400 MHz, DMSO-d6) 8 13. 30 (s, 1H, NH), 10.93 (s, 1H, NH), 7.56 (m, H), 7.41 (t, J= 5.6 Hz, 1H), 7.28 (m, 3H), 7.13 (t, = 7.8 Hz, lH), 6.90 (d, J =7.0 Hz, 1H), 6.75 (d, J=8. 6 Hz, 1H), 6.74 (s, 1H), 3.14 (s, 2H), 3.04 (m, 2H), 2.38 (m, 6H), 2.24 (s, 3H), 1.57 (s, 3H), 0.88 (t, J=7. 2 Hz, 6H).

[1098] MS m/z 487 [M-1].

Example 225 2- {5- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl}-N-(2-pyrrolidin- 1-yl- ethyl)-acetamide [1099] IH NMR (400 MHz, DMSO-d6) 8 13.29 (s, 1H, NH), 10.92 (s, 1H, NH), 7.64 (t, 1H), 7.56 (m, 1H), 7.27 (m, 3H), 7.13 (t, J= 7.8 Hz, lH), 6.90 (dd, J=0.78 Hz, J= 7.8 Hz, lH), 6.75 (dd, J= 0.78 Hz, J= 7.8 Hz, 1H), 6.74 (s, lH), 3.14 (s, 2H), 3.11 (m, 2H), 2.42 (m, 6H), 2.24 (s, 3H), 1.65 (m, 4H), 1.57 (s, 3H).

[1100] MS m/z 485 [M-1].

Example 226 3- [1- {4- [2- ( (cis)-3, 5-Dimethyl-piperazin-1-yl)-2-oxo-ethylj-3, 5- dimethyl-lH-pyrrol-2-yl}-meth- (Z)-ylidene]-4- (3-fluoro-phenyl)- 1,3-dihydro-indol-2-one [1101] 1H NMR (400 MHz, DMSO-d6) 8 13. 29 (s, 1H, NH), 10.92 (s, 1H, NH), 7.56 (m, 1H), 7.27 (m, 3H), 7.14 (t, J= 7.6 Hz, 1H), 6.92 (dd, J= 0.77 Hz, J= 7.8 Hz, 1H), 6.75 (dd, J= 0.78 Hz, J= 7.8 Hz, 1H), 6.74 (s, lH), 4.19 (m, 1H), 3.75 (m, 1H), 3.45 (d, J= 16.8Hz, 1H), 3.13 (d, J= 16.8Hz, 1H), 2.45 (m, 3H), 2.20 (m, 1H), 2.19 (s, 3H), 1.99 (m, 1H), 1.52 (s, 3H), 0.91 (m, 6H).

[1102] MS m/z 485 [M-1].

Example 227 2-{5-[4-(3-Fluoro-phenyl)-2-oxo-1,2-dihydro-indol-(3Z)- ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl}-N-(2-pyridin-4-y l- ethyl)-acetamide [1103] 1H NMR (400 MHz, DMSO-d6) b 13.29 (s, 1H, NH), 10.92 (s, 1H, NH), 8.41 (dd, 2H), 7.74 (t, 1H), 7.57 (m, 1H), 7.29 (m, 3H), 7.13 (m, 3H), 6.90 (d, 1H), 6.76 (d, 1H), 6.73 (s, 1H), 3.28 (m, 2H), 3.11 (s, 2H), 2.69 (t, 2H), 2.19 (s, 3H), 1.51 (s, 3H).

[1104] MS m/z 493 [M-1].

Example 228 2-Fluoro-5- {3- [1- [5-methyl-3- (4-pyrrolidin-1-yl-piperidine-l- carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-2-oxo-2, 3-dihydro- lH-indol-4-yl}-benzonitrile [1105] 1H NMR (400 MHz, DMSO-d6) 8 13.59 (s, NH, 1H), 11. 17 (s, NH, 1H), 7.93 (dd, J= 2.3 Hz, J= 6.3 Hz, 1H), 7.73 (m, 1H), 7.63 (m, 1H), 7.21 (t, J= 7.6 Hz, 1H), 6.94 (dd, J= 0. 8Hz, J= 7.8Hz, 1H), 6.87 (m, 1H), 6.78 (d, J= 6.6 Hz, 1H), 6.11 (d, J =. 1. 9Hz, 1H), 4.25 (m, lH), 3.85 (m, lH), 2.95 (m, 8H), 1.90 (m, 6H), 1.42 (m, lH).

[1106] MS m/z 522 [M-1].

Example 229 2- [4- (3-Cyano-4-fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (2-hydroxy- 3-[1, 2,3] triazol-2-yl-propyl)-amide [1107] 'H NMR (400 MHz, DMSO-d6) 8 13.79 (s, NH, 1H), 11.17 (s, NH, 1H), 8. 00 (t, 1H), 7.93 (s, 1H), 7.91 (dd, 1H), 7.75 (s, 2H), 7.68 (m, 1H), 7.50 (t, 1H), 7.21 (t, 1H), 6.94 (d, 1H), 6.78 (d, 1H), 6.51 (d, 1H), 5. 14 (d, 1H), 4.32 (m, 2H), 4.09 (m, 1H), 3.12 (m, 2H), 2.30 (s, 3H).

[1108] MS m/z 510 [M-1]. Example 230 5- {3- [1- [3- ( (cis)-3, 5-Dimethyl-piperazine-l-carbonyl)-5-methyl-lH- <BR> <BR> pyrrol-2-yl]-meth- (Z)-ylidene]-2-oxo-2, 3-dihydro-lH-indol-4-yl}-2-<BR> <BR> fluoro-benzonitrile [1109] IH NMR (400 MHz, DMSO-d6) 6 13.59 (s, NH, lH), 11.15 (s, NH, 1H), 7.93 (dd, J= 2.3 Hz, J= 6.3 Hz, 1H), 7.72 (m, 1H), 7.54 (m, 1H), 7.20 (t, J= 7.6 Hz, 1H), 6.94 (dd, J= 0.8 Hz, J= 7.8 Hz, 1H), 6.87 (s, 1H), 6.76 (dd, J= 0. 8HzJ= 7.8 Hz, 1H), 6.08 (d, J= 2. 0Hz, 1H), 4.18 (m, 1H), 3.57 (m, 1H), 2.42 (m, 2H), 2.31 (s, 3H), 2.26 (m, lH), 2.07 (m, 1H), 1.02 (m, 3H), 0.96 (m, 1H), 0.82 (m, 3H).

[1110] MS m/z 482 [M-l].

Example 231 3- [1- [3- (3-Dimethylamino-propyl)-4, 5, 6, 7-tetrahydro-1H-indol-2- yl]-meth- (Z)-ylidene]-4- (4-fluoro-phenyl)-1, 3-dihydro-indol-2-one [1111] 1H NMR (400 MHz, DMSO-d6) # 13. 25 (s, 1H, NH), 10.91 (s, 1H, NH), 7.45 (m, 2H), 7.34 (m, 2H), 7.11 (t, J= 7.6 Hz, 1H), 6.88 (dd, J= 0.78 Hz, J= 7.8 Hz, 1H), 6.82 (s, 1H), 6.71 (d, J= 7.8 Hz, 1H), 2.62 (m, 2H), 2.33 (m, 2H), 2.07 (s, 6H), 1.97 (m, 4H), 1.69 (m, 4H), 1.20 (m, 2H).

[1112] MS m/z 444 [M++1].

Example 232 3-[1-[3-(3-Dimethylamino-propyl)-4, 5,6, 7-tetrahydro-1H-indol-2- yl]-meth- (Z)-ylidene]-4- (2-fluoro-phenyl)-1, 3-dihydro-indol-2-one [1113]'H NMR (400 MHz, DMSO-d6) 8 13.25 (s, 1H, NH), 10.93 (s, 1H, NH), 7.57 (m, H), 7.44 (m, 1H), 7.37 (m, 2H), 7.14 (t, J= 7.8 Hz, lH), 6.92 (d, J= 7.8 Hz, lH), 6.75 (d, J= 7.4 Hz, 1H), 6.7 (s, 1H), 2.62 (t, J= 5.9Hz, 2H), 2.32 (m, 2H), 2.06 (s, 6H), 1.91 (m, 4H), 1.68 (m, 4H), 1.18 (m, 2H).

[1114] MS m/z 444 [M++1].

Example 233 4- (4-Chloro-phenyl)-3- [l- [3- (3-dimethylamino-propyl)-4, 5,6,7- tetrahydro-lH-indol-2-yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol-2- one [1115]'H NMR (400 MHz, DMSO-d6) 8 13.25 (s, 1H, NH), 10.92 (s, 1H, NH), 7.56 (m, 2H), 7.45 (m, 2H), 7.12 (t, J= 7.6 Hz, 1H), 6.89 (dd, J= 0.78 Hz, J= 7.8 Hz, 1H), 6.85 (s, lH), 6.71 (dd, J= 0.78 Hz, J= 7.8 Hz, 1H), 2.62 (m, 2H), 2.32 (m, 2H), 2.07 (s, 6H), 1.97 (m, 4H), 1.68 (m, 4H), 1.18 (m, 2H).

[1116] MS m/z 459 [M-1].

Example 234 4- (3-Chloro-phenyl)-3- [l- [3- (3-dimethylamino-propyl)-4, 5,6,7- tetrahydro-lH-indol-2-yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol-2- one [1117] IH NMR (400 MHz, DMSO-d6) 8 13.25 (s, lH, NH), 10.93 (s, lH, NH), 7.54 (m, H), 7.48 (m, 1H), 7.39 (m, 1H), 7.12 (t, J=7.8 Hz, 1H), 6.90 (d, J=6.6 Hz, 1H), 6.83 (s, lH), 6.73 (dd, J=0. 78Hz, J= 7. 8 Hz, 1H), 2.62 (m, 2H), 2.33 (m, 2H), 2.05 (s, 6H), 1.94 (m, 4H), 1.68 (m, 4H), 1.18 (m, 2H).

[1118] MS m/z 460 [M++1].

Example 235 4- (2-Chloro-phenyl)-3- [l- [3- (3-dimethylamino-propyl)-4, 5,6,7- tetrahydro-lH-indol-2-yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol-2- one [1119]'H NMR (400 MHz, DMSO-d6) 8 13.25 (s, 1H, NH), 10.93 (s, 1H, NH), 7.63 (dd, J= 1.2Hz, J= 7.8 Hz, 1H), 7.53 (m, 2H), 7.42 (m, lH), 7.14 (t, J= 7.6 Hz, lH), 6.91 (d, J= 7.8 Hz, lH), 6.68 (d, J= 7.8 Hz, 1H), 6.49 (s, 1H), 2.61 (m, 2H), 2.31 (m, 2H), 2.11 (s, 6H), 2.01 (m, 2H), 1.85 (m, 2H), 1.68 (m, 4H), 1.21 (m, 2H).

[1120] MS m/z 460 [M++1].

Example 236 4-Biphenyl-3-yl-3- [I- [3, 5-dimethyl-4- (4-pyrrolidin-1-yl-piperidine- 1-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-1,3-dihydro-in dol- 2-one [1121] MS m/z 569 [M-1].

Example 237 5- (4-Biphenyl-3-yl-2-oxo-1, 2-dihydro-indol- (3Z)-ylidenemethyl]- 2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3- [1, 2,3] triazol-1-yl-propyl)-amide [1122]'H NMR (400 MHz, DMSO-d6) 8 13.49 (s, 1H, NH), 11.06 (s, 1H, NH), 8.03 (d, J= 0.78 Hz, 1H), 7.67 (m, 6H), 7.39 (m, 5H), 7.20 (t, I= 7.6 Hz, 1H), 6.93 (dd, J = 0.78Hz, J=7. 8 Hz, 1H), 6.87 (s, 1H), 6.85 (s, 1H), 5.32 (m, 1H), 4.22 (m, 1H), 3.20 (m, 4H), 2.36 (s, 3H), 1.61 (s, 3H).

[1123] MS m/z 557 [M-1].

Example 238 4-Biphenyl-3-yl-3- [1- [4- ( (cis)-3, 5-dimethyl-piperazine-1-carbonyl)- 3,5-dimethyl-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-1,3-dihydro-i ndol- 2-one [1124] MS m/z 529 [M-1].

Example 239 4-(3-Fluoro-phenyl)-3-[1-[4-(4-hydroxy-piperidine-1-carbonyl )-3, 5- dimethyl-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol-2- one [1125] 1H NMR (400 MHz, DMSO-d6) 8 13. 41 (s, 1H, NH), 11.05 (s, 1H, NH), 7.57 (m, 1H), 7.28 (m, 3H), 7.17 (t, J= 7. 6 Hz, 1H), 6.92 (dd, J= 0. 78 Hz, J=7. 8 Hz, 1H), 6.78 (dd, J= 0.78 Hz, J= 7.8 Hz, 1H), 6.75 (s, 1H), 4.7 (d, J= 4.3 Hz, 1H), 3.95 (br m, 1H), 3.67 (m, 1H), 3.45 (br m, 1H), 3.07 (m, 2H), 2.23 (s, 3H), 1.69 (m, 2H), 1.58 (s, 3H), 1.24 (m, 2H).

[1126] MS m/z 458 [M-1]. Example 240 3- [l- [3, 5-Dimethyl-4- (4-pyridin-2-yl-piperazine-1-carbonyl)-lH- pyrrol-2-yl]-meth-(Z)-ylidene]-4-(3-fluoro-phenyl)-1,3-dihyd ro- indol-2-one [1127] 1H NMR (400 MHz, DMSO-d6) # 13.47 (s, 1H, NH), 11.07 (s, 1H, NH), 8.10 (dd, J= 1. 7 Hz, J= 4. 7Hz, 1H), 7.54 (m, 2H), 7.29 (m, 3H), 7.18 (t, J= 7. 6 Hz, 1H), 6.93 (dd, J= 0. 78 Hz, J= 7. 8 Hz, 1H), 6.79 (m, 3H), 6.64 (m, 1H), 3.47 (m, 4H), 3.49 (m, 4H), 2.26 (s, 3H), 1.62 (s, 3H).

[1128] MS m/z 520 [M-1].

Example 241 5- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyll-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- piperidin-1-yl-ethyl)-amide [1129 'H NMR (400 MHz, DMSO-d6) 8 13.45 (s, 1H, NH), 11.05 (s, 1H, NH), 7.58 (m, 1H), 7.30 (m, 4H), 7.17 (t, J= 7.8 Hz, 1H), 6.92 (dd, J= 1. 2 Hz, J= 7.8 Hz, 1H), 6.79 (dd, J=0. 78 Hz, J= 7.8 Hz, 1H), 6.77 (s, 1H), 3.27 (m, 2H), 2.39 (s, 3H), 2.36 (m, 6H), 1.73 (s, 3H), 1.47 (m, 4H), 1.38 (m, 2H).

[1130] MS m/z 485 [M-1].

Example 242 5- [4-Biphenyl-2-yl-2-oxo-1, 2-dihydro-indol- (3Z)-ylidenemethyl]- 2,4-dimethyl-lH-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)- amide [1131] 1H NMR (400 MHz, DMSO-d6) 613. 45 (s, 1H, NH), 11.05 (s, 1H, NH), 7.53 (m, 3H), 7.35 (m, 2H), 7.07 (m, 6H), 7.77 (d, J=7. 0 Hz, 1H), 6.73 (d, J= 7. 4 Hz, 1H), 6.56 (s, 1H), 3.34 (s, 2H), 2.48 (m, 6H), 2.36 (s, 3H), 1.73 (s, 3H), 0.95 (t, 6H).

[1132] MS m/z 531 [M-1]. <BR> <BR> <BR> <BR> <BR> <BR> <P>Example 243 2- [4-Biphenyl-2-yl-2-oxo-1, 2-dihydro-indol- (3Z)-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (3-pyrrolidin-1-yl-propyl)- amide [1133] 1H NMR (400#MHz, DMSO-d6) #13. 71 (s, 1H, NH), 10.91 (s, IH, NH), 7.84 (t, 1H), 7.64 (s, 1H), 7.41 (m, 3H), 7.24 (d, 1H), 7.07d (m, H), 6.76 (dd 1H), 6.38 (dd 1H), 6.28 (d, 1H), 3.19 (m, 2H), 2.50 (m, 4H), 2.41 (m, 2H), 2.28 (s, 3H), 1.65 (m, 6H).

[1134] MS m/z 529 [M-1].

Example 244 2-[4-(4-Chloro-phenyl)-2-oxo-1,2-dihydro-indol-(3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (3- pyrrolidin-1-yl-propyl)-amide [1135] 1H NMR (400 MHz, DMSO-d6) 8 13.81 (s, NH, 1H), 11. 12 (br s, NH, 1H), 7.99 (s, 1H), 7.88 (m, 1H), 7.44 (m, 2H), 7.35 (m, 2H), 7.19 (t, J= 7.8 Hz, 1H), 6.92 (d, I= 7.4Hz, 1H), 6.75 (d, J= 7.4Hz, 1H), 6.36 (s, lH), 3.12 (m, 2H), 2.42 (m, 6H), 2.30 (s, 3H), 1.67 (m, 4H), 1.60 (m, 2H).

[1136] MS m/z 487 [M-1].

Example 245 2- [4- (3-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (3- pyrrolidin-1-yl-propyl)-amide [1137] 1H NMR (400 MHz, DMSO-d6) # 13.81 (s, NH, lH), l 1. 16 (br s, NH, 1H), 7.99 (s, 1H), 7.88 (m, 1H), 7.42 (d, J= 7.4Hz, 1H), 7.39 (m, 2H), 7.32 (d, J = 7.0Hz, 1H), 7.20 (t, J= 7.6 Hz, 1H), 6.92 (d, J= 7.8Hz, 1H), 6.76 (d, J= 7.8Hz, 1H), 6.35 (s, lH), 3.12 (m, 2H), 2.42 (m, 6H), 2.30 (s, 3H), 1.69 (m, 4H), 1.60 (m, 2H).

[1138] MS m/z 487 [M-1].

Example 246 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (3- pyrrolidin-1-yl-propyl)-amide [1139] 1H NMR (400 MHz, DMSO-d6) # 13.81 (s, NH, lH), 11.14 (brs, NH, 1H, 7.98 (s, 1H), 7.88 (m, 1H), 7.44 (m, 1H), 7.18 (m, 4H), 6.92 (d, J= 7. 0Hz, 1H), 6.77 (d, J= 7. 0Hz, 1H), 6.34 (s, lH), 3.07 (m, 2H), 2.42 (m, 6H), 2.30 (s, 3H), 1.69 (m, 4H), 1.59 (m, 2H).

[1140] MSm/z471 [M-1].

Example 247 2- [4- (4-Bromo-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-1H-pyrrole-3-carboxylic acid (3- pyrrolidin-1-yl-propyl)-amide [1141] 1H NMR (400 MHz, DMSO-d6) # 13.81 (s, NH, lH), 11. 16 (br s, NH, 1H), 8.01 (s, 1H), 7.87 (m, 1H), 7.57 (m, 2H), 7.29 (m, 2H), 7.19 (t, J= 7.8Hz, 1H), 6.91 (d, J = 7.8Hz, 1H), 6.75 (dd, J = 1. 2Hz, J = 7.8Hz, 1H), 6.36 (m, lH), 3.15 (m, 2H), 2.42 (m, 6H), 2.30 (s, 3H), 1.67 (m, 4H), 1.61 (m, 2H).

[1142] MS m/z 531, 533 [M-1].

Example 248 5-Methyl-2- [2-oxo-4-phenyl-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-lH-pyrrole-3-carboxylic acid (3-pyrrolidin-1-yl- propyl)-amide [1143] 1H NMR (400 MHz, DMSO-d6) # 13.80 (s, NH, 1H), 11.16 (s, NH, 1H), 7.89 (s, 1H), 7.82 (m, 1H), 7.37 (m, 5H), 7.17 (t, J= 7.8Hz, 1H), 6.90 (d, J= 7. 0Hz, 1H), 6.75 (d, J= 7. 0Hz, 1H), 6.29 (m, 1H), 3.03 (m, 2H), 2.42 (m, 6H), 2.29 (s, 3H), 1.68 (m, 4H), 1.56 (m, 2H).

[1144] MS m/z 453 [M-1].

Example 249 5- [4- (3, 5-Difluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2- pyrrolidin-1-yl-ethyl)-amide [1145]'H NMR (400 MHz, DMSO-d6) 8 13.45 (s, NH, lH), 11. 08 (s, NH, 1H), 7.48 (m, 1H), 7.40 (m, 1H), 7.22 (m, 2H), 7.18 (t,'J= 7. 8Hz, 1H), 6.92 (dd, J= 0.8Hz, J = 7.4Hz, 1H), 6.80 (m, 2H), 3.26 (m, 2H), 2.51 (m, 2H), 2.44 (m, 4H), 2.36 (s, 3H), 1.78 (s, 3H), 1.64 (m, 4H).

[1146] MS m/z 489 [M-1].

Example 250 2- [4- (3, 5-Difluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (3- pyrrolidin-1-yl-propyl)-amide [1147] 1H NMR (400 MHz. DMSO-d6) # 13.77 (s, NH, 1H), 11. 13 (s, NH, 1H), 8.05 (s, 1H), 7.94 (m, 1H), 7.19 (t, J= 7.8Hz, lH), 7.11 (m, 1H), 7.05 (m, 2H), 6.93 (d, J= 7.8Hz, 1H), 6.78 (d, J= 7.8Hz, 1H), 6.38 (m, 1H), 3.10 (m, 2H), 2.42 (m, 6H), 2.30 (s, 3H), 1.68 (m, 4H), 1.59 (m, 2H).

[1148] MS m/z 489 [M-1].

Example 251 4- (3, 5-Difluoro-phenyl)-3- [1- [3, 5-dimethyl-4- (4-methyl-piperazine- l-carbonyl)-lH-pyrrol-2-yl]-meth-(Z)-ylidene]-1, 3-dihydro-indol- 2-one [1149] 1H NMR (400 MHz, DMSO-d6) 8 13.43 (s, NH, 1H), 11. 08 (s, NH, 1H), 7.39 (m, 1H), 7.20 (m, 3H), 6.94 (d, J= 7.4Hz, 1H), 6.80 (m, 2H), 3.42 (m, 4H), 2.26 (m, 4H), 2.22 (s, 3H), 2.15 (s, 3H), 1.65 (s, 3H).

[1150] MS m/z 475 [M-1].

Example 252 4- (3, 5-Difluoro-phenyl)-3- [1- [5-methyl-3- (4-pyrrolidin-1-yl- piperidine-1-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-1, 3- dihydro-indol-2-one [11511'H NMR (400 MHz, DMSO-d6) 8 13.54 (s, NH, 1H), 11. 12 (s, NH, 1H), 7.24 (m, 1H), 7.18 (m, 1H), 7.06 (m, 2H), 6.93 (m, 2H), 6.76 (d, J= 7. 0Hz, 1H), 6.09 (s, 1H), 4.11 (m, 1H), 3.59 (m, 1H), 2.84 (m, 2H), 2.45 (m, 4H), 2.31 (s, 3H), 2.17 (m, 1H), 1.58 (m, 1H), 1.65 (m, 5H), 1.21 (m, 2H).

[1152] MS m/z 515 [M-1].

Example 253 3- [l- {3, 5-Dimethyl-4- [3- (4-methyl-piperazin-1-yl)-3-oxo-propyl]- 1H-pyrrol-2-yl}-meth- (Z)-ylidene]-4- [3- (2-hydroxy-ethyl)-phenyl]- 1,3-dihydro-indol-2-one [1153] 1H NMR (400 MHz, DMSO-d6) 8 13.27 (s, NH, 1H), 10.85 (s, NH, 1H), 7.41 (t, J= 7.4Hz, 1H), 7.31 (d, J= 7. 4Hz, 1H), 7.23 (s, 1H), 7.18 (d, J= 7.8Hz, 1H), 7.09 (t, J= 7.8Hz, 1H), 6.86 (d, J= 7.8Hz, 1H), 6.71 (m, 2H), 4.64 (m, 1H), 3.60 (m, 2H), 3.37 (m, 2H), 3.24 (m, 2H), 2.76 (t, J= 7.4Hz, 2H), 2.35 (m, 4H), 2.21 (s, 3H), 2.13 (m, 4H), 2.07 (s, 3H), 1.49 (s, 3H).

[1154] MS m/z 511 [M-1].

Example 254 3-[1-{4-[3-((cis)-3,5-Dimethyl-piperazin-1-yl)-3-oxo-propyl] -3, 5- dimethyl-lH-pyrrol-2-yl}-meth- (Z)-ylidene]-4- [3- (2-hydroxy- ethyl)-phenyl]-l, 3-dihydro-indol-2-one [1155] MS m/z 525 [M-1].

Example 255 4-[3-(2-Hydroxy-ethyl)-phenyl]-3-[1-[3-methyl-4-(4-methyl- piperazine-1-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-1, 3- dihydro-indol-2-one [1156] 1H NMR (400 MHz, DMSO-d6) # 13.48 (s, NH, 1H), 11. 08 (s, NH, 1H), 7.44 (t, J = 7. 4Hz, 1H), 7.35 (d, J = 3.1Hz, 1H), 7.33 (d, J = 7. 8Hz, 1H), 7.26 (s, 1H), 7.22 (m, 1H), 7.18 (t, J= 7.8Hz, 1H), 6.90 (d, J= 7.8Hz, 1H), 6.78 (m, 2H), 4.64 (t, J= 5. 1Hz, 1H), 3.60 (m, 2H), 3.43 (m, 4H), 2.77 (t, J= 7.0Hz, 2H), 2.24 (m, 4H), 2.15 (s, 3H), 1.57 (s, 3H).

[1157] MS m/z 469 [M-1].

Example 256 3-[1-[4-((cis)-3,5-Dimethyl-piperazine-1-carbonyl)-3-methyl- 1H- pyrrol-2-yl]-meth-(Z)-ylidene]-4-[3-(2-hydroxy-ethyl)-phenyl ]-1, 3- dihydro-indol-2-one [1158] 1H NMR (400 MHz, DMSO-d6) 5 13.46 (s, NH, 1H), 11. 08 (s, NH, 1H), 7.44 (t, J = 7.8Hz, 1H), 7.34 (m, 2H), 7.26 (s, 1H), 7. 21 (d, J= 7.4Hz, 1H), 7.18 (t, J= 7.8Hz, 1H), 6.89 (d, J= 7.8Hz, 1H), 6.77 (m, 2H), 4.63 (t, J= 5. 1Hz, 1H), 4.10 (m, 1H), 3.60 (m, 2H), 2.77 (t, J= 7. 0Hz, 2H), 2.56 (m, 4H), 2.30 (m, 2H), 1.56 (s, 3H), 0.90 (m, 6H).

[1159] MS m/z 483 [M-1].

Example 257 2- [4-[3-(2-Hydroxy-ethyl)-phenyl]-2-oxo-1,2-dihydro-indol-(3Z) - ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (3- pyrrolidin-1-yl-propyl)-amide [1160] 'H NMR (400 MHz, DMSO-d6) 8 13.79 (s, NH, 1H), 11.08 (s, NH, 1H), 7.95 (m, 1H), 7.86 (s, 1H), 7.26 (d, J= 7.8Hz, 1H), 7.16 (m, 3H), 7.11 (d, J= 7.8Hz, 1H), 6. 88 (d, J= 7.8Hz, 1H), 6.73 (dd, J= 1. 2Hz,J = 7.8Hz, 1H), 6.32 (m, 1H), 4.55 (br m, 1H), 3.61 (m, 2H), 3.02 (m, 2H), 2.72 (t, J= 6.6Hz, 2H), 2.43 (m, 6H), 2.28 (s, 3H), 1.67 (m, 4H), 1.57 (m, 2H).

[1161] MS m/z 497 [M-1].

Example 258 3- [l- [3- ( (cis)-3, 5-Dimethyl-piperazine-l-carbonyl)-5-methyl-lH- pyrrol-2-yl]-meth- (Z)-ylidene]-4- [3- (2-hydroxy-ethyl)-phenyl]-1, 3- dihydro-indol-2-one [1162] 1H NMR (400 MHz, DMSO-d6) # 13.65 (s, NH, lH), 11. 20 (s, NH, 1H), 7.30 (br m, 1H), 7.20 (m, 1H), 7.18 (m, 3H), 6.96 (br m, 1H), 6.88 (dd, J= 0.8Hz, J= 7.8Hz, 1H), 6.71 (dd, J = 0.8Hz, J = 7.4Hz, 1H), 6.02 (d, J = 2.3Hz, 1H), 4.61 (m, 1H), 4.06 (m, 1H), 3.63 (m, 2H), 2.75 (m, 2H), 2.46 (m, 4H), 2.29 (s, 3H), 2.0 (m, 2H), 1.03 (m, 3H), 0.77 (m, 3H).

[1163] MS m/z 483 [M-1].

Example 259 (3- {3- [1- [3-Methyl-4- (morpholine-4-carbonyl)-lH-pyrrol-2-yl]- meth- (Z)-ylidene]-2-oxo-2, 3-dihydro-lH-indol-4-yl}-phenyl)-acetic acid [1164] [3-(2-Oxo-2,3-dihydro-1H-indol-4-yl)-phenyl]-acetic acid (80.1 mg, 0.3 mmol) was condensed with 3-methyl-4- (morpholine-4-carbonyl)-lH-pyrrole-2- carbaldehyde (66.7 mg, 0.3 mmol) in ethanol to give 75.3 mg of the titled compound.

[1165] 1H NMR (400 MHz, DMSO-d6) 8 13.50 (s, NH, IH), 12.29 (s, lH), 11. 09 (s, NH, 1H), 7.48 (t, J= 7.4 Hz, 1H), 7.37 (m, 2H), 7.30 (s, 1H), 7.27 (d, J = 7. 4Hz, 1H), 7.19 (t, J= 7.4Hz, 1H), 6.90 (dd, J = 0. 8Hz, J= 7.8Hz, 1H), 6.76 (m, 2H), 3.64 (s, 2H), 3.52 (m, 4H), 3.44 (m, 4H), 1. 58 (s, 3H).

[1166] MS m/z 472 [M++1].

Example 260 4-{3-[2-((cis)-3, 5-Dimethyl-piperazin-1-yl)-2-oxo-ethyl]-phenyl}-3- <BR> <BR> <BR> [1- [3-methyl-4- (morpholine-4-carbonyl)-lH-pyrrol-2-yl]-meth- (Z)-<BR> <BR> <BR> <BR> <BR> <BR> ylidene]-1, 3-dihydro-indol-2-one [1167] (3-{3-[1-[3-Methyl-4-(morpholine-4-carbonyl)-1H-pyrrol-2-yl] -meth-(Z)- ylidene]-2-oxo-2,3-dihydro-lH-indol-4-yl}-phenyl)-acetic acid was coupled with (2S, 6R)-2,6-dimethyl-piperazine (3 eq.), EDC (1.5 eq.) and HOBt (1 eq.) in THF using the general amidation procedure to give the titled compound.

[1168] 'H NMR (400 MHz, DMSO-d6) 8 13.50 (s, NH, lH), 11. 09 (s, NH, 1H), 7.46 (t, J= 7. 8Hz, 1H), 7.38 (d, J = 3.1Hz, 1H), 7.34 (br m, 1H), 7.27 (m, 2H), 7.19 (t, J= 7.8Hz, 1H), 6.90 (d, J= 7.4Hz, 1H), 6.79 (s, 1H), 6.75 (d, J= 7.8Hz, 1H), 4.21 (m, 1H), 3.82 (m, 1H), 3.76 (s, 2H), 3.51 (m, 4H), 3.44 (m, 4H), 2.42 (m, 4H), 1.97 (m, 1H), 1.60 (s, 3H), 0.90 (d, 3H), 0.81 (d, 3H).

[1169] MS m/z 566 [M-1].

Example 261 N (2-Dimethylamino-ethyl)-2- (3- {3- [l- [3-methyl-4- (morpholine-4- carbonyl)-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-2-oxo-2, 3-dihydro- lH-indol-4-yl}-phenyl)-acetamide [1170] (3- {3- [1- [3-Methyl-4- (morpholine-4-carbonyl)-1H-pyrrol-2-yl]-meth- (Z)- ylidene]-2-oxo-2, 3-dihydro-1H-indol-4-yl}-phenyl)-acetic acid (117.6 mg, 0.25 mmol) was coupled with N, N-dimethylethylenediamine (2 eq.), EDC (1.5 eq.) and HOBt (1 eq.) in DMF (1 mL) using the general amidation procedure to give 117.3 mg of the titled compound.

[1171] 1H NMR (400 MHz, DMSO-d6) # 13.50 (s, NH, lH), 11. 09 (s, NH, 1H), 7.98 (m, 1H), 7.45 (t, J= 7.8Hz, 1H), 7.36 (m, 3H), 7.24 (d, J = 7.4Hz, 1H), 7.19 (t, J = 7.6Hz, 1H), 6.90 (d, J= 7. 8Hz, 1H), 6.76 (m, 2H), 3.52 (m, 4H), 3.44 (m, 4H), 3.31 (s, 2H), 3.05 (m, 2H), 2.16 (t, J= 7. 0Hz, 2H), 2.03 (s, 6H), 1.57 (s, 3H).

[1172] MS m/z 540 [M-1].

Example 262 5- [4- (2-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-4-phenyl-lH-pyrrole-3-carboxylic acid methyl- (l- methyl-piperidin-4-yl)-amide [1173] MS m/z 533 [M-1].

Example 263 5- [4- (2-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-4-phenyl-lH-pyrrole-3-carboxylic acid (2- diethylamino-ethyl)-amide [1174] 1H NMR (400 MHz, DMSO-d6) 8 13.99 (s, NH, 1H),11. 21 (s, NH, 1H), 7.69 (d, J = 2. 9Hz, 1H), 7.32 (m, 1H), 7.21 (m, 4H), 7.04 (m, 1H), 6.98 (m, 1H), 6.92 (m, 4H), 6.79 (m, 1H), 6.69 (s, 1H), 6.68 (d, J= 7.8Hz, 1H), 3.05 (m, 2H), 2.30 (m, 6H), 0.82 (t, J=7. 0Hz, 6H).

[1175] MS m/z 521 [M-1].

Example 264 5- [4- (2-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-4-phenyl-lH-pyrrole-3-carboxylic acid (2- pyrrolidin-1-yl-ethyl)-amide [1176]'H NMR (400 MHz, DMSO-d6) 8 13.99 (s, NH, 1H), 11. 21 (s, NH, 1H), 7.70 (d, J= 3.4Hz, 1H), 7.32 (t, J = 7.3Hz, 1H), 7.23 (t, J= 7.4Hz, 1H), 7.18 (m, 3H), 7.04 (m, 1H), 6.97 (m, l. H), 6.90 (m, 3H), 6.83 (m, 1H), 6.78 (m, 1H), 6.67 (m, 2H), 3.10 (m, 2H), 2.27 (m, 6H), 1.57 (m, 4H).

[1177] MS m/z 519 [M-1].

Example 265 N,N-Dimethyl-2-(3-{3-[1-[3-methyl-4-(4-methyl-piperazine-1- carbonyl)-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-2-oxo-2, 3-dihydro- 1H indol-4-yl}-phenyl)-acetamide [1178] 1H NMR (400 MHz, DMSO-d6) # 13.47 (s, NH, 1H), 11. 08 (s, NH, 1H), 7.46 (m, 1H), 7.35 (m, 2H), 7.26 (m, 2H), 7.19 (t, J= 7.8Hz, 1H), 6.90 (dd, J= 0. 8Hz, J= 7.8Hz, 1H), 6.77 (m, 2H), 3.73 (s, 2H), 3.42 (m, 4H), 2.96 (s, 3H), 2.76 (s, 3H), 2.23 (m, 4H), 2.15 (s, 3H), 1.57 (s, 3H).

[1179] MS m/z 510 [M-1].

Example 266 2-(3-{3-[1-[3,5-Dimethyl-4-(4-pyrrolidin-1-yl-piperidine-1- carbonyl)-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-2-oxo-2, 3-dihydro- 1H-indol-4-yl}-phenyl)-N,N-dimethyl-acetamide [1180]'H NMR (400 MHz, DMSO-d6) 8 13.40 (s, NH, 1H), l 1. 01 (s, NH, 1H), 7.46 (m, 1H), 7.31 (m, 1H), 7.25 (m, 2H), 7. 16 (t, J= 7.4Hz, 1H), 6.90 (d, J= 7.8Hz, 1H), 6.75 (d, J= 7.4Hz, 1H), 6.69 (s, 1H), 4.08 (m, 1H), 3.73 (s, 2H), 3.40 (m, 1H), 2.95 (s, 3H), 2.90 (m, 2H), 2.76 (s, 3H), 2.43 (m, 4H), 2.20 (s, 3H), 2.16 (m, 1H), 1.74 (m, 2H), 1.63 (m, 4H), 1.50 (s, 3H), 1.15 (m, 1H).

[11811 MS m/z 578 [M-1].

Example 267 5- [4- (3-Dimethylcarbamoylmethyl-phenyl)-2-oxo-1, 2-dihydro- indol-(3Z)-ylidenemethyl]-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide [1182] 1H NMR (400 MHz, DMSO-d6) # 13.46 (s, NH, 1H), 11. 03 (s, NH, 1H), 7.45 (m, 1H), 7.34 (m, 2H), 7.25 (m, 2H), 7.16 (t, J= 7.8Hz, 1H), 6.90 (dd, J= 0. 8Hz, J= 7.8Hz, 1H), 6.75 (m, 2H), 3.73 (s, 2H), 3.23 (m, 2H), 2.95 (s, 3H), 2.77 (s, 3H), 2.52 (m, 6H), 2.36 (s, 3H), 1.64 (s, 3H), 0.95 (m, 6H) or (t, J= 7.0 Hz, 6H) [11831 MS m/z 540 [M-1].

Example 268 3- [1- [3, 5-Dimethyl-4- (4-pyrrolidin-1-yl-piperidine-l-carbonyl)-lH- pyrrol-2-yl]-meth-(Z)-ylidene]-4-[3-(2-hydroxy-ethyl)-phenyl ]-1, 3- dihydro-indol-2-one [1184] 1H NMR (400 MHz, DMSO-d6) # 13.40 (s, NH, 1H), 10. 99 (s, NH, IH), 7.43 (m, 1H), 7.31 (m, 1H), 7.24 (s, 1H), 7.20 (d, J= 7.4Hz, 1H), 7.15 (t, J= 7.4Hz, 1H), 6.89 (dd, J = 0.8Hz, J = 7.4Hz, 1H), 6.75 (dd, J= 0. 8Hz, J= 7.4Hz, 1H), 6.71 (s, 1H), 4.63 (t, J= 5. 1Hz, 1H), 4.17 (m, 1H), 3.59 (m, 3H), 2.92 (m, 2H), 2.76 (t, J= 7.4Hz, 2H), 2.43 (s, 3H), 2.20 (m, 5H), 1.78 (m, 2H), 1.64 (m, 5H), 1.49 (s, 3H), 1.22 (m, 1H).

[1185] MS m/z 537 [M-1].

Example 269 4- [3- (2-Dimethylamino-ethyl)-phenyl]-3- [1- [3-methyl-4- (morpholine-4-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-1, 3- dihydro-indol-2-one [1186]'H NMR (400 MHz, DMSO-d6) 8 13.50 (s, NH, lH), 11. 09 (s, NH, 1H), 7.44 (m, 1H), 7.38 (d, J= 3. lHz, 1H), 7.33 (m, 1H), 7.26 (m, 1H), 7.19 (m, 2H), 6.89 (dd, J = 1. 2Hz, J= 7.8Hz, 1H), 6.77 (m, 2H), 3.51 (m, 4H), 3.44 (m, 4H), 2.76 (t, J= 7.4Hz, 2H), 2.45 (m, 2H), 2.14 (s, 6H), 1.59 (s, 3H).

[1187] MS m/z 483 [M-1].

Example 270 4-[3-(2-Dimethylamino-ethyl)-phenyl]-3-[1-[4-(4-hydroxy- piperidine-l-carbonyl)-3, 5-dimethyl-lH-pyrrol-2-yl]-meth- (Z)- ylidene]-1,3-dihydro-indol-2-one [188] 'HNMR (400MHz, DMSO-d6) 8 13.41 (s, NH, lH), 11. 01 (brs, NH, 1H), 7.41 (m, 1H), 7.32 (m, 1H), 7.24 (s, 1H), 7.20 (m, 1H), 7.15 (t, J= 7.8Hz, 1H), 6.89 (dd, J= 1. 2Hz, J= 6.6Hz, 1H), 6.75 (dd, J= 0. 8Hz, J= 7.8Hz, 1H), 6.69 (s, 1H), 4.73 (m, 1H), 3.65 (m, 1H), 3.11 (m, 4H), 2.74 (t, J = 7.4Hz, 2H), 2.43 (m, 2H), 2.20 (s, 3H), 2.11 (s, 6H), 1.69 (m, 3H), 1.50 (s, 3H), 1.22 (m, 1H).

[1189] MS m/z 511 [M-1].

Example 271 3-{3-[1-[3-Methyl-4-(morpholine-4-carbonyl)-1H-pyrrol-2-yl]- meth- (Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-4-yl}-N-(2- pyrrolidin-1-yl-ethyl)-benzamide [1190] 1H NMR (400 MHz, DMSO-d6) # 13.50 (s, 1H, NH), 11.13 (s, 1H, NH), 8.53 (t, 1H), 7.93-7.97 (m, 2H), 7.64 (t, 1H), 7.58 (d, 1H), 7.39 (d, 1H), 7.22 (t, 1H), 6.93 (d, 1H), 6.82 (d, 1H), 6.80 (s, 1H), 3.51 (m, 4H), 3.43 (m, 4H), 3.3 (m, 2H), 2.54 (m, 2H), 2.45 (m, 4H), 1.62 (m, 4H), 1.54 (s, 3H, CH3).

[1191] MS m/z 554.3 [M++1]. Example 272 3-{3-[1-[3-Methyl-4-(morpholine-4-carbonyl)-1H-pyrrol-2-yl]- meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-4-yl}-N-(3- pyrrolidin-1-yl-propyl)-benzamide [1192] 1H NMR (400 MHz, DMSO-d6) 8 13.51 (s, 1H, NH), 11.14 (s, 1H, NH), 8. 65 (t, 1H), 7.95 (m, 1H), 7.90 (m, 1H), 7.64 (t, 1H), 7.57 (m, 1H), 7.39 (d, 1H), 7.23 (t, 1H), 6.94 (d, 1H), 6.83 (d, 1H), 6.81 (s, 1H), 3.52 (m, 4H), 3.43 (m, 4H), 3.28 (m, 2H), 2.38 (m, 6H), 1.64 (m, 6H), 1.55 (s, 3H).

[1193] MS m/z 568.3 [M++1].

Example 273 N (2-Dimethylamino-ethyl)-3- {3- [1- [3-methyl-4- (morpholine-4- carbonyl)-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-2-oxo-2, 3-dihydro- 1H-indol-4-yl}-benzamide [1194] 1H NMR (400 MHz, DMSO-d6) # 13.52 (s, 1H, NH), 11.15 (s, 1H, NH), 8.48 (t, 1H), 7.96 (m, 1H), 7.93 (m, 1H), 7.64 (t, 1H), 7.58 (m, 1H), 7.39 (d, 1H), 7.23 (t, 1H), 6.94 (d, 1H), 6.83 (d, 1H), 6.80 (s, 1H), 3.51 (m, 4H), 3.44 (m, 4H), 3.3 (m, 2H), 2.34 (t, 2H), 2.12 (s, 6H, 2xCH3), 1.55 (s, 3H, CH3).

[1195] MS m/z 528.2 [M++1].

Example 274 N-(3-Dimethylamino-propyl)-3- {3- [1- [3-methyl-4- (morpholine-4- carbonyl)-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-2-oxo-2, 3-dihydro- lH-indol-4-yl}-benzamide [1196] 1H NMR (400 MHz, DMSO-d6) 8 13.52 (s, 1H, NH), 11.14 (s, 1H, NH), 8.59 (t, 1H), 7.95 (m, 1H), 7.92 (m, 1H), 7.64 (t, 1H), 7.57 (m, 1H), 7.39 (d, 1H), 7.23 (t, 1H), 6.94 (d, 1H), 6.83 (d, lh), 6.81 (s, 1H), 3.51 (m, 4H), 3.43 (m, 4H), 3.25 (m, 2H), 2.19 (t, 2H), 2.06 (s, 6H), 1. 60 (m, 2H), 1.55 (s, 3H, 2xCH3).

[1197] MS m/z 542.3 [M++1]. <BR> <BR> <BR> <BR> <P>Example 275 N-Methyl-3- {3- [l- [3-methyl-4- (morpholine-4-carbonyl)-lH-pyrrol- 2-yl]-meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-4-yl}-N-( 1- methyl-piperidin-4-yl)-benzamide [1198] MS m/z 568 [M++1].

Example 276 2- {2- [4- (2-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-1H-pyrrol-3-yl}-N-(2-pyrrolidin-1-yl - ethyl)-acetamide [1199] 1H NMR (400 MHz, DMSO-d6) # 13.33 (s, NH, 1H), 10.98 (s, NH, 1H), 7.49 (m, 2H), 7.41 (m, 1H), 7.31 (m, 2H), 7.17 (t, J= 7.8Hz, 1H), 6.93 (d, J= 7.4Hz, 1H), 6.79 (d, J= 7. 4Hz, 1H), 6.57 (s, 1H), 5.91 (s, 1H), 3.09 (m, 2H), 2. 68 (m, 2H), 2.40 (m, 6H), 2.26 (s, 3H), 1.63 (m, 4H).

[1200] MS m/z 471 [M-1].

Example 277 N-(2,4-Dioxo-1, 2,3,4-tetrahydro-pyrimidin-5-ylmethyl)-2- {2- [4- (2- <BR> <BR> <BR> fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)-ylidenemethyl]-5-<BR> <BR> <BR> methyl-lH-pyrrol-3-yl}-acetamide [12011'H NMR (400 MHz, DMSO-d6) 6 13.39 (s, NH, 1H), 11. 02 (s, NH, 1H), 10.81 (br s, NH, 2H), 8. 04 (m, 1H), 7.52 (m, 1H), 7.42 (m, 1H), 7.32 (m, 2H), 7.19 (t, J= 7. 8Hz, 1H), 6.96 (dd, J = 1. 2Hz, J = 7.8Hz, 1H), 6.81 (dd, J= 0. 8Hz, J= 7. 4Hz, 1H), 6.62 (s, 1H), 5.93 (d, J= 2.3Hz, 1H), 5.18 (s, 1H), 3.88 (m, 2H), 2.81 (d, J= 11.3Hz, 2H), 2.29 (s, 3H).

[1202] MS m/z 498 [M-1]. Example 278 5-[4-(3-Amino-1H-indazol-5-yl)-2-oxo-1,2-dihydro-indol-(3Z)- ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2- diethylamino-ethyl)-amide [1203] MS m/z 510.5 [M-1].

Example 279 5- [4- (3-Amino-IH-indazol-5-yl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2- pyrrolidin-1-yl-ethyl)-amide [1204] IH NMR (400 MHz, DMSO-d6) 8 13.46 (s, 1H, NH), 11.51 (s, 1H, NH), 11.0 (s, 1H, NH), 7.73 (s, 1H), 7.41 (br s, 1H, NH), 7.35 (d, 1H), 7.14-7.22 (m, 2H), 6.89 (d, 1H), 6.82 (d, 1H), 6.76 (s, 1H), 5.37 (br s, 2H, NH2), 2.99 (m, 2H), 2.54 (m, 2H), 2.44 (m, 2H), 2.35 (s, 3H, CH3), 1.7 (m, 4H), 1.62 (m, 2H), 1.4 (s, 3H, CH3).

[1205] MS m/z 508.5 [M-1].

Example 280 3-{3-[1-[3-Methyl-4-(morpholine-4-carbonyl)-1H-pyrrol-2-yl]- meth- (Z)-ylidene]-2-oxo-2, 3-dihydro-lH-indol-4-yl}-benzoic acid [1206] 1H NMR (400 MHz, DMSO-d6) 8 13.51 (s, 1H, NH), 11.14 (s, 1H, NH), 8.05 (m, 1H), 7.95 (s, 1H), 7.7 (m, 2H), 7.40 (d, 1H), 7.22 (t, 1H), 6.94 (d, 1H), 6.79 (s, 1H), 3.51 (m, 4H), 3.43 (m, 4H), 1.55 (s, 3H, CH3).

[1207] MS m/z 458.4 [M++1].

Example 281 5- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- hydroxy-3-pyrrolidin-1-yl-propyl)-amide [1208] IH NMR (400 MHz, DMSO-d6) 8 13.46 (s, 1H, NH), 11.06 (s, 1H, NH), 7.58 (m, 1H), 7.46 (m, 1H), 7.25-7.35 (m, 3H), 7.18 (t, 1H), 6.93 (d, 1H), 6.78 (d, 1H), 6.77 (s, 1H), 3.68 (m, 1H), 3.36 (m, 2H), 3.28 (dd, 1H), 3.1 (dd, 1H), 2.52 (m, 4H), 2.37 (s, 3H, CH3), 1.71 (s, 3H, CH3), 1.66 (m, 4H).

[1209] MS m/z 503.4 [M++1]. Example 282 3- [l- [4- (3-Diethylamino-pyrrolidine-l-carbonyl)-3, 5-dimethyl-lH- pyrrol-2-yl]-meth-(Z)-ylidene]-4-(3-fluoro-phenyl)-1,3-dihyd ro- indol-2-one [1210] MS m/z 499 [M-1].

Example 283 3-[1-[3-(3-Diethylamino-pyrrolidine-1-carbonyl)-5-methyl-1H- pyrrol-2-yl]-meth- (Z)-ylidene]-4- (3-fluoro-phenyl)-1, 3-dihydro- indol-2-one [1211] MS m/z 485 [M-1].

Example 284 3-[1-{4-[2-(3-Diethylamino-pyrrolidin-1-yl)-2-oxo-ethyl]-3, 5- dimethyl-lH-pyrrol-2-yl}-meth- (Z)-ylidene]-4- (3-fluoro-phenyl)- 1,3-dihydro-indol-2-one [1212] MS m/z 513 [M-1].

Example 285 3- [1- {3- [2- (3-Diethylamino-pyrrolidin-1-yl)-2-oxo-ethyll-5-methyl- 1H-pyrrol-2-yl}-meth-(Z)-ylidene]-4-(3-fluoro-phenyl)-1,3- dihydro-indol-2-one [1213] MS m/z 499 [M-1].

Example 286 5- [4- (2, 4-Difluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- pyrrolidin-1-yl-ethyl)-amide [1214] IH NMR (400 MHz, DMSO-d6) 8 13.46 (s, NH, 1H), 11. 09 (s, NH, 1H), 7.49 (m, 3H), 7.30 (m, 1H), 7.20 (t, J= 7.8Hz, 1H), 6.96 (d, J= 7.8Hz, 1H), 6.81 (dd, J= 0. 8Hz, J= 7.8Hz, 1H), 6.59 (s, 1H), 3.27 (m, 2H), 2.48 (m, 6H), 2.36 (s, 3H), 1.74 (s, 3H), 1.64 (m, 4H).

[1215] MS m/z 489 [M-1].

Example 287 2- [4- (2, 4-Difluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyll-5-methyl-lH-pyrrole-3-carboxylic acid (3- pyrrolidin-l-yl-propyl)-amide [1216] 'H NMR (400 MHz, DMSO-d6) 8 13 : 79 (s, NH, 1H), 11. 18 (s, NH, 1H), 7.93 (m, 1H), 7.88 (m, 1H), 7.37 (m, 1H), 7.21 (m, 2H), 7.13 (m, 1H), 6.95 (d, J= 6.6Hz, 1H), 6.77 (d, J= 7.8Hz, 1H), 6.37 (m, 1H), 3.10 (m, 2H), 2.39 (m, 6H), 2.30 (s, 3H), 1.67 (m, 4H), 1.59 (m, 2H).

[1217] MS m/z 489 [M-1].

Example 288 4- (2, 4-Difluoro-phenyl)-3- [l- [3, 5-dimethyl-4- (4-methyl-piperazine- 1-carbonyl)-lH-pyrrol-2-yll-meth-(Z)-ylidene]-l, 3-dihydro-indol- 2-one [1218] 'H NMR (400 MHz, DMSO-d6) 8 13.45 (s, NH, 1H), 11. 09 (s, NH, 1H), 7.50 (m, 2H), 7.29 (m, 1H), 7.20 (t, J= 7.6Hz, 1H), 6.96 (dd, J = 0.8Hz, J = 7.8Hz, 1H), 6.81 (dd, J= 0. 8Hz, J= 7.4Hz, 1H), 6.57 (s, 1H), 3.28 (m, 4H), 2.27 (m, 4H), 2.23 (s, 3H), 2.16 (s, 3H), 1.62 (s, 3H).

[1219J MS m/z 475 [M-1].

Example 289 4- (2, 4-Difluoro-phenyl)-3- 1- [5-methyl-3- (4-pyrrolidin-1-yl- piperidine-1-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-1, 3- dihydro-indol-2-one [1220] 1H NMR (400 MHz, DMSO-d6) 8 13.63 (s, NH, 1H), 11.14 (s, NH, 1H), 7.40 (m, 1H), 7.29 (m, 1H), 7.20 (t, J= 7.8Hz, 1H), 7.16 (m, 1H), 6.95 (dd, J = 0.8Hz, J= 7.8Hz, 1H), 6.82 (s, 1H), 6.76 (dd, J= 0.8Hz, J= 7.4Hz, 1H), 6.08 (d, J= 2.3Hz, 1H), 4.09 (m, 1H), 3.58 (m, 1H), 2.87 (m, 2H), 2.45 (m, 4H), 2.31 (s, 3H), 2.19 (m, 1H), 1.82 (m, 1H), 1.66 (m, 5H), 1.21 (m, 2H).

[1221] MS m/z 515 [M-1].

Example 290 4-(3-Chloro-phenyl)-3-[1-[4-((R)-3-hydroxy-pyrrolidine-1- carbonyl)-3-methyl-1H-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one [1222]'H NMR (400 MHz, DMSO-d6) 8 13.50 (s, NH, 1H), 11. 14 (s, NH, 1H), 7.59 (m, 4H), 7.42 (m, 1H), 7.21 (t, J= 7.8Hz, 1H), 6.93 (dd, J= O. 8Hz, J= 7.8Hz, 1H), 6.85 (s, 1H), 6.81 (dd, J = 0.8Hz, J = 7.8Hz, 1H), 4.92 (m, 1H), 4.24 (m, 1H), 3.58 (m, 1H), 3.50 (m, 2H), 3.29 (m, 1H), 1.85 (m, 1H), 1.77 (m, 1H), 1.74 (s, 3H).

[1223] MS m/z 446 [M-1].

Example 291 4-(3-Chloro-phenyl)-3-[1-(3-((R)-3-hydroxy-pyrrolidine-1- carbonyl)-5-methyl-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one [1224] IH NMR (400 MHz, DMSO-d6) (2 conformational isomer) 8 13.65 (s, NH, 1H), 11.08 (br s, NH, 1H), 7.44 (m, 2H), 7.38 (m, 1H), 7.32 (m, 1H), 7.19 (m, 2H), 6.91 (d, J = 7. 8Hz, 1H), 6.75 (dd, J = 0.8Hz, J= 7.4Hz, 1H), 6.20 (m, 1H), 4.82 (m, 1H), 4.31 (m, O. SH), 4.13 (m, O. 5H), 3.30 (m, 4H), 2.31 (s, 3H), 1.82 (m, 2H).

[1225] MS m/z 446 [M-1].

Example 292 4-(2-Fluoro-phenyl)-3-[1-(4-((R)-3-hydroxy-pyrrolidine-1- carbonyl)-3-methyl-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-1, 3- dihydro-indol-2-one [1226] 1H NMR (400 MHz, DMSO-d6) # 13.52 (s, NH, 1H), 11. 08 (br s, NH, 1H), 7.56 (m, 2H), 7.43 (m, 3H), 7.23 (t, J= 7.8Hz, 1H), 6.95 (d, J= 7.8Hz, 1H), 6.84 (d, J = 7.8Hz, 1H), 6.71 (s, 1H), 4.92 (m, 1H), 4.22 (m, 1H), 3.58 (m, 1H), 3.94 (m, 1H), 3.28 (m, 2H), 1.86 (m, 1H), 1.72 (m, 1H), 1.68 (s, 3H).

[1227] MS m/z 430 [M-1].

Example 293 4- (3-Fluoro-phenyl)-3- [1- [4- ( (R)-3-hydroxy-pyrrolidine-1- carbonyl)-3, 5-dimethyl-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-1, 3- dihydro-indol-2-one [1228] 1H NMR (400 MHz, DMSO-d6) (2 conformational isomer) 8 13.39 (s, NH, 1H), 11. 04 (s, NH, 1H), 7.58 (m, 1H), 7.29 (m, 3H), 7.18 (t, J = 7.8Hz, 1H), 6.93 (dd, J = 1. 2Hz, J= 7.8Hz, 1H), 6.79 (dd, J= 0.8Hz, J = 7.8Hz, 1H), 6.75 (s, 1H), 4.95 (m, O. SH), 4.85 (m, 0. 5H), 4.29 (m, 0. SH), 4.15 (m, 0. 5H), 3.45 (m, 1H), 3.25 (m, 3H), 2.22 (s, 3H), 1.81 (m, 2H), 1.59 (s, 3H).

[1229] MS m/z 444 [M-1].

Example 294 4-(3-Fluoro-phenyl)-3-[1-{4-[2-((R)-3-hydroxy-pyrrolidin-1-y l)-2- oxo-ethyl]-3,5-dimethyl-1H-pyrrol-2-yl}-meth-(Z)-ylidene]-1, 3- dihydro-indol-2-one [1230]'H NMR (400 MHz, DMSO-d6) (2 conformational isomer) 8 13.29 (s, NH, 1H), 10.92 (s, NH, 1H), 7.57 (m, 1H), 7.28 (m, 3H), 7.12 (t, J = 7. 4Hz, 1H), 6.92 (dd, J = 0.8Hz, J = 7.8Hz, 1H), 6.76 (dd, J = 0.8Hz, J = 7. 6Hz, 1H), 6.74 (s, 1H), 4.99 (d, J= 3.5Hz, 0. SH), 4.88 (d, J= 3.5Hz, 0. SH), 4.29 (m, 0. SH), 4.21 (m, 0. SH), 3.54 (m, 1H), 3.37 (m, 1H), 3.25 (m, 2H), 2.20 (s, 3H), 1.82 (m, 2H), 1.52 (s, 3H).

[1231] MS m/z 458 [M-1].

Example 295 4- (2, 6-Difluoro-phenyl)-3- 1- [3-methyl-4- (4-methyl-piperazine-1- carbonyl)-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol-2- one [1232] 1H NMR (400 MHz, DMSO-d6) # 13.49 (s, NH, 1H), 10.19 (s, NH, 1H), 7.64 (m, 1H), 7.40 (d, J= 3. 1Hz, 1H), 7.35 (m, 2H), 7.26 (t, J= 7.8Hz, 1H), 6.99 (dd, J= 0.8Hz, J= 7.8Hz, 1H), 6.89 (d, J= 7.0 Hz, 1H), 6.29 (s, 1H), 3.44 (m, 4H), 2.23 (m, 4H), 2.15 (s, 3H), 1.62 (s, 3H).

[1233] MS m/z 461 [M-1].

Example 296 4- (2, 6-Difluoro-phenyl)-3- [l- [3, 5-dimethyl-4- (4-methyl-piperazine- 1-carbonyl)-lH-pyrrol-2-yl]-meth-(Z)-ylidene]-1, 3-dihydro-indol- 2-one [1234] MS m/z 475 [M-1].

Example 297 4-(3-Chloro-phenyl)-3-[1-[5-methyl-3-(4-methyl-ppezine-1- carbonyl)-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol-2- one [1235] 1H NMR (400 MHz, DMSO-d6) 8 13.63 (s, NH, 1H), 11. 09 (br s, NH, 1H), 7.44 (m, 2H), 7.37 (s, 1H), 7.32 (m, 1H), 7.18 (t, J= 7.8Hz, 1H), 6.94 (s, 1H), 6.91 (d, J= 7.8Hz, 1H), 6.75 (d, J= 7.4Hz, 1H), 6.06 (d, J= 2. 0Hz, 1H), 3.33 (m, 2H), 3.22 (m, 2H), 2.30 (s, 3H), 2.24 (m, 2H), 2.16 (s, 3H), 2.11 (m, 2H).

[1236] MS m/z 459 [M-1].

Example 298 4-(3-Fluoro-phenyl)-3-[1-[5-methyl-3-(4-methyl-piperazine-1- carbonyl)-1H-pyrrol-2-yl]-methy-(Z)-ylidene]-1,3-dihydro-ind ol-2- one [1237]'H NMR (400 MHz, DMSO-d6) 8 13.61 (s, NH, 1H), 11. 12 (s, NH, 1H), 7.46 (m, 1H), 7.19 (m, 4H), 6.94 (s, 1H), 6.91 (dd, J=1. 2Hz, J= 7.8Hz, 1H), 6.75 (dd, J=1. 2Hz, J= 7.8Hz, 1H), 6 05 (d, J= 2.3Hz, 1H), 3.21 (m, 4H), 2. 32 (s, 3H), 2.25 (m, 2H), 2.17 (s, 3H), 2.12 (m, 2H).

[1238] MS m/z 445 [M++1].

Example 299 5- [4- (2, 6-Difluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- pyrrolidin-1-yl-ethyl)-amide [1239] 1H NMR (400 MHz, DMSO-d6) 8 13.44 (s, NH, 1H), 10.12 (s, NH, 1H), 7.63 (m, 1H), 7.50 (m, 1H), 7.34 (m, 2H), 7.22 (t, J= 7.8Hz, 1H), 6.97 (dd, J=0.8Hz, J= 7.8Hz, 1H), 6.87 (d, J= 7.8Hz, 1H), 6.59 (s, 1H), 3.28 (m, 2H), 2.52 (m, 6H), 2.37 (s, 3H), 1.68 (s, 3H), 1.65 (m, 4H).

[1240] MS m/z 489 [M-1].

Example 300 2- [4- (2, 6-Difluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-1H-pyrrole-3-carboxylic acid (3- pyrrolidin-1-yl-propyl)-amide [1241] IH NMR (400 MHz, DMSO-d6) 8 13.79 (s, NH, 1H), 11. 17 (br s, NH, 1H), 7.91 (m, 1H), 7.85 (s, 1H), 7.48 (m, 1H), 7.22 (t, J= 7.4Hz, 1H), 7.14 (m, 2H), 6.97 (d, J= 7.8Hz, 1H), 6.80 (d, J= 7.8Hz, 1H), 6.35 (m, 1H), 3.61 (m, 2H), 2.41 (m, 6H), 2.30 (s, 3H), 1.68 (m, 4H), 1.58 (m, 2H).

[1242] MS m/z 489 [M--1] Example 301 4-(2,6-Difluoro-phenyl)-3-[1-[3,5-dimehtyl-4-(4-pyrrolidin-1 -yl- piperidine-l-carbonyl)-1H-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one [1243] MS m/z 529 [M-1].

Example 302 2- [4- (2-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- <BR> <BR> ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid [2- (4-acetyl-<BR> <BR> <BR> piperazin-1-yl)-ethyl]-amide [1244] 1H NMR (400 MHz, DMSO-d6) 8 13.80 (s, NH, lH), l 1. 13 (s, NH, 1H), 7.84 (s, 1H), 7.75 (m, 1H), 7.43 (m, 1H), 7.34 (m, 1H), 7.25 (m, 2H), 7.20 (t, J= 7.8Hz, 1H), 6.94 (d, J= 6.6Hz, 1H), 6.77 (d, J= 7.8Hz, 1H), 6.35 (s, 1H), 3.42 (m, 4H), 3.15 (m, 2H), 2.39 (m, 6H), 2.29 (s, 3H), 1.98 (s, 3H).

[1245] MS m/z 514 [M-1].

Example 303 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenementhyl]-5-methyl-1H-pyrrole-3-carboxylic acid [2-(4-acetyl- piperazin-l-yl)-ethyl]-amide [1246] 1H NMR (400 MHz, DMSO-d6) # 13.80 (s, NH, 1H), 11. 08 (s, NH, 1H), 7.99 (s, 1H), 7.75 (m, 1H), 7.43 (m, 1H), 7.17 (m, 4H), 6.91 (d, J= 6.6Hz, 1H), 6.75 (d, J= 6.6Hz, 1H), 6.35 (s, 1H), 3.42 (m, 4H), 3.15 (m, 2H), 2.39 (m, 6H), 2.29 (s, 3H), 1.98 (s, 3H).

[1247] MS m/z 514 [M-1].

Example 304 5- 4- (2-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-4-methyl-1H-pyrrole-3-carboxylic acid [2- (4-acetyl- piperazin-1-yl)-ethyl]-amide [1248] 1H NMR (400 MHz, DMSO-d6) 8 13.53 (s, NH, 1H), 11.17 (s, NH, 1H), 8.28 (br m, 1H), 7.83 (br s, 1H), 7.58 (m, 1H), 7.46 (m, 2H), 7.40 (t, J= 7.8Hz, 1H), 7.23 (t, J= 7.8Hz, 1H), 6.96 (dd, J= 0.8Hz, J= 7.4Hz, 1H), 6.83 (d, J= 7.8Hz, 1H), 6.72 (s, 1H), 4.38 (m, 1H), 3.96 (m, 1H), 3.53 (m, 5H), 3.20 (m, 2H), 2.98 (m, 3H), 2.01 (s, 3H), 1.80 (s, 3H).

[1249] MS m/z 514 [M-1].

Example 305 5- [4- (2-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-4-methyl-lH-pyrrole-3-carboxylic acid (2- piperidin-1-yl-ethyl)-amide [1250] IH NMR (400 MHz, DMSO-d6) 8 13.47 (s, NH,1H),11. 11 (br s, NH, 1H), 7.71 (m, 1H), 7.66 (d, J=3.5Hz, 1H), 7.56 (m, 1H), 7.44 (m, 3H), 7.22 (t, J=7. 4Hz, 1H), 6.95 (d, J=7.8Hz, 1H), 6.83 (d, J=7.8Hz, 1H), 6.71 (s, 1H), 3.23 (m, 2H), 2.32 (m, 6H), 1.75 (s, 3H), 1.45 (m, 4H), 1.34 (m, 2H).

[1251] MS m/z 471 [M-1].

Example 306 2- [4- (3-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-1H-pyrrole-3-carboxylic acid (2- piperidin-1-yl-ethyl)-amide [1252] 1H NMR (400 MHz, DMSO-d6) 8 13.69 (s, NH, 1H), 11. 11 (s, NH, 1H), 7.99 (s, 1H), 7.70 (m, 1H), 7.43 (m, 1H), 7.37 (m, 2H), 7. 30 (d, J= 7.4Hz, 1H), 7.18 (t, J= 7.8Hz, 1H), 6.91 (d, J= 7.8Hz, 1H), 6.75 (d, J= 7.8Hz, 1H), 6. 36 (s, 1H), 3.15 (m, 2H), 2.38 (m, 4H), 2.31 (m, 2H), 2.29 (s, 3H), 1.50 (m, 4H), 1.38 (m, 2H).

[1253] MS mlz 487 [M-1].

Example 307 5- [4- (3-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-4-methyl-lH-pyrrole-3-carboxylic acid (2- piperidin-1-yl-ethyl)-amide [1254] 1H NMR (400 MHz, DMSO-d6) 8 13.46 (s, NH, 1H), 11. 12 (s, NH, 1H), 7.75 (m, 1H), 7.67 (d, J= 3.5Hz, 1H), 7.57 (m, 2H), 7.52 (s, 1H), 7.40 (m, 1H), 7.21 (t, J= 7.4Hz, 1H), 6.92 (d, J= 7. 0Hz, 1H), 6.85 (s, 1H), 6.80 (d, J= 7. 8Hz, 1H), 3.25 (m, 2H), 2.41 (m, 6H), 1.84 (s, 3H), 1.48 (m, 4H), 1.36 (m, 2H).

[1255] MS m/z 487 [M-1].

Example 308 2-[4-(3-Chloro-phenyl)-2-oxo-1,2-dihydro-indol-(3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (2-hydroxy- 3-pyrrolidin-1-yl-propyl)-amide [1256] 1H NMR (400 MHz, DMSO-d6)# 13.82 (s, NH, 1H), 11. 18 (s, NH, 1H), 8.02 (s, 1H), 7.84 (m, 1H), 7.40 (m, 3H), 7.31 (m, 1H), 7.19 (t, 1H), 6.91 (d, 1H), 6.76 (d, 1H), 6.40 (s, 1H), 4.68 (m, 1H), 3.64 (m, 1H), 3.29 (m, 1H), 2.84 (m, 1H), 2.45 (m, 4H), 2.34 (m, 2H), 2.30 (s, 3H), 1.69 (m, 4H).

[1257] MS m/z 503 [M-1].

Example 309 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (2-hydroxy- 3-pyrrolidin-1-yl-propyl)-amide [1258] IH NMR (400 MHz, DMSO-d6) 8 13.84 (s, NH, 1H), 11. 10 (br s, NH, 1H), 8.01 (s, 1H), 7.85 (m, 1H), 7.42 (m, 1H), 7.15 (m, 4H), 6.91 (d, J= 7.8Hz, 1H), 6.75 (d, J= 7.8Hz, lH), 6.39 (s, 1H), 4.69 (m, 1H), 3.62 (m, 1H), 3.26 (m, 1H), 2.92 (m, 1H), 2.46 (m, 4H), 2.32 (m, 2H), 2.29 (s, 3H), 1.68 (m, 4H).

[1259] MS m/z 487 [M-1].

Example 310 5- [4- (3-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-4-methyl-lH-pyrrole-3-carboxylic acid (2-hydroxy- 3-pyrrolidin-1-yl-propyl)-amide [1260]'H NMR (400 MHz, DMSO-d6) 8 13.46 (s, NH, 1H), 11. 12 (s, NH, 1H), 7.82 (m, 1H), 7.71 (d, J= 3.1Hz, 1H), 7.58 (m, 2H), 7.52 (s, 1H), 7.41 (m, 1H), 7.21 (t, J= 7.8Hz, 1H), 6.92 (dd, J= 0.8Hz, J= 7.8Hz, 1H), 6.85 (s, 1H), 6.80 (dd, J= 0. 8Hz, J= 7.4Hz, 1H), 4.73 (m, 1H), 3.66 (m, 1H), 3.28 (m, 2H), 3.03 (m, 1H), 2.44 (m, 4H), 2.32 (m, 1H), 1.82 (s, 3H), 1.62 (m, 4H).

[1261] MS m/z 503 [M-1].

Example 311 5- [4- (2-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-4-methyl-lH-pyrrole-3-carboxylic acid (2-hydroxy- 3-pyrrolidin-1-yl-propyl)-amide [1262] 1H NMR (400 MHz, DMSO-d6) # 13.47 (s, NH, lH), 11. 13 (s, NH, 1H), 7.81 (m, 1H), 7.70 (d, J=3.1Hz, 1H), 7.57 (m, 1H), 7.42 (m, 3H), 7.21 (t, J=7. 8Hz, 1H), 6.95 (dd, J= 1. 2Hz, J= 7.8Hz, 1H), 6.83 (dd, J= 0.8Hz, J= 7.4Hz, 1H), 6.71 (s, 1H), 4.72 (m, 1H), 3.65 (m, 1H), 3.29 (m, 2H), 3.03 (m, 1H), 2.44 (m, 4H), 2.32 (m, 1H), 1.79 (s, 3H), 1.63 (m, 4H).

[1263] MS m/z 487 [M-1].

Example 312 5- [4- (3-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- hydroxy-3-pyrrolidin-1-yl-propyl)-amide [1264] IH NMR (400 MHz, DMSO-d6) 6 13.47 (s, NH, lH), 11. 06 (s, NH, 1H), 7.56 (m, 2H), 7.51 (s, 1H), 7.46 (m, 1H), 7.39 (m, 1H), 7.18 (t, J= 7.8Hz, 1H), 6.92 (d, J= 7.8Hz, 1H), 6.78 (d, J= 7.8Hz, 1H), 6.76 (s, 1H), 4.72 (m, 1H), 3.68 (m, 1H), 3.28 (m, 1H), 3.11 (m, 1H), 2.36 (m, 5H), 1.74 (s, 3H), 1.65 (m, 5H).

[1265] MS m/z 517 [M-1].

Example 313 4-(3-Chloro-phenyl)-3-[1-[4-((S)-3-hydroxy-pyrrolidine-1- carbonyl)-3,5-dimethyl-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-1, 3- dihydro-indol-2-one [1266]'H NMR (400 MHz, DMSO-d6) 8 13.38 (s, NH, 1H), l 1. 04 (s, NH, 1H), 7.56 (m, 2H), 7.52 (m, 1H), 7.39 (m, 1H), 7.17 (t, J= 7.4Hz, 1H), 6.92 (d, J= 7.8Hz, 1H), 6.78 (d, J= 7. 0Hz, 1H), 6.74 (s, 1H), 4.89 (m, 1H), 4.21 (m, 1H), 3.45 (m, 2H), 3.25 (m, 1H), 3.04 (m, 1H), 2.22 (s, 3H), 1.80 (m, 2H), 1.60 (s, 3H).

MS m/z 460 [M-1].

Example 314 4-(3-Chloro-phenyl)-3-[1-[4-((S)-3-hydroxy-pyrrolidine-1- carbonyl)-3-methyl-1H-pyrrol-2-yl]-methy-(Z)-ylidene]-1, 3- dihydro-indol-2-one [1267] IH NMR (400 MHz, DMSO-d6) 6 13.49 (s, NH, 1H), 11.13 (s, NH, 1H), 7.56 (m, 4H), 7.41 (m, 1H), 7.17 (t, J= 7.8Hz, 1H), 6.92 (dd, J= 0.8Hz, J= 7.8Hz, 1H), 6.85 (s, 1H), 6.80 (dd, J= 0.8Hz, J= 7.4Hz, 1H), 6.74 (s, 1H), 4.91 (m, 1H), 4.24 (m, 1H), 3.58 (m, 1H), 3.46 (m, 2H), 3.28 (m, 1H), 1.86 (m, 1H), 1.78 (m, 1H), 1.74 (s, 3H).

[1268] MS m/z 446 [M-1].

Example 315 4- (3-Chloro-phenyl)-3- [1- [3- ( (S)-3-hydroxy-pyrrolidine-1- carbonyl)-5-methyl-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-1, 3- dihydro-indol-2-one [1269] IH NMR (400 MHz, DMSO-d6) 8 13.64 (s, NH, 1H), 11.12 (s, NH, 1H), 7.44 (m, 2H), 7. 38 (m, 1H), 7.32 (m, 1H), 7.19 (m, 2H), 6.91 (d, J= 7.8Hz, 1H), 6.75 (d, J= 7. 0Hz, 1H), 6.18 (m, 1H), 4.91 (m, 1H), 4.22 (m, 1H), 3.40 (m, 2H), 3.21 (m, 2H), 2.30 (s, 3H), 1.81 (m, 2H).

[1270] MS m/z 446 [M-1].

Example 316 4-(2-Fluoro-phenyl)-3-[1-[4-((S)-3-hydroxy-pyrrolidine-1- carbonyl)-3-methyl-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one [1271] 1H NMR (400 MHz, DMSO-d6) # 13.50 (s, NH, 1H), 11. 15 (s, NH, 1H), 7.56 (m, 1H), 7.43 (m, 3H), 7.23 (t, J= 7.8Hz, 1H), 6.95 (dd, J= 0. 8Hz, J= 7.8Hz, 1H), 6.83 (dd, J= 0.8Hz, J= 7.8Hz, 1H), 6.71 (s, 1H), 4.92 (m, 1H), 4.22 (m, 1H), 3.58 (m, 1H), 3.45 (m, 2H), 3. 28 (m, 1H), 1.85 (m, 1H), 1.75 (m, 1H), 1.69 (s, 3H).

[1272] MS m/z 430 [M-1].

Example 317 4-(3-Fluoro-phenyl)-3-[1-[4-((S)-3-hydroxy-pyrrokidine-1- carbonyl)-3, 5-dimethyl-lH-pyrrol-2-yl]-meth-(Z)-ylidene]-1,3- dihydro-indol-2-one [1273] IH NMR (400 MHz, DMSO-d6) 8 13.38 (s, NH, 1H), 11. 04 (s, NH, 1H), 7.57 (m, 1H), 7.31 (m, 3H), 7.17 (t, J= 7.8Hz, 1H), 6.92 (d, J= 7.8Hz, 1H), 6.78 (d, J = 7.8Hz, 1H), 6.75 (s, 1H), 4.90 (m, 1H), 4.20 (m, 1H), 3.47 (m, 2H), 3.24 (m, 1H), 3.04 (m, 1H), 2.21 (s, 3H), 1.80 (m, 2H), 1.58 (s, 3H).

[1274] MS m/z 444 [M-1].

Example 318 4-(3-Fluoro-phenyl)-3-[1-{4-[2-((S)-3-hdroxy-pyrrolidin-1-yl )-2- oxo-ethyl]-3, 5-dimethyl-lH-pyrrol-2-yl}-meth-(Z)-ylidene]-1,3- dihydro-indol-2-one [1275] 1H NMR (400 MHz, DMSO-d6) 6 13.29 (s, NH, 1H), 10.92 (s, NH, 1H), 7.57 (m, 1H), 7.28 (m, 3H), 7.13 (t, J= 7.4Hz, 1H), 6.91 (d, J= 7. 0Hz, 1H), 6.76 (m, 2H), 4.92 (m, 1H), 4.22 (m, 1H), 3.54 (m, 2H), 3.28 (s, 2H), 3.22 (m, 2H), 2.19 (s, 3H), 1.81 (m, 2H), 1.52 (s, 3H).

[1276] MS m/z 458 [M-1]. <BR> <BR> <BR> <BR> <P>Example 319 4- (3-Fluoro-phenyl)-3- [l- [4- (4-hydroxy-piperidin-1-ylmethyl)-3, 5-<BR> <BR> <BR> dimethyl-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol-2- one [12771'H NMR (400 MHz, DMSO-d6) 8 13.28 (s, NH, 1H), 10.94 (s, NH, 1H), 7.57 (m, 1H), 7.28 (m, 3H), 7.13 (t, 1H), 6.91 (dd, 1H), 6.76 (m, 2H), 4.48 (d, 1H), 3.38 (m, 1H), 3.11 (s, 2H), 2.55 (m, 2H), 2.22 (s, 3H), 1.89 (m, 2H), 1.62 (m, 2H), 1.60 (s, 3H), 1.28 (m, 2H).

[1278] MS m/s 444 [M-1]. <BR> <BR> <P>Example 320 3- [l- (3, 5-Dimethyl-4-morpholin-4-ylmethyl-lH-pyrrol-2-yl)-meth-<B R> <BR> <BR> <BR> (Z)-ylidene]-4- (3-fluoro-phenyl)-1, 3-dihydro-indol-2-one [1279] 1H NMR (400 MHz, DMSO-d6) 8 13.28 (s, NH, 1h), 10.96 (s, NH, 1H), 7.57 (m, 1H), 7.28 (m, 3H), 7.13 (t, J= 7.4Hz, lH), 6.90 (dd, J= 0.8Hz, J= 7 4Hz, lH), 6.76 (m, 2H), 3.47 (m, 4H), 3.16 (s, 2H), 2.25 (s, 3H), 2.22 (m, 4H), 1.62 (s, 3H).

[1280] MS m/z 430 [M-1].

Example 321 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-4,5,6,7-tetrahydro-lH-indole-3-carboxylic acid [1281] IH NMR (400 MHz, DMSO-d6) 8 11.17 (s, NH, 1H), 8.05 (s, 1H), 7.44 (m, 1H), 7.20 (m, 4H), 6.92 (dd, J= 0.8Hz, J= 7.8Hz, 1H), 6.75 (dd, J= 0. 8Hz, J= 7.4Hz, 1H), 2.62 (m, 4H), 1.68 (m, 4H).

[1282] MS m/z 401 [M-1].

Example 322 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-4, 5,6, 7-tetrahydro-1H-indole-3-carboxylic acid (3- pyrrolidin-1-yl-propyl)-amide [1283 'H NMR (400 MHz, DMSO-d6) 5 13.53 (s, NH, 1H), 11. 06 (s, NH, 1H), 7.52 (m, 1H), 7.42 (m, 1H), 7.36 (s, 1H), 7.17 (m, 4H), 6.90 (d, J= 7.4Hz, 1H), 6.75 (d, J= 7.4Hz, 1H), 3.27 (m, 2H), 3.04 (m, 2H), 2.64 (m, 2H), 2.39 (m, 6H), 1.64 (m, 10H).

[1284] MS m/z 511 [M-1].

Example 323 4-(3-Fluoro-phenyl)-3-[1-[3-(3-hydroxy-pyrrolidine-1-carbony l)- 4,5,6, 7-tetrahydro-1H-indol-2-yl]-meth-(Z)-ylideney]-1,3-dihydro- indol-2-one [1285] IH NMR (400 MHz, DMSO-d6) 6 13.44 (s, NH, 1H), 11. 07 (s, NH, 1H), 7.46 (m, 1H), 7.25 (m, 1H), 7.17 (m, 3H), 6.90 (d, J= 7.8Hz, 1H), 6.78 (m, 1H), 6.73 (dd, J= 0. 8Hz, J= 7.8Hz, 1H), 4.88 (m, 1H), 4.20 (m, 1H), 3.35 (m, 2H), 3.18 (m, 1H), 2.86 (m, 1H), 2.65 (m, 2H), 2.28 (m, 2H), 1.70 (m, 6H).

[1286] MS m/z 470 [M-1].

Example 324 4- (2-Fluoro-phenyl)-3- [1- {3- ( (S)-2- (4-hydroxy-piperidin-1- ylmethyl)-pyrrolidine-l-carbonyl]-5-methyl-lH-pyrrol-2-yl}-m eth- (Z)-ylidene]-1,3-dihydro-indol-2-one [1287] MS m/z 527 [M-1].

Example 325 4-(2-Fluoro-phenyl)-3-[1-{3-[(S)-2-((R)-3-hydroxy-pyrrolidin -1- ylmethyl)-pyrrolidine-l-carbonyl]-5-methyl-lH-pyrrol-2-yl}-m eth- (Z)-ylidene]-1,3-dihydro-indol-2-one [1288] MS m/z 513 [M-1].

Example 326 4- (3-Fluoro-phenyl)-3- [1- {4- [ (S)-2- ( (R)-3-hydroxy-pyrrolidin-1- <BR> <BR> ylmethyl)-pyrrolidine-l-carbonyl]-3, 5-dimethyl-lH-pyrrol-2-yl}-<BR> <BR> meth- (Z)-ylidene]-1, 3-dihydro-indol-2-one [1289] 1H NMR (400 MHz, DMSO-d6) 8 13.31 (s, NH, 1H), 10.62 (s, NH, 1H), 7.56 (m, 1H), 7.24 (m, 3H), 7.16 (t, J=. 7.8Hz, 1H), 6.94 (d, J= 7.8Hz, 1H), 6.81 (s, 1H), 6.78 (d, J= 6.8Hz, 1H), 4.15 (m, 2H), 4.05 (m, 1H), 2.88 (m, 4H), 2.76 (m, 1H), 2.58 (m, 2H), 2.38 (m, 2H), 2.24 (s, 3H), 1.88 (m, 4H), 1.72 (m, 1H), 1.64 (s, 3H), 1.53 (m, 1H).

[1290] MS m/z 527 [M-1].

Example 327 4- (3-Fluoro-phenyl)-3- [1- {3- [ (S)-2- ( (R)-3-hydroxy-pyrrolidin-1- ylmethyl)-pyrrolidine-l-carbonyl]-5-methyl-lH-pyrrol-2-yl}-m eth- (Z)-ylidene]-1, 3-dihydro-indol-2-one [1291] MS m/z 513[M--1].

Example 328 2-14- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid {2-[4-(2- hydroxy-acetyl)-piperazin-l-yl]-ethyl}-amide [1292]'H NMR (400 MHz, DMSO-d6) 8 13.79 (s, NH, 1H), 11.12 (s, NH, 1H), 7.99 (s, 1H), 7.76 (m, 1H), 7.45 (m, 1H), 7.16 (m, 4H), 6.91 (d, 1H), 6.75 (d,. 1H), 6.36 (s, 1H), 4.52 (t, 1H), 4.07 (d, 2H), 3.46 (m, 2H), 3.36 (m, 2H), 3.16 (m, 2H), 2.39 (m, 6H), 2.29 (s, 3H).

[1293] MS m/z 530 [M-1] Example 329 4- (2, 6-Difluoro-phenyl)-3- [1- [4- (3-piperidin-1-yl-propionyl)- 1, 4,5,6,7, 8-hexahydro-pyrrolo[3,2-b]azepin-2-yl]-methy-(Z)- ylidene]-1,3-dihydro-indol-2-one [1294] 4- (3-Piperidin-1-yl-prdpionyl)-1, 4,5,6,7,8-hexahydro-pyrrolo [3,2-b] azepine- 2-carbaldehyde (80 mg, 0.26 mmol) was condensed with 4- (2, 6-difluoro-pheryl)-1, 3- dihydro-indol-2-one (61 mg, 0.25 mmol) and piperidine (1 drop) in ethanol (3 mL) at rt for over the weekend. The precipitate was filtered, washed with ethanol and dried to give 80 mg of the titled compound as a yellow solid.

[1295] 1H NMR (400 MHz, DMSO-d6) 8 13.46 (s, 1H, NH), 11.14 (s, 1H, NH), 7.62 (m, 1H), 7.25 (m, 1H), 6.99 (d, 1H), 6.87 (d, 1H), 6.37 (s, 1H), 6.21 (s, 1H), 3.47 (m, 2H), 2.72 (m, 2H), 2.38 (m, 2H), 2.3 (m, 2H), 2.13 (m, 4H), 1.68 (m, 2H), 1.60 (m, 2H), 1.37 (m, 4H), 1.31 (m, 2H).

[1296] MS m/z 531.2 [M++1].

Example 330 5- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-4-(3-methanesulfonyl-propyl)-2-methyl-1H- pyrrole-3-carboxylic acid [1297] IH NMR (400 MHz, DMSO-d6) 5 13.79 (s, NH, 1H), 12.22 (s, 1H), 11.17 (s, NH, 1H), 7.60 (m, 1H), 7.40 (m, 1H), 7.31 (m, 2H), 7.21 (t, J= 7.8Hz, 1H), 6.94 (d, J= 7. 0Hz, 1H), 6.79 (d, J= 7.4Hz, 1H), 6.77 (s, 1H), 2.92 (s, 3H), 2.69 (m, 2H), 2.48 (s, 3H), 2.32 (m, 2H), 1.61 (m, 2H).

[1298] MS m/z 481 [M-1].

Example 331 5- [4- (4-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)-<BR> <BR> ylidenemethyl]-4- (3-methanesulfonyl-propyl)-2-methyl-lH- pyrrole-3-carboxylic acid [1299] lH NMR (400 MHz, DMSO-d6) 8 13.80 (s, NH, 1H), 12.22 (s, 1H), 11.17 (s, NH, 1H), 7.62 (m, 2H), 7.48 (m, 2H), 7.21 (t, J= 7.8Hz, 1H), 6.94 (d, J= 7.8Hz, 1H), 6.77 (d, J= 7.8Hz, 1H), 6.75 (s, 1H), 2.94 (s, 3H), 2.73 (m, 2H), 2.47 (s, 3H), 2.34 (m, 2H), 1.63 (m, 2H).

[1300] MS m/z 497 [M-1].

Example 332 4-(3-Fluoro-phenyl)-3-[1-[4-((R)-3-hydroxy-pyrrolidine-1- <BR> carbonyl)-3- (3-methanesulfonyl-propyl)-5-methyl-lH-pyrrol-2-yl]-<BR&g t; <BR> meth- (Z)-ylidene]-1, 3-dihydro-indol-2-one [1301] IH NMR (400 MHz, DMSO-d6) 8 13.47 (s, NH, 1H), 11.10 (s, NH, 1H), 7.59 (m, 1H), 7.38 (m, 1H), 7.29 (m, 2H), 7.19 (t, J= 7.8Hz, 1H), 6.92 (d, J= 7.4Hz, 1H), 6.78 (d, J= 7.8Hz, 1H), 6.71 (d, J= 0. 8Hz, 1H), 4.92 (m, 1H), 4.22 (m, 1H), 3.48 (m, 2H), 3.21 (m, 2H), 2.89 (s, 3H), 2.71 (m, 2H), 2.24 (s, 3H), 2.08 (m, 2H), 1.82 (m, 2H), 1.52 (m, 2H).

[1302] MS m/z 550 [M-1].

Example 333 4- (3-Fluoro-phenyl)-3- [l- [3- (3-methanesulfonyl-propyl)-5-methyl- 4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)- ylidene]-1, 3-dihydro-indol-2-one [1303] 'H NMR (400 MHz, DMSO-d6) 6 13.52 (s, NH, 1H), 11.10 (s, NH, 1H), 7.60 (m, 1H), 7.40 (m, 1H), 7.31 (m, 2H), 7.19 (t, J= 7.8Hz, 1H), 6.93 (d, J= 7.4Hz, 1H), 6.78 (dd, J=0.8Hz, J=7.8Hz, 1H), 6.72 (s, 1H), 3.31 (m, 4H), 2.92 (s, 3H), 2.78 (m, 2H), 2.30 (m, 4H), 2.20 (s, 3H), 2.18 (s, 3H), 2.05 (m, 2H), 1.51 (m, 2H).

[1304] MS m/z 563 [M-1]. Example 334 4- (4-Chloro-phenyl)-3- [1- [3- (3-methanesulfonyl-propyl)-5-methyl- 4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrol-2-yl]-methy-(Z) - ylidene]-1,3-dihydro-indol-2-one [1305] 1H NMR (400 MHz, DMSO-d6) # 13.53 (s, NH, 1H), 11.10 (s, NH, 1H), 7.62 (m, 2H), 7.44 (m, 2H), 7.19 (t, J= 7.8Hz, 1H), 6.93 (d, J= 7.8Hz, 1H), 6.77 (dd, J= 0. 8Hz, J= 7.4Hz, 1H), 6.71 (s, 1H), 3.34 (m, 4H), 2.92 (s, 3H), 2.78 (m, 2H), 2.28 (m, 4H), 2.21 (s, 3H), 2.15 (s, 3H), 2.10 (m, 2H), 1.55 (m, 2H).

[1306] MS m/z 581 [M++1].

Example 335 3-[1-[3-((cis)-3,5-Dimethyl-piperazine-1-carbonyl)-5-methyl- 1H- pyrrol-2-yl]-meth- (Z)-ylidene]-4- [3- (2-hydroxy-ethoxy)-phenyl]- 1,3-dihydro-indol-2-one [1307] IH NMR (400 MHz, DMSO-d6) 8 13.63 (s, NH, 1H), 11.09 (s, NH, 1H), 7.30 (m, 1H), 7.16 (t, J= 7.8Hz, 1H), 6.98 (s, 1H), 6.90 (m, 4H), 6.73 (dd, J= 0. 8Hz, J= 7.8Hz, 1H), 6.03 (d, J= 2. 0Hz, 1H), 4.13 (m, 1H), 3.99 (m, 2H), 3.70 (m, 2H), 3.38 (m, 1H), 3.06 (m, 1H), 2.44 (m, 2H), 2.30 (s, 3H), 2.18 (m, 2H), 1.81 (m, 1H), 1.04 (m, 3H), 0.81 (m, 3H).

[1308] MS m/z 499 [M-1].

Example 336 3- [1- [3, 5-Dimethyl-4- (4-methyl-piperazine-1-carbonyl)-lH-pyrrol- 2-yl]-meth- (Z)-ylidene]-4- [3- (2-hydroxy-ethoxy)-phenyl]-1, 3- dihydro-indol-2-one [1309] IH NMR (400 MHz, DMSO-d6) 8 13.44 (s, NH, 1H), 11.01 (s, NH, 1H), 7.43 (t, J= 8.2Hz, 1H), 7.16 (t, J= 7.8Hz, 1H), 7.03 (m, 1H), 6.95 (m, 2H), 6.89 (dd, J= 1. 2Hz, J= 7.8Hz, 1H), 6.86 (s, 1H), 6.78 (dd, J= 0.8Hz, J= 7.4Hz, 1H), 4.84 (t, J- = 5. 5Hz, 1H), 3.98 (t, J= 5. lHz, 2H), 3.67 (m, 2H), 3.41 (m, 4H), 2.28 (m, 4H), 2.21 (s, 3H), 2.15 (s, 3H), 1.57 (s, 3H).

[1310] MS m/z 499 [M-1]./ Example 337 4- [3- (2-Hydroxy-ethoxy)-phenyl]-3- [1- [3-methyl-4- (4-methyl- piperazine-l-carbonyl)-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one [1311] IH NMR (400 MHz, DMSO-d6) 8 13.44 (s, NH, 1H), 11.04 (s, NH, 1H), 7.40 (t, J= 8.2Hz, 1H), 7.31 (d, J= 3. 1Hz, 1H), 7.14 (t, J= 7.8Hz, 1H), 7.00 (m, 1H), 6.91 (m, 2H), 6.87 (s, 1H), 6.85 (d, J= 7.4Hz, 1H), 6.74 (d, J= 7.8Hz, 1H), 4.79 (t, J =5.5Hz, 1H), 3.94 (t, J= 5. 1Hz, 2H), 3.63 (m, 2H), 3.38 (m, 4H), 2.19 (m, 4H), 2.10 (s, 3H), 1.59 (s, 3H).

[1312] MS m/z 485 [M-1].

Example 338 5-[4-[3-(2-Hydroxy-ethyoxy)-phenyl)-2-oxo-1,2-dihydro-indol- (3Z)- ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2- pyrrolidin-1-yl-ethyl)-amide [1313] 4- [3- (2-Hydroxy-ethoxy)-phenyl]-1, 3-dihydro-indol-2-one (0.25 mg) was condensed with 5-formyl-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1- yl-ethyl)-amide (0.25 mmol) and pyrrolidine (2 drops) in ethanol (2 mL) at rt for overnight to give 76.4 mg (60%) of the titled compound as a yellow solid.

[1314] 1H NMR (400 MHz, DMSO-d6) 8 13. 42 (s, NH, 1H), 10.97 (s, 1H, NH), 7.38 (m, 2H), 7.11 (t, 1H), 6.99 (m, 1H), 6.85 (dd, 1H), 6.82 (s, 1H), 6.73 (dd, 1H), 4.81 (m, 1H), 3.94 (t, 2H), 3.63 (m, 2H), 3.22 (m, 4H), 2.45 (m, 4H), 2.31 (s, 3H, CH3), 1.65 (s, 3H, CH3), 1.61 (m, 4H).

[1315] MS m/z 515.6 [M++1].

Example 339 3- [I- [3,5-Dimethyl-4-(4-pyrrolidin-1-yl-piperidine-1-carbonyl)-1H - pyrrol-2-yl]-meth- (Z)-ylidene]-4- [3- (2-hydroxy-ethoxy)-phenyl]- 1,3-dihydro-indol-2-one 11316] IH NMR (400 MHz, DMSO-d6) 8 13.42 (s, NH, 1H), 11.02 (br s, NH, 1H), 7.43 (t, J= 7.8Hz, 1H), 7.16 (t, J= 7.8Hz, 1H), 7.03 (m, 1H), 6.95 (m, 2H), 6.89 (d, J = 7.8Hz, 1H), 6.85 (s, 1H), 6.78 (d, J= 7.4Hz, 1H), 4.83 (m, 1H), 3.97 (m, 2H), 3.67 (m, 2H), 3.18 (m, 1H), 2.93 (m, 2H), 2.43 (m, 4H), 2.21 (s, 3H), 2.14 (m, 1H), 1.75 (m, 2H), 1.63 (m, 6H), 1.56 (s, 3H), 1.21 (m, 1H).

[13171 MS m/z 553 [M-1]. Example 340 4-[3-(2-Hydroxy-ethoxy)-phenyl]-3-[1-[5-methyl-3-(4-pyrrolid in-1- yl-piperidine-1-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]- 1,3- dihydro-indol-2-one [1318] IH NMR (400 MHz, DMSO-d6) 8 13.60 (s, NH, 1H), 11.08 (s, NH, 1H), 7.30 (t, J= 7.8Hz, 1H), 7.16 (t, J= 7.8Hz, 1H), 6.95 (m, 2H), 6.87 (m, 3H), 6.73 (d, J = 7. 4Hz, 1H), 6.03 (d, J= 2.3Hz, 1H), 4.86 (m, 1H), 4.02 (m, 1H), 3.97 (m, 2H), 3.68 (m, 2H), 3.45 (m, 1H), 2.75 (m, 2H), 2.46 (m, 4H), 2.29 (s, 3H), 2.13 (m, 1H), 1.79 (m, 1H), 1.66 (m, 6H), 1.15 (m, 1H).

[1319] MS m/z 539 [M-1].

Example 341 4- [3- (2-Hydroxy-ethoxy)-phenyt]-3- [l- [4- ( (R)-3-hydroxy- pyrrolidine-l-carbonyl)-3, 5-dimethyl-lH-pyrrol-2-yl]-meth- (Z)- ylidene]-1, 3-dihydro-indol-2-one [1320]'H NMR (400 MHz, DMSO-d6) 8 13.38 (s, NH, 1H), 11. 00 (s, NH, 1H), 7.43 (t, J= 8.2Hz, 1H), 7.15 (t, J= 7.4Hz, 1H), 7.02 (m, 1H), 6.95 (m, 2H), 6.89 (dd, J= 0. 8Hz, J= 7.8Hz, 1H), 6.85 (s, 1H), 6.77 (dd, J= 0. 8Hz, J= 7.8Hz, 1H), 4.91 (m, 1H), 4.84 (m, 1H), 4.21 (m, 1H), 3.98 (t, J= 5. 1Hz, 2H), 3.67 (m, 2H), 3.44 (m, 1H), 3.24 (m, 2H), 3.05 (m, 1H), 2.22 (s, 3H), 1.80 (m, 2H), 1.58 (s, 3H).

[1321] MS m/z 486 [M-1].

Example 342 5- [4- (4-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid [1322]'H NMR (400 MHz, DMSO-d6) 8 13.57 (s, NH, 1H), 12.05 (s, 1H), 11.05 (s, NH, 1H), 7.55 (m, 2H), 7.38 (m, 2H), 7.15 (t, J= 7.8Hz, 1H), 6.88 (dd, J= 0.8Hz, J= 7.8Hz, 1H), 6.73 (dd, J= 0.8Hz, J= 7.4Hz, 1H), 6.65 (s, 1H), 2.42 (s, 3H), 1.75 (s, 3H).

[1323] MS m/z 391 [M-1].

Example 343 2- [4- (4-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid [1324] MS m/z 377 [M-1].

Example 344 3- (1- [3, 5-Dimethyl-4- (4-morpholin-4-yl-piperidine-1-carbonyl)-lH- pyrrol-2-yl]-meth-(Z)-ylidene]-4-(3-fluoro-phenyl)-1,3-dihyd ro- indol-2-one 11325] To a stirred mixture of 4-amino-1-benzylpiperidine (1.53 mL, 7.5 mmol), K2C03 (2.28g, 16.5 mmol) and DMF (15 mL) heated at 50 °C was added dropwise over 60 min bis (2-bromoethyl) ether (0.96 mL, 7.65 mmol). After stirring for 6 hours at 80 °C, the solvent was removed by blowing with a stream of nitrogen over 2 hours.

The residue was purified on a silica gel column to give 1.7 g (87%) of 4- (1-benzyl- piperidin-4-yl)-morpholine as a waxy solid.

[1326] 1H NMR (400 MHz, DMSO-d6) 8 7.31 (m, 4H), 7.26 (m, 1H), 3.72 (t, 4H), 3.49 (s, 2H), 2.94 (br d, 2H), 2.54 (t, 4H), 2.19 (tt, 1H), 1.96 (td, 2H), 1.78 (br d, 2H), 1.55 (m, 2H).

[1327] 4- (1-benzyl-piperidin-4-yl)-morpholine (1.56 g, 6.0 mmol) was hydrogenated using Pd (OH) 2 (20% on carbon, 390 mg, 25 wt%), 1.7 M HCl (10.6 mL) in methanol (50 mL) at 50 °C for 10 hours. The resulted amine dihydrochloride off-white solid was subjected to free-basing using excess basic resin to give 932 mg (91 %) of 4-piperidin-4-yl-morpholine as waxy crystalline solid.

[1328] 1H NMR (400 MHz, DMSO-d6) 8 3.53 (br s, 4H), 3.30 (v br s, 1H), 2.92 (br d, 1H), 2.41 (s, 4H), 2.35 (m, 2H), 2.12 (brt, 1H), 1.65 (brd, 2H), 1.18 (brq, 2H).

[1329] MS m/z 171 [M++1].

[1330] 5- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)-ylidenemethyl]-2, 4- dimethyl-lH-pyrrole-3-carboxylic acid (1 eq.) and BOP (1.25 eq.) were suspended in DMF (5 mL) at rt and TEA (2.4 eq.) was added. After 15 mina, to the homogenous reaction mixture was added 4-piperidin-4-yl-morpholine (1.25 eq.) all at once. After stirring for 2 days, the reaction was added to a mixture of chloroform-isopropanol (5: 1) and 5% aq. LiCl. The organic layer was separated, washed with 5% aq. LiCl (2x), 1M aq. NaOH (3x), brine, dried and concentrated. The residue was purified to give the titled compound [1331] 1H NMR (400 MHz, DMSO-d6) 8 13.42 (s, 1H, NH), 11.04 (s, 1H, NH), 7.57 (q, J= 7.4 Hz, 1H), 7.29 (m, 3H), 7.18 (t, J= 7.6 Hz, 1H), 6.93 (d, J= 7.8 Hz, 1H), 6.79 (d, J= 7.4 Hz, 1H), 6.75 (s, 1H), 3.53 (m, 5H), 2.85 (m, 2H), 2.41 (m, 5H), 2.31 (m, 1H), 2.22 (m, 4H), 1.75 (m, 2H), 1.57 (m, 4H).

[1332] MS m/z 529.2 [M++1].

Example 345 4- (3, 4-Dimethoxy-phenyl)-3- [l- [3-methyl-4- (4-methyl-piperazine- 1-carbonyl)-lH-pyrrol-2-yl]-meth-(Z)-ylidene]-1, 3-dihydro-indol- 2-one [1333] 1H NMR (400 MHz, DMSO-d6) 8 13.47 (s, NH, 1H), 11.06 (s, NH, 1H), 7.35 (d, J= 3. 1Hz, 1H), 7.17 (t, J= 7.8Hz, 1H), 7.10 (d, J= 8.2Hz, 1H), 6.99 (d, J= 2. 0Hz, 1H), 6.92 (m, 2H), 6.88 (d, J= 7. 0Hz, 1H), 6.81 (d, J= 7.8Hz, 1H), 3.79 (s, 3H), 3.71 (s, 3H), 3.43 (m, 4H), 2.25 (m, 4H), 2.15 (s, 3H), 1.64 (s, 3H).

[1334] MS m/z 485 [M-1]. Example 346 4-(3,4-dimethoxy-phenyl)-3-[1-[3-((cis-3,5-dimethyl-piperazi ne-1- carbonyl)-5-methyl-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one [1335] IH NMR (400 MHz, DMSO-d6) 8 13.61 (s, NH, 1H), 11.06 (s, NH, 1H), 7.14 (m, 2H), 6.98 (m, 1H), 6.87 (m, 3H), 6.73 (dd, J= 0. 8Hz, J= 7.4Hz, 1H), 6.03 (s, 1H), 4.05 (m, 1H), 3.82 (s, 3H), 3.65 (s, 3H), 3.32 (m, 1H), 2.41 (m, 2H), 2.31 (s, 3H), 2.19 (m, 2H), 1.92 (br m, 1H), 0.99 (m, 3H), 0.79 (m, 3H). <BR> <BR> <BR> <BR> <BR> <BR> <P>[1336] MS m/z 499 [M-1].<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>Example 347 5- [4- (3, 4-Dimethoxy-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid (2- pyrrolidin-1-yl-ethyl)-amide [1337] 1H NMR (400 MHz, DMSO-d6) 8 13.46 (s, NH, 1H), 10.98 (s, NH, 1H), 7.42 (t, 1H), 7.14 (t, 1H), 7.11 (d, 1H), 6.98 (d, 1H), 6.91 (m, 2H), 6.86 (s, 1H), 6.79 (dd, 1H), 3.80 (s, 3H), 3.70 (s, 3H), 3.28 (m, 4H), 2.45 (m, 4H), 2.35 (s, 3H), 1.71 (s, 3H), 1.64 (m, 4H).

[1338] MS m/z 513 [M-1]. <BR> <BR> <P>Example 348 2- [4- (3, 4-Dimethoxy-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-1H-pyrrole-3-carboxylic acid (3- pyrrolidin-1-yl-propyl)-amide [1339] 1H NMR (400 MHz, DMSO-d6) 8 13.87 (s, NH, 1H), 11.06 (s, NH, 1H), 8.10 (s, 1H), 7.85 (m, 1H), 7.6 (m, 1H), 7.15 (t, J= 7.4Hz, 1H), 6.99 (d, J= 7.8Hz, 1H), 6.89 (s, 1H), 6.86 (d, J= 8. 2Hz, 1H), 6.77 (d, J= 7.8Hz, 1H), 6.33 (s, 1H), 3.81 (s, 3 H), 3.61 (s, 3H), 3.05 (m, 2H), 2.54 (m, 2H), 2.28 (s, 3H), 1.72 (m, 6H), 1.60 (m, 1H), 1.24 (m, 2H), 0.82 (m, 1H).

[1340] MS m/z 513 [M-1]. Example 349 4- (3, 4-Dimethoxy-phenyl)-3- 1- [5-methyl-3- (4-pyrrolidin-1-yl- piperidine-1-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-1,3 - dihydro-indol-2-one [1341] IH NMR (400 MHz, DMSO-d6) 8 13.61 (s, NH, 1H), 11.06 (s, NH, 1H), 7.14 (t, J= 7. 8Hz, 1H), 7.10 (br s, 1H), 6.97 (d, J= 8. 2Hz, 1H), 6.87 (m, 3H), 6.73 (dd, J=0.8Hz, J=7.8Hz, 1H), 6.04 (d, J=2.0Hz, 1H), 3.99 (m, 1H), 3.81 (s, 3H), 3.68 (s, 3H), 3.43 (m, 1H), 2.68 (m, 2H), 2.44 (m, 4H), 2.30 (s, 3H), 2.09 (m, 1H), 1.74 (m, 2H), 1.65 (m, 5H), 1.17 (m, 1H).

[1342] MS m/z 539 [M-1].

Example 350 4-(3,4-Dimethoxy-phenyl)-3-[1-[4-((R)-3-hydroxy-pyrrolidine- 1- carbonyl)-3, 5-dimethyl-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-1, 3- dihydro-indol-2-one [1343] 1H NMR (400 MHz, DMSO-d6) 8 13.37 (s, NH, 1H), 10.97 (s, NH, 1H), 7.14 (t, J= 7.8Hz, 1H), 7.09 (d, J= 8.2Hz, 1H), 6.97 (d, J= 2. 0Hz, 1H), 6.91 (dd, J= 2. 0Hz, J= 7. 8Hz, 1H), 6.88 (d, J = 6.6Hz, 1H), 6.94 (s, 1H), 6.79 (d, J = 6.6Hz, 1H), 4.90 (m, 1H), 4.21 (m, 1H), 3.79 (s, 3H), 3.71 (s, 3H-), 3.48 (m, 2H), 3.25 (m, 2H), 2.21 (s, 3H), 1.81 (m, 2H), 1.59 (s, 3H).

[1344] MS m/z 486 [M-1].

Example 351 2,4-Dimethyl-5- [4- (3-methylcarbamoyl-phenyl)-2-oxo-1,2-dihydro- indol- (3Z)-ylidenemethyl]-lH-pyrrole-3-carboxylic acid (2- pyrrolidin-1-yl-ethyl)-amide {1345J'H NMR (400 MHz, DMSO-d6) 5 13.46 (s, NH, 1H), 11.06 (s, NH, 1H), 8.52 (m, 1H), 7.95 (m, 1H), 7.90 (s, 1H), 7.62 (t, J= 7.8Hz, 1H), 7.56 (m, 1H), 7.43 (t, J=5.5Hz, 1H), 7.19 (t, J= 7.8Hz, 1H), 6.93 (dd, J= 0. 8Hz, J= 7.8Hz, 1H), 6.80 (dd, J= 0.8Hz, J= 7.4Hz, 1H), 6.72 (s, 1H), 3.24 (m, 2H), 2.75 (d, J= 4.7Hz, 3H), 2.42 (m, 4H), 2.35 (s, 3H), 1.64 (m, 4H), 1.58 (s, 3H).

[1346] MS m/z 510 [M-1].

Example 352 5- [4- (4-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(1, 1- dioxo-1#-thiomorpholin-4-yl)-ethyl]-amide [1347] IH NMR (400 MHz, DMSO-d6) 8 13.39 (s, NH, 1H), 10.99 (s, NH, 1H), 7.55 (m, 2H), 7.38 (m, 3H), 7.13 (t, J= 7.8Hz, 1H), 6. 88 (dd, J= 0.8Hz, J= 7.8Hz, 1H), 6.74 (dd, J= 1. 2Hz, J = 7.8 Hz, 1H), 6.60 (s, 1H), 3.22 (m, 2H), 3.00 (m, 4H), 2.87 (m, 4H), 2.54 (t, J= 6.3Hz, 2H), 2.32 (s, 3H), 1.68 (s, 3H).

[1348] MS m/z 552 [M-1].

Example 353 5- [4- (2-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-4-methyl-lH-pyrrole-3-carboxylic acid [2- (1, 1- dioxo-1#-thiomorpholin-4-yl)-ethyl]-amide 113491'H NMR (400 MHz, DMSO-d6) 8 13.48 (s, NH, 1H), 11.13 (s, NH, 1H), 7.76 (m, 1H), 7.68 (d, J= 3. 1Hz, 1H), 7.58 (m, 1H), 7.43 (m, 3H), 7.23 (t, J= 7.8Hz, 1H), 6.96 (d, J= 7. 8Hz, 1H), 6.83 (d, J= 7.4Hz, 1H), 6.72 (s, 1H), 3.24 (m, 2H), 3.04 (m, 4H), 2.91 (m, 4H), 2.57 (t, J= 6.6Hz, 2H), 1.78 (s, 3H).

[1350] MS m/z 551 [M-1].

Example 354 5- [4- (2, 6-Difluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-4-methyl-lH-pyrrole-3-carboxylic acid [2- (1, 1- dioxo-1#-thiomorpholin-4-yl)-ethyl]-amide [1351] IH NMR (400 MHz, DMSO-d6) 8 13.48 (s, NH, 1H), 11.18 (s, NH, 1H), 7.79 (t, 1H), 7.70 (d, 1H), 7.65 (m, 1H), 7.35 (m, 2H), 7.26 (t, 1H), 6.99 (d, 1H), 6.89 (d, 1H), 6.67 (s, 1H), 3.25 (m, 2H), 3.04 (m, 4H), 2.91 (m, 4H), 2.58 (t, 2H), 1.82 (s, 3H).

[1352] MS m/z 539 [M-1].

Example 355 5- [4- (2, 6-Difluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-2, 4-dimethyl-IH-pyrrole-3-carboxylic acid [2- (1, 1- dioxo-1#-thiomorpholin-4-yl)-ethyl]-amide [1353]'H NMR (400 MHz, DMSO-d6) 8 13.54 (s, NH, 1H), 11.00 (br s, NH, 1H), 7.63 (m, 1H), 7.47 (t, J= 5. 5Hz, 1H), 7.33 (m, 2H), 7.22 (t, J= 7.8Hz, 1H), 6.99 (d, J = 7.8Hz, 1H), 6.86 (d, J= 7.8Hz, 1H), 6.39 (s, 1H), 3.27 (m, 2H), 3.05 (m, 4H), 2.91 (m, 4H), 2.58 (t, J= 6.3Hz, 2H), 2.38 (s, 3H), 1.71 (s, 3H). <BR> <BR> <BR> <BR> <BR> <BR> <P>[1354] MS m/z 553 [M-1].<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>Example 356 2- [4- (2, 6-Difluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid [2- (1, 1- dioxo-1#-thiomorpholin-4-yl)-ethyl]-amide [1355]'H NMR (400 MHz, DMSO-d6) 8 13.80 (s, NH, 1H), 11.19 (s, NH, 1H), 7.91 (m, 1H), 7.81 (m, 1H), 7.51 (m, 1H), 7.20 (m, 3H), 6.98 (m, 1H), 6.82 (m, 1H), 6.40 (m, 1H), 3.18 (m, 2H), 3.12 (m, 4H), 2.95 (m, 4H), 2.55 (m, 2H), 2.31 (s, 3H).

[1356] MS m/z 539 [M-1]. <BR> <BR> <BR> <P>Example 357 5- [4- (2, 6-Difluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-2,3-dimethyl-1H-pyrrole-3-carboxylic acid [1357] 1H NMR (400 MHz, DMSO-d6) 8 13.69 (s, NH, 1H), 12.12 (s, 1H), 11.18 (s, NH, 1H), 7.64 (m, 1H), 7.34 (m, 2H), 7.24 (t, J= 7.8Hz, 1H), 7.00 (d, J= 7.8Hz, 1H), 6.89 (d, J= 7.8Hz, 1H), 6.64 (s, 1H), 3.32 (s, 3H), 1.79 (s, 3H).

[1358] MS m/z 393 [M-1]. <BR> <BR> <BR> <P>Example 358 2- [4- (2, 6-Difluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)-<BR> <BR> <BR> <BR> <BR> ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid [1359] 1H NMR (400 MHz, DMSO-d6) 8 12.10 (s, 1H), 11.13 (s, NH, 1H), 7.83 (s, 1H), 7.51 (m, 1H), 7.26 (t, J= 7.8Hz, 1H), 7.19 (m, 2H), 7.00 (dd, J= 0. 8Hz, J= 7.4Hz, 1H), 6.82 (d, J = 7.8Hz, 1H), 6.40 (d, J= 2.3Hz, 1H), 2.30 (s, 3H).

[1360] MS m/z 379 [M-1]. Example 359 5- [4- (2, 6-Difluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-4-methyl-lH-pyrroe-3-carboxylic acid [1361] IH NMR (400 MHz, DMSO-d6) 8 13.58 (s, NH, 1H), 11.22 (s, NH, 1H), 7.75 (d, J= 3. 1Hz, 1H), 7.64 (m, 1H), 7.34 (m, 2H), 7.27 (t, J= 7.8Hz, 1H), 7.00 (d, J = 7. 0Hz, 1H), 6.90 (d, J= 7.8Hz, 1H), 6.66 (s, 1H), 1.82 (s, 3H).

[1362] MS m/z 379 [M-1].

Example 360 3-[1-(4-{(S)-2-[(Cyclopropylmethyl-amino)-methyl]-pyrrolidin e-1- carbonyl}-3, 5-dimethyl-1 H-pyrrol-2-yl)-meth- (Z)-ylidene]-4- (3- fluoro-phenyl)-1, 3-dihydro-indol-2-one [1363] To a solution of 5- [4- (3-fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (70 mg, 0.185 mmol), EDC (70 mg, 0.37 mmol), HOBt (26 mg, 0.19 mmol) in DMF (4 mL) was added TEA (0.08 mL) and cyclopropylmethyl- (S)-l-pyrrolidin-2-ylmethyl-amine (0.05 mL, 0.37 mmol). The mixture was stirred at rt for 20 hours. The reaction was diluted with DCM, washed with water, NaHC03, dried and concentrated. The residue was purified on a silica gel column to give the titled compound.

[1364]'H NMR (400 MHz, CD2C12) 8 12.9 (br s, 1H, NH), 8.6 (br s, 1H), 7.06 (m, 1H), 6.8 9m, 4H), 6.6 (m, 1H), 6.45 (m, 2H), 4.07 (m, 1H), 2.9 (m, 3H), 2.6 (m, 2H), 2.4 (m, 1H), 2.0 (m, 1H), 1.92 (s, 3H, CH3), 1.3 (m, 2H), 1.26 (s, 3H, CH3), 0.84 (m, 2H), 0.3 (m, 2H), 0.08 (m, 2H).

[1365] MS m/z 513.6 [M++1].

Example 361 3-[1-(3-{(S)-2-[(Cyclopropylmethyl-amino)-methyl]-pyrrolidin e-1- carbonyl}-5-methyl-1 H-pyrrol-2-yl)-meth- (Z)-ylidene]-4- (3-ftuoro- phenyl)-1, 3-dihydro-indol-2-one [1366] To a solution of 2- [4- (3-fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (80 mg, 0.22 mmol), EDC (80 mg), HOBt (30 mg) in DMF (4 mL) was added TEA (0.08 mL) and cyclopropylmethyl- (S)-l-pyrrolidin-2-ylmethyl-amine (0.05 mL). The mixture was stirred at rt for 20 hours. The reaction was diluted with DCM, washed with water, NaHC03, dried and concentrated. The residue was purified on a silica gel column to give the titled compound.

[13671 MS m/z 499. 6 [M++1]. Example 362 4-(2,6-Difluoro-phenyl)-3-[1-[4-((S)-pyrrolidine-2-carbonyl) - 1,4,5,6,7,8-hexahydro-pyrrolo [3, 2-b] azepin-2-yl]-meth- (Z)- ylidene]-l, 3-dihydro-indol-2-one [1368] (S)-2-(2-Formyl-5, 6,7,8-tetrahydro-lH-pyrrolo [3,2-b] azepine-4-carbonyl)- pyrrolidine-1-carboxylic acid tert-butyl ester (0.2 mmol) was condensed with 4- (2, 6- difluoro-phenyl)-1, 3-dihydro-indol-2-one (0.2 mmol) and piperidine (2 drops) in ethanol (2 mL) to give 20 mg of the titled compound as a yellow solid.

[1369] 1H NMR (400 MHz, DMSO-d6) 6 13.52 (br s, 1H, NH), 11.16 (s, 1H, NH), 7.62 (m, 1H), 7.27 (m, 4H), 6.99 (d, 1H), 6.88 (d, 1H), 6.37 (s, 1H), 6.19 (s, 1H), 4.52 (s, 1H), 3.55 (m, 2H), 3.37 (m, 2H), 2.88 (m, 1H), 2.70 (m, 1H), 1.90 (m, 2H), 1. 62- 1.76 (m, 6H).

[1370] MS m/z 487. 4 [M-1].

Example 363 2- [4- (3, 5-Difluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (2-hydroxy- 3-pyrrolidin-1-yl-propyl)-amide [1371] 4- (3, 5-Difluoro-phenyl)-1, 3-dihydro-indol-2-one (73.5 mg, 0.3 mmol) was condensed with 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3- pyrrolidin-1-yl-propyl)-amide (excess) and piperidine in ethanol to give 40 mg of the titled compound as a yellow solid.

[1372] 1H NMR (400 MHz, DMSO-d6) 8 13.87 (s, NH, 1H), 11.20 (s, 1H, NH), 8.10 (m, s, 2H), 7.29 (m, 1H), 7.21 (t, 1H), 7.05 (m, 2H), 6.94 (dd, 1H), 6.78 (dd, 1H), 6.54 (d, 1H), 5.83 (d, 1H), 3.94 (m, 1H), 3.75 (m, 2H), 3.15 (m, 3H), 3.05 (m, 4H), 2.31 (s, 3H, CH3), 1.98 (m, 2H), 1.88 (m, 2H).

[1373] MS m/z 507.2 [M++1].

Example 364 2- [4- (2, 4-Difluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemeth, çll-5-methyl-lH-pyrrole-3-carboxylic acid (2-hydroxy- 3-pyrrolidin-1-yl-propyl)-amide [1374] 4- (2, 4-Difluoro-phenyl)-1, 3-dihydro-indol-2-one (73.5 mg, 0.3 mmol) was condensed with 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3- pyrrolidin-l-yl-propyl)-amide (excess) and piperidine in ethanol to give 75 mg (60%) of the titled compound as a yellow solid.

[1375] 1H NMR (400 MHz, DMSO-d6) # 13.86 (brs, NH, 1H), 11.17 (s, 1H, NH), 7.95 (m, 1H), 7.91 (m, 1H), 7. 38 (m, 1H), 7.21 (m, 1H), 7. 15 (m, t, 2H), 6.95 (dd, 1H), 6.77 (dd, 1H), 6.46 (m, 1H), 3.77 (m, 1H), 3.25 (m, 2H), 3.03 (m, 1H), 2.6-2.9 (m, 5H), 2.3 (s, 3H, CH3), 1.79 (m, 4H).

[1376] MS m/z 507.4 [M++1].

Example 365 2- [4- (3-Chloro-4-fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrDle-3-carboxylic acid (2-hydroxy- 3-pyrrolidin-1-yl-propyl)-amide [1377] 4- (3-Chloro-4-fluoro-phenyl)-1, 3-dihydro-indol-2-one (78.3 mg, 0.3 mmol) was condensed with 2-formyl-5-methyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3- pyrrolidin-1-yl-propyl)-amide (excess) and piperidine in ethanol to give 75 mg (60%) of the titled compound as a yellow solid.

[1378] 1H NMR (400 MHz, DMSO-d6) b 13.82 (s, NH, 1H), 11.16 (s, 1H, NH), 7.99 (s, 1H), 7.96 (m, 1H), 7.51 (dd, 1H), 7.42 (t, 1H), 7.31 (m, 1H), 7.20 (t, 1H), 6.93 (d, 1H), 6.78 (d, 1H), 6.47 (d, 1H), 3.82 (m, 1H), 3.27 (m, 2H), 2.7-3.05 (m, 6H), 2.30 (s, 3H, CH3), 1.83 (m, 4H).

[1379] MS m/z 523.4 [M++1].

Example 366 2- [4- (4-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (2-hydroxy- 3-pyrrolidin-1-yl-propyl)-amide [1380] Yellow solid.

[1381] 1H NMR (400 MHz, DMSO-d6) # 13.80 (br s, NH, 1H), 11.10 (s, 1H, NH), 7.93 (s, 1H), 7.86 (m, 1H), 7.39 (d, 2H), 7.29 (d, 2H), 7.14 (t, 1H), 6.86 (d, 1H), 6.70 (d, 1H), 6.40 (d, 1H), 3.78 (m, 1H), 3.22 (m, 3H), 3.02 (m, 1H), 2.7-2.9 (m, 4H), 2.25 (s, 3H, CH3), 1.79 (m, 4H).

[1382] MS m/z 505.4 [M++1].

Example 367 2- [4- (2, 3-Difluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (2-hydroxy- 3-pyrrolidin-1-yl-propyl)-methyl-amide [1383] 2- [4- (2, 3-Difluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (115 mg, 0.3 mmol) was coupled with 1- methylamino-3-pyrrolidin-1-yl-propan-2-ol (3 eq.), EDC (2 eq.), HOBt (1 eq.) in DMF (1.5 mL) to give 108 mg of the titled compound as a yellow solid.

[1384] MS 521. 2 [M++1].

Example 368 4-(3-Fluoro-phenyl)-3-[1-[4-((R)-3-hydroxy-pyrrolidin-1- ylmethyl)-3,5-dimethyl-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-1,3 - dihydro-indol-2-one [1385]'H NMR (400 MHz, DMSO-d6) 8 13.30 (s, NH, 1H), 10.92 (s, NH, 1H), 7.57 (m, 1H), 7.29 (m, 3H), 7.14 (t, 1H), 6.91 (d, 1H), 6.76 (m, 2H), 4.17 (m, 1H), 2.45 (m, 2H), 2.29 (s, 3H), 2.21 (m, 2H), 1.95 (m, 1H), 1.62 (s, 3H), 1.58 (m, 2H), 1.28 (m, 1H), 0.82 (m, 1H).

[13861 MS m/z 430 [M--1] Example 369 4- (2-Fluoro-phenyl)-3- [1- [4- (3-hydroxy-piperidin-1-ylmethyl)-3, 5- dimethyl-lH-pyrrol-2-yll-meth- (Z)-ylidene]-1, 3-dihydro-indol-2- one [1387] IH NMR (400 MHz, DMSO-d6) 6 13.27 (s, NH, 1H), 10.90 (s, NH, 1H), 7.49 (m, 1H), 7.35 (m, 3H), 7.11 (t, J= 7.8Hz, 1H), 6.88 (d, J= 7.8Hz, 1H), 6.74 (d, J= 8. 2Hz, 1H), 6.56 (s, 1H), 4.45 (m, 1H), 3.10 (m, 2H), 2.19 (s, 3H), 2.11 (m, 2H), 1.68 (m, 2H), 1.50 (s, 3H), 1.41 (m, 2H), 1.25 (m, 2H), 0.95 (m, 1H).

[1388] MS m/z 444 [M-1].

Example 370 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (2- piperidin-l-yl-ethyl)-amide [1389] 2-[4-(3-Fluoro-phenyl)-2-oxo-1,2-dihydro-indol-(3Z)-ylidenem entyl]-5- methyl-lH-pyrrole-3-carboxylic acid (90.5 mg) was coupled with 2-piperidin-1-yl- ethylamine (48 mg, 1.5 eq.), HOBt (1 eq.), EDC (1.5 eq.) and TEA (3 drops) in THF (2 mL), DMF (0.3 mL) at rt for overnight to give 82 mg (70%) of the titled compound as a yellow solid.

[1390] IH NMR (400 MHz, DMSO-d6) 8 13.80 (br s, NH, 1H), 11.12 (s, 1H, NH), 7.99 (s, 1H), 7.70 (t, 1H), 7.45 (m, 1H), 7.17 (m, 4H), 6.91 (dd, 1H), 6.76 (dd, 1H), 6.35 (d, 1H), 3.13 (m, 2H), 2.37 (m, 4H), 2.29 (m, s, 5H), 1.50 (m, 4H), 1.39 (m, 2H).

[1391] MS m/z 473.6 [M++1].

Example 371 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid [2- (3- acetylamino-pyrrolidin-1-yl)-ethyl]-amide [1392] 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (90.5 mg) was coupled with N-[1-(2-amino- ethyl)-pyrrolidin-3-yl]-acetamide (58.5 mg, 1.5 eq.), HOBt (1 eq.), EDC (1.5 eq.) and TEA (3 drops) in THF (2 mL), DMF (0.3 mL) at rt for overnight to give 97 mg (78%) of the titled compound as a yellow solid.

[1393] IH NMR (400 MHz, DMSO-d6) 8 13.80 (s, NH, 1H), 11.12 (s, 1H, NH), 7.99 (s, 1H), 7.98 (m, 1H), 7.77 (t, 1H), 7.45 (m, 1H), 7.17 (m, 4H), 6.91 (dd, 1H), 6.74 (dd, 1H), 6.35 (d, 1H), 4.14 (m, 1H), 3.12 (m, 2H), 2.6-2.72 (m, 2H), 2.42 (m, 3H), 2.33 (m, 1H), 2.29 (s, 3H, CH3), 2.05 (m, 1H), 1.76 (s, 1H, CH3), 1.53 (m, 1H).

[1394] MS m/z 516.4 [M++1].

Example 372 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (1-methyl- piperidin-4-ylmethyl)-amide [1395] 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (90.5 mg) was coupled with C-(1-methyl- piperidin-4-yl)-methylamine (1.5 eq.), HOBt (1 eq.), EDC (1.5 eq.) and TEA (3 drops) in THF (2 mL), DMF (0.3 mL) at rt for overnight to give 65 mg (55%) of the titled compound as a yellow solid.

[1396] IH NMR (400 MHz, DMSO-d6) b 13.80 (br s, NH, 1H), 11.11 (s, 1H, NH), 8.00 (s, 1H), 7.81 (t, 1H), 7.42 (m, 1H), 7.16 (m, 4H), 6.91 (dd, 1H), 6.75 (dd, 1H), 6.39 (d, 1H), 2.90 (t, 2H), 2.72 (m, 2H), 2.29 (s, 3H, CH3), 2.13 (s, 3H, CH3), 1.79 (m, 2H), 1.54 (m, 2H), 1.38 (m, 1H), 1.12 (m, 2H).

[1397] MS m/z 473.6 [M++1].

Example 373 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid [2- (4- hydroxy-piperidin-l-yl)-ethyl]-amide [1398] 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (90.5 mg) was coupled with 1- (2-amino-ethyl)- piperidin-4-ol (54 mg, 1.5 eq.), HOBt (1 eq.), EDC (1.5 eq.) and TEA (3 drops) in THF (2 mL), DMF (0.3 mL) at rt for overnight to give 69.8 mg (57%) of the titled compound as a yellow solid.

[1399] 1H NMR (400 MHz, DMSO-d6) # 13.80 (br s, NH, 1H), 11.12 (s, 1H, NH), 7.99 (s, 1H), 7.71 (t, 1H), 7.43 (m, 1H), 6.91 (d, 1H), 6.76 (d, 1H), 6.35 (d, 1H), 4.53 (d, 1H), 3.43 (m, 1H), 3.12 (m, 2H), 2.71 (m, 2H), 2.30 (m, 2H), 2.29 (s, 3H, CH3), 2.05 (m, 2H), 1.69 (m, 2H), 1.38 (m, 2H).

[1400] MS m/z 489.4 [M++1].

Example 374 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid [3- (1, 1- dioxo-1$1% 6&-thiomorpholin-4-yl)-2-hydroxy-propyl]-amide [1401] 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (108 mg, 0.3 mmol) was coupled with 1-amino- 3- (l, l-dioxo-1X6-thiomorpholin-4-yl)-propan-2-ol (1.8 mmol), HOBt (1 eq.), EDC (1.5 eq.) and TEA (3 drops) in THF (1 mL), acetonitrile (1 mL) at rt for overnight to give 107 mg (65%) of the titled compound as a yellow solid.

[1402] IHNMR (400MHz, DMSO-d6) 6 13.84 (br s, NH, 1H), 11.13 (s, 1H, NH), 8.00 (s, 1H), 7.79 (t, 1H), 7.44 (m, 1H), 7.17 (m, 4H), 6.91 (dd, 1H), 6.76 (dd, 1H), 6.42 (d, 1H), 4.76 (d, 1H), 3.67 (m, 1H), 3.17 (m, 1H), 3.06 (m, 4H), 2.96 (m, 6H), 2.29 (s, 3H, CH3).

[1403] MS n/z 551.2 [M-1].

Example 375 5- [4- (4-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid [3- (1, 1- dioxo-116-thiomorpholin-4-yl)-2-hydroxy-propyl]-amide [1404] 5- [4- (4-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)-ylidenemethyl]-2, 4- dimethyl-1H-pyrrole-3-carboxylic acid (112 mg, 0.3 mmol) was coupled with 1- amino-3-(1,1-dioxo-1#6-thiomorpholin-4-yl)-propan-2-ol (1.8 mmol), HOBt (1 eq.), EDC (1.5 eq.) and TEA (3 drops) in THF (1 mL), acetonitrile (1 mL) at rt for overnight to give 96.2 mg (55%) of the titled compound.

[1405] 1H NMR (400 MHz, DMSO-d6) b 13.49 (s, NH, 1H), 11.10 (br s, 1H, NH), 7.59 (d, 1H), 7.44 (m, 1H), 7.17 (t, 1H), 6.91 (d, 1H), 6.77 (d, 1H), 6.65 (s, 1H), 4.8 (m, 1H), 3.71 (m, 1H), 3.35 (m, 1H), 3.12 (m, 1H), 3.05 (m, 4H), 2.94 (m, 4H), 2.5 (m, 1H), 2.43 (m, 1H), 2.37 (s, 3H, CH3), 1.72 (s, 3H, CH3).

[1406] MS m/z 581.2 [M-1].

Example 376 5- [4- (2, 6-Difluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-4-methyl-lH-pyrrole-3-carboxylic acid [3- (1, 1- dioxo-116-thiomorpholin-4-yl)-2-hydroxy-propyl]-amide [1407] 5- [4- (2, 6-Difluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)-ylidenemethyl]-4- methyl-lH-pyrrole-3-carboxylic acid (114 mg, 0.3 mmol) was coupled with 1-amino- 3- (1, 1-dioxo-1 X6-thiomorpholin-4-yl)-propan-2-ol (1.8 mmol), HOBt (1 eq.), EDC (1.5 eq.) and TEA (3 drops) in THF (1 mL), acetonitrile (1 mL) at rt for overnight to give 102 mg (60%) of the titled compound.

[1408] IH NMR (400 MHz, DMSO-d6) 8 13.52 (s, NH, 1H), 11.20 (br s, 1H, NH), 7.81 (d, 1H), 7.74 (d, 1H), 7.65 (m, 1H), 7.34 (m, 2H), 7.25 (t, 1H), 6.99 (dd, 1H), 6.88 (d, 1H), 6.66 (s, 1H), 4.83 (d, 1H), 6.66 (s, 1 H), 4.83 (m, 1 H), 3.70 (m, 1 H), 3.35 (m, 1 H), 3.08 (m, 1 H), 3.04 (m, 4H), 2.93 (m, 4H), 2.50 (m, 1 H), 2.40 (m, 1 H), 1.81 (s, 3H, CH3).

[1409] MS n/z 569.2 [M-1].

Example 377 4- (2, 6-Difluoro-phenyl)-3- [1- [3-methyl-4- ( (S)-3-pyrrolidin-1- ylmethyl-piperidine-l-carbonyl)-lH-pyrrol-2-yl]-meth-(Z)- ylidene]-l, 3-dihydro-indol-2-one [1410] 5- [4- (2, 6-Difluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)-ylidenemethyl]-4- methyl-lH-pyrrole-3-carboxylic acid (114 mg, 0.3 mmol) was coupled with (R)-3- pyrrolidin-1-ylmethyl-piperidine (99 mg, 2 eq.), HOBt (1 eq.), EDC (1.5 eq.) and TEA (3 drops) in THF (1 mL) and aceonitrile (1 mL) at rt for overnight to give 111.3 mg (70%) of the titled compound as a yellow solid.

[1411] MS m/z 531 [M++1]. Example 378 4- (4-Chloro-phenyl)-3- [l- [3, 5-dimethyl-4- ( (S)-3-pyrrolidin-1- ylmethyl-piperidine-l-carbonyl)-lH-pyrrol-2-yl]-meth- (Z)- ylidene]-1,3-dihydro-indol-2-one [1412] 5- [4- (4-Chloro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)-ylidenemethyl]-2, 4- dimethyl-lH-pyrrole-3-carboxylic acid (112 mg, 0.3 mmol) was coupled with (R)-3- pyrrolidin-1-ylmethyl-piperidine (99 mg, 2 eq.), HOBt (1 eq.), EDC (1.5 eq.) and TEA (3 drops) in THF (1 mL) and acetonitrile (1 mL) at rt for overnight to give 89.5 mg (55%) of the titled compound as a yellow solid.

[1413] MS m/z 543 [M++1]. <BR> <BR> <BR> <BR> <BR> <BR> <P>Example 379 4- (3-Fluoro-phenyl)-3- [1- [5-methyl-3- (4-pyrrolidin-1-ylmethyl- piperidine-l-carbonyl)-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one [1414] 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (108 mg, 0.3 mmol) was coupled with (R)-3- pyrrolidin-1-ylmethyl-piperidine (99 mg, 2 eq.), HOBt (1 eq.), EDC (1.5 eq.) and TEA (3 drops) in THF (1 mL), acetonitrile (1 mL) at rt for overnight to give 107 mg (70%) of the titled compound as a yellow solid.

[1415] MS 513.2 [M++1].

Example 380 3- [l- [3, 5-Dimethyl-4- (l-methyl-1, 2,3,6-tetrahydro-pyridin-4-yl)- 1H-pyrrol-2-yl]-meth-(Z)-ylidene]-4-(3-fluoro-phenyl)-1, 3- dihydro-indol-2-one [1416] 1H NMR (400 MHz, DMSO-d6) 8 13.4 (s, 1H, NH), 10. 95 (s, 1H, NH), 7.56 (m, 1H), 7.28 (m, 3H), 7.14 (t, 1H), 6.91 (dd, 1H), 6.77 (dd, 1H), 6.76 (s, 1H), 5.40 (m, 1H), 2.95 (m, 2H), 2.50 (m, 2H), 2.25 (s, 3H, CH3), 2.21 (s, 3H, CH3), 2.17 (m, 2H), 1.55 (s, 3H, CH3).

[1417] MS m/z 428. 2 [M++1].

Example 381 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid [2- (2, 2,2- trifluoro-ethylamino)-ethyl]-amide [1418] A mixture of 2-[4-(3-fluoro-phenyl)-2-oxo-1,2-dihydro-indol-(3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (53 mg, 0.15 mmol), HOBt (28 mg), EDC (36 mg), TEA (0.042 mL) and N1-(2, 2,2-trifluoro-ethyl)-ethane-1,2- diamine (0.036 mL) in DMF (1 mL) was stirred at rt for 48 hours. The solvent was removed and diluted with sat. NaHCO. It was then extracted with DCM, dried and concentrated. The residue was purified on a silica gel column to give 52 mg (71%) of the titled compound.

[1419] 1H NMR (400 MHz, DMSO-d6) 8 13.8 (s, 1H, NH), 11.14 (s, 1H, NH), 7.98 (s, 1H), 7.8 (t, 1H), 7.45 (m, 1H), 7.19 (m, 4H), 6.93 (d, 1H), 6.78 (d, 1H), 6.38 (d, 1H), 3.26 (m, 2H), 3.12 (m, 2H), 2.67 (t, 2H), 2.31 (s, 3H, CH3).

[1420] MS m/z 487.4 [M++1].

Example 382 3-[1-[4-(1-Acetyl-piperidine-4-carbonyl)-1, 4,5,6,7,8-hexahydro- pyrrolo {3, 2-b] azepin-2-yl]-meth- (Z)-ylidene]-4- (3-fluoro-phenyl)- 1,3-dihydro-indol-2-one [1421] 4- (1-Acetyl-piperidine-4-carbonyl)-1, 4,5,6,7,8-hexahydro-pyrrolo [3,2- b] azepine-2-carbaldehyde (56 mg) was condensed with 4- (3-fluoro-phenyl)-1, 3- dihydro-indol-2-one (40 mg) and piperidine (2 drops) in ethanol (1 mL) at rt for overnight. The solvent was concentrated and the residue was purified on a silica gel column to give 50 mg of the title compound as a yellow solid.

[1422] IH NMR (400 MHz, CD2CI2) 8 13.47 (s, 1H, NH), 9.16 (br s, 1H, NH), 7.48 (m, 1H), 7.2-7.3 (m, 4H), 6.97 (d, 1H), 6.88 (d, 1H), 6.76 (s, 1H), 6.09 (s, 1H), 4.50 (d, 1H), 3.77 (d, 1H), 2.91 (m, 2H), 2.78 (m, 2H), 2.4 (m, 1H), 2.04 (s, 3H, CH3), 1.94 (m, 1H), 1.82 (m, 3H), 1.70 (m, 3H), 1.57 (m, 3H).

[1423] MS m/z 527.4 [M++1].

Example 383 (R)-1- {2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-1H-pyrrole-3-carbonyl}-piperidine-3- carboxylic acid cyclopropylamide Nx Chiral o-/0 F o-/ N /I N 1 0 N N [1424] 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)-ylidenemethyl]-5- methyl-lH-pyrrole-3-carboxylic acid (108 mg, 0.3 mmol) was coupled with (R)- piperidine-3-carboxylic acid cyclopropylamide (69.3 mg, 1.5 eq.), HOBt (40.5 mg, 1 eq.), EDC (86 mg, 1.5 eq.) and TEA (0.06 mL) in DMF (1 mL) to give 57 mg (37%) of the titled compound.

[1425] MS m/z 513.4 [M++1].

Example 384 4-(3-Fluoro-phenyl)-3-[1-[4-methyl-3-(4-methyl-piperazine-1- carbonyl)-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol-2- one [1426] MS m/z 443.4 [M-1].

Example 385 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-4-methyl-lH-pyrrole-3-carboxylic acid (3- pyrrolidin-1-yl-propyl)-amide [1427] 1H NMR (400 MHz, DMSO-d6) 8 13.50 (s, 1H, NH), 11.10 (s, 1H, NH), 7.63 (m, 2H), 7.4 (m, 1H), 7.22 (s, 1H), 7.14 (m, 3H), 7.01 (d, 1H), 6.86 (dd, 1H), 6.71 (dd, 1H), 2.97 (m, 2H), 1.98 (s, 3H, CH3), 1.59 (m, 4H), 1.50 (m, 2H), 1.2 (m, 3H), 0.78 (m, 3H).

[1428] MS m/z 473.1 [M++1].

Example 386 3- 1- [3, 5-Dimethyl-4- (l-methyl-piperidin-4-yl)-lH-pyrrol-2-yl]- meth- (Z)-ylidene]-4- (3-fluoro-phenyl)-1, 3-dihydro-indol-2-one [1429]'H NMR (400 MHz, DMSO-d6) 8 13.32 (s, 1H, NH), 10.9 (s, 1H, NH), 7.56 (m, 1H), 7.27 (m, 3H), 7.12 (m, 1H), 6.90 (dd, 1H), 6.75 (m, 2H), 2.78 (m, 2H), 2.34 (m, 1H), 2.27 (s, 3H, CH3), 2.14 (s, 3H, CH3), 1.86 (m, 2H), 1.74 (m, 2H), 1.59 (s, 3H, CH3), 1.44 (m, 2H).

[1430] MS m/z 430.2 [M++1]. <BR> <BR> <P>Example 387 3- [l- [3, 5-Dimethyl-4- (l-methyl-piperidin-4-yl)-lH-pyrrol-2-yl]-<BR> <BR> meth- (Z)-ylidene]-4- (4-fluoro-phenyl)-1, 3-dihydro-indol-2-one [1431] 1H NMR (400 MHz, DMSO-d6) 8 13.31 (s, 1H, NH), 10.89 (s, 1H, NH), 7.43 (m, 1H), 7.35 (m, 1H), 7.11 (t, 1H), 6.89 (dd, 1H), 6.73 (dd, 1H), 6.68 (s, 1H), 2.78 (m, 2H), 2.34 (m, 1H), 2.34 (m, 1H), 2.27 (s, 3H, CH3), 2.13 (s, 3H, CH3), 1.85 (m, 2H), 1.76 (m, 2H), 1.60 (s, 3H CH3), 1.43 (m, 2H).

[1432] MS m/z 428.6 [M-1].

Example 388 4-(2,3-Difluoro-phenyl)-3-[1-[3,5-dimethyl-4-(1-methyl-piper idin- 4-yl)-lH-pyrrol-2-yl]-meth-(Z)-ylidene]-1, 3-dihydro-indol-2-one [1433] 1H NMR (400 MHz, DMSO-d6) 8 13.35 (s, 1H, NH), 10.96 (s, 1H, NH), 7.58 (m, 1H), 7. 39 (m, 1H), 7.28 (m, 1H), 7.16 (t, 1H), 6.95 (dd, 1H), 6.81 (dd, 1H), 6.62 (s, 1H), 2.78 (m, 2H), 2.35 (m, 1H), 2.28 (s, 3H, CH3), 2.14 (s, 3H, CH3), 1.86 (m, 2H), 1.75 (m, 2H), 1.61 (s, 3H, CH3), 1.45 (m, 2H).

[1434] MS m/z 446.6 [M-1].

Example 389 4-(3,5-Difluoro-phenyl)-3-[1-[3,5-dimethyl-4-(1-methyl-piper idin- 4-yl)-lH-pyrrol-2-yl]-meth-(Z)-ylidene]-1, 3-dihydro-indol-2-one [1435] IH NMR (400 MHz, DMSO-d6) 8 13.35 (s, 1H, NH), 10.93 (s, 1H, NH), 7. 37 (m, 1H), 7.2 (m, 2H), 7.13 (t, 1H), 6.92 (dd, 1H), 6.79 (s, 1H), 6.77 (dd, 1H), 2.78 (m, 2H), 2.36 (m, 1H), 2.28 (s, 3H, CH3), 2.14 (s, 3H, CH3), 1.86 (m, 2H), 1.77 (m, 2H), 1.67 (s, 3H, CH3), 1.45 (m, 2H).

[1436] MS m/z 446. 5 [M-1].

Example 390 4- (2, 6-Difluoro-phenyl)-3- [l- [3, 5-dimethyl-4- (l-methyl-piperidin- 4-yl)-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol-2-one [1437]'H NMR (400 MHz, DMSO-d6) 5 13.36 (s, 1H, NH), 10.96 (s, 1H, NH), 7.61 (m, 1H), 7. 32 (m, 2H), 7.17 (t, 1H), 6.96 (dd, 1H), 6.83 (dd, 1H), 6.56 (s, 1H), 2.78 (m, 2H), 2.34 (m, 1H), 2.28 (s, 3H, CH3), 2.14 (s, 3H, CH3), 1.86 (m, 2H), 1.75 (m, 2H), 1.58 (s, 3H, CH3), 1.45 (m, 2H).

[1438] MS m/z 446.5 [M-1].

Example 391 4- (3, 4-Dimethoxy-phenyl)-3- [l- [3, 5-dimethyl-4- (l-methyl- piperidin-4-yl)-lH-pyrrol-2-yll-meth- (Z)-ylidene]-1, 3-dihydro- indol-2-one [1439] IH NMR (400 MHz, DMSO-d6) 8 13.29 (s, 1H, NH), 10.84 (s, 1H, NH), 7.09 (m, 2H), 6.96 (d, 1H), 6.89 (dd, 1H), 6.86 (d, 1H), 6.84 (s, 1H), 6.76 (d, 1H), 3.80 (s, 3H, CH3), 3.71 (s, 3H, CH3), 2.86 (m, 2H), 2.40 (m, 1H), 2.27 (s, 3H, CH3), 2.22 (m, 2H), 1.78 (m, 2H), 1.61 (s, 3H, CH3), 1.47 (m, 2H).

[1440] MS m/z 472.4 [M++1].

Example 392 5-14- (2, 3-Difluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-2, 4-dimethyl-lH-pyrrole-3-carboxylic acid [1441] IH NMR (400 MHz, DMSO-d6) 8 12.13 (s, 1H, OH), 11.28 (s, 1H, NH), 7.88 (m, 1H), 7.44 (m, 1H), 7.18-7. 32 (m, 3H), 6.98 (dd, 1H), 6.80 (dd, 1H), 6.40 (d, 1H), 2.30 (s, 3H, CH3).

[1442] MS m/z 379.4 [M-1].

Example 393 4- (2, 4-Difluoro-phenyl)-3- [1- 3, 5-dimethyl-4- (l-methyl-piperidin- 4-yl)-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol-2-one [1433] 1H NMR (400 MHz, DMSO-d6) # 13.67 (s, 1H, NH), 12.12 (br s, 1H, COOH), 11.17 (s, 1H, NH), 7.61 (m, 1H), 7.41 (m, 1H), 7.30 (m, 1H), 7.24 (t, 1H), 6.99 (dd, 1H), 6.87 (dd, 1H), 6.70 (s, 1H), 1.82 (s, 3H, CH3).

[1444] MS Mlz 393.2 [M-1].

Example 394 4- (2, 4-Difluoro-phenyl)-3- 1- [3, 5-dimethyl-4- (l-methyl-piperidin- 4-yl)-lH-pyrrol-2-yl]-meth-(Z)-ylidene]-1, 3-dihydro-indol-2-one [1445]'H NMR (400 MHz, DMSO-d6) 8 13.33 (s, 1H, NH), 10. 93 (s, 1H, NH), 7.45 (m, 2H), 7.28 (m, 1H), 7.14 (t, 1H), 6.93 (dd, 1H), 6.77 (dd, 1H), 6.56 (s, 1H), 2.79 (m, 2H), 2.35 (m, 1H), 2.28 (s, 3H, CH3), 2.14 (s, 3H, CH3), 1.86 (m, 2H), 1.77 (m, 2H), 1.64 (s, 3H, CH3), 1.45 (m, 2H).

[1446] MS m/z 448.1 [M++1].

Example 395 4- (2, 3-Difluoro-phenyl)-3- 1- [3, 5-dimethyl-4- (4-methyl-piperazine- 1-carbonyl)-1H-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol- 2-one [14471 Yellow solid.

[1448] 1H NMR (400 MHz, DMSO-d6) 5 13.45 (s, 1H, NH), 11.12 (s, 1H, NH), 7.6 (m, 1H), 7.41 (m, 1H), 7.29 (m, 1H), 7.22 (t, 1H), 6.98 (dd, 1H), 6.85 (dd, 1H), 6.62 (d, 1H), 3.32 (m, 4H), 2.23 (s, m, 7H), 2.14 (s, 3H, CH3), 1.59 (s, 3H, CH3).

[1449] MS m/z 475.4 [M-1].

Example 396 4- (2, 3-Difluoro-phenyl)-3- [1- [3, 5-dimethyl-4- (4-pyrrolidin-1-yl- piperidine-1-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-1, 3- dihydro-indol-2-one [1450] Yellow solid.

[1451] 1H NMR (400 MHz, DMSO-d6) # 13.43 (br s, 1H, NH), 11. 11 (s, lh, NH), 7.59 (m, 1H), 7.40 (m, lh), 7.29 (m, 1H), 6.98 (dd, 1H), 6.85 (dd, 1H), 6.62 (s, 1H), 3.32 (m, 2H), 2.94 (m, 2H), 2.43 (m, 4H), 2.22 (s, 3H, CH3), 2.14 (m, 1H), 1.77 (m, 2H), 1.63 (m, 4H), 1.58 (s, 3H), 1.22 (m, 2H).

[1452] MS m/z 529.5 [M-1].

Example 397 4-(2,3-Difluoro-phenyl)-3-[1-[3,5-dimethyl-4-((S)-2-pyrrolid in-1- ylmethyl-pyrrolidine-l-carbonyl)-lH-pyrrol-2-yl]-meth- (Z)- ylidene]-1,3-dihydro-indol-2-one [1453] Yellow solid.

[1454] 1H NMR (400 MHz, DMSO-d6) 8 13.4 (br s, 1H, NH), 11.10 (s, 1H, NH), 7.59 (m, 1H), 7.40 (m, 1H), 7.29 (m, 1H), 7.21 (t, 1H), 6.97 (dd, 1H), 6.85 (dd, 1H), 6.61 (s, 1H), 4.22 (m, 1H), 3.12 (m, 2H), 2.45 (m, 4H), 2.23 (s, 3H, CH3), 2.1 (m, 2H), 1.85 (m, 4H), 1.65 (m, 2H), 1.6 (s, 3H, CH3), 1.45 (m, 2H).

[1455] MS m/z 529.5 [M-1]. Example 398 4-(2,3-Difluoro-phenyl)-3-[1-[3-((cis)-3,5-dimethyl-piperazi ne-1- carbonyl)-5-methyl-lH-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3- dihydro-indol-2-one [1456] Orange solid.

114571'H NMR (400 MHz, DMSO-d6) 5 13.59 (s, 1H, NH), 11.16 (s, 1H, NH), 7.44 (m, 1H), 7.14-7.3 (m, 3H), 6.97 (dd, 1H), 6.86 (s, 1H), 6.79 (dd, 1H), 6.06 (d, 1H), 4.15 (m, 1H), 3.47 (m, 1H), 3.32 (m, under water peak), 2.45 (m, under DMSO peak), 2. 31 (s, 3H, CH3), 2.05 (m, 1H), 1.03 (s, 3H, CH3), 0.8 (s, 3H, CH3).

[1458] MS m/z 475.4 [M-1].

Example 399 2- [4- (2, 3-Difluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (3- pyrrolidin-1-yl-propyl)-amide [1459] Orange solid.

[1460] 'H NMR (400 MHz, DMSO-d6) 8 13.8 (s, 1H, NH), 11.2 (s, 1H, NH), 7.9 (m, 2H), 7.28 (m, 1H), 7. 26 (m, 1H), 7.22 (t, 1H), 7.14 (m, 1H), 6.97 (dd, 1H), 6.79 (dd, 1H), 6.38 (d, 1H), 3.09 (m, 2H), 2.41 (m, 6H), 2.3 (s, 3H, CH3), 1.68 (m, 4H), 1.58 (m, 2H).

[1461] MS m/z 489. 4 [M-1].

Example 400 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-iodo-4-methyl-lH-pyrrole-3-carboxylic acid (3- pyrrolidin-1-yl-propyl)-amide [1462] Earthy yellow solid.

[1463] 1H NMR (400 MHz, DMSO-d6) 8 11.24 (s, 1H, NH), 7.8 (t, 1H), 7.44 (m, 1H), 7.2 (m, 4H), 7.1 (s, 1H), 6.93 (dd, 1H), 6.78 (dd, 1H), 3.02 (m, 2H), 2.40 (m, 6H), 1.96 (s, 3H, CH3), 1.63 (m, 4H), 1.52 (m, 2H).

[1464] MS m/z 597.3 [M-1].

Example 401 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid [ (S)-2- hydroxy-3- (3-methyl-2, 5-dioxo-imidazolidin-1-yl)-propyl]-amide [1465] Orange solid.

[1466] 1H NMR (400 MHz, DMSO-d6) 8 13.84 (s, 1H, NH), 11.13 (s, 1H, NH), 8.0 (s, 1H), 7.82 (t, 1H), 7.42 (m, 1H), 7.15 (m, 4H), 6.91 (d, 1H), 6.76 (d, 1H), 6.42 (d, 1H), 4.98 (d, 1H), 3.96 (s, 2H), 3.76 (m, 2H), 3.25 (m, 1H), 3.15 (m, 1H), 2.95 (m, 1H), 2.86 (s, 3H, CH3), 2.3 (s, 3H, CH3).

[1467] MS m/z 532. 4 [M++1].

Example 402 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid [ (R)-2- hydroxy-3- (3-methyl-2, 5-dioxo-imidazolidin-1-yl)-propyl]-amide [1468] IH NMR (400 MHz, DMSO-d6) 6 13.82 (s, 1H, NH), 11.13 (s, 1H, NH), 8.0 (s, 1H), 7.83 (t, 1H), 7.42 (m, 1H), 7.15 (m, 4H), 6.91 (d, 1H), 6.76 (d, 1H), 6.43 (d, 1H), 4.98 (d, 1H), 3.96 (s, 2H), 3.76 (m, 2H), 3.25 (m, 1H), 3.15 (m, 1H), 2.95 (m, 1H), 2.86 (s, 3H, CH3), 2.30 (s, 3H, CH3).

Example 403 4- (3-Fluoro-phenyl)-3- [l- [5-methyl-3- (3-morpholin-4-yl-azetidine- 1-carbonyl)-1H-pyrrol-2-yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol- 2-one [1469] Yellow solid.

[1470] lHNMR (400MHz, DMSO-d6) 6 13.68 (s, 1H, NH), 11.14 (s, 1H, NH), 7.51 (s, 1H), 7.48 (m, 1H), 7.2 (m, 4H), 6.92 (dd, 1H), 6.77 (dd, 1H), 6.2 (d, 1H), 3.92 (m, 1H), 3.78 (m, 2H), 3.67 (m, 1H), 3.57 (m, 4H), 3.0 (m, 1H), 2.29 (s, 3H, CH3), 2.25 (m, 4H).

Example 404 3- [1-13- [3- ( (2R, 6S)-2,6-Dimethyl-morpholin-4-yl)-azetidine-1- <BR> <BR> carbonyl]-5-methyl-lH-pyrrol-2-yl}-meth- (Z)-ylidene]-4- (3-fluoro-<BR> <BR> phenyl)-1, 3-dihydro-indol-2-one [1471] Yellow solid.

[1472] 1H NMR (400 MHz, DMSO-d6) 8 13.78 (s, 1H, NH), 11.14 (s, 1H, NH), 7.52 (s, 1H), 7.48 (m, 4H), 7.25 (m, 4H), 6.92 (dd, 1H), 6.77 (dd, 1H), 6.2 (d, 1H), 3.8 (m, 1H), 3.78 (m, 2H), 3.67 (m, 1H), 3.55 (m, 2H), 2.96 (m, 1H), 2.74 (m, 1H), 2.60 (m, 1H), 2.3 (s, 3H, CH3), 1.45 (m, 2H), 1.05 (d, 3H, CH3), 0.99 (d, 3H, CH3) Example 405 4-(3-Fluoro-phenyl)-3-[1-{3-[(S)-2-((S)-3-fluoro-pyrrolidin- 1- <BR> <BR> <BR> ylmethyl)-pyrrolidine-l-carbonyl]-5-methyl-lH-pyrrol-2-yl}-m eth-<BR> <BR> <BR> <BR> <BR> <BR> (Z)-ylidene]-1, 3-dihydro-indol-2-one [1473] To a solution of 2- [4- (3-fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (100 mg, 0.28 mmol), EDC (115 mg, 0.3 mmol), HOBt (40 mg, 0.3 mmol) in DMF (4 mL) was added TEA (0.14 mL) and (S)-3-fluoro-1-(S)-1-pyrrolidin-2-ylmethyl-pyrrolidine (100 mg, 0.58 mmol).

- The mixture was stirred at rt for 20 hours. The reaction was diluted with DCM, washed with water, NaHCO3, dried and concentrated. The residue was purified on a silica gel column to give the titled compound.

[1474] MS m/z 517.4 [M++1].

Example 406 4- (3-Fluoro-phenyl)-3- [1- {3- ( (R)-2- ( (S)-3-fluoro-pyrrolidin-1- ylmethyl)-pyrrolidine-l-carbonyl]-5-methyl-lH-pyrrol-2-yl}-m eth- (Z)-ylidene]-1, 3-dihydro-indol-2-one 114751 To a solution of 2- [4- (3-fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-1H-pyrrole-3-carboxylic acid (100 mg, 0.28 mmol), EDC (120 mg, 0.63 mmol), HOBt (40 mg, 0.3 mmol) in DMF (4 mL) was added TEA (0.15 mL) and (S)-3-fluoro-1-(R)-1-pyrrolidin-2-ylmethyl-pyrrolidine (95 mg, 0.55 mmol). The mixture was stirred at rt for 20 hours. The reaction was diluted with DCM, washed with water, NaHC03, dried and concentrated. The residue was purified on a silica gel column to give the titled compound.

[1476] MS m/z 517.4 [M++1].

Example 407 3- [l- [3- (4-Cyclopropylamino-piperidine-l-carbonyl)-5-methyl-lH- pyrrol-2-yl]-meth- (Z)-ylidene]-4- (3-fluoro-phenyl)-1, 3-dihydro- indol-2-one [1477] To a solution of 2- [4- (3-fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (105 mg, 0.29 mmol), EDC (120 mg, 0.58 mmol), HOBt (40 mg, 0.3 mmol) in DMF (4 mL) was added TEA 90.15 mL) and cyclopropyl-piperidin-4-yl-amine. The mixture was stirred at rt for 20 hours. The reaction was diluted with DCM, washed with water, NaHCO3, dried and concentrated. The residue was purified on a silica gel column to give the titled compound.

[1478] 1H NMR (400 MHz, CDC13) 8 13. 32 (s, 1H, NH), 8. 35 (s, 1H), 7.46 (m, 1H), 7.23 (m, 1H), 7.12 (m, 3H), 7.02 (br s, 1H, NH), 6.83 (dd, 1H), 6.79 (dd, 1H), 5.99 (d, 1H), 4.44 (m, 1H), 3.66 (m, 1H), 2.81 (m, 1H), 2.34 (s, 3H, CH3), 2.15 (m, 1H), 2.0 (m, 1H), 1.80 (m, 1H), 1.69 (m, 2H), 1.28 (m, 1H), 1.1 (m, 1H), 0.47 (m, 2H), 0.34 (m, 2H).

[1479] MS m/z 485.2 [M++1].

Example 408 3-fl- [3- ( (2R, 4R)-2-Cyclopropylaminomethyl-4-hydroxy- <BR> <BR> pyrrolidine-l-carbonyl)-5-methyl-1 (Z)-<BR> <BR> ylidene]-4- (3-fluoro-phenyl)-1, 3-dihydro-indol-2-one [1480] To a solution of cis-4-hydroxy-D-proline (6.5 g, 0.05 mol) in 10% TEA/ MeOH (80 mL) was added di-tert-butyl dicarbonate (21.6 g, 2 eq.). After refluxing for 45 mins, the reaction was allowed to cool to rt and the solvent was removed under reduced pressure. The residue was adjusted to pH 3-4 and extracted with ethyl acetate.

The combined organic layer was dried and concentrated to give 8 g of (2R, 4R)-4- hydroxy-pyrrolidine-l, 2-dicarboxylic acid I-tert-butyl ester as a white semi-solid.

[1481] IH NMR (400 MHz, DMSO-d6) # 4.13 (m, 1H), 4.01 (m, 1H), 3.41 (m, 1H), 3.12 (m, 1H), 2. 25 (m, 1H), 1.76 (m, 1H), 1.31 and 1.37 (2s, 9H, Boc).

[1482] Cyclopropylamine was coupled with (2R, 4R)-4-hydroxy-pyrrolidine-1,2- dicarboxylic acid 1-tert-butyl ester (8 g), EDC, HOBt, TEA in DMF to give 5 g of (2R, 4R)-2-cyclopropylcarbamoyl-4-hydroxy-pyrrolidine-1-carboxyli c acid tert-butyl ester as a white semi-solid.

[14831 1H NMR (400 MHz, DMSO-d6) 8 4.06 (m, 1H), 3.97 (m, 1H), 3.42 (m, 1H), 3.15 (m, 1H), 2.62 (m, 1H), 2.23 (m, l H), 1.64 (m, 1H), 1.33 (Boc), 0.61 (m, 2H), 0.42 (m, 2H).

[1484] (2R, 4R)-2-Cyclopropylcarbamoyl-4-hydroxy-pyrrolidine-1-carboxyli c acid tert-butyl ester (5 g) was deprotected using 50 mL of 30% TFA in DCM at rt for 2 hours to give 3g of (2R, 4R)-4-hydroxy-pyrrolidine-2-carboxylic acid cyclopropylamide as a light yellow oil.

[1485]'H NMR (400 MHz, DMSO-d6) 8 4.32 (m, 1H), 4.1 (m, 1H), 3.2 (m, 2H), 2.67 (m, 1H), 2.35 (m, 1H), 1.85 (m, 1H), 0.67 (m, 2H),. 0.45 (m, 2H). [1486] (2R, 4R)-4-Hydroxy-pyrrolidine-2-carboxylic acid cyclopropylamide (3 g) was reduced using LAH (2 g) in THF (150 mL) to give 1 g of (3R, 5R)-5- cyclopropylaminomethyl-pyrrolidin-3-ol.

[1487] To a mixture of 2- [4- (3-fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (100 mg, 0.28 mmol), EDC (64 mg, 1.2 eq.), HOBt (45 mg, 1.2 eq.) in DMF (3 mL) was added TEA (0.098 mL) and (3R, 5R)-5-cyclopropylaminomethyl-pyrrolidin-3-ol. The mixture was stirred at rt for overnight. After the usual work up, 65 mg of the titled compound was obtained as a yellow solid.

[1488] 1H NMR (400 MHz, DMSO-d6) 8 10.95 (s, 1H, NH), 7.46 (m, 1H), 7.19 (m, 5H), 6.94 (d, 1H), 6.76 (d, 1H), 6.16 (s, 1H), 4.1 (m, 2H), 4.0 (m, 1H), 3.48 (m, 1H), 3.16 (m, 1H), 2.80 (m, 1H), 2.55 (d, 1H), 2.33 (s, 3H, CH3), 2.15 (m, 2H), 1.72 (m, 1H), 0.34 (m, 2H), 0.2 (m, 2H).

[1489] MS m/z 501.4 [M++1].

Example 409 2-[4-(2,3-Difluoro-phenyl)-2-oxo-1,2-dihydro-indol-(3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (3- cyclopropylamino-2-hydroxy-propyl)-amide [1490] Red solid.

[1491] MS m/z 491. 3 [M-1].

Example 410 2- [4- (2, 3-Difluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (2-hydroxy- 3-pyrrolidin-1-yl-propyl)-amide [1492] Red solid.

[1493] 1H NMR (400 MHz, DMSO-d6) 8 13.82 (s, 1H, NH), 11.20 (s, 1H, NH), 8. 0 (dd, 2H), 7.69 (m, 1H), 7.65 (m, 1H), 7.44 (m, 1H), 7.27 (m, 1H), 7.23 (t, 1H), 7.14 (m, 1H), 6.98 (dd, 1H), 6.80 (dd, 1H), 6.47 (m, 1H), 3.77 (m, lh), 3.20 (m, 1H), 3.05 (m, 1H), 2.31 (s, 3H, CH3), 1.82 (m, 4H), 1.63 (m, 2H), 1.1 (m, 1H), 0.8 (m, 4H).

. [1494] MS m/z 505.4 [M-1].

Example 411 4-(2,3-Difluoro-phenyl)-3-[1-{3-[(S)-2-((R)-3-hydroxy-pyrrol idin-1- ylmethyl)-pyrrolidine-l-carbonyl]-5-methyl-lH-pyrrol-2-yl}-m eth- (Z)-ylidene]-1, 3-dihydro-indol-2-one [14951 Yellow solid.

[1496] MS m/z 531. 5 [M-1].

Example 412 4-(2,3-Difluoro-phenyl)-3-[1-{3-[(S)-2-((S)-3-fluoro-pyrroli din-1- ylmethyl)-pyrrolidine-l-carbonyl]-5-methyl-lH-pyrrol-2-yl}-m eth- (Z)-ylidene]-1,3-dihydro-indol-2-one [14971 Yellow solid.

[1498] MS m/z 533.5 [M-1].

Example 413 3-[1-[3-((S)-3-Cyclopropylaminomethyl-piperidine-1-carbonyl) -5- methyl-1H-pyrrol-2-yl]-methyl-(Z)-ylidene]-4-(3-fluoro-pheny l)-1,3- dihydro-indol-2-one [1499] Yellow solid.

[1500] MS m/z 497. 6 [M-1].

Example 414 4-(4-Chloro-phenyl)-3-[1-[3-((S)-3-cyclopropylaminomethyl- piperidine-l-carbonyl)-5-methyl-1H-pyrrol-2-yl]-meth- (Z)- ylidene]-1,3-dihydro-indol-2-one [1501] Yellow solid.

[1502] MS m/z 513.6 [M-1].

Example 415 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (2-hydroxy- 3-pyrrolidin-1-yl-propyl)-methyl-amide 11503] Yellow solid.

[1504] 1H NMR (400 MHz, DMSO-d6) 6 13.56 (s, 1H, NH), 11.01 (br s, 1H, NH), 7.46 (m, 1H), 7.24 (m, 1H), 7.17 (m, 3H), 6.91 (m, 1H), 6.85 (s, 1H), 6.74 (d, 1H), 6.09 (s, 1H), 4.70 (m, 1H), 3.55 (m, 1H), 2.93 (m, 1H), 2.83 (s, 3H, CH3), 2.25 (m, 4H), 2.12 (m, 4H), 1.70 (m, 2H), 1.51 (m, 3H).

[1505] MS m/z 503.4 [M++1].

Example 416 2- [4- (3-Fluoro-phenyl)-2-oxo-1, 2-dihydro-indol- (3Z)- ylidenemethyl]-5-methyl-lH-pyrrole-3-carboxylic acid (3- cyclopropylamino-2-hydroxy-propyl)-amide [1506] Yellow solid.

[1507] 1H NMR (400 MHz, DMSO-d6) # 13.85 (s, 1H, NH), 11.14 (s, 1H, NH), 8. 0 (s, 1H), 7.83 (t, 1H), 7.44 (m, 1H), 7.18 (m, 4H), 6.93 (dd, 1H), 6.78 (dd, 1H), 6.42 (d, 1H), 3.61 (m, 1H), 3.14 (m, 2H), 3.02 (m, 2H), 2.5-2.62 (m, 3H), 2.31 (s, 3H, CH3), 2.13 (m, 2H).

[1508] MS mlz 475.2 [M++1].

Example 417 4- (3-Fluoro-phenyl)-3- 1- 4- (2-pyrrolidin-1-yl-ethyl)-4, 5,6,7- tetrahydro-lH-indol-2-yl]-meth- (Z)-ylidene]-1, 3-dihydro-indol-2- one [1509] 4- (2-Pyrrolidin-1-yl-ethyl)-4, 5,6, 7-tetrahydro-1H-indole-2-carbaldehyde (0.2 mmol) was condensed with 4- (3-fluoro-phenyl)-1, 3-dihydro-indol-2-one (0.2 mmol) and piperidine (2 drops) in ethanol at rt for overnight. The solvent was removed and the residue was purified on a silica gel column to give 25 mg of the titled compound as a yellow solid.

[1510] 1H NMR (400 MHz, CD30D) 8 7.52 (m, 1H), 7.14-7.24 (m, 4H), 6.94 (d, 1H), 6.8 (d, 1H), 6.74 (s, 1H), 6.07 (s, 1H), 3.22 (m, 4H), 3.12 (m, 2H), 2.70 (m, 3H), 2.01 (m, 6H), 1.95 (m, 1H), 1.75 (m, 2H), 1.42 (m, 1H).

[1511] MS m/z 456 [M++1].

Biological Evaluation [1512] It will be appreciated that, in any given series of compounds, a range of biological activities will be observed. In its presently preferred aspects, this invention relates to novel 4-aryl substituted indolinones capable of modulating, regulating and/or inhibiting protein kinase activity. The following assays may be employed to. select those compounds demonstrating the optimal degree of the desired activity.

I. Assay Procedures [1513] The following in vitro assays may be used to determine the level of activity and effect of the different compounds of the present invention on one or more of the PKs. Similar assays can be designed along the same lines for any PK using techniques well known in the art.

[1514] Several of the assays described herein are performed in an ELISA (Enzyme- Linked Immunosorbent Sandwich Assay) format (Voller, et al., 1980,"Enzyme- Linked Immunosorbent Assay,"Manual of Clinical Immunology, 2d ed., Rose and Friedman, Am. Soc. Of Microbiology, Washington, D. C., pp. 359-371). The general procedure is as follows: a compound is introduced to cells expressing the test kinase, either naturally or recombinantly, for a selected period of time after which, if the test kinase is a receptor, a ligand known to activate the receptor is added. The cells are lysed and the lysate is transferred to the wells of an ELISA plate previously coated with a specific antibody recognizing the substrate of the enzymatic phosphorylation reaction. Non-substrate components of the cell lysate are washed away and the amount of phosphorylation on the substrate is detected with an antibody specifically recognizing phosphotyrosine compared with control cells that were not contacted with a test compound.

[1515] The presently preferred protocols for conducting the ELISA experiments for specific PKs is provided below. However, adaptation of these protocols for determining the activity of compounds against other RTKs, as well as for CTKs and STKs, is well within the scope of knowledge of those skilled in the art. Other assays described herein measure the amount of DNA made in response to activation of a test kinase, which is a general measure of a proliferative response. The general procedure for this assay is as follows: a compound is introduced to cells expressing the test kinase, either naturally or recombinantly, for a selected period of time after which, if the test kinase is a receptor, a ligand known to activate the receptor is added.

After incubation at least overnight, a DNA labeling reagent such as 5- bromodeoxyuridine (BrdU) or H3-thymidine is added. The amount of labeled DNA is detected with either an anti-BrdU antibody or by measuring radioactivity and is compared to control cells not contacted with a test compound.

GST-FLK-1 BIOASSAY [1516] This assay analyzes the tyrosine kinase activity of GST-Flkl on poly (glu-tyr) peptides.

Materials and Reagents: 1. Coming 96-well ELISA plates (Corning Catalog No. 25805-96).

2. poly (glu-tyr) 4: 1, lyophilizate (Sigma Catalog No. P0275), 1 mg/ml in sterile PBS.

3. PBS Buffer: for 1 L, mix 0.2 g KH2PO4, 1.15 g Na2HP04, 0.2 g KCI and 8 g NaCl in approx. 900ml dH20. When all reagents have dissolved, adjust the pH to 7.2 with HC1. Bring total volume to 1 L with dH20.

4. PBST Buffer: to 1 L of PBS Buffer, add 1.0 ml Tween-20.

5. TBB-Blocking Buffer: for 1 L, mix 1.21 g TRIS, 8.77 g NaCl, 1 ml TWEEN-20 in approximately 900 ml dH20. Adjust pH to 7.2 with HC1. Add 10 g BSA, stir to dissolve. Bring total volume to 1 L with dH2O. Filter to remove particulate matter.

6.1% BSA in PBS : add 10 g BSA to approx. 990 ml PBS buffer, stir to dissolve. Adjust total volume to 1 L with PBS buffer, filter to remove particulate matter.

7.50 mM Hepes pH 7.5.

8. GST-Flklcd purified from sf9 recombinant baculovirus transformation (SUGEN, Inc.).

9.4% DMSO in dH20.

10.10 mM ATP in dH2O.

11.40 mM MnCl2 12. Kinase Dilution Buffer (KDB): mix 10 ml Hepes (pH 7.5), 1 ml 5M NaCl, 40 n. L 100 mM sodium orthovanadate and 0.4 ml of 5% BSA in dH20 with 88.56 ml dH20.

13. NUNC 96-well V bottom polypropylene plates, Applied Scientific Catalog # AS-72092 14. EDTA: mix 14.12 g ethylenediaminetetraacetic acid (EDTA) with approx. 70 ml dH20. Add 10 N NaOH until EDTA dissolves. Adjust pH to 8.0. Adjust total volume to 100 ml with dH2O.

15.1° and 2° Antibody Dilution Buffer: mix 10 ml of 5% BSA in PBS buffer with 89.5 ml TBST.

16. Anti-phosphotyrosine rabbit polyclonal antisera (SUGEN, Inc.) 17. Goat anti-rabbit HRP conjugate.

18. ABST solution: To approx. 900 ml dH20 add 19.21 g citric acid and 35.49 g Na2HP04. Adjust pH to 4.0 with phosphoric acid. Add 2,2'- Azinobis (3-ethyl-benzthiazoline-6-sulfonic acid (ABTS, Sigma, Cat.

No. A-1888, hold for approx. I/2 hour, filter.

19.30% Hydrogen Peroxide.

20. ABST/H2O2 : add 3 ! 11 of H202 to 15 ml of ABST solution.

21.0.2MHC1.

Procedure: 1. Coat Coming 96-well ELISA plates with 2 pg of polyEY in 100 p1 PBS/well, hold at room temperature for 2 hours or at 4° C overnight.

Cover plates to prevent evaporation.

2. Remove unbound liquid from wells by inverting plate. Wash once with TBST. Pat the plate on a paper towel to remove excess liquid.

3. Add 100 µl of 1% BSA in PBS to each well. Incubate, with shaking, for 1 hr. at room temperature.- 4. Repeat step 2.

5. Soak wells with 50 mM HEPES (pH7.5,150 Ill/well).

6. Dilute test compound with dH20/4% DMSO to 4 times the desired final assay concentration in 96-well polypropylene plates.

7. Add 25 z1 diluted test compound to each well of ELISA plate. In control wells, place 25 ul of dH20/4% DMSO.

8. Dilute GST-Flkl 0.005 Ug (5 ng)/well in KDB.

9. Add 50 1 of diluted enzyme to each well.

10. Add 25 p1 0. 5 M EDTA to negative control wells.

11. Add 25 µl of 40 mM MnCl2 with 4X ATP (2 zM) to all wells (100 µl final volume, 0.5 zip ATP final concentration in each well).

12. Incubate, with shaking, for 15 minutes at room temperature.

13. Stop reaction by adding 25 ul of 500 mM EDTA to each well.

14. Wash 3X with TBST and pat plate on paper towel to remove excess liquid.

15. Add 100 p1 per well anti-phosphotyrosine antisera, 1: 10, 000 dilution in antibody dilution buffer. Incubate, with shaking, for 90 min. at room temperature.

16. Wash as in step 14.

17. Add 100 gl/well of goat anti-rabbit HRP conjugate (1: 6,000 in antibody dilution buffer). Incubate, with shaking, for 90 minutes are room temperature.

18. Wash as in Step 14.

19. Add 100 p1 room temperature ABST/H202 solution to each well.

20. Incubate, with shaking for 15 to 30 minutes at room temperature.

21. If necessary, stop reaction by adding 100 pt1 of 0.2 M HCI to each well.

22. Read results on Dynatech MR7000 ELISA reader with test filter at 410 nM and reference filter at 630 nM.

PYK2 BIOASSAY [1517] This assay is used to measure the in vitro kinase activity of HA epitope- tagged full length pyk2 (FL. pyk2-HA) in an ELISA assay.

Materials and Reagents: 1. Coming 96-well ELISA plates.

2.12CA5 monoclonal anti-HA antibody (SUGEN, Inc.) 3. PBS (Dulbecco's Phosphate-Buffered Saline (Gibco Catalog # 450- 1300EB) 4. TBST Buffer: for 1 L, mix 8. 766 g NaCI, 6.057 g TRIS and 1 ml of 0.1% Triton X-100 in approx. 900 ml dH20. Adjust pH to 7.2, bring volume to 1 L.

5. Blocking Buffer: for 1 L, mix 100 g 10% BSA, 12.1 g 100 mM TRIS, 58.44 g 1M NaCl and 10 mL of 1% TWEEN-20.

6. FL. pyk2-HA from sf9 cell lysates (SUGEN, Inc.).

7.4% DMSO in MilliQue H20.

8.10 mM ATP in dH20.

9.1M MnCl2.

10. 1M MgCl2.

11.1M Dithiothreitol (DTT).

12. lOX Kinase buffer phosphorylation: mix 5.0 ml 1M Hepes (pH 7.5), 0.2 ml 1M MnCl2, 1. 0 ml 1 M MgClz, 1.0 ml 10% Triton X-100 in 2.8 ml dH20. Just prior to use, add 0.1 ml 1M DTT.

13. NUNC 96-well V bottom polypropylene plates.

14.500 mM EDTA in dH20.

15. Antibody dilution buffer: for 100 mL, 1 mL 5% BSA/PBS and 1 mL 10% Tween-20 in 88 mL TBS.

16. HRP-conjugated anti-Ptyr (PY99, Santa Cruz Biotech Cat. No. SC- 7020).

17. ABTS, Moss, Cat. No. ABST-2000.

18.10% SDS.

Procedure: 1. Coat Coming 96 well ELISA plates with 0.5 u. g per well 12CA5 anti- HA antibody in 100 vul PBS. store overnight at 4°C.

2. Remove unbound HA antibody from wells by inverting plate. Wash plate with dH2O. Pat the plate on a paper towel to remove excess liquid.

3. Add 150 p1 Blocking Buffer to each well. Incubate, with shaking, for 30 min at room temperature.

4. Wash plates with TBS-T.

5. Dilute lysate in PBS (1.5 ag lysate/100 J. I PBS).

6. Add 100 p1 of diluted lysate to each well. Shake at room temperature for 1 hr.

7. Wash as in step 4.

8. Add 50 p1 of 2X kinase Buffer to ELISA plate containing captured pyk2-HA.

9. Add 25 uL of 400 uM test compound in 4% DMSO to each well. For control wells use 4% DMSO alone.

10. Add 25 cl of 0.5 M EDTA to negative control wells.

11. Add 25 fil of 20 zM ATP to all wells. Incubate, with shaking, for 10 minutes.

12. Stop reaction by adding 25 µl 500 mM EDTA (pH 8. 0) to all wells.

13. Wash as in step 4.

14. Add 100 uL HRP conjugated anti-Ptyr diluted 1: 6000 in Antibody Dilution Buffer to each well. Incubate, with shaking, for 1 hr. at room temperature.

15. Wash plate 3X with TBST and 1X with PBS.

16. Add 100 uL of ABST solution to each well.

17. If necessary, stop the development reaction by adding 20 uL 10% SDS to each well.

18. Read plate on ELISA reader with test filter at 410 nM and reference filter at 630 nM.

FGFR1 BIOASSAY [1518] This assay is used to measure the in vitro kinase activity of FGF1-R in an ELISA assay.

Materials and Reagents: 1. Costar 96-well ELISA plates (Corning Catalog # 3369).

2. Poly (Glu-Tyr) (Sigma Catalog # P0275).

3. PBS (Gibco Catalog &num 450-1300EB) 4.50 mM Hepes Buffer Solution.

5. Blocking Buffer (5% BSA/PBS).

6. Purified GST-FGFR1 (SUGEN, Inc.) 7. Kinase Dilution Buffer.

Mix 500 p1 1M Hepes (GIBCO), 20 tl 5% BSA/PBS, 10 p1 lOOmM sodium orthovanadate and 50 {il 5M NaCl.

8. 10mM ATP 9. ATP/MnCI2 phosphorylation mix: mix 20 u. L ATP, 400 µL 1M MnCl2 and 9.56 ml dH2O.

10. NUNC 96-well V bottom polypropylene plates (Applied Scientific Catalog &num AS-72092).

11.0.5M EDTA.

12.0.05% TBST Add 500 pL TWEEN to 1 liter TBS.

13. Rabbit polyclonal anti-phosphotyrosine serum (SUGEN, Inc.).

14. Goat anti-rabbit IgG peroxidase conjugate (Biosource, Catalog # ALI0404).

15. ABTS Solution.

16. ABTS/H202 solution.

Procedure: 1. Coat Costar 96 well ELISA plates with 1 ug per well Poly (Glu-Tyr) in' 1001il PBS. Store overnight at 4° C.

2. Wash coated plates once with PBS.

3. Add 150 L of5% BSA/PBS Blocking Buffer to each well. Incubate, with shaking, for 1 hr at room temperature.

4. Wash plate 2x with PBS, then once with 50mM Hepes. Pat plates on a paper towel to remove excess liquid and bubbles.

5. Add 25pL of 0.4 mM test compound in 4% DMSO or 4% DMSO alone (controls) to plate.

6. Dilute purified GST-FGFR1 in Kinase Dilution Buffer (5 ng kinase/50ul KDB/well).

7. Add 50pL of diluted kinase to each well.

8. Start kinase reaction by adding 25ul/well of freshly prepared ATP/Mn++ (0.4 ml 1M MnCl2, 40 pL 10 mM ATP, 9.56 ml dH20), freshly prepared).

9. Stop reaction with 25gL of 0. 5M EDTA.

10. Wash plate 4x with fresh TBST.

11. Make up Antibody Dilution Buffer: For 50 ml, mix 5 ml of 5% BSA, 250 ul of 5% milk and 50 ul of lOOmM sodium vanadate, bring to final volume with 0.05% TBST.

12. Add 100 Al per well of anti-phosphotyrosine (1: 10000 dilution in ADB). Incubate, with shaking for 1 hr. at room temperature.

13. Wash as in step 10.

14. Add 100 j. l per well of Biosource Goat anti-rabbit IgG peroxidase conjugate (1: 6000 dilution in ADB). Incubate, with shaking for 1 hr. at room temperature.

15. Wash as in step 10 and then with PBS to remove bubbles and excess TWEEN.

16. Add 100 Al of ABTS/H202 solution to each well.

17. Incubate, with shaking, for 10 to 20 minutes. Remove any bubbles.

18. Read assay on Dynatech MR7000 ELISA reader: test filter at 410 nM, reference filter at 630 nM.

PDGFR BIOASSAY [1519] This assay is used to the in vitro kinase activity of PDGFR in an ELISA assay.

Materials and Reagents: 1. Coming 96-well ELISA plates 2.28D4C10 monoclonal anti-PDGFR antibody (SUGEN, Inc.).

3. PBS.

4. TBST Buffer.

5. Blocking Buffer (same as for EGFR bioassay).

6. PDGFR-ß expressing NIH 3T3 cell lysate (SUGEN, Inc.).

7. TBS Buffer.

8. TBS + 10% DMSO.

9. ATP.

10. MnCl2.

11. Kinase buffer phosphorylation mix: for 10 ml, mix 250 p1 1M TRIS, 200 p1 SM NaCI, 100 p1 1M MnCl2 and 50p1 100 mM Triton X-100 in enough dH20 to make 10 ml.

12. NUNC 96-well V bottom polypropylene plates.

13. EDTA.

14. Rabbit polyclonal anti-phosphotyrosine serum (SUGEN, Inc.).

15. Goat anti-rabbit IgG peroxidase conjugate (Biosource Cat. No.

ALI0404).

16. ABTS.

17. Hydrogen peroxide, 30% solution.

18. ABTS/H202- 19.0.2 M HCI.

Procedure: 1. Coat Coming 96 well ELISA plates with 0.5 Mg 28D4C10 in 100 p1 PBS per well, hold overnight at 4° C.

2. Remove unbound 28D4C10 from wells by inverting plate to remove liquid. Wash Ix with dH2O. Pat the plate on a paper towel to remove excess liquid.

3. Add 150 p1 of Blocking Buffer to each well. Incubate for 30 min. at room temperature with shaking.

4. Wash plate 3x with deionized water, then once with TBST. Pat plate on a paper towel to remove excess liquid and bubbles.

5. Dilute lysate in HNTG (10 µglysate/100 µl HNTG).

6. Add 100 u. I of diluted lysate to each well. Shake at room temperature for 60 min.

7. Wash plates as described in Step 4.

8. Add 80 p. 1 working kinase buffer mix to ELISA plate containing captured PDGFR.

9. Dilute test compound 1: 10 in TBS in 96-well polypropylene plates.

10. Add 10 ul diluted test compound to ELISA plate. To control wells, add 10 p1 TBS + 10% DMSO. Incubate with shaking for 30 minutes at room temperature.

11. Add 10 nl ATP directly to all wells except negative control well (final well volume should be approximately 100 ul with 20 D. M ATP in each well.) Incubate 30 minutes with shaking.

12. Stop reaction by adding 10 p1 of EDTA solution to each well.

13. Wash 4x with deionized water, twice with TBST.

14. Add 100 lil anti-phosphotyrosine (1: 3000 dilution in TBST) per well.

Incubate with shaking for 30-45 min. at room temperature.

15. Wash as in Step 4.

16. Add 100 J. I Biosource Goat anti-rabbit IgG peroxidase conjugate (1: 2000 dilution in TBST) to each well. Incubate with shaking for 30 min. at room temperature.

17. Wash as in Step 4.

18. Add 100 µl of ABTS/H2O2 solution to each well.

19. Incubate 10 to 30 minutes with shaking. Remove any bubbles.

20. If necessary stop reaction with the addition of 100 ul 0. 2 M HC1 per well.

'21. Read assay on Dynatech MR7000 ELISA reader with test filter at 410 nM and reference filter at 630 nM.

CELLULAR HER-2 KINASE ASSAY [1520] This assay is used to measure HER-2 kinase activity in whole cells in an ELISA format.

Materials and Reagents: 1. DMEM (GIBCO Catalog #11965-092).

2. Fetal Bovine Serum (FBS, GIBCO Catalog #16000-044), heat inactivated in a water bath for 30 min. at 56° C.

3. Trypsin (GIBCO Catalog #25200-056).

4. L-Glutamine (GIBCO Catalog #25030-081).

5. HEPES (GIBCO Catalog #15630-080).

6. Growth Media: Mix 500 ml DMEM, 55 ml heat inactivated FBS, 10 ml HEPES and 5.5 ml L-Glutamine.

7. Starve Media: Mix 500 ml DMEM, 2.5 ml heat inactivated FBS, 10 ml HEPES and 5.5 ml L-Glutamine.

8. PBS.

9. Flat Bottom 96-well Tissue Culture Micro Titer Plates (Corning Catalog # 25860).

10.15 cm Tissue Culture Dishes (Corning Catalog #08757148).

11. Coming 96-well ELISA Plates.

12. NUNC 96-well V bottom polypropylene plates.

13. Costar Transfer Cartridges for the Transtar 96 (Costar Catalog #7610).

14. SUMO 1 : monoclonal anti-EGFR antibody (SUGEN, Inc.).

15. TBST Buffer.

16. Blocking Buffer: 5% Carnation Instant Milk@ in PBS.

17. EGF Ligand: EGF-201, Shinko American, Japan. Suspend powder in 100 cl of lOmM HCI. Add lOOuL lOmM NaOH. Add 800 pL PBS and transfer to an Eppendorf tube, store at-20°C until ready to use.

18. HNTG Lysis Buffer: For Stock 5X HNTG, mix 23.83 g Hepes, 43.83 g NaCl, 500 ml glycerol and 100 ml Triton X-100 and enough dH20 to make 1 L of total solution.

For 1X HNTG*, mix 2 ml 5X HNTG, 100 uL O. 1M Na3V04, 250 gL 0.2M Na4P207 and 100 gL EDTA.

19. EDTA.

20. Na3V04 : To make stock solution, mix 1.84 g Na3VO4 with 90 ml dH20. Adjust pH to 10. Boil in microwave for one minute (solution becomes clear). Cool to room temperature. Adjust pH to 10. Repeat heating/cooling cycle until pH remains at 10.

21.200mMNa4P207.

22. Rabbit polyclonal antiserum specific for phosphotyrosine (anti-Ptyr antibody, SUGEN, Inc.).

23. Affinity purified antiserum, goat anti-rabbit IgG antibody, peroxidase conjugate (Biosource Cat &num ALI0404).

24. ABTS Solution.

25.30 % Hydrogen peroxide solution.

26. ABTS/H202.

27.0.2 M HCI.

Procedure: 1. Coat Coming 96 well ELISA plates with SUMO1 at 1.0 ug per well in PBS, 100 ul final volume/well. Store overnight at 4°C.

2. On day of use, remove coating buffer and wash plate 3 times with dH20 and once with TBST buffer. All washes in this assay should be done in this manner, unless otherwise specified.

3. Add 100 gL of Blocking Buffer to each well. Incubate plate, with shaking, for 30 min. at room temperature. Just prior to use, wash plate.

4. Use EGFr/HER-2 chimera/3T3-C7 cell line for this assay.

5. Choose dishes having 80-90 % confluence. Collect cells by trypsinization and centrifuge at 1000 rpm at room temperature for 5 min.

6. Resuspend cells in starve medium and count with trypan blue.

Viability above 90% is required. Seed cells in starve medium at a density of 2,500 cells per well, 90 pL per well, in a 96 well microtiter plate. Incubate seeded cells overnight at 37° under 5% CO2.

7. Start the assay two days after seeding.

8. Test compounds are dissolved in 4% DMSO. Samples are then further diluted directly on plates with starve-DMEM. Typically, this dilution will be 1: 10 or greater. All wells are then transferred to the cell plate at a further 1: 10 dilution (101 sample and media into 90 psi of starve media). The final DMSO concentration should be 1% or lower. A standard serial dilution may also be used.

9. Incubate under 5% C02 at 37°C for 2 hours.

10. Prepare EGF ligand by diluting stock EGF (16.5 uM) in warm DMEM to 150 nM.

11. Prepare fresh HNTG* sufficient for 100 AL per well; place on ice.

12. After 2 hour incubation with test compound, add prepared EGF ligand to cells, 50 AL per well, for a final concentration of 50 nM. Positive control wells receive the same amount of EGF. Negative controls do not receive EGF. Incubate at 37° C for 10 min.

13. Remove test compound, EGF, and DMEM. Wash cells once with PBS.

14. Transfer HNTG* to cells, 100 uL per well. Place on ice for 5 minutes.

Meanwhile, remove blocking buffer from ELISA plate and wash.

15. Scrape cells from plate with a micropipettor and homogenize cell material by repeatedly aspirating and dispensing the HNTG* lysis buffer. Transfer lysate to a coated, blocked, washed ELISA plate.

16. Incubate, with shaking, at room temperature for 1 hr.

17. Remove lysate, wash. Transfer freshly diluted anti-Ptyr antibody (1: 3000 in TBST) to ELISA plate, 100 AL per well.

18. Incubate, with shaking, at room temperature, for 30 min.

19. Remove anti-Ptyr antibody, wash. Transfer freshly diluted BIOSOURCE antibody to ELISA plate (1 : 8000 in TBST, 100 uL per well).

20. Incubate, with shaking, at room temperature for 30 min.

21. Remove BIOSOURCE antibody, wash. Transfer freshly prepared ABTS/H202 solution to ELISA plate, 100 gL per well.

22. Incubate, with shaking, for 5-10 minutes. Remove any bubbles.

23. Stop reaction by adding 100 AL of 0.2M HC1 per well.

24. Read assay on Dynatech MR7000 ELISA reader with test filter set at 410 nM and reference filter at 630 nM.

CDK2/CYCLIN A ASSAY [15211 This assay is used to measure the in vitro serine/threonine kinase activity of human cdk2/cyclin A in a Scintillation Proximity Assay (SPA).

Materials and Reagents.

1. Wallac 96-well polyethylene terephthalate (flexi) plates (Wallac Catalog # 1450-401).

2. Amersham Redivue [y33P] ATP (Amersham catalog &num AH 9968).

3. Amersham streptavidin coated polyvinyltoluene SPA beads (Amersham catalog &num RPNQ0007). The beads should be reconstituted in PBS without magnesium or calcium, at 20 mg/ml.

4. Activated cdk2/cyclin A enzyme complex purified from Sf9 cells (SUGEN, Inc.).

5. Biotinylated peptide substrate (Debtide). Peptide biotin-X- PKTPKKAKKL is dissolved in dHaO at a concentration of 5 mg/ml.

6.20% DMSO in dH20.

7. Kinase buffer: for 10 ml, mix 9.1 ml dH20,0.5 ml TRIS (pH 7.4), 0.2 ml 1M MgCl2, 0.2 ml 10% NP40 and 0.02 ml 1M DTT, added fresh just prior to use.

8.10 mM ATP in dH20.

9.1M Tris, pH adjusted to 7.4 with HCI.

10. 1M MgC12.

11.1M DTT.

12. PBS (Gibco Catalog # 14190-144).

13. O. 5M EDTA.

14. Stop solution: For 10 ml, mix 9.25 ml PBS, 0.05 ml 10 mM ATP, 0.1 ml 0.5 M EDTA, 0.1 ml 10% Triton X-100 and 1.5 ml of 50 mg/ml SPA beads.

Procedure: 1. Prepare solutions of test compounds at 4x the desired final concentration in 5% DMSO. Add 10 uL to each well. For positive and negative controls, use 10 gL 20% DMSO alone in wells.

2. Dilute the peptide substrate (deb-tide) 1: 250 with dH20 to give a final concentration of 0.02 mg/ml.

3. Mix 24 uL 0.1 mM ATP with 24 'Ci y33P ATP and enough dH20 to make 600 uL : 4. Mix diluted peptide and ATP solutions 1: 1 (600 gL + 600 oL per plate). Add 10 gL of this solution to each well.

5. Dilute 5 AL of cdk2/cyclin A solution into 2.1 ml 2x kinase buffer (per plate). Add 20 uL enzyme per well. For negative controls, add 20 pL 2x kinase buffer without enzyme.

6. Mix briefly on a plate shaker; incubate for 60 minutes.

7. Add 200 uL stop solution per well.

8. Let stand at least 10 min.

9. Spin plate at approx. 2300 rpm for 10-15 min.

10. Count plate on Trilux reader.

MET TRANSPHOSPHORYLATION ASSAY [1522] This assay is used to measure phosphotyrosine levels on a poly (glutamic acid: tyrosine, 4: 1) substrate as a means for identifying agonists/antagonists of met transphosphorylation of the substrate.

Materials and Reagents: 1. Coming 96-well ELISA plates, Coming Catalog # 25805-96.

2. Poly (glu-tyr), 4: 1, Sigma, Cat. No; P 0275.

3. PBS, Gibco Catalog &num 450-1300EB 4.50 mM HEPES 5. Blocking Buffer: Dissolve 25 g Bovine Serum Albumin, Sigma Cat.

No A-7888, in 500 ml PBS, filter through a 4 pm filter.

6. Purified GST fusion protein containing the Met kinase domain, SUGEN, Inc.

7. TBST Buffer.

8.10% aqueous (MilliQue H20) DMSO.

9.10 mM aqueous (dH2O) Adenosine-5'-triphosphate, Sigma Cat. No. A- 5394.

10.2X Kinase Dilution Buffer: for 100 ml, mix 10 mL 1 M HEPES at pH 7.5 with 0.4 mL 5% BSA/PBS, 0.2 mL 0.1 M sodium orthovanadate and 1 mL 5M sodium chloride in 88.4 mL dHzO.

11.4X ATP Reaction Mixture: for 10 mL, mix 0.4 mL 1 M manganese chloride and 0.02 mL 0.1 M ATP in 9.56 mL dHzO.

12.4X Negative Controls Mixture: for 10 mL, mix 0.4 mL 1 M manganese chloride in 9.6 mL dH20.

13. NUNC 96-well V bottom polypropylene plates, Applied Scientific Catalog # S-72092 14.500 mM EDTA.

15. Antibody Dilution Buffer: for 100 mL, mix 10 mL 5% BSA/PBS, 0.5 mL 5% Carnations Instant Milk in PBS and 0.1 mL 0.1 M sodium orthovanadate in 88.4 mL TBST.

16. Rabbit polyclonal antophosphotyrosine antibody, SUGEN, Inc.

17. Goat anti-rabbit horseradish peroxidase conjugated antibody, Biosource, Inc.

18. ABTS Solution: for 1 L, mix 19.21 g citric acid, 35.49 g Na2HP04 and 500 mg ABTS with sufficient dH20 to make 1 L.

19. ABTS/H202 : mix 15. mL ABST solution with 2pL H202 five minutes before use.

20.0.2 M HC1 Procedure:' 1. Coat ELISA plates with 2 Mg Poly (Glu-Tyr) in 100 uL PBS, hold overnight at 4 ° C.

2. Block plate with 150 uL of 5% BSA/PBS for 60 min.

3. Wash plate twice with PBS then once with 50 mM Hepes buffer pH 7.4.

4. Add 50 gl of the diluted kinase to all wells. (Purified kinase is diluted with Kinase Dilution Buffer. Final concentration should be 10 ng/well.) 5. Add 25 uL of the test compound (in 4% DMSO) or DMSO alone (4% in dH20) for controls to plate.

6. Incubate the kinase/compound mixture for 15 minutes.

7. Add 25 gL of 40 mM MnCl2 to the negative control wells.

8. Add 25 pL ATP/MnCl2 mixture to the all other wells (except the negative controls). Incubate for 5 min.

9. Add 25 L 500 mM EDTA to stop reaction.

10. Wash plate 3x with TBST.

11. Add 100 pL rabbit polyclonal anti-Ptyr diluted 1: 10,000 in Antibody Dilution Buffer to each well. Incubate, with shaking, at room temperature for one hour.

12. Wash plate 3x with TBST.

13. Dilute Biosource HRP conjugated anti-rabbit antibody 1: 6,000 in Antibody Dilution buffer. Add 100 uL per well and incubate at room temperature, with shaking, for one hour.

14. Wash plate 1X with PBS.

15. Add 100 gl of ABTS/H202 solution to each well.

16. If necessary, stop the development reaction with the addition of 100 p. 1 of 0.2M HCl per well.

17. Read plate on Dynatech MR7000 ELISA reader with the test filter at 410 nM and the reference filter at 630 nM.

IGF-1 Transphosphorylation Assay [1523] This assay is used to measure the phosphotyrosine level in poly (glutamic acid: tyrosine, 4: 1) for the identification of agonists/antagonists of gst-IGF-1 transphosphorylation of a substrate.

Materials and Reagents: 1. Coming 96-well ELISA plates.

2. Poly (Glu-Tyr), 4: 1, Sigma Cat. No. P 0275.

3. PBS, Gibco Catalog # 450-1300EB.

4.50 mM HEPES 5. TBB Blocking Buffer: for 1 L, mix 100 g BSA, 12.1 gTRIS (pH 7.5), 58. 44 g sodium chloride and 10 mL 1% TWEEN-20.

6. Purified GST fusion protein containing the IGF-1 kinase domain (SUGEN, Inc.) 7. TBST Buffer: for 1 L, mix 6.057 g Tris, 8. 766 g sodium chloride and 0.5 ml TWEEN-20 with enough dH20 to make 1 liter.

8. 4% DMSO in Milli-Q H20.

9.10 mM ATP in dH20.

10.2X Kinase Dilution Buffer: for 100 mL, mix 10 mL 1 M HEPES (pH 7.5), 0.4 mL 5% BSA in dH20, 0.2 mL 0.1 M sodium orthovanadate and 1 mL 5 M sodium chloride with enough dH20 to make 100 mL.

11.4X ATP Reaction Mixture: for 10 mL, mix 0.4 mL 1 M MnCl2 and 0.008 mL 0.01 M ATP and 9.56 mL dH20.

12.4X Negative Controls Mixture: mix 0.4 mL 1 M MnCl2 in 9.60 mL du20.

13. NUNC 96-well V bottom polypropylene plates.

14.500 mM EDTA in dH20.

15. Antibody Dilution Buffer: for 100 mL, mix 10 mL 5% BSA in PBS, 0.5 mL 5% Carnation Instant Non-fat Milk in PBS and 0. 1 mL 0.1 M sodium orthovanadate in 88.4 mL TBST.

16. Rabbit Polyclonal antiphosphotyrosine antibody, SUGEN, Inc.

17. Goat anti-rabbit HRP conjugated antibody, Biosource.

18. ABTS Solution.

20. ABTS/H202 : mix 15 mL ABTS with 2 pL H2°2 5 minutes before using.

21.0.2MHClindH20.

Procedure: 1. Coat ELISA plate with 2.0 Ug/well Poly (Glu, Tyr), 4: 1 (Sigma P0275) in 100 gi PBS. Store plate overnight at 4° C.

2. Wash plate once with PBS.

3. Add 100 p1 of TBB Blocking Buffer to each well. Incubate plate for 1 hour with shaking at room temperature.

4. Wash plate once with PBS, then twice with 50 mM Hepes buffer pH 7.5.

5. Add 25 pL of test compound in 4% DMSO (obtained by diluting a stock solution of 10 mM test compound in 100% DMSO with dH20) to plate.

6. Add 10.0 ng of gst-IGF-1 kinase in 50 p1 Kinase Dilution Buffer to all wells.

7. Start kinase reaction by adding 25p1 4X ATP Reaction Mixture to all test wells and positive control wells. Add 25µl 4X Negative Controls Mixture to all negative control wells. Incubates for 10 minutes, with shaking, at room temperature.

8. Add 2510. 5M EDTA (pH 8.0) to all wells.

9. Wash plate 4x with TBST Buffer.

10. Add rabbit polyclonal anti-phosphotyrosine antisera at. a dilution of 1: 10,000 in 1OOKLI Antibody Dilution Buffer to all wells. Incubate, with shaking, at room temperature for 1 hour.

11. Wash plate as in step 9.

12. Add 100 pL Biosource anti-rabbit HRP at a dilution of 1: 10,000 in Antibody dilution buffer to all wells. Incubate, with shaking, at room temperature for 1 hour.

13. Wash plate as in step 9, follow with one wash with PBS to remove bubbles and excess Tween-20.

14. Develop by adding 1 00Ll/well ABTS/H202 to each well.

15. After about 5 minutes, read on ELISA reader with test filter at 410 nm and referenced filter at 630 nm.

BrdU INCORPORATION ASSAYS [1524] The following assays use cells engineered to express a selected receptor and then evaluate the effect of a compound of interest on the activity of ligand-induced DNA synthesis by determining BrdU incorporation into the DNA.

[1525] The following materials, reagents and procedure are general to each of the following BrdU incorporation assays. Variances in specific assays are noted.

General Materials and Reagents: 1. The appropriate ligand.

2. The appropriate engineered cells.

3. BrdU Labeling Reagent: 10 mM, in PBS, pH7.4 (Roche Molecular Biochemicals, Indianapolis, IN).

4. FixDenat: fixation solution (Roche Molecular Biochemicals, Indianapolis, IN).

5. Anti-BrdU-POD : mouse monoclonal antibody conjugated with peroxidase (Chemicon, Temecula, CA).

6. TMB Substrate Solution: tetramethylbenzidine (TMB, ready to use, Roche Molecular Biochemicals, Indianapolis, IN).

7. PBS Washing Solution: 1X PBS, pH 7.4.

8. Albumin, Bovine (BSA), fraction V powder (Sigma Chemical Co., USA).

General Procedure: 1. Cells are seeded at 8000 cells/well in 10% CS, 2mM Gln in DMEM, in a 96 well plate. Cells are incubated overnight at 37 C in 5% C02.

2. After 24 hours, the cells are washed with PBS, and then are serum- starved in serum free medium (0% CS DMEM with 0.1% BSA) for 24 hours.

3. On day 3, the appropriate ligand and the test compound are added to the cells simultaneously. The negative control wells receive serum free DMEM with 0.1% BSA only ; the positive control cells receive the ligand but no test compound. Test compounds are prepared in serum free DMEM with ligand in a 96 well plate, and serially diluted for 7 test concentrations.

4. After 18 hours of ligand activation, diluted BrdU labeling reagent (1: 100 in DMEM, 0.1% BSA) is added and the cells are incubated with BrdU (final concentration is 10 uM) for 1.5 hours.

5. After incubation with labeling reagent, the medium is removed by decanting and tapping the inverted plate on a paper towel. FixDenat solution is added (50 Rl/well) and the plates are incubated at room temperature for 45 minutes on a plate shaker.

6. The FixDenat solution is removed by decanting and tapping the inverted plate on a paper towel. Milk is added (5% dehydrated milk in PBS, 200 gl/well) as a blocking solution and the plate is incubated for 30 minutes at room temperature on a plate shaker.

7. The blocking solution is removed by decanting and the wells are washed once with PBS. Anti-BrdU-POD solution is added (1: 200 dilution in PBS, 1% BSA, 50 pI/well) and the plate is incubated for 90 minutes at room temperature on a plate shaker.

8. The antibody conjugate is removed by decanting and rinsing the wells 5 times with PBS, and the plate is dried by inverting and tapping on a paper towel.

9. TMB substrate solution is added (100 ll/well) and incubated for 20 minutes at room temperature on a plate shaker until color development is sufficient for photometric detection.

10. The absorbance of the samples are measured at 410 nm (in"dual wavelength"mode with a filter reading at 490 nm, as a reference wavelength) on a Dynatech ELISA plate reader.

EGF-Induced BrdU Incorporation Assay Materials and Reagents: 1. Mouse EGF, 201 (Toyobo Co., Ltd., Japan).

2.3T3/EGFRc7.

Remaining Materials and Reagents and Procedure, as above.

EGF-Induced Her-2-driven BrdU Incorporation Assay Materials and Reagents: 1. Mouse EGF, 201 (Toyobo Co., Ltd., Japan).

2.3T3/EGFr/Her2/EGFr (EGFr with a Her-2 kinase domain).

Remaining Materials and Reagents and Procedure, as above.

EGF-Induced Her-4-driven BrdU Incorporation Assay Materials and Reagents: 1. Mouse EGF, 201 (Toyobo Co., Ltd., Japan).

2.3T3/EGFr/Her4/EGFr (EGFr with a Her-4 kinase domain).

Remaining Materials and Reagents and Procedure, as above.

PDGF-Induced BrdU Incorporation Assay Materials and Reagents: 1. Human PDGF B/B (Boehringer Mannheim, Germany).

2.3T3/EGFRc7.

Remaining Materials and Reagents and Procedure, as above.

FGF-Induced BrdU Incorporation Assay Materials and Reagents: 1. Human FGF2/bFGF (Gibco BRL, USA).

2.3T3c7/EGFr Remaining Materials and Reagents and Procedure, as above.

IGFl-Induced BrdU Incorporation Assay Materials and Reagents: 1. Human, recombinant (G511, Promega Corp., USA) 2.3T3/IGFlr.

Remaining Materials and Reagents and Procedure, as above.

Insulin-Induced BrdU Incorporation Assay Materials and Reagents: 1. Insulin, crystalline, bovine, Zinc (13007, Gibco BRL, USA).

2.3T3/H25.

Remaining Materials and Reagents and Procedure, as above.' HGF-Induced BrdU Incorporation Assay Materials and Reagents: 1. Recombinant human HGF (Cat. No. 249-HG, R&D Systems, Inc.

USA).

2. BxPC-3 cells (ATCC CRL-1687).

Remaining Materials and Reagents, as above.

Procedure: 1. Cells are seeded at 9000 cells/well in RPMI 10% FBS in a 96 well plate. Cells are incubated overnight at 37 C in 5% C02.

2. After 24 hours, the cells are washed with PBS, and then are serum starved in 100 jl serum-free medium (RPMI with 0.1% BSA) for 24 hours.

3. On day 3,25 u. l containing ligand (prepared at 1 pg/ml in RPMI with 0.1% BSA; final HGF conc. is 200 ng/ml) and test compounds are added to the cells. The negative control wells receive 25 PI serum-free RPMI with 0.1% BSA only; the positive control cells receive the ligand (HGF) but no test compound. Test compounds are prepared at 5 times their final concentration in serum-free RPMI with ligand in a 96 well plate, and serially diluted to give 7 test concentrations. Typically, the highest final concentration of test compound is 100 pM, and 1: 3 dilutions are used (i. e. final test compound concentration range is 0.137-100 pM).

4. After 18 hours of ligand activation, 12.5 p1 of diluted BrdU labeling reagent (1: 100 in RPMI, 0.1% BSA) is added to each well and the cells are incubated with BrdU (final concentration is 10 M) for 1 hour.

5. Same as General Procedure.

6. Same as General Procedure.

7. The blocking solution is removed by decanting and the wells are washed once with PBS. Anti-BrdU-POD solution (1: 100 dilution in PBS, 1% BSA) is added (100 pl/well) and the plate is incubated for 90 minutes at room temperature on a plate shaker.

8. Same as General Procedure.

9. Same as General Procedure.

10. Same as General Procedure.

Exponential BrdU Incorporation Assay [15261 This assay is used to measure the proliferation (DNA synthesis) of exponentially growing A431 cells. The assay will screen for compounds that inhibit cell cycle progression.

Materials and Reagents: [1527] Healthy growing A431 cells. The remainder of the Materials and Reagents are the same as listed above in the general protocol section.

Procedure: 1. A431 cells are seeded at 8000 cells/well in 10% FBS, 2mM Gln in DMEM, on a 96-well plate. Cells are incubated overnight at 37° C in 5% CO2 2. On day 2, test compounds are serially diluted to 7 test concentrations in the same growth medium on a 96-well plate and then are added to the cells on a 96-well tissue culture plate.

3. After 20-24 hours of incubation, diluted BrdU labeling reagent (1: 100 in DMEM, 0.1% BSA) is added and the cells are incubated with BrdU (final concentration is 10 M) for 2 hours.

Steps 5-10 of the General Procedure are used to complete the assay.

Src Transphosphorylation Assay [1528] This assay is used to screen for inhibitors of the tyrosine kinase Src.

Materials and Reagents: 1. Coating buffer: PBS containing sodium azide (0.2mg/ml).

2.1% w/v BSA in PBS.

3. Wash buffer: PBS containing 0.05% v/v Tween 20 (PBS-TWEEN) 4.500mM HEPES pH7.4.

5. ATP (40 uM) + MgCl2 (80mM) in distilled water.

6. MgCl2 (80mM) in distilled water (for no ATP blanks).

7. Test compounds, I OmM in DMSO.

8. Assay Buffer: 100 mM HEPES, pH 7.4, containing 2mM DTT, 0.2mM sodium orthovanadate and 0.2mgs/ml BSA.

9. Partially purified recombinant human Src (UBI (14-117) 10. Anti-phosphotyrosine (SUGEN rabbit polyclonal anti-PY).

11. HRP-linked goat anti-rabbit Ig (Biosource International #6430) 12. HRP substrate ABTS or Pierce Peroxidase substrate.

13. Coming ELISA plates.

Procedure: 1. Coat plates with 1 OOul of 20ug/ml poly (Glu-Tyr) (Sigma Cat.

No. P0275) containing 0.01% sodium azide. Hold overnight at 4° C.

2. Block with 1% BSA at lOOu. l/well for one hour at room temperature.

3. Plate test compounds (lOmM in DMSO) at 2ul/well on a Costar plate ready for dilution with dH20 and plating to reaction plates.

4. Dilute Src kinase 1: 10,000 in Reaction Buffer, for 5 plates prepare 25 ml as follows: 2.5mls 1M HEPES pH7.4 (stored sterile at 4°C), 21.85 ml distilled water, 0.1 ml 5% BSA, 0.5 ml 10 mM sodium orthovanadate (stored sterile at 4° C), 50 gl 1. OM DTT (stored frozen at - 20° C), and 2.5 ul Src Kinase (stored frozen at-80°C).

5. Add 48p1 of distilled water to the 2z1 of each compound in the dilution plate then add 25, -well of this to the reaction plate.

6. Add 50µl of HRP to each reaction buffer well and then zip ATP- MgCl2/well (MgCl2 only to no ATP blanks). Incubate at room temperature for 15 minutes on plate shaker. Stop reaction by adding 25p1 of O. SM EDTA to each well.

7. Wash 4X with PBS-TWEEN.

8. Add 100p1 anti-phosphotyrosine (1: 10,000 of anti-pTyr serum or 1: 3,000 of 10% glycerol diluted PA-affinity purified antibody) in PBS- TWEEN containing 0.5% BSA, 0.025% Non-fat milk powder and 100 uM sodium orthovanadate. Incubate with continuous shaking at room temperature for one hour.

9. Wash plates 4X with PBS-TWEEN.

10. Add 1001il HRP-linked Ig (1: 5,000) in PBS-TWEEN containing 0.5% BSA, 0.025% Non-fat milk powder, 100 µM sodium orthovanadate.

Incubate with shaking at room temperature for one hour.

11. Wash plates 4X with PBS-TWEEN and then once with PBS.

12. Develop plate using ABTS or other peroxidase substrate.

Cell cycle analysis: [15291 A431 cells in standard growth medium are exposed to a desired concentration of a test compound for 20-24 hours at 37 °C. The cells are then collected, suspended in PBS, fixed with 70% ice-cold methanol and stained with propidium iodide. The DNA content is then measured using a FACScan flow cytometer. Cell cycle phase distribution can then be estimated using CellFIT software (Becton-Dickinson).

HUV-EC-C Assay [1530J This assay is used to measure a compound's activity against PDGF-R, FGF- R, VEGF, aFGF or Flk-1/KDR, all of which are naturally expressed by HW-EC cells.

DAY 0 1. Wash and trypsinize HUV-EC-C cells (human umbilical vein endothelial cells, (American Type Culture Collection, catalogue no. 1730 CRL).

Wash with Dulbecco's phosphate-buffered saline (D-PBS, obtained from Gibco BRL, catalogue no. 14190-029) 2 times at about 1 ml/10 cm2 oftissue culture flask.

Trypsinize with 0.05% trypsin-EDTA in non-enzymatic cell dissociation solution (Sigma Chemical Company, catalogue no. C-1544). The 0.05% trypsin is made by diluting 0.25% trypsin/1 mM EDTA (Gibco, catalogue no. 25200-049) in the cell dissociation solution. Trypsinize with about 1 ml/25-30 cm2 of tissue culture flask for about 5 minutes at 37°C. After cells have detached from the flask, add an equal volume of assay medium and transfer to a 50 ml sterile centrifuge tube (Fisher Scientific, catalogue no. 05-539-6).

2. Wash the cells with about 35 ml assay medium in the 50 ml sterile centrifuge tube by adding the assay medium, centrifuge for 10 minutes at approximately 200x g, aspirate the supernatant, and resuspend with 35 ml D-PBS.

Repeat the wash two more times with D-PBS, resuspend the cells in about 1 ml assay medium115 cm2 of tissue culture flask. Assay medium consists of F12K medium (Gibco BRL, catalogue no. 21127-014) and 0.5% heat-inactivated fetal bovine serum.

Count the cells with a Coulter Counter@ (Coulter Electronics, Inc.) and add assay medium to the cells to obtain a concentration of 0.8-1.0 x 105 cells/ml.

3. Add cells to 96-well flat-bottom plates at 100 pl/well or 0.8-1.0 x 104 cells/well, incubate-24h at 37°C, 5% C02.

DAY 1 1. Make up two-fold test compound titrations in separate 96-well plates, generally 50 uM on down to 0 p. M. Use the same assay medium as mentioned in day 0, step 2 above. Titrations are made by adding 90 pI/well of test compound at 200 gM (4X the final well concentration) to the top well of a particular plate column.

Since the stock test compound is usually 20 mM in DMSO, the 200 p. M drug concentration contains 2% DMSO.

A diluent made up to 2% DMSO in assay medium (F12K + 0.5% fetal bovine serum) is used as diluent for the test compound titrations in order to dilute the test compound but keep the DMSO concentration constant. Add this diluent to the remaining wells in the column at 60 pI/well. Take 60 pI from the 120 p1 of 200 zM test compound dilution in the top well of the column and mix with the 60 ul in the second well of the column. Take 60 ul from this well and mix with the 60 u. l in the third well of the column, and so on until two-fold titrations are completed. When the next-to-the-last well is mixed, take 60 ul of the 120 ul in this well and discard it.

Leave the last well with 60 p1 of DMSO/media diluent as a non-test compound- containing control. Make 9 columns of titrated test compound, enough for triplicate wells each for: (1) VEGF (obtained from Pepro Tech Inc., catalogue no. 100-200, (2) endothelial cell growth factor (ECGF) (also known as acidic fibroblast growth factor, or aFGF) (obtained from Boehringer Mannheim Biochemica, catalogue no. 1439 600), or, (3) human PDGF B/B (1276-956, Boehringer Mannheim, Germany) and assay media control. ECGF comes as a preparation with sodium heparin.

2. Transfer 50 µl/well of the test compound dilutions to the 96-well assay plates containing the 0.8-1. 0x104 cells/100 µl/well of the HUV-EC-C cells from day 0 and incubate ~2 h at 37° C, 5% C02.

3. In triplicate, add 50 µl/well of 80 ug/ml VEGF, 20 ng/ml ECGF, or media control to each test compound condition. As with the test compounds, the growth factor concentrations are 4X the desired final concentration. Use the assay media from day 0 step 2 to make the concentrations of growth factors. Incubate approximately 24 hours at 37°C, 5% C02. Each well will have 50 111 test compound dilution, 50 gel growth factor or media, and 100 µl cells, which calculates to 200 ul/well total. Thus the 4X concentrations of test compound and growth factors become 1X once everything has been added to the wells.

DAY 2 1. Add3H-thymidine (Amersham, catalogue no. TRK-686) at 1 pLCi/well (10 pI/well of 100 pCi/ml solution made up in RPMI media + 10% heat-inactivated fetal bovine serum) and incubate-24 h at 37°C, 5% C02. RPMI is obtained from Gibco BRL, catalogue no. 11875-051.

DAY 3 1. Freeze plates overnight at-20°C.

DAY 4 Thaw plates and harvest with a 96-well plate harvester (Tomtec Harvester 969) onto filter mats (Wallac, catalogue no. 1205-401), read counts on a Wallac BetaplateTM liquid scintillation counter.

In Vivo Animal Models XENOGRAFT ANIMAL MODELS [1531] The ability of human tumors to grow as xenografts in athymic mice (e. g., Balb/c, nu/nu) provides a useful in vivo model for studying the biological response to therapies for human tumors. Since the first successful xenotransplantation of human tumors into athymic mice, (Rygaard and Povlsen, 1969, Acta Pathol. Microbial.

Scand. 77: 758-760), many different human tumor cell lines (e. g., mammary, lung, genitourinary, gastro-intestinal, head and neck, glioblastoma, bone, and malignant melanomas) have been transplanted and successfully grown in nude mice. The following assays may be used to determine the level of activity, specificity and effect of the different compounds of the present invention. Three general types of assays are useful for evaluating compounds: cellular/catalytic, cellular/biological and in vivo.

The object of the cellular/catalytic assays is to determine the effect of a compound on the ability of a TK to phosphorylate tyrosines on a known substrate in a cell. The object of the cellular/biological assays is to determine the effect of a compound on the biological response stimulated by a TK in a cell. The object of the in vivo assays is to determine the effect of a compound in an animal model of a particular disorder such as cancer.

[1532] Suitable cell lines for subcutaneous xenograft experiments include C6 cells (glioma, ATCC # CCL 107), A375 cells (melanoma, ATCC # CRL 1619), A431 cells (epidermoid carcinoma, ATCC # CRL 1555), Calu 6 cells (lung, ATCC # HTB 56), PC3 cells (prostate, ATCC # CRL 1435), SKOV3TP5 cells, S114 (NIH3T3 fibroblast cell line genetically engineered for cMet and HGF expressions from NCI), U-87MG (human malignant glioma, ATCC HTB 14) and NIH 3T3 fibroblasts genetically engineered to overexpress EGFR, PDGFR, lGF-lR or any other test kinase. The following protocol can be used to perform xenograft experiments: [1533] Female athymic mice (BALB/c, nu/nu) are obtained from Simonsen Laboratories (Gilroy, CA). All animals are maintained under clean-room conditions in Micro-isolator cages with Alpha-dri bedding. They receive sterile rodent chow and water ad libitum.

[1534] Cell lines are grown in appropriate medium (for example, MEM, DMEM, Ham's F10, or Ham's F12 plus 5%-10% fetal bovine serum (FBS) and 2 mM glutamine (GLN)). All cell culture media, glutamine, and fetal bovine serum are purchased from Gibco Life Technologies (Grand Island, NY) unless otherwise specified. All cells are grown in a humid atmosphere of 90-95% air and 5-10% C02 at 37°C. All cell lines are routinely subcultured twice a week and are negative for mycoplasma as determined by the Mycotect method (Gibco).

11535] Cells are harvested at or near confluency with 0.05% Trypsin-EDTA and pelleted at 450 x g for 10 min. Pellets are resuspended in sterile PBS or media (without FBS) to a particular concentration and the cells are implanted into the hindflank of the mice (8-10 mice per group, 2-10 x 106 cells/animal). Tumor growth is measured over 3 to 6 weeks using venier calipers. Tumor volumes are calculated as a product of length x width x height unless otherwise indicated. P values are calculated using the Students t-test. Test compounds in 50-100 L excipient (DMSO, or VPD: D5W) can be delivered by IP injection at different concentrations generally starting at day one after implantation.

TUMOR INVASION MODEL [1536] The following tumor invasion model has been developed and may be used for the evaluation of therapeutic value and efficacy of the compounds identified to selectively inhibit KDR/FLK-1 receptor.

Procedure [1537] 8 week old nude mice (female) (Simonsen Inc.) are used as experimental animals. Implantation of tumor cells can be performed in a laminar flow hood. For anesthesia, Xylazine/Ketamine Cocktail (100 mg/kg ketamine and 5 mg/kg Xylazine) are administered intraperitoneally. A midline incision is done to expose the abdominal cavity (approximately 1.5 cm in length) to inject 107 tumor cells in a volume of 100 ul medium. The cells are injected either into the duodenal lobe of the pancreas or under the serosa of the colon. The peritoneum and muscles are closed with a 6-0 silk continuous suture and the skin is closed by using wound clips.

Animals are observed daily.

Analysis [1538] After 2-6 weeks, depending on gross observations of the animals, the mice are sacrificed, and the local tumor metastases to various organs (lung, liver, brain, stomach, spleen, heart, muscle) are excised and analyzed (measurement of tumor size, grade of invasion, immunochemistry, in situ hybridization determination, etc.).

Additional assays [1539] Additional assays which may be used to evaluate the compounds of this invention include, without limitation, a bio-flk-1 assay, an EGF receptor-HER2 chimeric receptor assay in whole cells, a bio-src assay, a bio-lck assay and an assay measuring the phosphorylation function of raf. The protocols for each of these assays may be found in U. S. Application Ser. No. 09/099,842, which is incorporated by reference, including any drawings, herein. Additionally, U. S. Patent No. 5,792,783, filed June 5,1996 and U. S. Application Serial No. 09/322,297, filed May 28,1999 are incorporated by reference as if fully set forth herein.

[1540] The present invention is not to be limited in scope by the exemplified aspects which are intended as illustrations of single aspects of the invention, and any clones, DNA or amino acid sequences which are functionally equivalent are within the scope of the invention. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

[1541] All references cited herein are hereby incorporated by reference in their entirety..

Table 2 Kinase Inhibition of Selected Compounds Kinase Inhibition of Selected Compounds FGFR1 FLK-1 EGFR PDGFR MET FGFR3 SRC P38 Example<BR> <BR> IC50(µM) IC50(µM) IC50(µM) IC50(µM) IC50(µM) IC50(µM) IC50(µM) IC50(µM)<BR> <BR> <BR> <BR> <BR> 3 0. 031 0. 009 >20 0. 44 0. 078 1. 02 >10 4 0.74 0.074 >20 14.60 0.70 >20 >10 6 0.057 0.021 16.19 2.95 0.073 4.93 >10 10 1.54 0.18 >20 11.93 0.23 1.82 >10 13 <0. 0091 0.013 13.12 2.32 0.10 0.021 1.05 >10 15 2.07 0.032 >20 10.13 0.37 0.072 2.27 4.9 18 1.19 0.42 9.33 10.36 0.27 0.35 7.81 9.5 20 1.15 0.23 >20 3.39 0.52 1.29 10.38 >10 22 0.057 0.016 15. 92 1.64 0.14 0.074 1.58 13.1 25 0.56 0.18 >20 11. 68 0.11 0.34 9.86 >10 27 0.63 0.17 >20 >20 0.15 0.61 13.87 >10 29 0.029 0.041 12.88 0.69 0.065 0.32 1.25 >10 32 0.35 0.051 >20 11.63 0.12 1.77 5.37 >10 34 0.50 1.06 >20 >20 0.13 0.94 7.26 >10 35 0.22 0.092 >20 1.59 0.34 1.99 9.72 >10 38 0.080 0.029 16.35 2.19 0.11 0.046 1.25 >10 40 0.19 0.041 >20 11.08 0.27 0.38 6.57 >10 41 0.56 0.079 >20 3.84 0.32 0.79 5.42 >10 46 0.022 0.009 >20 4.19 0.12 0.009 0.66 >10 48 0.60 0.012 >20 8.39 1.06 0.19 3,. 80 >10 52 0.035 0.005 >20 1.54 0.092 <0.0091 0.54 >10 53 1.15 0.021 >20 >20 0.29 0.68 13.49 >10 57 0.26 0.029 >20 >20 0.42 0.087 4.74 >10 58 0.25 0.054 >20 16.06 0.073 0.22 4.81 >10 60 0.15 0.018 7.01 2.37 0.25 0.55 2.01 7.9 61 0.021 0.006 >20 9.12 0.11 <0.0091 1.72 6.3 63 0.24 0.043 14.98 2.18 0.043 0.094 1.14 93 0.083 <0.0091 >20 3.76 0.08 >20 99 0.61 0.17 >20 >20 0.18 >20 104 0.3 0.066 >20 18.97 0.58 7.09 119 0.24 0.18 >20 9.87 0.059 8.61 140 0.52 0.075 >20 >20 0.68 4.31 [1542] Table 2 shows data of kinase inhibition of selected compounds. The Example numbers of Table 2 correspond to the Example numbers in Table I of the specification.

Scatter Assay [1543] Materials and Reagents: 1. HGF: recombinant human HGF, Cat. No. 249-HG, R&D Systems, Inc., USA. HGF is dissolved in PBS with 0.1% BSA at a stock concentration of 50 mg/ml.

[1544] Procedure: 1. cell lineL MDCK clone &num 2.

2. MDCK cell were plated in 96-well plate in MEM with 10% FBS at low density of 25 cells/well and grown to small colonies of 10-15 cells.

3. Cells were then treated with HGF (50 ng/Ml) in the presence of various concentrations of compounds diluted in MEM with 0.5% FBS.

4. After overnight incubation, cells were fixed and stained with 0.2% crystal violet in 10% buffer Formalin.

5. Plates were allowed to air dry.

6. Photographs were taken of individual colonies.

Met Phosphorylation-Cellular Assay [1545] Materials and Reagents: 1. Falcon 10 cm culture dishes.

2. A549 lung carcinoma cells.

3. F12K growth medium (with 2% FBS + 2mM glutamine.

4. F12K assay medium (with 0.1% BSA).

5. Fisher cell scrapers.

6. Lysis buffer (HNTG, 1 mM sodium orthovanidate, 1 mM PMSF and 2mM sodium fluoride).

7.1.5 mi Eppendorf tubes.

8. Eppendorf microcentrifuge.

9. BCA assay reagents A and B (#23223 and 23224, Pierce).

10. Sample tube rotator.

11. Gel blot container rotator.

12.5X sample buffer.

13. Novex pre-cast tris-glycine 8% acrylamide gels.

14. Bio-Rad electrophoresis chamber.

15. SDS-PAGE buffer.

16. TBS (pH 7.6) + 0. 1% Triton X-100 (TBST), with and wihtout 5% milk.

17. Western blot transfer buffer.

18. Osmonics nitrocellulose paper.

19. Bio-Rad Transblot paper.

20. Gel transfer apparatus.

21. Anti-phosphotyrosine (mouse monoclonal).

22. Bio-Rad Kaleidoscope Prestained Standards (161-0324).

23. Anti-h-met (C-28) rabbit polyclonal, conjugated and non-conjugated with agarose (#sc-161 AC and sc-161, Santa Cruz Biotechnology, Inc.).

24. Donkey and anti-rabbit Ig-HRP (NA 934, Amersham).

25. Sheet anti-mouseIg-HRP (NA 931, Amersham).

26. SuperSignal West Pico Chemiluminescent Substrate (#34080, Pierce).

27. Saran Wrap.

28. Kodak BioMax exposure cassette.

29. Fuji X-ray film.

30. Kodak film developer.

Precedure : 1. Plate cells in 10 cm dishes with growth medium with 2% FBS + 2mM glutamine. Grow to near confluency.

2. Serum starve cells overnight in assay medium with 0.1% BSA.

3. Add drug to the plates, one dose per plate, usually in a 2-flod titration.

Add asay medium (with the same DMSO concentration as the drugs) for no drug.

4. Incubate plates 4-5 hours with the drug, then add HG, 50 ng/ml for 10 minutes.

5. Wash plates once with PBS, add 400 pl lysis buffer, and scrape off the cells. Collect in 1.5 ml Eppendorf tubes.

6. After about 10-20 minutes in the lysis buffer, centrifuge lysates in a microcentrifuger at full speed (14,000g) and collect the supernatants in a separate Eppendorf tube.

7. Determine protein concentration with the BCA assay reagents.

8. Adjust sample concentration to 0.5 mg protein in 0.4 ml using lysis buffer.

9. Add 15 RI anti-h-met AC for immunoprecipitation, rotate samples for 2 hours at 4°C.

10. Wash samples 3 times with lysis buffer and resuspend in 35 111 5X sample buffer.

11. Boil sample at 100°C for 10 minutes and microcentrifuge at highest setting for 30 minutes to pellet the agarose beads.

12. Load 15 p1 each to 2 gels, one for anti-phosphorylation and the other for anti-h-met. Also load 10 p1 of prestained standards, one lane per gel.

13. Run gel around 100-125 V, then transfer gel to nitrocellulose either overnight at 70 mAmps or 1 hour at 500 mAmps.

14. Block membranes on rotator for 1 hour in TBS + 0.1% Triton X-100 (TBST) + 5% PBS. All steps from this point are at room temperature unless otherwise unless otherwise noted.

15. Add 0. pg/ml antiphosphotyrosine and 0.25 g/ml anti-h-met on rotator either for 2 hours or overnight.

16. Wash membranes 3 times 5 minutes each in TBST on rotator.

17. Add HRP-conjugated antibodies) sheep anti-mouse for the antiphosphotyroeins ; donkey anti-rabbit for the nati-h-met) at 1: 5000 for approximately 45 minutes on rotator.

18. Wash membranes 3 times for 5 minutes each in TBST on rotator.

19. Add the 2 reagents in th3e SuperSignal kit together in equal volumes (3 ml + 3 ml for each blot), rotate for 1-2 minutes.

20. Wrap blots in Saran Wrap and tape securely inside the exposure cassette.

21. In the darkroom with only the safety light on, place a sheet of film inside the cassette. After an allotted time, remove film and place in the developer machine for automatic processing. Experiment with the exposure time to get proper exposure.